<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99149</Key_PaperID>
<Key_SessionID>11045</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Old and New Tools in the Clinical Diagnosis of Inherited Bone Marrow Failure Syndromes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99150</Key_PaperID>
<Key_SessionID>11045</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Inherited Bone Marrow Failure Syndromes: Considerations Pre- and Post-Transplant</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99151</Key_PaperID>
<Key_SessionID>11045</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>I will discuss the off-label use of androgen formulations and eltrombopag in the treatment of bone marrow failure syndromes.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Treatment of Inherited Bone Marrow Failure Syndromes Beyond Transplant</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99149</Key_PaperID>
<Key_SessionID>11045</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Old and New Tools in the Clinical Diagnosis of Inherited Bone Marrow Failure Syndromes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99150</Key_PaperID>
<Key_SessionID>11045</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		11:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:00 AM
	
 
</PaperStartTime>
<PaperTitle>Inherited Bone Marrow Failure Syndromes: Considerations Pre- and Post-Transplant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99151</Key_PaperID>
<Key_SessionID>11045</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>I will discuss the off-label use of androgen formulations and eltrombopag in the treatment of bone marrow failure syndromes.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		12:00 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:30 AM
	
 
</PaperStartTime>
<PaperTitle>Treatment of Inherited Bone Marrow Failure Syndromes Beyond Transplant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99152</Key_PaperID>
<Key_SessionID>11046</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Implications of Somatic Mutations in Aplastic Anemia and Myelodysplastic Syndromes in the Genomics Age</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99153</Key_PaperID>
<Key_SessionID>11046</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Acquired Ribosomopathies, Red Cell Failure, and Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99154</Key_PaperID>
<Key_SessionID>11046</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Hematopoiesis, Aging, and Bone Marrow Failure</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99152</Key_PaperID>
<Key_SessionID>11046</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		3:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		2:45 PM
	
 
</PaperStartTime>
<PaperTitle>Clinical Implications of Somatic Mutations in Aplastic Anemia and Myelodysplastic Syndromes in the Genomics Age</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99153</Key_PaperID>
<Key_SessionID>11046</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:45 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:15 PM
	
 
</PaperStartTime>
<PaperTitle>Acquired Ribosomopathies, Red Cell Failure, and Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99154</Key_PaperID>
<Key_SessionID>11046</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		4:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:45 PM
	
 
</PaperStartTime>
<PaperTitle>Hematopoiesis, Aging, and Bone Marrow Failure</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99155</Key_PaperID>
<Key_SessionID>11047</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Emerging Cardiovascular Complications of SCD</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99156</Key_PaperID>
<Key_SessionID>11047</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Chronic Organ Failure in Adult SCD</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99157</Key_PaperID>
<Key_SessionID>11047</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Evolving Treatment Paradigms in SCD</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99155</Key_PaperID>
<Key_SessionID>11047</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		4:30 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		4:00 PM
	
 
</PaperStartTime>
<PaperTitle>Emerging Cardiovascular Complications of SCD</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99156</Key_PaperID>
<Key_SessionID>11047</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		5:00 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		4:30 PM
	
 
</PaperStartTime>
<PaperTitle>Chronic Organ Failure in Adult SCD</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99157</Key_PaperID>
<Key_SessionID>11047</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		5:30 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		5:00 PM
	
 
</PaperStartTime>
<PaperTitle>Evolving Treatment Paradigms in SCD</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99158</Key_PaperID>
<Key_SessionID>11048</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Optimizing the Care Model for an Uncomplicated Acute Pain Event in SCD</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99159</Key_PaperID>
<Key_SessionID>11048</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Pain Measurement Tools in SCD: Where Are We Now?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99160</Key_PaperID>
<Key_SessionID>11048</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Targeting Novel Mechanisms of Pain in SCD</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99158</Key_PaperID>
<Key_SessionID>11048</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		3:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		2:45 PM
	
 
</PaperStartTime>
<PaperTitle>Optimizing the Care Model for an Uncomplicated Acute Pain Event in SCD</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99159</Key_PaperID>
<Key_SessionID>11048</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:45 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:15 PM
	
 
</PaperStartTime>
<PaperTitle>Pain Measurement Tools in SCD: Where Are We Now?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99160</Key_PaperID>
<Key_SessionID>11048</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		4:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:45 PM
	
 
</PaperStartTime>
<PaperTitle>Targeting Novel Mechanisms of Pain in SCD</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99161</Key_PaperID>
<Key_SessionID>11049</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>New Therapeutic Targets in Transfusion-Dependent and Non-Transfusion-Dependent Thalassemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99162</Key_PaperID>
<Key_SessionID>11049</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Iron Overload in Thalassemia: Different Organs at Different Rates</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99163</Key_PaperID>
<Key_SessionID>11049</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>The Impact of Bone Disease and Pain in Thalassemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99161</Key_PaperID>
<Key_SessionID>11049</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		8:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		8:00 AM
	
 
</PaperStartTime>
<PaperTitle>New Therapeutic Targets in Transfusion-Dependent and Non-Transfusion-Dependent Thalassemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99162</Key_PaperID>
<Key_SessionID>11049</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		7:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:00 AM
	
 
</PaperStartTime>
<PaperTitle>Iron Overload in Thalassemia: Different Organs at Different Rates</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99163</Key_PaperID>
<Key_SessionID>11049</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		8:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:30 AM
	
 
</PaperStartTime>
<PaperTitle>The Impact of Bone Disease and Pain in Thalassemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99164</Key_PaperID>
<Key_SessionID>11050</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>New Diseases, New Mechanisms, and New Therapies in Congenital Neutropenia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99165</Key_PaperID>
<Key_SessionID>11050</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Use of rG-CSF in treatment of drug-induced neutropenia</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Drug-Induced Neutropenia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99166</Key_PaperID>
<Key_SessionID>11050</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Chronic Neutropenia in Large Granular Lymphocytic Leukemia and Rheumatoid Arthritis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99164</Key_PaperID>
<Key_SessionID>11050</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		7:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:00 AM
	
 
</PaperStartTime>
<PaperTitle>New Diseases, New Mechanisms, and New Therapies in Congenital Neutropenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99165</Key_PaperID>
<Key_SessionID>11050</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Use of rG-CSF in treatment of drug-induced neutropenia</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		8:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		8:00 AM
	
 
</PaperStartTime>
<PaperTitle>Drug-Induced Neutropenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99166</Key_PaperID>
<Key_SessionID>11050</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		8:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:30 AM
	
 
</PaperStartTime>
<PaperTitle>Chronic Neutropenia in Large Granular Lymphocytic Leukemia and Rheumatoid Arthritis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99167</Key_PaperID>
<Key_SessionID>11051</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Plasma Exchange for Thrombotic Microangiopathies Other Than Thrombotic Thrombocytopenic Purpura</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99168</Key_PaperID>
<Key_SessionID>11051</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This paper describes the off-label use of extracorporeal photopheresis</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Extracorporeal Photopheresis for Graft Versus Host Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99169</Key_PaperID>
<Key_SessionID>11051</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Desensitization of Human Leukocyte Antigen Alloimmunized Recipients of Allogeneic Transplant</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99167</Key_PaperID>
<Key_SessionID>11051</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		7:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:00 AM
	
 
</PaperStartTime>
<PaperTitle>Plasma Exchange for Thrombotic Microangiopathies Other Than Thrombotic Thrombocytopenic Purpura</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99168</Key_PaperID>
<Key_SessionID>11051</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This paper describes the off-label use of extracorporeal photopheresis</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		8:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:30 AM
	
 
</PaperStartTime>
<PaperTitle>Extracorporeal Photopheresis for Graft Versus Host Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99169</Key_PaperID>
<Key_SessionID>11051</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		8:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		8:00 AM
	
 
</PaperStartTime>
<PaperTitle>Desensitization of Human Leukocyte Antigen Alloimmunized Recipients of Allogeneic Transplant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99170</Key_PaperID>
<Key_SessionID>11052</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Gene Therapy Comes of Age</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99171</Key_PaperID>
<Key_SessionID>11052</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Using Pharmacokinetic Data to Individualize Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99172</Key_PaperID>
<Key_SessionID>11052</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Hemostatic Therapy for Patients With Inhibitors: Beyond Bypassing Agents</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99170</Key_PaperID>
<Key_SessionID>11052</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Gene Therapy Comes of Age</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99171</Key_PaperID>
<Key_SessionID>11052</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		11:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:00 AM
	
 
</PaperStartTime>
<PaperTitle>Using Pharmacokinetic Data to Individualize Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99172</Key_PaperID>
<Key_SessionID>11052</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		12:00 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:30 AM
	
 
</PaperStartTime>
<PaperTitle>Hemostatic Therapy for Patients With Inhibitors: Beyond Bypassing Agents</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99173</Key_PaperID>
<Key_SessionID>11053</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Superficial Vein Thrombosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99174</Key_PaperID>
<Key_SessionID>11053</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Distal Deep Vein Thrombosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99175</Key_PaperID>
<Key_SessionID>11053</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Subsegmental Pulmonary Embolism</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99173</Key_PaperID>
<Key_SessionID>11053</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		3:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		2:45 PM
	
 
</PaperStartTime>
<PaperTitle>Superficial Vein Thrombosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99174</Key_PaperID>
<Key_SessionID>11053</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:45 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:15 PM
	
 
</PaperStartTime>
<PaperTitle>Distal Deep Vein Thrombosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99175</Key_PaperID>
<Key_SessionID>11053</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		4:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:45 PM
	
 
</PaperStartTime>
<PaperTitle>Subsegmental Pulmonary Embolism</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99176</Key_PaperID>
<Key_SessionID>11054</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Incidental VTE: Is Anticoagulation Indicated?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99177</Key_PaperID>
<Key_SessionID>11054</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>When Can We Stop Anticoagulation in Patients With Cancer-Associated Thrombosis?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99178</Key_PaperID>
<Key_SessionID>11054</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Will discuss (but not recommend) thrombosis prophylaxis in cancer patients with direct oral anticoagulants</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Direct Oral Anticoagulants: Now Also for Prevention and Treatment of Cancer-Associated VTE?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99176</Key_PaperID>
<Key_SessionID>11054</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		2:30 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		2:00 PM
	
 
</PaperStartTime>
<PaperTitle>Incidental VTE: Is Anticoagulation Indicated?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99177</Key_PaperID>
<Key_SessionID>11054</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:00 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		2:30 PM
	
 
</PaperStartTime>
<PaperTitle>When Can We Stop Anticoagulation in Patients With Cancer-Associated Thrombosis?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99178</Key_PaperID>
<Key_SessionID>11054</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Will discuss (but not recommend) thrombosis prophylaxis in cancer patients with direct oral anticoagulants</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		3:30 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:00 PM
	
 
</PaperStartTime>
<PaperTitle>Direct Oral Anticoagulants: Now Also for Prevention and Treatment of Cancer-Associated VTE?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99179</Key_PaperID>
<Key_SessionID>11055</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Thrombocytopenia in Pregnancy: Evaluation and Management</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99180</Key_PaperID>
<Key_SessionID>11055</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Iron-Deficiency in Pregnancy: Clinical Implications and Management</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99181</Key_PaperID>
<Key_SessionID>11055</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Preventing Venous Thromboembolism during Pregnancy and Postpartum: Crossing the Threshold</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99179</Key_PaperID>
<Key_SessionID>11055</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		10:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		9:30 AM
	
 
</PaperStartTime>
<PaperTitle>Thrombocytopenia in Pregnancy: Evaluation and Management</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99180</Key_PaperID>
<Key_SessionID>11055</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		10:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:00 AM
	
 
</PaperStartTime>
<PaperTitle>Iron-Deficiency in Pregnancy: Clinical Implications and Management</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99181</Key_PaperID>
<Key_SessionID>11055</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Preventing Venous Thromboembolism during Pregnancy and Postpartum: Crossing the Threshold</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99182</Key_PaperID>
<Key_SessionID>11056</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>rituximab</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Approach to the Patient With Thrombotic Microangiopathy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99183</Key_PaperID>
<Key_SessionID>11056</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Assessing Thrombocytopenia in the Intensive Care Unit: The Past, Present, and Future</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99184</Key_PaperID>
<Key_SessionID>11056</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>most drugs used to treat HIT are off-label -- this will be made clear in my presentation (including the 1-2 drugs that are "on-label"</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>HITs and Misses of 100 Years of Heparin</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99182</Key_PaperID>
<Key_SessionID>11056</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>rituximab</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Approach to the Patient With Thrombotic Microangiopathy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99183</Key_PaperID>
<Key_SessionID>11056</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		11:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:00 AM
	
 
</PaperStartTime>
<PaperTitle>Assessing Thrombocytopenia in the Intensive Care Unit: The Past, Present, and Future</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99184</Key_PaperID>
<Key_SessionID>11056</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>most drugs used to treat HIT are off-label -- this will be made clear in my presentation (including the 1-2 drugs that are "on-label"</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		12:00 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:30 AM
	
 
</PaperStartTime>
<PaperTitle>HITs and Misses of 100 Years of Heparin</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99185</Key_PaperID>
<Key_SessionID>11057</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Anticoagulation With Ventricular Assist Devices and Extracorporeal Membrane Oxygenation: Walking the Tightrope</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99186</Key_PaperID>
<Key_SessionID>11057</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Thrombolytic drugs for DVT are off-label

Stents for iliac vein use are off-label</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Thrombectomy and Thrombolysis for the Prevention and Treatment of Post-Thrombotic Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99187</Key_PaperID>
<Key_SessionID>11057</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Inferior Vena Cava Filters</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99185</Key_PaperID>
<Key_SessionID>11057</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		8:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:30 AM
	
 
</PaperStartTime>
<PaperTitle>Anticoagulation With Ventricular Assist Devices and Extracorporeal Membrane Oxygenation: Walking the Tightrope</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99186</Key_PaperID>
<Key_SessionID>11057</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Thrombolytic drugs for DVT are off-label

Stents for iliac vein use are off-label</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		8:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		8:00 AM
	
 
</PaperStartTime>
<PaperTitle>Thrombectomy and Thrombolysis for the Prevention and Treatment of Post-Thrombotic Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99187</Key_PaperID>
<Key_SessionID>11057</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		9:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		8:30 AM
	
 
</PaperStartTime>
<PaperTitle>Inferior Vena Cava Filters</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99188</Key_PaperID>
<Key_SessionID>11058</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Advances in the Diagnosis and Treatment of von Willebrand Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99189</Key_PaperID>
<Key_SessionID>11058</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Eltrombopag for increasing the platelet count in patients with inherited thrombocytopanias</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Hereditary Thrombocytopenias: A Growing List of Disorders</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99190</Key_PaperID>
<Key_SessionID>11058</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Management of Newly Diagnosed Immune Thrombocytopenia: Can We Change Outcomes?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99188</Key_PaperID>
<Key_SessionID>11058</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		3:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		2:45 PM
	
 
</PaperStartTime>
<PaperTitle>Advances in the Diagnosis and Treatment of von Willebrand Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99189</Key_PaperID>
<Key_SessionID>11058</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Eltrombopag for increasing the platelet count in patients with inherited thrombocytopanias</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:45 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:15 PM
	
 
</PaperStartTime>
<PaperTitle>Hereditary Thrombocytopenias: A Growing List of Disorders</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99190</Key_PaperID>
<Key_SessionID>11058</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		4:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:45 PM
	
 
</PaperStartTime>
<PaperTitle>Management of Newly Diagnosed Immune Thrombocytopenia: Can We Change Outcomes?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99191</Key_PaperID>
<Key_SessionID>11059</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Improving Care in the Emergency Department for Patients With SCD</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99192</Key_PaperID>
<Key_SessionID>11059</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Rigorous and Practical Quality Indicators in SCD Care</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99193</Key_PaperID>
<Key_SessionID>11059</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Lifespan Approaches to Care and Transition in SCD</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99191</Key_PaperID>
<Key_SessionID>11059</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		11:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:00 AM
	
 
</PaperStartTime>
<PaperTitle>Improving Care in the Emergency Department for Patients With SCD</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99192</Key_PaperID>
<Key_SessionID>11059</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		12:00 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:30 AM
	
 
</PaperStartTime>
<PaperTitle>Rigorous and Practical Quality Indicators in SCD Care</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99193</Key_PaperID>
<Key_SessionID>11059</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Lifespan Approaches to Care and Transition in SCD</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99194</Key_PaperID>
<Key_SessionID>11060</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Emerging Infectious Diseases: Clinical Significance and Implications for Transfusion</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99195</Key_PaperID>
<Key_SessionID>11060</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Prevention of Pathogen Transmission via Blood Transfusion</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99196</Key_PaperID>
<Key_SessionID>11061</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>NETs as Friends or Foes: Lessons From Human Neonates and Translational Models</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99197</Key_PaperID>
<Key_SessionID>11061</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>NETs: "Nuclear" Weapons of Inflammation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99198</Key_PaperID>
<Key_SessionID>11062</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>The Case For</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99199</Key_PaperID>
<Key_SessionID>11062</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Rituximab for acquired TTP</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>The Case Against</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99200</Key_PaperID>
<Key_SessionID>11063</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Too Many Donors to Choose From: Which Way Do We Turn?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99201</Key_PaperID>
<Key_SessionID>11063</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Getting Patients to Transplant: Barriers and Bridges</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99202</Key_PaperID>
<Key_SessionID>11064</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>SCI-50</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>DNA Methylation in Cancer and Development: An Evolving Paradigm</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99202</Key_PaperID>
<Key_SessionID>11064</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		10:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-50</PaperNumber>
<PaperStartTime>
	
	
	
		9:30 AM
	
 
</PaperStartTime>
<PaperTitle>DNA Methylation in Cancer and Development: An Evolving Paradigm</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99203</Key_PaperID>
<Key_SessionID>11064</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>SCI-51</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Beyond Cytosine Methylation: Ten-Eleven Translocation Proteins, Oxidized Methylcytosines, and Cancer</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99203</Key_PaperID>
<Key_SessionID>11064</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		10:30 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-51</PaperNumber>
<PaperStartTime>
	
	
	
		10:00 AM
	
 
</PaperStartTime>
<PaperTitle>Beyond Cytosine Methylation: Ten-Eleven Translocation Proteins, Oxidized Methylcytosines, and Cancer</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99500</Key_PaperID>
<Key_SessionID>11064</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>SCI-52</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>RNA Methylation and Its Role in the Hematopoietic System</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99500</Key_PaperID>
<Key_SessionID>11064</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-52</PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>RNA Methylation and Its Role in the Hematopoietic System</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99206</Key_PaperID>
<Key_SessionID>11065</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-28</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Primary Antibody Deficiencies: Scientific Discoveries Leading to Challenging Paradigms in a Complex Disease Landscape</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99206</Key_PaperID>
<Key_SessionID>11065</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		4:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-28</PaperNumber>
<PaperStartTime>
	
	
	
		4:00 PM
	
 
</PaperStartTime>
<PaperTitle>Primary Antibody Deficiencies: Scientific Discoveries Leading to Challenging Paradigms in a Complex Disease Landscape</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99207</Key_PaperID>
<Key_SessionID>11065</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>CTLA4-Ig
JAK inhibitors, Ruxolitinib</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-29</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Genetic Disorders of Immune Tolerance: The Flip Side of Immune Deficiency Where Autoimmunity Trumps Infection</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99207</Key_PaperID>
<Key_SessionID>11065</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>CTLA4-Ig
JAK inhibitors, Ruxolitinib</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		5:00 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-29</PaperNumber>
<PaperStartTime>
	
	
	
		4:30 PM
	
 
</PaperStartTime>
<PaperTitle>Genetic Disorders of Immune Tolerance: The Flip Side of Immune Deficiency Where Autoimmunity Trumps Infection</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99205</Key_PaperID>
<Key_SessionID>11065</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-30</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Diagnostic Challenges in the Era of Genomic Sequencing and Newborn Screening</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99205</Key_PaperID>
<Key_SessionID>11065</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		5:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-30</PaperNumber>
<PaperStartTime>
	
	
	
		5:00 PM
	
 
</PaperStartTime>
<PaperTitle>Diagnostic Challenges in the Era of Genomic Sequencing and Newborn Screening</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99213</Key_PaperID>
<Key_SessionID>11066</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-22</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>New Bone Marrow Failure Genes: DNAJC21 and ERCC6L2</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99213</Key_PaperID>
<Key_SessionID>11066</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		2:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-22</PaperNumber>
<PaperStartTime>
	
	
	
		2:00 PM
	
 
</PaperStartTime>
<PaperTitle>New Bone Marrow Failure Genes: DNAJC21 and ERCC6L2</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99209</Key_PaperID>
<Key_SessionID>11066</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-23</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>GATA2 in Bone Marrow Failure</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99209</Key_PaperID>
<Key_SessionID>11066</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:00 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-23</PaperNumber>
<PaperStartTime>
	
	
	
		2:30 PM
	
 
</PaperStartTime>
<PaperTitle>GATA2 in Bone Marrow Failure</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99211</Key_PaperID>
<Key_SessionID>11066</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-24</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Deconstructing Niche Contributions to Bone Marrow Failure and Leukemogenesis in Shwachman-Diamond Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99211</Key_PaperID>
<Key_SessionID>11066</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		3:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-24</PaperNumber>
<PaperStartTime>
	
	
	
		3:00 PM
	
 
</PaperStartTime>
<PaperTitle>Deconstructing Niche Contributions to Bone Marrow Failure and Leukemogenesis in Shwachman-Diamond Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99214</Key_PaperID>
<Key_SessionID>11067</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-4</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>NGS-Based Diagnostics in Hematopathology: Strategies for Implementation in a Clinical Environment</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99214</Key_PaperID>
<Key_SessionID>11067</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		10:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-4</PaperNumber>
<PaperStartTime>
	
	
	
		9:30 AM
	
 
</PaperStartTime>
<PaperTitle>NGS-Based Diagnostics in Hematopathology: Strategies for Implementation in a Clinical Environment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99221</Key_PaperID>
<Key_SessionID>11067</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-5</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Understanding  the Genome: Professional Guidelines in Clinical Genomic Testing and Interpretation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99221</Key_PaperID>
<Key_SessionID>11067</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		10:30 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-5</PaperNumber>
<PaperStartTime>
	
	
	
		10:00 AM
	
 
</PaperStartTime>
<PaperTitle>Understanding  the Genome: Professional Guidelines in Clinical Genomic Testing and Interpretation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99216</Key_PaperID>
<Key_SessionID>11067</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-6</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Whole Exome Sequencing in Patients With Hematologic Malignancies: Ready for Real-Time Precision Medicine?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99216</Key_PaperID>
<Key_SessionID>11067</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-6</PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Whole Exome Sequencing in Patients With Hematologic Malignancies: Ready for Real-Time Precision Medicine?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99222</Key_PaperID>
<Key_SessionID>11068</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>SCI-44</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>In Vitro Hematopoietic Reprogramming and Generation of Hematopoietic Stem Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99222</Key_PaperID>
<Key_SessionID>11068</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		8:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-44</PaperNumber>
<PaperStartTime>
	
	
	
		7:30 AM
	
 
</PaperStartTime>
<PaperTitle>In Vitro Hematopoietic Reprogramming and Generation of Hematopoietic Stem Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99227</Key_PaperID>
<Key_SessionID>11068</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>SCI-45</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>RNAi Screens for Maintenance of Hematopoietic Stem Cell Phenotype During Culture</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99227</Key_PaperID>
<Key_SessionID>11068</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		8:30 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-45</PaperNumber>
<PaperStartTime>
	
	
	
		8:00 AM
	
 
</PaperStartTime>
<PaperTitle>RNAi Screens for Maintenance of Hematopoietic Stem Cell Phenotype During Culture</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99228</Key_PaperID>
<Key_SessionID>11068</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>SCI-46</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Enforcing Post-Transcriptional Circuitries to Achieve Human Hematopoietic Stem Cell Expansion</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99228</Key_PaperID>
<Key_SessionID>11068</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		9:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-46</PaperNumber>
<PaperStartTime>
	
	
	
		8:30 AM
	
 
</PaperStartTime>
<PaperTitle>Enforcing Post-Transcriptional Circuitries to Achieve Human Hematopoietic Stem Cell Expansion</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99231</Key_PaperID>
<Key_SessionID>11069</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-1</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Poly-P as Modulator of Hemostasis, Thrombosis, and Inflammation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99231</Key_PaperID>
<Key_SessionID>11069</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		4:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-1</PaperNumber>
<PaperStartTime>
	
	
	
		4:00 PM
	
 
</PaperStartTime>
<PaperTitle>Poly-P as Modulator of Hemostasis, Thrombosis, and Inflammation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99233</Key_PaperID>
<Key_SessionID>11069</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-2</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Mediators of Disseminated Intravascular Coagulation: Molecular Mechanisms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99233</Key_PaperID>
<Key_SessionID>11069</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		5:00 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-2</PaperNumber>
<PaperStartTime>
	
	
	
		4:30 PM
	
 
</PaperStartTime>
<PaperTitle>Mediators of Disseminated Intravascular Coagulation: Molecular Mechanisms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99235</Key_PaperID>
<Key_SessionID>11069</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-3</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Impact of the Coagulation System on the Pathogenesis of Alzheimer's Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99235</Key_PaperID>
<Key_SessionID>11069</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		5:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-3</PaperNumber>
<PaperStartTime>
	
	
	
		5:00 PM
	
 
</PaperStartTime>
<PaperTitle>Impact of the Coagulation System on the Pathogenesis of Alzheimer's Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99238</Key_PaperID>
<Key_SessionID>11070</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>SCI-47</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>New Approaches to Human Immunology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99238</Key_PaperID>
<Key_SessionID>11070</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		8:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-47</PaperNumber>
<PaperStartTime>
	
	
	
		7:30 AM
	
 
</PaperStartTime>
<PaperTitle>New Approaches to Human Immunology</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99239</Key_PaperID>
<Key_SessionID>11070</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>SCI-48</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>IL-17-Driven Immune Signaling in Autoimmunity and Fungal Infections</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99239</Key_PaperID>
<Key_SessionID>11070</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		8:30 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-48</PaperNumber>
<PaperStartTime>
	
	
	
		8:00 AM
	
 
</PaperStartTime>
<PaperTitle>IL-17-Driven Immune Signaling in Autoimmunity and Fungal Infections</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99240</Key_PaperID>
<Key_SessionID>11070</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>SCI-49</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Dissecting Human Antibody Responses: Useful, Basic, and Surprising Findings</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99240</Key_PaperID>
<Key_SessionID>11070</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		9:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-49</PaperNumber>
<PaperStartTime>
	
	
	
		8:30 AM
	
 
</PaperStartTime>
<PaperTitle>Dissecting Human Antibody Responses: Useful, Basic, and Surprising Findings</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99241</Key_PaperID>
<Key_SessionID>11071</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber>SCI-41</PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Congenital Sideroblastic Anemias: Iron and Heme Lost in Mitochondrial Translation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99241</Key_PaperID>
<Key_SessionID>11071</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		10:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-41</PaperNumber>
<PaperStartTime>
	
	
	
		9:30 AM
	
 
</PaperStartTime>
<PaperTitle>Congenital Sideroblastic Anemias: Iron and Heme Lost in Mitochondrial Translation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99242</Key_PaperID>
<Key_SessionID>11071</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>SCI-42</PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Understanding the Transferrin Receptor and Cellular Iron Deficiency Outside the Erythron</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99242</Key_PaperID>
<Key_SessionID>11071</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		10:30 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-42</PaperNumber>
<PaperStartTime>
	
	
	
		10:00 AM
	
 
</PaperStartTime>
<PaperTitle>Understanding the Transferrin Receptor and Cellular Iron Deficiency Outside the Erythron</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99243</Key_PaperID>
<Key_SessionID>11071</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>SCI-43</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Iron Supplementation: What's New?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99243</Key_PaperID>
<Key_SessionID>11071</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-43</PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Iron Supplementation: What's New?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99244</Key_PaperID>
<Key_SessionID>11072</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-13</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Emerging T Cell Engineering Approaches: New Targets and New Cell Sources</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99244</Key_PaperID>
<Key_SessionID>11072</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		2:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-13</PaperNumber>
<PaperStartTime>
	
	
	
		2:00 PM
	
 
</PaperStartTime>
<PaperTitle>Emerging T Cell Engineering Approaches: New Targets and New Cell Sources</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99245</Key_PaperID>
<Key_SessionID>11072</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Tocilizumab for CRS after CAR-T cell therapy.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-14</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Understanding Outcomes of CD19-Targeted CAR T Cell Immunotherapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99245</Key_PaperID>
<Key_SessionID>11072</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Tocilizumab for CRS after CAR-T cell therapy.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:00 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-14</PaperNumber>
<PaperStartTime>
	
	
	
		2:30 PM
	
 
</PaperStartTime>
<PaperTitle>Understanding Outcomes of CD19-Targeted CAR T Cell Immunotherapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99246</Key_PaperID>
<Key_SessionID>11072</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>cyclophosphamide/fludarabine</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-15</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Enhancing the Efficacy of CAR T Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99246</Key_PaperID>
<Key_SessionID>11072</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>cyclophosphamide/fludarabine</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		3:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-15</PaperNumber>
<PaperStartTime>
	
	
	
		3:00 PM
	
 
</PaperStartTime>
<PaperTitle>Enhancing the Efficacy of CAR T Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99252</Key_PaperID>
<Key_SessionID>11073</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-25</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Reciprocal Interactions Between Platelets and Metastatic Tumors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99252</Key_PaperID>
<Key_SessionID>11073</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		10:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-25</PaperNumber>
<PaperStartTime>
	
	
	
		9:30 AM
	
 
</PaperStartTime>
<PaperTitle>Reciprocal Interactions Between Platelets and Metastatic Tumors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99251</Key_PaperID>
<Key_SessionID>11073</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-26</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Platelet and Megakaryocytic Regulation of Tumor Progression</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99251</Key_PaperID>
<Key_SessionID>11073</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-26</PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Platelet and Megakaryocytic Regulation of Tumor Progression</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99253</Key_PaperID>
<Key_SessionID>11073</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-27</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Role of Platelets in Adaptive Changes to Anti-Angiogenesis Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99253</Key_PaperID>
<Key_SessionID>11073</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		10:30 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-27</PaperNumber>
<PaperStartTime>
	
	
	
		10:00 AM
	
 
</PaperStartTime>
<PaperTitle>Role of Platelets in Adaptive Changes to Anti-Angiogenesis Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99256</Key_PaperID>
<Key_SessionID>11074</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-37</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Population Genetics Approaches to Quantify Clonal Evolution</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99256</Key_PaperID>
<Key_SessionID>11074</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		10:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-37</PaperNumber>
<PaperStartTime>
	
	
	
		9:30 AM
	
 
</PaperStartTime>
<PaperTitle>Population Genetics Approaches to Quantify Clonal Evolution</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99258</Key_PaperID>
<Key_SessionID>11074</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-38</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Clonal Evolution During Stress Hematopoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99258</Key_PaperID>
<Key_SessionID>11074</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		10:30 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-38</PaperNumber>
<PaperStartTime>
	
	
	
		10:00 AM
	
 
</PaperStartTime>
<PaperTitle>Clonal Evolution During Stress Hematopoiesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99259</Key_PaperID>
<Key_SessionID>11074</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-39</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Clonal Evolution in the Setting of Germline Predisposition</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99259</Key_PaperID>
<Key_SessionID>11074</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-39</PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Clonal Evolution in the Setting of Germline Predisposition</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99257</Key_PaperID>
<Key_SessionID>11074</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Decitabine for AML</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-40</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>Clonal Evolution and Relapse in Adult De Novo Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99257</Key_PaperID>
<Key_SessionID>11074</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Decitabine for AML</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	
	
	
		11:30 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-40</PaperNumber>
<PaperStartTime>
	
	
	
		11:00 AM
	
 
</PaperStartTime>
<PaperTitle>Clonal Evolution and Relapse in Adult De Novo Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99260</Key_PaperID>
<Key_SessionID>11075</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-7</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Normal Plasma Cell Biology: Natural Achilles Heels as Targets in Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99260</Key_PaperID>
<Key_SessionID>11075</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		4:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-7</PaperNumber>
<PaperStartTime>
	
	
	
		4:00 PM
	
 
</PaperStartTime>
<PaperTitle>Normal Plasma Cell Biology: Natural Achilles Heels as Targets in Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99261</Key_PaperID>
<Key_SessionID>11075</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-8</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Protein Homeostasis: A Key Target in Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99261</Key_PaperID>
<Key_SessionID>11075</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		5:00 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-8</PaperNumber>
<PaperStartTime>
	
	
	
		4:30 PM
	
 
</PaperStartTime>
<PaperTitle>Protein Homeostasis: A Key Target in Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99262</Key_PaperID>
<Key_SessionID>11075</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-9</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Cereblon and Redox in Plasma Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99262</Key_PaperID>
<Key_SessionID>11075</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		5:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-9</PaperNumber>
<PaperStartTime>
	
	
	
		5:00 PM
	
 
</PaperStartTime>
<PaperTitle>Cereblon and Redox in Plasma Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99464</Key_PaperID>
<Key_SessionID>11076</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Most of the drugs used in AL amyloidosis are approved for multiple myeloma. We use them off-label in AL amyloidosis.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>AL Amyloidosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99263</Key_PaperID>
<Key_SessionID>11077</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Chromosome Structure and Function in Health and Disease</PaperTitle>
<Paperdate>2017-12-12</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99264</Key_PaperID>
<Key_SessionID>11077</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Epigenetic Regulation in Normal and Malignant Hematopoiesis</PaperTitle>
<Paperdate>2017-12-12</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99265</Key_PaperID>
<Key_SessionID>11077</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Therapeutic Targeting of Chromatin</PaperTitle>
<Paperdate>2017-12-12</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99266</Key_PaperID>
<Key_SessionID>11078</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>North American Perspective</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99267</Key_PaperID>
<Key_SessionID>11078</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>European Perspective</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99268</Key_PaperID>
<Key_SessionID>11079</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	1:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:30 PM
 
</PaperStartTime>
<PaperTitle>Basic Science</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99269</Key_PaperID>
<Key_SessionID>11079</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:45 PM
 
</PaperStartTime>
<PaperTitle>Clinical Science/Translational Resarch</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99270</Key_PaperID>
<Key_SessionID>11080</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:15 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:00 AM
 
</PaperStartTime>
<PaperTitle>The Molecular Pathology of Pediatric Acute Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99271</Key_PaperID>
<Key_SessionID>11081</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Physician Stress and Burnout</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99273</Key_PaperID>
<Key_SessionID>11083</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>Health Care Quality: Overcoming Barriers to Evidence-Based Care</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99274</Key_PaperID>
<Key_SessionID>11083</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Implementation Science Research for Effective Guideline Implementation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99275</Key_PaperID>
<Key_SessionID>11083</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Implementation Is Practical:Examples of Successful, Large-Scale Guideline Implementations</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108897</Key_PaperID>
<Key_SessionID>11084</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>Reduction of inappropriate transfusions for patients with iron deficiency anemia (IDA) in the Emergency Department (ED) via guidelines and physician education</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108898</Key_PaperID>
<Key_SessionID>11084</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>will discuss a study aimed at decreasing off-labl use of rVIIa and PCCs</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>Improvement of compliance and utilization of recombinant VIIa, prothrombin complex concentrates (PCCs), and blood products</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108899</Key_PaperID>
<Key_SessionID>11084</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Reduction in admission rate for children with SCD presenting with vaso-occlusive crisis (VOC) via initiation of individualized pain plans (IPPs)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99276</Key_PaperID>
<Key_SessionID>11085</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) for treatment of HIT.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:40 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Introduction to ASH Guideline Initiatives</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99277</Key_PaperID>
<Key_SessionID>11085</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:55 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:50 AM
 
</PaperStartTime>
<PaperTitle>Panel on Prevention of VTE in Surgical Hospitalized Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99278</Key_PaperID>
<Key_SessionID>11085</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:55 AM
 
</PaperStartTime>
<PaperTitle>Panel on Prevention of VTE in Nonsurgical Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99279</Key_PaperID>
<Key_SessionID>11085</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:10 AM
 
</PaperStartTime>
<PaperTitle>Panel on Treatment of VTE</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99280</Key_PaperID>
<Key_SessionID>11085</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>PCC for DOAC related bleeding. LMWH therapy for bridge therapy.</OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:20 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Panel on Optimal Management of Anticoagulation Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99281</Key_PaperID>
<Key_SessionID>11085</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:25 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:20 AM
 
</PaperStartTime>
<PaperTitle>Panel on Prevention and Treatment of VTE in Patients With Cancer</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99282</Key_PaperID>
<Key_SessionID>11085</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:40 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:35 AM
 
</PaperStartTime>
<PaperTitle>Panel on Heparin-Induced Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99283</Key_PaperID>
<Key_SessionID>11085</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:10 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:05 AM
 
</PaperStartTime>
<PaperTitle>Panel on Thrombophilia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99284</Key_PaperID>
<Key_SessionID>11085</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>All anticoagulation therapy in pediatrics is off-label.  No particular brand name of anticoagulation is recommended in the VTE guidelines</OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:35 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Panel on VTE in Pediatric Populations</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99285</Key_PaperID>
<Key_SessionID>11085</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:25 AM
 
</PaperStartTime>
<PaperTitle>Panel on VTE in the Context of Pregnancy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99286</Key_PaperID>
<Key_SessionID>11085</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:05 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Panel on Diagnosis of VTE</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99599</Key_PaperID>
<Key_SessionID>11085</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:50 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:40 AM
 
</PaperStartTime>
<PaperTitle>Introduction to ASH VTE guidelines</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99288</Key_PaperID>
<Key_SessionID>11086</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Panel Discussion</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108907</Key_PaperID>
<Key_SessionID>11087</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>What is Therapy-Related Myeloid Neoplasm (t-MN)? A Look at History, Morphology, Cytogenetics, and Molecular Studies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108908</Key_PaperID>
<Key_SessionID>11087</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>Has Our Approach to Treatment Changed in the Era of Recently Approved Therapies?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108909</Key_PaperID>
<Key_SessionID>11087</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>How Do We Approach Transplant in the Era of Targeted Therapies?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108910</Key_PaperID>
<Key_SessionID>11087</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>What Tools Can We Use to Counsel Our Patients in the Setting of Novel Therapies?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109016</Key_PaperID>
<Key_SessionID>11088</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Multifaceted Strategy to Treat Sickle Cell Disease in Ghanaian Children</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99503</Key_PaperID>
<Key_SessionID>11089</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>The Art of Perception</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99289</Key_PaperID>
<Key_SessionID>11090</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Graft Versus Tumor Effects and Why People Relapse</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99290</Key_PaperID>
<Key_SessionID>11090</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Checkpoint inhibitors for post BMT relapse
Sorafenib for post BMT maintenance 
Lenalidamid for post BMT maintenance
HMAs for post BMT maintenance  </OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Drugs to Prevent and Treat Relapse Following Allogeneic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99291</Key_PaperID>
<Key_SessionID>11090</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Cells to Prevent and Treat Relapse Following Allogeneic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99289</Key_PaperID>
<Key_SessionID>11090</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		3:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		2:45 PM
	
 
</PaperStartTime>
<PaperTitle>Graft Versus Tumor Effects and Why People Relapse</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99290</Key_PaperID>
<Key_SessionID>11090</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Checkpoint inhibitors for post BMT relapse
Sorafenib for post BMT maintenance 
Lenalidamid for post BMT maintenance
HMAs for post BMT maintenance  </OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:45 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:15 PM
	
 
</PaperStartTime>
<PaperTitle>Drugs to Prevent and Treat Relapse Following Allogeneic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99291</Key_PaperID>
<Key_SessionID>11090</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		4:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:45 PM
	
 
</PaperStartTime>
<PaperTitle>Cells to Prevent and Treat Relapse Following Allogeneic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99292</Key_PaperID>
<Key_SessionID>11091</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Premalignant Pediatric Hematologic Disorders: When to Treat and How</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99293</Key_PaperID>
<Key_SessionID>11091</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Crisis Management in the Treatment of Childhood Acute Lymphocytic Leukemia: Putting Right What Can Go Wrong (Emergency Complications of Disease and Treatment)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99294</Key_PaperID>
<Key_SessionID>11091</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Incorporation of Non-Chemotherapeutic Agents in Pediatric Acute Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99292</Key_PaperID>
<Key_SessionID>11091</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		7:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:00 AM
	
 
</PaperStartTime>
<PaperTitle>Premalignant Pediatric Hematologic Disorders: When to Treat and How</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99293</Key_PaperID>
<Key_SessionID>11091</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		8:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:30 AM
	
 
</PaperStartTime>
<PaperTitle>Crisis Management in the Treatment of Childhood Acute Lymphocytic Leukemia: Putting Right What Can Go Wrong (Emergency Complications of Disease and Treatment)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99294</Key_PaperID>
<Key_SessionID>11091</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		8:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		8:00 AM
	
 
</PaperStartTime>
<PaperTitle>Incorporation of Non-Chemotherapeutic Agents in Pediatric Acute Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99295</Key_PaperID>
<Key_SessionID>11092</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Management of Multiple Myeloma in the Relapsed/Refractory Patient</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99296</Key_PaperID>
<Key_SessionID>11092</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Carfilzomib, Ixazomib, pomalidomide and daratumumab are not approved to be used in the upfront setting</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Management of Multiple Myeloma in the Newly Diagnosed Patient</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99297</Key_PaperID>
<Key_SessionID>11092</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Emerging Options in Multiple Myeloma: Targeted, Immune, and Epigenetic Therapies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99295</Key_PaperID>
<Key_SessionID>11092</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:45 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:15 PM
	
 
</PaperStartTime>
<PaperTitle>Management of Multiple Myeloma in the Relapsed/Refractory Patient</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99296</Key_PaperID>
<Key_SessionID>11092</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Carfilzomib, Ixazomib, pomalidomide and daratumumab are not approved to be used in the upfront setting</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		3:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		2:45 PM
	
 
</PaperStartTime>
<PaperTitle>Management of Multiple Myeloma in the Newly Diagnosed Patient</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99297</Key_PaperID>
<Key_SessionID>11092</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		4:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:45 PM
	
 
</PaperStartTime>
<PaperTitle>Emerging Options in Multiple Myeloma: Targeted, Immune, and Epigenetic Therapies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99298</Key_PaperID>
<Key_SessionID>11093</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Lenalidomid, carfilzomib, and dexamethasone which has been used in clinical trials for smoldering multiple myeloma. I will review and discuss these papers.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Should Smoldering Myeloma Be Treated?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99299</Key_PaperID>
<Key_SessionID>11093</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Is Molecular Remission the Goal of Multiple Myeloma Therapy?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99300</Key_PaperID>
<Key_SessionID>11093</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Bortezomib as consolidation and maintenance therapy
Carfilzomib-Lenalidomide-Dexamethasone for continued therapy
Thalidomide, Lenalidomide and Bortezomib in various combinations for consolidation and/or maintenance therapy</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Continuous Versus Fixed Duration Therapy in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99298</Key_PaperID>
<Key_SessionID>11093</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Lenalidomid, carfilzomib, and dexamethasone which has been used in clinical trials for smoldering multiple myeloma. I will review and discuss these papers.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Should Smoldering Myeloma Be Treated?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99299</Key_PaperID>
<Key_SessionID>11093</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		11:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:00 AM
	
 
</PaperStartTime>
<PaperTitle>Is Molecular Remission the Goal of Multiple Myeloma Therapy?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99300</Key_PaperID>
<Key_SessionID>11093</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Bortezomib as consolidation and maintenance therapy
Carfilzomib-Lenalidomide-Dexamethasone for continued therapy
Thalidomide, Lenalidomide and Bortezomib in various combinations for consolidation and/or maintenance therapy</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		12:00 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:30 AM
	
 
</PaperStartTime>
<PaperTitle>Continuous Versus Fixed Duration Therapy in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99301</Key_PaperID>
<Key_SessionID>11094</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Uncoding the Genetic Heterogeneity of MDS</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99302</Key_PaperID>
<Key_SessionID>11094</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Current Treatment Algorithm for the Management of MDS</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99303</Key_PaperID>
<Key_SessionID>11094</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>I will be discussing investigational drugs in the treatment of MDS including novel formulations of azanuclesoides, novel epigenomic modulators, combinations involving immune checkpoint inhibitors, agents targeting specific genotypic subsets, kinase inhibitors and BCL2 inhibitors.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Incorporating Novel Approaches in the Management of MDS Beyond Hypomethylating Agents</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99301</Key_PaperID>
<Key_SessionID>11094</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Uncoding the Genetic Heterogeneity of MDS</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99302</Key_PaperID>
<Key_SessionID>11094</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		11:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:00 AM
	
 
</PaperStartTime>
<PaperTitle>Current Treatment Algorithm for the Management of MDS</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99303</Key_PaperID>
<Key_SessionID>11094</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>I will be discussing investigational drugs in the treatment of MDS including novel formulations of azanuclesoides, novel epigenomic modulators, combinations involving immune checkpoint inhibitors, agents targeting specific genotypic subsets, kinase inhibitors and BCL2 inhibitors.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		12:00 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:30 AM
	
 
</PaperStartTime>
<PaperTitle>Incorporating Novel Approaches in the Management of MDS Beyond Hypomethylating Agents</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99304</Key_PaperID>
<Key_SessionID>11095</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Where Did It Start? Mutation Order and What It Means in MPN</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99305</Key_PaperID>
<Key_SessionID>11095</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Interferon</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>What Are the Current Treatment Approaches for Patients With Polycythemia Vera and Essential Thrombocythemia?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99306</Key_PaperID>
<Key_SessionID>11095</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Current Treatment Algorithm for the Management of Patients With Myelofibrosis, JAK Inhibitors, and Beyond</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99304</Key_PaperID>
<Key_SessionID>11095</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		3:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		2:45 PM
	
 
</PaperStartTime>
<PaperTitle>Where Did It Start? Mutation Order and What It Means in MPN</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99305</Key_PaperID>
<Key_SessionID>11095</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Interferon</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:45 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:15 PM
	
 
</PaperStartTime>
<PaperTitle>What Are the Current Treatment Approaches for Patients With Polycythemia Vera and Essential Thrombocythemia?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99306</Key_PaperID>
<Key_SessionID>11095</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		4:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:45 PM
	
 
</PaperStartTime>
<PaperTitle>Current Treatment Algorithm for the Management of Patients With Myelofibrosis, JAK Inhibitors, and Beyond</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99307</Key_PaperID>
<Key_SessionID>11096</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Treatment-Free Remission: Who, How, and Why?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99308</Key_PaperID>
<Key_SessionID>11096</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>TKI-Associated Cardiovascular Toxicity: What to Consider</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99309</Key_PaperID>
<Key_SessionID>11096</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Novel Approaches to Therapy in CML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99307</Key_PaperID>
<Key_SessionID>11096</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		2:30 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		2:00 PM
	
 
</PaperStartTime>
<PaperTitle>Treatment-Free Remission: Who, How, and Why?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99308</Key_PaperID>
<Key_SessionID>11096</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:00 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		2:30 PM
	
 
</PaperStartTime>
<PaperTitle>TKI-Associated Cardiovascular Toxicity: What to Consider</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99309</Key_PaperID>
<Key_SessionID>11096</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		3:30 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:00 PM
	
 
</PaperStartTime>
<PaperTitle>Novel Approaches to Therapy in CML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99310</Key_PaperID>
<Key_SessionID>11097</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Implications of Minimal Residual Disease in Adult ALL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99311</Key_PaperID>
<Key_SessionID>11097</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off label use of ponatinib and blinatumomab</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Current Management of Philadelphia Chromosome Positive ALL and the Role of Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99312</Key_PaperID>
<Key_SessionID>11097</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>How Should We Incorporate Novel Therapies Into the Management of ALL?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99310</Key_PaperID>
<Key_SessionID>11097</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Implications of Minimal Residual Disease in Adult ALL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99311</Key_PaperID>
<Key_SessionID>11097</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off label use of ponatinib and blinatumomab</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		11:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:00 AM
	
 
</PaperStartTime>
<PaperTitle>Current Management of Philadelphia Chromosome Positive ALL and the Role of Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99312</Key_PaperID>
<Key_SessionID>11097</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		12:00 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:30 AM
	
 
</PaperStartTime>
<PaperTitle>How Should We Incorporate Novel Therapies Into the Management of ALL?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99313</Key_PaperID>
<Key_SessionID>11098</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Classification and Risk Assessment in AML: Integrating Cytogenetics and Molecular Profiling</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99314</Key_PaperID>
<Key_SessionID>11098</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>How and When to Decide Between Epigenetic Therapy and Chemotherapy in Patients With AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99315</Key_PaperID>
<Key_SessionID>11098</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This presentation includes novel agents in clinical development that do not yet have label indications in AML.  Use of sorafenib, azacitidine, or decitabine for AML therapy is off label.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Role of Targeted Therapy in the Management of Patients With AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99313</Key_PaperID>
<Key_SessionID>11098</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		7:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:00 AM
	
 
</PaperStartTime>
<PaperTitle>Classification and Risk Assessment in AML: Integrating Cytogenetics and Molecular Profiling</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99314</Key_PaperID>
<Key_SessionID>11098</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		8:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:30 AM
	
 
</PaperStartTime>
<PaperTitle>How and When to Decide Between Epigenetic Therapy and Chemotherapy in Patients With AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99315</Key_PaperID>
<Key_SessionID>11098</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This presentation includes novel agents in clinical development that do not yet have label indications in AML.  Use of sorafenib, azacitidine, or decitabine for AML therapy is off label.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		8:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		8:00 AM
	
 
</PaperStartTime>
<PaperTitle>Role of Targeted Therapy in the Management of Patients With AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99316</Key_PaperID>
<Key_SessionID>11099</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>The Mutational Landscape of CLL and Its Impact on Prognosis and Treatment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99317</Key_PaperID>
<Key_SessionID>11099</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Optimizing Frontline Therapy of CLL Based on Clinical and Biological Factors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99318</Key_PaperID>
<Key_SessionID>11099</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>venetoclax</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>How Should We Sequence and Combine Novel Therapies in CLL?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99316</Key_PaperID>
<Key_SessionID>11099</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		7:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:00 AM
	
 
</PaperStartTime>
<PaperTitle>The Mutational Landscape of CLL and Its Impact on Prognosis and Treatment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99317</Key_PaperID>
<Key_SessionID>11099</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		8:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		7:30 AM
	
 
</PaperStartTime>
<PaperTitle>Optimizing Frontline Therapy of CLL Based on Clinical and Biological Factors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99318</Key_PaperID>
<Key_SessionID>11099</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>venetoclax</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		8:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		8:00 AM
	
 
</PaperStartTime>
<PaperTitle>How Should We Sequence and Combine Novel Therapies in CLL?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99319</Key_PaperID>
<Key_SessionID>11100</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Biology of CNS Lymphoma and the Potential of Novel Agents</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99320</Key_PaperID>
<Key_SessionID>11100</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Thiotepa, temsirolimus, lenalidomide, ibrutinib.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Therapy of Primary CNS Lymphoma: Role of Intensity, Radiation, and Novel Agents</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99321</Key_PaperID>
<Key_SessionID>11100</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>CNS lymphoma: lenalidomide, ibrutinib, rituximab, nivolumab</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CNS Prophylaxis for Lymphoma: Who, What, and When?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99319</Key_PaperID>
<Key_SessionID>11100</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Biology of CNS Lymphoma and the Potential of Novel Agents</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99320</Key_PaperID>
<Key_SessionID>11100</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Thiotepa, temsirolimus, lenalidomide, ibrutinib.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		11:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:00 AM
	
 
</PaperStartTime>
<PaperTitle>Therapy of Primary CNS Lymphoma: Role of Intensity, Radiation, and Novel Agents</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99321</Key_PaperID>
<Key_SessionID>11100</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>CNS lymphoma: lenalidomide, ibrutinib, rituximab, nivolumab</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		12:00 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:30 AM
	
 
</PaperStartTime>
<PaperTitle>CNS Prophylaxis for Lymphoma: Who, What, and When?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99322</Key_PaperID>
<Key_SessionID>11101</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Role of the Microenvironment Across Histological Subtypes of NHL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99323</Key_PaperID>
<Key_SessionID>11101</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Harnessing the Power of the Immune System in NHL: Immunomodulators, Checkpoint Inhibitors, and Beyond</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99324</Key_PaperID>
<Key_SessionID>11101</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Cellular Immunotherapy for NHL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99322</Key_PaperID>
<Key_SessionID>11101</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		10:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		9:30 AM
	
 
</PaperStartTime>
<PaperTitle>Role of the Microenvironment Across Histological Subtypes of NHL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99323</Key_PaperID>
<Key_SessionID>11101</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		10:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:00 AM
	
 
</PaperStartTime>
<PaperTitle>Harnessing the Power of the Immune System in NHL: Immunomodulators, Checkpoint Inhibitors, and Beyond</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99324</Key_PaperID>
<Key_SessionID>11101</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Cellular Immunotherapy for NHL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99325</Key_PaperID>
<Key_SessionID>11102</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Tailoring Frontline Therapy in Diffuse Large B-Cell Lymphoma: Who Should We Treat Differently?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99326</Key_PaperID>
<Key_SessionID>11102</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Primary Mediastinal B Cell Lymphoma: Biology and Evolving Therapeutic Strategies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99327</Key_PaperID>
<Key_SessionID>11102</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Optimizing Therapy in Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99325</Key_PaperID>
<Key_SessionID>11102</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		3:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		2:45 PM
	
 
</PaperStartTime>
<PaperTitle>Tailoring Frontline Therapy in Diffuse Large B-Cell Lymphoma: Who Should We Treat Differently?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99326</Key_PaperID>
<Key_SessionID>11102</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:45 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:15 PM
	
 
</PaperStartTime>
<PaperTitle>Primary Mediastinal B Cell Lymphoma: Biology and Evolving Therapeutic Strategies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99327</Key_PaperID>
<Key_SessionID>11102</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		4:15 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		3:45 PM
	
 
</PaperStartTime>
<PaperTitle>Optimizing Therapy in Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99328</Key_PaperID>
<Key_SessionID>11103</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Only in the context of clinical trials.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Insights Into Hodgkin Lymphoma Biology: Implications for Prognosis and Novel Therapeutics</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99329</Key_PaperID>
<Key_SessionID>11103</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>brentuximab vedotin, nivolumab and pembrolizumab in clinical trials in earlier lines of HL therapy </OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Emerging Role of Novel Therapies in Hodgkin Lymphoma: Proceed With Caution</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99330</Key_PaperID>
<Key_SessionID>11103</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Chemotherapy and anti-CD20 antibody treatment in NLPHL</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Unique Disease Deserving Unique Management</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99328</Key_PaperID>
<Key_SessionID>11103</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Only in the context of clinical trials.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Insights Into Hodgkin Lymphoma Biology: Implications for Prognosis and Novel Therapeutics</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99329</Key_PaperID>
<Key_SessionID>11103</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>brentuximab vedotin, nivolumab and pembrolizumab in clinical trials in earlier lines of HL therapy </OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		11:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:00 AM
	
 
</PaperStartTime>
<PaperTitle>Emerging Role of Novel Therapies in Hodgkin Lymphoma: Proceed With Caution</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99330</Key_PaperID>
<Key_SessionID>11103</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Chemotherapy and anti-CD20 antibody treatment in NLPHL</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		12:00 PM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		11:30 AM
	
 
</PaperStartTime>
<PaperTitle>Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Unique Disease Deserving Unique Management</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99331</Key_PaperID>
<Key_SessionID>11104</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Follicular Lymphoma: Are We Ready for a Risk-Adapted Approach?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99332</Key_PaperID>
<Key_SessionID>11104</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Bortezomib, carfilzomib, venetoclax, daratumumab and ixazomib are not approved for the treatment of patients with Waldenstrom.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Biology and Management of Lymphoplasmacytic Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99333</Key_PaperID>
<Key_SessionID>11104</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Update on Nodal and Primary Splenic Marginal Zone Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99331</Key_PaperID>
<Key_SessionID>11104</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		10:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		9:30 AM
	
 
</PaperStartTime>
<PaperTitle>Follicular Lymphoma: Are We Ready for a Risk-Adapted Approach?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99332</Key_PaperID>
<Key_SessionID>11104</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Bortezomib, carfilzomib, venetoclax, daratumumab and ixazomib are not approved for the treatment of patients with Waldenstrom.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		10:30 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:00 AM
	
 
</PaperStartTime>
<PaperTitle>Biology and Management of Lymphoplasmacytic Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99333</Key_PaperID>
<Key_SessionID>11104</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Update on Nodal and Primary Splenic Marginal Zone Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99334</Key_PaperID>
<Key_SessionID>11105</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>1. CD19 CAR T cells for the treatment of B-cell malignancies
2. Tocilizumab for the management of severe cytokine release syndrome</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Toxicities of Chimeric Antigen Receptor T Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99335</Key_PaperID>
<Key_SessionID>11105</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Toxicities of Checkpoint Inhibitors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99337</Key_PaperID>
<Key_SessionID>11106</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-16</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Genome Editing Strategies to Treat Beta-Hemoglobinopathies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99337</Key_PaperID>
<Key_SessionID>11106</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		10:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-16</PaperNumber>
<PaperStartTime>
	
	
	
		9:30 AM
	
 
</PaperStartTime>
<PaperTitle>Genome Editing Strategies to Treat Beta-Hemoglobinopathies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99339</Key_PaperID>
<Key_SessionID>11106</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-17</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>In Situ Capture of the Molecular Composition of Erythroid Transcriptional Enhancers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99339</Key_PaperID>
<Key_SessionID>11106</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		10:30 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-17</PaperNumber>
<PaperStartTime>
	
	
	
		10:00 AM
	
 
</PaperStartTime>
<PaperTitle>In Situ Capture of the Molecular Composition of Erythroid Transcriptional Enhancers</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99343</Key_PaperID>
<Key_SessionID>11106</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Deferasirox</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-18</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Delayed Globin Synthesis Leads to Excessive Heme and the Macrocytic Anemia of Diamond Blackfan Anemia and del(5q) Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99343</Key_PaperID>
<Key_SessionID>11106</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Deferasirox</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-18</PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Delayed Globin Synthesis Leads to Excessive Heme and the Macrocytic Anemia of Diamond Blackfan Anemia and del(5q) Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99386</Key_PaperID>
<Key_SessionID>11107</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-19</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Gene Therapy: Where We Started and Where the Field is Going</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99386</Key_PaperID>
<Key_SessionID>11107</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		2:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-19</PaperNumber>
<PaperStartTime>
	
	
	
		2:00 PM
	
 
</PaperStartTime>
<PaperTitle>Gene Therapy: Where We Started and Where the Field is Going</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99345</Key_PaperID>
<Key_SessionID>11107</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-20</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Valine as a Key Metabolic Regulator of Hematopoietic Stem Cell Maintenance</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99345</Key_PaperID>
<Key_SessionID>11107</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		3:00 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-20</PaperNumber>
<PaperStartTime>
	
	
	
		2:30 PM
	
 
</PaperStartTime>
<PaperTitle>Valine as a Key Metabolic Regulator of Hematopoietic Stem Cell Maintenance</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99346</Key_PaperID>
<Key_SessionID>11107</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-21</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Novel Conditioning Regimens for Blood Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99346</Key_PaperID>
<Key_SessionID>11107</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		3:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-21</PaperNumber>
<PaperStartTime>
	
	
	
		3:00 PM
	
 
</PaperStartTime>
<PaperTitle>Novel Conditioning Regimens for Blood Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99348</Key_PaperID>
<Key_SessionID>11108</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-10</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Thrombosis-on-a-Chip: A New Way to Model a Complex Process</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99348</Key_PaperID>
<Key_SessionID>11108</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		8:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-10</PaperNumber>
<PaperStartTime>
	
	
	
		7:30 AM
	
 
</PaperStartTime>
<PaperTitle>Thrombosis-on-a-Chip: A New Way to Model a Complex Process</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99349</Key_PaperID>
<Key_SessionID>11108</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-11</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Magnetically Powered Microbots: A Novel Approach to Thrombolysis?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99349</Key_PaperID>
<Key_SessionID>11108</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		8:30 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-11</PaperNumber>
<PaperStartTime>
	
	
	
		8:00 AM
	
 
</PaperStartTime>
<PaperTitle>Magnetically Powered Microbots: A Novel Approach to Thrombolysis?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99350</Key_PaperID>
<Key_SessionID>11108</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-12</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Engineered Blood Vessels</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99350</Key_PaperID>
<Key_SessionID>11108</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		9:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-12</PaperNumber>
<PaperStartTime>
	
	
	
		8:30 AM
	
 
</PaperStartTime>
<PaperTitle>Engineered Blood Vessels</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99351</Key_PaperID>
<Key_SessionID>11109</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-31</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Novel Glycan Dependent Platelet Clearance Mechanisms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99351</Key_PaperID>
<Key_SessionID>11109</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		4:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-31</PaperNumber>
<PaperStartTime>
	
	
	
		4:00 PM
	
 
</PaperStartTime>
<PaperTitle>Novel Glycan Dependent Platelet Clearance Mechanisms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99352</Key_PaperID>
<Key_SessionID>11109</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-32</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Targeting Hemorrhage: Alternative Storage of Platelets for Hemostatic Transfusion</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99352</Key_PaperID>
<Key_SessionID>11109</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		5:00 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-32</PaperNumber>
<PaperStartTime>
	
	
	
		4:30 PM
	
 
</PaperStartTime>
<PaperTitle>Targeting Hemorrhage: Alternative Storage of Platelets for Hemostatic Transfusion</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99353</Key_PaperID>
<Key_SessionID>11109</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-33</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Splenic Mechanisms of Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99353</Key_PaperID>
<Key_SessionID>11109</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		5:30 PM
	
 
</PaperEndTime>
<PaperNumber>SCI-33</PaperNumber>
<PaperStartTime>
	
	
	
		5:00 PM
	
 
</PaperStartTime>
<PaperTitle>Splenic Mechanisms of Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99354</Key_PaperID>
<Key_SessionID>11110</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-34</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>T-Cell Memory and Exhaustion</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99354</Key_PaperID>
<Key_SessionID>11110</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	
	
	
		10:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-34</PaperNumber>
<PaperStartTime>
	
	
	
		9:30 AM
	
 
</PaperStartTime>
<PaperTitle>T-Cell Memory and Exhaustion</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99355</Key_PaperID>
<Key_SessionID>11110</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>SCI-35</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Biology of PD-1 Checkpoint Blockade</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99355</Key_PaperID>
<Key_SessionID>11110</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	
	
	
		10:30 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-35</PaperNumber>
<PaperStartTime>
	
	
	
		10:00 AM
	
 
</PaperStartTime>
<PaperTitle>Biology of PD-1 Checkpoint Blockade</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99465</Key_PaperID>
<Key_SessionID>11110</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>SCI-36</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Biology of LAG3 Checkpoint Blockade</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>B</Key_AorB>
<Key_PaperID>99465</Key_PaperID>
<Key_SessionID>11110</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	
	
	
		11:00 AM
	
 
</PaperEndTime>
<PaperNumber>SCI-36</PaperNumber>
<PaperStartTime>
	
	
	
		10:30 AM
	
 
</PaperStartTime>
<PaperTitle>Biology of LAG3 Checkpoint Blockade</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99357</Key_PaperID>
<Key_SessionID>11111</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Investigational inhibitors of activated kinases in AML</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Targeting Somatic Kinase Mutations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99358</Key_PaperID>
<Key_SessionID>11111</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Targeting the Epigenome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99359</Key_PaperID>
<Key_SessionID>11111</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Targeting Regulators of Differentiation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99361</Key_PaperID>
<Key_SessionID>11112</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Genome Organization Drives Chromosome Fragility</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99362</Key_PaperID>
<Key_SessionID>11112</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>DNA Repair Targets in Bone Marrow Failure and Cancer</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99363</Key_PaperID>
<Key_SessionID>11112</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting DNA Damage and Repair in Cancer: Bench to Bedside in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99366</Key_PaperID>
<Key_SessionID>11113</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:55 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting Activated Protein C to Treat Hemophilia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99371</Key_PaperID>
<Key_SessionID>11113</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>I will discuss the use of two inhibitors of the tyrosine kinase Btk in my talk. I will refer to them by the names that they are known in the literature</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:20 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:55 PM
 
</PaperStartTime>
<PaperTitle>Targeting ITAM Receptors in Disease With Ibrutinib and Other Tyrosine Kinase Inhibitors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99372</Key_PaperID>
<Key_SessionID>11113</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:20 PM
 
</PaperStartTime>
<PaperTitle>Initiation of Surface-Mediated Thrombosis Events</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108954</Key_PaperID>
<Key_SessionID>11113</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	6:10 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Best of ASH in Hemostasis and Thrombosis 1</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108955</Key_PaperID>
<Key_SessionID>11113</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:20 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	6:10 PM
 
</PaperStartTime>
<PaperTitle>Best of ASH in Hemostasis and Thrombosis 2</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108956</Key_PaperID>
<Key_SessionID>11113</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	6:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	6:20 PM
 
</PaperStartTime>
<PaperTitle>Best of ASH in Hemostasis and Thrombosis 3</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104277</Key_PaperID>
<Key_SessionID>11113</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>547</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Identification of a VWFA1 Mutation Attenuating Thrombus Growth but Not Platelet Adhesion</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99375</Key_PaperID>
<Key_SessionID>11114</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Clonal Hematopoiesis Influences Cardiovascular Risk</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99376</Key_PaperID>
<Key_SessionID>11114</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Sex Matters: The Hormonal Milieu Regulates Thrombosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99377</Key_PaperID>
<Key_SessionID>11114</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Lipids, Hematopoiesis, and Athero-Thrombosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99378</Key_PaperID>
<Key_SessionID>11115</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Gut Microbes, Platelet Function and Thrombosis Risk</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99381</Key_PaperID>
<Key_SessionID>11115</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Microbiome Metabolites Regulate Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99384</Key_PaperID>
<Key_SessionID>11116</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Finding Driver Variants in Leukemia Genomic Datasets</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99385</Key_PaperID>
<Key_SessionID>11116</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Statistical and Genomic Approaches in Rare Disease Research</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99391</Key_PaperID>
<Key_SessionID>11139</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>Statistics and Trial Design</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99507</Key_PaperID>
<Key_SessionID>11140</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Didactic Session 2: Non-Traditional Career Development: FDA</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99508</Key_PaperID>
<Key_SessionID>11140</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>Didactic Session 2: Non-Traditional Career Development: NHLBI</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99981</Key_PaperID>
<Key_SessionID>11140</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Didactic Session 2: Non-Traditional Career Development: Pharmaceutical Industry</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99394</Key_PaperID>
<Key_SessionID>11142</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	1:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:30 PM
 
</PaperStartTime>
<PaperTitle>Breakout Rotation 1: Statistical Considerations for Basic/Translational / Phase I Trials</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99510</Key_PaperID>
<Key_SessionID>11143</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	1:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:30 PM
 
</PaperStartTime>
<PaperTitle>Breakout Rotation 1: Statistics and Trial Design; Statistical Considerations in Phase II/III Clinical Trials</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99392</Key_PaperID>
<Key_SessionID>11144</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	1:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:30 PM
 
</PaperStartTime>
<PaperTitle>Breakout Rotation 1: Statistical Considerations in Health Outcomes and Clinical Effectiveness Research</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99395</Key_PaperID>
<Key_SessionID>11145</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Investigational agents for the treatment of malignancies</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Breakout Rotation 2: Research Teams in Translational Studies (including optimizing partners in the lab)</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99504</Key_PaperID>
<Key_SessionID>11159</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Time Management and Balance: Adult/ Clinical</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99506</Key_PaperID>
<Key_SessionID>11160</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Trainee Didactic Session: Drug Development</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99400</Key_PaperID>
<Key_SessionID>11161</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>How to Build a Research Team; Research Teams in Clinical Trials</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99401</Key_PaperID>
<Key_SessionID>11162</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>How to Build a Research Team; Research Teams in Health Outcomes and Clinical Effectiveness Research</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99405</Key_PaperID>
<Key_SessionID>11163</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>How to Set-up a Laboratory Research Program</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99404</Key_PaperID>
<Key_SessionID>11164</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Bridging the Translational Divide</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99406</Key_PaperID>
<Key_SessionID>11177</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Knowles Adult Learning Theory</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99407</Key_PaperID>
<Key_SessionID>11177</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>The Flipped Classroom: Pros</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99408</Key_PaperID>
<Key_SessionID>11177</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>The Flipped Classroom: Cons</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99409</Key_PaperID>
<Key_SessionID>11177</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>An Overview of Qualitative Research Methodology</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99410</Key_PaperID>
<Key_SessionID>11177</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>ASH Medical Educators Institute Spotlight</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99412</Key_PaperID>
<Key_SessionID>11178</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>How to Change Your K to an R</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99474</Key_PaperID>
<Key_SessionID>11178</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>How to Get Your First Grant</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99477</Key_PaperID>
<Key_SessionID>11178</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>How to Respond to the Pain of Reviewers' Critiques</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99414</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Clinical Malignant Hematology/ BMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99416</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Clinical Malignant Hematology/ BMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99418</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>Clinical Non-Malignant Hematology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99419</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Non-Malignant Hematology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99422</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Laboratory &amp; Translational Hematology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99423</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>Laboratory &amp; Translational Hematology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99426</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>Industry Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99427</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>Industry Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99430</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>Government Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99431</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	1:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:30 PM
 
</PaperStartTime>
<PaperTitle>Government Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99434</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	2:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:45 PM
 
</PaperStartTime>
<PaperTitle>Pediatric Hematology/ Oncology Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99435</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Pediatric Hematology/ Oncology Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99438</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>Medical Educators in Hematology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99440</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Medical Educators in Hematology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99443</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Transfusion Medicine</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99444</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Transfusion Medicine</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99448</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Careers in Hematology (Private Practice Careers)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99457</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>PhD Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99459</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>PhD Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99461</Key_PaperID>
<Key_SessionID>11181</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Clinical Careers in Hematology (Private Practice Careers)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99415</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Clinical Malignant Hematology/ BMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99417</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Clinical Malignant Hematology/ BMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99420</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>Clinical Non-malignant Hematology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99421</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Non-malignant Hematology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99424</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>Laboratory &amp; Translational Hematology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99428</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>Industry Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99429</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>Industry Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99432</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>Government Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99433</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	1:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:30 PM
 
</PaperStartTime>
<PaperTitle>Government Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99436</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	2:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:45 PM
 
</PaperStartTime>
<PaperTitle>Pediatric Hematology/ Oncology Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99437</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Pediatric Hematology/ Oncology Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99441</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Medical Educators in Hematology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99442</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>Medical Educators in Hematology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99445</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Transfusion Medicine</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99446</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Transfusion Medicine</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99458</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>PhD Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99460</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>PhD Careers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99462</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Clinical Careers in Hematology (Private Practice Careers)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99463</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Careers in Hematology (Private Practice Careers)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108943</Key_PaperID>
<Key_SessionID>11182</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Laboratory &amp; Translational  Hematology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99450</Key_PaperID>
<Key_SessionID>11231</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>The working group would like to invite Dr. Christian Cable back to lead another session regarding the Accreditation Council for Graduate Medical Education (ACGME). As Dr. Cable is a former hematology/oncology training program director himself and is now serving as the chair of the ACGMEs Residency Review Committee, it is an especially useful session for the program directors. (45 minutes)</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>ACGME Update 2017</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99451</Key_PaperID>
<Key_SessionID>11231</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>How to have an effective career development talk with fellows, with a focus on counseling fellows for careers in hematology. Scenarios that will be covered include Should I double-board? Lab based science vs. clinical research.  There will be two speakers for this session and the session will include table top exercises which will take the place of the breakout sessions.  (75 minutes) </OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Having The Talk With Fellows</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99452</Key_PaperID>
<Key_SessionID>11231</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>This session will be a chance to refocus on the basics of a hematology fellowship  teaching hematology to fellows. The speakers will share innovated tools theyve employed. There will be two speakers for this session and the session will include table top exercises which will take the place of the breakout sessions.  (105 minutes) </OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>Its in Our Blood</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99550</Key_PaperID>
<Key_SessionID>11316</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:10 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:40 AM
 
</PaperStartTime>
<PaperTitle>Anemias in Pregnancy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99553</Key_PaperID>
<Key_SessionID>11316</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:40 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:10 AM
 
</PaperStartTime>
<PaperTitle>Sickle Cell Disease in Adults: What does the consultant hematologist need to know?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99554</Key_PaperID>
<Key_SessionID>11316</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	9:10 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	8:40 AM
 
</PaperStartTime>
<PaperTitle>Hematologic Manifestations of Rheumatologic Disease &amp; Vice Versa</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99555</Key_PaperID>
<Key_SessionID>11316</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	10:10 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:40 AM
 
</PaperStartTime>
<PaperTitle>Uncommon Coagulopathies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99556</Key_PaperID>
<Key_SessionID>11316</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	10:40 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:10 AM
 
</PaperStartTime>
<PaperTitle>Eosinophilia &amp; Mastocytosis: The Other White Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99558</Key_PaperID>
<Key_SessionID>11316</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	11:10 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	10:40 AM
 
</PaperStartTime>
<PaperTitle>Thrombosis in Unusual Places</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99560</Key_PaperID>
<Key_SessionID>11316</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Registration</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99562</Key_PaperID>
<Key_SessionID>11316</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:40 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Welcoming Remarks</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99563</Key_PaperID>
<Key_SessionID>11316</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	11:25 AM
 
</PaperStartTime>
<PaperTitle>Concluding Remarks</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99564</Key_PaperID>
<Key_SessionID>11316</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:25 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:10 AM
 
</PaperStartTime>
<PaperTitle>Panel Discussion I</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99565</Key_PaperID>
<Key_SessionID>11316</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	9:40 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	9:25 AM
 
</PaperStartTime>
<PaperTitle>Coffee and Networking Break</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99566</Key_PaperID>
<Key_SessionID>11316</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	11:25 AM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	11:10 AM
 
</PaperStartTime>
<PaperTitle>Panel Discussion II</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107457</Key_PaperID>
<Key_SessionID>11475</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>78</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Nemo-like Kinase Hyper-Activated in Erythroid Progenitors in Models of Diamond Blackfan Anemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108518</Key_PaperID>
<Key_SessionID>11475</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>79</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Hscb, a Mitochondrial Iron-Sulfur Cluster Assembly Co-Chaperone, Is a Novel Candidate Gene for Congenital Sideroblastic Anemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106170</Key_PaperID>
<Key_SessionID>11475</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>80</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Overlap of SEC23A and SEC23B Function Suggests a Novel Therapeutic Approach for Congenital Dyserythropoietic Anemia Type II</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107829</Key_PaperID>
<Key_SessionID>11475</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>81</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Megakaryocytic TGF1 Partitions Hematopoiesis into Amplifying Stem and Progenitor Cells and Maturing Effector Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103069</Key_PaperID>
<Key_SessionID>11475</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>82</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Hematopoietic-Specific CSNK2B Loss in Mice Causes Impaired Erythropoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106665</Key_PaperID>
<Key_SessionID>11475</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>83</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Ribosome Biogenesis Controls Erythroid Differentiation Via a p53-Dependent Transcriptional Checkpoint and Its Limitation By RPS14 Haploinsufficiency Results in Selective Defects in Translation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104681</Key_PaperID>
<Key_SessionID>11476</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>10</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Deubiquitinase USP7 Regulates Erythroid Development Via Deubiquinating GATA1</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108707</Key_PaperID>
<Key_SessionID>11476</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>11</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Acute Deletion of Tet2 or Tet3 Transiently Dysregulate Murine Erythropoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105856</Key_PaperID>
<Key_SessionID>11476</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>12</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>A Pharmacologic Approach Using Pomalidomide and Dexamethasone to Study Stage-Specific Regulation of Erythroid Progenitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107342</Key_PaperID>
<Key_SessionID>11476</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>7</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Integrating Enhancer Mechanisms to Establish a Hierarchical Blood Development Program</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103368</Key_PaperID>
<Key_SessionID>11476</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>8</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>RGL2 Deficiency Impairs Human Erythropoiesis By Altering Terminal Erythroid Differentiation and Apoptosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104153</Key_PaperID>
<Key_SessionID>11476</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>9</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Fyn Kinase Is Involved in EPO Receptor Signaling and Is Required to Harmonize the Response to Oxidation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104429</Key_PaperID>
<Key_SessionID>11477</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>223</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>NCOA4 Links Iron Bioavailability to DNA Metabolism</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100768</Key_PaperID>
<Key_SessionID>11477</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>224</PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>The Macrophage Nuclear Receptor Coactivator 4 Counteracts Iron-Deficiency Anemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106041</Key_PaperID>
<Key_SessionID>11477</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>225</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>NCOA4 Acts in Hepatocytes to Regulate Ferritin Subunit Levels and Hepatic Iron Storage</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107335</Key_PaperID>
<Key_SessionID>11477</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>226</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Deletion of BMP6 Worsens the Phenotype of Hemojuvelin-Deficient Mice and Attenuates Hepcidin Levels Reached after LPS Stimulation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106659</Key_PaperID>
<Key_SessionID>11477</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>227</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Red Blood Cell Transfusions Shape Macrophages Towards an Anti-Inflammatory Functional Phenotype and Impair the Immune Response to Infectious Cues</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106042</Key_PaperID>
<Key_SessionID>11477</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>228</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>The Tmprss6-/- Mouse Model of Iron Refractory Iron Deficiency Anemia (IRIDA) Exhibits Disrupted Phosphate Homeostasis, Elevated Circulating FGF23 Levels, and Increased Fgf23 Expression in Bone Marrow</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105225</Key_PaperID>
<Key_SessionID>11478</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber>169</PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Genome-Wide CRISPR/Cas9-Mediated Loss-of-Function Screening in Human Erythroleukemic Cells Identifies Novel Cellular Components Involved in Iron and Heme Trafficking</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101751</Key_PaperID>
<Key_SessionID>11478</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber>170</PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>Characterization of Iron Metabolism in Mouse Model of Congenital Polycythemia with Human Gain-of-Function Erythropoietin Receptor</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102069</Key_PaperID>
<Key_SessionID>11478</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber>171</PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Establishment and Characterization of in Vitro Model of X-Linked Sideroblastic Anemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102849</Key_PaperID>
<Key_SessionID>11478</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>172</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Influential Role of Macrophages in Hepcidin Regulation in Apo-Transferrin Treated -Thalassemic Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108400</Key_PaperID>
<Key_SessionID>11478</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>173</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Iron Binding to Specific Lobes of Transferrin Differentially Affects Erythropoiesis and Hepcidin Signaling</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106529</Key_PaperID>
<Key_SessionID>11478</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>174</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Transient Reduction of Transferrin Saturation Contributes to Hepcidin Inhibition Independently of Erfe in Mice Treated with Erythropoietin</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103912</Key_PaperID>
<Key_SessionID>11479</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>283</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Fetal Hemoglobin (HbF) Silencer BCL11A Acts through a Novel DNA-Motif in the Gamma-Globin Promoters, Simplifying the Model for Hemoglobin Switching</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106232</Key_PaperID>
<Key_SessionID>11479</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>284</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>CRISPR/Cas9 Genome Editing to Treat Sickle Cell Disease and B-Thalassemia: Re-Creating Genetic Variants to Upregulate Fetal Hemoglobin Appear Well-Tolerated, Effective and Durable. </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105678</Key_PaperID>
<Key_SessionID>11479</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>285</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Ulk1 Kinase Mediates Clearance of Free -Globin in -Thalassemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107447</Key_PaperID>
<Key_SessionID>11479</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>286</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>High-Resolution CRISPR Functional Genomics Reveals Critical Vulnerabilities of the NuRD Complex for Fetal Hemoglobin Control</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105190</Key_PaperID>
<Key_SessionID>11479</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>287</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>SIRT1 Increases the Expression of Fetal Hemoglobin Genes in Human Adult and Cord Blood Erythroblasts</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105904</Key_PaperID>
<Key_SessionID>11479</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>288</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>A Long Noncoding RNA from the HBS1L-MYB Intergenic Region on Chr6q23 Regulates Human Fetal Hemoglobin Expression</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99936</Key_PaperID>
<Key_SessionID>11480</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>355</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Gene Therapy for Beta Thalassemia: Preliminary Results from the PHASE I/II Tiget-Bthal Trial of Autologous HematopoieticStem CellsGenetically Modified with GLOBE Lentiviral Vector</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99635</Key_PaperID>
<Key_SessionID>11480</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>356</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Oral Administration of the LSD1 Inhibitor OG-S1335 Increases Fetal Hemoglobin in Humanized Transgenic Sickle Cell Disease Mice and in Baboons</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103294</Key_PaperID>
<Key_SessionID>11480</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>357</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Unrelated Donor Peripheral Blood Stem Cell Transplantation for Thalassaemia: A Single Institution Experience of 53 Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103957</Key_PaperID>
<Key_SessionID>11480</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>358</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Lesional Mechanism of Alpha Thalassemias: Towards a Common Mechanism Alpha Thal / Beta Thal</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106983</Key_PaperID>
<Key_SessionID>11480</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>We will discuss hydroxyurea, which is not FDA approved for use in pediatric patients with sickle cell disease, and metformin as a fetal hemoglobin inducing agent, an off-label use.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>359</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Metformin Induction of Fetal Hemoglobin</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105489</Key_PaperID>
<Key_SessionID>11480</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>360</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Clinical Outcomes up to 3 Years Following Lentiglobin Gene Therapy for Transfusion-Dependent -Thalassemia in the Northstar Hgb-204 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105530</Key_PaperID>
<Key_SessionID>11481</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>535</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>CRISPR/Cas9 Gene-Edited Hematopoietic Stem Cell Therapy for Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101931</Key_PaperID>
<Key_SessionID>11481</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>536</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>Domain-Focused CRISPR-Cas9 Screen Identifies Hri Kinase As a Regulator of Fetal Hemoglobin in Adult Human Erythroid Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101422</Key_PaperID>
<Key_SessionID>11481</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>537</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Reawakening of Human Fetal Hemoglobin and an Epigenetic Path to the Clinic for Sickle Cell Disease and Beta-Thalassemia: Identification of an Orally-Available, Potent, and Selective Euchromatic Histone Lysine Methyltransferase 1 and 2 (EHMT1/2) Inhibitor</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108564</Key_PaperID>
<Key_SessionID>11481</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>538</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Enucleation and Beta-Globin Expression in Induced Red Blood Cells: A Platform to Model Sickle Cell Anemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104369</Key_PaperID>
<Key_SessionID>11481</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>539</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Clot Formation Under Physiological Flow Conditions Is Altered in Sickle Cell Disease As Measured By a Multiparameter Microfluidic System</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100645</Key_PaperID>
<Key_SessionID>11481</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>540</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Role for Platelets in Mediating Neutrophil Recruitment in TNF- Induced Vaso-Occlusive Processes in Animals with Sickle Cell Anemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104738</Key_PaperID>
<Key_SessionID>11482</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>439</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Critical Role of Protein Arginine Deiminase 4 in Mast Cell Extracellular Trap Formation Leading to Neuropathic Pain in Sickle Mice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108045</Key_PaperID>
<Key_SessionID>11482</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>440</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Uncoupling Sickle Hematopoiesis Induced Angiotensin Receptor Signaling in Sickle Nephropathy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107367</Key_PaperID>
<Key_SessionID>11482</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>441</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Enhanced Renal Clearance of Heme Triggers Acute Kidney Injury in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107967</Key_PaperID>
<Key_SessionID>11482</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>442</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of Protein Disulfide Isomerase Ameliorates Vaso-Occlusion and Thrombosis in a Mouse Model of Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107096</Key_PaperID>
<Key_SessionID>11482</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>443</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Vitamin D Repletion Mitigates Oxidative Stress Induced Pulmonary Artery Remodeling in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107391</Key_PaperID>
<Key_SessionID>11482</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>444</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Apocynin Improves Functional Microvascular Blood Flow in Sickle Cell Disease during Contractile Exercise</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101772</Key_PaperID>
<Key_SessionID>11483</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>613</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Crizanlizumab 5.0 Mg/Kg Increased the Time to First on-Treatment Sickle Cell Pain Crisis: A Subgroup Analysis of the Phase II Sustain Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101349</Key_PaperID>
<Key_SessionID>11483</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>614</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Cerebral Metabolic Stress Is Lower in Patients with Sickle Cell Anemia on Hydroxyurea Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104658</Key_PaperID>
<Key_SessionID>11483</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Hydroxyurea is not approved by the FDA for the treatment of children with sickle cell anemia.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>615</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>Personalized Hydroxyurea Dosing to Reduce Time to MTD and Optimize the HbF Response: Results from the TREAT Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103301</Key_PaperID>
<Key_SessionID>11483</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>616</PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Multi-Disciplinary Obstetrics and Sickle Cell Disease Clinic in Low Resource Setting Lowers Maternal and Perinatal Death Rates to the Same Levels As Those without Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102332</Key_PaperID>
<Key_SessionID>11483</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber>617</PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Health-Related Quality of Life at 1 Year in the Drepagreffe Trial Comparing Chronic Transfusion to Transplantation in Children with Sickle Cell Anemia and a History of Abnormal Cerebral Velocities</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103169</Key_PaperID>
<Key_SessionID>11483</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber>618</PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>In Children with Sickle Cell Anemia, Low Baseline BMI Is Associated with a Longitudinal Decline in FEV1 % Predicted</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108433</Key_PaperID>
<Key_SessionID>11484</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>685</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Phase 3 Study of L-Glutamine in Sickle Cell Disease: Analyses of Time to First and Second Crisis and Average Cumulative Recurrent Events</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102801</Key_PaperID>
<Key_SessionID>11484</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>686</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>HMOX1 and Acute Kidney Injury in Sickle Cell Anemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100571</Key_PaperID>
<Key_SessionID>11484</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>687</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Acute Chest Syndrome Among Hospitalized Children with Vaso-Occlusive Crisis: A Nationwide Study in the United States</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102708</Key_PaperID>
<Key_SessionID>11484</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber>688</PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>The First Two Years of Life in Sickle Cell Anemia Infants: Results of a Comprehensive Longitudinal Study </PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105584</Key_PaperID>
<Key_SessionID>11484</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>689</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106938</Key_PaperID>
<Key_SessionID>11484</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>690</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Biomarker Signatures of Sickle Cell Disease Severity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108081</Key_PaperID>
<Key_SessionID>11485</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>757</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Increased Volume and Distinct Pattern of Silent Cerebral Infarcts in Healthy, Young Adults with Sickle Cell Trait</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102783</Key_PaperID>
<Key_SessionID>11485</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>HU is licensed in Europe in the prevention of recurrent painful vaso-occlusive crises (VOC) including acute chest syndromes in adults, adolescents and children older than 2 years with sickle-cell disease (SCD). We will discuss in this abstract about the use of HU in SCD patients with severe anemia without VOC</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>758</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Off-Label Prescription of Hydroxycarbamide (Hydroxyurea, HU) for Severe Anemia: Preliminary Results from European Non-Interventional, Multicentric, Prospective Escort-HU Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106600</Key_PaperID>
<Key_SessionID>11485</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Hydroxyurea for children with sickle cell anemia</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>759</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Novel Use of Hydroxyurea in an African Region with Malaria (NOHARM): A Randomized Controlled Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104179</Key_PaperID>
<Key_SessionID>11485</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>760</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Effects of Hydroxyurea (HU) on Neurocognitive Performance in Children with Sickle Cell Disease: A Prospective Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108787</Key_PaperID>
<Key_SessionID>11485</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>761</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Methacholine Challenge Test Reveals a High Prevalence of Subclinical Severe Airway Hyper-Reactivity in Children and Yound Adults with Sickle Cell Disease Which Correlates with Higher Sickle Acute Events and Acute Chest</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102087</Key_PaperID>
<Key_SessionID>11485</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>762</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Simultaneous Point-of-Care Detection of Anemia and Sickle Cell Disease in Tanzania: The RAPID Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107658</Key_PaperID>
<Key_SessionID>11486</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>541</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>BAALC Is a Key Mediator of Leukemia Development in Congenital Neutropenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106871</Key_PaperID>
<Key_SessionID>11486</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>542</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>Establishment of the Safe and Efficient CRISPR/Cas9-RNP Based Gene-Correction Platform of ELANEMutations in iPSCs of Severe Congenital Neutropenia (CN) Patients with No Response to G-CSF and High Risk to Develop Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105255</Key_PaperID>
<Key_SessionID>11486</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>543</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Combinatorial CSF3R and RUNX1 Mutations Involved in the Leukemic Progression of Severe Congenital Neutropenia Confer a G-CSF-Dependent Premalignant State in Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107382</Key_PaperID>
<Key_SessionID>11486</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>544</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Severe Congenital Neutropenia-Associated Mutations Reveal Stage-Specific Gfi1-Dependent Checkpoints in Myeloid Development</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100588</Key_PaperID>
<Key_SessionID>11486</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>545</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>The Effect of the MK0339 Neutrophil Elastase Inhibitor on Proliferation and Maturation of iPSC Derived from Patients with ELANE, TCIRG1 and Whim Syndrome Associated Neutropenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102278</Key_PaperID>
<Key_SessionID>11486</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>546</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Hematopoietic Stem Cell Transplantation May Lower the Risk of Leukemia in ELANE Neutropenia: Historical Trends from a French Severe Chronic Neutropenia Registry (FSCNR) Cohort</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107929</Key_PaperID>
<Key_SessionID>11487</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>445</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>PD-1 Mediates Lineage Fate Determination and Function of Myeloid Cells in Response to Tumor-Mediated Emergency Myelopoiesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100739</Key_PaperID>
<Key_SessionID>11487</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>446</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Lactate Release By Bone Marrow Neutrophils Promotes Their Inflammatory Mobilization Via Endothelial GPR81 Signaling</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104261</Key_PaperID>
<Key_SessionID>11487</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>447</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>The Clinical-Stage sGC Stimulator IW-1701 Prevents Increase of Plasma Biomarkers of Intravascular Inflammation and Suppresses Leukocyte-Endothelial Interactions in Tnf-Treated Mice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102449</Key_PaperID>
<Key_SessionID>11487</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>448</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Hematologic Response to Oral Eliglustat in Treatment-Naive Patients with Gaucher Disease Type 1: Final Results from a Phase 2 and the Phase 3 Engage Trials</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104364</Key_PaperID>
<Key_SessionID>11487</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>449</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Monotcytes/Macrophages Are Involved in Erythrocytosis Caused By Both EPO-Dependent and -Independent Activation of EPOR</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105303</Key_PaperID>
<Key_SessionID>11487</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>450</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Abrogated GADD45b-Mediated Integrity Control of Hematopoietic Stem Cells upon ER Stress and DNA Damage Triggers Lymphopoiesis over Granulopoiesis in Congenital Neutropenia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105985</Key_PaperID>
<Key_SessionID>11488</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>691</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>In Vitro Generation of Human Pluripotent Stem Cell-Derived T Cells for Immunotherapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106660</Key_PaperID>
<Key_SessionID>11488</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>692</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>TCR-Identical CD8+ T-Cells Can Have Distinct Killing Efficacy Determined By Events Beyond the T-Cell Receptor</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106355</Key_PaperID>
<Key_SessionID>11488</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>693</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Tumor-Intrinsic RIG-I Signaling Promotes Anti-CTLA-4 Checkpoint Inhibitor-Mediated Anticancer Immunity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106089</Key_PaperID>
<Key_SessionID>11488</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber>694</PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>Modeling and Understanding the Biology of Transplant-Mediated HIV Cure in a Non-Human Primate Model</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107749</Key_PaperID>
<Key_SessionID>11488</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>695</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Results from a First-in-Human Study with Bnz-1: A Novel Peptide Inhibitor of IL-2, IL-9 and IL-15 for the Treatment of T-Cell Malignancies That Safely and Selectively Decreases Regulatory T-Cells, Natural Killer Cells, and CD8+ Central Memory T-Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102703</Key_PaperID>
<Key_SessionID>11488</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>696</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Amg592 Is an Investigational IL-2 Mutein That Induces Highly Selective Expansion of Regulatory T Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103898</Key_PaperID>
<Key_SessionID>11489</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>619</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>A Spic/BCLAF1 Complex Suppresses Pre-B Cell Receptor Signaling in Response to RAG-Mediated DNA Breaks</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100731</Key_PaperID>
<Key_SessionID>11489</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>620</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Phospholipase Cgamma Pathway-Dependent mTOR Signaling Controls IL-7-Mediated Early B Cell Development</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106832</Key_PaperID>
<Key_SessionID>11489</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>621</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>The Deubiquitinase Activity of CYLD Is Required for Maturation of B Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104649</Key_PaperID>
<Key_SessionID>11489</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>622</PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Using Multiplexed Genome Editing to Distinguish between Loss- and Gain-of-Function Variants in CARD11</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106354</Key_PaperID>
<Key_SessionID>11489</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber>623</PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Identification and Validation of Molecular Markers of Tumor Cell Resistance to Natural Killer Cells through CRISPR-Based Screens and Large-Scale Phenotypic Screens of Pooled Tumor Cell Lines</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108303</Key_PaperID>
<Key_SessionID>11489</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber>624</PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>Notch Signaling Promotes the Differentiation of Human CLEC9A+ Dendritic Cells from Hematopoietic Stem and Progenitor Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106497</Key_PaperID>
<Key_SessionID>11490</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>451</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Expression of Functional Human Proteinase Activated Receptor (PAR)-1 on Mouse Platelets</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107076</Key_PaperID>
<Key_SessionID>11490</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>452</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Apoptosis Signal-Regulating Kinase 1 (ASK1) Is a Novel Regulator of Heparin-Induced Thrombocytopenia and Thrombosis in Mice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103599</Key_PaperID>
<Key_SessionID>11490</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>453</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Analysis of a Naturally Occurring PAR4 Variant By Hydrogen/Deuterium Exchange Reveals Its Structural Rearrangement upon Activation By Thrombin and the Molecular Basis for Altered Reactivity</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107684</Key_PaperID>
<Key_SessionID>11490</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>454</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Platelet Cyclophilin D-Dependent Events Limit Venous Thrombotic Occlusion and Platelet Accretion</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108812</Key_PaperID>
<Key_SessionID>11490</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>455</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mitochondrial Fission Protein Drp1 Regulates Megakaryocyte and Platelet Mitochondrial Morphology, Platelet Numbers, and Platelet Function</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108553</Key_PaperID>
<Key_SessionID>11490</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>456</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Transcript Expression, Intron Retention, and RNA Editing Are Conserved in Human Platelets over a 4 Year Period</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104277</Key_PaperID>
<Key_SessionID>11491</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>547</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Identification of a VWFA1 Mutation Attenuating Thrombus Growth but Not Platelet Adhesion</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104325</Key_PaperID>
<Key_SessionID>11491</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>548</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>Development of a Pure Small Molecule V3 Antagonist</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103398</Key_PaperID>
<Key_SessionID>11491</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>549</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Multimerin-1 Binds to Specific Motifs in Vessel Wall Collagens and Contributes to Thrombosis: Novel Insights Regarding the Mechanisms That Support Human and Mouse Platelet Adhesion</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105916</Key_PaperID>
<Key_SessionID>11491</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>550</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Structure of an Extended 3 Integrin</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107185</Key_PaperID>
<Key_SessionID>11491</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>551</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Mice Lacking Platelet TGF-1 Are Protected from Aortic Stenosis Progression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108313</Key_PaperID>
<Key_SessionID>11491</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>552</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Junctional Adhesion Molecule-a, Suppresses Integrinv3 Activation to Control Neovascularization</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103588</Key_PaperID>
<Key_SessionID>11492</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>13</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Recombinant Human Thrombopoietin (rhTPO) and High-Dose Dexamethasone (HD-DXM) Versus High-Dose Dexamethasone Monotherapy As Frontline Treatment in Newly Diagnosed Adult Immune Thrombocytopenia (ITP)a Prospective, Multicentre, Randomised, Controlled Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100126</Key_PaperID>
<Key_SessionID>11492</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Romiplostim is approved for use in adults with chronic ITP; use in children with ITP is investigational.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>14</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107276</Key_PaperID>
<Key_SessionID>11492</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Rozanolixizumab is pre-approval and is in phase II development. It is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody, developed with the aim of reducing levels of pathogenic IgG autoantibodies in autoimmune and alloimmune diseases</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>15</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101970</Key_PaperID>
<Key_SessionID>11492</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Fostamatinib is an investigational product being evaluated in adult patients with ITP and is currently not approved by the FDA or other health authorities.
</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>16</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Long-Term Maintenance of Platelet Responses in Adult Patients with Persistent/Chronic Immune Thrombocytopenia Treated with Fostamatinib: 1-Year Efficacy and Safety Results</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105691</Key_PaperID>
<Key_SessionID>11492</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>17</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, Demonstrates Superiority to Placebo for the Treatment of Chronic Immune Thrombocytopenic Purpura in a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105516</Key_PaperID>
<Key_SessionID>11492</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>18</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Superiority of Avatrombopag to Placebo in Increasing Platelet Counts in Patients with Chronic Liver Disease-Associated Thrombocytopenia Undergoing Scheduled Procedures: Results from 2, Phase 3 Randomized Studies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104623</Key_PaperID>
<Key_SessionID>11493</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>229</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Low-Dose Decitabine Restores Immune Tolerance in ITP By Modulating Regulatory T Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106979</Key_PaperID>
<Key_SessionID>11493</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>230</PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>Blockade of the Neonatal Fc Receptor (FcRn) Represents an Effective Mechanism for the Removal of Pathogenic Autoantibodies in Primary Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102788</Key_PaperID>
<Key_SessionID>11493</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>231</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Erythrocyte-Specific Antibodies As a Potential New Therapeutic Modality in Autoimmune and Inflammatory Disorders Beyond Immune Thrombocytopenia (ITP)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101388</Key_PaperID>
<Key_SessionID>11493</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>232</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Atorvastatin May Reverse Corticosteroid-Resistant Immune Thrombocytopenia Via Improving Impaired Bone Marrow Endothelial Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108264</Key_PaperID>
<Key_SessionID>11493</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>233</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Maternal Anti-IIb Antibodies Target Fetal Hematopoietic Stem Cells and May Lead to Pancytopenia and Miscarriage in Fnait</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103644</Key_PaperID>
<Key_SessionID>11493</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>234</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Reduced PTEN Involved in Primary Immune Thrombocytopenia Via Contributing to B Cell Hyper-Responsiveness</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101581</Key_PaperID>
<Key_SessionID>11494</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Romiplostim is a thrombopoietin receptor agonist, currently FDA approved for treatment of ITP.  We report a phase 2 clinical trial with romiplostim for Chemotherapy-Induced Thrombocytopenia.  This use is off-label.  This study was IRB approved and registered in Clinicaltrials.gov.  </OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>289</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT). Results of a Phase 2 Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104502</Key_PaperID>
<Key_SessionID>11494</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Avatrombopag is a novel orally-active thrombopoietin (TPO) receptor agonist which is currently under evaluation for increasing platelet counts in patients with chronic liver disease and thrombocytopenia.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>290</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Avatrombopag, a Novel Thrombopoietin Receptor Agonist, Increases Platelet Counts without Increasing Platelet Activation in Patients with Thrombocytopenia Due to Chronic Liver Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102241</Key_PaperID>
<Key_SessionID>11494</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>291</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Platelet Response to Lusutrombopag, a Thrombopoietin Receptor Agonist, in Patients with Chronic Liver Disease and Thrombocytopenia Undergoing Non-Emergency Invasive Procedures: Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105722</Key_PaperID>
<Key_SessionID>11494</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>292</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Aging-Associated Inflammation Due to Elevated Levels of TNF- Increases Activation of the Integrin IIb3 and the Procoagulant Potential of Platelets</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106239</Key_PaperID>
<Key_SessionID>11494</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>293</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>The Identification of the Amino Acids on Platelet Factor 4 That Bind Pathogenic Antibodies in Heparin-Induced Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102597</Key_PaperID>
<Key_SessionID>11494</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>294</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Lysine-Histone Triggers Thrombotic Thrombocytopenic Purpura in Zebrafish and Mice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103491</Key_PaperID>
<Key_SessionID>11495</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>361</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Prenatal Transplantation of Placental Cells Engineered to Express FVIII Leads to Corrective Plasma Levels of FVIII after Birth</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102968</Key_PaperID>
<Key_SessionID>11495</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>362</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Lettuce Plants Expressing High Levels of Factor VIII Antigen in the Chloroplast for Oral Tolerance in Hemophilia a</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103337</Key_PaperID>
<Key_SessionID>11495</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>363</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Phe174-Mutated Human Factor X As Bypassing Agent to the Direct FXa Inhibitors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107668</Key_PaperID>
<Key_SessionID>11495</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>364</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Differential Role of Plasma and Platelet-Derived Factor V In Vivo</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108299</Key_PaperID>
<Key_SessionID>11495</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>365</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Platelet FV Deficiency Restores Survival of TFPI Null Mice Independently of Plasma FV</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102961</Key_PaperID>
<Key_SessionID>11495</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>366</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Factor V Atlanta: A Novel Mutation in the F5 Gene Reveals Potential New Cis-Acting Elements Involved in Regulating FV-Short and TFPI Levels</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101941</Key_PaperID>
<Key_SessionID>11496</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>235</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Activated Factor IX As a Candidate for the Initial Protease in the Coagulation Cascade</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102542</Key_PaperID>
<Key_SessionID>11496</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>236</PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>The Anti-Factor XII Antibody AB052 Is Antithrombotic without Hemostatic Impairment in a Primate Model of Extracorporeal Membrane Oxygenation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107724</Key_PaperID>
<Key_SessionID>11496</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>237</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Mice Lacking Factor XIII Have Significant Protection from the Progression of Neuroinflammatory Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103160</Key_PaperID>
<Key_SessionID>11496</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>238</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Hydrogen-Deuterium Exchange Plus Mass Spectrometry (HX-MS) Reveals a Novel Mechanism Underlying the pH-Dependent Regulation of ADAMTS13 Activity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101217</Key_PaperID>
<Key_SessionID>11496</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>239</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>A Re-Evaluation of Murine TFPI and Comparison to TFPI in Man: Murine Plasma TFPI Is Derived from TFPI</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107296</Key_PaperID>
<Key_SessionID>11496</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>240</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Ancestral Sequence Reconstruction of Von Willebrand Factor Reveals Highly Conserved Structure/Function</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102056</Key_PaperID>
<Key_SessionID>11497</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber>175</PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Reprogrammed CD4+ T Cells That Express FoxP3+ Effectively Control Inhibitory Antibody Development in Hemophilic Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102067</Key_PaperID>
<Key_SessionID>11497</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber>176</PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>Generation of FVIII-Specific Tregs Expressing a Chimeric Antigen Receptor (CAR) to Suppress Inhibitor Development in Hemophilia a Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102578</Key_PaperID>
<Key_SessionID>11497</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber>177</PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>HLA-DRB1-Peptide Binding Prediction and Risk of Inhibitor Development in Non-Severe Hemophilia a</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106750</Key_PaperID>
<Key_SessionID>11497</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>178</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>A Novel Von Willebrand Factor Fragment Acts As a Chaperone to Prolong the Half-Life of Recombinant Human FVIII (Simoctocog Alfa) in Hemophilia a Dogs and FVIII/VWF Double Knockout Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101866</Key_PaperID>
<Key_SessionID>11497</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>179</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>FVIII Proteins with a Modified Immunodominant T-Cell Epitope Exhibit Reduced Immunogenicity and Normal Procoagulant Activity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107434</Key_PaperID>
<Key_SessionID>11497</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>180</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>The CXCL12/CXCR4 and VEGF165/Nrp1 Pathways Have Differential Effects on Pathological Neo-Angiogenesis and Vascular Remodeling in Hemophilic Arthropathy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105669</Key_PaperID>
<Key_SessionID>11498</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>19</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Genotype-Phenotype Relationship and the Role of Alloantibodies in Type 3 VWD in the Zimmerman Program</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106353</Key_PaperID>
<Key_SessionID>11498</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>20</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Characterization of the Pathogenicity of Novel Sequence Variants Identified in Type 1 VWD Subjects in the Zimmerman Program for the Molecular and Clinical Biology Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106127</Key_PaperID>
<Key_SessionID>11498</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>21</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Endothelial Colony Forming Cells from Individuals with Low VWF Levels Demonstrate Impairment in Stimulated VWF Release</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102521</Key_PaperID>
<Key_SessionID>11498</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>22</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101418</Key_PaperID>
<Key_SessionID>11498</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>23</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Practical Application of the Athndataset: Evaluating Uptake of Extended Half-Life Factor Concentrates in Patients with Moderate and Severe Hemophilia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100480</Key_PaperID>
<Key_SessionID>11499</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>84</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Pivotal Trial with Intravenous Plasminogen Replacement in Patients with Plasminogen Deficiency Demonstrates Long-Term Efficacy for Treatment and Prevention of Ligneous Lesions</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102837</Key_PaperID>
<Key_SessionID>11499</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>85</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102859</Key_PaperID>
<Key_SessionID>11499</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>86</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101277</Key_PaperID>
<Key_SessionID>11499</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>87</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Phase 1/2 Trial of Subcutaneously Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics and Activity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105084</Key_PaperID>
<Key_SessionID>11499</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>88</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Longitudinal Antibody Signatures Following FVIII Replacement Therapy in Previously Untreated Patients with Severe Hemophilia  New Insights from the Hemophilia Inhibitor PUP Study (HIPS)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102722</Key_PaperID>
<Key_SessionID>11499</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>89</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108222</Key_PaperID>
<Key_SessionID>11499</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>90</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>Elucidating the Excessive Pro-Coagulant Effect of a Sequence Identical Analogue to ACE910 in Combination with Bypassing Agents</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105555</Key_PaperID>
<Key_SessionID>11500</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>457</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Exome Sequencing Studies Identify Mutations in STAB2 As a Genetic Risk for Venous Thromboembolic Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102874</Key_PaperID>
<Key_SessionID>11500</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>458</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>A New Assay for Platelet-Activating HIT Antibodies, the PEA, Is Specific, Reproducible and Relatively Independent of the Choice of Platelet Donor</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103065</Key_PaperID>
<Key_SessionID>11500</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>459</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>CD39 and CD73 Activity Are Protective in a Mouse Model of Antiphospholipid Antibody-Induced Miscarriage</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102648</Key_PaperID>
<Key_SessionID>11500</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>460</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Applying Neural Networking Identifies Antiphospholipid Syndrome Patients with an Accuracy of 98.7%</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107509</Key_PaperID>
<Key_SessionID>11500</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>461</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of the Thrombophilic Response to rFVIIa-Induced Hemostasis Activation in Factor V Leiden Carriers By Monitoring of Activated Protein C (APC) In Vivo</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105065</Key_PaperID>
<Key_SessionID>11500</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>462</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Fibrinogen and Clot Structure Is Affected By Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101849</Key_PaperID>
<Key_SessionID>11501</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>553</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Thrombotic Events in Patients with Myeloma Treated with Immunomodulatory Drugs; Results of the Myeloma XI Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104728</Key_PaperID>
<Key_SessionID>11501</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>554</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>RNA Sequencing Approaches to Identify Novel Biomarkers for Venous Thromboembolism (VTE) in Lung Cancer</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102405</Key_PaperID>
<Key_SessionID>11501</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>555</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>The Identification ofHigh Risk APS Patients for Thrombosis with Triple Antiphospholipid AntibodyPositivity Is Platform Dependent</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107117</Key_PaperID>
<Key_SessionID>11501</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>556</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Rebound Hypercoagulability Following a Conventional Course of Anticoagulationand the Risk ofRecurrent Venous ThromboembolisminYoung Patients: First Analysis of the Kids-DOTT Multicenter Trial-Derived Biobank</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106575</Key_PaperID>
<Key_SessionID>11501</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>557</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Elevated Gas6 Plasma Level As a Predictor of Venous Thromboembolism Recurrence and Mortality in a Prospective Multicenter Cohort of Elderly Patients with Venous Thromboembolism</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103577</Key_PaperID>
<Key_SessionID>11501</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>558</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Development and External Validation of Thrombosis Lymphoma /Throly/ Score - Interim Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104979</Key_PaperID>
<Key_SessionID>11502</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>625</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D Pilot Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101357</Key_PaperID>
<Key_SessionID>11502</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>626</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>An Individual Participant Data Meta-Analysis of 13 Randomized Trials to Evaluate the Impact of Prophylactic Use of Heparin in Oncological Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101863</Key_PaperID>
<Key_SessionID>11502</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>627</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>The Khorana Score for the Prediction of Venous Thromboembolism in Patients with Solid Cancer: An Individual Patient Data Meta-Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108033</Key_PaperID>
<Key_SessionID>11502</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>628</PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Outcome on Reinstitution of Anticoagulation Following Intracranial Hemorrhage: A Single Institutional Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105924</Key_PaperID>
<Key_SessionID>11502</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber>629</PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Effect of Andexanet-TFPI Interaction on in Vitro Thrombin Formation and Coagulation Markers in the TF-Pathway</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106345</Key_PaperID>
<Key_SessionID>11502</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber>630</PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>GLS-409, a Synergistic Inhibitor of Both P2Y1 and P2Y12: Efficacy in a Canine Model of Recurrent Coronary Thrombosis and Reversibility of Human Platelet Inhibition</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104113</Key_PaperID>
<Key_SessionID>11503</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>697</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Outcomes Following Placement of Venous Stents for Treatment of Thrombotic Venous Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100044</Key_PaperID>
<Key_SessionID>11503</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>698</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Electrical Calf Muscle Stimulation on the Residual Venous Obstruction and DVT Recurrence after Cessation of Standard Anticoagulation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102404</Key_PaperID>
<Key_SessionID>11503</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>699</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Diagnosis and Management of Paget-Schroetter Syndrome in Children: An Institutional Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102858</Key_PaperID>
<Key_SessionID>11503</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber>700</PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>Comparative Risk of Acute Kidney Injury with Oral Anticoagulant Use Among Patients with Nonvalvular Atrial Fibrillation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104227</Key_PaperID>
<Key_SessionID>11503</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>701</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Unfractionated Heparin Use in Children: Clinical Outcomes in a Pediatric Cohort Managed Using an Anti-Factor Xa Based Nomogram</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108586</Key_PaperID>
<Key_SessionID>11503</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>702</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Aspirin Thromboprophylaxis in Joint Replacement Surgery</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107616</Key_PaperID>
<Key_SessionID>11504</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>763</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Platelets Loaded with Recombinant ADAMTS13 Are Efficacious in Inhibiting Arterial Thrombosis Under Flow: A Potential Novel Therapeutic for Acquired TTP</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102329</Key_PaperID>
<Key_SessionID>11504</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>764</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Recreation of Fetal Neonatal Alloimmune Thrombocytopenia in CRISPR/Cas9 Gene-Edited Mice Expressing the Human Platelet Alloantigen, HPA-1a</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108670</Key_PaperID>
<Key_SessionID>11504</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>765</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Anemic Conditions Acceptable in Restrictive Transfusion Practice Induce Gut Inflammation and Injury in an Animal Model of Preterm Infants</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106429</Key_PaperID>
<Key_SessionID>11504</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>766</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Gastrointestinal Flora Dictates the Biological Response in Murine Transfusion Related Acute Lung Injury (TRALI)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107445</Key_PaperID>
<Key_SessionID>11504</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>767</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Protective Role of HO-1 Expressing CD16+ Patrolling Monocytes Against Hemolysis-Induced Endothelial Damage and Vaso-Occlusive Crisis in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108575</Key_PaperID>
<Key_SessionID>11504</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>768</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Primed CD4 T Cells to an Intracellular Alloantigen Facilitate Alloimmunization Following Subsequent Transfusion</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105160</Key_PaperID>
<Key_SessionID>11505</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>703</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients </PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101197</Key_PaperID>
<Key_SessionID>11505</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>704</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Hemostatic Efficacy of Pathogen-Inactivated Buffy Coat-Derived Platelet Concentrates in Hemato-Oncological Patients: Outcomes of the Prepares Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102203</Key_PaperID>
<Key_SessionID>11505</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>705</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Prediction of Extended Red Blood Cell Phenotype from Exome Next Generation Sequencing Data</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107171</Key_PaperID>
<Key_SessionID>11505</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber>706</PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>Glucose-6-Phosphate Dehydrogenase Deficiency in Blood Donors Is Associated with Decreased Post-Transfusion Red Cell Recovery</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99822</Key_PaperID>
<Key_SessionID>11505</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>707</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Platelet Transfusions for Thrombocytopenic Preterm Neonates: The Monet Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102813</Key_PaperID>
<Key_SessionID>11505</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>708</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Antigen-Mediated Immune Suppression Is Antigen Specific</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101442</Key_PaperID>
<Key_SessionID>11506</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>709</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Antagonizing PPAR Expands Human Hematopoietic Stem and Progenitor Cells By Switching on FBP1-Repressed Glycolysis and Preventing Differentiation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103224</Key_PaperID>
<Key_SessionID>11506</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>710</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Scribble Controls HSC Self-Renewal through Polarity-Dependent Activation of the Hippo Signaling Pathway</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103647</Key_PaperID>
<Key_SessionID>11506</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>711</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Genetic Ablation or Pharmacological Inhibition of PRMT5 Affects Maintenance of Genomic Integrity in Hematopoietic Stem Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99593</Key_PaperID>
<Key_SessionID>11506</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber>712</PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>FANCD2 and HES1 Synergistically Regulate the Immunometabolism of Hematopoietic Stem Cells through Transcriptional Suppression of Pparg-mediated Fatty Acid Oxidation and Oxidative Phosphorylation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104887</Key_PaperID>
<Key_SessionID>11506</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>713</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Fetal Inactivation of the Nuclear Interacting SET DomainProtein 1 Impairs Terminal Erythroid Maturation and Results in AcuteErythroleukemia in Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106022</Key_PaperID>
<Key_SessionID>11506</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>714</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Single Cell-Resolution Analysis of HSC Dysfunction in Mir-146a knockout Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104345</Key_PaperID>
<Key_SessionID>11507</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>631</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Inflammation-Produced TNF Protects HematopoieticStem Cells from Necroptosis via Canonical NF-B Pathway</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103363</Key_PaperID>
<Key_SessionID>11507</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>632</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Clonal Hematopoiesis: Cell of Origin, Lineage Repartition and Dynamic Evolution during Chemotherapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107578</Key_PaperID>
<Key_SessionID>11507</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>633</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>Mitochondrial Morphology Controls Hematopoietic Stem Cell Self-Renewal and Confers Them Divisional Memory</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106821</Key_PaperID>
<Key_SessionID>11507</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>634</PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>A Stem Cell-Based Epigenetic Memory Mediates Interferon Response-Heterogeneity within the Hematopoietic System</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104068</Key_PaperID>
<Key_SessionID>11507</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber>635</PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Junctional Adhesion Molecule 2 Intensifies T Lymphopoiesis of Hematopoietic Stem Cells By Facilitating Notch/Delta Signaling</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107214</Key_PaperID>
<Key_SessionID>11507</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber>636</PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>27-Hydroxycholesterol Induces Hematopoietic Stem Cell Mobilization and Extramedullary Hematopoiesis Mediated By Estrogen Receptor Alpha</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105026</Key_PaperID>
<Key_SessionID>11508</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>769</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Unravelling Cell Cycle and Ontogeny Transcriptional Heterogeneity in Hematopoietic Stem Cells through Integrated Single Cell RNA-Seq</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105999</Key_PaperID>
<Key_SessionID>11508</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>770</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Integrative Epigenetic and Single-Cell RNA-Seq Profiling of Human Hematopoietic Stem Cells Reveals Epigenetic Reprogramming of Enhancer and Regulatory Elements during Normal Aging</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104163</Key_PaperID>
<Key_SessionID>11508</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>771</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Novel Role of CEBP As a Transcriptional Repressor of Transposable Elements</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101995</Key_PaperID>
<Key_SessionID>11508</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>772</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Control of Hematopoietic Stem Cell Function through Epigenetic Regulation of Energy Metabolism and Genome Integrity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105488</Key_PaperID>
<Key_SessionID>11508</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>773</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Distinct Signaling Centers Define Stages of Human Erythropoiesis and Harbor Common Variations of Red Blood Cell Traits</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105477</Key_PaperID>
<Key_SessionID>11508</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>774</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Fetal and Adult Erythroid Chromosomal Architectures Identifies a Novel Fetal Hemoglobin Regulatory Region</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102987</Key_PaperID>
<Key_SessionID>11509</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>91</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Adenosine from Niche-Associated Tregs Maintains Hematopoietic Stem Cell Quiescence</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107964</Key_PaperID>
<Key_SessionID>11509</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>92</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Attenuation of CXCR4/SDF-1 Axis in Bone Marrow Mesenchymal Stromal Cells Impairs Hematopoietic Niche Activity and Promotes Stem Cell Aging</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106937</Key_PaperID>
<Key_SessionID>11509</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>93</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Osteoblastic Cell-Derived Extracellular Vesicles Transfer Small RNAs That Alter the Physiology of Hematopoietic Cells In Vivo</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105085</Key_PaperID>
<Key_SessionID>11509</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>94</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Leukemic Stem Cells Co-Opt Normal Bone Marrow Niches As a Source of Energy and Antioxidant Defence</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106856</Key_PaperID>
<Key_SessionID>11509</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>95</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Aging of Hematopoietic Stem Cells Is Driven By Regional Specialization of Marrow Macrophages</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108298</Key_PaperID>
<Key_SessionID>11509</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>96</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>EBF1As a Novel Regulator of Bone MarrowMesenchymal StromalProgenitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100779</Key_PaperID>
<Key_SessionID>11510</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber>133</PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>Loss of ASXL1 in the Bone Marrow Niche Dysregulates Hematopoietic Stem Cell Fates through RNA Polymerase II Complex</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108750</Key_PaperID>
<Key_SessionID>11510</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber>134</PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Defective Notch Activation in Mesenchymal Cells Contributes to Myeloproliferative Neoplasm in Aged Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102393</Key_PaperID>
<Key_SessionID>11510</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber>135</PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>The Age of the Hematopoietic Microenvironment Specifies Lineage Commitment in MLL-Rearranged Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106971</Key_PaperID>
<Key_SessionID>11510</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber>136</PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>Defining the Transcriptional Code That Specifies Sinusoidal Endothelial Cells in the HSPC Niche</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108193</Key_PaperID>
<Key_SessionID>11510</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber>137</PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>Correlative Lightsheet and Electron Microscopy Applied to a Zebrafish Model of Fetal Bone Marrow: Resolving the Ultrastructure of a Single Hematopoietic Stem Cell in the Niche</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100790</Key_PaperID>
<Key_SessionID>11510</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber>138</PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>IFNg Increases HSC Homing and Induces Relocalization within the Bone Marrow Niche</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107067</Key_PaperID>
<Key_SessionID>11511</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	6:30 PM
 
</PaperEndTime>
<PaperNumber>871</PaperNumber>
<PaperStartTime>
	6:15 PM
 
</PaperStartTime>
<PaperTitle>A Zebrafish Model of Diamond-Blackfan Anemia Results in Bone Marrow Failure and Demonstrates Defective Translation in Erythroid Cells By Ribosome Footprinting</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107985</Key_PaperID>
<Key_SessionID>11511</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	6:45 PM
 
</PaperEndTime>
<PaperNumber>872</PaperNumber>
<PaperStartTime>
	6:30 PM
 
</PaperStartTime>
<PaperTitle>Fetal Erythropoiesis Is Defective in Rpl11 Heterozygous Mice and Increases in Severity in Young Animals</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105353</Key_PaperID>
<Key_SessionID>11511</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:00 PM
 
</PaperEndTime>
<PaperNumber>873</PaperNumber>
<PaperStartTime>
	6:45 PM
 
</PaperStartTime>
<PaperTitle>RPL11 Haploinsufficient Mice Have a CFU-E/Proerythroblast Block, Elevated Erythroblast Heme, Reduced Gata1, and Increased Ribosomal Protein Gene Expression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103073</Key_PaperID>
<Key_SessionID>11511</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:15 PM
 
</PaperEndTime>
<PaperNumber>874</PaperNumber>
<PaperStartTime>
	7:00 PM
 
</PaperStartTime>
<PaperTitle>Diamond-Blackfan Anemia Phenotype Caused By Deficiency of Adenosine Deaminase 2</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108241</Key_PaperID>
<Key_SessionID>11511</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>875</PaperNumber>
<PaperStartTime>
	7:15 PM
 
</PaperStartTime>
<PaperTitle>The Activated TGF Pathway in Shwachman Diamond Syndrome Impairs Hematopoiesis and Is Down-Regulated By Deletion of 7q</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101721</Key_PaperID>
<Key_SessionID>11511</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:45 PM
 
</PaperEndTime>
<PaperNumber>876</PaperNumber>
<PaperStartTime>
	7:30 PM
 
</PaperStartTime>
<PaperTitle>Attenuated Protein Synthesis Drives the Hematopoietic Defects in Shwachman-Diamond Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107506</Key_PaperID>
<Key_SessionID>11512</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>775</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Patient-Tailored Mouse Genome Editing Recapitulates Hematopoietic and Systemic Manifestations of Barth Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105605</Key_PaperID>
<Key_SessionID>11512</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>776</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Eltrombopag Promotes DNA Repair in Human Hematopoietic Stem and Progenitor Cells: Implications for the Treatment of Fanconi Anemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101979</Key_PaperID>
<Key_SessionID>11512</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>777</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100676</Key_PaperID>
<Key_SessionID>11512</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>778</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Tumor Necrosis Factor- in Target Cells but Not in Effector Cells Plays Critical Roles in Development of Murine Immune-Mediated Bone Marrow Failure</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107522</Key_PaperID>
<Key_SessionID>11512</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>779</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103748</Key_PaperID>
<Key_SessionID>11512</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>780</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Frequency and Evolution of TP53 Mutant Clones in Shwachman Diamond Syndrome. a Cohort Study from the French Severe Chronic Neutropenia (SCN) Registry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104050</Key_PaperID>
<Key_SessionID>11513</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>241</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>CARM1/PRMT4 As a Novel Therapeutic Target for AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108166</Key_PaperID>
<Key_SessionID>11513</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>242</PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>LSD1 Inhibition Exerts Its Anti-Leukemic Effect By Recommissioning PU.1- and C/Ebp-Dependent Enhancers in AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108514</Key_PaperID>
<Key_SessionID>11513</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>243</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Genetically-Defined AML Subgroups Represent Diverse Epigenetic Heterogeneity Landscape</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102321</Key_PaperID>
<Key_SessionID>11513</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>244</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Disruption of CTCF Boundary Remodels Chromatin Domain and Reprograms HOX Gene Transcription in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102450</Key_PaperID>
<Key_SessionID>11513</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>245</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemic Pathogenesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104628</Key_PaperID>
<Key_SessionID>11513</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>246</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Dot1l Reverses the Abnormal Self-Renewal Conferred on HSPCs through Cohesin Haploinsufficiency By Diminishing Expression of Hoxa7 and Hoxa9</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102677</Key_PaperID>
<Key_SessionID>11514</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>781</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>SRPK1 Is a Therapeutic Vulnerability in Acute Myeloid Leukemia through Its Effects on Alternative Isoforms of Epigenetic Regulators Including BRD4</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104651</Key_PaperID>
<Key_SessionID>11514</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>782</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Genome-Wide CRISPR/Cas9 Screen Reveals That the Dcps Scavenger Decapping Enzyme Is Essential for AML Cell Survival</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106927</Key_PaperID>
<Key_SessionID>11514</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>783</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>HOXA9 Recruitment of Methyltransferase Complexes Alters Enhancer Landscape during Leukemic Transformation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107295</Key_PaperID>
<Key_SessionID>11514</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>784</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>CBF-SMMHC Inhibition Disrupts Enhancer Chromatin Dynamics and Represses MYC Transcriptional Program in Inv(16) Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106959</Key_PaperID>
<Key_SessionID>11514</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>785</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Splicesome Mutant MDS and AML Cells Activate Innate Immune Signaling By Regulating the Expression of Therapeutically Targetable IRAK4 Isoforms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102971</Key_PaperID>
<Key_SessionID>11514</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>786</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Essential Role of c-MYC for Natural Killer Cell Development, Proliferation and Anti-Tumor Activity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108160</Key_PaperID>
<Key_SessionID>11515</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>559</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Single-Cell Methylome and Transcriptome High-Resolution Maps Define the Effects of Epigenetic Modifiers on the Landscape of Hematopoietic Differentiation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106129</Key_PaperID>
<Key_SessionID>11515</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>560</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>CREBBP Histone Acetyltransferase Domain Mutations Result in Dexamethasone Resistance in B-Progenitor Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105630</Key_PaperID>
<Key_SessionID>11515</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>561</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>TCF3-Hlf Hijacks ERG to Activate Leukemia-Critical Super-Enhancers in t(17;19) Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101134</Key_PaperID>
<Key_SessionID>11515</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>562</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Mutant ASXL1 Cooperates with BAP1 to Promote Myeloid Leukemogenesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102095</Key_PaperID>
<Key_SessionID>11515</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>563</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>MMSET I Acts As an Oncoprotein and Regulates GLO1 Expression in T(4;14) Multiple Myeloma Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104273</Key_PaperID>
<Key_SessionID>11515</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>564</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Gain-of-Function of ASXL1 Truncating Protein in the Pathogenesis of Myeloid Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101867</Key_PaperID>
<Key_SessionID>11516</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	6:30 PM
 
</PaperEndTime>
<PaperNumber>877</PaperNumber>
<PaperStartTime>
	6:15 PM
 
</PaperStartTime>
<PaperTitle>Acute Myeloid Leukemia with Mutated NPM1 Is Dependent on the Cytoplasmic Localization of NPM1c</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105742</Key_PaperID>
<Key_SessionID>11516</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	6:45 PM
 
</PaperEndTime>
<PaperNumber>878</PaperNumber>
<PaperStartTime>
	6:30 PM
 
</PaperStartTime>
<PaperTitle>The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103909</Key_PaperID>
<Key_SessionID>11516</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:00 PM
 
</PaperEndTime>
<PaperNumber>879</PaperNumber>
<PaperStartTime>
	6:45 PM
 
</PaperStartTime>
<PaperTitle>Oncogenic Mutations in XPO1 Promote Lymphoid Transformation By Altering Nuclear/Cytoplasmic Localization of NFB Signaling Intermediates</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108310</Key_PaperID>
<Key_SessionID>11516</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:15 PM
 
</PaperEndTime>
<PaperNumber>880</PaperNumber>
<PaperStartTime>
	7:00 PM
 
</PaperStartTime>
<PaperTitle>Vcp-Regulated Homologous Recombination Represents a New Druggable Vulnerability in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100159</Key_PaperID>
<Key_SessionID>11516</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>881</PaperNumber>
<PaperStartTime>
	7:15 PM
 
</PaperStartTime>
<PaperTitle>Inhibiting the Mitochondrial Sulfhydryl Oxidase Alr Reduces Cox17 and Alters Mitochondrial Cristae Structure Leading to the Differentiation of AML and Stem Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108329</Key_PaperID>
<Key_SessionID>11516</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:45 PM
 
</PaperEndTime>
<PaperNumber>882</PaperNumber>
<PaperStartTime>
	7:30 PM
 
</PaperStartTime>
<PaperTitle>PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying Lactonases</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101212</Key_PaperID>
<Key_SessionID>11517</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>787</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Cell-Intrinsic Depletion of AML1-ETO-Positive Pre-Leukemic HSCs By Kras Activating Mutation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100281</Key_PaperID>
<Key_SessionID>11517</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>788</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Tafazzin (TAZ) Regulates the Differentiation of AML Cells By Reducing Levels of the Phospholipid Phosphatidylethanolamine</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100253</Key_PaperID>
<Key_SessionID>11517</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>789</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Deficiency of Cux1, Encoded on Human Chromosome 7q, Causes Aberrant Hematopoietic Stem Cell Function and Spontaneous Myeloproliferative Disease in Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101620</Key_PaperID>
<Key_SessionID>11517</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>790</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Stag2 regulates Hematopoietic Differentiation and Self-Renewal</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105923</Key_PaperID>
<Key_SessionID>11517</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>791</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>m6a Regulates Differentiation State and mRNA Translation in Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106334</Key_PaperID>
<Key_SessionID>11517</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>792</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>The Cold-Shock Protein Ybx1 Is Required for Development and Maintenance of Acute Myeloid Leukemia (AML) in Vitro and In Vivo</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108539</Key_PaperID>
<Key_SessionID>11518</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>793</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Vascular E-Selectin Mediates Chemo-Resistance in Acute Myeloid Leukemia Initiating Cells Via Canonical Receptors PSGL-1 (CD162) and Hcell (CD44) and AKT Signaling</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105322</Key_PaperID>
<Key_SessionID>11518</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>794</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107797</Key_PaperID>
<Key_SessionID>11518</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>795</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103000</Key_PaperID>
<Key_SessionID>11518</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>796</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>A p53-MDM2 Interaction Inhibitor, DS-5272, Inhibits the Development of MLL-Fusion Leukemia with the Assistance of Tumor Immunity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105096</Key_PaperID>
<Key_SessionID>11518</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>797</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Resistance to SL-401 in AML and BPDCN Is Associated with Loss of the Diphthamide Synthesis Pathway Enzyme DPH1 and Is Reversible By Azacitidine</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108269</Key_PaperID>
<Key_SessionID>11518</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>798</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Integrated Molecular Analysis Identifies Replicative Stress As Sensitizer to Imetelstat Therapy in AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102218</Key_PaperID>
<Key_SessionID>11519</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>295</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3-Mutated Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108729</Key_PaperID>
<Key_SessionID>11519</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>296</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Factors Predicting Response and Resistance to Midostaurin in FLT3 Positive and FLT3 Negative AML in 483 Primary AML Patient Samples</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107543</Key_PaperID>
<Key_SessionID>11519</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>297</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Targeting Mitochondrial Translation Overcomes Venetoclax Resistance in Acute Myeloid Leukemia (AML) through Activation of the Integrated Stress Response</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105000</Key_PaperID>
<Key_SessionID>11519</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>298</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Elevated Expression of the S100A8/S100A9 Complex in AML Correlates with Reduced Sensitivity to the BCL2 Inhibitor Venetoclax</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100210</Key_PaperID>
<Key_SessionID>11519</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>299</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Mitochondrial Carrier Homolog 2 (MTCH2) Regulates the Differentiation of AML Cells By Controlling Pyruvate Entry into the Mitochondria, Nuclear Localization of Pyruvate Dehydrogenase Complex and H3 and H4 Histone Acetylation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104073</Key_PaperID>
<Key_SessionID>11519</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ixazomib use in AML will be discussed</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>300</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Validation of FOXM1 As a Therapeutic Target in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107536</Key_PaperID>
<Key_SessionID>11520</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>715</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Mechanisms of NT5C2 mutations Driving Thiopurine Resistance in Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102493</Key_PaperID>
<Key_SessionID>11520</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>716</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825 Targets Both NOTCH1-MYC Regulatory Circuit and Leukemia-Microenvironment in T-ALL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101938</Key_PaperID>
<Key_SessionID>11520</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>717</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106023</Key_PaperID>
<Key_SessionID>11520</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber>718</PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>Autoimmunity Checkpoints As Therapeutic Targets in B- and T-Cell Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108232</Key_PaperID>
<Key_SessionID>11520</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>719</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>A Novel, Highly Selective IRAK1 Inhibitor Jh-X-119-01 Shows Synergistic Tumor Cell Killing with Ibrutinib in MYD88 Mutated B-Cell Lymphoma Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100628</Key_PaperID>
<Key_SessionID>11520</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>720</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Histone Deacetylase Inhibitors Downregulate CCR4 Expression and Decrease Mogamulizumab Efficacy in CCR4-Positive Mature T-Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102311</Key_PaperID>
<Key_SessionID>11521</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>799</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Activity of CD19/CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105308</Key_PaperID>
<Key_SessionID>11521</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>800</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Integrated ATAC-Seq and Chemosensitivity Profiling Identifies Rational Drug Combinations in Ibrutinib-Treated CLL Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104000</Key_PaperID>
<Key_SessionID>11521</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>801</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting Maternal Embryonic Leucine Zipper Kinasewith OTSSP167 Displays Anti-Tumor Activities in Chronic Lymphocytic Leukemia through Down-Regulation of FoxM1</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107324</Key_PaperID>
<Key_SessionID>11521</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>802</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Ibrutinib Discontinuation in Waldenstrm Macroglobulinemia: Etiologies, Outcomes, and IgM Rebound</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108157</Key_PaperID>
<Key_SessionID>11521</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>803</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>BTKCys481Ser Mutation Drives Ibrutinib Resistance through ERK1/2 Hyperactivation, and Can Confer a Protective Effect on Bystander Waldenstroms Macroglobulinemia and ABC DLBCL Cells through Paracrine Mediated Pro-Survival Signaling</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103233</Key_PaperID>
<Key_SessionID>11521</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>804</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Blocking of Transient Receptor Potential Vanilloid1 (TRPV1) Promotes Lysosomal Destabilization and Enhances Bortezomib-Induced ER Stress and Cell Death Via HSP70 and LAMP3 Down-Regulation: Novel Therapeutic Target for Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107082</Key_PaperID>
<Key_SessionID>11522</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>100</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Absence of Silent Inactivation Using Intravenous Pegaspargase in Pediatric Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102285</Key_PaperID>
<Key_SessionID>11522</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>101</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Dexamethasone Pharmacokinetics Following Standard and Short Dosing Schedules in Patients on the UKALL2011 Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103104</Key_PaperID>
<Key_SessionID>11522</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>102</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104888</Key_PaperID>
<Key_SessionID>11522</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>97</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>A Treatment Protocol with Imatinib and Intensive Chemotherapy for Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia Patients: A Single-Arm, Intergroup Study (EsPhALL 2010-2014)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101926</Key_PaperID>
<Key_SessionID>11522</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>98</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106569</Key_PaperID>
<Key_SessionID>11522</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>99</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100502</Key_PaperID>
<Key_SessionID>11523</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	6:30 PM
 
</PaperEndTime>
<PaperNumber>883</PaperNumber>
<PaperStartTime>
	6:15 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Childrens Oncology Group</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107471</Key_PaperID>
<Key_SessionID>11523</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	6:45 PM
 
</PaperEndTime>
<PaperNumber>884</PaperNumber>
<PaperStartTime>
	6:30 PM
 
</PaperStartTime>
<PaperTitle>TP53, ETV6 and RUNX1 Germline Variants in Patients Developing Secondary Neoplasms after Treatment for Childhood Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103700</Key_PaperID>
<Key_SessionID>11523</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:00 PM
 
</PaperEndTime>
<PaperNumber>885</PaperNumber>
<PaperStartTime>
	6:45 PM
 
</PaperStartTime>
<PaperTitle>Common Genetic Variants in Trypsin Regulating Genes Are Associated with AsparAginase-Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102159</Key_PaperID>
<Key_SessionID>11523</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:15 PM
 
</PaperEndTime>
<PaperNumber>886</PaperNumber>
<PaperStartTime>
	7:00 PM
 
</PaperStartTime>
<PaperTitle>Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100804</Key_PaperID>
<Key_SessionID>11523</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>887</PaperNumber>
<PaperStartTime>
	7:15 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99995</Key_PaperID>
<Key_SessionID>11523</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>KTE-C19 is not yet approved for treatment of adult R/R ALL.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:45 PM
 
</PaperEndTime>
<PaperNumber>888</PaperNumber>
<PaperStartTime>
	7:30 PM
 
</PaperStartTime>
<PaperTitle>Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103053</Key_PaperID>
<Key_SessionID>11524</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Randomized trial to compare observation with azacitidine in maintenance setting of AML</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>463</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients ( 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107072</Key_PaperID>
<Key_SessionID>11524</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>464</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100147</Key_PaperID>
<Key_SessionID>11524</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>465</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Clofarabine-Based Consolidation Improves Relapse-Free Survival of Patients with Acute Myeloid Leukemia with Complex or Micro-Complex Karyotype: Results from the Randomized ALFA-0702 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102190</Key_PaperID>
<Key_SessionID>11524</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>466</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Role of Allogeneic Reduced Intensity Conditioning Stem Cell Transplantation (RIC-SCT) in Older Patients with Acute Myeloid Leukemia (AML): Analysis of the ALFA-1200 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103709</Key_PaperID>
<Key_SessionID>11524</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>467</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105277</Key_PaperID>
<Key_SessionID>11524</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>468</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Flow Cytometric Minimal Residual Disease As Risk Stratification Tool in Younger Adults with NPM1 Wild Type Standard Risk Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101950</Key_PaperID>
<Key_SessionID>11525</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>637</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104650</Key_PaperID>
<Key_SessionID>11525</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>United States FDA approval for enasidenib in treatment of relapsed/refractory AML is expected prior to the annual ASH congress. The current abstract presents results from a phase 1 study of enasidenib in patients with untreated AML. Ivosidenib approval is not expected in 2017 and, thus, the results reported here are not off-label as no label exists as yet.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>638</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 (mIDH2) Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104004</Key_PaperID>
<Key_SessionID>11525</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>United States FDA approval for enasidenib in treatment of relapsed/refractory AML is expected prior to the annual ASH congress. The current abstract presents results from a phase 1 study of enasidenib in patients with untreated AML. Ivosidenib approval is not expected in 2017 and, thus, the results reported here are not off-label as no label exists as yet.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>639</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104405</Key_PaperID>
<Key_SessionID>11525</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>INCB052793 is an investigational drug that is not yet approved in any treatment setting</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>640</PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106189</Key_PaperID>
<Key_SessionID>11525</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber>641</PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Oral Arsenic Plus Retinoic Acid Versus Intravenous Arsenic Plus Retinoic Acid for Non-High Risk Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trials</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101041</Key_PaperID>
<Key_SessionID>11525</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber>642</PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia Improved Long Term Relapse-Free Survival: 7-Year Results from a Randomized Controlled Trial, JALSG-APL204</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101383</Key_PaperID>
<Key_SessionID>11526</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>565</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Minimal-Residual Disease Guided Treatment with Azacitidine in MDS/AML Patients at Imminent Risk of Relapse: Results of the Prospective RELAZA2 Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105606</Key_PaperID>
<Key_SessionID>11526</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>566</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>Low Relapse Rate in Younger Patients  60 Years Old with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Treated with Crenolanib and Cytarabine/Anthracycline Chemotherapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104478</Key_PaperID>
<Key_SessionID>11526</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>567</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108361</Key_PaperID>
<Key_SessionID>11526</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>568</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>IDH1/2-Mutated Acute Myeloid Leukemia Has Impaired DNA Damage Response and Is Sensitive to Monotherapy with the PARP Inhibitior Olaparib</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104896</Key_PaperID>
<Key_SessionID>11526</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>569</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Mature Analysis of the Prospective Oxford Down Syndrome (DS) Cohort Study: Timing and Clinical Impact of Preleukemic GATA1 Mutations and Lessons for Management of Newborns with DS</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103519</Key_PaperID>
<Key_SessionID>11526</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>570</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Molecular Epidemiology of Acute Myeloid Leukemia (AML): Novel Association of Clinical Epidemiologic Exposures with Unique Mutation Groups on Exome Sequencing of Leukemia DNA in the Mayo Clinic AML Epidemiology Cohort</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107689</Key_PaperID>
<Key_SessionID>11527</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Tocilizumab for cytokine release syndrome and neurotoxicity after CAR-T cell therapy.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>805</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104521</Key_PaperID>
<Key_SessionID>11527</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>806</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>A Novel Low Affinity CD19CAR Results in Durable Disease Remissions and Prolonged CAR T Cell Persistence without Severe CRS or Neurotoxicity in Patients with Paediatric ALL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100680</Key_PaperID>
<Key_SessionID>11527</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>807</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105595</Key_PaperID>
<Key_SessionID>11527</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>808</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Pre-Clinical Activity of Allogeneic Anti-CD22 CAR-T Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104492</Key_PaperID>
<Key_SessionID>11527</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>809</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CD4/CD8 T-Cell Selection Enhances CD22 CAR-T Cell Transduction and in-Vivo CAR-T Expansion: Updated Results on Phase I Anti-CD22 CAR Dose Expansion Cohort</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102948</Key_PaperID>
<Key_SessionID>11527</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>810</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors Outperform Single or Bivalent Cars in Eradicating CD19+CD22+, CD19-, and CD22- Pre-B Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102838</Key_PaperID>
<Key_SessionID>11528</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Blinatumomab in minimal residual disease
Nelarabine in minimal residual disease</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber>139</PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Minimal Residual Disease (MRD) and MRD-Based Treatment Decisions in Ph/BCR-ABL Negative Adult Acute Lymphoblastic Leukemia (ALL): Experience from the German Multicenter Study Group for Adult ALL (GMALL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102426</Key_PaperID>
<Key_SessionID>11528</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber>140</PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Intensification of Oral Methotrexate Is Not Superior to Standard Methotrexate Dosing during Maintenance in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Childrens Oncology Group (COG) Study AALL0932 </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101703</Key_PaperID>
<Key_SessionID>11528</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber>141</PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>UKALL 2011: Randomised Trial Investigating a Short Induction Dexamethasone Schedule for Children and Young Adults with Acute Lymphoblastic Leukaemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103844</Key_PaperID>
<Key_SessionID>11528</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber>142</PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>Individualized 6-Mercaptopurine Increments in Consolidation Treatment of Childhood Acute Lymphoblastic Leukemia: A NOPHO ALL2008 Randomized Controlled Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102616</Key_PaperID>
<Key_SessionID>11528</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Inotuzumab is not approved for use. </OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber>143</PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106206</Key_PaperID>
<Key_SessionID>11528</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber>144</PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>Acute Lymphoblastic Leukemia Cells Bypass the Blood Brain Barrier to Enter the CNS Via a Neuronal Developmental Pathway</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103421</Key_PaperID>
<Key_SessionID>11529</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber>145</PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104537</Key_PaperID>
<Key_SessionID>11529</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber>146</PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>The Intermediate Dose Verse Conventional Dose Cytarabine in Induction Therapy in Adult Acute Myeloid Leukemia: A Phase  Randomized Controlled Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102709</Key_PaperID>
<Key_SessionID>11529</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber>147</PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>Prolonged Arsenic Trioxide (ATO) and All-Trans Retinoic Acid (ATRA) Therapy for Relapsed Acute Promyelocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102598</Key_PaperID>
<Key_SessionID>11529</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber>148</PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>The Impact of the Administration Schedule and Mutational Profile on Outcomes of Patients with Relapsed and Refractory Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Large, International, Multi-Center Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102532</Key_PaperID>
<Key_SessionID>11529</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Cladribine is labeled for hairy cell leukemia. Here we describe its use in acute myeloid leukemia which has been done in other published regimens (e.g. CLAG and CLAG-M)</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber>149</PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101993</Key_PaperID>
<Key_SessionID>11529</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ixazomib is being used for acute myeloid leukemia but is FDA approved for multiple myeloma</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber>150</PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106668</Key_PaperID>
<Key_SessionID>11530</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Sorafenib for the treatment of AML. </OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>721</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104989</Key_PaperID>
<Key_SessionID>11530</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>722</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107890</Key_PaperID>
<Key_SessionID>11530</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>723</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102183</Key_PaperID>
<Key_SessionID>11530</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber>724</PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100879</Key_PaperID>
<Key_SessionID>11530</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>725</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102244</Key_PaperID>
<Key_SessionID>11530</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>726</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99795</Key_PaperID>
<Key_SessionID>11531</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	6:30 PM
 
</PaperEndTime>
<PaperNumber>889</PaperNumber>
<PaperStartTime>
	6:15 PM
 
</PaperStartTime>
<PaperTitle>Randomized Phase2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100832</Key_PaperID>
<Key_SessionID>11531</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	6:45 PM
 
</PaperEndTime>
<PaperNumber>890</PaperNumber>
<PaperStartTime>
	6:30 PM
 
</PaperStartTime>
<PaperTitle>Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105791</Key_PaperID>
<Key_SessionID>11531</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Decitabine for the treatment of elderly AML</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:00 PM
 
</PaperEndTime>
<PaperNumber>891</PaperNumber>
<PaperStartTime>
	6:45 PM
 
</PaperStartTime>
<PaperTitle>Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102820</Key_PaperID>
<Key_SessionID>11531</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:15 PM
 
</PaperEndTime>
<PaperNumber>892</PaperNumber>
<PaperStartTime>
	7:00 PM
 
</PaperStartTime>
<PaperTitle>Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106767</Key_PaperID>
<Key_SessionID>11531</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>893</PaperNumber>
<PaperStartTime>
	7:15 PM
 
</PaperStartTime>
<PaperTitle>BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100360</Key_PaperID>
<Key_SessionID>11531</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>GMI-1271 is an E-selectin antagonist being evaluated for the treatment of hematologic malignancies.  It is an investigational agent and has not been approved for use. </OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:45 PM
 
</PaperEndTime>
<PaperNumber>894</PaperNumber>
<PaperStartTime>
	7:30 PM
 
</PaperStartTime>
<PaperTitle>GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108199</Key_PaperID>
<Key_SessionID>11532</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>811</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100527</Key_PaperID>
<Key_SessionID>11532</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>812</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Targeting the Transcriptional Addiction of Leukemia Stem Cells By a New Class of Protein Kinase Inhibitors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105011</Key_PaperID>
<Key_SessionID>11532</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>VENCLEXTA (venetoclax) is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. COTELLIC (cobimetinib) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K
mutation, in combination with vemurafenib. Idasanutlin is a MDM2 inhibitor in development for acute myeloid leukemia as combination therapy.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>813</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100211</Key_PaperID>
<Key_SessionID>11532</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>814</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101563</Key_PaperID>
<Key_SessionID>11532</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off label use of nivolumab</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>815</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100343</Key_PaperID>
<Key_SessionID>11532</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Selinexor for relapsed/refractory AML</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>816</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102977</Key_PaperID>
<Key_SessionID>11533</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>301</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>MiR-126 Promotes Leukemogenesis in Inv(16) Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104413</Key_PaperID>
<Key_SessionID>11533</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>302</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>H3K27M/I Mutations Promote Context-Dependent Transformation in Acute Myeloid Leukemia with RUNX1 Alterations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102798</Key_PaperID>
<Key_SessionID>11533</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>303</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>NPM1c Alters FLT3-D835Y Localization and Signaling Thereby Inducing a Fulminant Myeloproliferative Disorder in Mice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108567</Key_PaperID>
<Key_SessionID>11533</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>304</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Utility of Detecting Rare Clonal Hematopoiesis for Predicting Leukemic Transformation in Healthy Individuals</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106781</Key_PaperID>
<Key_SessionID>11533</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>305</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>JAK2 Variants Associated with Secondary-AML from MPN</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107248</Key_PaperID>
<Key_SessionID>11533</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>306</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Marrow Stromal Cells Secrete FGF2 in Exosomes, Providing Paracrine Protection for Leukemia Cells from Kinase Inhibitors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106035</Key_PaperID>
<Key_SessionID>11534</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>24</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>The LSC17 Leukemic Stem Cell Signature Predicts Outcome in Pediatric Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102024</Key_PaperID>
<Key_SessionID>11534</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>25</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Functional Properties of Exon 17 KIT Mutations in Pediatric CBF AML Predict for Inferior Outcome and Enhanced Response to Tyrosine Kinase Inhibition: A Report from the Childrens Oncology Group</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104212</Key_PaperID>
<Key_SessionID>11534</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>26</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107778</Key_PaperID>
<Key_SessionID>11534</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>27</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Response Kinetics and Factors Predicting Survival Among Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104293</Key_PaperID>
<Key_SessionID>11534</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>28</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Simultaneous Identification and Stratification of Low Molecular Risk AML Patients Using a Single LSC17-Based Nanostring Assay at Diagnosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100932</Key_PaperID>
<Key_SessionID>11534</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>29</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Early Detection of WT1 minimal Residual Disease Predicts Outcome in Acute Myeloid Leukemia and Identify Patients with High Risk of Relapse Independently of Allogeneic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106067</Key_PaperID>
<Key_SessionID>11535</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>103</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Mutation Patterns Identify Adult Patients with De Novo Acute Myeloid Leukemia (AML) Aged 60 Years or Older Who Respond Favorably to Standard Chemotherapy: an Analysis of Alliance Studies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104750</Key_PaperID>
<Key_SessionID>11535</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>104</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>RARB Translocations in Acute Promyelocytic Leukemia without Raratranslocation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102293</Key_PaperID>
<Key_SessionID>11535</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>105</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Podoplanin Expression in the Bleeding Complications of Acute Promyelocytic Leukemias</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107413</Key_PaperID>
<Key_SessionID>11535</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>106</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Novel Therapeutic Targets for DNMT3A Mutant Myeloid Neoplasms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100257</Key_PaperID>
<Key_SessionID>11535</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>107</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Evaluation of Cancer Testis Antigens (CTAs) As Immuno-Therapeutic Targets in Pediatric AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101458</Key_PaperID>
<Key_SessionID>11535</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>108</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Eomes+ T-betint CD8 T Cells Are Functionally Impaired and Associate with Primary Refractory Disease in Patients with Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104697</Key_PaperID>
<Key_SessionID>11536</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>475</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Characterization of Causal Variants at the GATA3 Loci Associated with Susceptibility to Ph-like Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107116</Key_PaperID>
<Key_SessionID>11536</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>476</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Genomic Profiling Identifies Genomic Alterations That Define Philadelphia-like B-Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105248</Key_PaperID>
<Key_SessionID>11536</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>477</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Genomic and Outcome Analyses of Philadelphia Chromosome-like (Ph-like) NCI Standard Risk B-Acute Lymphoblastic Leukemia (SR B-ALL) Patients Treated on Childrens Oncology Group (COG) AALL0331</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104731</Key_PaperID>
<Key_SessionID>11536</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>478</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Intensifying Treatment in Childhood B-Lymphoblastic Leukemia with IKZF1 Deletions Negates Its Adverse Outcome: Results of Ma-Spore ALL 2003 and 2010 Studies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106785</Key_PaperID>
<Key_SessionID>11536</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>479</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting of the Interleukin-7 Receptor Alpha-Chain (IL-7R) Blocks B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Development and Reduces Leukemic Infiltration to the Central Nervous System (CNS)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102980</Key_PaperID>
<Key_SessionID>11536</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>480</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Clonal Competition of Cancer Cells during Acute Lymphoblastic Leukemia Treatment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104136</Key_PaperID>
<Key_SessionID>11537</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>367</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Hedgehog Pathway Mutations Drive Oncogenic Transformation in High-Risk T-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105024</Key_PaperID>
<Key_SessionID>11537</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>368</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Aberrant FLT3 Transcription Arised from Polycomb Repressive Complex 2 Inactivation Indiactes a Potential Therapy Target for Pediatric T Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106925</Key_PaperID>
<Key_SessionID>11537</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>369</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>A Role for the CRM1 Nuclear Export Receptor in HOXA Gene Deregulation and CALM-AF10 Leukemogenesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104016</Key_PaperID>
<Key_SessionID>11537</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>370</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>SOCS5 Regulates JAK-STAT Signaling and T-ALL Development</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103746</Key_PaperID>
<Key_SessionID>11537</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>371</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Adipocyte Induced Antagonism of ALL Growth Highlightsa Novel Inhibitory Niche and Potential Therapeutic Opportunity</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100266</Key_PaperID>
<Key_SessionID>11537</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>372</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Flow Cytometry Based MRD Monitoring Is an Accurate Risk Stratification Tool in Acute T-Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106112</Key_PaperID>
<Key_SessionID>11538</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>30</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Large Multi-Ethnic Genome Wide Association Study Reveals Novel Genetic Associations with Childhood Acute Lymphoblastic Leukemia at Chromosomes 8q24 and 17q12</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104581</Key_PaperID>
<Key_SessionID>11538</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>31</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>TP53 Germline Variations Influence the Predisposition and Prognosis of Acute Lymphoblastic Leukemia in Children</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103675</Key_PaperID>
<Key_SessionID>11538</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>32</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Genetic Variants in the HLA-genes Are Associated with PEG-asparaginase Allergy - a Genome Wide Association Study on the NOPHO ALL2008 Protocol</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102384</Key_PaperID>
<Key_SessionID>11538</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>33</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Metabolomic Profiling Improves Prediction of Early Disease Response and Relapse in Pediatric Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104948</Key_PaperID>
<Key_SessionID>11538</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>34</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>A CRISPR/Cas9 Based Kinome Screen Identifies Bruton Tyrosine Kinase (BTK) As an Important Determinant of Asparaginase Treatment Response in Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107429</Key_PaperID>
<Key_SessionID>11538</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>35</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Distinct MiR-126 Expression Describes a Non-Genetic but Functional Intra-Tumoral Heterogeneity in Primary Human B-ALL and Can be Prospectively Used to Identify Aggressive Subclones in NSG Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104171</Key_PaperID>
<Key_SessionID>11539</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>36</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Identification of Recurrent Non-Coding Driver Mutations in Non-Hodgkin Lymphomas through Integrative Genomic Analysis of 777 Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105763</Key_PaperID>
<Key_SessionID>11539</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>37</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105903</Key_PaperID>
<Key_SessionID>11539</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>38</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Genetically-Defined Diffuse Large B-Cell Lymphoma Subsets Arise By Distinct Pathogenetic Mechanisms and Predict Outcome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105317</Key_PaperID>
<Key_SessionID>11539</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>39</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Burkitt Lymphoma Genome Sequencing Project (BLGSP): Integrative Genomic and Transcriptomic Characterization of Burkitt Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101305</Key_PaperID>
<Key_SessionID>11539</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>40</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Genetic Characterization and Clinical Impact of Loss of MHC Class I and II Expression in De NovoDiffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101853</Key_PaperID>
<Key_SessionID>11539</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>41</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Germinal Center Program De-Synchronization and Intra-Patient Heterogeneity in Follicular Lymphoma B-Cells Revealed By Integrative Single-Cell Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103926</Key_PaperID>
<Key_SessionID>11540</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>307</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108223</Key_PaperID>
<Key_SessionID>11540</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>308</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Hierarchy in Somatic Mutations Detected in Circulating and Tissue-Resident Follicular Lymphoma Precursors before Clinical Diagnosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107849</Key_PaperID>
<Key_SessionID>11540</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>309</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Combined Genotype Analysis of Tumor and Cell-Free DNA By Ultra-Deep Targeted Sequencing: Correlation with PET-Scan Imaging in a Prospective Cohort of Diffuse Large B-Cell Lymphoma Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107709</Key_PaperID>
<Key_SessionID>11540</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>310</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Circulating Tumor DNA Is a Reliable Measure of Tumor Burden at Diagnosis of Diffuse Large B Cell Lymphoma: An International Reproducibility Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107270</Key_PaperID>
<Key_SessionID>11540</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>311</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Therapeutic Targeting of HDAC3 in FOXO1-Mutant DLBCL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105757</Key_PaperID>
<Key_SessionID>11540</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>312</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Exportin-1 Connects Dynamic Transcription and Translation of Genotoxic Stress Genes in Diffuse Large B-Cell Lymphoma Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107720</Key_PaperID>
<Key_SessionID>11541</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>643</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>SIRT3 Is a Novel Metabolic Driver of and Therapeutic Target for Chemotherapy Resistant Dlbcls</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107055</Key_PaperID>
<Key_SessionID>11541</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>644</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Catalytically Active UCH-L1 Is Required for MYC Driven B-Cell Lymphomagenesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107362</Key_PaperID>
<Key_SessionID>11541</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>645</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100050</Key_PaperID>
<Key_SessionID>11541</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>646</PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Smoothened Stabilizes and Protects TRAF6 from Proteosomal Degradation: A Novel Non-Canonical Role of Smoothened with Implications in Lymphoma Biology</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101884</Key_PaperID>
<Key_SessionID>11541</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber>647</PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Functional Analyses of BTK Mutations in Follicular Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102879</Key_PaperID>
<Key_SessionID>11541</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber>648</PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldestrostom Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105440</Key_PaperID>
<Key_SessionID>11542</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated, in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia and, in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. GAZYVA is also indicated in combination with chemotherapy, followed by GAZYVA maintenance in patients achieving a response, in previously untreated advanced FL (EU, Switzerland). In this abstract, an exploratory post hoc analysis of phase III data for GAZYVA plus chemotherapy in previously untreated patients with follicular lymphoma or diffuse large B-cell lymphoma is reported.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>727</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106957</Key_PaperID>
<Key_SessionID>11542</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>728</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>The Tumor Microenvironment Is Independently Prognostic of Conventional and Clinicogenetic Risk Models in Follicular Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101310</Key_PaperID>
<Key_SessionID>11542</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>729</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Lenalidomide Treatment Restores In Vivo T Cell Activity in Relapsed/Refractory FL and DLBCL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103757</Key_PaperID>
<Key_SessionID>11542</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber>730</PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>Novel Mechanism of Post-Transcriptional Regulation of PD-L1 Expression By 3-UTR Binding Proteins</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101609</Key_PaperID>
<Key_SessionID>11542</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>731</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T-Cell Leukemia/Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105622</Key_PaperID>
<Key_SessionID>11542</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>732</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of the Integrin V3 Improves the Immune and Anti-Lymphoma Effects of Bexarotene in Cutaneous T-Cell Lymphoma (CTCL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105076</Key_PaperID>
<Key_SessionID>11543</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated, in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia and, in combination with bendamustine (benda) followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. GAZYVA is also indicated in combination with chemotherapy, followed by GAZYVA maintenance in patients achieving a response, in previously untreated advanced FL (EU, Switzerland). Atezolizumab (atezo), which targets programmed death-ligand 1 (PD-L1), has a complementary mechanism of action to G and has the potential to improve outcomes when added to G-chemotherapy in FL. In this abstract, interim data from a Phase Ib/II study on G-benda-atezo induction followed by maintenance with G-atezo, are reported</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>481</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101116</Key_PaperID>
<Key_SessionID>11543</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>bortezomib and lenalidomide for untreated follicular lymphoma</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>482</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100764</Key_PaperID>
<Key_SessionID>11543</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>483</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99991</Key_PaperID>
<Key_SessionID>11543</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>484</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99821</Key_PaperID>
<Key_SessionID>11543</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ofatumumab is off label for treatment of follicular lymphoma.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>485</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100618</Key_PaperID>
<Key_SessionID>11543</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>486</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107064</Key_PaperID>
<Key_SessionID>11544</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber>151</PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101647</Key_PaperID>
<Key_SessionID>11544</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>tk</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber>152</PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkins Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104930</Key_PaperID>
<Key_SessionID>11544</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Rituximab for mantle cell lymphoma</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber>153</PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103595</Key_PaperID>
<Key_SessionID>11544</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Discussion of lenalidomide use in the frontline setting for mantle cell lymphoma</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber>154</PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100664</Key_PaperID>
<Key_SessionID>11544</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber>155</PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102972</Key_PaperID>
<Key_SessionID>11544</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase.   </OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber>156</PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acs Phase II Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102347</Key_PaperID>
<Key_SessionID>11545</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off-label use of vemurafenib is discussed in the context of a clinical trial.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber>409</PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>The Chemotherapy-Free Combination of Vemurafenib and Rituximab Produces Deep and Durable Responses in Relapsed or Refractory Hairy Cell Leukemia (HCL) Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99739</Key_PaperID>
<Key_SessionID>11545</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber>410</PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3K Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102094</Key_PaperID>
<Key_SessionID>11545</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This is a phase I study evaluating the safety and efficacy of CC-122 in combination with obinutuzmab in patients with R/R B-cell NHL. CC-122 is an investigational agent and has not yet been approved in the US.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber>411</PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>CC-122, a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed and Refractory (R/R) BCell NonHodgkin Lymphoma (NHL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106253</Key_PaperID>
<Key_SessionID>11545</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber>412</PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104949</Key_PaperID>
<Key_SessionID>11545</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber>413</PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De NovoFollicular Lymphoma Treated Initially with Immunochemotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104625</Key_PaperID>
<Key_SessionID>11545</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Phase II study investigating pembrolizumab in relapsed follicular lymphoma. </OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber>414</PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101114</Key_PaperID>
<Key_SessionID>11546</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Brentuximab vedotin in untreated Hodgkin lymphoma</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>733</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105418</Key_PaperID>
<Key_SessionID>11546</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>734</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 20 Gy Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104506</Key_PaperID>
<Key_SessionID>11546</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>735</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Advanced-Stage Hodgkin Lymphoma in the East of England Cancer Network: A 10-Year Comparative Analysis of Outcomes for Patients Treated with ABVD or Escalated BEACOPPin the Non-Trial Setting Compared with Age-Matched Patients Treated in the Multinational RATHLTrial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103173</Key_PaperID>
<Key_SessionID>11546</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Brentuximab Vedotin in first-line for unfavorable, early-stage, Hodgkin Lymphoma</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber>736</PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100436</Key_PaperID>
<Key_SessionID>11546</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>737</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Early Interim PET in Patients with Advanced-Stage Hodgkins Lymphoma Treated within the Phase 3 GHSG HD18 Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100560</Key_PaperID>
<Key_SessionID>11546</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This is a prospective phase II clinical trial. </OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>738</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101568</Key_PaperID>
<Key_SessionID>11547</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Yes, brentuximab vedotin is being investigated in a novel combination. </OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>649</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100964</Key_PaperID>
<Key_SessionID>11547</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Nivolumab, a fully human antiPD-1 monoclonal antibody, is approved in the US for the treatment of adults with cHL that has relapsed or progressed following auto-HCT and BV treatment or 3 or more prior lines of systemic therapy (including auto-HCT). This phase 2 clinical trial included BV-na&amp;hibar;ve patients who had received &lt;3 prior therapies.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>650</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100481</Key_PaperID>
<Key_SessionID>11547</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Nivolumab, a fully human antiPD-1 monoclonal antibody, is approved in the US for the treatment of adults with cHL that has relapsed or progressed following auto-HCT and BV treatment or 3 or more prior lines of systemic therapy (including auto-HCT). This phase 2 clinical trial assessed the safety and efficacy of nivolumab as a front-line therapy, either alone or in combination with chemotherapy. 		</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>651</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102247</Key_PaperID>
<Key_SessionID>11547</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>652</PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106787</Key_PaperID>
<Key_SessionID>11547</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber>653</PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100054</Key_PaperID>
<Key_SessionID>11547</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber>654</PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102371</Key_PaperID>
<Key_SessionID>11548</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This information will be disclosed to the audience.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>817</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III M&amp;#65;&amp;#86;&amp;#79;&amp;#82;&amp;#73;&amp;#67;Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106143</Key_PaperID>
<Key_SessionID>11548</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>818</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101731</Key_PaperID>
<Key_SessionID>11548</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Duvelisib in T cell lymphoma
Bortezomib in T cell lymphoma</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>819</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-, Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106122</Key_PaperID>
<Key_SessionID>11548</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>820</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102983</Key_PaperID>
<Key_SessionID>11548</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>821</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B- and T-Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106383</Key_PaperID>
<Key_SessionID>11548</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>822</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK, DUSP22 and TP63 Gene Rearrangement Status  a Joined Nordic Lymphoma Group and Mayo Clinic Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105723</Key_PaperID>
<Key_SessionID>11549</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>571</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>In Vitro and pre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53-Wild-Type T-Cell Lymphomas That Are Targetable with the -Helical p53 Stapled Peptide Alrn-6924</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103555</Key_PaperID>
<Key_SessionID>11549</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>dasatinib, lymphoma treatment</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>572</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>Targeting T-Cell Receptor Signaling Pathway in Angioimmunoblastic T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102382</Key_PaperID>
<Key_SessionID>11549</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>573</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>High Frequency of CD74 Expression in B-Cell Non-Hodgkins Lymphoma (NHL) and Targeting with SRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent In Vitro Cytotoxicty and In Vivo Anti-Tumor Activity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105933</Key_PaperID>
<Key_SessionID>11549</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>574</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Targeting the Paracaspase MALT1: A Potential Therapy to Overcome Ibrutinib Resistance in Relapsed/Refractory Mantle Cell Lymphoma Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106595</Key_PaperID>
<Key_SessionID>11549</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>BCL-2 inhibitor venetoclax is approved in high risk CLL failing treatment with a BTK inhibitor. Here we demonstrate first time evidence of single agent activity of venetoclax both, ex vivo and in human offering a novel agent in T-PLL. </OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>575</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>First in Human Response of BCL-2 Inhibitor Venetoclax in T-Cell Prolymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107645</Key_PaperID>
<Key_SessionID>11549</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>576</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled By Functional Lipoprotein Nanoparticles and the B Cell Receptor Inhibitor Ibrutinib: A Therapeutic Strategy Dependent on Cell of Origin (COO)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104531</Key_PaperID>
<Key_SessionID>11550</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>109</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Generation and Application of T-Cell Lymphoma Patient Derived Tumor Xenograft Models</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107066</Key_PaperID>
<Key_SessionID>11550</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>110</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>CD19-Chimeric Antigen Receptor (CAR) Engineered Natural Killer (NK) Cell Therapy: Novel Off the Shelf Immunotherapy in CD20 Resistant B-Cell Non-Hodgkin Lymphoma (NHL) Cell Lines, Primary NHL Cells, and aHuman Lymphoma Xenograft Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107555</Key_PaperID>
<Key_SessionID>11550</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>111</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>B-Cell Receptor Antigens As the Targeting Moiety for Bispecific Constructs  a Novel Treatment Approach for B-Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100776</Key_PaperID>
<Key_SessionID>11550</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>112</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>ALX148 Is a High Affinity Sirp Fusion Protein That Blocks CD47, Enhances the Activity of Anti-Cancer Antibodies and Checkpoint Inhibitors, and Has a Favorable Safety Profile in Preclinical Models</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105971</Key_PaperID>
<Key_SessionID>11550</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>113</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Eradication of Systemic Lymphoma By Local Immunotherapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105990</Key_PaperID>
<Key_SessionID>11550</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>114</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Integration of Whole Exome and RNA Sequencing Identifies Neoepitope Vaccine Candidates in &gt;90 Percent of Follicular Lymphoma Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105399</Key_PaperID>
<Key_SessionID>11551</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Assuming approval of CTL019 (tisagenlecluecel)  in pediatric ALL in August 2017, this abstracts discusses clinical trial results of CTL019 in patients with DLBCL</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>577</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99983</Key_PaperID>
<Key_SessionID>11551</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Axi-cel (KTE-C19) is not yet approved for the treatment of refractory, aggressive NHL.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>578</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99962</Key_PaperID>
<Key_SessionID>11551</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Axi-cel (KTE-C19) is not yet approved for the treatment of refractory, aggressive NHL.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>579</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105709</Key_PaperID>
<Key_SessionID>11551</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>580</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102372</Key_PaperID>
<Key_SessionID>11551</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>581</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103102</Key_PaperID>
<Key_SessionID>11551</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>582</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Effect of Rituximab in Primary Central Nervous System Lymphoma  results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104869</Key_PaperID>
<Key_SessionID>11552</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber>187</PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Encouraging Early Results from the First in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105769</Key_PaperID>
<Key_SessionID>11552</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber>188</PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107039</Key_PaperID>
<Key_SessionID>11552</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Clinical trial of lenalidomide and obinutuzumab with standard chemotherapy in DLBCL</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber>189</PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100623</Key_PaperID>
<Key_SessionID>11552</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Obinutuzumab in first line treatment of diffuse large B cell lymphoma</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>190</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (&lt; 60 years): Third Planned Interim and Final Analyses of the Gained Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102843</Key_PaperID>
<Key_SessionID>11552</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>brentuximab vedotin</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>191</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100682</Key_PaperID>
<Key_SessionID>11552</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This is a phase I study evaluating the safety and efficacy of CC-486 in patients with high-risk, previously untreated DLBCL, grade 3B FL, or transformed lymphoma. CC-486 is an investigational agent and has not yet been approved in the US.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>192</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>A Phase I, Open-Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102985</Key_PaperID>
<Key_SessionID>11553</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>823</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Results of PET-Guided Radiation Therapy in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma Treated with R-CHOP in British Columbia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106792</Key_PaperID>
<Key_SessionID>11553</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated, in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia and, in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. GAZYVA is also indicated in combination with chemotherapy, followed by GAZYVA maintenance in patients achieving a response, in previously untreated advanced FL (EU, Switzerland). In this abstract, an investigation of the prognostic value of quantitative PET for progression-free survival, based on Phase III trial data for GAZYVA plus chemotherapy in previously untreated patients with diffuse large B-cell lymphoma, are reported.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>824</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108824</Key_PaperID>
<Key_SessionID>11553</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>825</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108279</Key_PaperID>
<Key_SessionID>11553</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>826</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107230</Key_PaperID>
<Key_SessionID>11553</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>827</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105031</Key_PaperID>
<Key_SessionID>11553</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>828</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Diffuse Large B-Cell Lymphomas Transformed from or with Concurrent Follicular Lymphoma Demonstrate Similar Clinical Outcomes As De-Novo Diffuse Large B-Cell Lymphomas, Except for Cases Harboring Double Hit Rearrangements</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106003</Key_PaperID>
<Key_SessionID>11554</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber>415</PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Immunohistochemistry-Defined Cell of Origin and MYC Rearrangements on Outcomes in Patients with PET-Defined Stage I/II Diffuse Large B-Cell Lymphoma Treated with R-CHOP  Radiotherapy: An International Multi-Center Retrospective Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100994</Key_PaperID>
<Key_SessionID>11554</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber>416</PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>A New Immunohistochemical Algorithm Using Four Antibodies Has a High Concordance with Gene Expression Profiling Defined ABC and GCB Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107657</Key_PaperID>
<Key_SessionID>11554</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber>417</PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Genomic Profiling (CGP) Identifies Novel BCL6 Rearrangements in Diverse Subtypes of Non-Hodgkin Lymphoma (NHL) As Well As Known Rearrangements Not Detected Using Standard of Care (SOC) Assays</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105778</Key_PaperID>
<Key_SessionID>11554</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The Ventana BCL-2 assay is an investigational device. Limited by Federal (or United States) law to investigational use. Not for sale in the United States. The assay is not approved for clinical use.</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber>418</PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106940</Key_PaperID>
<Key_SessionID>11554</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber>419</PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106533</Key_PaperID>
<Key_SessionID>11554</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber>420</PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>The Prognostic Significance of the Complete IgH Rearrangement Pattern Using the BIOMED-2 Protocol in Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105823</Key_PaperID>
<Key_SessionID>11555</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber>193</PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107264</Key_PaperID>
<Key_SessionID>11555</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber>194</PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>Predicting Clinical Response and Safety of JCAR017 in B-NHL Patients: Potential Importance of Tumor Microenvironment Biomarkers and CAR T-Cell Tumor Infiltration</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105749</Key_PaperID>
<Key_SessionID>11555</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber>195</PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>High Expression of Programmed Death-Ligand 1 (PD-L1) Correlates with Macrophage Gene Expression and Is Associated with Prolonged Progression-Free Survival (PFS) in Patients (pts) with First-Line (1L) Diffuse Large B-Cell Lymphoma (DLBCL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101577</Key_PaperID>
<Key_SessionID>11555</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>196</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Clinical Characteristics and Outcome of Diffuse Large B-Cell Lymphoma with 9p24.1 Copy Number Alterations</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107990</Key_PaperID>
<Key_SessionID>11555</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>197</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Significance of PD-1 and PD-L1 Expression and Ongoing Interaction in the Tumor Microenvironment in Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106039</Key_PaperID>
<Key_SessionID>11555</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>198</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Increased Incidence of Autoimmune and Infectious Diseases Among a Large Group of Diffuse Large B-Cell Lymphoma (DLBCL) Survivors: A Population-Based Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103483</Key_PaperID>
<Key_SessionID>11556</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>373</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Epidemiology, Clinical Features, and Outcome of HTLV-1 Related Adult T-Cell Leukemia-Lymphoma in a Prevalent Area in the United States</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104542</Key_PaperID>
<Key_SessionID>11556</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The anti-CD30 monomethyl-auristatin-E conjugate brentuximab vedotin (BV). It has been an effective treatment option for Hodgkin lymphoma, anaplastic T-cell lymphomas, and various peripheral lymphoma types. As part of the HONORS award, we wanted to propose in-depth characterization of CD30 expression and clinical investigation of BV in ATLL.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>374</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Targeting CD30 Expression in Adult T-Cell Leukemia-Lymphoma (ATLL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100338</Key_PaperID>
<Key_SessionID>11556</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>375</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Gray Zone Lymphoma (GZL) with Features Intermediate between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): A Pathologic Consensus Study with Patient Outcomes and Prognosticationacross 15 North American Centers</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105105</Key_PaperID>
<Key_SessionID>11556</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>376</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL  a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106138</Key_PaperID>
<Key_SessionID>11556</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>377</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103664</Key_PaperID>
<Key_SessionID>11556</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>378</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Liquid Biopsy for the Identification of Intravascular Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99778</Key_PaperID>
<Key_SessionID>11557</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>42</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105062</Key_PaperID>
<Key_SessionID>11557</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>43</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>SETD2 Loss of Function Is a Recurrent Event in Advanced-Phase Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104964</Key_PaperID>
<Key_SessionID>11557</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>44</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>De Novo UBE2A Mutations Are Recurrently Acquired during CML Progression and Interfere with Myeloid Differentiation Pathways</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103960</Key_PaperID>
<Key_SessionID>11557</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>45</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107994</Key_PaperID>
<Key_SessionID>11557</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>46</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Regulation of Asymmetric Division in Myeloid Leukemogenesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107853</Key_PaperID>
<Key_SessionID>11557</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>47</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104013</Key_PaperID>
<Key_SessionID>11558</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	6:30 PM
 
</PaperEndTime>
<PaperNumber>895</PaperNumber>
<PaperStartTime>
	6:15 PM
 
</PaperStartTime>
<PaperTitle>PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101164</Key_PaperID>
<Key_SessionID>11558</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	6:45 PM
 
</PaperEndTime>
<PaperNumber>896</PaperNumber>
<PaperStartTime>
	6:30 PM
 
</PaperStartTime>
<PaperTitle>Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100250</Key_PaperID>
<Key_SessionID>11558</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:00 PM
 
</PaperEndTime>
<PaperNumber>897</PaperNumber>
<PaperStartTime>
	6:45 PM
 
</PaperStartTime>
<PaperTitle>Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100087</Key_PaperID>
<Key_SessionID>11558</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:15 PM
 
</PaperEndTime>
<PaperNumber>898</PaperNumber>
<PaperStartTime>
	7:00 PM
 
</PaperStartTime>
<PaperTitle>Response to Front-Line Imatinib Treatment in Children and Adolescents with CML  Data from a Large Pediatric Cohort</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100531</Key_PaperID>
<Key_SessionID>11558</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>899</PaperNumber>
<PaperStartTime>
	7:15 PM
 
</PaperStartTime>
<PaperTitle>Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107605</Key_PaperID>
<Key_SessionID>11558</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:45 PM
 
</PaperEndTime>
<PaperNumber>900</PaperNumber>
<PaperStartTime>
	7:30 PM
 
</PaperStartTime>
<PaperTitle>Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106001</Key_PaperID>
<Key_SessionID>11559</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>247</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Cytogenetics-Based Risk Prediction of Blastic Transformation of CML Treated with Tyrosine Kinase Inhibitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103767</Key_PaperID>
<Key_SessionID>11559</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>248</PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>Whats Next in CML  a Prospective Study EvaluatingSanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105367</Key_PaperID>
<Key_SessionID>11559</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>249</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Persistence of Residual Circulating CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102704</Key_PaperID>
<Key_SessionID>11559</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>250</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100381</Key_PaperID>
<Key_SessionID>11559</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>251</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105632</Key_PaperID>
<Key_SessionID>11559</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>252</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Incidence of Low Level Mutations in Newly Diagnosed CML Patients: A Substudy of the German Tiger Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101387</Key_PaperID>
<Key_SessionID>11560</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>313</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102752</Key_PaperID>
<Key_SessionID>11560</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>314</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102046</Key_PaperID>
<Key_SessionID>11560</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>315</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100190</Key_PaperID>
<Key_SessionID>11560</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>316</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Advanced Phases at Diagnosis of Childhood Chronic Myeloid Leukemia : The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105068</Key_PaperID>
<Key_SessionID>11560</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>317</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101367</Key_PaperID>
<Key_SessionID>11560</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>318</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106037</Key_PaperID>
<Key_SessionID>11561</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>fludarabine/melphalan as conditioning regimen for hematopoietic cell transplantation for myelofibrosis.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber>199</PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Survival in Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation Using Fludarabine/Melphalan Conditioning Regimen</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100993</Key_PaperID>
<Key_SessionID>11561</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber>200</PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104379</Key_PaperID>
<Key_SessionID>11561</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber>201</PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Characteristics and Survival of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of Therapy with JAK2 Inhibitor Ruxolitinib</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101667</Key_PaperID>
<Key_SessionID>11561</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>202</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102779</Key_PaperID>
<Key_SessionID>11561</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>203</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>SETBP1 and NRAS Mutations Are Frequent Events in Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML) Lacking JAK-STAT Activating Mutations</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104063</Key_PaperID>
<Key_SessionID>11561</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>204</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Advanced Forms of the Myeloproliferative Neoplasms AreAssociated with  Chromosomal Abnormalities Involving 1q and 12q: Implicating MDM2 and MDM4 in Disease Progression</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100591</Key_PaperID>
<Key_SessionID>11562</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>319</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Hydroxycarbamide Plus Aspirin Vs Aspirin Alone in Intermediate Risk Essential Thrombocythemia: Results of the PT-1 International, Prospective, Randomized Clinical Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106570</Key_PaperID>
<Key_SessionID>11562</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>320</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103543</Key_PaperID>
<Key_SessionID>11562</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>321</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103857</Key_PaperID>
<Key_SessionID>11562</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>322</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Results from the 208-Week (4-Year) Follow-up of RESPONSETrial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103259</Key_PaperID>
<Key_SessionID>11562</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pegylated Interferons are actually used for patients with MPN but off-label. Our goal is to show that these drugs can be useful for patients with myelofibrosis-associated MPNs.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>323</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104045</Key_PaperID>
<Key_SessionID>11562</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>324</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Pulmonary Hypertension Independently Shortens Survival of Patients with Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100916</Key_PaperID>
<Key_SessionID>11563</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>253</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103107</Key_PaperID>
<Key_SessionID>11563</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>idasanutlin (RG7388) is an oral MDM2 inhibitor that is currently being evaluated in early and late phase trials for various malignancies and does not have an FDA approved indication at present. We evaluated the safety and tolerability in a phase I trial in patients with polycythemia vera and essential thrombocythemia. </OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>254</PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>Open Label Phase I Study of Single Agent Oral RG7388 (idasanutlin) in Patients with Polycythemia Vera and Essential Thrombocythemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104189</Key_PaperID>
<Key_SessionID>11563</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Sotatercept is not currently approved for any clinical indication</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>255</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106641</Key_PaperID>
<Key_SessionID>11563</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Study drug is LCL161; non FDA approved, clinical trial drug : smac mimetic, in investigation/clinical trials for pts with various heme malignancies; in this abstract will be presenting first in MPN clinical trial results</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>256</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107297</Key_PaperID>
<Key_SessionID>11563</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This is a clinical trial of this medication.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>257</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Phase 2 Trial of Single-Agent Cobimetinib for Adults with BRAF V600-Mutant and Wild-Type Histiocytic Disorders</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100073</Key_PaperID>
<Key_SessionID>11563</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>258</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104499</Key_PaperID>
<Key_SessionID>11564</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>379</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Molecular and Functional Characterization of Disease-Propagating Stem Cells in Juvenile Myelomonocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104706</Key_PaperID>
<Key_SessionID>11564</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>380</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Targeting the Epigenetic and Metabolic Vulnerabilities of Ezh2-Deficiency-Induced Myeloid Neoplasms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102446</Key_PaperID>
<Key_SessionID>11564</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>381</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105437</Key_PaperID>
<Key_SessionID>11564</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>382</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Functional and Molecular Basis of Thrombopoietin Receptor Activation By Mutant Calreticulin</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107740</Key_PaperID>
<Key_SessionID>11564</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>383</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Targeting the Mechanism of c-Mpl Exon-Inclusion through Antisense Oligonucleotides Yields a Dominant Negative Isoform</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100098</Key_PaperID>
<Key_SessionID>11564</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>384</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103623</Key_PaperID>
<Key_SessionID>11565</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>We administered crizotinib to a chemotherapy refractory JMML patients with an ALK tyrosine kinase fusion. </OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>487</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107888</Key_PaperID>
<Key_SessionID>11565</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>488</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Jarid2 Restricts Long-Term Repopulating Stem Cell Capacity in Multipotent Progenitors and Acts As Tumor Suppressor in Chronic Myeloid Neoplasms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105646</Key_PaperID>
<Key_SessionID>11565</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>489</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>High Mobility Group A1 Chromatin Remodeling Proteins: Potential Therapeutic Targets Involved in Polycythemia Vera Transformation to Acute Leukemia in Humans and JAK2 V617F Transgenic Mouse Models</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101296</Key_PaperID>
<Key_SessionID>11565</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>490</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>A Single-Cell Approach to Unraveling Abnormal Megakaryocyte Differentiation and Function in Myelofibrosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103722</Key_PaperID>
<Key_SessionID>11565</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>491</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Personalized Prognostic Predictions for Patients with Myeloproliferative Neoplasms through Integration of Comprehensive Genomic and Clinical Information</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108846</Key_PaperID>
<Key_SessionID>11565</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>492</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107703</Key_PaperID>
<Key_SessionID>11566</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>48</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Loss of Toll-like Receptor 2 Results in Accelerated Leukemogenesis in the NUP98-HOXD13 Mouse Model of MDS</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106682</Key_PaperID>
<Key_SessionID>11566</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>49</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Bone Marrow Stem Cells from Patients with Myelodysplastic Syndrome (MDS) Engraft and Migrate in-between the Humanized Niches in Immuno-Compromised Mouse Models</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108274</Key_PaperID>
<Key_SessionID>11566</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>50</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Overexpression of Histone Demethylase KDM6B in the Hematopoietic Compartment Promotes the Effect of Innate Immune Activation and Results in Myelodysplastic Syndrome (MDS)-like Phenotype in Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101476</Key_PaperID>
<Key_SessionID>11566</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>51</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Immunodepletion of MDSC By AMV564, a Novel Tetravalent Bispecific CD33/CD3 T Cell Engager Restores Immune Homeostasis in MDS in Vitro</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102476</Key_PaperID>
<Key_SessionID>11566</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>52</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>The S100A9/Fto Axis Induces Formation of RNA:DNA Hybrids That Serve As Damps Initiating Myeloid Skewing &amp; Genetic Injury in MDS</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104648</Key_PaperID>
<Key_SessionID>11566</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>53</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>The TGF-/SMAD Signaling Pathway As a Mediator of NK Cell Dysfunction and Immune Evasion in Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106894</Key_PaperID>
<Key_SessionID>11567</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>115</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Unrecognized Clonal Hematopoiesis of Indeterminate Potential in Solid Tumors: Implications for Interpretation of Molecular Testing</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100154</Key_PaperID>
<Key_SessionID>11567</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>116</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Spliceosomal Mutations Induce R Loop-Associated ATR Signaling</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102420</Key_PaperID>
<Key_SessionID>11567</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>117</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>A Non-Human Primate CRISPR/Cas9 Model of Clonal Hematopoiesis of Indeterminate Potential Demonstrates Expansion of TET2-Disrupted Clones</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103547</Key_PaperID>
<Key_SessionID>11567</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>118</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Modeling ASXL1 Mutation Revealed Myelodysplasia Caused By Derepression of p16Ink4a through Aberrant PRC1-Mediated Histone Modification</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104428</Key_PaperID>
<Key_SessionID>11567</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>119</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>RUNX1 Deficiency and SRSF2 Mutation Cooperate to Promote Myelodysplastic Syndrome Development</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105382</Key_PaperID>
<Key_SessionID>11567</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>120</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Functional and Biological Implications of CUX1 Mutations and Deletions in Myeloid Neoplasms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104479</Key_PaperID>
<Key_SessionID>11568</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber>157</PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104104</Key_PaperID>
<Key_SessionID>11568</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber>158</PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>A Prognostic Classifier Based on Early Platelet Drop in Lower-Risk MDS. a Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102459</Key_PaperID>
<Key_SessionID>11568</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Use of decitabine off-label to treat CMML patients</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber>159</PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents. a Report on 183 Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104592</Key_PaperID>
<Key_SessionID>11568</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber>160</PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100158</Key_PaperID>
<Key_SessionID>11568</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber>161</PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>Bone Marrow Levels of PARP1 mRNA Predict Response to Treatment with 5-Azacytidine in Patients with Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105666</Key_PaperID>
<Key_SessionID>11568</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>ruxolitinib, a JAK 1/2 inhibitor FDA approved for myelofibrosis, will be discussed for the treatment of chronic myelomonocytic leukemia.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber>162</PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108181</Key_PaperID>
<Key_SessionID>11569</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber>421</PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>High Rates of Atherosclerotic Disease-Related Mortalityin Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Patients Associated with TET2-Mutations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104533</Key_PaperID>
<Key_SessionID>11569</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber>422</PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>The Use of Immunosuppressive Therapy (IST) in Patients with the Myelodysplastic Syndromes (MDS): Clinical Outcomes and Their Predictors in a Large International Patient Cohort</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106249</Key_PaperID>
<Key_SessionID>11569</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber>423</PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>Immune Checkpoint Profiling of TP53 Mutant and Wild-Type Myeloid Malignancies: TP53 Mutations Direct Immune Tolerance Via an Immunosuppressive Phenotype</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104679</Key_PaperID>
<Key_SessionID>11569</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber>424</PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>Mutational Signatures Associated with Intensity and Duration of Smoking in Myelodysplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100901</Key_PaperID>
<Key_SessionID>11569</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber>425</PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Treatment with Iron Chelation Therapy in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104660</Key_PaperID>
<Key_SessionID>11569</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber>426</PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>Feeding the Fire: The Comorbid and Inflammatory Backdrop of Clonal Hematopoiesis of Indeterminate Potential (CHIP) By Mutation Subtype</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108063</Key_PaperID>
<Key_SessionID>11570</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>583</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Non-Random Interactions between Founder and Subclonal Mutations Shape the Clinical and Morphological Features of MDS</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107745</Key_PaperID>
<Key_SessionID>11570</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>584</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>Somatic PRPF8 Mutations in Myeloid Neoplasia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107866</Key_PaperID>
<Key_SessionID>11570</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>585</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Potential Familial Predisposition to Hematologic Neoplasm Detected Incidentally in Adult Patients Presenting with Myeloid Neoplasms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103076</Key_PaperID>
<Key_SessionID>11570</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>586</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Clinical Features and Biological Implications of U2AF1 Mutations in Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103087</Key_PaperID>
<Key_SessionID>11570</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Azacitidine in relapsed/refractory AML.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>587</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Granulomonocytic Progenitors (GMPs) Are Key Target Cells of Azacitidine in MDS and AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105164</Key_PaperID>
<Key_SessionID>11570</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>588</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102836</Key_PaperID>
<Key_SessionID>11571</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>259</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>The Contribution of Gene Mutations to Long-Term Clinical Outcomes: Data from the Randomised UK LRF CLL4 Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103986</Key_PaperID>
<Key_SessionID>11571</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>260</PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>BRAF and BIRC3 Mutations Stratify a Poor Prognostic Subgroup in FCR Treated Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100815</Key_PaperID>
<Key_SessionID>11571</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>261</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Apoptosis ResistanceandNOTCH1 MutationsImpair Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) Patients Treatedwith Ibrutinib</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102162</Key_PaperID>
<Key_SessionID>11571</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>262</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Dissecting the Role of Individual Bcl-2 Members in Response and Resistance to Ibrutinib or Venetoclax in CLL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106467</Key_PaperID>
<Key_SessionID>11571</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>263</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Mechanisms of Venetoclax Resistance in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103914</Key_PaperID>
<Key_SessionID>11571</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>We will be discussing the use of a splicing modulator in combination with the FDA-approved drug venetoclax in chronic lymphocytic leukemia patients cells and mouse models</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>264</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Splicing Modulation Perturbs Key Survival Pathways and Sensitizes Chronic Lymphocytic Leukemia to Venetoclax Treatment</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106845</Key_PaperID>
<Key_SessionID>11572</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>385</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>IL-10 Receptor Deficiency Aggravates Exhaustion of CD8+ T-Cells and Impedes Their Control of Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107899</Key_PaperID>
<Key_SessionID>11572</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>386</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Defining the Diversity and Specificity of Neoantigen-Specific T Cells in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99871</Key_PaperID>
<Key_SessionID>11572</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>387</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Ibrutinib Disrupts IL-4R - IL-4 Axis By Inhibiting IL-4R Signaling and Reversing Th2/Th1 Polarization through Diminished CLECL1 in CLL B Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107969</Key_PaperID>
<Key_SessionID>11572</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>388</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Wnt5a Induces ROR1 to Complex with DOCK2 and Promote Proliferation of Chronic Lymphocytic Leukemia Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107679</Key_PaperID>
<Key_SessionID>11572</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>389</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Wnt5a Induces ROR1 to Bind and Activate Cortactin, Which Functions in Planar Cell Polarity and Migration of Chronic Lymphocytic Leukemia Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102723</Key_PaperID>
<Key_SessionID>11572</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>390</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K- Inhibitor Treatment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106532</Key_PaperID>
<Key_SessionID>11573</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>54</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>IGHV-D-J Repertoire Analysis Obtained By High-Throughput Sequencing of CD5+ B-Cells in CLL Patients: Prognostic Markers and Disease Development Implications</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108761</Key_PaperID>
<Key_SessionID>11573</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>55</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Single-Cell Joint Methylomics and Transcriptomics Define the Epigenetic Evolution and Lineage Histories of Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103448</Key_PaperID>
<Key_SessionID>11573</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>56</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Clinical Importance of DNA Methylation Signatures in Chronic Lymphocytic Leukaemia Patients Treated with Chemo-Immunotherapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103347</Key_PaperID>
<Key_SessionID>11573</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>57</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Genome-Wide DNA Methylation Profiling of Chronic Lymphocytic Leukemia Subsets Carrying Stereotyped B Cell Receptors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104355</Key_PaperID>
<Key_SessionID>11573</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>58</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>CLL Stereotyped Subset #4 Igs Acquire Binding to Viable B Lymphocyte Surfaces By Somatic Mutations, Isotype Class Switching, and with the Prerequisite of IG Self-Association</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102815</Key_PaperID>
<Key_SessionID>11573</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>59</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Interferon Regulatory Factor 4 Orchestrates the Response to B-Cell Receptor in Chronic Lymphocytic Leukemia Cells By Regulating Ikaros</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107661</Key_PaperID>
<Key_SessionID>11574</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber>427</PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104020</Key_PaperID>
<Key_SessionID>11574</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>We will describe a trial combining ibrutinib with venetoclax in relapsed refractory CLL. Both drugs are approved as single agents for CLL.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber>428</PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106923</Key_PaperID>
<Key_SessionID>11574</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Combination of ibrutinib and venetoclax is not FDA approved</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber>429</PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104907</Key_PaperID>
<Key_SessionID>11574</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>VENCLEXTA (venetoclax) is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated:
 in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia.
 in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber>430</PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia  Results from a Phase 1b Study (GP28331)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107539</Key_PaperID>
<Key_SessionID>11574</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber>431</PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100491</Key_PaperID>
<Key_SessionID>11574</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This is a phase 1b/2 investigational study of acalabrutinib plus obinutuzumab in CLL.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber>432</PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107757</Key_PaperID>
<Key_SessionID>11575</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>829</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Durable and Specific Inhibition of ROR1 SignalingAssociates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106081</Key_PaperID>
<Key_SessionID>11575</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>830</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104302</Key_PaperID>
<Key_SessionID>11575</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>831</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100926</Key_PaperID>
<Key_SessionID>11575</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>832</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101201</Key_PaperID>
<Key_SessionID>11575</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>833</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101477</Key_PaperID>
<Key_SessionID>11575</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>834</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Analysis of PET-CT to Identify Richters Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107615</Key_PaperID>
<Key_SessionID>11576</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>493</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Results from the Phase 3 DUOTM Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103752</Key_PaperID>
<Key_SessionID>11576</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ofatumumab combined with ibrutinib in 1st-line and relapsed/refractory CLL</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>494</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Bendamustine Followed By Ofatumumab and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BIO Trial of the German CLL Study Group (GCLLSG)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102592</Key_PaperID>
<Key_SessionID>11576</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This trial investigates combination of ibrutinib with chemoimmunotherapy in CLL (the combination is not FDA approved).   </OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>495</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101497</Key_PaperID>
<Key_SessionID>11576</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ibrutinib does not have a label in combination with FCR</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>496</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100772</Key_PaperID>
<Key_SessionID>11576</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>497</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Phase II, Multicenter Trial, Exploring Chemo-Sparing Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Induction Phase of the Icll-07 Filo Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100575</Key_PaperID>
<Key_SessionID>11576</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This is a Phase 1/2 investigational study of acalabrutinib in chronic lymphocytic leukemia.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>498</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106756</Key_PaperID>
<Key_SessionID>11577</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>121</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab throughAugmentation of Macrophage-Induced ADCP</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102912</Key_PaperID>
<Key_SessionID>11577</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>122</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>New Bone Cell Type Identified As Driver of Drug Resistance in Multiple Myeloma: The Bone Marrow Adipocyte</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104688</Key_PaperID>
<Key_SessionID>11577</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>123</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106722</Key_PaperID>
<Key_SessionID>11577</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>124</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Mesenchymal Stromal Cell Sialylation Enhances Immune Suppression in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102996</Key_PaperID>
<Key_SessionID>11577</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>125</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Apoptotic Osteocytes Promote Myeloma Dissemination to New Bone Sites Via Suppression of Immune Surveillance in Bone Marrow </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100679</Key_PaperID>
<Key_SessionID>11577</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>126</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Runx2 Deficiency in Committed Osteoblasts Promotes Myeloma Cell Homing to and Progression in New Bone Sites</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105997</Key_PaperID>
<Key_SessionID>11578</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>60</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Identification of Novel Oncogenes and Tumor Suppressor Genes in Newly Diagnosed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108683</Key_PaperID>
<Key_SessionID>11578</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>61</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Comprehensive Identification of Fusion Transcripts in Multiple Myeloma: An Mmrf Commpass Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107237</Key_PaperID>
<Key_SessionID>11578</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>62</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Single-Cell RNA Sequencing Reveals Distinct Transcriptomic Profiles of Multiple Myeloma with Implications for Personalized Medicine</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104666</Key_PaperID>
<Key_SessionID>11578</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>63</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Transcriptional Plasticity Compensates for Ikaros and Aiolos Proteasomal Degradation and Mediates Resistance to IMiDs in Multiple Myeloma (MM)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108377</Key_PaperID>
<Key_SessionID>11578</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>64</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105891</Key_PaperID>
<Key_SessionID>11578</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>65</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>MYC Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of MYC and a Distinct Downstream Gene Expression Pattern</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103858</Key_PaperID>
<Key_SessionID>11579</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>391</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Whole Exome Sequencing of Paired MGUS/SMM to MM Patients Reveals Novel Subclonal Tumour Evolution Models in Disease Progression of Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104620</Key_PaperID>
<Key_SessionID>11579</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>392</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106361</Key_PaperID>
<Key_SessionID>11579</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>393</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>MYC Translocations Identified By Sequencing Panel in Smoldering Multiple Myeloma Strongly Predict for Rapid Progression to Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103853</Key_PaperID>
<Key_SessionID>11579</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>394</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>High-Risk Cytogenetics in Newly Diagnosed Multiple Myeloma: Prognostic Relevance of Co-Segregations and Analysis of the Role of Double Versus Single Autotransplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100839</Key_PaperID>
<Key_SessionID>11579</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>395</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105511</Key_PaperID>
<Key_SessionID>11579</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>396</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>The Mutational Landscape of Relapse in High Risk Myeloma Is Significantly Impacted By the Depth of Response but Not Maintenance Lenalidomide</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102991</Key_PaperID>
<Key_SessionID>11580</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>499</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>A First in Class APRIL Fully Blocking Antibody Targets Novel Immune Regulation of APRIL in Multiple Myeloma: Further Therapeutic Implication</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100592</Key_PaperID>
<Key_SessionID>11580</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>500</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Preclinical Characterization of AMG 424, a Novel Humanized T CellRecruiting Bispecific Anti-CD3/CD38 Antibody</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104422</Key_PaperID>
<Key_SessionID>11580</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>501</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>T Cell Engagement without Cytokine Storm: A Novel Bcma x CD3 Antibody Killing Myeloma Cells with Minimal Cytokine Secretion</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106073</Key_PaperID>
<Key_SessionID>11580</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>502</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108439</Key_PaperID>
<Key_SessionID>11580</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>503</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Production of Universal Anti-Bcma CAR-T Cells with Reduced Alloreactivity, but Potent Effector Function for the Treatment of Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100985</Key_PaperID>
<Key_SessionID>11580</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>504</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>T Cells Expressing Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptors with Antigen Recognition Domains Made up of Only Single Human Heavy Chain Variable Domains Specifically Recognize Bcma and Eradicate Tumors in Mice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104858</Key_PaperID>
<Key_SessionID>11581</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>589</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Mitochondria Are Transferred from Non-Malignant Stroma Cells to Malignant Plasma Cells, Via Tunnelling Nanotubules in a CD38 Dependent Mechanism, a Process That Promotes Myeloma Proliferation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100006</Key_PaperID>
<Key_SessionID>11581</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>590</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>Novel Stem Cell-Targeted Therapy for Multiple Myeloma Based on Dual Inhibition of EZH1/2</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102777</Key_PaperID>
<Key_SessionID>11581</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>591</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>A CK1/CK1-to--Catenin Circuit Is a Therapeutic Vulnerability for Primary and Drug Resistant Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103364</Key_PaperID>
<Key_SessionID>11581</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>592</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Computational Modeling of Protein Networks Predicts Treatment Outcomes in Multiple Myeloma (MM)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103111</Key_PaperID>
<Key_SessionID>11581</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>593</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>The Interaction of NEK2 with USP7 Causes Resistance to Proteasome Inhibitor in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106180</Key_PaperID>
<Key_SessionID>11581</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>594</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Novel Mechanisms Underlying IMiDs Resistance in Multiple Myeloma: Therapeutic Implications</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106279</Key_PaperID>
<Key_SessionID>11582</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>505</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106805</Key_PaperID>
<Key_SessionID>11582</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>506</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for RRMM: Initial Safety and Efficacy Report from a Clinical Pilot Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100472</Key_PaperID>
<Key_SessionID>11582</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Daratumumab in AL amyloidosis - off label use</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>507</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103681</Key_PaperID>
<Key_SessionID>11582</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Daratumumab in AL amyloidosis</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>508</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101099</Key_PaperID>
<Key_SessionID>11582</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>509</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with Relapsed or Refractory AL Amyloidosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106028</Key_PaperID>
<Key_SessionID>11582</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>510</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106015</Key_PaperID>
<Key_SessionID>11583</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Carfilzomib is used with cyclophosphamide and dexamethasone.  The label is with lenalidomide and dexamethasone, or just with dexamethasone</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>835</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100871</Key_PaperID>
<Key_SessionID>11583</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>836</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/ Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102369</Key_PaperID>
<Key_SessionID>11583</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>837</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107861</Key_PaperID>
<Key_SessionID>11583</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>838</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100079</Key_PaperID>
<Key_SessionID>11583</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>839</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106082</Key_PaperID>
<Key_SessionID>11583</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>We describe the use of lenalidomide-elotuzumab as maintenance therapy for multiple myeloma. This combination (with dexamethasone) is currently FDA approved for use in patients with relapsed multiple myeloma.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>840</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103756</Key_PaperID>
<Key_SessionID>11584</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ixazomib in first line treatment of multiple myeloma</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber>433</PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101163</Key_PaperID>
<Key_SessionID>11584</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Elotuzumab in combination with lenalidomide and dexamethasone is being investigated for the treatment of patients with newly diagnosed multiple myeloma.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber>434</PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101743</Key_PaperID>
<Key_SessionID>11584</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber>435</PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102882</Key_PaperID>
<Key_SessionID>11584</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber>436</PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106337</Key_PaperID>
<Key_SessionID>11584</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber>437</PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108246</Key_PaperID>
<Key_SessionID>11584</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Fluzone High-Dose Influenza Vaccine is FDA approved for seasonal influenza vaccination in individuals 65 years or older.  </OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber>438</PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>Two Dose Series of High-Dose Influenza Vaccine Is Associated with Longer Duration of Serologic Immunity in Patients with Plasma Cell Disorders</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107491</Key_PaperID>
<Key_SessionID>11585</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>66</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Mechanisms Governing Endogenous Thymic Regeneration</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105787</Key_PaperID>
<Key_SessionID>11585</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>67</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>The Damage Sensory Molecule TRPA1 Positively Regulates Endogenous Thymic Regeneration after Damage</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103062</Key_PaperID>
<Key_SessionID>11585</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>68</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Reduction in Bone Marrow Insulin-like Growth Factor-1 Levels Enhances Long-Term Hematopoietic Stem Cell Engraftment Following Bone Marrow Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104710</Key_PaperID>
<Key_SessionID>11585</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>69</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>A Critical Role for Donor-Derived IL-22 in Cutaneous Chronic Gvhd</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100216</Key_PaperID>
<Key_SessionID>11585</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>70</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Vitamin C Stabilizes Foxp3 Expression in Induced Treg Cells By Targeted DNA Demethylation and Prevents Murine Model of Acute Graft Versus Host Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107581</Key_PaperID>
<Key_SessionID>11585</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>71</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>The Innate Immune Sensor Sting Can Augment or Ameliorate Graft-Versus-Host Disease Dependent on the Genetic Disparity between Donors and Recipients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105419</Key_PaperID>
<Key_SessionID>11586</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber>205</PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Nrf2 Is a Critical Mediator of CD4 T Cell-Induced Acute Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106879</Key_PaperID>
<Key_SessionID>11586</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber>206</PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>Lysosomal Acid Lipase Is a Potential Therapeutic Target for Controlling Gvhd after Allogeneic Hematopoietic Cell Transplantation in Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107980</Key_PaperID>
<Key_SessionID>11586</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber>207</PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Identification of Leukemia Associated Minor Histocompatibility Antigens through Computational Prediction and Targeted Mass Spectrometry</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104062</Key_PaperID>
<Key_SessionID>11586</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>208</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of Sirt-1 Alleviates Acute and Chronic Graft-Versus-Host-Disease While Preserving Graft-Versus-Leukemia Effect</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100032</Key_PaperID>
<Key_SessionID>11586</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>209</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Bim Regulates the Survival and Suppressive Capability of CD8+ Foxp3+ Regulatory T Cells during Graft Versus Host Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108797</Key_PaperID>
<Key_SessionID>11586</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>210</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Id3 Is Essential for Mediating Ezh2-Regulated Persistence of Alloreactive T Cells in Gvhd Target Tissues in Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104781</Key_PaperID>
<Key_SessionID>11587</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>841</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Cytokine Release Syndrome and Tumor Responses in a First-in-Man Trial of a Novel Affinity-Enhanced TCR-Gene Transduced T Cell Transfer Targeting NY-ESO-1 Antigen</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105880</Key_PaperID>
<Key_SessionID>11587</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>842</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Enhancing CAR T Cell Anti-Tumor Efficacy through Secreted Single Chain Variable Fragment (scFv) Immune Checkpoint Blockade</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107211</Key_PaperID>
<Key_SessionID>11587</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>843</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Mouse CD19-Targeted Chimeric Antigen Receptors That Include a 41BB Co-Stimulatory Domain Induce NFkB Signaling to Enhance T Cell Proliferation, Viability, and Leukemia Killing</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108186</Key_PaperID>
<Key_SessionID>11587</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>844</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>An Off-the-Shelf, Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102448</Key_PaperID>
<Key_SessionID>11587</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>845</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103148</Key_PaperID>
<Key_SessionID>11587</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>846</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105675</Key_PaperID>
<Key_SessionID>11588</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber>163</PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>Generation of Clonal Antigen Specific CD8+ Cytotoxic T Lymphocytes from Renewable Pluripotent Stem Cells for Off-the-Shelf T Cell Therapeutics</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105321</Key_PaperID>
<Key_SessionID>11588</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber>164</PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Adoptively Transferred Donor-Derived Tumor-Directed T Cells with Relapsed AML Post-Allogeneic HSCT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104156</Key_PaperID>
<Key_SessionID>11588</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber>165</PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting JAK2 Kinase Promotes Foxp3 Stability and Function of CD8iTregs in Prevention of Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107637</Key_PaperID>
<Key_SessionID>11588</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber>166</PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>Effect of Chronic Endogenous Antigen Stimulation on CAR T Cell Persistence and Memory Formation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107012</Key_PaperID>
<Key_SessionID>11588</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber>167</PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>NKG2A Represents an Important Immune Checkpoint for Human Cytokine-Induced Memory-like NK Cells in Patients with AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100905</Key_PaperID>
<Key_SessionID>11588</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber>168</PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>Mutated NPM1 As Target for Immunotherapy of Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101475</Key_PaperID>
<Key_SessionID>11589</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>655</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>The Exhaustion of Adult Hematopoietic Stem Cells in Ex Vivo Cultures Can Be Overcome by a Histone Deacetylase Inhibitor</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104319</Key_PaperID>
<Key_SessionID>11589</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>656</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101179</Key_PaperID>
<Key_SessionID>11589</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>657</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>Enhanced In Vivo Persistence and Proliferation of NK Cells Expanded in Culture with the Small Molecule Nicotinamide: Development of a Clinical-Applicable Method for NK Expansion</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99589</Key_PaperID>
<Key_SessionID>11589</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>658</PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Single UM171 Expanded Cord Blood Transplant Is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107411</Key_PaperID>
<Key_SessionID>11589</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber>659</PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Phenotype Does Not Always Equal Function: HDAC Inhibitors and UM171, but Not SR1, Lead to Rapid Upregulation of CD90 on Non-Engrafting CD34+CD90-Negative Human Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105083</Key_PaperID>
<Key_SessionID>11589</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber>660</PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38CD45RACD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105075</Key_PaperID>
<Key_SessionID>11590</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>661</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Outcomes of Graft Failures after Umbilical Cord Blood Transplantation in Acute Leukemia: A Study from Eurocord and the Acute Leukemia Working Party of the EBMT</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100148</Key_PaperID>
<Key_SessionID>11590</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>662</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Phase 2 Trials with Mgta-456, Single Cord Blood Units (CBU) Expanded with an Aryl Hydrocarbon Receptor (AHR) Antagonist, Demonstrate Uniform Engraftment and Rapid Hematopoietic Recovery in Patients Following Myeloablative or Non-Myeloablative Conditioning</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100631</Key_PaperID>
<Key_SessionID>11590</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>663</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>Long-Term Outcome after Haploidentical Hematopoietic Cell Transplantation Utilizing CD34+ Selected/CD3CD19+ Depleted or Tcr+/CD19+ Depleted Grafts in Pediatric Patients with Hemoglobinopathies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105881</Key_PaperID>
<Key_SessionID>11590</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>664</PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Evaluation of Infectious Complications after Haploidentical Stem Cell Transplantation in Adult Patients with Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103060</Key_PaperID>
<Key_SessionID>11590</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber>665</PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Severe Cytokine Release Syndrome Is a Fatal Complication after PBSC, but Not after BM Haploidentical Transplantation with Post-Transplant Cyclophosphamide</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105962</Key_PaperID>
<Key_SessionID>11590</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber>666</PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>Transplant-Associated Thrombotic Microangiopathy (TA-TMA): Not a Singular Entity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103553</Key_PaperID>
<Key_SessionID>11591</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	6:30 PM
 
</PaperEndTime>
<PaperNumber>907</PaperNumber>
<PaperStartTime>
	6:15 PM
 
</PaperStartTime>
<PaperTitle>Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100673</Key_PaperID>
<Key_SessionID>11591</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	6:45 PM
 
</PaperEndTime>
<PaperNumber>908</PaperNumber>
<PaperStartTime>
	6:30 PM
 
</PaperStartTime>
<PaperTitle>Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101450</Key_PaperID>
<Key_SessionID>11591</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:00 PM
 
</PaperEndTime>
<PaperNumber>909</PaperNumber>
<PaperStartTime>
	6:45 PM
 
</PaperStartTime>
<PaperTitle>Busulfan Fludarabine (BU-FLU) Compared to Thiotepa Busulfan Fludarabine (TBF) for Allogeneic Transplants in Acute Myeloid Leukemia (AML) or Refractory Anemia with Excess Blasts (RAEB) in Remission</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101575</Key_PaperID>
<Key_SessionID>11591</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:15 PM
 
</PaperEndTime>
<PaperNumber>910</PaperNumber>
<PaperStartTime>
	7:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100046</Key_PaperID>
<Key_SessionID>11591</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>911</PaperNumber>
<PaperStartTime>
	7:15 PM
 
</PaperStartTime>
<PaperTitle>Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy?  a Multicenter EBMT-PDWP Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103238</Key_PaperID>
<Key_SessionID>11591</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:45 PM
 
</PaperEndTime>
<PaperNumber>912</PaperNumber>
<PaperStartTime>
	7:30 PM
 
</PaperStartTime>
<PaperTitle>Second Allogeneic Hematopoietic Stem Cell Transplantation for Post-Transplant Relapsed Acute Leukemia in Children - an EBMT PDWP Retrospective Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102486</Key_PaperID>
<Key_SessionID>11592</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>745</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Hematopoietic Stem Cell Transplantation at Home</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102257</Key_PaperID>
<Key_SessionID>11592</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>746</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Functional Signatures Revealed By Deep Phenotyping of CMV-Specific CD8+ T Cells Predict Risk of Early CMV Reactivation after Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105806</Key_PaperID>
<Key_SessionID>11592</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>747</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Adoptive T-Cell Therapy with 3rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104316</Key_PaperID>
<Key_SessionID>11592</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber>748</PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>Influence of MHC Class I Chain-Related Gene  (MICA) Polymorphisms on Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101204</Key_PaperID>
<Key_SessionID>11592</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>749</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>A Protective Role of DNA Repair Genes Against Acute Graft Versus Host Disease in Children</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102946</Key_PaperID>
<Key_SessionID>11592</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>750</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Intestinal Microbiota Injury during Allo-Hsct Is Generalizable across Transplantation Centers and Is Associated with Increased Mortality, Broad-Spectrum Antibiotics, and Decreased Calorie Intake</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106769</Key_PaperID>
<Key_SessionID>11593</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber>211</PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) Expand and Persist over Time after Post-Allograft Infusion in Patients Given  T-Cell and B-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation ( haplo-HSCT) Contributing to Accelerate Immune Recovery</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104734</Key_PaperID>
<Key_SessionID>11593</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The drug is abatacept.  It is approved for rheumatoid arthritis. We have used abatcept in a GVHD prevention trial.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber>212</PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>T Cell Costimulation Blockade with Abatacept Nearly Eliminates Early Severe Acute Graft Versus Host Disease after HLA-Mismatched (7/8 HLA Matched) Unrelated Donor Transplant, with a Favorable Impact on Disease-Free and Overall Survival</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100878</Key_PaperID>
<Key_SessionID>11593</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off-label use of grafalon, fludarabine, melphalan and thiotepa for conditioning.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber>213</PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>First Results of a Prospective Multicenter Phase I/II Clinical Trial in Adult Patients Using Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100894</Key_PaperID>
<Key_SessionID>11593</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off-label use of grafalon, fludarabine, melphalan and thiotepa for conditioning.</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>214</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: Results of a Prospective Multicenter Phase I/II Clinical Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100940</Key_PaperID>
<Key_SessionID>11593</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>215</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Post-Transplant Cyclophosphamide (PT-Cy) for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Transplantation from HLA Identical Sibling and Matched Unrelated Donor for Patients with Acute Leukemia, on Behalf of ALWP-EBMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100051</Key_PaperID>
<Key_SessionID>11593</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>216</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Grade II Acute Gvhd Improves Progression-Free Survival after Myeloablative HLA-Matched Bone Marrow Transplant with Posttransplantation Cyclophosphamide</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108258</Key_PaperID>
<Key_SessionID>11594</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Interleukin-2 - used here as a therapy for chronic Graft-versus-Host Disease</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>511</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103865</Key_PaperID>
<Key_SessionID>11594</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>512</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>The Multicentre, Double-Blinded, Placebo-Controlled Clinical-Trial (Pre-GvHD) for Prediction and Pre-Emptive Treatment of Acute GvHD</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104267</Key_PaperID>
<Key_SessionID>11594</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>513</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase I/II Study on the Anti-CD3/CD7 Immunotoxin Combination (T-GuardTM) for the Treatment of Steroid-Refractory Acute Gvhd</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100737</Key_PaperID>
<Key_SessionID>11594</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>514</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Treatment of Patients with Therapy-Refractory Acute GvHD with the Novel MSC Product MSC-Ffm Resulted in Excellent Response and Low Mortality: Post-Approval Observational Data from 69 Consecutive Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107907</Key_PaperID>
<Key_SessionID>11594</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off Label use of Interleukin-2</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>515</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Extra-Corporeal Photopheresis Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease: Efficacy, Safety and Immune Correlates</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101283</Key_PaperID>
<Key_SessionID>11594</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>516</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Day 100 Levels of Blood Immune Cells Are Prognostic Biomarkers for Allogeneic Hematopoietic Stem Cell Transplant Outcomes: Results from BMT CTN 0201</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100823</Key_PaperID>
<Key_SessionID>11595</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>72</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101258</Key_PaperID>
<Key_SessionID>11595</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>73</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Comparison of Chronic Graft-Versus-Host Disease Severity and Functional Status after Cord Blood, Haploidentical Related and 1-Allele Mismatched Unrelated Donor Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104015</Key_PaperID>
<Key_SessionID>11595</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Daily administration of low-dose IL-2 therapy in patients with cGVHD induces selective expansion of Treg and results in clinical improvement in approximately 50% of patients. We performed single cell mass cytomtery (CyTOF) analyses on PBMC samples from patients with active cGVHD receiving daily low dose IL-2 therapy of our phase 2 trial[Koreth J, Blood. 2016;128(1):130-137].</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>74</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells and Suppresses Circulating T Follicular Helper Cells in Patients with Chronic Gvhd</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108069</Key_PaperID>
<Key_SessionID>11595</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>75</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Increased TLR7 Signaling of BCR-Activated B Cells in Chronic Graft-Versus Host Disease (cGVHD)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105913</Key_PaperID>
<Key_SessionID>11595</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>76</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Outcome of Children Developing Grade III-IV Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Report on Behalf of the EBMT Paediatric Diseases Working Party</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105391</Key_PaperID>
<Key_SessionID>11595</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>77</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Human Gastro-Intestinal Graft-Versus-Host Disease Is Mediated By Retinoic Acid-Responsive CD8+ Effector T-Cells Under IL-23 Polarising Conditions</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104813</Key_PaperID>
<Key_SessionID>11596</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>271</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Next Generation Sequencing (NGS)-Based Post-Transplant Monitoring in Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HCT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102310</Key_PaperID>
<Key_SessionID>11596</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>272</PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>Outcome of Children Relapsing after First Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia: A Retrospective I-BFM Analysis of 336 Children between 2005 and 2016</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101023</Key_PaperID>
<Key_SessionID>11596</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>273</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Adoptive Cellular Therapy with Donor Lymphocyte Infusion Versus a Second Allogeneic Hematopoietic Cell Transplant for Post-Allograft Relapsed Acute Myeloid Leukemia: An Intent-to-Treat Analysis on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108416</Key_PaperID>
<Key_SessionID>11596</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>274</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102276</Key_PaperID>
<Key_SessionID>11596</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ipilimumab and nivolumab are both being used off label to treat relapsed hematologic malignancies in this clinical trial</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>275</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Optimizing Checkpoint Blockade As a Treatment for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102314</Key_PaperID>
<Key_SessionID>11596</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Azacitidine and Lenalidomide used as Investigational Medicinal Products in combination as a post- transplant salvage therapy.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>276</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107557</Key_PaperID>
<Key_SessionID>11597</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>331</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Individualized Treatment Summaries and Survivorship Care Plans (SCPs) for Hematopoietic Cell Transplant (HCT) Survivors Reduces Cancer Treatment Distress in a Randomized, Multicenter Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106387</Key_PaperID>
<Key_SessionID>11597</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>332</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Effect of Autologous Hematopoietic Stem Cell Transplant (aHSCT) on the Development of Second Primary Malignancies (SPM) in Multiple Myeloma Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103763</Key_PaperID>
<Key_SessionID>11597</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>333</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Allogeneic Hematopoietic Cell Transplantation Causes Accelerated Aging Both of the Hematopoietic and Somatic Systems</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103496</Key_PaperID>
<Key_SessionID>11597</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>334</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Late Fatal Infections Remains Frequent Cause of Mortality in Pediatric Allogeneic Stem Cell Transplant Recipients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103476</Key_PaperID>
<Key_SessionID>11597</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>335</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Late Fatal Infections Remain Higher Than Expected in Adults Receiving Allogeneic Stem Cell Transplant</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100687</Key_PaperID>
<Key_SessionID>11597</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>336</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Long-Term Morbidity Associated with Chronic Graft Vs. Host Disease (cGvHD)  a Blood or Marrow Transplant Survivor Study (BMTSS)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102335</Key_PaperID>
<Key_SessionID>11598</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>397</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisonefor Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100867</Key_PaperID>
<Key_SessionID>11598</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Bortezomib and High-Dose Melphalan as conditioning regimen before autologous stem cell transplantation in de novo multiple myeloma patients</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>398</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104453</Key_PaperID>
<Key_SessionID>11598</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>399</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101714</Key_PaperID>
<Key_SessionID>11598</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>400</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102360</Key_PaperID>
<Key_SessionID>11598</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>401</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma: An Analysis of Phase 3 EMN02/HO95 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102714</Key_PaperID>
<Key_SessionID>11598</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>KRd, transplant and maintenance with lenalidomide are not approved for the treatment of high-risk Smoldering Myeloma patients.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>402</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100951</Key_PaperID>
<Key_SessionID>11599</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>337</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Reduction in Late Mortality after Autologous Blood or Marrow Transplantation (autoBMT) in Childhood  a Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100362</Key_PaperID>
<Key_SessionID>11599</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>338</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Optimizing the Pretransplant Regimen for Autologous Stem Cell Transplantation in Acute Myelogenous Leukemia: Better Outcomes with Busulfan and Melphalan Compared with Busulfan and Cyclophosphamide in High Risk Patients Autografted in First Complete Remission</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105373</Key_PaperID>
<Key_SessionID>11599</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pembrolizumab is an anti-PD-1 antibody that disrupts the immune checkpoint PD-1/PD-1 ligand axis, thus augmenting T cell and NK cell function against cancers. We used pembrolizumab during lymphodepleted state after high dose therapy to augment immune reaction against multiple myeloma, along with standard of care low dose lenalidomide maintenance. </OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>339</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104503</Key_PaperID>
<Key_SessionID>11599</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ipilimumab and nivolumab used in combination as post autologous stem cell transplantation consolidation for hematologic malignancies</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>340</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Preliminary Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies  Cpit-001 Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100467</Key_PaperID>
<Key_SessionID>11599</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>341</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104523</Key_PaperID>
<Key_SessionID>11599</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>342</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from theComprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100660</Key_PaperID>
<Key_SessionID>11600</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>847</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/ II Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103885</Key_PaperID>
<Key_SessionID>11600</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>848</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Analysis of 10,462 8/8 HLA- Matched Unrelated Donor Transplants Could Not Identify a Donor Selection Score, As Younger Age Is the Only Significant Donor Characteristic Associated with Survival</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102861</Key_PaperID>
<Key_SessionID>11600</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>849</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99943</Key_PaperID>
<Key_SessionID>11600</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>850</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104257</Key_PaperID>
<Key_SessionID>11600</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>851</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Selecting between HLA-Matched Siblings and HLA- Haploidentical Related Donors for Acute Leukemia in the Era of Post-Transplant Cyclophosphamide: The Center for International Blood and Marrow Transplant Registry and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104837</Key_PaperID>
<Key_SessionID>11600</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>852</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Haploidentical T-Repleted Stem Cell Transplantation (SCT) Has Comparable Survival to 10/10 and 9/10 Unrelated SCT in Poor-Cytogenetics Risk Acute Myeloid Leukemia in First Complete Remission: A Studyon Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106634</Key_PaperID>
<Key_SessionID>11601</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>595</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Monosomy 7 or Deletion 7q: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105344</Key_PaperID>
<Key_SessionID>11601</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>596</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with t(6;9)(p23;q34);dek-NUP214 Is Followed By a Low Relapse Risk and Favorable Outcome in Early Phase- a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103323</Key_PaperID>
<Key_SessionID>11601</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>597</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Idarubicin Intensified Bucy Regimen in Allogeneic Peripheral Blood Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia: A Multicenter, Randomized Study (NCT 01766375)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102456</Key_PaperID>
<Key_SessionID>11601</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>598</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101393</Key_PaperID>
<Key_SessionID>11601</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>599</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>AML SCT-BFM 2007: Results of the Prospective Hematopoietic Stem Cell Transplantation (HCT) Trial of the Berlin-Frankfurt-Mnster (BFM) Study Group for Children with Very High Risk Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105487</Key_PaperID>
<Key_SessionID>11601</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>600</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Comparison of Outcomes after Myeloablative Versus Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105777</Key_PaperID>
<Key_SessionID>11602</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>523</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Interim Results from a Phase I/II Clinical Gene Therapy Study for Newly Diagnosed Infants with X-Linked Severe Combined Immunodeficiency Using a Safety-Modified Lentiviral Vector and Targeted Reduced Exposure to Busulfan</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104745</Key_PaperID>
<Key_SessionID>11602</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Use of fludarabine and cyclophosphamide as a CAR T-cell conditioning regimen.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>524</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor with a CD28 Costimulatory Moiety Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102055</Key_PaperID>
<Key_SessionID>11602</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>525</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Low Dose CD22-Directed CAR-T Cell Therapy in 10 Relapsed B Acute Lymphoblastic Leukemia Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105795</Key_PaperID>
<Key_SessionID>11602</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>526</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Results from the Hgb-207 (Northstar-2) Trial: A Phase 3 Study to Evaluate Safety and Efficacy of Lentiglobin Gene Therapy for Transfusion-Dependent -Thalassemia (TDT) in Patients with Non-0/0 Genotypes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101288</Key_PaperID>
<Key_SessionID>11602</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>527</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105888</Key_PaperID>
<Key_SessionID>11602</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>528</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Development of a Treg Lineage Specific Lentiviral Vector for the Treatment of IPEX Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106047</Key_PaperID>
<Key_SessionID>11603</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>601</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B  1 Year Follow up and Impact of Baseline Characteristics on Transgene-Derived Factor IX Activity and Persistence</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100544</Key_PaperID>
<Key_SessionID>11603</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This study reports the findings from a phase 1/11 study AMT-060 (AAV5-hFIX) gene therapy for the treatment of haemophilia B. AMT-060 is currently not commercially available and is not licensed for the treatment of haemophilia B. </OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>602</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>Stable Elevations in FIX Activity and Reductions in Annualized Bleeding Rate over up to 2 Years of Follow-up of Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104216</Key_PaperID>
<Key_SessionID>11603</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>603</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Achievement of Normal Circulating Factor VIII Activity Following Bmn 270 AAV5-FVIII Gene Transfer: Interim, Long-Term Efficacy and Safety Results from a Phase 1/2 Study in Patients with Severe Hemophilia a</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108679</Key_PaperID>
<Key_SessionID>11603</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>604</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Spk-8011: Preliminary Results from a Phase 1/2 Dose Escalation Trial of an Investigational AAV-Mediated Gene Therapy for Hemophilia a</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104860</Key_PaperID>
<Key_SessionID>11603</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>605</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Liver-Directed Gene Therapy for Hemophilia B with Immune Stealth Lentiviral Vectors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104373</Key_PaperID>
<Key_SessionID>11603</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>606</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Aberrant Clonal Hematopoiesis of the Erythroid and Myeloid Lineages in a Lentivirally Barcoded Rhesus Macaque</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108685</Key_PaperID>
<Key_SessionID>11604</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>853</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>A Functional Approach to Precision Medicine Identifies Targeted Therapies for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103276</Key_PaperID>
<Key_SessionID>11604</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The drugs used in off label are approved for cancer indications accept for AML.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>854</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105905</Key_PaperID>
<Key_SessionID>11604</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>855</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108505</Key_PaperID>
<Key_SessionID>11604</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>856</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Systematic Combinatorial Chimeric Antigen Receptor Therapies to AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105222</Key_PaperID>
<Key_SessionID>11604</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>857</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeted Inhibition of STAT/TET1 Axis As a Potent Therapeutic Strategy for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102680</Key_PaperID>
<Key_SessionID>11604</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>858</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Direct Pharmacological Inhibition of the Transcription Factor PU.1in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106219</Key_PaperID>
<Key_SessionID>11605</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>673</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Monoclonal Gammopathies: Electronic Subspecialty Consultation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107643</Key_PaperID>
<Key_SessionID>11605</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>674</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Von Willebrand Disease Screening in Women Undergoing Hysterectomy for Heavy Menstrual Bleeding</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107466</Key_PaperID>
<Key_SessionID>11605</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>675</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102063</Key_PaperID>
<Key_SessionID>11605</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>676</PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Trends of Splenectomy in Pediatric Patients with Immune Thrombocytopenia before and after the ASH 2011 Evidence-Based Practice Guidelines</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103427</Key_PaperID>
<Key_SessionID>11605</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Lenalidomide in the use of first-line and refractory MCL, diffuse large B-Cell lymphoma (DLBCL), and indolent NHL</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber>677</PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>Venous Thromboembolism in Patients with B-Cell Non-Hodgkin Lymphoma (NHL) Treated with Lenalidomide</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102903</Key_PaperID>
<Key_SessionID>11605</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber>678</PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>A Retrospective Chart Review to Assess Burden of Illness Among Patients with Severe Aplastic Anemia with Insufficient Response to Immunosuppressive Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108744</Key_PaperID>
<Key_SessionID>11606</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	9:45 AM
 
</PaperEndTime>
<PaperNumber>127</PaperNumber>
<PaperStartTime>
	9:30 AM
 
</PaperStartTime>
<PaperTitle>High Prevalence of Severe Acute Malnutrition in Children with Sickle Cell Anemia over 5 Years of Age in Northern Nigeria</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100473</Key_PaperID>
<Key_SessionID>11606</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	10:00 AM
 
</PaperEndTime>
<PaperNumber>128</PaperNumber>
<PaperStartTime>
	9:45 AM
 
</PaperStartTime>
<PaperTitle>Longitudinal Trend in Emergency Department Reliance for Pain Among Sickle Cell Disease Patients in Wisconsin</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102248</Key_PaperID>
<Key_SessionID>11606</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	10:15 AM
 
</PaperEndTime>
<PaperNumber>129</PaperNumber>
<PaperStartTime>
	10:00 AM
 
</PaperStartTime>
<PaperTitle>Men with Sickle Cell Disease Show Significant Concerns over Safety While Being Treated for Vaso-Occlusive Crises: Preliminary Observations from the Escaped Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102484</Key_PaperID>
<Key_SessionID>11606</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	10:30 AM
 
</PaperEndTime>
<PaperNumber>130</PaperNumber>
<PaperStartTime>
	10:15 AM
 
</PaperStartTime>
<PaperTitle>Opioid Utilization Patterns in United States Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103172</Key_PaperID>
<Key_SessionID>11606</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>131</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Health Care Utilization Trajectories and Associated Factors for Transitioning Adolescents/Young Adults with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103589</Key_PaperID>
<Key_SessionID>11606</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>132</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Prevention of Acute Chest Syndrome By Implementing a Standardized Process to Improve Incentive Spirometry Use in Hospitalized Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106188</Key_PaperID>
<Key_SessionID>11607</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>New oral anticoagulants are used in our patient population and are considered off-label use.  </OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber>217</PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic (VTE-PACC):a Systems-Based, Personalized, Multidisciplinary Program to Increase Venous Thromboembolism (VTE) Risk Assessment, Education and Anticoagulant Prophylaxis in Cancer Outpatients Initiating Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100683</Key_PaperID>
<Key_SessionID>11607</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber>218</PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101335</Key_PaperID>
<Key_SessionID>11607</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber>219</PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Prevalence of Venous Thromboembolism in Cancer Patients in the Emergency Department and Associated Healthcare Resource Utilization and Expenditure in the United States</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102470</Key_PaperID>
<Key_SessionID>11607</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>220</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Adding Aspirin to Warfarin without an Apparent Indication: An Exploration of Patients Anticoagulated for Atrial Fibrillation or Venous Thromboembolic Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101806</Key_PaperID>
<Key_SessionID>11607</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>221</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Adult Hemophagocytic Lymphohistiocytosisa Quality Improvement Initiative</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104570</Key_PaperID>
<Key_SessionID>11607</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>222</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Increased Toxicity Among Adolescents and Young Adults Treated for Acute Lymphoblastic Leukemia at U.S. Childrens Hospitals</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107644</Key_PaperID>
<Key_SessionID>11608</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:15 AM
 
</PaperEndTime>
<PaperNumber>607</PaperNumber>
<PaperStartTime>
	7:00 AM
 
</PaperStartTime>
<PaperTitle>Survival By Race/Ethnicity in Children and Adolescents with Hodgkin Lymphoma Treated on Cooperative Group Trials in the U.S. and Canada: A Pooled Analysis of Childrens Oncology Group Trials</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100974</Key_PaperID>
<Key_SessionID>11608</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 AM
 
</PaperEndTime>
<PaperNumber>608</PaperNumber>
<PaperStartTime>
	7:15 AM
 
</PaperStartTime>
<PaperTitle>Risk of Subsequent Malignant Neoplasms in Survivors of Adolescent and Young Adult (AYA) Lymphoma and Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105771</Key_PaperID>
<Key_SessionID>11608</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>609</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Cost-Effectiveness Analysis of CTL019 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United States</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103388</Key_PaperID>
<Key_SessionID>11608</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>610</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>A Multicenter Comparison of Rates of Central Venous Catheter-Associated Bloodstream Infections By Central Venous Catheter Type Among Pediatric Patients Receiving Treatment for Newly Diagnosed Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102606</Key_PaperID>
<Key_SessionID>11608</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>611</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Are Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL) Receiving Pediatric or Adult ALL Regimens: A Population-Based Statewide Evaluation of the Approach to AYA ALL across Pediatric and Adult Cancer Centers</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106943</Key_PaperID>
<Key_SessionID>11608</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>612</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Recession Increases Need for Intensive Care in Pediatric Hematologic Malignancy Presentation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100935</Key_PaperID>
<Key_SessionID>11609</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>859</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Racial Disparities in End-of-Life Care Planning and Hospital Utilization: A Single Center Retrospective Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105226</Key_PaperID>
<Key_SessionID>11609</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>860</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Factors Determining Utilization of Stem Cell Transplant (SCT) for Initial Therapy of Multiple Myeloma (MM) By Patient Race: Exploring Intra-Racial Healthcare Disparities</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106804</Key_PaperID>
<Key_SessionID>11609</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>861</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Enrollment of Older Adults in Clinical Trials Evaluating Patients with Hematologic Malignancies  the Food and Drug Administration (FDA) Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106890</Key_PaperID>
<Key_SessionID>11609</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>862</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100131</Key_PaperID>
<Key_SessionID>11609</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>863</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Improvement of Relative Survival in Elderly Patients with Acute Myeloid Leukemia Emerging from Population-Based Cancer Registries in Switzerland from 2001-2013</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103232</Key_PaperID>
<Key_SessionID>11609</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>864</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104600</Key_PaperID>
<Key_SessionID>11610</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>343</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Long-Term Survival of Older Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agent Therapy: A Large Population-Based Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105887</Key_PaperID>
<Key_SessionID>11610</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>344</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Survival Among Acute Myeloid Leukemia Patients Conditional on Years Already Survived and Relative to the General Population in the United States</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108380</Key_PaperID>
<Key_SessionID>11610</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>345</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Prospective Study of an Antifungal Program to Reduce Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Receiving Induction and Re-Induction Chemotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102973</Key_PaperID>
<Key_SessionID>11610</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>346</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Hospice Use Among Patients with Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108790</Key_PaperID>
<Key_SessionID>11610</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>347</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Survival Among Acute Lymphocytic Leukemia Patients Conditional on Years Already Survived and Relative to the General Population in the United States</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101328</Key_PaperID>
<Key_SessionID>11610</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>348</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>Application and Outcomes of Bendamustine- or Bortezomib-Based Therapy for Waldenstroms Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107734</Key_PaperID>
<Key_SessionID>11611</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>529</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of NCI Comprehensive Cancer Center Designation, Provider Specialization and Patient Sharing with Community Providers on Outcomes for Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105479</Key_PaperID>
<Key_SessionID>11611</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>530</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Prevalence and Risk-Factors for Financial Burden in Patients with Chronic Graft-Versus-Host Disease: A Cross-Sectional Survey from the Chronic Gvhd Consortium</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105758</Key_PaperID>
<Key_SessionID>11611</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>531</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Using Electronic Medical Record Data and Block Group Level Estimates of Poverty to Investigate the Association between Socioeconomic Status and Bloodstream Infection Among Pediatric Patients with Acute Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107403</Key_PaperID>
<Key_SessionID>11611</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>532</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Predictors for Recurrent 30-Day Unplanned Readmissions in Patients with Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106764</Key_PaperID>
<Key_SessionID>11611</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>533</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>the Impact of Dedicated Emergency and Admission Units on Infection and Death Risks in Hematological Patients Presented to a Tertiary Care Center </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101434</Key_PaperID>
<Key_SessionID>11611</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>534</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103131</Key_PaperID>
<Key_SessionID>11612</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>865</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Mortality Trends and Causes of Death in Persons with Sickle Cell Disease in the United States, 1979-2014</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107149</Key_PaperID>
<Key_SessionID>11612</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>866</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Current Healthcare Utilization Patterns and Most Common Reasons for Admission Amongst Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104005</Key_PaperID>
<Key_SessionID>11612</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>867</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Decreased Hospital Readmissions for Vaso Occlusive Crisis with Implementation of a Sickle Cell Pain Action Plan (SPAP)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105358</Key_PaperID>
<Key_SessionID>11612</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Hydroxyurea is not FDA approved for use in children with sickle cell anemia.</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>868</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Targeted Education after an Emergency Department Visit Increases Hydroxyurea Initiation in Children with Sickle Cell Anemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101800</Key_PaperID>
<Key_SessionID>11612</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>869</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Habit, a Feasibility Trial to Improve Hydroxyurea Adherence, Improves Quality of Life in Youth with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106889</Key_PaperID>
<Key_SessionID>11612</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>870</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Impact of Sickle Cell Therapies on Growth Patterns</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100900</Key_PaperID>
<Key_SessionID>11613</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>751</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Quality of Life in Patients with -Thalassemia: Transfusion Dependent Versus Non-Transfusion Dependent</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103005</Key_PaperID>
<Key_SessionID>11613</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Rituximab and romiplostim for treatment of pediatric immune thrombocytopenia.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>752</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Health Related Quality of Life and Fatigue Improve on Second Line Treatments in Pediatric Immune Thrombocytopenia (ITP)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107976</Key_PaperID>
<Key_SessionID>11613</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>753</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Enhancing the Khorana Score: Traditional VTE Risk Factors Are Important in Predicting Long Term VTE Risk in Cancer Patients Initiating Chemotherapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104580</Key_PaperID>
<Key_SessionID>11613</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber>754</PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>Incidence of Venous Thromboembolism and Impact on Mortalityin Patients with Primary CNS Lymphoma: A Population Based Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103004</Key_PaperID>
<Key_SessionID>11613</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>755</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Mortality Trends and Causes of Death in Persons with Hemophilia in the United States, 1999-2014</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103168</Key_PaperID>
<Key_SessionID>11613</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>756</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>The Relationship of Joint Range of Motion to Factor Activity in Patients with Hemophilia a and B without Prophylaxis: A Longitudinal Assessment of the CDC-UDC Hemophilia Dataset</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99771</Key_PaperID>
<Key_SessionID>11614</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>277</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Transfusion Dependence and Use of Hospice Among Medicare Beneficiaries with Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100980</Key_PaperID>
<Key_SessionID>11614</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>278</PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>Advance Directive Utilization Decreases Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107876</Key_PaperID>
<Key_SessionID>11614</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>279</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Creation of Individualized Care Plans in High Risk Oncology Patients: A Team Based Model to Decrease Unnecessary Hospitalizations and ED Utilization</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100062</Key_PaperID>
<Key_SessionID>11614</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>280</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Quality of Life of Informal Caregivers of Hematopoietic Cell Transplant Recipients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107556</Key_PaperID>
<Key_SessionID>11614</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>281</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Days Spent at Home in the Last 6 Months of Life. a Potential Patient-Determined Quality Indicator for Patients with Hematologic Malignancies at the End of Life</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103101</Key_PaperID>
<Key_SessionID>11614</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>282</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Bolus Versus Prolonged Infusion of Broad-Spectrum Beta-Lactams for Patients with Hematologic Malignancies and High Risk Febrile Neutropenia  a Single Center Prospective Unblinded Randomized Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105002</Key_PaperID>
<Key_SessionID>11615</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	6:30 PM
 
</PaperEndTime>
<PaperNumber>913</PaperNumber>
<PaperStartTime>
	6:15 PM
 
</PaperStartTime>
<PaperTitle>Secondary Cancers in Hodgkin Lymphoma: A Comprehensive Analysis of Incidence and Trends in Survivors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107563</Key_PaperID>
<Key_SessionID>11615</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	6:45 PM
 
</PaperEndTime>
<PaperNumber>914</PaperNumber>
<PaperStartTime>
	6:30 PM
 
</PaperStartTime>
<PaperTitle>The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103928</Key_PaperID>
<Key_SessionID>11615</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:00 PM
 
</PaperEndTime>
<PaperNumber>915</PaperNumber>
<PaperStartTime>
	6:45 PM
 
</PaperStartTime>
<PaperTitle>Survival Outcome and Insurance Status Among Hodgkins Lymphoma (HL) Patients: Data from SEER 2007-2014</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107021</Key_PaperID>
<Key_SessionID>11615</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:15 PM
 
</PaperEndTime>
<PaperNumber>916</PaperNumber>
<PaperStartTime>
	7:00 PM
 
</PaperStartTime>
<PaperTitle>Insurance Status ImpactsSurvivalin Burkitt Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100091</Key_PaperID>
<Key_SessionID>11615</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>917</PaperNumber>
<PaperStartTime>
	7:15 PM
 
</PaperStartTime>
<PaperTitle>Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101560</Key_PaperID>
<Key_SessionID>11615</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:45 PM
 
</PaperEndTime>
<PaperNumber>918</PaperNumber>
<PaperStartTime>
	7:30 PM
 
</PaperStartTime>
<PaperTitle>Medical Comorbidities Assessed By CIRS Negatively Impact Survival in the Era of Targeted Therapies in CLL: A Multicenter Retrospective Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102002</Key_PaperID>
<Key_SessionID>11616</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>679</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103277</Key_PaperID>
<Key_SessionID>11616</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>680</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101985</Key_PaperID>
<Key_SessionID>11616</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>681</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>Symptom Burden of Busulfan and Melphalan Versus Melphalan Alone for Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100016</Key_PaperID>
<Key_SessionID>11616</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>682</PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Population Trends in Incidence of Second Malignant Neoplasm and Cause-Specific Mortality in Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105120</Key_PaperID>
<Key_SessionID>11616</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated, in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia and, in combination with bendamustine (benda) followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. GAZYVA is also indicated in combination with chemotherapy, followed by GAZYVA maintenance in patients achieving a response, in previously untreated advanced FL (EU, Switzerland). In this abstract, HRQOL data from an open-label, single-arm Phase II study of the combination of GAZYVA and benda in patients with previously untreated CLL, are reported.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber>683</PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105376</Key_PaperID>
<Key_SessionID>11616</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber>684</PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>Financial Burden and Patient-Reported Outcomes after Hematopoietic Cell Transplantation: Impact of Pre-Treatment Awareness of Transplant-Associated Costs</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103539</Key_PaperID>
<Key_SessionID>11617</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>349</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Perceptions of Prognosis and Treatment Risk in Older Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103432</Key_PaperID>
<Key_SessionID>11617</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>350</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Risk and Outcomes of Second Malignant Neoplasms in Chronic Myeloid Leukemia Survivors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105366</Key_PaperID>
<Key_SessionID>11617</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>351</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>The Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients with Essential Thrombocythemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99815</Key_PaperID>
<Key_SessionID>11617</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>352</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Understanding Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia in a Real-World Setting</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101240</Key_PaperID>
<Key_SessionID>11617</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>353</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Impact of Transfusion Dependency on Health-Related Quality of Life Outcomes in Newly Diagnosed Patients with Myelodysplastic Syndromes (MDS). Analysis on 669 Patients By Disease Risk</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104134</Key_PaperID>
<Key_SessionID>11617</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>354</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>The Impact of Phlebotomy and Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients with Polycythemia Vera</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101439</Key_PaperID>
<Key_SessionID>11618</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>469</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Cellular Stressors Contribute to the Expansion of Multiple Hematopoietic Clones of Varying Leukemic Potential</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102935</Key_PaperID>
<Key_SessionID>11618</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>470</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Necessity of Smc3 in Embryonic and Adult Hematopoiesis with an Emphasis on Myeloid Compartment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103964</Key_PaperID>
<Key_SessionID>11618</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>471</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Progression to AML Is Predictable and Distinct from Age Related Clonal Hematopoiesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105858</Key_PaperID>
<Key_SessionID>11618</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>472</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Branched Chain Amino Acid Catabolism Restricts Alpha-Ketoglutarate Levels Resembling IDHmut-Driven DNA Hypermethylation in AML Stem Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99918</Key_PaperID>
<Key_SessionID>11618</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>473</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Spliceosomal Dysfunction Is a Critical Mediator of IDH2 Mutant Leukemogenesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106368</Key_PaperID>
<Key_SessionID>11618</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>474</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>Molecular Pathogenesis of Progressive Refractoriness in MLL-Rearranged AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101668</Key_PaperID>
<Key_SessionID>11619</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	12:15 PM
 
</PaperEndTime>
<PaperNumber>403</PaperNumber>
<PaperStartTime>
	12:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Profiling Defines Distinct Prognostic Subgroups in Chilhood Acute Myeloid Leukemia: A Report from the French ELAM02 Study Group</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101838</Key_PaperID>
<Key_SessionID>11619</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	12:30 PM
 
</PaperEndTime>
<PaperNumber>404</PaperNumber>
<PaperStartTime>
	12:15 PM
 
</PaperStartTime>
<PaperTitle>Genomic Landscapes in Elderly AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102408</Key_PaperID>
<Key_SessionID>11619</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	12:45 PM
 
</PaperEndTime>
<PaperNumber>405</PaperNumber>
<PaperStartTime>
	12:30 PM
 
</PaperStartTime>
<PaperTitle>IDH1 and IDH2: Founding or Progressor Mutations in Myeloid Neoplasms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107081</Key_PaperID>
<Key_SessionID>11619</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:00 PM
 
</PaperEndTime>
<PaperNumber>406</PaperNumber>
<PaperStartTime>
	12:45 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Impact of Clonal Hematopoiesis in Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108022</Key_PaperID>
<Key_SessionID>11619</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber>407</PaperNumber>
<PaperStartTime>
	1:00 PM
 
</PaperStartTime>
<PaperTitle>Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Childrens Oncology Group</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108240</Key_PaperID>
<Key_SessionID>11619</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber>408</PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>Acute Myeloid Leukemia (AML) Patients Demonstrate Increased Prevalence of AML-Defining Mutations in Peripheral Blood Years Prior to the Development of Overt Leukemia: A Case-Control Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101471</Key_PaperID>
<Key_SessionID>11620</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Venetoclax for AML</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber>181</PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103416</Key_PaperID>
<Key_SessionID>11620</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:30 PM
 
</PaperEndTime>
<PaperNumber>182</PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>Clonal Evolution of FLT3-ITD Positive AML in Patients Treated with Midostaurin in Combination with Chemotherapy within the Ratify (CALGB 10603) and AMLSG 16-10 Trials</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104124</Key_PaperID>
<Key_SessionID>11620</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber>183</PaperNumber>
<PaperStartTime>
	2:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106752</Key_PaperID>
<Key_SessionID>11620</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>184</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Distinct Outcome Based on Fusion Transcript in t(16;21) Rearranged Pediatric AML, a Collaborative Retrospective Analysis By the I-BFM SG</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107129</Key_PaperID>
<Key_SessionID>11620</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>185</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107558</Key_PaperID>
<Key_SessionID>11620</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>186</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Neurofibromin 1 gene Mutations Are Recurrent Events in Adult Patients with Acute Myeloid Leukemia (AML), Associate with Poor Outcome and Refine the Adverse European Leukemianet (ELN) Risk Category</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108162</Key_PaperID>
<Key_SessionID>11622</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>265</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Crowdsourcing a High-Risk Classifier for Multiple Myeloma Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106825</Key_PaperID>
<Key_SessionID>11622</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:30 PM
 
</PaperEndTime>
<PaperNumber>266</PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Genomic Characterization of Refractory Multiple Myeloma Reveals a Complex Mutational and Structural Landscape Associated with Drug Resistance</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106966</Key_PaperID>
<Key_SessionID>11622</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>267</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107293</Key_PaperID>
<Key_SessionID>11622</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>268</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Adar-Mediated Aberrant a-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105507</Key_PaperID>
<Key_SessionID>11622</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>269</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of the Epigenetic Modifier EZH2 By Mir-138 Upregulates Tumor Suppressor Gene Rbpms and Contributes to Drug Susceptibility in Preclinical Model of Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103714</Key_PaperID>
<Key_SessionID>11622</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>270</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>IKZF1/3 and CRL4CRBN E3 Ubiquitin Ligase Mutations Associate with IMiD Resistance in Relapsed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107410</Key_PaperID>
<Key_SessionID>11623</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:45 AM
 
</PaperEndTime>
<PaperNumber>325</PaperNumber>
<PaperStartTime>
	7:30 AM
 
</PaperStartTime>
<PaperTitle>Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108740</Key_PaperID>
<Key_SessionID>11623</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 AM
 
</PaperEndTime>
<PaperNumber>326</PaperNumber>
<PaperStartTime>
	7:45 AM
 
</PaperStartTime>
<PaperTitle>Integrative Analysis of the Genomic Landscape Underlying Multiple Myeloma at Diagnosis: An Mmrf Commpass Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103651</Key_PaperID>
<Key_SessionID>11623</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:15 AM
 
</PaperEndTime>
<PaperNumber>327</PaperNumber>
<PaperStartTime>
	8:00 AM
 
</PaperStartTime>
<PaperTitle>Plasma Cell Disease Genotyping with the Liquid Biopsy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104687</Key_PaperID>
<Key_SessionID>11623</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:30 AM
 
</PaperEndTime>
<PaperNumber>328</PaperNumber>
<PaperStartTime>
	8:15 AM
 
</PaperStartTime>
<PaperTitle>Integrative Oncogenomic Analysis Combining Whole Genome, Transcriptome and Epigenome Identifies Altered Chromatin Accessibility Landscape in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100260</Key_PaperID>
<Key_SessionID>11623</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:45 AM
 
</PaperEndTime>
<PaperNumber>329</PaperNumber>
<PaperStartTime>
	8:30 AM
 
</PaperStartTime>
<PaperTitle>Genomic Discovery and Clonal Tracking in Multiple Myeloma By Cell Free DNA Sequencing</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101760</Key_PaperID>
<Key_SessionID>11623</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	9:00 AM
 
</PaperEndTime>
<PaperNumber>330</PaperNumber>
<PaperStartTime>
	8:45 AM
 
</PaperStartTime>
<PaperTitle>The Genomic Landscape of Multiple Myeloma Complex Structural Variations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102647</Key_PaperID>
<Key_SessionID>11625</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Use off-label of drugs for the dose and/or schedule and/or association.
</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	6:30 PM
 
</PaperEndTime>
<PaperNumber>901</PaperNumber>
<PaperStartTime>
	6:15 PM
 
</PaperStartTime>
<PaperTitle>Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100870</Key_PaperID>
<Key_SessionID>11625</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Use of approved agent ixazomib in a novel combination </OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	6:45 PM
 
</PaperEndTime>
<PaperNumber>902</PaperNumber>
<PaperStartTime>
	6:30 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106598</Key_PaperID>
<Key_SessionID>11625</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:00 PM
 
</PaperEndTime>
<PaperNumber>903</PaperNumber>
<PaperStartTime>
	6:45 PM
 
</PaperStartTime>
<PaperTitle>Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106908</Key_PaperID>
<Key_SessionID>11625</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:15 PM
 
</PaperEndTime>
<PaperNumber>904</PaperNumber>
<PaperStartTime>
	7:00 PM
 
</PaperStartTime>
<PaperTitle>Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103621</Key_PaperID>
<Key_SessionID>11625</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>905</PaperNumber>
<PaperStartTime>
	7:15 PM
 
</PaperStartTime>
<PaperTitle>Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108810</Key_PaperID>
<Key_SessionID>11625</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:45 PM
 
</PaperEndTime>
<PaperNumber>906</PaperNumber>
<PaperStartTime>
	7:30 PM
 
</PaperStartTime>
<PaperTitle>Bortezomib, Lenalidomide and Low-Dose Dexamethasone (VRD) Versus Lenalidomide and Low-Dose Dexamethasone (Ld) for Newly-Diagnosed Multiple Myeloma- a Randomized Phase III Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102915</Key_PaperID>
<Key_SessionID>11626</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>739</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107984</Key_PaperID>
<Key_SessionID>11626</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber>740</PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103803</Key_PaperID>
<Key_SessionID>11626</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:30 PM
 
</PaperEndTime>
<PaperNumber>741</PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104255</Key_PaperID>
<Key_SessionID>11626</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>BCMA targeted CAR T cells for the treatment of MM
Tocilizumab for the treatment of CRS
Cetuximab for the treatment of CRS</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber>742</PaperNumber>
<PaperStartTime>
	3:30 PM
 
</PaperStartTime>
<PaperTitle>Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102318</Key_PaperID>
<Key_SessionID>11626</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>743</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100893</Key_PaperID>
<Key_SessionID>11626</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Use off-label of drugs for the dose and/or schedule and/or association. </OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	4:15 PM
 
</PaperEndTime>
<PaperNumber>744</PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Bortezomib- or Lenalidomide-Based Induction Treatment on High Risk Cytogenetic Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Enrolled in the Gimema-MM-03-05 and EMN01 Trials</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107458</Key_PaperID>
<Key_SessionID>11627</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	10:45 AM
 
</PaperEndTime>
<PaperNumber>667</PaperNumber>
<PaperStartTime>
	10:30 AM
 
</PaperStartTime>
<PaperTitle>Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneit HCT: A CIBMTR Report</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101447</Key_PaperID>
<Key_SessionID>11627</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	11:00 AM
 
</PaperEndTime>
<PaperNumber>668</PaperNumber>
<PaperStartTime>
	10:45 AM
 
</PaperStartTime>
<PaperTitle>Transplantation Outcome By Disease Risk and Donor Type over Time: An Analysis of 100,000 Allogeneic Stem Cell Transplantation on Behalf of the Acute Leukemia Working Party of the EBMT</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103033</Key_PaperID>
<Key_SessionID>11627</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	11:15 AM
 
</PaperEndTime>
<PaperNumber>669</PaperNumber>
<PaperStartTime>
	11:00 AM
 
</PaperStartTime>
<PaperTitle>Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Adult Patients with t(4;11)(q21;q23) KMT2A/AFF1 (MLL/AF4) B-Acute Lymphoblastic Leukemia in First Complete Remission (CR1): Favorable Outcome of Patients with Negative Minimal Residual Disease (MRD) Status at Transplant. a Report from the Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation (ALWP-EBMT)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103152</Key_PaperID>
<Key_SessionID>11627</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	11:30 AM
 
</PaperEndTime>
<PaperNumber>670</PaperNumber>
<PaperStartTime>
	11:15 AM
 
</PaperStartTime>
<PaperTitle>Selecting the Best Donor for T Cell-Replete Haploidentical Transplantation: Importance of HLA Disparity, NK Alloreactivity, and Other Clinical Variables</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99861</Key_PaperID>
<Key_SessionID>11627</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	11:45 AM
 
</PaperEndTime>
<PaperNumber>671</PaperNumber>
<PaperStartTime>
	11:30 AM
 
</PaperStartTime>
<PaperTitle>Early Transplant Improves Outcomes in Patients with Chronic Granulomatous Disease: Results from United States Immunodeficiency Network (USIDNET)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99796</Key_PaperID>
<Key_SessionID>11627</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	12:00 PM
 
</PaperEndTime>
<PaperNumber>672</PaperNumber>
<PaperStartTime>
	11:45 AM
 
</PaperStartTime>
<PaperTitle>Decline in Late Mortality after Allogeneic Blood or Marrow Transplantation (alloBMT) Performed in Childhood - a Report from the BMT Survivor Study-2 (BMTSS-2)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107794</Key_PaperID>
<Key_SessionID>11628</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber>517</PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Adults</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107313</Key_PaperID>
<Key_SessionID>11628</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber>518</PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Graft-Vs-Leukemia Effect in Acute Lymphoblastic Leukemia: Mild Acute Graft-Vs-Host Disease Protects Against Relapse and Improves Survival after Allogeneic Transplantation: A CIBMTR Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106886</Key_PaperID>
<Key_SessionID>11628</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Anti T-cell lymphocyte Globulin as GVHD prophylaxis</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber>519</PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Prophylaxis with ATLG Significantly ImprovesChronic Graft-Versus-Host Disease/Relapse-Free Survivaland Quality of Lifeafter a Myeloablative HLA Identical Sibling Transplant for Acute Leukemia Patients in Complete Remission. Long-Term Follow-up of the Randomized ATG Familystudy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105524</Key_PaperID>
<Key_SessionID>11628</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber>520</PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Impact of In Vivo T-Cell Depletion in Patients with Myelodysplastic Syndromes Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Registry Study from the Chronic Malignancies Working Party of the EBMT</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100291</Key_PaperID>
<Key_SessionID>11628</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>High-dose treosulfan (mostly in combination with fludarabine) has been and is currently being investigated in several clinical trials as a new preparative regimen for allogeneic hematopoietic stem cell transplantation. This abstract describes the final results of the largest international prospective multicenter phase III trial with 467 randomized patients comparing treosulfan/ fludarabine to busulfan/fludarabine (reference arm) in elderly or comorbid patients with acute myeloid leukemia or myelodysplastic Syndrome.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber>521</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Final Results of a Prospective Randomized Multicenter Phase III Trial Comparing Treosulfan/Fludarabine to Reduced Intensity Conditioning with Busulfan/Fludarabine Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Elderly or Comorbid Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103085</Key_PaperID>
<Key_SessionID>11628</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	6:00 PM
 
</PaperEndTime>
<PaperNumber>522</PaperNumber>
<PaperStartTime>
	5:45 PM
 
</PaperStartTime>
<PaperTitle>The Measurable Residual Disease Status of Acute Myeloid Leukemia in First Complete Remission at Allogeneic Hematopoietic Cell Transplantation Interacts with Conditioning Intensity to Predict Outcome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107316</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>919</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Exteriorisation of Mannoses on Human Erythrocyte Membrane Skeleton Provides Eat Me Signals for Oxidatively Damaged Cells to be Cleared By Macrophages: A Pathway Mediating Hemolysis in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105964</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>920</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>RASA3 Deficiency Contributes to Anemia By Multiple Mechanisms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108627</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>921</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>GWAS of Complete Blood Count (CBC) Measures in 13,403 Blood Donors in the Multi-Racial RBC-Omics Study Reveal Novel Genetic Loci in Minority Populations Which Provide Insights into the Pathways That May Connect Them to Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104010</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>922</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bok Promotes Erythropoiesis in a Mouse Model of Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107219</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>923</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>VPS4A: A Novel Candidate Gene for Congenital Dyserythropoietic Anemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105249</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>924</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Fine Temporal Mapping of Plasmodium Falciparum growth Inhibition in Hypoxic Sickle Cell Trait Erythrocytes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107152</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>925</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of the Transcription Factor RUNX1 Causes Glycosyltransferase a Repression</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108068</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>926</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hypoxic Response-Dependent Genetic Regulation Revealed By Allele-Specific Expression in Reticulocytes of Chuvash Polycythemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102953</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>927</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical and Serological Characteristics of Cold Autoimmune Hemolytic Anemia with Concomitant Cold Agglutinin and Donath-Landsteiner Antibodies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104447</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>928</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Incidence of Thromboembolic Events Is Increased in a Retrospective Analysis of a Large Cold Agglutinin Disease (CAD) Cohort</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104914</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>929</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Flow Cytometric Osmotic Fragility Test Is an Effective Screening Method for Dehydrated Hereditary Stomatocytosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105545</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>930</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Chuvash Polycythemia Patients from Afghanistan and Southern India Share a Common VHL Gene Haplotype. Support for Its Origin before Asians and Europeans Diverged</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108301</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>931</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>SF3B1 Gene Expression in Erythroid Cells Is Regulated By Intron Retention Via a Posttranscriptional Mechanism Involving Cryptic Exons Proposed to Function As Splicing Decoys</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101903</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>932</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clonal Tracking of the Source of Red Cell and Platelet Production in Rhesus Macaques</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100014</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>933</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Examining the CREB Transcriptional Program in Erythropoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101025</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>934</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparative Proteomics and Functional Analysis of Red Blood Cell Membrane Proteins in the Rare in(Lu) Blood Type</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104827</Key_PaperID>
<Key_SessionID>11629</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>935</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Is the Time of Revisiting Classification of Thalassemia Syndromes According with the Phenotype Severity?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104945</Key_PaperID>
<Key_SessionID>11630</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>936</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inadequacy of Ferritin Trends for Predicting Changes in LIC Risk Category in Transfusion Depedent and Well Chelated Patients with Haemoglobinopathies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108280</Key_PaperID>
<Key_SessionID>11630</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>937</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103617</Key_PaperID>
<Key_SessionID>11630</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>938</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Generation of Patient-Derived Human Induced Pluripotent Stem Cells in X-Linked Sideroblastic Anemia and Novel Therapeutic Strategies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105235</Key_PaperID>
<Key_SessionID>11630</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>939</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prevalence of Occult Celiac Disease in Females with Iron Deficiency in the United States: An Nhanes Analysis.</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107970</Key_PaperID>
<Key_SessionID>11630</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>940</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Restriction of HIV-1 Infection in Sickle Cell Disease Trait</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106217</Key_PaperID>
<Key_SessionID>11630</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>941</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Phlebotomy for Pediatric and Young Adult Oncology Patients Treats Transfusional Iron Overload</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104083</Key_PaperID>
<Key_SessionID>11630</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>942</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Effects of Sucrosomial iron in Pre-Clinical and Clinical Conditions of Inflammation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104713</Key_PaperID>
<Key_SessionID>11630</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>943</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Systemic Biomarkers Show Elevated Oxidative Stress and Chronic Inflammation in Two Disorders of Neurodegeneration with Brain Iron Accumulation (NBIA)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104215</Key_PaperID>
<Key_SessionID>11631</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>944</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Let-7 Chronoregulatory Cascade Components May Act Independently to Regulate Fetal Hemoglobin in Human Adult Erythroblasts</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105558</Key_PaperID>
<Key_SessionID>11631</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>945</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>GATA-1 Deacetylation and Interaction with HDAC1 Is Critical for GATA-1 Mediated Gene Transcription</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104693</Key_PaperID>
<Key_SessionID>11631</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>946</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Induced Pluripotent Stem Cell (iPSC)-Based Mapping of Globin Expression throughout Human Erythropoietic Development</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107770</Key_PaperID>
<Key_SessionID>11631</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>947</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Introduction of Two Simultaneous Mutations By Genome Editing Greatly Enhances the Accumulation of the Endogenous Fetal Hemoglobin in Human Normal Erythroid Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100595</Key_PaperID>
<Key_SessionID>11631</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>948</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impairment in the Mesenchymal Bone-Marrow Niche of Beta-Thalassemia Patients and Association with Prolonged Iron Exposure</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104874</Key_PaperID>
<Key_SessionID>11631</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>949</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Renal Function in Transfusion-Dependent -Thalassemia Patients: A Decade of Follow-up and Comparison between Chelation Regimes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104758</Key_PaperID>
<Key_SessionID>11631</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>950</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Leptin Is Associated with the Degree of Anemia and the Erythropoietin Levels in  Thalassemia Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106754</Key_PaperID>
<Key_SessionID>11631</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>951</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Low Impact of Genetic Modifiers on the Phenotype of Homozygous Beta Thalassemia in the Last Decennial Cohort of Thalassemia Newborns in Sardinia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105196</Key_PaperID>
<Key_SessionID>11631</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>952</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>An Urgent Need for Improving Thalassemia Care in Adult Patients Due to a Wide Gap on Current Real-Life Practice and Recommended Clinical Practice Guidelines</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107837</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>953</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Longitudinal Monitoring of RBC Adhesion in Patients with SCD Is Heterogeneous and Clinically informative </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108009</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>954</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>PADI4 Gene Polymorphism As a Risk Factor for Acute Chest Syndrome in Sickle Cell Anemia Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108658</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>955</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pathological Role of Halted Proteasome Machinery in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108745</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>956</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Locus on Chromosome 5 Is Associated with Red Cell Allo-Immunization in Adults with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102845</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>957</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Tissue-Resident TSP1-CD47 Signaling Promotes Sickle Cell-Associated Arterial Vasculopathy and Pulmonary Hypertension</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107577</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>958</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hairy Platelet-Derived Extracellular Vesicles Promote Lung Vaso-Occlusion in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104066</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>959</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Adhesion of Sickle RBCs to Heme-Activated Endothelial Cells Correlates with Patient Clinical Phenotypes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105339</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>960</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Loss of NRF2 Function Worsens the Pathophysiology of Sickle Cell Disease in a Transgenic Mouse Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107569</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>961</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Rock Inhibitor Fasudil Reduces LeukocyteEndothelium Interactions in the Microvasculature of a Sickle Cell Mouse Model of Allergic Inflammation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101469</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The presentation describes genetic results relating to prasugrel for treatment of sickle cell, which is not an approved indication. </OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>962</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Candidate Gene Associations with Vaso-Occlusive Crisis in Children with Sickle Cell Anemia Enrolled in the Multinational DOVE Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103163</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Administration of plerixafor in sickle cell patients is IND approved under IND 122657 
</OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>963</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Studies of White Cell, Platelet, and Coagulation Activation with Plerixafor Administration in Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107261</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>964</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Patient-Specific Adhesion of Sickle Red Blood Cells in Shear-Gradient Microscale Flow</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107609</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>965</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>RON Kinase Inhibition Reduces Renal Endothelial Injury in Sickle Cell Disease Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103522</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>966</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bone Marrow Characterization in Sickle Cell Disease: Inflammation and Stress Erythropoiesis Lead to Suboptimal CD34 Recovery Compared to Normal Volunteer Bone Marrow</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106222</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>967</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Quantitative Proteomics Identify Urinary Hgfl Protein As a Potential Marker for the Development of Chronic Kidney Disease in Sickle Cell Disease Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107798</Key_PaperID>
<Key_SessionID>11632</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>968</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>In VivoEffects of LSD1 Inhibition By Small Chemical Inhibitors in Sickle Cell Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105693</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>969</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pegylated Carboxyhemoglobin Bovine (SANGUINATE) Restores RBCs Roundness and Reduces Pain during a Sickle Cell Vaso-Occlusive Crisis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103331</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>970</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pain and Opioid Use after Reversal of Sickle Cell Disease Following Hematopoietic Stem Cell Transplant</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107268</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>971</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prevalence and Correlates of Growth Failure in African Patients with Sickle Cell Disease: A Multinational Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103893</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>972</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Reduced Cerebrovascular Reserve Capacity in Adults with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105335</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>973</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Elipsis: A Longitudinal Study of Electronic Patient-Reported Outcomes, Actigraphy and Biomarkers to Identify and Assess at-Home Vaso-Occlusive Crises in Adults and Adolescents with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105884</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>974</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study of PF-04447943 in Patients with Stable Sickle Cell Disease: Changes in Exploratory Biomarkers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99924</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>975</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106056</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>976</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cancer and Sickle Cell Disease (SCD): Predictors of Incident Cancer and Survival Compared to Non-SCD Patients in California</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101254</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>977</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hydroxyurea Therapy Prevents High Risk Trans-Cranial Doppler Development in Children with Sickle Cell Disorders</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104174</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>978</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism Is Associated with a Significant Decrease in Incidence of Bleeding Compared to Vitamin K Antagonists and Low-Molecular-Weight Heparins</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102290</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>979</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE): Interim Overall Results</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104144</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>980</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106209</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>981</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Low Fixed Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Disease in Nigeria</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105147</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>982</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Acute Vaso-Occlusive Pain Associated with the Onset of Menstruation Is Distinct from Dysmenorrhea in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107946</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>983</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Developmental Outcomes of Children Exposed to Maternal Sickle Cell Disease (SCD)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108296</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>984</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ambulatory Hypertension in a Pediatric Cohort of Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108148</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>985</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Apolipoprotein L1 Genetic Variants Are Associated with Evidence of Early Kidney Injury in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106802</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>986</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Predictive Value of Gradual Change in Renal Function on Vasculopathy Related Complications and Mortality in Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102957</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>987</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Echocardiografic Abnormalities in Patients with Sickle Cell/-Thalassemia Do Not Depend on the -Thalassemia Phenotype</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103517</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>988</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Effect of Acute Transfusion on Cerebral Oxygenation in Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105706</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>989</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Identification of Patient-Specific Factors Associated with Alloimmunization in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105455</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>990</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Successful Plerixafor-Mediated Mobilization, Apheresis, and Lentiviral Vector Transduction of Hematopoietic Stem Cells in Patients with Severe Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108165</Key_PaperID>
<Key_SessionID>11633</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>991</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prospective Controlled Trial on Endurance Exercise Training in Adult Sickle Cell Disease Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102898</Key_PaperID>
<Key_SessionID>11634</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1000</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluating the Clinical Utility of Testing for Autoimmune Disorders in the Setting of Leukopenia/Neutropenia in an Ambulatory Hematology Clinic. </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108322</Key_PaperID>
<Key_SessionID>11634</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1001</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Interaction between Integrin Mac-1 (M2, CD11b/CD18) and Sirp Mediates Macrophage Fusion</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100922</Key_PaperID>
<Key_SessionID>11634</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1002</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparability of Pharmacodynamics and Immunogenicity of B12019, a Proposed Pegfilgrastim Biosimilar to Neulasta</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107331</Key_PaperID>
<Key_SessionID>11634</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>992</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Metabolic Remodeling of Neutrophils at Inflammatory Site Drives Invadosome Formation Favoring Transcellular Migration</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108849</Key_PaperID>
<Key_SessionID>11634</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>993</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting the NF-b-Dependent HIF-1 Pathway Reprograms Macrophage Polarization Induced By Oxidized LDL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104561</Key_PaperID>
<Key_SessionID>11634</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>994</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Neutrophil Extracellular Traps Exacerbate Inflammatory Responses and Thrombotic Tendency in Both a Murine Colitis Model and Patients with Inflammatory Bowel Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100602</Key_PaperID>
<Key_SessionID>11634</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>995</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100718</Key_PaperID>
<Key_SessionID>11634</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>996</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Outcomes for G-CSF Treatment of Patients with Glycogen-Sstorage Disease Type Ib</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108611</Key_PaperID>
<Key_SessionID>11634</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>997</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Platelet Factor 4 (PF4)-Mediated Neutrophil Extracellular Trap Compaction Limits Endothelial Injury and Promotes Survival Following Lipopolysaccharide Challenge</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107087</Key_PaperID>
<Key_SessionID>11634</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>998</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Glia Maturation Factor-Gamma Modulates M2 Activation of Macrophage Via Suppression of Mitochondria Function</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104756</Key_PaperID>
<Key_SessionID>11634</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>999</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Role of Soluble Interleukin-2 Receptor (sIL-2r) in Diagnosis of Adult Hemophagocytic Lymphohistiocytosis (HLH): A Single Center Retrospective Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105148</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1003</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Coinfection with HCV or HBV Increases the Risk of Lymphoma in HIV-Positive Patients: A Combined Analysis of the Lymphovir-ANRS-CO16 and Fhdh-ANRS-CO4 Cohorts</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104377</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1004</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Epigenetic Control of Foxp3, CAMTA1 and FUT7 Genes in Human Regulatory T Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105998</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1005</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>U Distinct Roles of IL-12R1 and IL-23R in the Development of Acute and Chronic Gvhd</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103227</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1006</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Early B Cell Development Is Impaired in Patients with Active Hemophagocytic Lymphohistiocytosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103579</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1007</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Lenalidomide Acts As a Positive Immunomodulator through Modulating the Functions of Human Plasmacytoid Dendritic Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108794</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1008</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prostaglandin E2 Promotes Recovery of Thymus in Survivors of the Hematopoietic Acute Radiation Syndrome (H-ARS)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104680</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1009</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Discrete Modes of Migration Define Human NK Cell Development from Hematopoietic Stem Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104526</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1010</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hiv Specific T Cells Generated from Hiv Naive Adult and Cord Blood Donors Target a Range of Novel Viral Epitopes: Implications for a Cure Strategy after Allogeneic HSCT and CBT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107206</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1011</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Plasma InflammatoryProtein Profiles Distinguish Hemophagocytic Lymphohistiocytosis from Sepsis and SIRS</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106751</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1012</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Role of HO-1 in B Lymphocyte Proliferation and Development in Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101202</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1013</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Human Herpes-Virus 6 Infection in Immunocompromised Patients after Chemotherapy and Autologous Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107682</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1014</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Timing and Epidemiology of Enterococcus Faecium and E. Faecalis Bloodstream Infections (BSI) in Patients with Acute Leukemia Receiving Chemotherapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107462</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1015</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Obesity-Induced Chronic Inflammation Suppresses the Function of Non-Malignant Immune Cells While Upregulating PD-L1 on Human B-ALL Cell Lines</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108788</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1016</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Role of Bone Marrow Aspirate and Biopsy in the Diagnosis of HIV Patients Presenting with Low Blood Counts</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108040</Key_PaperID>
<Key_SessionID>11635</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Zinc sulphate is approved by FDA and EMEA for the treatment of common cold and dermopathies. The use as immunostimulant after HSCT is off-label. These results are from a clinical trial approved by local ethical committes, and registered with an EUDRACT number by the portal of the Italian Agency of Drugs (AIFA) </OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1017</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cytokine Release from Stimulated PBMC after-HSCT: Results of a Post-Transplant Zinc Oral Supplementation Trial (ZENITH)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107785</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1018</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>1,4-Galactosyltransferase 1 Is a Key Regulator of Thrombopoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105576</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1019</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Unique Transmembrane Domain Interactions Differentially Modulate Platelet IIb3 and v3 Function</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106605</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1020</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Protein Kinase C-Dependent Von Willebrand Factor Secretion Is a Dual-Phased Process That Originates from 2 Distinct Intracellular Compartments</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103989</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1021</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Microrna-15a-5p Regulates Multiple Components of GPVI-Mediated Platelet and Megakaryocyte Activation Pathway</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105370</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1022</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Anatomy of the Extracellular Clasps That Regulate Platelet IIb3 and v3 Function</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108456</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1023</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Agonist-Induced Signaling and Integrin-Mediated Function in Murine Platelets Is Distinctly Regulated By the  Isoform of the Catalytic Subunit of Protein Phosphatase 1</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108271</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1024</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ultra-Low Von Willebrand Factor (VWF) Adsorption Under Shear with a Polymer Coating for Blood-Contacting Devices</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104198</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1025</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>GPVI Intracellular Signaling Is Activated in Platelets from Patients with Essential Thrombocythemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103574</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1026</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Fractalkine Treated of CD11b+CX3CR1+Monocytes Promotes Angiogenesis through Pigment Epithelium-Derived Factor</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107774</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1027</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>PTPN7 Tyrosine Phosphatase Negatively Regulates Thromboxane Generation and Erk Phosphorylation in Platelets</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108024</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1028</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Platelet Activation and Shear-dependent Changes in Filamin a Conformation Downstream of Ligand Binding to IIb3, GPIb and 21 Are Reversible in Time, but Those Downstream of Fibrin Binding to alphaIIbbeta3 Are Not</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106124</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1029</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Vascular and Hemostatic Alterations Associated with Pulmonary Hypertension in -Thalassemia Hemoglobin E Patients Receiving Regular Transfusion and Iron Chelation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105023</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1030</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of Btk Does Not Block Platelet Activation By GPVI: Studies with Ibrunitib, Acalabrutinib and Patients with X-Linked Agammaglobulinaemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104180</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1031</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Characterization of a Nanobody That Binds Von Willebrand Factor and Prevents Von Willebrand Factor Cleavage By Plasmin</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106919</Key_PaperID>
<Key_SessionID>11636</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1032</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>ASK1 Activation in Platelets By Oxidized LDL Is Independent of CD36</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103785</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1033</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>MT-Associated Protein Dysfunction May Lead to Impaired Ppf of Megakaryocytes in Corticosteroid-Resistant/Relapse Immune Thrombocytopenia Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103687</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1034</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pro-Platelet Formation Is Impaired in Megakaryocytes of MYH9-Related Disease Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108266</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1035</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A CRISPR-Cas9 Generated Etv6 mutant Mouse Exhibits Decreased Platelet Counts and Functional Platelet Defects</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108075</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1036</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Increased MHC Class I Expression on Platelets in Human and Murine Sepsis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104599</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>In this study, romiplostim was used to treat multiple different etiologies of thrombocytopenia beyond the FDA-approved indication of ITP.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1037</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Romiplostim for the Management of Perioperative Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106442</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1038</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mesenchymal Stem Cells Improve Platelet Counts in Mice with ITP</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104435</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1039</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Corticosteroids PlusIntravenous Immunoglobulin Compared with Corticosteroids for the Treatment of Immune Thrombocytopenia in Pregnancy: An Observational Multicenter Study in China</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106083</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1040</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prevalence of Cardiovascular Risk Factors and Incidence of Venous and Arterial Thrombosis in Non-Splenectomized Immune Thrombocytopenia Adult Patients in Sweden and France. Results from Two Nationwide Studies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105981</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1041</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Risk Factors for Bleeding, Including Platelet Count Threshold, in Newly Diagnosed ITP Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106807</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1042</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Glucocorticoids Reduce the Number and Function of CD19+CD24hiCD38hi Regulatory B Cells in Patients with Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108129</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1043</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Effective Treatment of Thrombotic Microangiopathy Associated with Lupus Nephritis with Eculizumab:a Series of 8 Cases</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105172</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1044</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The WASP P460S Mutation Causes a New Phenotype of WASP Mutations Related Disorder X-Linked Pancytopenia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105899</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1045</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Cytomegalovirus (CMV) Reactivation on Clinical Course and Immunomodulatory Effect in Children with Immune-Thrombocytopenia (ITP)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107693</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1046</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Sequestration Pattern in ITP Liver/Spleen Scan Correlates with the Presence of Anti-Glycoprotein V Antibodies in ITP Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104152</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1047</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Aberrant Level of Estrogen Correlateswith Defective Thrombopoiesis during Pregnancy in Patients with Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107133</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1048</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Multiple Electrode Impedance-Based Platelet Aggregometry to Light Transmission Aggregometry for Diagnosis of Qualitative Platelet Defects</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107063</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1049</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Descriptive Analysis of the Demographics and Presenting Symptoms of Patients in the U.S. Thrombotic Microangiopathy (USTMA) TTP Registry</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106517</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1050</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Early Increased Platelet Count Is a Predictive Factor for a Long-Term Response in High-Dose Dexamethasone Treatment for Newly-Diagnosed Immune Thrombocytopenia Patients.</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103046</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1051</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Landscape of Transcriptome Sequencing in Childhood Immune Thrombocytopenia(ITP)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102427</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1052</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>PRN1008, a Reversible Covalent BTK Inhibitor in Clinical Development for Immune Thrombocytopenic Purpura</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100886</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1053</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Occurrence and Management of Cataracts in Adult Patients (pts) with Chronic Immune Thrombocytopenia (cITP) during Long-Term Treatment with Eltrombopag (EPAG): Results from the Extend Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102196</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1054</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Vaccination Associated and Non-Vaccination Associated Paediatric Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100059</Key_PaperID>
<Key_SessionID>11637</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Romiplostim is approved for use in adults with chronic ITP; some of the patients in this study - all of whom were adults with ITP - had ITP that was of shorter duration.</OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1055</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of the Effects of the Thrombopoietin (TPO) Receptor Agonist Romiplostim in Patients with Immune Thrombocytopenia (ITP) for 1 Year Vs. &gt;1 Year</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104601</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1056</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Quantitative Structural Characterization of Fibrinogen's C Regions in Fibrin Monomers and Oligomers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100959</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1057</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Interfering with Protein Z Dependent Inhibition of Factor Xa Improves Coagulation in Hemophilia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107189</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1058</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Missense Mutation in the Loss-of-Function Intolerant Actr2 Gene Suppresses Thrombosis Via Multiple Mechanisms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100537</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1059</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Poor Agreement between Commercially Available Anti-Cardiolipin and Anti-2glycoprotein I IgG and IgM Solid Phase Assays Hampers Uniformity in the Classification of Antiphospholipid Syndrome Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102353</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1060</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prothrombinase Inhibition By Tfpi Requires Three Distinct Interactions with Factors Va and X</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107267</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1061</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Extravascular Distribution of Conventional and Ehl FIX Products Using In Vivo SPECT Imaging Analysis in Hemophilia B Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102239</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1062</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Assessment of a Novel Dielectric Microsensor for Monitoring Coagulation Factor Therapy in Children with Hemophilia with and without Inhibitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105870</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1063</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mechanisms Linking Fibrin(ogen) Structure/Function to Tumor Metastasis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108574</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1064</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Factor VIII Binds to an Acidic Fibrinogen Variant, a Critical Component of the High-Affinity Fibrin Binding Site, Resulting in Increased Cofactor Activity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107865</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1065</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Extrinsic Complex Structure Developed through Novel Simulation Methodology: Key Putative Atomic-Level Interactions Identified</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107854</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1066</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Specific Factor VIII Domains on Uptake By Dendritic Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108562</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1067</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Hepatocyte Transcription Repressor DACH1 Inhibits Fibrinolysis and Increases Risk of Thrombosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104270</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1068</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cytoplasmic Phospholipase A2 Is Essential in GPVI Signaling Initiated Procoagulant Platelet Formation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104635</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1069</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Plasminogen Activator Inhibitor Type 1 (PAI-1) and Thrombophilia: A 10 Year Retrospective Review of Clinical Data at a Large Children's Hospital</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107898</Key_PaperID>
<Key_SessionID>11638</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1070</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Plasma-Derived FVII Efficacy for the Treatment of Bleeding in a Murine Model of Hemophilia a</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102374</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1071</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108496</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1072</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Hypofibrinolytic Defect of Nephrotic Syndrome Is Directly Proportional to Disease Severity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107150</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1073</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pharmacokinetics of Subcutaneously Administered Simoctocog Alfa with Von Willebrand Factor Fragment Candidates in a Minipig Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106594</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1074</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Immunohistochemical Analyses and Quantitative RT-PCR of Angiogenic Factors in a Porcine Von Willebrand Disease Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104298</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1075</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Contribution of Select ISTH-BAT Subscores to the Total Score in Type 1 VWD </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105306</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1076</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bay 81-8973 Prophylaxis Frequency and Long-Term Bleed Outcomes in the Leopold I Extension Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108191</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1077</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Incidence of Thrombo-Embolic Events in Relation to Activated Prothrombin Complex Concentrate Exposure: A Literature Meta-Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107718</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1078</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Alterations in Cytokine Profiles Have Potential Uses As Biomarkers for Pediatric Venous Thromboembolism</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106806</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1079</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Meaningful Reduction of Annual Bleeding Rate with Lower Dose Prophylaxis in Minimally Treated Children with Hemophilia in India</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107912</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1080</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Bispecific Antibody Lacks Measurability in Routine Coagulation Assays and Comparability to Factor VIII</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106762</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1081</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Perioperative Management of Von Willebrand Disease: An Institutional Experience</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106685</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1082</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Dysfibrinogenemias Affecting Platelet Aggregation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107640</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1083</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bispecific Antibodies with Native Human IgG Structure As Mimetics for FVIII Activity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105416</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1084</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Biomarkers of Endothelial Function in Sepsis-Associated Disseminated Intravascular Coagulation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105671</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1085</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Quantitative Analysis of Von Willebrand Factor (VWF) Multimers in Von Willebrand Disease (VWD) Patients Recruited through the Zimmerman Program for the Molecular and Clinical Biology of VWD</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100797</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1086</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Single Institutional Study on Pregnancy Outcomes in Patients with Von Willebrand Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101262</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1087</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Von Willebrand Factor Levels in Polycythemia Vera Are Not Reduced and Can be Predicted By Erythrocyte Counts</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101345</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1088</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Acquired Von Willebrand Disease in Patients with Waldenstrm Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102700</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1089</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103453</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1090</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Risk for Major Cardiovascular Event and Venous Thromboembolism in Patients with Factor VII and Factor V Deficiency. </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104228</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1091</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>An Open-Label Study of the Safety and Efficacy of Morotocog Alfa (AF-CC) in Previously Untreated Patients Aged &lt;6 Years in Usual Care Settings</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100082</Key_PaperID>
<Key_SessionID>11639</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Nonacog beta pegol (N9-GP) is a recombinant glycoPEGylated factor IX with an extended half-life, developed as a factor replacement therapy for hemophilia B</OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1092</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Nonacog Beta Pegol for Prophylactic Treatment of Children with Hemophilia B: Up to 3.5-Year Data from the Paradigm5 Clinical Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105815</Key_PaperID>
<Key_SessionID>11640</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1093</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Arteriolar Bottle-Necks in the Lung Are the Site of Pulmonary Thrombo-Embolism</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104240</Key_PaperID>
<Key_SessionID>11640</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1094</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Development and Validation of a 30-Day Mortality Prediction Model for Patients with Cancer-Associated Thrombosis (CAT) in the Riete Database</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106485</Key_PaperID>
<Key_SessionID>11640</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1095</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Longitudinal Haemostatic Biomarker Trajectories Predict Cancer-Associated Venous Thromboembolism</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104211</Key_PaperID>
<Key_SessionID>11640</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1096</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Tissue Factor-Related Biomarkers and Prediction of Cancer-Associated VTE: Correlative Analyses of the Phacs Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107496</Key_PaperID>
<Key_SessionID>11640</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1097</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of the Hemostatic Profile in Mice with Chronic Liver Disease: Effects of Protein S and Combined Gas6 and Protein S Deficiencies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105375</Key_PaperID>
<Key_SessionID>11640</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1098</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Children with CVC-VTE: A Very High Risk Group for Recurrent Thrombosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108079</Key_PaperID>
<Key_SessionID>11640</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Atorvastatin as an adjunct therapy for acute venous thrombosis</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1099</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Atorvastatin As an Adjunct Therapy in Patients with Acute Venous Thromboembolism</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103308</Key_PaperID>
<Key_SessionID>11640</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1100</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Epidemiology and Long-Term Outcomes of Estrogen/Progesterone Associated Distal Deep-Vein Thrombosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107550</Key_PaperID>
<Key_SessionID>11640</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1101</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Validation of Outcome Instrumentsfor Venous Thrombosis in Children</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104079</Key_PaperID>
<Key_SessionID>11640</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1102</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Profile of Thrombosis Distribution Following Haploidentical and Identical-Sibling Transplantation: A 15-Year Experience at a Single Center in China</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105770</Key_PaperID>
<Key_SessionID>11640</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1103</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Thrombin Generation As a Predictive Biomarker for Venous Thromboembolism in Patients with Pancreatic and Lung Cancer Undergoing Systemic Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100742</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1104</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102737</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1105</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Apixaban Is Safe and Effective in Morbidly Obese Patients: A Retrospective Analysis of 390 Patients with BMI 40</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106855</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1106</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Factors Influencing Management of Anticoagulation in Thrombocytopenic Patients with Hematological Malignancy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107151</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1107</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106050</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1108</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Bleeding Risk between Rivaroxaban and Apixaban - a Pilot Feasibility Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103755</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>rivaroxaban therapy in daily-care patients with splanchnic vein thrombosis - rivaroxaban is not specifically approved to be used in patients with splanchnic vein thrombosis (but no anticoagulant drugs are specifically approved)</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1109</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Splanchnic Vein Thrombosis Treatment with Rivaroxaban - a Case Series from the Prospective Dresden Noac Registry (NCT01588119)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101676</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1110</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Procoagulant Phospholipid Dependent Clotting Time: A New Tool for the Identification of Multiple Myeloma Patients at Risk Poor Treatment Response</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102466</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1111</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Laboratory Assays to Address the Problem of Heparin-Protamine Balance Following Neonatal Open Heart Surgery</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103507</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1112</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Peak Plasma Rivaroxaban Levels in Individuals Weighing over 120 Kilograms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101887</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1113</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Effectiveness and Safety of Rivaroxaban Versus Warfarin for Treatment of Venous Thromboembolism in Patients with Known Primary Hypercoagulable States</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105849</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1114</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Treatment of Venous Thromboembolism in Acute Leukemia: A Systematic Review</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103791</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1115</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Measuring the Anticoagulation Effects of Exosite I Thrombin Inhibitors: Utility and Limitations of Clotting Assays, Thromboelastography, and Calibrated Automated Thrombography</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105929</Key_PaperID>
<Key_SessionID>11641</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1116</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pharmacokinetics and Pharmacodynamics of Ionis-FXIRx, an Antisense Inhibitor of FactorXI, in Patients with End-Stage Renal Disease on Hemodialysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108565</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1117</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>GWAS of Osmotic Hemolysis in 12,352 Healthy Blood Donors Identifies Red Cell Genetic Variants Associated with Steady State Hemolysis in Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108651</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1118</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Next Generation DNA Sequencing of the RH Locus in 1135 DonorsImplicates RHCE-RHD(2)-RHCE Hybrid Alleles As Causative of C+ Antigen</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102825</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1119</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Final Result of a Pilot Study Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102978</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Sanguinate, a product produced by Prolong Pharmaceuticals, is purified bovine hemoglobin that has been pegylated and combined with carbon monoxide in a buffered aqueous solution. It was designated as an oxygen transfer agent and a carbon monoxide- releasing molecule to suppress vasoconstriction for critical care patients with severe anemia unable to receive red blood cells.</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1120</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Sanguinate: A Novel Blood Substitute Product</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104274</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1121</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Specialized Proresolving Mediators (SPMs) Help to Alleviate the Cold Platelet Storage Lesion</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107587</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1122</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Platelet Aggregation Is Important for Efficient Clot Retraction</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107472</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1123</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Murine Studies to Test the Efficacy of Platelet Transfusions in the Management of Platelet Function Disorders</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103502</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1124</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Transfusion Associated Circulatory Overload in Ambulatory Transfusions</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103449</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1125</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A New Centrifugation-Free Approach for Reducing IgA Levels in Units of Stored Red Blood Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103978</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1126</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Increased Mitochondrial DNA in an ECMO Model Is Associated with Loss of Platelet Function</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108710</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1127</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Retrospective Analysis Using Statistical Modeling on the Effect of Repeated Stimulated Granulocyte Donation on Hematopoietic Indices in Granulocytapheresis Donors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107730</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1128</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Extended Molecular RBC Antigen Matching between Blood Donors and Patients with Hematological Diseases</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104557</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1129</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Beliefs and Patterns of Practice in the Management of Hyperleukocytosis and Leukostasis Among Health Care Providers for Patients with Acute Leukemia: A Large North American Web-Based Survey</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106059</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1130</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pre-Transfusion Rejuvenation of RBCs for Red Blood Cell Exchange: Report of Feasibility</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107143</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1131</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Safe and Effective Implementation of a Red Blood Cell (RBC) Transfusion Hemoglobin (Hb) Threshold of 7 g/Dl on an Inpatient Stem Cell Transplant Unit: A Single Institution Experience</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99800</Key_PaperID>
<Key_SessionID>11642</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1132</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Epidemiologic Characterization of Transfusion Recipients with Red Blood Cell Alloantibodies from Four US Regions: Evidence from the REDS-III Recipient Database</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103521</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1133</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>G-CSF Signaling Counteracts TGF--PAI-1-Dependent Retention of Hematopoietic Stem Cells in the Niche</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108210</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1134</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Lnk/Sh2b3 Deficiency Restores Hematopoietic Stem Cell Function and Genome Integrity in Fanconi Anemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103575</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1135</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>PDK1 Regulates HSCs Via the Foxo Pathway during Murine Fetal Liver Hematopoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106523</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1136</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>IL6 SignalingRegulates Embryonic HematopoieticStem CellEmergence</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100136</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1137</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Traf2 and Nck-Interacting Kinase Is a Conserved Regulator of Self-Renewal in Hematopoietic and Leukemia Stem Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107166</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1138</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Gene-Specific Lineage Involvement of Age-Related Clonal Hematopoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105342</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1139</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pharmacological Inhibition of Luteinizing Hormone Signaling Promotes HSC Quiescence and Hematopoietic Regeneration</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103120</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1140</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Molecular Determinants for Polycomb Group Protein YY1 Control of Hematopoietic Stem Cell Quiescence</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103305</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1141</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prevalence and Dynamics of Clonal Hematopoiesis Caused By Leukemia Associated Mutations in Elderly Individuals without Hematologic Disorders</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107217</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1142</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Bioreactor Simulating Pulse-Pressure Mediated Circumferential Stretch Stimulates Hematopoietic Stem Cell Formation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101965</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1143</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Induction of Arterial Type of Hemogenic Endothelium from Human Pluripotent Stem Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107023</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1144</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians. Further Clues Linking Chip with Cardiovascular Risk</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106160</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1145</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hematopoietic Stem Cell Potential within the Primary Sorted Lineage Positive Population: What Are We Losing with Hematopoietic Stem Cell Purification?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105931</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1146</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>HDAC8 Regulates Long-Term Hematopoietic Stem Cell Maintenance Under Stress By Modulating p53 Activity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102513</Key_PaperID>
<Key_SessionID>11643</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1147</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>YAP Regulates Hematopoietic Stem Cell Formation in Response to the Biophysical Forces of Blood Flow</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108557</Key_PaperID>
<Key_SessionID>11644</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1148</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>PRMT5 Regulates DNA Repair By Controlling the Alternative Splicing of Epigenetic Factors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104729</Key_PaperID>
<Key_SessionID>11644</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1149</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>mTOR-C/EBP-c-Myc Axis Regulates the Behavior of Myeloid-Biased Hematopoietic Stem Cells Under Stress Conditions</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104996</Key_PaperID>
<Key_SessionID>11644</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1150</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Cluster of Enhancer Modules Directs Differential Myc Expression Along the Normal and Leukemic Hematopoietic Stem Cell Hierarchies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107868</Key_PaperID>
<Key_SessionID>11644</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1151</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prostaglandin E2 Protects HSC from DNA Damage Induced By Ionizing Radiation By Preventing Generation of Reactive Oxygen Species and Histone Acetylation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104069</Key_PaperID>
<Key_SessionID>11644</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1152</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Differential Phosphoproteomics Provides New Insights into Role of DYRK1A in Lymphopoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104787</Key_PaperID>
<Key_SessionID>11644</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1153</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Thrombopoietin-Receptor Agonist Romiplostim Attenuates Hematopoietic System Injury By Promoting the Recovery of Early Hematopoiesis and the Hematopoietic Environment in the Bone Marrow and Spleen of Mice Exposed to Lethal Total Body -Irradiation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106812</Key_PaperID>
<Key_SessionID>11644</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1154</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cell-Stage Dependent Outcomes of the NAMPT/SIRT2-Mediated Activation of LMO2 By Deacetylation in Normal Hematopoiesis and in T-ALL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102092</Key_PaperID>
<Key_SessionID>11644</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1155</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Signal-Transducing Adaptor Protein-2 Blocks B Cell Recovery Under Hematological Stress at Pre-B Stage Via TLR4 Signaling</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106325</Key_PaperID>
<Key_SessionID>11644</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1156</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Adenosine Signaling Regulates Erythroid Commitment Via Modulation of Metabolic Reprogramming in Stress Erythropoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101334</Key_PaperID>
<Key_SessionID>11645</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1157</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Endothelial Cell-Selective Adhesion Molecule (ESAM) Plays Important Roles in the Adult-Type Hemoglobin Synthesis during Fetal Erythropoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102394</Key_PaperID>
<Key_SessionID>11645</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1158</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The E3 Ligase Itch Is a Regulator of Bone Marrow Mesenchymal Stem Cells and the Hematopoietic Stem Cell Niche</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107383</Key_PaperID>
<Key_SessionID>11645</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1159</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Sequential Cellular Niche Plays a Crucial Role in the Generation of Enucleated Erythrocytes from Human Pluripotent Stem Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106671</Key_PaperID>
<Key_SessionID>11645</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1160</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bone Marrow Stromal Cell Mediated Drug Resistance in AML Cells: Role of Extracellular Vesicles and AKT Signaling</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100807</Key_PaperID>
<Key_SessionID>11645</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1161</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mechanisms of Regulatory T Cell Recruitment By Mesenchymal Stem Cells in Vitro</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105879</Key_PaperID>
<Key_SessionID>11645</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1162</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Concurrent Ex Vivo Differentiation of a Vascular Niche and Hematopoietic Stem/Progenitor Cells from Human iPSCs</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105211</Key_PaperID>
<Key_SessionID>11645</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1163</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bone Marrow Stromal Cells Induce ALDH+ Stem Cell Phenotype and Chemotherapy Resistance in AML Cells through TGF-1 Mediated Signaling: Reversal By TGF Inhibitor Galunisertib</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104482</Key_PaperID>
<Key_SessionID>11645</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1164</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Plasma-Derived Exosomes in Acute Myeloid Leukemia Carry Dipeptidylpeptidase-4 and Inhibit Normal Human Hematopoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104870</Key_PaperID>
<Key_SessionID>11645</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1165</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Acute Lymphoblastic Leukaemia (ALL) Cells and Commonly-Used Chemotherapy Drugs Can Induce Bone Marrow-Derived Mesenchymal Stromal Cells to Become Cancer Associated Fibroblasts (CAF), Leading to Enhanced ALL Proliferation and Treatment Resistance</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105785</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1166</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Two Distinct but Functionally Related Autoreactive T Cell Populations in Paroxysmal Nocturnal Hemoglobinuria and Idiopathic Aplastic Anemia: Glycosylphosphatidylinositol-Specific and IFN-Producing T Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101732</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Romiplostim is a thrombopoietin-mimetic protein that enhances platelet production. We evaluated the efficacy and safety of RMP in patients with aplastic anemia that was refractory to immunosuppressive therapy. </OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1167</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hematologic Response to Romiplostim Treatment Is Associated with Stimulation of Primitive Stem/Progenitor Cells and Stromal Cells in Patients with Aplastic Anemia Refractory to Immunosuppressive Therapy: A 2-Year Interim Exploratory Analysis of a Phase 2 Clinical Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106362</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1168</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Immunosuppressive Therapy for Pediatric Aplastic Anemia: A North American Pediatric Aplastic Anemia Consortium (NAPAAC) Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101674</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1169</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Acquired Somatic Mutations in T Cells in Patients with Aplastic Anemia and Hypoplastic Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103576</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1170</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inducible SBDS Deficiency and Germline FANCC/FANCG Deficiency Differentially Impact the Capacity of Bone Marrow Niches to Engraft Hematopoietic Stem Cells after Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108112</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1171</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>High Frequency of Subclonal Myeloid Mutations Can be Found in Large Granular Lymphocyte Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108220</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1172</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mutations in Ribosomal Protein Genes L9 and L15 Link to DBA with Specific Clinical Phenotypes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104645</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1173</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Quantities and Functions of NK Cells in Severe Aplastic Anemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101241</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1174</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Whole Genome Sequencing to Detect Small Deletions in Ribosomal Protein Genes in Diamond Blackfan Anemia Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104085</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1175</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Thrombosis in Non-Hemolytic Paroxysmal Nocturnal Haemogloinuria</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108827</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1176</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>PNH-Phenotype Cells and HLA Class I Allele-Lacking Leukocytes Shared By Family Members Who Developed Acquire Aplastic Anemia: Studies on Six Pairs of Patients in Different Families</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100995</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1177</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>MDS and AML in Shwachman-Diamond Syndrome: Clinical Features and Outcomes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107436</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1178</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Quercetin: A Novel Targeted Chemoprevention for Patients with Fanconi Anemia (FA)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108206</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1179</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Paroxysmal Nocturnal Hemoglobinuria Results from Initial Clonal PIG-a Mosaicism</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102963</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1180</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>MCM2-7 and FANCD2 Are Required for RAD51 Function in Homologous Recombination and ICL Repair</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101344</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1181</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Recurrent STAT3 Mutations in the Lymphocytes of Pure Red Cell Aplasia without T-Cell Large Granular Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101402</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1182</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Characterization and Genotype-Phenotype Correlation of Fanconi Anemia Patients in Israel</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104513</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1183</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Tacrolimus Is Effective Immunosuppressive Therapy in Aplastic Anemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106392</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1184</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Donor Telomere Length Influences Engraftment and Outcome in Aplastic Anemia Patients Undergoing Matched Related Stem CellTransplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102455</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1185</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Clinical and Hematologic Course of Fanconi Anemia Amongst Affected Siblings</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106071</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1186</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Retrospective Outcomes of Prolonged-Duration Calcineurin Inhibitor Immunosuppression in Severe Aplastic Anemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103499</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1187</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Results of Gau-PED Study: Prevalence of Gaucher Disease in Paediatric Patients Selected By an Appropriate Diagnostic Algorithm</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105266</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1188</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of the C5aC5aR Axis By the L-Aptamer Aon-D21 As a New Strategy to Ameliorate Uncontrolled Migration/Motility of Hematopoietic Stem Cells - Potential Therapeutic Implications for Paroxysmal Nocturnal Hemoglobinuria</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106460</Key_PaperID>
<Key_SessionID>11646</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1189</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Peripheral Stem Cell Transplantation Versus Bone Marrow Transplantation in Severe Aplastic Anemia - a Cohort of 149 Patients from a Single Medical Center in Taiwan</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108340</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1190</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Myeloid Progenitors of Defined Features Provide Permissiveness to Leukemic Transformation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108368</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1191</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Creatine Kinase Pathway Inhibition Alters GSK3 and WNT Signaling in EVI1-Positive Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106715</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1192</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Rhob Overexpression Boosts Relapse of t(8;21)RUNX1-RUNX1T1 Rearranged Acute Myeloid Leukemia.</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108025</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1193</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Transcriptomic and Network Signatures of Cryptic Fusion CBFA2T3-GLIS2 in Pediatric AML Reveals Clinical Considerations and Implications</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105091</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1194</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Myeloma Cell Addiction to the Transcription Factor TCF11</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107399</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1195</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The CDK7 Inhibitor THZ1 Alters RNA Polymerase Dynamics at the 5 and 3 Ends of Genes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106084</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1196</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Spatially Resolved, Multiplexed Digital Characterization of Protein Distribution and Abundance in Formalin-Fixed, Paraffin-Embedded (FFPE) Diffuse Large B Cell Lymphoma Tissue Sections Based on the Nanostring Digital Spatial Profiling (DSP) Technology</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107567</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1197</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>AML Differentially Alters Fate and Function of Mesenchymal Stem- and Osteolineage Cells in the Leukemic Niche</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105072</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1198</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Abrogating Treatment Resistance By Mir-451 in FLT3-ITD-Positive Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108351</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1199</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Aberrant HCK Survival Signaling By Mutated MYD88 Requires PAX5 in Waldenstroms Macroglobulinemia and ABC DLBCL Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106135</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1200</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>EZH1/2, SWI/SNF, and MLL2 Dependent Heterochromatin Formation and Abnormal Transcriptome in Hematological Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105098</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1201</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Identification of Long Non-Coding RNAs Regulated By the TAL1 Complex in T-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105452</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1202</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Common Fetal Hemoglobin Variants Modify Hematological Phenotypes in MDS/MPN/Myeloma Patients Receiving Cytotoxic Drugs</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106770</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1203</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>High Expression of the DNMT3A Embedded Pri-Mir-1301 Associates with Improved Outcome in Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108583</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1204</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>ADAR1-Mediated GLI1 Editing Promotes Malignant Self-Renewal in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101101</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1205</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Modulation of TET2 Activity with Ascorbic Acid in Myeloid Neoplasia: Diagnostic and Therapeutic Implications</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102262</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1206</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Nmp1 and Cohesin Mutations Cooperate to Generate Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103015</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1207</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Altered Enhancer Activity Represses CEBPEExpression in MLL-Rearranged Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103942</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1208</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Lineage Deconvolution Using Chromatin Accessibility and DNA Methylation Shows a Spectrum of Lineage Characteristics and Differentiation States across Acute Leukemias</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106381</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1209</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Functional Genomic Landscape of Epigenetic Dependencies in Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108542</Key_PaperID>
<Key_SessionID>11647</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1210</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Reciprocal Regulation of BCL6 and MLL Expression As a Vulnerability in MLL-Rearranged Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108509</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1211</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>BCL6 Enables RAS-Driven Pre-B Cell Transformation in Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107996</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1212</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Integration of Functional Dependencies and Molecular Alterations of Myeloma Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108657</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1213</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Transcriptional Regulation of the CDC42 Signaling Pathway By Ikaros in T-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102402</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1214</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Wt1 Haploinsufficiency Induces an Age-Dependent Enhancement in Stem Cell Self-Renewal and Cooperates with FLT3-ITD to Drives Leukemogenesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103273</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1215</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Contrasting Stage Dependent Requirements for the Histone Methyltransferase EZH2 during the Evolution of Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107726</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1216</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>DOCK2 Knockdown Mitigates Disease Progression in Murine Models Harboring a FLT3/ITD Mutation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101289</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1217</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Therapeutic Efficacy of Mcl-1 Antagonism in Large Granular Lymphocyte Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103690</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1218</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction As a Developmental Susceptibility to ETV6-RUNX1</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106699</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1219</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>FBXO11 Is Recurrently Mutated in Burkitt Lymphoma and Its Inactivation Accelerates Lymphomagenesis in E-Myc mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101799</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1220</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Canonical Notch Signaling Is Required for KrasG12D-Induced Myeloproliferative Neoplasm</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104573</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1221</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Genetic Validation of the Palmitoylation/Depalmitoylation Cycle As a Drug Target in NRAS Mutant Hematologic Malignancies In Vivo</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105684</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1222</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Constitutive Activation of Ras and Inactivation of Ink4a/Arf Allele Induce a Fully Penetrant B-Cell Acute Lymphoblastic Leukemia Phenotype in Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107782</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1223</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Par-4 Overexpression Impedes Leukemogenesis in the E-TCL1 Leukemia Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103134</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1224</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Significance of Phd Finger Protein 2 As a Novel Ikaros Target in Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102128</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1225</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>RUNX1 Enhances Leukemia Cell Engraftment in the Vascular Niche through up-Regulating E-Selectin</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108659</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1226</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Changes in Subcellular Localization of GSK3 As a Novel Driver of AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105760</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1227</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Role of Kdm6a in Malignant Hematopoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104246</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1228</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Functional Investigation of the Gene Nfkbiz and the Impact of 3'UTR Mutations in Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104798</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1229</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>RUNX1 Mutations Lead to a Myeloid Differentiation Block in Association with Enhanced Proliferation By Altering the RUNX1 Transcriptional Program</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106488</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1230</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Leukemogenic Pathway of MLL-AF4 Fusion-Positive Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107009</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1231</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Dysregulation of the ASPP Protein Family (Apoptosis Stimulating Proteins of TP53) Is a Common Feature in High-Risk Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102119</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1232</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cell-Autonomous Feedback Loop of RUNX1-p53-CBFB in Acute Myeloid Leukemia Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106419</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1233</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Arsenic Trioxide and Interferon-Alpha Eradicate Adult T Cell Leukemia Initiating Cells through PML/p53 Senescence and Activation of Innate Immunity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101843</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1234</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Overcoming Tyrosine Kinase Inhibitor Resistance to SEPT9-ABL1 Chimeric Fusion Protein Using CRM1 Inhibitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104690</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1235</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Fbxw11 Triggers a Dual Signaling Axis to Exert Proliferation Effects on Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106281</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1236</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Loss of CDKN2C Accelerates Progression of Notch-1 Induced T Lymphoblastic Leukemia Via Activation of LMO2</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108415</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1237</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Delineating the Functional Consequences of CEBPA Mutations in Acute Myeloid Leukaemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100432</Key_PaperID>
<Key_SessionID>11648</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1238</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Small Interfering RNA-Mediated Knockdown of SATB1 Increases Cell Proliferation through NF-b Activation in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106380</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1239</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeted Therapy with BET Protein and Beta-Catenin Antagonists Against Ruxolitinib Resistant Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107892</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1240</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pharmacologic Inhibition of PI3K Prolongs Survival of Mutant Shp2E76K-Expressing Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108289</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1241</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Novel Method for Overcoming Plasma Protein Inhibition of FLT3 Tyrosine Kinase Inhibitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103230</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1242</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Acquired Gene Mutation of MAP4K2 Identified from Myelodysplastic Syndromes Patients Confers Azacitidine Resistance</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106198</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1243</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103234</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1244</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>XPO1 Inhibition Targets Transcriptional Vulnerability of FLT3-ITD+D835 Double Mutant AML through p53 Accumulation and Inhibition of Oncogenic Transcription Factors: Lesson Learned from Cage Sequencing of Primary AML Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103225</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1245</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Novel Oxidative Phosphorylation Inhibitor Iacs-010759 Induces AMPK-Dependent Apoptosis of AML Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107091</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1246</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>LSD1 Inhibition Leads to Differentiation in Hoxa9/Meis1- but Not in MN1-Induced Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108060</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1247</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102949</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1248</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of Unc-51 like Autophagy Activating Kinase 1 (ULK1) Is Highly Synergistic with Chemotherapy and Bcl2 Inhibition in Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106559</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1249</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103998</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1250</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cytokine Activation of JAK Kinases Rescues FLT3-Mutant AML from FLT3 Inhibition and Requires PIM Kinases</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107006</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1251</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>DNA Damaging Agents Cause a Sub-Cellular Re-Localisation of Nucleophosmin in annpm1 Mutated Acute Myeloid Leukemia (AML) Cell Line and in Primary AML Cells Carrying an npm1 Mutation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101638</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1252</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Variable Expression Levels of the Hematopoietic Stem Cell Surface Antigen ESAM Depict Heterogeneity and Fluctuations in Leukemic Stem Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106004</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1253</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Pharmacological IGF1R-IRS1/2 Inhibitor NT157 Presents Multiple Anti-Neoplastic Effects in Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103749</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1254</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Molecular and Pharmacological Inhibition of ATP Binding Cassette Transporter ABCB6 Decreases Chemoresistance in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101287</Key_PaperID>
<Key_SessionID>11649</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1255</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting PI3K, mTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101747</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1256</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pharmacodynamic Study of Copanlisib in Patients with Non-Hodgkin's Lymphoma and Advanced Solid Tumors: Confirmation of on-Target PI3K Inhibitory Activity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105300</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1257</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Meninges Enhance Acute Lymphoblastic Leukemia Chemoresistance in the Central Nervous System</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103832</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1258</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>High Glutathione and NAD(P)H Levels, and Increased Protein Folding Capacity Are Involved in Mediating Proteasome Inhibitor-Resistance in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105607</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1259</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Repression of the Orphan Nuclear Receptor Esrrb Results in Glucocorticoid Resistance in ALL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105937</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1260</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102437</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1261</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>FOXM1 Is Associated with Development of Therapeutic Resistance in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105124</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1262</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CDK9 Inhibition with LDC526 Is an Effective Treatment for T-Cell Prolymphocytic Leukemia (T-PLL) in Vitro</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100516</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1263</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Downregulation of BMI-1 By the Small Molecule PTC596 Induces Mitochondrial Apoptosis in Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107421</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1264</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting of Glutamine Pathways Restores Sensitivity in Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107157</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1265</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103256</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1266</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ibrutinib in Combination with Anti-CD20-Antibody Negatively Affects Antibody Dependent Cellular Cytotoxic (ADCC) on Mantle Cell Lymphoma Cell Lines, Not Reversed By the Addition of Lenalidomide</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104918</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>CHERYL TBC</OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1267</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Greater Efficacy and Potency of Obinutuzumab Compared with Rituximab in Chronic Lymphocytic Leukemia Patients Confirmed By a Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102381</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Acalabrutinib is an investigational agent for the treatment of hematologic malignancies.</OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1268</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Exposure-Response of the Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in the Treatment of Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103685</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1269</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Sustained Reduction of Intracellular Calcium Is Important to Maximise GA101-Mediated Direct Cell Death in B-Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106149</Key_PaperID>
<Key_SessionID>11650</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>We used imatinib to NK/T cell lines to explore new therapeutic target. </OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1270</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Imatinib Induces Apoptosis of NK/T Cell Neoplasms by Inhibiting Hematopoietic Cell Kinase and NQO2</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100183</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1271</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product in a First-in-Human Trial (PALL) in Pediatric Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102149</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1272</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101702</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1273</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Results of the Full Pediatric, Minimal Residual Disease (MRD)-Oriented Trial LAL-RI/2008 for Adolescents and Young Adults (AYA) with Standard Risk (SR), Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101727</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1274</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>High PDGFRA Expression Does Not Serve As Effective Therapeutic Target in ERG-Deleted B-Cell Precursor Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100011</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1275</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Intermittent Vs Continuous Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102274</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1276</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Management of Coagulopathy Associated with CTL019 CAR T-Cell Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106398</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1277</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Beyond Cytokine Storm: Optimizing Treatment Strategies to Target the Complex Interplay between CAR Mediated Inflammatory Response, Disseminated Intravascular Coagulation and Macrophage Activation Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100594</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1278</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Age and ABO Blood Group Are Significant Predictors of Thrombosis in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100303</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1279</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>No Association between Relapse Risk and Thiopurine Methyltransferase Activity By Either Geno- or Phenotype in the NOPHO ALL-2008 Protocol</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102299</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1280</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CTL019 Therapy Appears Safe and Effective in Pediatric Patients with Down Syndrome with Relapsed/ Refractory (r/r) Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107336</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1281</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Humoral Immunogenicity (Anti-mCAR19 Antibodies) on CTL019 Cellular Kinetics, Efficacy, and Safety</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107233</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1282</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Widening Survival Disparities between AYA with ALL Treated in Pediatric Vs. Adult Centers: A Population-Based Study Using the IMPACT Cohort</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108738</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1283</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Migration in the Management of Philadelphia Positive ALL: Towards a Lower Risk of VTE</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101669</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1284</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Decreasing Dose and Duration of Dexamethasone Therapy for Low-Risk Childhood Acute Lymphoblastic Leukemia Aiming to Avoid Serious Viral Infections Results in Significant Increase in Isolated CNS Relapse: A Prospective Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100036</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1285</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical and Pathological Features of B-Cell Acute Lymphoblastic Leukemia Following Maintenance Treatment with Lenalidomide for Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100622</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1286</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated with ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107102</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1287</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Aspariginase-Triggered Hyperglycerimedia: An Analysis on Germline Regulatory Gene Variations in Adult Acute Lymphoblastic Leukemia Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103710</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1288</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Lack of Certain Level of Myelosuppression during Induction Phase Is Associated with Poor Prognosis in Children and Adolescent with B-Cell Precursor Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106530</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1289</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Genetic Profiling in Childhood T-Cell Acute Lymphoblastic Leukemia By Targeted Sequencing</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101895</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1290</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Isolated Myeloperoxidase Expression in Pediatric B/Myeloid Mixed Phenotype Acute Leukemia Is Associated with Improved Survival Using ALL-Only Regimens</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107080</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1291</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Nucleolin As a Survival Predictor in Acute Lymphoblastic Leukemia and Its Promotion to Drug Resistance By ERK Pathway</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101026</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1292</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Epstein Barr Virus-Associated Lymphoproliferative Disorder during Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107110</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1293</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Correlation Studies between Central Nervous System Involvement By Flow Cytometry and the Prognosis of Children Acute Lymphoblastic Leukemia: A Single Chinese Centers Experience By Cclg- ALL 2008</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107968</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1294</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Acute Lymphoblastic Leukemia/Lymphoma in the Elderly: The Mayo Clinic Experience</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103995</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1295</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pneumocystis Jiroveci Pneunomia Prophylaxis during Maintenance Therapy with Hyper-CVAD Regimens for Adult Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100583</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1296</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Feasibility and Outcome of Late Intensification with Native L-Asparaginase for Acute Lymphoblastic Leukemia in the Elderly : A Single Center Experience</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101017</Key_PaperID>
<Key_SessionID>11651</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1297</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Patient and Therapy-Related Factors Affecting the Toxicity of Pegylated-Asparaginase for the Treatment of Adult Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104398</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1298</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104424</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>United States FDA approval for enasidenib in treatment of relapsed/refractory AML is expected prior to the annual ASH congress. The current abstract presents results from a phase 1 study of enasidenib in patients with untreated AML. Ivosidenib approval is not expected in 2017 and, thus, the results reported here are not off-label as no label exists as yet.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1299</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Continuing Enasidenib Treatment for Patients with Mutant-IDH2 (mIDH2) Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Survival and Responses over Time</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104070</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1300</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Clinical Implication and Prognostic Impact of Dynamic Molecular Evolution in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105623</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1301</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival (Potential Cure) over the Past Four Decades: Analysis of SWOG Trial Data</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103729</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1302</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Obesity Is Associated with Favorable Cytogenetic Abnormalities in Pediatric Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108734</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1303</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Phase I Clinical Trials in Acute Myeloid Leukemia: A Pooled Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103055</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1304</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Autoimmune Diseases, Infections, Use of Antibiotics and the Risk of Acute Myeloid Leukemia: A National Population-Based Case-Control Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103077</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1305</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Does NSAID Consumption Reduce the Risk of Acute Myeloid Leukemia? a National Population-Based Case-Control Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102692</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1306</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Acute Myeloid Leukemia: Results of a Prospective, Randomized, Multicenter, Noninferiority Phase 3 Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103526</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1307</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Therapy-Related Myeloid NeoplasmsAre Not Always Dismal If They Have Better Cytogenetic Profile and LongerLatency Period from Preceding Anti-Cancer Treatment</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102596</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1308</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Tetraploidy in Acute Myeloid Leukemia Is Associated with Poor Outcomes Regardless of the Presence of Favorable Risk Features, and Requires an Allogeneic Stem Cell Transplant in First Remission</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107460</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1309</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Myeloid Malignancies Following Luminal Gastrointestinal Cancer: High Incidence of Deletion 5q and DNTM3A Mutations</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105101</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1310</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Invasive Aspergillosis (IA) in Acute Myeloid Leukemia (AML): When Is Prophylaxis Appropriate?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107748</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1311</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Comparison of Clinical Characteristics and Treatment Outcome in Myeloid Sarcoma Versus Acute Myeloid Leukemia Patients without Extramedullary Involvement  Case Control Study of the Polish Adult Leukemia Group (PALG)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100726</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1312</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101428</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1313</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101532</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1314</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Impact of Morphological Cellularity in Early Assessment Bone Marrow Biopsy after 7+3 Induction in Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101912</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1315</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Decitabine As First-Line Therapy for Elderly Patients with Acute Myeloid Leukemia.aReal Life Multicentric Experience of the Northern Italy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99823</Key_PaperID>
<Key_SessionID>11652</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1316</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Excessive Early Death after Intensive Chemotherapy for Acute Myeloid Leukemia Occurs in Patients over 65 Years with High Co-Morbidity, and in Patients over 50 Years with High Co-Morbidity When Postponed Early Death Is Included</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104990</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1317</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bone Marrow Infiltrating T-Cell Signatures Following Allo-HCT for Adult Acute Lymphoblastic Leukaemia Differentiate between Patients in Continuous CR and Those with Persistent Minimal Residual Disease or Relapse</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108019</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1318</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of B-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103343</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>CTL119 is a CAR-modifed T cell product under investigation for B-ALL</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1319</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108842</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1320</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Association of APEX1 and NUDT15 Polymorphisms with Mercaptopurine-Related Neutropenia in Pediatric Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104971</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1321</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate Adct-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106316</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ruxolitinib is not approved for patients with Ph-like ALL</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1322</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104944</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1323</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric- Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106990</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1324</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CD19-Specific Chimeric Antigen Receptor-Modified T Cells with Safety Switch Produced Under Point-of-Care Using the Sleeping Beauty System for the Very Rapid Manufacture and Treatment of B-Cell Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105560</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1325</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Synthetic Lethal Screening Identifies CHK1 Inhibition As an Exploitable Vulnerability in EZH2 Deficient T-ALL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106137</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>CD19-specific CAR T cells for R/R B-ALL</OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1326</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104730</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1327</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CD9 Blockade Effectively Suppresses Disease Progression of Pediatric B-Precursor Acute Lymphoblastic Leukemia and Enhances Chemosensitivity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105641</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1328</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World US Practices</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105957</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1329</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Chemical Inhibition of the Macrophage Inhibitor Factor (MIF) Induces Cell Cycle Arrest and Apoptosis in Lymphoid and Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102886</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1330</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Economic Value of CTL019 Therapy for Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia in the United Kingdom</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101483</Key_PaperID>
<Key_SessionID>11653</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1331</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Semi-Quantitative Analysis of CD19 and CD22 Expression in B-Lymphoblastic Leukemia and Implications for Targerted Immunotherapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107752</Key_PaperID>
<Key_SessionID>11654</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>In this study, midostaurin was used in combination with azacitidine in patients with AML who were unfit for standard induction chemotherapy.  At the time, midostaurin had not been approved for use in AML.  Since initiation and completion of the study, midostaurin was approved in combination with standard induction chemotherapy for patients with FLT3-mutant AML.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1332</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108866</Key_PaperID>
<Key_SessionID>11654</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1333</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting Systemic Inflammatory Response Syndrome As Initial Therapy and Oral Arsenic Based Consolidation Regimen for Acute Promyelocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103136</Key_PaperID>
<Key_SessionID>11654</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Priming with azacitidine followed sequentially by either intensive chemotherapy or azacitidine based on response is not approved and was conducted within a clinical trial</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1334</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients &gt; 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103836</Key_PaperID>
<Key_SessionID>11654</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1335</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcome of NPM1 Mutated Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMAs): A Report on 71 Cases</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101294</Key_PaperID>
<Key_SessionID>11654</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1336</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Treatment with Low-Dose Daunorubicin Reduces the Number of Leukemia Stem Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101461</Key_PaperID>
<Key_SessionID>11654</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Lenalidomide for AML
Azacitidine for AML</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1337</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102308</Key_PaperID>
<Key_SessionID>11654</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1338</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Radius-X: An Expanded Treatment Protocol of Midostaurin in Adults with Newly Diagnosed FLT3-MutationPositive Acute Myeloid Leukemia Eligible for Standard Chemotherapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103284</Key_PaperID>
<Key_SessionID>11654</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1339</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Synergy of Vitamin C with Decitabine Activates TET2 in Leukemic Cells and Significantly Improves Overall Survival in Elderly Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106430</Key_PaperID>
<Key_SessionID>11654</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1340</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Determinants of Early Death and Outcomes for Acute Promyelocytic Leukemia in the Arsenic Era: A Real World Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106411</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1341</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Oral Arsenic and Retinoic Acid for Children with Non High-Risk Acute Promyelocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104420</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1342</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pre-Clinical Activity of SN37169, a Novel Hypoxia-Activated FLT3 Inhibitor Prodrug in FLT3-Mutated AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101992</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1343</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase I Study of FLX925, a Dual FLT3 and CDK4/6 Inhibitor in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107872</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1344</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108402</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Nivolumab: Anti-PD1 antibody, immune checkpoint therapy</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1345</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) orFrontline Elderly AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104474</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>CPX-351 for use in medically less-fit adults with newly diagnosed AML or other high-grade myeloid neoplasm</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1346</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Randomized Study of CPX-351 for Medically Less-Fit Adults with Newly Diagnosed Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100582</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1347</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hypomethylating Agent Leads to Enhanced Immunogenicity of a Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine and Prolonged Survival in an Immunocompetent Mouse Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107582</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1348</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100048</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pembrolizumab is investigational and is not intended for off-label drug use based on this data. </OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1349</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106018</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1350</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of Oxphos with Iacs-010759 Depletes AML Leukemia Initiating Cells (LIC) in Vitro and Improves Survival in Pre-Clinical AML Models</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106589</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1351</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CAR T Cells Targeting FLT3 on AML Confer Potent Anti-Leukemic Activity and Act Synergistically with the FLT3 Inhibitor Midostaurin</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107257</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1352</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Synergistic Activity of IDH1 Inhibitor Bay-1436032 with Azacitidine in IDH1 Mutant Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108276</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Venetoclax is FDA approved for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy. This presentation will discuss the investigational use of venetoclax in combination with azacitidine (FDA approved for myelodysplastic syndrome), decitabine (FDA approved for myelodysplastic syndrome), or low-dose cytarabine, all three of which represent low-intensity standard options as monotherapy for treatment of acute myeloid leukemia. </OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1353</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103559</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1354</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of a FLT3 Bite for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104771</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1355</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Novel Bispecific AntibodyTargeting CD45 and 90Y-DOTA Is Effective Therapyfor Acute Myeloid Leukemia in Preclinical Murine Models</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105942</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Venetoclax is not yet approved to treat myeloid malignancies.</OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1356</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Results of Off-Label Venetoclax Use in Combination with Low-Intensity Chemotherapy in Patients with Relapsed and Refractory Myeloid Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100566</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1357</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>IMGN779, a Next Generation CD33-Targeting ADC, Combines Effectively with Cytarabine in Acute Myeloid Leukemia (AML) Preclinical Models, Resulting in Increased DNA Damage Response, Cell Cycle Arrest and Apoptosis In Vitro and Prolonged Survival In Vivo</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102206</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Reports results of clinical trials of a molecule not yet available on the market</OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1358</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of the Correlation between Response and Duration of Treatment in a Phase 2 Study of Pracinostat Plus Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104118</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1359</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106048</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1360</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CPX-351 Exposure-Response Based on Cumulative Dose of Cytarabine and Daunorubicin in Patients with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108096</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1361</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Anti-IL1RAP/CD3 Bispecific Antibody (BsAb) Is a Promising Novel and Effective Therapy for Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104054</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1362</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>BCL-2 Antagonist ABT-199 Combined with Complex I Inhibitor Iacs-010759 Blocks Mitochondrial Respiration and Facilitates Anti-Leukemia Efficacy in Pre-Clinical AML Models</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105708</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1363</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CD33/CD3-Bispecific T-Cell Engaging (BiTE) Antibody Constructs Efficiently Target Monocytic CD14+hla-DRlow IDO+aml-MDSCs</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100130</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1364</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Modulating the Immunologic Microenvironment in AML By Blocking Both CXCR4 and PD-L1</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101886</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1365</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107240</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1366</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Rates of Adverse Events per Patient-Year in a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108219</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1367</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of ROS-Induced Nrf2 Antioxidant Pathway Activation May Explain Synergy between Venetoclax and Hypomethylating Agents Against Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100896</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1368</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Preclinical and Early Phase 1 Clinical Data of AZD2811 Nanoparticle in AML, an Aurora B Kinase Inhibitor</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103250</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1369</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A 11-Year Clinical Summary of DC - CIK / NK Cell Immunotherapy for 152 Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108348</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1370</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Direct Comparison of Anti-CD33 and Anti-CD123 Chimeric Antigen Receptor T Cells with CD28 or 41BB Co-Stimulatory Domains for Treatment of Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104602</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1371</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106427</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1372</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of the Histone Chaperone, FACT (Facilitates Chromatin Transcription) By the Novel Small Molecule CBL0137 (Curaxin) Shows Promising Efficacy in Pre-Clinical Models of Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108554</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1373</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>DNA Aptamer Against Anti- Programmed Cell Death-1 (Anti-PD1-Apt) Induces Robust Anti-Leukemic Activity in Vitro and In Vivo Humanized NSG Mice with Myeloid Leukemia Xenografts</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106534</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1374</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>An mTORC1/2 Kinase Inhibitor Remarkably Enhances the Cytotoxicity of Gemtuzumab Ozogamicin By Activating Lysosomal Function and Cell Cycle Promotion in AML Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107092</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1375</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108286</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1376</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Autologous T Cells Modified to Co-Express CD33-Specific Chimeric Antigen Receptor and a Kill Switch for Treatment of CD33+ Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106895</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1377</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106632</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1378</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106150</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1379</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106131</Key_PaperID>
<Key_SessionID>11655</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1380</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108602</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1381</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>JAK3Variants in Adults with Myeloid Malignancies and Potential for Response to JAK3 Inhibition</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105125</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1382</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Clinical and Biological Implications of Aberrant Alternative Splicing in Patients with De Novo, Non-M3 Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99592</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1383</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of the Profile of the AML Drug Midostaurin (Rydapt) As a Kinase Inhibitor with Those of Its Predominant Primary Human Metabolites</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105847</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1384</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>PHF6 Mutations Defines a Subgroup of Mixed Phenotype of Acute Leukemia with Aberrant T-Cell Differentiation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100466</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1385</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101960</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1386</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Aldehyde Dehydrogenase 2 (ALDH2) Expression Predicts a Poor Prognosis in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102927</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1387</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Whole-Genome Mate Pair Sequencing Transforms Cytogenetic Analysis of Hematologic Malignancies: Development of a Targeted Panel to Detect Diagnostic/Prognostic Chromosomal Rearrangements and Copy Number Changes in AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103290</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1388</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>MiR-181a Down-Regulates PARP1 By Enhancing Its Acetylation in MLL-Rearranged AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103583</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1389</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Presence of Post Induction Minimal Residual Disease (MRD) Is an Independent Predictor for Relapse and Is Associated with Inferior Survival in Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104107</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1390</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pharmacodynamic Monitoring of Targeted Therapy with MidostaurinBy Plasma Inhibitor Activity (PIA) Analysis in FLT3-ITD Positive AML Patients Enrolled in the AMLSG16-10 Trial: A Study of the AML Study Group (AMLSG)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104495</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1391</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>IQGAP1: A Potential Therapeutic Target in Acute Myelogenous Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104769</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1392</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Biology and Prognostic Markers in Young Children with Acute Myeloid Leukemia -the Jccg Study, JPLSG AML-05-</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104995</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1393</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>TherapyInduced Senescence Is a Predictor of Treatment Outcome in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105288</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1394</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Acute Myeloid Leukaemia Induces p16 Driven Senescence in the Bone Marrow Microenvironment to Support Their Proliferation and Survival</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105639</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1395</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Galectin 3 Protein Network Analysis By Reverse Protein Arrays Demonstrates Regulation of MCL-1, PKC Delta and CD74 Associated with Poor Survival in Patients with AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105886</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1396</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcome of Acute Myeloid Leukemia Patients with Abnormal 12p after Allogeneic Hematopoietic Cell Transplantation at Fred Hutchinson Cancer Research Center</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106259</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1397</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Outcomes and Mutation Clearance in Children with Acute Myeloid Leukemia Treated with Low-Dose Chemotherapy Plus G-CSF for Remission Induction</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106613</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1398</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107678</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1399</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>AML1/ETO and FLT3-ITD Cooperate to Induce Acute Myeloid Leukemia in Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108631</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1400</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Association between Gene Expression Levels of Candidate Cytarabine Pathway and Treatment Outcome Using Publically Available Data from Target Project</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103380</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1401</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Recurrent Genetic Variants of Long Non-Coding RNAs (lncRNAs) Independently Associate with Clinical Outcome of Younger Adults with Cytogenetically Normal Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100196</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1402</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>HMGA2 Gene Expression Profile Improves Risk Stratification in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101137</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1403</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>An Artificial Intelligence Approach in Classifying Acute Myeloid Leukemia and Myelodysplastic Syndrome for Minimal Residual Disease Detection with Post Induction Prognosis Analysis Using Flow Cytometry</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102017</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1404</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Molecular Landscape and Clinical Features of Acute Myeloid Leukemia (AML) with Complex Karyotype (CK)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102975</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1405</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Combinatorial Use of Bexarotene Plus ATRA for the Treatment of Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103568</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1406</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Personalized Circulating Tumor DNA Dynamically Predicts Response and/or Relapse in Hematological Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104292</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1407</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Histone Modification Patterns Using RPPA-Based Profiling Predict Outcome in Acute Myeloid Leukemia Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104588</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1408</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>APersonalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105110</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1409</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Patterns of Genomic Associations Can Define Acute Myeloid Leukemia (AML) Phenotype</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104857</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1410</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>RNA Sequencing Illustrates the Genetic Backgrounds of Pediatric Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105485</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1411</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparative Assessment of FLT3 Variant Allele Frequency By Capillary Electrophoresis and Next-Generation Sequencing in FLT3mut+ patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Who Received Gilteritinib Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105873</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1412</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcomes in Older Adults (age  70) with Acute Myeloid Leukemia Based on Choice of Frontline Treatment for Proliferative or Non-Proliferative Phenotype</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106125</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1413</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Negative Impact of FLT3-ITD Mutation in Elderly Acute Myeloid Leukemia Patients (Age 70) Is Karyotype Dependent</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106060</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1414</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Knowledge-Based Approach for Clinical Annotation of Oncogenic Variants to Support Patient-Tailored Diagnosis in Myeloid Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106420</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1415</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Features and Prognostic Impact of RUNX1 and PTPN11 Mutations in Pediatric Acute Myeloid Leukemia the Jccg Study, JPLSG AML-05</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106502</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1416</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>In Depth Molecular Characterization of AML with RUNX1-RUNX1T1 at Diagnosis and Relapse</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106717</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1417</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>NPM1 Mutated AML Can Relapse with Wildtype NPM1 and Evolve with Novel Mutations: Implications for Pathobiology and MRD Monitoring</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106677</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1418</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clonal Progression during First Course of Chemotherapy in Acute Myeloid Leukemia Suboptimal Responders Heralds Reinduction Failure and Early Death</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106850</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1419</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Implications of Minimal Residual Disease Detection in Acute Myeloid Leukemia (AML) with Cytarabine Based Therapy of Differing Dose Intensities</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107004</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1420</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Microdeletion in Chromosome 17 Cytoband q21.31 Identified As Located within the KANSL1 Gene Prevailed inFlt3-ITD Negative Normal Karyotype AML Patients As Opposed to Their AML Counterparts and Influenced the Phenotype of the Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107368</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>41</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1421</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>New Concepts of Flow Cytometry Analysis in Oncohematology: Application to Diagnosis and Follow up (Minimal Residual Disease) in AML, ALL and MDS</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107494</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>42</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1422</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107680</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>43</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1423</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Role of Comprehensive Mutational Profiling in Predicting Patients Who May Benefit from Autologous Hematopoietic Cell Transplant for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107867</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>44</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1424</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Concordance between Bone Marrow and Peripheral Blood Samples for Assessment of FLT3 Internal Tandem Duplication (ITD) Mutations: Data from Patients Screened for Participation in Quantum-R, a Global, Randomized, Open-Label, Phase 3 Study Examining the Effect of Quizartinib Monotherapy Vs Salvage Chemotherapy on Overall Survival in Patients with FLT3- ITD - Mutated AML Who Are Refractory to or Have Relapsed after First-Line Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108229</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>45</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1425</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of HLA-B Dimorphism in the Leader Peptide on Clinical Outcome in AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108464</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>46</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1426</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Genome-Wide Association Study (GWAS) Identifies SNPs in GPR56 and IGF1R Predictive of Leukemic Cell in Vitro cytarabine Sensitivity in Pediatric AML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104391</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>47</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1427</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Implantation of Patient-Derived Acute Leukemia Cells into the Hematopoietic Niche of Immunocompromised Mice Favors Faithful Recapitulation of the Disseminated Growth of Human Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99814</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>48</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1428</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Marrow Hypocellularity, but Not Residual Blast Count, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103550</Key_PaperID>
<Key_SessionID>11656</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>49</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1429</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A New Valuable Tool in Monitoring Minimal Residual Disease for Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108350</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1430</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>GATA3 rs3824662A Allele Is Overrepresented in Adult Patients with Ph-like ALL, Especially in Patients with CRLF2 Abnormalities</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102567</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1431</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Development and Validation of an Rnaseq NGS Assay to Comprehensively Detect Clinically Relevant ALL Gene Fusions </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108805</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1432</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Landscape of Circular RNAs in Drug Resistant TCF3-Rearranged Childhood Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102665</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1433</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Proteogenomic Landscape of High Hyperdiploid and ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106295</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1434</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Dynamics of Measurable Disease at Remission Determines Survival in Patients (pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108304</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1435</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104792</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1436</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Rapid Screening of Targetable Kinase Gene Fusions in Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100781</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1437</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Label-Free Analyses of Minimal Residual Disease in ALL Using Deep Learning and Imaging Flow Cytometry</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105379</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1438</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cathepsin G Is Expressed By B Cell Acute Lymphoblastic Leukemia and Is an Effective Immunotherapeutic Target</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107376</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1439</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Significance of Cytogenetic Abnormalities in Patients with Philadelphia-Negative ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission: A CIBMTR Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106090</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1440</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Stat5 Feedback Control Switches MYC- and BCL6-Dependent Cell Fates in Normal and Transformed B Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103299</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1441</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Heterogeneous BCR-ABL Signal Patterns Identified By Fluorescence in Situ Hybridization Can Predict Leukemic Clonal Evolution and Poor Prognosis in BCR-ABL-Positive Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102900</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1442</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Therapy-Related ALL Has Distinct Clinical and Pathologic Features Compared to De Novo ALL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104087</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1443</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>miRNA Profiling in Pediatric T-ALL with Use of Next-Generation Sequencing: Focus on T-ALL Pathobiology and Heterogeneity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103540</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1444</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Epigenetic and Genetic Landscapes of Pediatric T-Cell Acute Lymphoblastic Leukemia (T-ALL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104992</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1445</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Genetic Activation and Therapeutic Targeting of PIM1 in T-Cell Acute Lymphoblastic Leukemia/Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101404</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1446</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>PTEN Alterations Are Related to Unfavorable Prognosis in Children with T-Cell Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM Protocols</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101784</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1447</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>MAP3K7 Is Recurrently Deleted in Pediatric T-Lymphoblastic Leukemia and Affects Cell Proliferation Independently of NF-B</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105738</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1448</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104051</Key_PaperID>
<Key_SessionID>11657</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1449</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Computational Biology Model of ETP-ALL Used to Accurately Classify ETP-ALL Vs Non ETP-ALL Patients with Genomic Input</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102965</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1450</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107454</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1451</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Malignant NK Cells from EBV(+) Human Extranodal NK/T Cell Lymphoma Exhibit Features of a Distinct NK Cell Developmental Subset Found in Mucosal Associated Lymphoid Tissue</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106794</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1452</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Detection of Recurrent Genetic Mutations in Intravascular Large B-Cell Lymphoma By Comprehensive Genetic Analyses Using Peripheral Blood Circulating Cell-Free DNA</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100820</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1453</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Novel Subtypes Based on Microenvironment Immune Signature Provides Prognostic Stratification and Therapeutic Strategy in Peripheral T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107485</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1454</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Common Genetic Polymorphisms Contribute to the Association between Non-Melanoma Skin Cancer and Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107648</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1455</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>North American Adult T Cell Leukemia Lymphoma (ATLL) Is Characterized By Distinct, Therapeutically Targetable Mutations in Epigenetic Modifiers</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104008</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1456</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>DUSP22 Rearrangements Identify a Molecularly Distinct Type of Anaplastic Large Cell Lymphoma Characterized By DNA Hypomethylation and Lack of Activated STAT3</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106466</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1457</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Dissection of Clonal Evolution By Temporal Mutation Profiling in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105547</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1458</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>PD-L1 Is Regulated By Interferon Gamma and Interleukin 6 through STAT1 and STAT3 Signaling in Cutaneous T-Cell Lymphoma </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105569</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1459</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Beyond MYD88: Implications of TNFAIP3 Loss on MYD88 Driven Lymphomas</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106029</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1460</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Genomic Characteristics Clinical Phenotype and Disease Course of TP53 Mutated Diffuse Large B Cell Lymphoma at Diagnosis and Relapse</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101611</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1461</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Intracellular TCR Signaling Pathway As a Novel Therapeutic Target in AITL Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108452</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1462</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mutated MYD88 Homozygosity Is Increased in Previously Treated Patients with Waldenstroms Macroglobulinemia, and Associates with CXCR4 Mutation Status and Ibrutinib Exposure</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108326</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1463</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mutation Spectrum of Transformed Nodular Lymphocyte Predominant Hodgkin Lymphoma and Comparison with De Novo Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108374</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1464</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Genomic Landscape of Primary Cutaneous Diffuse Large B Cell Lymphoma, Leg Type</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105221</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1465</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Deletion 7q Is Associated with KLF2 and NOTCH2 Mutations and Is Strongly Correlated with Splenic Marginal Zone Lymphoma but Also Found in Lymphoplasmacytic Lymphoma and Hairy Cell Leukemia Variant</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107501</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1466</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Reproducibility of m7-FLIPI Risk Scores in Follicular Lymphoma Using Tumor Biopsies and Blood Specimens</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103063</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1467</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Combined Clinical and Gene Expression Score Identifies Follicular Lymphoma Patients with High Risk of Transformation in the Rituximab Era</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103532</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1468</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Genetic Background of Chronic Active EpsteinBarr Virus Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105683</Key_PaperID>
<Key_SessionID>11658</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1469</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>FoxM1: A New Therapeutic Target for Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107747</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1470</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Deletion of Rhoh Accelerates Development of Diffuse Large B Cell Lymphoma in Bcl-6 Transgenic Mouse Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104076</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1471</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Understanding Apoptotic Blocks in Double Hit and Other Non-Hodgkin Lymphomas By BH3 Profiling</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106407</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1472</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting Bromodomain and External Domain Epigenetic Reader Protein As Effective Strategy for Double-Hit and Triple-Hit B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106988</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1473</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Harnessing Microfluidic Single Cell (MF-SC) and 3D Organ-on-Chip Assay Technologies for the Investigation of Immunotherapy and Study of Tumor Microenvironment (TME) in Antibody-Resistant Non-Hodgkin Lymphoma (NHL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108752</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1474</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Lymphoma Microenvironment Signature Predicts Clinical Outcomes in Diffuse Large B-Cell Lymphoma Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107723</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1475</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>PD-L1 Expression and Gene Amplification in CD30+ Diffuse Large B-Cell Lymphoma (DLBCL): Significance of TP53 Genetic Impact and Clinicopathologic Characteristics</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105637</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1476</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting Burkitt's Lymphoma Using Novel, Discrete Carbon Nanotubes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108522</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1477</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Precision in PD-L1 Assessment in Diffuse Large B Cell Lymphoma: Greater Biological Insight Using in Situ Hybridization Approach</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107231</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1478</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>XIAP Knockdown Can Increase the Activity of Caspase 3 and 7, and Restore the Apoptotic Response in Cell Line Models of Rituximab Relapse/Refractory B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105311</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1479</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting DNA Repair Mechanisms to Overcome Drug Resistance in Diffuse Large B Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108527</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1480</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Downregulation of the Tumor Suppressor SAMHD1 in Classical Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104933</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1481</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Deferasirox Induces Apoptosis in Mantle Cell Lymphoma in a Mechanism Involving Cyclin-D1, p53 and the Ribonucleotide Reductase</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108098</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1482</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Low Circulating B Lymphocytes in Newly Diagnosed Follicular and Diffuse Large B Cell Lymphoma: Differences Compared to Normal Subjects and Possible Prognostic Role</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100611</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1483</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>High Expression of FGF2/SDC1 Signaling Contributes to Poor Clinical Outcome in Hodgkin Lymphoma Patients and SDC1 siRNA Suppresses Proliferation, Migration, and Invasion in Hodgkin Lymphoma Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101158</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1484</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Stratification By MYC Protein Expression Level Improves the Prognostic Impact of MYC Translocation in Patients with Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102719</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1485</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Microenvironment-Specific Activation of Notch2 in Splenic Marginal Zone Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103034</Key_PaperID>
<Key_SessionID>11659</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1486</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Maria: Accurate Prediction of MHC-II Peptide Presentation with Deep-Learning and Lymphoma Patient MHC-II Ligandome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101351</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ixazomib has not been approved for Waldenstrom macroglobulinemia.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1487</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prospective Phase II Study of Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenstrm Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104471</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1488</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline Waldenstrom Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99666</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1489</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Maintenance Rituximab after First Line Treatment in Veterans with Follicular Lymphoma Is Associated with Prolonged Overall Survival</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106731</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated, in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia and, in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. GAZYVA is also indicated in combination with chemotherapy, followed by GAZYVA maintenance in patients achieving a response, in previously untreated advanced FL (EU, Switzerland). In this abstract, an exploratory analysis of whether early disease progression predicts overall survival is reported, based on Phase III trial data on GAZYVA plus chemotherapy in previously untreated patients with follicular lymphoma.</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1490</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Early Disease Progression Predicts Poorer Survival in Patients with Follicular Lymphoma (FL)in the GALLIUM Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107024</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1491</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Standardized IGH-Based Next-Generation Sequencing for MRD Detection in Follicular Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108175</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1492</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Outcomes of Lenalidomide and Rituximabin Rituximab-Resistant Patients with Indolent B Cell and Mantle Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104751</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1493</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Real Life Data on Clinical Aspects and Treatment of Marginal Zone Lymphoma: An Analysis from the NF10 Project, an International, Prospective, Observational Study of the Fondazione Italiana Linfomi</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105986</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1494</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of PET Staging of Follicular Lymphoma on Treatment Outcomes and Prognosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103934</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1495</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100649</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1496</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>R-DHA-Oxaliplatin before Autologous Stem Cell Transplantation Prolongs PFS and OS As Compared to R-DHA-Carboplatin and R-DHA-Cisplatin in Patients with Mantle Cell Lymphoma, a Subgroup Analysis of the LyMa Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102451</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1497</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Metformin and the Incidence of Lymphoid Malignancies in Patients with Type 2 Diabetes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105004</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1498</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103515</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1499</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Complex Karyotype Predicts the Prognostics Impact of WBC Count in Untreated Mantle Cell Lymphoma and Is Associated with Shortened Survival Independent of Specific Cytogenetic Abnormalities</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103774</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The drug ofatumumab is currently approved for chornic lymphocytic leukemia. The current study evaluates the efficacy and safety of ofatumumab in combination with benadamustine, followed by ofatumumab maintenance in indolent Non-Hogkin's Lypmhoma.</OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1500</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkins Lymphoma after Prior Rituximab</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103353</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1501</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Surveillance Imaging during First-Remission in Follicular Lymphoma Does Not Impact Overall Survival</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103569</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1502</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Whimsical (Waldenstrms Macroglobulinemia Study Involving CArt-wheeL): Empowering Patients Internationally to Contribute Patient-Derived Data for Observational Research</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108151</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1503</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Patients with Primary Refractory Mantle Cell Lymphoma, a Single Center Retrospective Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100426</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1504</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Factors Impact on Pharmacokinetics of CT-P10 and Reference Rituximab in Patients with Advanced-Stage Follicular Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104641</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1505</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Initial Salvage Approaches for Relapsed/Refractory Mantle Cell Lymphoma Have Comparable Response Rates, Progression-Free and Overall Survival</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100552</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1506</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103179</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1507</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104853</Key_PaperID>
<Key_SessionID>11660</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1508</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Value of P53 and Myc Protein Expression in Follicular Lymphomas in the PRIMA Trial in the Lysa Group</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104836</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Phase 3 study of the efficacy and safety of CD30-directed antibody-drug conjugate brentuximab vedotin versus physician's choice (methotrexate or bexarotene) in previously treated patients with CD30-expressing primary CTCL.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1509</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105187</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1510</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Interim Results from a Phase 1 Study of Adct-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102219</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1511</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Early Reduction of Serum TARC Levels Predicts Prognosis of Patients Treated with a PET-Adapted Strategy for Advanced Stage Hodgkin Lymphoma (HL) in the GITIL/FIL HD0607 Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102415</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1512</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcome of Patients with Gamma Delta T Cell Lymphomas: Analysis of 1429 Cases Registered in the Prospective T-Cell Project</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104665</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1513</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Second Primary Malignancies and Cardiovascular Mortality in Hodgkin disease Survivors  a Surveillance, Epidemiology, and End Results Registry Database Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106853</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1514</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Systemic ALK-Positive Anaplastic Large-Cell Lymphoma (ALCL): Final Analysis of an International, Individual Patient Data Study of 263 Adults</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106157</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Oral 5-azacitidine for the treatment of patients with lymphoma of multiple subtypes.
Romidepsin for the treatment of patients with advanced B-cell and Hodgkin lymphoma</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1515</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106051</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1516</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Measurement of PD-1 Expression on Lymphoma Cells By Flow Cytometry Is a Useful Tool in Diagnosing and Monitoring Minimal Residual Disease in Angioimmunoblastic T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101451</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1517</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Role of FDG PET for Evaluation of Bone Marrow Status and Prognosis in T Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103516</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1518</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Improved Prognosis of Extranodal NK/T-Cell Lymphoma, Nasal Type (ENKL) of Nasal Origin but Not Extranasal Origin: An Analysis of NKEA Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101062</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1519</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>FDG-PET Utilizing Deauville Scoring Is Superior to Conventional Imaging for Staging and Response Assessment in Pediatric and Adult Patients with Nodular Lymphocyte Predominant Hodgkins Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101964</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1520</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hodgkin Lymphoma and Female Fertility: A Multicenter Study of Fertility in Women Treated with Doxorubicin, Bleomycin, Vinblastine and Dacarbazine</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104991</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1521</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Regaining the Tumor Control in Relapsed/Refractory Hodgkin Lymphoma after Nivolumab Failure with Addition of Another Antineoplastic Agent</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107455</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1522</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Data from the Dose Escalation Part of the Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103701</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1523</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Single Institutional Experience of 49 Patients with Large Granular Lymphocytic Leukemia: Clinical and Immunophenotypic Characteristics and the Significance of Immune Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103959</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1524</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106610</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1525</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Lympho- and Myeloproliferative Malignancies Occurring in the Same Host: Description of a Nationwide Discovery Cohort</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106833</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1526</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>High Throughput T Cell Receptor Sequencing Augments Diagnosis and Response Assessment in Patients with Angioimmunoblastic T Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107913</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This a phase II  study evaluating ibrutinib in classical Hodgkin lymphoma which is an off label indication.</OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1527</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>APhase II Multicenter Single Arm Study of Ibrutinib in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102379</Key_PaperID>
<Key_SessionID>11661</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Brentuximab vedotin (BV) is a monoclonal anti-CD30 antibody with an anti-microtubule agent, Monomethyl auristatin E (MMAE), which disrupts the cell cycle of CD30 positive cells.  This study used an off-label dosing of 1.2 mg/kg (capped at 120mg) IV given over 30 minutes on Days 1, 8 and 15 every 28 days to patients with CD30 positive malignancies who had progressive or refractory disease after standard BV dosing.</OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1528</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Pilot Study of Weekly Brentuximab Vedotin in Patients with CD30+ Malignancies Resistant to Every 3 Week Brentuximab Vedotin</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105825</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1529</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting CD38 with Daratumumab Suppresses B-Cell Receptor Signaling and Enhances the Activity of Ibrutinib in Waldenstrom Macroglobulinemia Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105470</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1530</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102875</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1531</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Combination of Lenalidomide and Rituximab (R2) Targets Immune Dysfunction in FL By Activating T and NK CellsEx Vivoand Is Differentiated from Chemotherapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108588</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1532</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Novel Antibody-Cell Conjugation Method to Enhance Cellular Therapies for the Treatment of Hematological Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101545</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1533</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>TAK-243, a Small Molecule Inhibitor of Ubiquitin-Activating Enzyme (UAE), Induces ER Stress and Apoptosis in Diffuse Large B-Cell Lymphoma (DLBCL) Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107862</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1534</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Combination of IRAK4 Inhibitor CA-4948 with BCL2 Inhibitor Venetoclax Induces Tumor Regression in an ABC-DLBCL Xenograft Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106766</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1535</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Doxorubicin-Loaded Platelets Conjugated with Anti-CD22 Mabs: A Novel Targeted Delivery System for B-Cell Lymphoma Treatment with Cardiac Avoidance</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107093</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ibrutinib is being evaluated pre-clinically in Hodgkin Lymphoma which is an off label indication </OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1536</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bruton Tyrosine Kinase Inhibition in Classical Hodgkin Lymphoma Cell Lines and Animal Models</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106801</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1537</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ibrutinib As a Possible Therapeutic Strategy for Epstein-Barr Virus-Positive Lymphoma/Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103923</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1538</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting Mcl-1 By Proteasome Inhibitors Enhances the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108515</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1539</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Humanized EBV-LPD Recaptilates Human Non GC DLBCL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101509</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1540</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Polatuzumab Vedotin Alone or in Combination with Obinutuzumab Synergistically Enhances in-Vitro Cytotoxicity and Cytokine Release Against CD20+/ CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102784</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Duvelisib is a PI3K-delta/gamma inhibitor that is in preclinical and clinical testing, but is not yet approved.</OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1541</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Dual PI3K-, Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108436</Key_PaperID>
<Key_SessionID>11662</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1542</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106657</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1543</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase 3 GOYA Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107863</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>liposomal doxorubicin (Doxil)</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1544</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Multicenter Phase I Dose-Finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin in Combination with Pegylated Liposomal Doxorubicin for the Treatment of Adults with Relapsed or Refractory Cutaneous and Peripheral T-Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106516</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The use of rituximab in B-cell post-transplant lymphoproliferative disease.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1545</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Follow-up of a Prospective Phase II Trial of Extended Treatment with Rituximab in Patients with B-Cell Post-Transplant Lymphoproliferative Disease and Comparison with a Cohort of Patients Treated in Real Life. Analysis on Behalf of the Spanish Lymphoma Group (GELTAMO)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106283</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1546</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Significance of Interim 11c-Methionine PET for the Treatment of Primary Central Nervous System Lymphoma (PCNSL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99990</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Axi-cel (KTE-C19) is not yet approved for the treatment of refractory, aggressive NHL.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1547</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100355</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1548</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Novel Targeted Drug Apatinib in Relapse or Refractory Non-Hodgkin Lymphoma: An Open Label, Single-Armed, Exploratory Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100757</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1549</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Excellent Outcome of Elderly Patients with Favourable-Prognosis DLBCL Treated with 4 Cycles CHOP/Chlip-14 Plus 8 Applications of Rituximab and a PET-Based Intensification Strategy That Includes Involved-Site Radiotherapy (IS-RT): Results of the First 120 Patients of the OPTIMAL&gt;60 Trial of the Dshnhl</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100819</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1550</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102089</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This is a phase I study evaluating the safety and efficacy of CC-122 in patients with R/R DLBCL, grade 1-3a FL, or transformed lymphoma. CC-122 is an investigational agent and has not yet been approved in the US.
</OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1551</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102984</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1552</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103457</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ibritumomab tiuxetan use in diffuse large B-cell lymphoma </OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1553</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103969</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1554</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104454</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1555</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105491</Key_PaperID>
<Key_SessionID>11663</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1556</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Randomized, Double-Blind, Phase III Study Comparing Proposed Biosimilar Rituximab (RTXM83) Versus Reference Rituximab, Both in Combination with CHOP, in the First Line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101584</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1557</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Improved Survival in Overweight and Obese Patients with Non-Hodgkin's Lymphoma Treated with Rituximab Containing Chemotherapy for Curative Intent</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103511</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1558</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Multi-State Model for Senior Patients with Diffuse Large B Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101084</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1559</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Geltamo-IPI Distinctly Identifies a Very High Risk Group in Difuse Large B-Cell Lymphoma (DLBCL) of Non B-Germinal-Center Origin Treated with Chemo-Immunotherapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102650</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1560</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B-Cell Lymphoma - a Nordic Lymphoma Group Population Based Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101627</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1561</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Gender-Based Differences in Efficacy of Immuno-Chemotherapy for Diffuse Large B-Cell Lymphoma Revisited: A Danish Population-Based Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102643</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1562</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Multicenter Case Series of Primary Adrenal Lymphoma (PAL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107602</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1563</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105482</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1564</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcome of Primary Mediastinal B Cell Lymphoma: Comparative Analysis of 123 Patients Treated with Different Strategies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104259</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1565</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Clinical Features and Outcomes in Patients with Primary Central Nervous System Lymphoma Treated within and Outside a Clinical Trial: A Retrospective Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100294</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1566</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Pre-Therapeutic Haemoglobin Levels on the Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with Anthracycline Containing Chemotherapy before and after the Introduction of Rituximab: A Nation-Wide Cohort Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106564</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1567</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Central Nervous System Relapse in HIV Positive Patients Affected By Diffuse Large B Cell Lymphoma. Is the CNS-IPI Score Useful in This Population?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105219</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1568</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hypercalcaemia at Diagnosis Is an Independent Predictor of Poor Survival in Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103008</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1569</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Stage I Lymphoma: Difference in Survival Outcome By Site of Involvement</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103849</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1570</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Impact of Past History of Other Malignancies in Diffuse Large B Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106921</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1571</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Age-Related Chromosomal Aberrations in Patients with Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99907</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1572</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>DA.R-EPOCH Vs. R-CHOP for High-Risk Diffuse Large B- Cell Lymphoma: The Mayo Clinic Florida Experience</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103061</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1573</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Intensive Etoposide Aracytine Consolidation Following Rituximab Methotrexate Temozolomide Induction in Newly Diagnosed Primary Central Nervous System Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107078</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1574</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Changing Face of Adult Posttransplant Lymphoproliferative Disorder: Dramatic Changes in Histology between 1999-2013</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102862</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off label use of pembrolizumab and nivolumab for non Hodgkin Lymphoma</OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1575</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle> Clinical Outcomes of Anti PD-1 Immunotherapy in Patients with Relapsed/Refractory Non Hodgkin Lymphomas </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102676</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1576</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Absolute Monocyte Count at Diagnosis Could Improve the Prognostic Role of Final FDG-PET in Diffuse Large B Cell Lymphoma Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105297</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1577</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Real World Outcome in a Patient Cohort with Newly Diagnosed Diffuse Large B Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100540</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1578</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Post-Transplant Lymphoproliferative Disorder Subtype on Survival</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104475</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1579</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Monomorphic Post Transplant Lymphoproliferative Disorder (Diffuse Large B Cell Lymphoma subtype) Successfully Treated without Chemotherapy after Solid Organ Transplant in Children</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102986</Key_PaperID>
<Key_SessionID>11664</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1580</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Use of Bortezomib-Containing Regimens in the Frontline Treatment of Patients with Plasmablastic Lymphoma: A Multicenter Retrospective Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102033</Key_PaperID>
<Key_SessionID>11665</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1581</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Nilotinib/Interferon- Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104796</Key_PaperID>
<Key_SessionID>11665</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1582</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>ABL001 with Catalytic-Site Inhibitors Limit the CML Immature Cell Population: Re-Differentiation of CML-iPSCs Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103639</Key_PaperID>
<Key_SessionID>11665</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1583</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Role of Signal Transducing Adaptor Protein (STAP) Family in Chronic Myelogenous Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101785</Key_PaperID>
<Key_SessionID>11665</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1584</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CXCL12-Expressing Bone Marrow Niches Differentially Regulate CML Compared to Normal Stem Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102082</Key_PaperID>
<Key_SessionID>11665</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1585</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mutation Screening at Diagnosis Reveals a High Frequency of ASXL1 Mutations in CML Patients Who Fail to Achieve Molecular Remission Criteria after One Year of TKI Treatment</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107808</Key_PaperID>
<Key_SessionID>11665</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1586</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Allosteric Bcr-Abl Inhibitor ABL001 Overcomes Bcr-Abl Tyrosine Kinase Inhibitor Resistance and Enhances MDM2 Inhibitor CGM097 Activity in Blast Crisis CML Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107793</Key_PaperID>
<Key_SessionID>11665</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1587</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Role of Somatic Mutations in Clonal Evolution of Chronic Myeloid Leukemia from Chronic Phase to Blast Phase</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105107</Key_PaperID>
<Key_SessionID>11665</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1588</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting WEE1 Kinase after G2/M Checkpoint Arrest Induces Apoptosis in Chronic Myeloid Leukemia Progenitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100684</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1589</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100201</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1590</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Cardiac, Vascular and Hypertensive Safety of Bosutinib in Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia Resistant or Intolerant to Prior Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107075</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1591</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of BCR-ABL Tyrosine Kinase Inhibitors on Atherosclerosis Plaque Rupture</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106893</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1592</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>In Vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104847</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1593</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104195</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1594</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105695</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>pioglitazone</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1595</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pilot Study of Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia with Deep Molecular Response (EDI-PIO)  Evaluation of Pioglitazone in Treatment-Free Remission</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104838</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1596</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>E14a2 and e14a2+e13a2 BCR-ABL Transcripts Are Associated with Earlier Cytogenetic and Molecular Response Rates in CML-CP Treated with Imatinib</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102639</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1597</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107565</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This abstract discusses the investigational approach of treatment-free remission following nilotinib therapy in patients with chronic myeloid leukemia in chronic phase (CML-CP). Nilotinib is a tyrosine kinase inhibitor indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) CML-CP, and for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant to or intolerant to prior therapy that included imatinib.</OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1598</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108484</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1599</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Dynamics of Methylation Profiling in Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105010</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1600</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Outcome in Children and Adolescents with Chronic Myeloid Leukemia in Chronic Phase Treated with High-Dose Imatinib. the Italian Experience</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103720</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1601</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106450</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1602</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Plasma Fms-Related Tyrosine Kinase 3 Ligand (Flt3L) Levels at Diagnosis Correlate with Treatment Response in Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106425</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1603</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107763</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1604</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>First-Line Dasatinib in BCR-ABL1+ Chronic Myeloid Leukemia in Early Chronic Phase: A Gimema Prospective Multicentric Observational Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107444</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1605</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106094</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1606</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Second Generation Tyrosine Kinase Inhibitors (2G-TKI) in the Frontline Treatment of Elderly Patients with Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103867</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1607</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcomes after Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Phase Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107315</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1608</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>RIZ1 Gene Promoter Methylation Increases with Progression of Chronic Myeloid Leukaemia to Advanced Phases</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108359</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1609</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103933</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1610</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Xpert BCR-ABL Ultra, a High Sensitivity Assay, Demonstrates a Limit of Detection Reaching MR4.5 and below</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105980</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1611</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107153</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1612</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Changes in RT-qPCR Levels during and after TKI Interruptions for Attempted Conceptions in Women with CML</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105058</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1613</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Dasatinib-Induced Lymphocyte Elevation and Imbalance of T Cell Receptor V Beta Gene Expression in Chronic Phase Chronic Myelogenous Leukemia Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104525</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1614</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>ABCG2 but Not ABCB1 RNA Levels at Diagnosis and during Treatment Correlates with Response to Imatinib and 2G-Tkis Front-Line Therapy in Chronic Phase CML Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99881</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1615</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101069</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1616</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Observational Study of CML Italian Patients Who Discontinued TKIs</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102305</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1617</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101437</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1618</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results By 3-Month BCR-ABL1 Transcript Level</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101696</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1619</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101746</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1620</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102030</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1621</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102604</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1622</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102992</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1623</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Survival Outcome of Secondary Solid Cancer in Patients with Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103266</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1624</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103684</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1625</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Arterial Thrombotic Events in CML Patients Treated with First-Line Nilotinib: Incidence, Management and Impact on the Long Term Outcome - a Gimema CML WP Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105878</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1626</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of an Automated Immunoassay for Quantification of Imatinib in Plasma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106509</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1627</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Altered Expression of Pdgfr and Its Downstream Signalling Components May be Causal in the Development of Imatinib Induced Thrombocytopenia in CML Patients Receiving Imatinib Treatment</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108328</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1628</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107939</Key_PaperID>
<Key_SessionID>11666</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>41</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1629</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Identification of a Safe Haven for RT-qPCR Responses in CML: Can We Reduce the Frequency of Molecular Monitoring?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108714</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1630</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Congenital Thrombocytopenia and Myelofibrosis Due to Germline Mutations in G6b-B, a Megakaryocyte-Specific Immunoreceptor Tyrosine-Based Inhibitory Motif (ITIM) Receptor</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105371</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1631</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105843</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1632</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106910</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1633</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Examining the Treatment Patterns and Blood Counts Among Patients with Polycythemia Vera Treated with Hydroxyurea in the United States: An Analysis from the Reveal Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108453</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1634</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Relative Lymphocytosis Is Associated with Improved Outcome in Myelofibrosis and May Account for the Favorable Prognosis of the Calr mutation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106626</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1635</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Treatment of Myeloproliferative Neoplasms in Blastic Phase with Azacytidine. Clinical Results and Identification of Prognostic Factors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107345</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1636</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Characteristics of 809 Patients with Essential Thrombocythemia in Real-World Clinical Practice: A Chart Review Study in the United States</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99627</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>description of off-label drug and its purpose</OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1637</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Role of Symptom Burden in Disability Leave Among Patients with Myeloproliferative Neoplasms (MPNs): Findings from the Living with MPN Patient Survey</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105445</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1638</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Next-Generation Sequencing with a 54-Gene Panel Identifies Unique Mutational Profile and Prognostic Markers in Chinese Patients with Myelofibrosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105988</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1639</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Ruxolitinib-Response Feature on Outcome in Myelofibrosis: A Multicentre Study on 356 Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104443</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pegylated Interferon in patients with ET and PV</OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1640</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Correlation of Mutational Profile and Response in Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Pegylated Interferon Alfa 2a As Part of a Prospective Phase II Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104678</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1641</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104970</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1642</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Age Is Not a Predictive Marker in Molecularly Annotated Elderly Patients with Myelofibrosis Treated with Ruxolitinib: a Multicenter Study on 277 Patients.</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105046</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1643</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99679</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1644</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Extreme Thrombocytosis: Influence of Care Setting and Likelihood of Occult Malignancy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99719</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1645</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Phenotypic and Prognostic Relevance of the Who Diagnostic Distinction between Polycythemia Vera and JAK2-Mutated Essential Thrombocythemia: Combined Analysis of 785 Informative Cases</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100141</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1646</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Germline Mutations Occurring Outside the Negatively Charged Amino Acid Stretches of the Exon 9 of Calr: A Predisposition to Hematological Malignancies?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101093</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1647</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeted Sequencing of Paired Samples in Patients Evolving from Chronic to Blast Phase Myelofibrosis with Parallel Cytogenetic Information</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101752</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1648</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Long-Term Safety and Efficacy Study of Givinostat in Patients with Polycythemia Vera: The First 4 Years of Treatment</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102781</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ruxolitinib - approved for 'chronic' phase PV and MF, not for blast-phase. Being tested here in advanced disease. </OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1649</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase Ib Study to Assess the Safety and Tolerability ofRuxolitinib in Combination with Azacitidine in Patients with Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN (The Bloodwise / TAP PHAZAR Study on Behalf of the UK MPN CSG)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103320</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Cladribine and midostaurin have been used as offlabel drugs for mastocytosis treatment</OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1650</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Selection and Efficacy of Cytoreductive Agents in Patients with Mastocytosis Included in the Registry of the European Competence Network on Mastocytosis (ECNM)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103717</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1651</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Usefulness of a Sequencing Panel in Myeloproliferative Neoplasms Lacking Mutations in Driver Genes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104090</Key_PaperID>
<Key_SessionID>11667</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1652</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Genomic Profiling of Blast Phase in Philadelphia-Negative Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101426</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1653</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Gain-of-Function Mutation in EPO Gene Causes Familial Erythrocytosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104157</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1654</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101205</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1655</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Role of the Axis TGF-1/Mir-382-5p/SOD2 in the Induction of Oxidative Stress in CD34+ Hematopoietic Stem/Progenitor Cells from Primary Myelofibrosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106724</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1656</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Localization of Mutant Calreticulin in the Golgi Apparatus Is Required for Its Oncogenic Capacity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101302</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1657</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108792</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1658</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Chromatin Regulator Mutations Are Drivers of Clonal Evolution in the Early Multipotent HSC Compartment of Primary Myelofibrosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103182</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1659</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Identification of Candidate Progenitor Populations Which Causes Transient Abnormal Myelopoiesis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107721</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1660</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Selective Inhibition of Nucleocytoplasmic Transport Overcomes Ruxolitinib Resistance in Myelofibrosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101293</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1661</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102736</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1662</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Regulation of Lysyl Oxidase, a Key Regulator of Bone Marrow Fibrosis, in Myelofibrosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105732</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1663</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Germline ERBB2 Variants Associate with Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107845</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1664</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Neoplastic Monocyte-Derived Osteoclasts Are Highly Proliferative, but Sub-Functional in MPN-Associated Myelofibrosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102753</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1665</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Rare Type 1-like and Type 2-like Calrecticulin Mutants Induce Similar Myeloproliferative Neoplasms Than Type 1 and Type 2 Mutants in Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106270</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1666</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>ASXL1 Mutation Change the Migration Ability in JAK2V617F Positive Cell Lines through SDF-1/CXCR4 Axis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103632</Key_PaperID>
<Key_SessionID>11668</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1667</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>JAK2 V617F Progenitors Utilize Adaptations to Cell-Autonomous and Microenvironment-Dependent Inflammatory Stress in Polycythemia Vera, Likely Exhibiting Barrier Against Rapid Transformation to Myelofibrosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101098</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1668</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>TET2 and MSH6: A Novel Role for MMR in the Pathogenesis of Myeloid Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103461</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1669</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ultra-Deep Sequencing As a Predictive Tool for MDS Progression after Allogeneic Hematopoietic Cell Transplant</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108307</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1670</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Germline SAMD9 and SAMD9L Alterations in Adult Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107308</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1671</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Variant Interpretation between Manual Expert Curator and Automated in-Silico Classification Using Acmg/AMP Guidelines in Myeloid Malignancies in a Routine NGS Setting</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101181</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1672</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Constitutional SAMD9L Mutations Cause Familial Myelodisplastic Syndrome with Monosomy 7 and Stable Revertant Mosaicism</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106882</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1673</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Chemotherapy and Radiation Results in Distinct Patterns of Somatic Mutations in Subsequent Myeloid Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100914</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1674</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Innate Immune Signal Pathway Activation Induced By Combined Loss of Del(5q) MDS Genes, Tifab and Mir-146a, Accelerates Hematopoietic Stem Cell Exhaustion Driven By Chronic Exposure to a TLR Ligands</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102706</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1675</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Molecular Genetics Provides Important Information for Initial Evaluation of Patients with Suspected MDS</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103980</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1676</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Aberrant Hedgehog Signaling in Myelodysplastic Syndrome Accelerates Leukemic Transformation Via Smoothened-Dependent and Smoothened-Independent Gli1 Activation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104496</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1677</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104657</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1678</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mutation-Specific Signaling Profiles and Therapeutic Vulnerabilities of Induced Pluripotent Stem Cell Models of Juvenile Myelomonocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105044</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1679</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Transcriptome of DNA Repair Genes in CMML: Rationale for TargetingERCC1 andCDKN1AAs a Synthetic Lethality Approach</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105253</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1680</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluating the Mesenchymal Stromal Cell (MSCs) Contribution in Pre-Leukemic Myelodysplastic Syndromes in Different Patient Risk Groups</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105629</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1681</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Novel In Vivo Models Uncover Non-Cell-Autonomous Effects of Myelodysplastic Syndrome (MDS) on Marrow Osteolineage Cells and Hematopoietic Dysfunction</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105920</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1682</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evolution in Myeloid Neoplasms Clonal Architecture Post Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106447</Key_PaperID>
<Key_SessionID>11669</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1683</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Azacitidine Directly Acts on the Mesenchymal Stromal Cell Compartment in Myelodysplastic Syndromes to Alter Niche Function and Suppress Malignant Hematopoeitic Stem/Progenitor Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103837</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1684</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prevalence of Clonal Hematopoiesis and Mutation Patterns in Unexplained Anemia of Community-Dwelling Elderly Individuals: A Case-Control Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108044</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1685</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Germline Tissues and DNA Sequencing Analysis Methods for Optimal Somatic Variant Detection in Myelodysplastic Syndrome (MDS)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105976</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1686</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>An MDS Specific Frailty Index Based on Cumulative Deficits Adds Independent Prognostic Value to Established Clinical Prognostic Scoring Systems</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104732</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1687</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcome of Myelodysplastic Syndrome Patients with TP53 Mutation Treated with Hypomethylating Agents</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106457</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1688</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Implication of Gene Mutations in Children Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108660</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Investigational drug in clinical trial for MDS.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1689</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103282</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1690</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Red Blood Cell Transfusion Intensity on Progression-Free Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS Registry</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103420</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1691</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Rates of Severe Bleeding Are Low in Patients with MDS and Severe Thrombocytopenia and May be Mitigated By Tranexamic Acid</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106302</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1692</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Geriatric Screening Tool (G8) Provides an Independent Prognostic Index for Azacitidine Treated Elderly MDS Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106636</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1693</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Outcome of Patients with High Risk MDS Achieving Stable Disease after Treatment with 5- Azacitidine. a Retrospective Analysis of the Hellenic (Greek) Mds Study Group</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108568</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1694</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Infections in Patients with Myelodysplastic Syndrome. Looking for the Escape Clause!</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104826</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1695</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Global and Targeted RNA-Sequencing Assessment of Cancer Testis Antigen Re-Expression Following Azacitidine in Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105552</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Lenalidomide administration to patients with MDS and Del(5)q chromosomal abnormality, but not only with the classical Del(5)q syndrome.</OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1696</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106948</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1697</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Outcomes of Decitabine Treatment for Patients with Lower-Risk Myelodysplastic Syndrome By the International Prognostic Scoring System</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108192</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1698</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108534</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1699</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Immunological Correlates of Treatment with the CTLA-4 Inhibitor Ipilimumab in Patients with Refractory Myelodysplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100903</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1700</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Novel Single Next-Generation Sequencing (NGS) Approach for the Molecular Karyotyping and Genotyping of Patients with Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105634</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1701</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Clinical Significance of Chromosome 17 Abnormalities in Myelodysplastic Syndrome Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106218</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1702</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cytokine Receptor-like Factor 2 (CRLF2) Overexpression in Myeloid Malignancies Secondary to Multiple Isodicentric Y Chromosomes: A Novel Cytogenetic Entity?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102591</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1703</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Effect of Azacitidine on CD4+CD25+Foxp3+ Regulatory T Cell on Immunity in Myelodysplastic Syndrome Survivors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99794</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1704</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Benefit and Improvement of Mitochondrial Function in Low Risk Myelodysplastic Syndrome Treated By Combination Ultra Coenzyme Q10 and L-Carnitine</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100431</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1705</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Dyserythropoiesis Evaluated By Red Score and Hepcidin/Ferritin Levels Predicts Response to Epoetin Zeta in Lower Risk MDS</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101028</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1706</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Simple Tool for the Prediction of Azacytidine Treatment Failure in Patients with Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101267</Key_PaperID>
<Key_SessionID>11670</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1707</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Diagnostic Value of Flow CytometryTechnique By European Leukemianet for Idiopathic Cytopenia of Undetermined Significance</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106580</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1708</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107424</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1709</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Immunoglobulin Heavy Chain Variable Region (IgHV) Unmutated, but Not Mutated, Chronic Lymphocytic Leukemia (CLL) Arises in a CD34+ Progenitor</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106475</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1710</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CLL-Specific B Cell Receptor Immunoglobulin Stereotypes Are Very Infrequent in Low Count Monoclonal B Cell Lymphocytosis: Implications for Disease Ontogeny</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107775</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1711</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>International, Practice-Based Recommendations for Prediction of Bleedings and Anti-Platelet/Anti-Coagulant (AP/AC) Co-Medications in CLL Patients Taking Ibrutinib</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107358</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1712</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>High Prevalence of Multiple B Cell Clones in Patients with Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103711</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1713</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Progression of Chronic Lymphocytic Leukemia (CLL) Is Characterized By a Progressive Increase of the Exhausted T-Cell Phenotype and Immunosuppression Induced By Leukemic Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106068</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1714</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Development and Validation of a New Tool for the Characterization of Immunoglobulin Gene Rearrangements in Patients with Chronic Lymphocytic Leukemia By Deep Next Generation Sequencing</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106175</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1715</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical, Genomic Profile and Recurrent Somatic Mutations in 205 Chronic Lymphocytic Leukemia Treatment-Naive Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107803</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1716</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>IgM and IgD Differential CLL BCRs Organization and Interaction with Co-Receptors before and during Ibrutinib Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106727</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1717</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Regulation and Impact of BCR Induced Autophagy in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104028</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1718</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Transcriptome Analysis of the Lymph Node Microenvironment in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104551</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1719</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Applicability of the Chronic Lymphocytic Leukemia (CLL)-IPI on Patients Treated with Front-Line Ibrutinib in the Real World: The Case for New Prognostic Models</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105027</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1720</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clonal Evolution of Molecular and Cytogenetic Aberrations in 80 CLL Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105054</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1721</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hyper-Activation of the Adenosinergic Axis in the E-TCL1 Chronic Lymphocytic Leukemia Mouse Model Offers Therapeutic Opportunities</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105224</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1722</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105298</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1723</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Integrative Epigenomics Reveals Novel Chronic Lymphocytic Leukemia-Specific Chromatin States Associated with Epigenetic and Transcriptional Heterogeneity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103708</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1724</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Co-Expression and Functional Interaction between CXCR4 and CD74 in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100529</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1725</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>NOTCH1 Aberrant Activation Is a Common Nonmutational Early Event in Chronic Lymphocytic Leukemia Hematopoietic Stem-Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101698</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1726</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prediagnostic Progression of Lymphocytosis in Chronic Lymphocytic Leukemia Is Predictive of Progression Free Survival As Early As Five Years Prior to Diagnosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102243</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1727</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>New Generation Sequencing of Targeted Genes in Hairy Cell Leukemia Highlighted Mutations Associated to BRAFV600E and a New Recurrent Altered Gene, KDM6A, in Hairy Cell Leukemia Variant Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102808</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1728</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102990</Key_PaperID>
<Key_SessionID>11671</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1729</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Gain of the Short Arm of Chromosome 2 (2pgain) Plays an Important Role in CLL Drug Resistance, and Has to be Systematically Considered before Deciding an Adapted Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107936</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Gazyva and Methylpredinosolone for the treatment of CLL</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1730</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) Combination for Patients with Chronic Lymphocytic Leukemia (CLL) - a Phase Ib/II Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107999</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1731</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Immune Recovery Refines the Prognostic Impact of Minimal Residual Disease on Overall and Progression Free Survivals after Frontline Fludarabine, Cyclophosphamide and Rituximab (FCR) in CLL Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107932</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1732</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Strategy of the Management of Patients with Chronic Lymphocytic Leukemia in the Post-Induction Period Based on the Results of the Evaluation of Minimal Residual Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105783</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1733</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Multicentre Retrospective Analysis of Chronic Lymphocytic Leukaemia Patients Treated with Idelalisib, Real World Data from the UK and Republic of Ireland  a Cohort of 68 Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106075</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Idelalisib and ofatumumab are used as frontline therapy for CLL and they are not currently approved in this combination in this setting.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1734</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104283</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1735</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Exposure-Response of Entospletinib (ENTO) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105363</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1736</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab Decreases Treg-Mediated Immunosuppression and Potentiates CD8+ T-Cell-Induced Killing of Chronic Lymphocytic Leukemia (CLL) Cells Ex Vivo</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102250</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1737</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Do Statins Enhance the Anti-Cancer Activity of Venetoclax?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102749</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1738</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103121</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1739</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Chronic Lymphocytic Leukemia International Prognostic INDEX (CLL-IPI) Predicts Prognosis of CLL: A Systematic Review and Meta-Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103384</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1740</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mode of Progression after First Line Treatment Correlates with Outcome of Chronic Lymphocytic Leukemia (CLL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100335</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1741</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1/2 ACE-CL-001 Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99903</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1742</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>IGHV Mutation Status and Outcome in CLL Patients Treated with Chemoimmunotherapy: A Nationwide Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100489</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ibrutinib, a BTK inhibitor, is approved in the US for the treatment of various B-cell malignancies. Use of ibrutinib is investigational in patients with diffuse large B-cell lymphoma and follicular lymphoma, and investigational in combination with ofatumumab or R-CHOP.   Temsirolimus is an mTOR inhibitor approved in the US for the treatment of advanced renal cell carcinoma. Use of temsirolimus is investigational in the US in patients with mantle cell lymphoma.</OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1743</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101175</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1744</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101269</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>BGB-3111 is an investigational agent and not approved in the United States. </OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1745</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101468</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1746</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-&amp;#98;eing in Older Patients &amp;#87;ith Treatment-Na&amp;#239;ve (TN) Chronic Lymphocytic Leukemia Treated &amp;#87;ith Ibrutinib (Ibr): 3-Year Follow-up of the R&amp;#69;&amp;#83;&amp;#79;&amp;#78;&amp;#65;&amp;#84;&amp;#69;-2 Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102357</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1747</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Atrial Fibrillation (AF) and Ibrutinib, a Monocentric Experience: Should Cardiological Evaluation be a Guide in Clinical Practice?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104714</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ibrutinib as an early intervention strategy in patients with CLL</OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1748</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102974</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1749</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Sequencing Therapy in Chronic Lymphocytic Leukemia (CLL): Treatment Patterns and Associated Outcomes in Community Practice for Patients with Relapsed/Refractory CLL in the United States</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101257</Key_PaperID>
<Key_SessionID>11672</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1750</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Nave Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108457</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1751</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Deconvolution of the Immune Microenvironment Can Predict the Outcome of Myeloma Patients and Inform Potential Intervention Strategies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103715</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1752</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Arginine Deprivation Sustains Plasma Cell Fitness Via GCN2: A Novel Immuno-Metabolic Check-Point</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107459</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1753</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Dynamic Regulation of Histone Acetylation By Nuclear Proteolysis Controls Cell Cycle Gene Expression and Chromosome Integrity in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107667</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1754</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Molecular Analysis of Cereblon-Related Immunomodulatory DrugResistance in Commpass Multiple Myeloma Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108077</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1755</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ywhae Located on Chromosome 17p13 Promotes Myeloma Cells Proliferation Via Induction of Anti-Apoptosis and Survival Signaling Pathways</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108468</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1756</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Versican (VCAN) Proteolysis Predicts T-Cell Infiltration in Myeloma Bone Marrow Post- Autologous Stem Cell Transplant (ASCT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108727</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1757</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Development of New Scoring System for Whole Body Magnetic Resonance Imaging for Evaluation of Multiple Myeloma Lesions</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105946</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1758</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Simultaneous Detection of Single Nucleotide Variants and Expression of RNA and Protein in Multiple Myeloma Bone Marrow Aspirates</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106616</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>Bortezomib in AL amyloidosis</OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1759</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106947</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1760</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107263</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1761</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>JMJD3 Is a Potential Tumor Suppressor Gene That Cooperates with TP53in Chromosome 17p13</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103828</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1762</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>LNA -Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101414</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1763</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Significance of Medullary Abnormalities of the Appendicular Skeleton Detected By Low-Dose Whole-Body Multidetector Computed Tomography in Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103155</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1764</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Molecular Characterization of WaldenstrMs Macroglobulinemia Patients Using Peripheral Blood Cell-Free Tumor DNA</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103404</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1765</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Role of CD24 in Multiple Myeloma Tumorigenicity and the Effect of the Microenvironment on CD24 Expression</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102300</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1766</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Kinome Expression Profiling in Multiple Myeloma Identifies New Therapeutic Targets</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102728</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1767</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104374</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1768</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Myeloma-Associated Adipocytes Exhibit Reduced Adipogenic Gene Expression and Delipidation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105081</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1769</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Pliancy of Plasma Cell Differentiation Status Conceals a Gradient of Chromosomal Instability in Newly Diagnosed Multiple Myeloma Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100783</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1770</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Human Myeloma Cell Lines Mutation Landscape: Toward a Rationale Use of Cell Lines to Assess Drug Efficacy Prediction in Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101699</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1771</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Biological and Prognostic Impact of Apobec-Induced Mutations in the Spectrum of Plasma Cell Dyscrasias</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107915</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1772</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Using Single Cell RNA Sequencing to Characterize Cell-Type Specific Gene Expression in a Mouse Model of Multiple Myeloma Treated with the cIAP Antagonist LCL161</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108572</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1773</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clonality Analysis Reveals the Order of Acquisition of Copy Number Alterations in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106608</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1774</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Identification of a Patients-Derived CD34+ Myeloma Cell Population with Tumor-Propagating Capacity and Resistance to Anticancer Drugs</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105213</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1775</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Low Intensity Vibration Treatment Reduces Myeloma Cell-Induced Osteoclast Formation By Inhibiting IL-6 and GFI-1 Production By MM Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103671</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1776</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Exosomes-Derived EGFR Ligand Amphiregulin (AREG) Is a New Pro-Osteoclastogenic Factor in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104041</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1777</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Combined Inhibition of Chk1 and Wee1 As a New Therapeutic Strategy for High-Risk Multiple Myeloma Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100745</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1778</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeted Remodeling of the Tumor Microenvironment Via Mechanical Stimulation Defines a Novel Therapeutic Strategy in Myeloma Bone Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107498</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1779</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Validation of Dynamic Biomarker-Based Risk Progression Model for Smoldering Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108092</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1780</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>High-Risk Myeloma Is Demarcated By Immunoglobulin Lambda Light Chain Translocations</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105200</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1781</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>IL-32 Induces M2 Macrophage Polarization with Enhanced Ability of Macrophage-Mediated Drug Resistance in Myeloma Cells through STAT3 and NF-b Activation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106318</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1782</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Altered Expression of CCR10 Indicates Malignant Transformation of Bone Marrow Plasma Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107103</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1783</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>New Alternatives for the Evaluation of Minimal Residual Disease (MRD) Detection By Next Generation Sequencing in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100989</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1784</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Direct Assessment of IgA and IgG Paraprotein By Hevylite Assay and Correlation to IMWG Response and Progression-Free Survival in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients in the Prospective Phase III GMMG-MM5 Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103122</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1785</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Investigation of Mitochondrial Biogenesis in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103538</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1786</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>KRAS-Mutated Myeloma Cells Exploit Autophagy and Macropinocytosis to Tolerate Glutamine-Deprived Conditions</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103786</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1787</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>NEDD4-1 Modulates the Resistance of Multiple Myeloma to Bortezomib Via PTEN/PI3K/Akt Signaling Pathway</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104911</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1788</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Myeloma Lytic Bone Lesions Characterization with WB-LDCT and 18f-FDG PET/MRI</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99842</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1789</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Substratification of Patients with Newly Diagnosed Standard-Risk Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101900</Key_PaperID>
<Key_SessionID>11673</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1790</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Single-Cell Analysis of Mesenchymal Stem Cells Reveals Their Molecular and Functional Heterogeneity in Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102997</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1791</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inhibiting TGF Signaling in CAR T-Cells May Significantly Enhance Efficacy of Tumor Immunotherapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107094</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1792</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Identification of Metabolic Enzymes ENO1 and KMO As Novel Immunotherapeutic Targets in Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104966</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1793</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Epigenetic Modifications of the Bone Marrow (BM) Niche in Multiple Myeloma (MM) - a Three-Dimensional (3D) in Vitro Approach</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105383</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1794</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Lenalidomide Enhances Anti-Bcma Chimeric Antigen Receptor T Cell Function Against Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107790</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1795</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Germinal Center Kinase As a Therapeutic Target in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101020</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1796</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104044</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1797</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Translational Research of PT-112, a Clinical Agent in Advanced Phase I Development: Evident Bone Tropism, Synergy in Vitro with Bortezomib and Lenalidomide, and Potent Efficacy in the Vk*MYC Mouse Model of Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106549</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1798</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Molecular Pathways Responsible for Adaptive Resistance to Single-Checkpoint Inhibition May Reveal Biomarkers and Immunotherapy Targets in Multiple Myeloma Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101417</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1799</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103151</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1800</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>HDAC11 Is a Candidate Therapeutic Target in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103244</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1801</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Immunomodulatory Drugs, through Loss of Ikaros and Aiolos,DerepressCD38and FunctionallySynergise with Daratumumab</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107016</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>Radium-223 dichloride (Xofigo) is approved for the treatment of patients with castration-resistant prostate cancer symptomatic bone metastases, and no known visceral metastatic disease.</OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1802</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Combination of Radium-223 Dichloride and Bortezomib Effectively Reduces Tumor Burden and Lesion Area in the Syngeneic, Systemic 5TGM1 Multiple Myeloma Mouse Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105500</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1803</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Upregulation of CD38 Expression on Multiple Myeloma Cells By the HDAC Inhibitor Ricolinostat Augments the Efficacy of Daratumumab</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106514</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1804</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Preclinical Evaluation of the First in Class BMI1 Inhibitor PTC-028 Confirms Potent Efficacy to Target BMI1-Addiction in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108333</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1805</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Novel Combination Therapies with the RNA Polymerase I Inhibitor CX-5461 Significantly Improve Efficacy in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101424</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1806</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inecalcitol Induces CD38 Expression in Multiple Myeloma Cell Lines More Efficiently Than All-Trans Retinoic Acid (ATRA)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108354</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1807</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ruxolitinib Rescues Mice from Lethal Interferon Beta Toxicity and TLS</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100509</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1808</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>B Cell-Derived Induced Pluripotent Stem Cells Are Useful for Determining the Cellular Origin of Abnormal B Cells in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108641</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1809</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Combined Nanoparticle Delivery of PARP and DNA-PK Inhibition for Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107620</Key_PaperID>
<Key_SessionID>11674</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1810</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>CD75s Represents a Therapeutic Target for Antibody-Based Immunotherapy of B Cell Lymphoma and Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102454</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1811</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx)Failure</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102365</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1812</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106390</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1813</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Development of JCARH125: Optimization of a Fully Human Anti-Bcma CAR for Use in the Treatment of Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106437</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1814</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Thalidomide and Dexamethasone Maintenance after Autologous Stem Cell Transplantation in Newly Diagnosed Korean Multiple Myeloma Patients: A Prospective Multi-Center Study in Asia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106878</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1815</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107372</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1816</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107044</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1817</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107524</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1818</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107807</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Daratumumab for the treatment of AL amyloidosis </OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1819</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab Is Safe and Highly Effective in AL Amyloidosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107998</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1820</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pan-PIM Kinase Inhibitors Enhance Lenalidomides Anti-Myeloma Activity Via Cereblon-IKZF1/3 Cascade</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108317</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1821</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Consolidation with Bortezomib, Lenalidomide and Dexamethasone Upgrades the Complete Remission Rate after Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108376</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1822</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Characteristics and Outcomes of Myeloma Patients Exhibiting Translocation (14;16): An Ultra-High-Risk Group of Myeloma Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108638</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1823</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Identification of Acetylation, Immune Cell Alterations and Gene Signature As Dynamic Biomarkers of Response to Panobinostat Treatment in Multiple Myeloma Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105273</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1824</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with 2 Prior Lines of Therapy: Updated Analysis of MMY1001</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105429</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1825</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Benefit of Depth of Response for Relapsed/Refractory Multiple Myeloma Patients Treated on Clinical Trials: Retrospective Analysis from Two Tertiary Centres</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105599</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1826</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105820</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1827</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bion-1301, a First-in-Class APRIL Neutralizing Antibody for the Treatment of Multiple Myeloma: Preclinical Safety, and Analysis of Pharmacokinetics - Pharmacodynamics Relationship</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105912</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1828</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103367</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1829</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting the MALAT1/PARP1/LIG3 Complex Induces DNA Damage and Apoptosis in Multiple Myeloma Mouse Models</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106152</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1830</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>In Vivo Vaccination Effect in Clinical Responders to Anti-Myeloma Monoclonal Antibody Isatuximab</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104393</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1831</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102363</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1832</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Systematic Review and Network Meta-Analysis of Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma PostAutologous Stem Cell Transplant</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104595</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1833</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Outcomes of IMiD Based Trials in Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Pooled Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104835</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1834</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>the Safety and Efficacy of Pomalidomide in Combination with Cyclophosphamide and Dexamethasone (PCD) in the Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-Labeled, Multicenter Phase II Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102746</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1835</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103474</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1836</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Minimal Residual Disease (MRD) Assessed By Flow Cytometry in Patients with AL Amyloidosis Treated with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104096</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1837</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab Monotherapy in Thirty-Two Heavily Pre-Treated Patients with Advanced Systemic Light-Chain Amyloidosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103112</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Bendamustine, a bifunctional alkylating agent, is approved for use in CLL and non-Hodgkin's lymphoma. In this phase 2 study we use it as an experimental therapy to treat AL amyloidosis. </OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1838</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99711</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>As per the title: Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) plus Cyclophosphamide, Bortezomib, and Dexamethasone CyBorD in Previously Untreated and Relapsed Patients Pts with Multiple Myeloma MM</OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1839</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone CyBorD in Previously Untreated and Relapsed Patients Pts with Multiple Myeloma MM</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99972</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1840</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102993</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1841</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide; A Report on Early Efficacy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100273</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1842</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect MM Patient Registry</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100802</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1843</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Carfilzomib Weekly 20/56mg/m, Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100917</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1844</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100941</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1845</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101380</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1846</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Prognostic and Predictive Value of IKZF1 and IKZF3 Expression in T-Cells in Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101460</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1847</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101608</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1848</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Miroir: A National, Multicenter, Non-Interventional Study of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) in France</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101692</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1849</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Addition of Cyclophosphamide to Pomalidomide and Dexamethasone in Case of Suboptimal Response to Pomalidomide and Dexamethasone Alone in Relapsed and/or Refractory Multiple Myeloma: Results of the GMMG-Perspective Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102006</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1850</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102212</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>41</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1851</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events  Interim Results of the Myeloma UK Seven Biomarker Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104074</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>42</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1852</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104362</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>43</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1853</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Time to Improve Bortezomib and Lenalidomide Lines of Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100928</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>44</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1854</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106294</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>45</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1855</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prospective Study of Cardiac Events during Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106377</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>46</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1856</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab Combined with Pomalidomide and Dexamethasone (DPd) for Patients with Relapsed/Refractory Multiple Myeloma in a Single Institution</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106813</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ixazomib/Thalidomide/Dexamethasone is not an approved treatment regimen for multiple myeloma</OffLabelUseDescription>
<Order>47</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1857</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107369</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>48</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1858</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107469</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>49</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1859</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107783</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>50</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1860</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Statin Use Is Associated with Decreased Mortality in Multiple Myeloma- a SEER Medicare Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107927</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>51</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1861</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108087</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>52</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1862</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108407</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>53</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1863</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>An Open-Label Phase I/II Study of Carfilzomib, Bendamustine and Dexamethasone (CBD) in Newly Diagnosed Multiple Myeloma Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105296</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Bortezomib is not indicated in combination with doxoarubicin and dexamethasone (PAD) for newly diagnosed patients in EMEA</OffLabelUseDescription>
<Order>54</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1864</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105596</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>55</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1865</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105658</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>56</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1866</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Activity and Safety of Daratumumab Monotheray in Patients with Relapsed and Refractory Multiple Myeloma Requiring Dialysis: Preliminary Results of Spanish, Retrospective, Multicenter Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105804</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>57</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1867</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pembrolizumab (anti-PD-1) Treatment Increases Anti-Tumor Activities of XBP1/CD138/CS1-Specific Cytotoxic T Lymphocytes Against Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105895</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>58</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1868</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105952</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>59</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1869</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106099</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>60</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1870</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) Compared to Bortezomib-Dexamethasone (Vel-Dex) As Induction Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104389</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>61</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1871</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Pneumococcal Vaccination on Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104512</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Apixaban 2.5mg bd for thromboprophylaxis in myeloma patients treated with IMiD-containing regimens</OffLabelUseDescription>
<Order>62</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1872</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Apixaban Is Safe and Effective Thromboprophylaxis in Myeloma Patients Treated with Immunomodulatory Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104832</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Filanesib in combination with Pom-Dex for relapsed-refractory MM patients</OffLabelUseDescription>
<Order>63</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1873</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103400</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pembrolizumab (Anti-PD1 MoAb) as consolidation in MM</OffLabelUseDescription>
<Order>64</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1874</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Immune Predictors of Response to Pembrolizumab Monotherapy As Consolidation in Multiple Myeloma Patients: Results of the GEM-Pembresid Clinical Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103987</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>65</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1875</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Infections and Immune System Impairment in Multiple Myeloma: Increasing Frequency of Serious Complications in the Novel Agents Era. a Retrospective Real Life Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104282</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>66</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1876</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Enhancing Proteasome-Inhibitory Activity and Specificity of Bortezomib By Endocytosis-Mediated Uptake of CD38 Targeted Nanoparticles in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103255</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>67</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1877</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Significance of Plasmablastic Plasma Cells in the Era of Novel Agents in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100430</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>68</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1878</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Renal Response in Relapsedrefractorymultiplemyelomapatientswithsevere Renal Impairmentattreatmentinitiation: Intermediate Data of a Large,Observational, Prospectivestudy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99989</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>As per the title: Interim Safety Analysis of a Phase 2 Randomized Study of Daratumumab Dara, Lenalidomide R, Bortezomib V, and Dexamethasone d; DaraRVd vs. RVd in Patients Pts with Newly Diagnosed Multiple Myeloma MM Eligible for HighDose Therapy HDT and Autologous Stem Cell Transplantation ASCT</OffLabelUseDescription>
<Order>69</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1879</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Interim Safety Analysis of a Phase 2 Randomized Study of Daratumumab Dara, Lenalidomide R, Bortezomib V, and Dexamethasone d; DaraRvd Vs. Rvd in Patients Pts with Newly Diagnosed Multiple Myeloma MM Eligible for HighDose Therapy HDT and Autologous Stem Cell Transplantation ASCT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100289</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>70</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1880</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Carfilzomib-Based Combination Regimens Are Highly Effective Frontline Therapies for Multiple Myeloma and WaldenstrMs Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102518</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>71</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1881</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Novel Cardiac Biopsy Scoring Tool to Predict Clinical Outcomes in Cardiac Light Chain (AL) Amyloidosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100831</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>72</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1882</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Natural History and Outcomes of Asymptomatic IgM Monoclonal Gammopathy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103927</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>73</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1883</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101087</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Nelfinavir is an approved HIV protease inhibitor.
Overcome lenalidomide-resistance in myeloma in combination with lenalidomide/dexamethason</OffLabelUseDescription>
<Order>74</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1884</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II trial - SAKK 39/10</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101523</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>75</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1885</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Overall Survival of Relapsed/Refractory Multiple Myeloma Patients Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone: Results from the Phase 3 Endeavor Study According to Age Subgroup</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101691</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>76</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1886</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102151</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>77</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1887</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102409</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>78</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1888</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102870</Key_PaperID>
<Key_SessionID>11675</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>Daratumumab was used in this trial for on-label indications, but was infused at a rate not included in the manufacture's labeling.</OffLabelUseDescription>
<Order>79</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1889</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108694</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1890</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Novel Role for AMP-Activated Protein Kinase (AMPK)in Controlling T Cell Sensitivity to IL-6</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105289</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1891</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Role of Glucose Transporter 1 in Graft-Versus-Host Disease and Graft-Versus-Tumor Effect</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108187</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1892</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Novel Variant Ig Domain (vIgD) Proteins Generated Via Directed Evolution of Igsf Domains Have Therapeutic Efficacy in Animal Models of Graft Versus Host Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107698</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1893</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Application of 'Drug-Reversible' CAR-T Cells Directed Against Recipient Hematopoietic Cells As a Selective Conditioning Strategy for Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107817</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1894</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Non-Genotoxic Conditioning for Hematopoietic Stem Cell Transplant Using a Human Antibody Drug Conjugate Targeting C-KIT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106525</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1895</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prophylactic Effects of Recombinant Thrombomodulin Against Sclerodermatous Chronic Graft-Versus-Host Disease in a Rodent Model</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100846</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>RGI-2001 was injected into donor mice for mobilizing iNKT cells into the spleen. </OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1896</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Treatment of Donors with Liposomal Alpha-Galactosylceramide Results in the In Vivo Expansion of Invariant Natural Killer T Cells and Reduced Incidence of Acute Graft Versus Host Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101622</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1897</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Liposomal Alpha-Galactosylceramide Ameliorates Graft-Versus-Host Disease with Remaining Intensified GVL Gained By Dose-Reduction of Posttransplant Cyclophosphamaide after Haploidentical HSCT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103088</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1898</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Quantifying the Size and Diversity of the Human Alloresponse Via High-Throughput T Cell Receptor Sequencing</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103473</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1899</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone-Marrow Transplantation in Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103764</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1900</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>BET-Inhibition By JQ1 Promotes Proliferation and Self-Renewal Capacity of Hematopoietic Stem Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104383</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1901</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Single-Cell Transcriptomicsof Human Plasma Cells from HLA-Sensitized PatientsReveals Population Heterogeneity and Drug Resistance Adaptations</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105264</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1902</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>In Utero Hematopoietic Cell Transplantation of Lineage- c-Kit- Sca-1- Cells Is Responsible for Tolerance Induction</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100331</Key_PaperID>
<Key_SessionID>11676</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1903</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>O-Fucose and Fringe-Modified Recombinant Notch Peptides As Decoy Molecules to Promote Hematopoietic Progenitor Mobilization</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104562</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1904</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Complement Promotes Gvhdthrough Suppressing Autophagy in Recipient Dendritic Cells after Allogeneic Hematopoietic Cell Transplantation in Mice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104684</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1905</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Engineering Human Induced Pluripotent Stem Cells with Novel Chimeric Antigen Receptors to Generate Natural Killer (NK) Cell Cancer Immunotherapies with Targeted Anti-Tumor Activity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104214</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1906</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Gene Editing of TracLocus Utilizing Megatal Nucleases Increases Expression of Transgenic TCRs Delivered Via Lentiviral Vector-Mediated Gene Transfer</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105417</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1907</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluating Cyclin A1 As an Immunotherapeutic Target in Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106684</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The heterologous prime/boost vaccine design consists of a primer DNA-fusion vaccine (pDOM-HA-1) encoding the HLA-A2-restricted HA-1 peptide (VLHDDLLEA) followed by a booster MVA vaccine (MVA-HA-1) encoding the same HA-1 epitope. HA-1 is an ideal target for therapeutic strategies to enhance Graft versus Leukaemia (GvL) effects. Studies have shown that the presence of HA-1 specific cytotoxic T cells in patients following donor lymphocyte infusion for relapsed disease is associated with disease remission, and that these cells kill the allogeneic HA-1 expressing tumours in vitro.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1908</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Vaccination with a DNA and MVA 'Prime-Boost' Regimen Induces Strong CD8+ T-Cell Responses Against the Immunodominant Minor Histocompatibility Antigen, HA-1: Results of a First-in-Man Phase I Clinical Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105276</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1909</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Evidence That Deficiency of the Methylcytosine Dioxygenase TET2 Gene Promotes the Clonal Expansion and Therapeutic Efficacy of CD19-Directed T Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104520</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1910</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Drug-Regulated CAR Platform (DARIC) Induces Effective and Reversible Tumor Control In Vivo Using Non-Immunosuppressive Rapamycin Dosing</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107452</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1911</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Novel TGF-/Interleukin Receptor Signal Conversion Platform That Protects CAR/TCR T Cells from TGF--Mediated Immune Suppression and Induces T Cell Supportive Signaling Networks</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105759</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1912</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Novel Adapter Chimeric Antigen Receptor (aCAR) T Cells for Temporally Controllable Targeting of Single and Multiple Tumor Antigens</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104960</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1913</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Development of T-Cell Therapy By Exploiting Modified Antibodies Specific for A2/NY-ESO-1 for Refractory Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108122</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1914</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Engineering CD5-Targeted Chimeric Antigen Receptors and Edited T Cells for the Treatment of T-Cell Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100026</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1915</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Novel Method for Highly Sensitive Detection and Isolation of Chimeric Antigen Receptor and Cancer Associated Antigen-Expressing Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99734</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1916</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Co-Transplantation of CAR-Gene Engineered Precursor T Cells Leads to Suppressed T Cell Development and Increased NK Cell-Based CAR-Mediated Anti-Leukemic Activity</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101326</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1917</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Anti-CD123 CAR T-Cell Therapy for the Treatment of Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102497</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1918</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Perforin Is Dispensable for Anti-CD19 CAR-T Cell Cytotoxicity but Contributes to CAR-T Cell Contraction and Regulates Host Inflammatory Response</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103638</Key_PaperID>
<Key_SessionID>11677</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1919</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104408</Key_PaperID>
<Key_SessionID>11678</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1920</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Combination of GRO and AMD3100 Leads to Rapid and Robust Mobilization of Hematopoietic Stem Cells in Nonhuman Primates</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105827</Key_PaperID>
<Key_SessionID>11678</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1921</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bone Marrow Transplant Product Quality Has Decreased over Time, a Retrospective Examination of NMDP Collected Bone Marrow Products from 1994-2016</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104217</Key_PaperID>
<Key_SessionID>11678</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1922</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Plerixafor Overcomes Lenalidomide-Associated Stem Cell Collection Failure and Affects Collected Myeloid and Erythroid Progenitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107019</Key_PaperID>
<Key_SessionID>11678</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1923</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Human Papillomavirus (HPV)--Specific T-Cells Can be Generated from Unimmunized Donors for Third Party Cell Therapy of HPV-Associated Neoplasms</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107877</Key_PaperID>
<Key_SessionID>11678</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1924</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hierarchical Differences in Defensin Gene Expression in Plasmacytoid Dendritic Cells and Progenitor Cells from Five Different Hematopoietic Stem Cell Transplant Graft Types</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104439</Key_PaperID>
<Key_SessionID>11678</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ofatumumab in autologous stem cell collection</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1925</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ofatumumab, Very Late Antigen 4 (VLA4), and Dendritic Cells inPatients Undergoing Autologous Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (ASCT) for Relapsedb-Cell Non-Hodgkins Lymphomas (NHL)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104313</Key_PaperID>
<Key_SessionID>11678</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1926</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Novel High-Throughput Microfluidic Technology for Isolating Lymphocytes from Buffy Coats for Allogeneic Cellular Therapies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103440</Key_PaperID>
<Key_SessionID>11678</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1927</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Towards a Closed System for Extracting Lymphocytes from Whole Blood</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108345</Key_PaperID>
<Key_SessionID>11678</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1928</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Detection of Minimal Residual Disease in Autograft Is Prognostic of Survival Following Stem Cell Transplant in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105674</Key_PaperID>
<Key_SessionID>11678</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1929</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of Bone Marrow Derived MSC for Steroid Refractory Acute Gvhd Associates with Age and a Defined Molecular Profile of MSC Donors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103943</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1930</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mixed Chimerism of Bone Marrow CD34+ Sorted Cells after Matched or Haploidentical Allogeneic Stem Cell Transplantation for Myeloid Malignancies Is Predictive of Relapse</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108244</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1931</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pre-Transplantation Suppression of Haemopoiesis Is Associated with a High Rate of Macrophage Activation Syndrome in Ptcy Haploidentical Transplantation for Haemoglobinopathies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106930</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Eculizumab is a complement inhibitor approved fro atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. use of this agent in hematopoietic cell transplant-associated thrombotic microangiopathy is discussed here. </OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1932</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104923</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1933</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comorbidity-Driven Risk across Preparative Regimens for Allogeneic Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107100</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1934</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>T-Cell Replete Peripheral Blood Haploidentical Transplant Using Immunogenic Dose of Cyclophosphamide with Fludarabine and Melphalan Results in Enhanced Cytokine Release Syndrome (CRS) with Robust Immune Recovery and Low Relapse Rates</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103552</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1935</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Early HHV-6 Reactivation in CMV-Seronegative Cord Blood Transplant Recipients Is Associated with Inferior Relapse-Free and Overall Survival</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106413</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1936</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hospital in the Home Delivery of Conditioning Therapy for Allogeneic Haematopoietic Stem Cell Transplantation: A Novel Single Centre Patient Focused Approach</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108185</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1937</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Discover Trial: Application of the Karius Plasma Next-Generation Sequencing Test for Pathogen Detection in Allogeneic Stem-Cell Transplant Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103311</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1938</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Allogeneic Transplantation for TP53+ AML: Prognostic Factors for Survival</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106378</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1939</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Tacrolimus Pharmacogenetics and Steady State Drug Concentrations in Cancer Patients Undergoing Allogeneic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105686</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1940</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outpatient Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Is Feasible. Experience in a Single Latin-American Center</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108294</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1941</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Acute Kidney Injury before Day 90 Predicts for Both Early and Late Mortality after FluBu4</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107842</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1942</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Similar Survival but Increased Toxicity with a Sequential Versus Concurrent FluBu4 Regimen</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107891</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1943</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Use of Next Generation Sequencing and Single Nucleotide Polymorphism (SNP) Fingerprinting to Assess Post Transplant Engraftment Status</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104001</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1944</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Splenomegaly on Outcomes of Fully Matched Sibling Bone Marrow Transplant Among Children with Low Risk Thalassemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107115</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Leflunomide is an anti-rheumatoid arthritis drug, which is also effective as an anti-cytomegalovirus agent and has been used in CMV reactivations in post renal transplant setting.</OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1945</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Use of Leflunomide for Treatment of Cytomegalovirus Infection in Recipients of Allogeneic Stem Cell Transplant</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104266</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1946</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pooled Analysis of Day +100 Survival for Defibrotide-Treated Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) and Ventilator or Dialysis Dependence Following Hematopoietic Stem Cell Transplantation (HSCT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106674</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1947</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Analysis of Risk Factors Regarding Short- and Long-Term Mortality of Critically Ill Patients with Hematologic Malignancies or Following Stem Cell Transplantation Requiring Treatment on the Intensive Care Unit</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104250</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Defibrotide is approved for treatment of hepatic VOD/SOS with renal/pulmonary dysfunction post-HSCT in the United States and for treating severe hepatic VOD/SOS post-HSCT in the European Union. </OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1948</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Defibrotide in Pediatric Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Final Results from the Expanded-Access Program</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106799</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1949</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Novel Risk Factors for Epstein-Barr Virus (EBV) Reactivation and Post-Transplant Lymphoproliferative Disorder (PTLD) after Allogeneic Hematopoietic Stem Cell Transplant</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107513</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1950</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104378</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1951</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>HHV-6 Prophylaxis with Foscanet Improves Hematopoietic Engraftment after Umbilical Cord Blood Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103056</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1952</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clofarabine/Busulfan-Based Reduced Intensity Conditioning Regimens Provides Very Good Survivals in Patients Allografted in Remission for Acute Myeloid Leukemia: A Retrospective Study on Behalf of the SFGM-TC</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106406</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1953</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparative Evaluation of CD34+/CD33+/CD3+/CD19+ Microparticles in Peripheral Blood of Patients during Allogeneic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105694</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1954</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Variability of Nutritional Practices in Peritransplant Period after Allogeneic Hematopoietic Stem Cell Transplantation: A Survey By the Complications and Quality of Life Working Party of the EBMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103279</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1955</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Use of Busulfan in Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Adults: A Survey By the Complications and Quality of Life Working Party of the EBMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107666</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>CD34 selection with CliniMACS system for enrichment of graft boost</OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1956</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Treatment of Secondary Post-Transplant Engraftment Failure with Donor CD34+ Enriched, T-Cell Depleted Peripheral Blood Stem Cells Isolated By the Clinimacs System</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108644</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1957</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparable Clinical Outcomes between Haploidentical Family Donor and Other Donor Types after Hematopoietic Stem Cell Transplantation for Rare Pediatric Rare non-Malignant Diseases</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107474</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1958</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Clinical and Morphological Practices in the Diagnosis of Transplant-Associated Microangiopathy: A Study on Behalf of the Complications and Quality of Life Working Party of the EBMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102571</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1959</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Presence of Recipient CMV Immunodominant Human Leukocyte Antigen (HLA) Alleles Affect Outcomes after Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102804</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1960</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prospective Phase Study of Reduced Toxicity Conditioning Consisted of High Dose-Cytarabine, Fludarabine, Cyclophosphamide +/- Total Body Irradiation Followed By Allogeneic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100828</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1961</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Prognostic Impact of the Donor/Recipient CMV Serostatus in Patients with Different Chronic Hematological Disorders after Allogeneic Hematopoietic Stem Cell Transplantation: A Report from the Infectious Diseases Working Party of EBMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100954</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1962</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Durable Remission of Refractory and Advanced Stage Mycosis Fungoides/Sezary Syndrome (MF/SS) Utilizing an Outpatient Alemtuzumab and Fludarabine-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101200</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1963</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Analysis of Genetic Variants Related to the Hepatic Veno-Occlusive Disease in Pediatric Patients Receiving HSCT with Targeted Dose Busulfan Based Conditioning</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101304</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1964</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clofarabine-Based Reduced Intensity Conditioning Regimen with Post-Transplant Cyclophosphamide and Peripheral Stem Cell Graft in Adults with Myeloid Malignancies: Results of the Clo-Baltimore Regimen</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101444</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1965</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pre-Transplant Transferrin Saturation Levels As a Predictive Marker for Invasive Fungal Disease Following Allogeneic Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99639</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Gemcitabine, clofarabine and busulfan: High-dose use for transplantation for lymphoma. </OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1966</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle> Gemcitabine/Clofarabine/Busulfan: A New MyeloablativeReduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas  </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100084</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1967</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pretransplant Clinical Factors Can be Used to Predict the Risk of Cytokine Release Syndrome after Haploidentical Peripheral Blood Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100412</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1968</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Adverse Events Associated with Cryopreserved and Non-Cryopreserved Hematopoietic Stem Cell Infusion: A Prospective and Multicenter Surveillance Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101981</Key_PaperID>
<Key_SessionID>11679</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1969</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network Meta-Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102215</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4479</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chromosome 6 Loss-of-Heterozygosity in Pre-Transplant Blood Samples of Patients with Severe Aplastic Anemia Is Associated with Lower Risk of Acute Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100882</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4480</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Potential of Plasmatic Biomarkers to Predict Acute Gvhd Severity: A Validation Study in a Prospective Cohort of 177 Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100488</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>TBD - Blurb Needed</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4481</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ibrutinib Inhibits Cgvhd Pathogenic Pre-Germinal Center B-Cells and Follicular Helper Cells While Preserving Immune Memory and Th1 T-Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103945</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4482</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Donor-Derived Marrow Mesenchymal Stem Cells Co-Transplantation Following Haploidentical Hematopoietic Stem Cell Transplantation: A Multicenter Clinical Study in 35 Severe Aplastic Anemia Children</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99675</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4483</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105911</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4484</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against Adv, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103144</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4485</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Minnesota Refined Acute Gvhd Score Predicts Response to Initial Therapy, Survival and Non-Relapse Mortality after Haploidentical Transplantation with Post-Transplant Cyclophosphamide</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103560</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4486</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pediatric Acute Gvhd Grade, Risk Prediction and Response to Upfront Steroids in 370 Children Treated at the University of Minnesota</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104336</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4487</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of Somatic Mutations in Expanded T Cell Clones of Patients with Chronic Graft-Versus-Host Disease (GVHD)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100068</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4488</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Donor EBV-Positive Serostatus Increases the Risk of Chronic GvHD in Patients with Myeloid and Lymphoid Malignancies Other Than Acute Leukemia: Infectious Diseases Working Party EBMT Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104775</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4489</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Low Peripheral Blood Eosinophil Counts in Patients with Acute Graft-Versus-Host-Disease Prior to Systemic Corticosteroid Therapy Is Associated with Poor Prognosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107402</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4490</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Second Line Systemic Treatments Including Extracorporeal Photopheresis Among Patients with Chronic Graft Versus Host Disease (cGVHD) in the United States, 2009-2016</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107175</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4491</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Early and Profound Exhausted Phenotype of Central Memory and Memory Stem T Cells in the Bone Marrow of AML Patients Characterizes and Predicts Relapse after Allo-HSCT</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100326</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4492</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Graft-Versus-Host Disease Prophylaxis with Posttransplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106240</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4493</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Risk Factors for Occurrence and Outcome of Acute Graft Versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant: Analysis of 7 Year Health Care Utilization Project Data</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108409</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4494</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Incidence of CMV Reactivation after Haploidentical Donor Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide, and Its Impact on Transplant Outcomes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103281</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4495</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MSCs Derived from Human Amnion Possess a Higher Proliferation Activity and Clearer Stem Cell PropertiesThan from Bone Marrows and They Exhibit Similar Immunosuppressive Ability in Vitro</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108086</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4496</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Analysis of Anti-CMV T-Cell Immunity and CMV Reactivation after Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104394</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4497</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Level of IL-2-Receptor and of TIM-3 in Plasma at Day +18 after Allogeneic Transplantation Can Identify Early Patients at Risk for Treatment Related Mortality</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104490</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4498</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pro-Tmune, the Next Generation Graft for Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety and Efficacy Data</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105542</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4499</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>cGvHD - CIBMTR Risk Score Stratification in 207 Consecutive Adults after Unmanipulated PBSC Haploidentical Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108343</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4500</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>the Efficacy of Extra-Corporal Photopheresis for Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: A Retrospective, Matched, Case-Control Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106705</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4501</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mass Cytometry Reveals the Broad Effect of CMV Reactivation on Adaptive and Innate Immune Recovery in HSCT Patients Undergoing Adoptive T Cell Therapy for Viral Infections</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105286</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4502</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Landscape of Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation Is Superdominated By Distinct T Cell Populations Bearing T-Cell Receptor Clonotypes Shared Among Different Individuals</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102282</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4503</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Breath Analysis in Gastrointestinal Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation (HCT)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103478</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4504</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Outcome of Patients Receiving Extracorporeal Photopheresis for Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies: Results from an Observational Study on 106 Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100553</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4505</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of T Cell Subsets and Cytokines between Steady-State and G-CSF-Primed Bone Marrow and Its Association with Graft-Versus-Host-Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107570</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4506</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Day 90 Post-Allogeneic Hematopoietic Cell Transplantation T Cell Receptor Diversity Level Correlates with Risk of Relapse in Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104158</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4507</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Investigating the Relationship between Graft-Versus-Host Disease Incidence and Increased Risk of Death within Three Years after Allogeneic Hematopoietic Stem Cell Transplantation in Patients Receiving Antibiotics Containing Activity Against Obligate Anaerobes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100061</Key_PaperID>
<Key_SessionID>11680</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4508</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of the Use and Type of Antibiotics on Acute-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100330</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1991</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Sarcopenia Is a Clinically Relevant and Independent Predictor of Adverse Outcomes after Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107843</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1992</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph+ Acute Lymphoblastic Leukemia (ALL) Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107337</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>CD19 CAR T-cell therapy for relapsed CD19+ disease post-allograft.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1993</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Automated Manufacture of CAR19 Donor Lymphocytes Incorporated into an Escalated Dose DLI Protocol: Preliminary Results from the CARD Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104247</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1994</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Autoimmune Cytopenias (AIC) Following Allogeneic Haematopoietic Stem Cell Transplant for Acquired Aplastic Anaemia: A Joint Study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106077</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1995</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Melphalan-Based Regimen Is a Safe and Effective Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation in Older Adults (70 years) with Hematological Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107132</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1996</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Analysis of the Hematopoietic System in Long-Term Survivors of Allogeneic Stem Cell Transplantation and Their Respective Donors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102445</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1997</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pre-Transplant Exhausted Marrow Infiltrating T Lymphocytes in MRD Negative Patients with Acute Leukemia Predict Early Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106864</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1998</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pre-Transplant Minimal Residual Disease Determined By Multiparameter Flow Cytometry Is Better Than RQ-PCR to Predict the Outcomes of Ph+ALL Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108733</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1999</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Increased Proportion of Sickle Cell Disease Patients Develop Cardiovascular Disease Risk Factors Following Successful Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102078</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2000</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Minimal Residual Disease after Allogeneic Stem Cell Transplantation Was Associated with Poor Outcomes in Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103158</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2001</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Benefits Patients with Persistent Disease and Results in a High Rate of Residual Disease Clearance</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100460</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2002</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Prophylactic Modified Donor Lymphocyte Infusion after Allogeneic Peripheral Blood Stem Cell Transplantation for Very High-Risk Hematological Malignancies: Low Incidence of Relapse without Increasing the Risk of Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108642</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2003</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Consolidative CD8+ Memory T-Cell Donor Lymphocyte Infusion Augments Donor Chimerism with a Low Risk of Gvhd Following Matched Related Donor Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101233</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2004</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Osteonecrosis after Allogeneic HSCT in Children with High-Risk or Relapsed ALL Treated in the ALL-SCT 2003 Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103059</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2005</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104371</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2006</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Profile of Posterior Reversible Encephalopathy Syndrome(PRES)-Related Epilepsy in Patients Following Haploidentical Hematopoietic Stem Cell Transplantation:a 10-Year Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100515</Key_PaperID>
<Key_SessionID>11681</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2007</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107365</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2008</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105251</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2009</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Role of Upfront Autologous Hematopoietic Cell Transplantation in the Treatment of Mantle Cell Lymphoma, a Population Based Study Using the National Cancer Data Base (NCDB)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107599</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2010</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108283</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2011</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Analysis and Outcomes of Non-Utilization of Collected Peripheral Blood Stem Cell (PBSC) for Autologous Stem Cell Transplants (ASCT) in Transplant Eligible Patients Undergoing Treatment of Multiple Myeloma (MM)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108421</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2012</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Combined Immune Score of Lymphocyte to Monocyte Ratio and Immunoglobulin Levels Predicts Progression-Free Survival of Myeloma Patients after Autologous Transplant</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107363</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2013</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100124</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2014</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Role of High Dose Chemotherapy and Autologous Stem Cell Transplant in Relapsed Ewing's Sarcoma - a Systematic Review</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101048</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2015</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101173</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2016</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101715</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2017</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102084</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2018</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkins Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102921</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2019</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Duration of Induction Therapy on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103051</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2020</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Hematopoietic, Immune Recovery and Outcomes after Autologous Stem Cell Transplantation Following Plerixafor Plus G-CSF Versus Chemotherapy and G-CSF Based Mobilization in Pediatric Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103270</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>ixazomib for autologous stem cell transplantation</OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2021</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyLome (IFM)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103527</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Bendamustine incorporation in the conditioning regimen prior to autologous hematopoietic stem cell transplantation for the treatment of lymphoma.</OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2022</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103646</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2023</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104297</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2024</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Revised-International Staging System (R-ISS) Is Independently Predictive and Prognostic for Early Relapse (&lt;24 months) after Upfront Autologous Hematopoietic Cell Transplantation (AHCT) for Newly Diagnosed Multiple Myeloma (MM</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105227</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2025</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106319</Key_PaperID>
<Key_SessionID>11682</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2026</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Indications for Hematopoietic Stem Cell Transplantation in Patients with Waldenstroms Macroglobulinemia: A Consensus Project of the EBMT Lymphoma Working Party (LWP)/ European Consortium for Waldenstrom's Macroglobulinemia (ECWM)/International Waldenstrom's Macroglobulinemia Foundation (IWMF)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103086</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2027</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Identical Siblings Versus Unmanipulated Haploidentical Donors in Relapsing or Refractory Acute Myeloid Leukemia: A Retrospective Study from the ALWP of the EBMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100848</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2028</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Validation of Scores Predicting Non-Relapse Mortality in Patients with Myelodysplastic Syndrome: A Study on 1276 Patients on Behalf the Chronic Malignancies Working Party of the EBMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101436</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2029</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Donor Type in Patients with Acute Myeloid Leukemia Given Allogeneic Hematopoietic Cell Transplantation after Low-Dose TBI Based Regimen: A Study from the Acute Leukemia Working Party of the EBMT and Eurocord</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102626</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2030</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Follow-up on Adult Patients with Philadelphia-Chromosome Positive Acute Myeloid Leukemia Who Were Treated with Interim Imatinib Followed By Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103014</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2031</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Prognostic Impact of Minimal ResidualDisease on Risk of Progression and Progression Free Survival in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103242</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2032</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Poor Outcome of Domino Hematopoietic Stem Cell Transplantation in Humans  an International Case Series</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103971</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2033</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Fludarabine/Melphalan 100 Conditioning Therapy Followed By Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104538</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2034</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Outcomes of Post-Transplant Cyclophosphamide between Haplo-Identical and Matched/Mismatched Donor Peripheral Blood Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105712</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2035</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Haploidentical Hematopoietic Stem Cell Allogeneic Transplantation with High Dose Post Transplantation Cyclophosphamide for Patients over 60 Years of Age</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106178</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Bendamustine in allogeneic stem cell transplantation conditioning.</OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2036</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results </PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106841</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2037</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>In AML RAS pathway Mutations Confer Worse Outcome in IDH1 and IDH2 Mutated AML Patients Receiving Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107305</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2038</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Allogeneic Hematopoietic Stem Cell Transplantation for Patients over 60 Years with Acute Myeloid Leukemia: A Single Center Donor Comparison</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107886</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2039</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Mobilized Peripheral Blood Stem Cells Versus Unmanipulated Bone Marrow Haploidentical Transplantation Using Post-Transplant Cyclophosphamide: A Retrospective Study of SFGM-TC in 176 Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108862</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2040</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Allogeneic Haematopoietic Cell Transplantation in Aplastic Anaemia: A Dataset of 240 Cases</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100390</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2041</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The European Group for Blood and Marrow Transplantation Risk Score Predicts Outcome of Elderly Patients with Allogeneic Stem Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101136</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2042</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>An Artificial Intelligence Approach for Predicting Allogeneic Hematopoietic Stem Cell Transplantation Outcome By Detecting Pre-Transplant Minimal Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry Data</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102432</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2043</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Selecting Optimal Cord Blood Units: The Limitations of Cell Dose</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102725</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2044</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Patient-Based Prediction Algorithm of Relapse after Allo-HSCT for Acute Leukemia Using Machine Learning Approach</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103293</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2045</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Effect of Sorafenib Therapy on the Outcome of Acute Myeloid Leukemia with FLT3-ITD Undergoing Allogeneic Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103880</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2046</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Haplo-Identical Stem Cell Transplantation for Patients with Multiple Myeloma Who Relapsed after Autografting. a Study from the Cmwp of EBMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104225</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2047</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Current IST-Free/Relapse-Free Survival As a Surrogate Estimate of OS after Allotransplant for Acute Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104833</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2048</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105319</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2049</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Unrelated Cord Blood Transplantation for Familial Hemophagocytic Lymphohistiocytosis: Risk Factors and Long Term Follow-up. an Analysis on Behalf of Eurocord, Cord Blood Committee of Cellular Therapy and Immunobiology Working Party of the EBMT and Inborn Errors Working Party of the EBMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105747</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2050</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Myeloablative Hematopoietic Cell Transplantation (HCT) for Low and Intermediate Disease Risk Index Myeloid Malignancies Results in Better Outcomes Compared to Reduced Intensity HCT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106835</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2051</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>First-Line Choice for Severe Aplastic Anemia in Children: Transplantation from a Haplo-Identical Donor Versus Immunosuppressive Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107292</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2052</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Challenging the Prognostic Value of MRDSequential Tumor-Ablative Conditioning of FA5-Bucy for Ph-Positive Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107957</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2053</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Pediatric Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108249</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2054</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Outcomes after Matched Sibling, Unrelated, or Haploidentical Allogeneic Hematopoietic Cell Transplantations (HCT). a Real World Experience of Gatmo (Grupo Argentino de Trasplante de Mdula sea)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108595</Key_PaperID>
<Key_SessionID>11683</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2055</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Risk Factors Predicting Graft-Versus-Host Disease and Relapse-Free Survival (GRFS) after Allogeneic Hematopoietic Stem Cell Transplantation in Relapse/Refractory Non-Hodgkin Lymphomas</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106110</Key_PaperID>
<Key_SessionID>11684</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2056</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Factor IX with Minimal Immune Response</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107155</Key_PaperID>
<Key_SessionID>11684</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2057</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Role of Transgene Levels in Immune Tolerance Induction after AAV Gene Therapy in Hemophilia B Canine Models</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104012</Key_PaperID>
<Key_SessionID>11684</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2058</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Predictable Protein Expression with Enhanced Factor IX Activity Following Administration of a Modified AAV5-hFIX Vector to Nonhuman Primates</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105572</Key_PaperID>
<Key_SessionID>11684</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2059</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Long Term Follow up after Adoptive Transfer of CD19-Specific CAR+T Cells Genetically Modified Via Non-Viral Sleeping Beauty System Following Hematopoietic Stem Cell Transplantation (HSCT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105836</Key_PaperID>
<Key_SessionID>11684</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2060</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Shortening the Time to Manufacture CAR+ T Cells with Sleeping BeautySystem Supports T-Cell Engraftment and Anti-Tumor Effects in Patients with Refractory CD19+Tumors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101371</Key_PaperID>
<Key_SessionID>11684</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2061</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Synergistic T-Cell Signal By CD79A/CD40 Costimulatory Endodomain Enhances CD19 Chimeric Antigen Receptor T-Cell Proliferation and Survival</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106730</Key_PaperID>
<Key_SessionID>11684</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2062</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>New Antibcma-CAR for Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103142</Key_PaperID>
<Key_SessionID>11684</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2063</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Platelet-Targeted Gene Therapy of Hemophilia a Using Hematopoietic Stem Cells Derived from Genome-Edited Induced Pluripotent Stem Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101890</Key_PaperID>
<Key_SessionID>11684</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2064</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Engineering Precision Medicine to Enhance Graft-Versus-Lymphoma Activity:Hematopoietic Stem Cells Modified with Chimeric Antigen Receptors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100953</Key_PaperID>
<Key_SessionID>11684</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2065</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Megakaryocytic Microparticles for Gene- and Cell- Therapies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108321</Key_PaperID>
<Key_SessionID>11684</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2066</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Potential Therapy for Beta-Thalassemia (ST-400) and Sickle Cell Disease (BIVV003)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108007</Key_PaperID>
<Key_SessionID>11684</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2067</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Precise Tool to Edit Human Hematopoietic Stem Cells at High Efficiency and Decipher and Optimize the Different Double Strand Break Repair Outcomes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107419</Key_PaperID>
<Key_SessionID>11685</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2068</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100972</Key_PaperID>
<Key_SessionID>11685</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2069</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Novel Human Anti-HLA-Bw4 and B61 Monoclonal Antibodies Kill Malignant B Cells Via CDC/ADCC While Sparing Normal Peripheral Blood Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102258</Key_PaperID>
<Key_SessionID>11685</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2070</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Development of Novel Proteasome-HDAC6 Hybrid Inhibitors for Resistant ALL Phenotype</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104138</Key_PaperID>
<Key_SessionID>11685</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2071</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical BET Inhibitor RG6146 Demonstrates Potent and on-Target Activity in Pre-Clinical Models of Hematological Malignancy and Combines with Anti-CD20 and BCL-2 Inhibition to Provide Superior Efficacy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104609</Key_PaperID>
<Key_SessionID>11685</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2072</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of WHSC1 As a Promising Therapeutic Strategy in Childhood ALL</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105619</Key_PaperID>
<Key_SessionID>11685</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2073</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106737</Key_PaperID>
<Key_SessionID>11685</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2074</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Precision Chemotherapy for Patients with Acute Myeloid Leukemia Using the Ichemo Prediction and Optimization Tool</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108099</Key_PaperID>
<Key_SessionID>11685</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2075</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Exploiting an Asp-Glu Switch in Glycogen Synthase Kinase 3 to Design Paralog Selective Inhibitors for Acute Myeloid Leukemia Treatment</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107059</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2076</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Major Bleeding and Bleeding Events Requiring Hospitalization in the First Three Months Following Vitamin K Antagonists Therapy in Patients with First Venous Thromboembolism</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107106</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2077</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Targeting Transition:a NovelPartnership withFamily Medicine to Enhance Quality of Care and Outcomes for Adolescents and Young Adults with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107015</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>The thrombopoietin receptor agonist (TPO-RA) eltrombopag was approved for the treatment of chronic immune thrombocytopenia (cITP), &gt;12 months after initial ITP diagnosis.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2078</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Treatment Patterns Among Patients with Newly Diagnosed, Persistent, and Chronic Immune Thrombocytopenia (ITP) Treated with Eltrombopag in Real World Setting in the US</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104653</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2079</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Supplemental Oxygen during Air Travel in Sickle Cell Disease Common Clinical Practices</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108524</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2080</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Factors Related to Iron Chelation Therapy Adherence in Young Adults with Thalassemia: A Framework from the Patient Perspective</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105578</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2081</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Developing a Problem-Solving Intervention to Address Methods of Self-Management and Transition Challenges in Adolescents with Sickle Cell Disease: A Qualitative Investigation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107384</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2082</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Evidence-Based Diagnosis of Venous Thromboembolism: A Systematic Review</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104396</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off-label use of KCentra and NovoSeven will be discussed with regard to complex coagulation factor management</OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2083</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Implementation and Impact of a Multidisciplinary Coagulation Factor Stewardship Program</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107696</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2084</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Do Sequential Compression Devices Prevent Venous Thromboembolism in Hospital Inpatients?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108555</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2085</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Recent Trends in the Incidence of Heparin-Induced Thrombocytopenia: Data from the 2009-2014 National Inpatient Sample</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108549</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2086</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Recent Trends in the Incidence and Outcomes of Thrombotic Thrombocytopenic Purpura in the United States: Data from the 2009-2014 National Inpatient Sample</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105347</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2087</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Real World Outcomes of Ferric Carboxymaltose and Ferumoxytol Iron Replacement Therapy: A Retrospective Analysis of Electronic Health Records</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105594</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2088</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>US Economic Impact of Recombinant FVIII Vs Plasma-Derived FVIII/VWF in Previously Untreated Hemophilia a Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106638</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2089</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Novel System for Newborn Screening of Thalassemia and Hemoglobinopathies Using Capillary Electrophoresis Is Superior Than Isoelectric Focusing</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106987</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2090</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cost Reduction with Enoxaparin Vs. Heparin for Prophylactic and Therapeutic Use: A Retrospective Analysis in a Community Hospital Setting</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108189</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2091</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99696</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2092</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Implementation of Electronic Health Record Tools for Prevention of Venous Thromboembolism in Hospitalized Children with Cancer and Blood Disorders</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100142</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2093</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Increasing Ideal Coagulation Factor Dosing in the Pediatric Emergency Department: A Quality Improvement Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100629</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2094</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Direct Medical Care Cost Associated with -Thalassemia Care in Turkey</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101255</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2095</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical and Economic Burden of Transfusion-Dependent -Thalassemia in Adult Patients in the United States</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101630</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2096</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Catheter-Related Thrombosis Incidence and Risk Factors in Adult Cancer Patients with Central Venous Access Devices</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102275</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2097</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A New Era in Malaria Diagnosis and Surveillance Using an Automated Analyzer</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102501</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2098</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Quality of Care in United States Children with Sickle Cell Anemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102945</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2099</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Optimizing Iron Overload Screening in a Pediatric Center for Cancer and Blood Disorders</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103408</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2100</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Bleeding Events and Obstetric Complications of Pregnancy in Hospitalized Patients with Hemophilia: Results from Nationwide Inpatient Sample Database 2003-2011</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104058</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>10 minutes administration is off label.</OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2101</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Reduction in Intravenous Infusion Duration of Enzyme Replacement Therapy to Ten Minutes with Velaglucerase Alfa in Adult Patients with Type 1 Gaucher Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104176</Key_PaperID>
<Key_SessionID>11686</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2102</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical and Germline Risk Factors for the Occurrence of Multiple Treatment Toxicities during Childhood Acute Lymphoblastic Leukemia (ALL) Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107035</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2103</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparative Efficacy and Safety of Gemtuzumab Ozogamicin (GO) Plus Daunorubicin-Cytarabine Combination and Comparators As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104143</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2104</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Differences in Infection Prophylaxis between Pediatric AML Study Groups within the International BFM Study Group</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105143</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2105</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Meta-Analysis of the Prognostic Accuracy of Clinical Prediction Rules for Post-Pulmonary Embolism Mortality in Patients with Cancer</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107245</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Hydroxyurea for managing polycythemia vera
Peginterferon for managing polycythemia vera and myelofibrosis</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2106</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Variance between Experts and Oncology Healthcare Providers in Managing Polycythemia Vera and Myelofibrosis: Analysis of an Online Treatment Decision Support Tool</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105927</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2107</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Utilization of Palliative Care Among Patients with Hematologic Malignancies: An Extensive National Analysis to Define Trends and Patterns</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102982</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2108</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Costs and in-Hospital Mortality Rates in Autologous Stem Cell Transplant for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample (NIS) Database</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102413</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2109</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Health Care Utilization and Cost of Allogeneic Hematopoietic Cell Transplantation in Children with Malignant and Non-Malignant Diseases</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106999</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2110</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Acute Lymphoblastic Leukemia in the Elderly: Trends in Mortality Rates, Hospital Cost, Lengthof Stay, and Complication Rates in Patients Aged 60 and Older</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104366</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2111</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Front-Line Ibrutinib or Chemoimmunotherapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107777</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2112</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Collaborative Physician-Pharmacist Multiple Myeloma Clinic Improves Guideline Adherence and Prevents Treatment Delays</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106255</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2113</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Treatment Patterns and Survival Outcomes in Latin American Patients with Newly Diagnosed Multiple Myeloma: A Retrospective Medical Chart Review Study, 2008-2016</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107973</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2114</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Counseling Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Regarding Expected Survival with Azacitidine (aza) Therapy: Are We Using Accurate Estimates?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108850</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2115</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Patient Interest in and Feasibility of a Mobile Health App to Support Patients Undergoing Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105714</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2116</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Collaborative Risk-Adapted Treatment for Pediatric Acute Lymphoblastic Leukemia in Mexico</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108632</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2117</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Use of Herpes Zoster Prophylaxis in Myeloma Patients Treated with Proteasome Inhibitors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106716</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2118</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Real-World Occurrence of Symptoms and Toxicities and Associated Cost Implications in Acute Myeloid Leukemia (AML) Treatment Episodes: A Retrospective Database Analysis in the US</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107288</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2119</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Disease Factors and Not Comorbidity Drives Clinical Decisions in Elderly Patients with Follicular Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103349</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2120</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Financial Incentives and Rituximab Maintenance: Association of Treatment Location with Prolonged Maintenance in Non-Hodgkin Lymphoma Patients Treated in the United States</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99999</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2121</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Longer Length of Stay and No Chemotherapy Is Associated with Greater Likelihood of Death during Hospitalization in Patients with Diffuse Large B-Cell Lymphoma: An Analysis from the National Inpatient Sample (NIS)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100545</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2122</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Chronic Lymphocytic Leukemia Patient Reported Outcomes and Quality of Life: Findings from the Cancer Experience Registry</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101764</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2123</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Out-of-Pocket (OOP) Costs Associated with Tyrosine Kinase Inhibitors (TKIs) Used for the Treatment of US Patients Diagnosed with Chronic Myeloid Leukemia (CML): A US Retrospective Claims Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100944</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2124</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Quality Improvement Initiative Advancing CLL Care Practices across Four US Health Systems</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101457</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2125</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Collaborative Pharmacist-Physician Multi-Professional Pre-Chemotherapy Assessment in Hematology Cancer Patients Is an Efficient &amp; Cost-Effective Model for Service Delivery of Outpatient Systemic Anti-Cancer Therapy (SACT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101739</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2126</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Economic Analysis of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Remission Induction Chemotherapy from a Hospital Management Perspective</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102037</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2127</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Distribution of Lymphomas in Mexico: A Descriptive Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102266</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2128</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Real World Clinical and Economic Burden of Patients with Hodgkin Lymphoma (HL) Who Fail Frontline (FL) Therapy in the US</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102406</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2129</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>AMultidisciplinary Effort to Decrease Time from Admission to Chemotherapy on an Inpatient Oncology Unit</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102827</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2130</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Clinical Benefits of Achieving Deep Remission to Second-Line Therapy in Patients with Relapse/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)  a Real-World Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102866</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>As this is a Rituximab pharmacovigilance work, actual use is recorded and therefore some off-label  utilization detected</OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2131</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Post-Marketing Surveillance with a Biosimilar of Rituximab (Novex) in Argentina</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103823</Key_PaperID>
<Key_SessionID>11687</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2132</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Diagnostic Pathways of Myeloma Patients Presenting to Hospital Care and Relationship to End Organ Damage: An Analysis from the Teamm (Tackling EArly Morbidity and Mortality in Myeloma) Trial in 977 Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101557</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2133</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mortality Among Californias Sickle Cell Data Collection Cohort, 2005-2015</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104765</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2134</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Is Sepsis a Risk Factor for Bleeding in Adults with Hematologic Malignancies?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104056</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2135</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Validation of the Modified Self-Administered Pediatric Bleeding Assessment Questionnaire (Self-PBQ) in Children Aged 8-12 Years</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102759</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2136</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Health-Related Quality of Life and Satisfaction of Children with Severe Hemophilia a Treated with Turoctocog Alfa Pegol (N8-GP)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108623</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2137</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Apixaban and Rivaroxaban for the Treatment of Upper Extremity Deep Vein Thrombosis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100337</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2138</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Assessment of Health-Related Quality of Life in Adults Hospitalized with Sickle Cell Disease Vaso-Occlusive Crisis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103533</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2139</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Delayed Anticoagulant Initiation in Patients with Sickle Cell Disease and Newly Diagnosed Venous Thromboembolism: A Population-Based Cohort Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105502</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2140</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Provider Perspectives of Necessary Factors in Sickle Cell Disease Health Care Transition: Results from an Online Survey</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106226</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2141</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Sexual Health in Patients with Hemophilia; The Insights from the Patient Reported Outcomes, Burdens and Experiences (PROBE) Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105406</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2142</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Does Treatment Satisfaction Influence Adherence to Treatment?:Impact of AF Patients Treatment Satisfaction on Adherence to Oral Anticoagulation Treatment</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106277</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2143</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Association of Monoclonal Gammopathy with Progression to End-Stage Renal Disease Among a National Cohort of US Veterans</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106934</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2144</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Identification of Cases with Major Hemorrhage in Routinely Recorded Healthcare Data</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105672</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2145</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Direct Oral Anticoagulants in Anti-Phospholipid Syndrome</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103874</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2146</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107717</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2147</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>In Hospital Burden of Venous Thromboembolism in Cancer: A 13 Year Analysis</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107523</Key_PaperID>
<Key_SessionID>11688</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2148</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Disseminated Intravascular Coagulation and Annual Trends in in-Hospital Outcomes Based on Etiology from 2002 to 2014</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104220</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2149</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Survival Trends in Young Patients with Multiple Myeloma: Focus on Racial-Ethnic Minorities</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106768</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The abstract discusses maintenance treatment with any product in the US and Canada. In Canada, there are no licensed indications for this purpose. In the US, there were no licenced indications at the start of the study, although lenadidomide has recently been approved by the FDA.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2150</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Active Maintenance Treatment (MT) Compared to No MT on the Quality of Life (QoL) of Patients with Multiple Myeloma (MM) Following First Autologous Stem Cell Transplant (ASCT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99790</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2151</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Decreased Early Mortality in Young Adults with Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108425</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2152</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Second Primary Malignancies in Patients with Non-Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102932</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2153</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Venous Thrombotic Events Are Independently Associated with Inferior Survival Outcome in Pediatric Cancer Patients: A Multicenter Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104582</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2154</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Age (75 years) and Not Choice of First-Line Therapy Improves Overall Survival in Transplant Ineligible NDMM Patients: Results from a Large UK Real-World Dataset</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104470</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2155</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Healthcare Consumption Amongst Older Patients with High Risk AML Treated with Hypomethylating Agents Is Similar to That of Patients Receiving Induction Chemotherapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100662</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2156</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Trends and Outcomes in the Use of Radiation Therapy and Chemotherapy for the Treatment of Hodgkins Lymphoma: An Analysis from SEER Database 1985-2014</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104312</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Both azacitadine and decitabine are not indicated for AML treatment by FDA. But they are both listed at the NCCN guideline</OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2157</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Utilization of Hypomethylating Agents and Associated Outcomes in Elderly Acute Myeloid Leukemia (AML) Patients: A Population Based Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105848</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2158</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Factors Associated with Non-Melanoma Skin Cancer (NMSC) Among Chronic Lymphocytic Leukemia (CLL) Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106304</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2159</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Autoimmune Diseases and Prognosis across Lymphoma Subtypes</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108054</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2160</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Successful Implementation of a Blood Management Program for Patients with Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100067</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2161</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Myeloproliferative Neoplasms and Depressive Symptoms, Diagnosis, and Associations</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104307</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2162</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Duration Matters: Impact of Time from Diagnosis on Symptoms in Patients with Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105444</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2163</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Deutsche Studiengruppe Multiples Myelom (DSMM) Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 MM Patients with Extensive, Complete and Repeated and Long-Term Follow-up</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107528</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2164</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Social Support Source and Effectiveness Are Associated with Distress Among Hematopoietic Stem Cell Transplant Survivors Experiencing Stress Due to Negative Life Events after Treatment</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108245</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2165</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Survival of Chronic MyeloidLeukemiaPatients in Comparison to General Population in the Tyrosine Kinase InhibitorsEra: A US Population Based Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104586</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2166</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Cost Effectiveness of Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL) after Failure of Autologous Stem Cell Transplantation (ASCT) and Treatment with Brentuximab Vedotin (BV) Treatment in Australia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106076</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2167</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108655</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2168</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Quantitative Testing of the Myelofibrosis Symptom Assessment Form Version 4.0, a Harmonized Patient-Reported Outcome Measure for Collecting Key Secondary Endpoint Data in Myelofibrosis Clinical Trials</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102854</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2169</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Patient-Reported Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab Monotherapy, Results of a Phase 2 Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106092</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2170</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Using Big-Data to Evaluate in-Hospital Morbidity and Mortality in Systemic Light Chain (AL) Amyloidosis after High Dose Therapy and Autologous Stem Cell Transplant (HDT/ASCT)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102981</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2171</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Multiple Myeloma Patients and Risk of Skeletal Related Events  Real-World Evidence in US Oncology Clinics</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104794</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2172</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Low Risk for Viral Reactivation during Induction for Acute Myeloid Leukemia in Hepatitis B Silent Carriers Who Are Negative for Hepatitis B Surface Antigen</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106904</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2173</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Patient-Reported Distress in Hodgkin Lymphoma Patients on Active Therapy Vs. Long-Term Survivors</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103508</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2174</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Risk of Herpes Zoster in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine or Bendamustine</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104263</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2175</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Impact of Earlier Vs. Later Monitoring on Disease Progression and Economic Outcomes Among Patients with Chronic Myeloid Leukemia in the Real-World Setting</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104450</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2176</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>HM-PRO: A Novel Patient-Reported Outcome Measure in Hematological Malignancy for Use in Clinical Practice</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105935</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2177</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Similar Survival for African American and Caucasian Multiple Myeloma Patients Receiving Auto-SCT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105673</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2178</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Comparative Analysis of Gene Expression Status to Predict Response to Initial Multiple Myeloma Treatment: Utility of the Mmrf Commpass Database in Validating Historical Findings</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107252</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2179</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Association between Patient-Reported Outcomes and Physical Activity Measured on the Apple Watch in Patients with Hematological Malignancies</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101005</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2180</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Quality of Life and Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Non-Interventional Study with NEPA  a Netupitant/Palonosetron Fixed Dose Combination</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103676</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2181</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Is Quality of Life (QOL) Predictive for Clinical Response in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients Treated with Dasatinib?</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104194</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2182</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Patient-Reported Disease Burden in the Elderly Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105628</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2183</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Healthcare Burden of Patients with Follicular Lymphoma (FL) in Routine Clinical Care in the United States</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106117</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2184</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Survival Outcomes after First-Line Therapy in Follicular Lymphoma Patients Treated with Bendamustine and Rituximab Vs Other Rituximab Combinations in the United States</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106225</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2185</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Economic Impact and Healthcare Utilization in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Routine Clinical Care in the United States (US)  a Claims Database Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105982</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2186</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mut and FLT3-Wt Acute Myeloid Leukemia: A Multi-Country Medical Chart Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100222</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2187</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Multi-State Model for Follicular Lymphoma in Patients with Early Progression to Second Line Therapy</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101259</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2188</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Treatment Sequence of Lenalidomide (LEN) and Hypomethylating Agents (HMAs) and the Impact on Clinical Outcomes for Patients with Myelodysplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102253</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>41</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2189</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma Post Autologous Stem Cell Transplant: A Comparison of Real-World Treatment Outcomes and Costs</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102429</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>42</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2190</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102494</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>43</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2191</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Socioeconomic Outcomes Among Long-Term Childhood Acute Lymphoblastic Leukemia Survivors Enrolled between 1971 and 1998 in the EORTC Children Leukemia Group Trials 58741, 58831/2 and 58881</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104288</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>44</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2192</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Updated Population Based Survival Analysis in Patients with Chronic Myeloid Leukemia: Increased Survival but Continued Disparities for Older Patients</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106221</Key_PaperID>
<Key_SessionID>11689</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>45</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>2193</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Nutrition and Supplement Use Characteristics in the Myeloproliferative Neoplasms: Results from the Nutrient Survey</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109029</Key_PaperID>
<Key_SessionID>11713</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	1:20 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:05 PM
 
</PaperStartTime>
<PaperTitle>Geospatial Exposure to Benzene and Lymphoma Risk in Georgia </PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109030</Key_PaperID>
<Key_SessionID>11713</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	2:25 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:10 PM
 
</PaperStartTime>
<PaperTitle>Adherence to Oral Chemotherapy in Children with ALL: Contribution to Disparities in Outcomes</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109031</Key_PaperID>
<Key_SessionID>11713</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	1:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:30 PM
 
</PaperStartTime>
<PaperTitle>A Prospective Study of Serum Microbial Translocation and Inflammation Associated Biomarkers and Risk of AIDS-Related Non-Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109032</Key_PaperID>
<Key_SessionID>11713</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:55 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:45 PM
 
</PaperStartTime>
<PaperTitle>Immunological Aging in Adolescent/Young Adult Hodgkin Lymphoma Survivors Compared to Their Unaffected Twins</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109033</Key_PaperID>
<Key_SessionID>11713</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:20 PM
 
</PaperStartTime>
<PaperTitle>Genetic Risk Factors for CLL Precursors in Families</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109043</Key_PaperID>
<Key_SessionID>11713</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	2:10 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:55 PM
 
</PaperStartTime>
<PaperTitle>Early-Age Leukemias in Brazil</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109021</Key_PaperID>
<Key_SessionID>11714</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:50 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:35 PM
 
</PaperStartTime>
<PaperTitle>Pre-Existing Chip and Risk of Therapy-Related Myeloid Neoplasms</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109022</Key_PaperID>
<Key_SessionID>11714</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:50 PM
 
</PaperStartTime>
<PaperTitle>Next Steps with Chip and Myeloid Neoplasms  Informing Risk &amp;amp; Prevention</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109023</Key_PaperID>
<Key_SessionID>11714</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:20 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:05 PM
 
</PaperStartTime>
<PaperTitle>Risk Prediction for MDS: Novel Clinical and Molecular Risk Factors and Development of Prevention Strategies</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109024</Key_PaperID>
<Key_SessionID>11714</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:20 PM
 
</PaperStartTime>
<PaperTitle>Clinical Epidemiology &amp; Impact of Therapy-Related AML</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109034</Key_PaperID>
<Key_SessionID>11715</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:55 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Elucidating the Association of Obesity with Multiple Myeloma Risk: Prospective Studies of Body Size throughout Life and Weight Stability </PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109035</Key_PaperID>
<Key_SessionID>11715</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:55 PM
 
</PaperStartTime>
<PaperTitle>iStopMM - A Nationwide Screening Study of MGUS</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109037</Key_PaperID>
<Key_SessionID>11715</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	4:50 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:35 PM
 
</PaperStartTime>
<PaperTitle>Inequalities in Treatment and Outcomes in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109038</Key_PaperID>
<Key_SessionID>11715</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	5:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:50 PM
 
</PaperStartTime>
<PaperTitle>Can We Move Towards Prevention in Multiple Myeloma?</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109039</Key_PaperID>
<Key_SessionID>11715</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:20 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:05 PM
 
</PaperStartTime>
<PaperTitle>Functional Follow-up of Potential Risk Variants</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109044</Key_PaperID>
<Key_SessionID>11715</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	4:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:20 PM
 
</PaperStartTime>
<PaperTitle>Differential DNA Methylation Consistent with Progression of Multiple Myeloma </PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109025</Key_PaperID>
<Key_SessionID>11716</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:05 PM
 
</PaperStartTime>
<PaperTitle>Review of Epidemiology and Risk Factors for Pediatric T-Cell Lymphoma/Leukemia</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109026</Key_PaperID>
<Key_SessionID>11716</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Review of Epidemiology of Risk Factors for Adult Peripheral T-Cell Lymphoma/Leukemia </PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109028</Key_PaperID>
<Key_SessionID>11716</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>T-Cell Lymphomas on a Nation-Wide Level - Experiences from the Population-Based Swedish Lymphoma Registry</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102211</Key_PaperID>
<Key_SessionID>11717</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-11</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Cadre (Coeur Artres et Drpanocytose*) Study * Heart Arteries and Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101997</Key_PaperID>
<Key_SessionID>11717</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-19</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Setting up a Pediatric Oncology Program in Cambodia- Successes and Challenges</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102161</Key_PaperID>
<Key_SessionID>11717</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-2</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Developing and Expanding Hematopathology Services to Support Clinical Care and Research Efforts in Malawi</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101643</Key_PaperID>
<Key_SessionID>11717</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-21</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Journey of Stem Cell Transplantation in Bangladesh: A Hike to State of Art with Collaboration between DMCH &amp;amp; MGH.</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101637</Key_PaperID>
<Key_SessionID>11717</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-22</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Where There's a Will, There's a Way: Establishing Haematopoietic Stem Cell Transplantation in Myanmar</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101484</Key_PaperID>
<Key_SessionID>11717</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-23</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Capacity Building Initiative to Improve Clinical Outcomes in Pediatric Acute Lymphoblastic Leukemia in the U.S-Mexico Border Region</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102562</Key_PaperID>
<Key_SessionID>11717</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-25</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>DFCI/Bch-Hito Quality Improvement Project for Hematologic Malignancies: Implementation and Validation of MRD By FLOW Cytometry in Pediatric ACUTE Leukemias Treatment Protocols</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102444</Key_PaperID>
<Key_SessionID>11717</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-26</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Feasibility of Minimal Residual Disease Studies By Multiparametric Flow Cytometry for Acute Myeloid Leukemia in a Developing Country.</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99978</Key_PaperID>
<Key_SessionID>11717</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-27</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sickkids-Caribbean Initiative: Collaborating to Improve the Diagnosis and Care of Children with Cancer and Serious Blood Disorders in the Caribbean</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101754</Key_PaperID>
<Key_SessionID>11717</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-3</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Developing Haemophilia Care in Malawi: A Collaborative Capacity Building Initiative</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100405</Key_PaperID>
<Key_SessionID>11717</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-5</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Diagnosing Hematological Malignancies in Rural Rwanda Using Digital Pathology Applications: A Collaboration between a Local Pathologist and U.S. Based-Volunteer Hematopathologists</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101607</Key_PaperID>
<Key_SessionID>11717</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-9</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prevalence and Mapping of Sickle Cell Disease in Northwestern Tanzania</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108996</Key_PaperID>
<Key_SessionID>11718</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	1:20 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:10 PM
 
</PaperStartTime>
<PaperTitle>Children with Cancer Predisposition Syndromes in Germany: Activities of the Society of Pediatric Oncology and Hematology</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108997</Key_PaperID>
<Key_SessionID>11718</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	1:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:20 PM
 
</PaperStartTime>
<PaperTitle>Surprises in "Solving" Families with Predisposition to Hematopoietic Malignancy</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108998</Key_PaperID>
<Key_SessionID>11718</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	1:40 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:30 PM
 
</PaperStartTime>
<PaperTitle>Incorporating MDS/AML Molecular Profiling at Diagnosis into the Evaluation of Hereditary Leukemia Predispositions</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108999</Key_PaperID>
<Key_SessionID>11718</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:55 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:40 PM
 
</PaperStartTime>
<PaperTitle>Unique Role of Genetic Counselors in Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109000</Key_PaperID>
<Key_SessionID>11719</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:55 PM
 
</PaperStartTime>
<PaperTitle>Synonymous Exonic Substitutions Constitute a New Class of Mutations Causing GATA2 Deficiency</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109001</Key_PaperID>
<Key_SessionID>11719</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:05 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Evaluation of DDX41 Risk Alleles in Non-Familial Cases, General Individuals, and Donr-Derived Leukemias</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109002</Key_PaperID>
<Key_SessionID>11719</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:25 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>A Novel Murine Model of an ETV6 Germline Mutation</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109003</Key_PaperID>
<Key_SessionID>11719</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	2:40 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:25 PM
 
</PaperStartTime>
<PaperTitle>Clinical and Molecular Features of Patients with SAMD9L-Germline Mutations</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109004</Key_PaperID>
<Key_SessionID>11720</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:50 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:40 PM
 
</PaperStartTime>
<PaperTitle>Spectrum of SAMD9/SAMD9L-Related Bone Marrow Failure and Myeloid Neoplasia</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109005</Key_PaperID>
<Key_SessionID>11720</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:50 PM
 
</PaperStartTime>
<PaperTitle>A New Cancer Predisposition Syndrome with a Common Path to AML</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109006</Key_PaperID>
<Key_SessionID>11720</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:10 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Challenge of Identifying Novel Predisposing Variants in Familial MDS/AML</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109007</Key_PaperID>
<Key_SessionID>11720</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:25 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:10 PM
 
</PaperStartTime>
<PaperTitle>Mecom/EVI1: A Novel Candidate Gene for Hereditary Hematological Malignancies</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109008</Key_PaperID>
<Key_SessionID>11721</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:50 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:40 PM
 
</PaperStartTime>
<PaperTitle>Predisposition to Pediatric Myelofibrosis and Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109009</Key_PaperID>
<Key_SessionID>11721</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:50 PM
 
</PaperStartTime>
<PaperTitle>JAK/STAT Pathway Aberrations in RUNX1 Mutated Patients</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109010</Key_PaperID>
<Key_SessionID>11721</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:10 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:00 PM
 
</PaperStartTime>
<PaperTitle>Germline Contributors to Myeloid Malignancy Susceptibility: Integrating Clues from the Malignant Genome</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109011</Key_PaperID>
<Key_SessionID>11721</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	4:25 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:10 PM
 
</PaperStartTime>
<PaperTitle>Hiding Beneath the Surface: Unbiased Screening of the Germline Identifies Unsuspected Cancer Predispositions in Pediatric Leukemia Patients</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109012</Key_PaperID>
<Key_SessionID>11722</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:10 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:55 PM
 
</PaperStartTime>
<PaperTitle>Immune Defects Associated with GATA2 Mutation</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109013</Key_PaperID>
<Key_SessionID>11722</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:25 PM
 
</PaperStartTime>
<PaperTitle>Reporting in Scandanavian Populations</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109014</Key_PaperID>
<Key_SessionID>11722</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:35 PM
 
</PaperStartTime>
<PaperTitle>Predisposition to Familial MPNs</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109015</Key_PaperID>
<Key_SessionID>11722</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:55 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>SAMD9/9L Germline Mutations in Familial MDS/AML</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108913</Key_PaperID>
<Key_SessionID>11727</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Defining Clinical Benefit: Evolving Regulatory Considerations for Drug Development in AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108914</Key_PaperID>
<Key_SessionID>11727</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>Midostaurin</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108915</Key_PaperID>
<Key_SessionID>11727</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Daunorubicin/Cytarabine</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108916</Key_PaperID>
<Key_SessionID>11727</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:15 PM
 
</PaperStartTime>
<PaperTitle>Gemtuzumab Ozogamicin</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108939</Key_PaperID>
<Key_SessionID>11727</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Enasidenib</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108975</Key_PaperID>
<Key_SessionID>11731</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:05 PM
 
</PaperStartTime>
<PaperTitle>Mitochondrial Regulation of Hematopoietic Stem Cells</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108976</Key_PaperID>
<Key_SessionID>11731</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	1:25 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>The PI3 Kinases Alpha and Delta Are Required for the Loss of Hematopoietic Stem Cell Quiescence during Stress</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108977</Key_PaperID>
<Key_SessionID>11731</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	1:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:25 PM
 
</PaperStartTime>
<PaperTitle>Lnk/Sh2b3 Deficiency Restores Hematopoietic Stem Cell Function and Genome Integrity in Fanconi Anemia</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108978</Key_PaperID>
<Key_SessionID>11731</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	1:50 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:35 PM
 
</PaperStartTime>
<PaperTitle>Kdm6b Is Required for Hematopoietic Stem Cell Self-Renewal Under Proliferative Stress</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108979</Key_PaperID>
<Key_SessionID>11732</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:50 PM
 
</PaperStartTime>
<PaperTitle>The Labile Iron Pool As a Rheostat for Hematopoietic Stem Cell Function</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108980</Key_PaperID>
<Key_SessionID>11732</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:10 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>BCAT1 Restricts -Ketoglutarate Levels in AML Stem Cells Leading to DNA Hypermethylation Mimicking Idhmut-AML</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108981</Key_PaperID>
<Key_SessionID>11732</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:20 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:10 PM
 
</PaperStartTime>
<PaperTitle>Interplay between Epigenetics and Metabolism in Hematopoiesis and Leukemia</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108982</Key_PaperID>
<Key_SessionID>11732</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	2:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:20 PM
 
</PaperStartTime>
<PaperTitle>Characterization of HSCs and Progenitors Using a Novel Mouse Expressing a G0 Marker</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108992</Key_PaperID>
<Key_SessionID>11733</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	5:10 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>Domain-Focused CRISPR Dropout Screens in AML</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108993</Key_PaperID>
<Key_SessionID>11733</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:20 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:10 PM
 
</PaperStartTime>
<PaperTitle>New Therapeutic Targets in AML</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108994</Key_PaperID>
<Key_SessionID>11733</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:30 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:20 PM
 
</PaperStartTime>
<PaperTitle>A Non-Cell-Intrinsic Tumor-Promoting Function of Tet2 in Myeloid Cells</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108995</Key_PaperID>
<Key_SessionID>11733</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Genome-Wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108988</Key_PaperID>
<Key_SessionID>11734</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:25 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:15 PM
 
</PaperStartTime>
<PaperTitle>Identifying Novel Therapeutic Vulnerabilities in Spliceosomal Mutant Leukemias</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108989</Key_PaperID>
<Key_SessionID>11734</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:25 PM
 
</PaperStartTime>
<PaperTitle>The 7q Tumor Suppressor, CUX1, Inhibits MDS/MPN in Mice</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108990</Key_PaperID>
<Key_SessionID>11734</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:35 PM
 
</PaperStartTime>
<PaperTitle>Role of Cbfbsmmhc / RUNX1 in Maintaining MYC Levels By Modulating Chromatin Dynamics in AML</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108991</Key_PaperID>
<Key_SessionID>11734</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>T/Myeloid Biphenotypic Leukemia Caused By the Fusion Translocation ETV6-NCOA2 (TEL-TIF2)</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108983</Key_PaperID>
<Key_SessionID>11735</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:35 PM
 
</PaperStartTime>
<PaperTitle>Hematopoietic Stem Cells Depend on Low Protein Synthesis to Maintain the Integrity of Their Proteome</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108984</Key_PaperID>
<Key_SessionID>11735</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:55 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Clonal Hematopoiesis in Human Aging and Disease</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108985</Key_PaperID>
<Key_SessionID>11735</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:55 PM
 
</PaperStartTime>
<PaperTitle>Transcriptional Hierarchy within the Bone Marrow Niche</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108986</Key_PaperID>
<Key_SessionID>11735</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	3:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:05 PM
 
</PaperStartTime>
<PaperTitle>Megakaryocyte-Mediated Activation of the Transcription Factor Gli1 in Fibrosis-Driving Cells in Myelofibrosis</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108987</Key_PaperID>
<Key_SessionID>11735</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	3:25 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:15 PM
 
</PaperStartTime>
<PaperTitle>Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108919</Key_PaperID>
<Key_SessionID>11737</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	1:20 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:05 PM
 
</PaperStartTime>
<PaperTitle>Aging Vascular Endothelium Modulate Hematopoietic Stem Cell Activity</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108920</Key_PaperID>
<Key_SessionID>11737</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	1:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:20 PM
 
</PaperStartTime>
<PaperTitle>Molecular Mechanisms That Contribute to Hematopoietic Stem Cell Aging</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108921</Key_PaperID>
<Key_SessionID>11737</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	1:50 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:35 PM
 
</PaperStartTime>
<PaperTitle>Defects in Aging Marrow Macrophages Regulate Hematopoietic Stem Cells</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108922</Key_PaperID>
<Key_SessionID>11737</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	2:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:50 PM
 
</PaperStartTime>
<PaperTitle>Creation of a Non-Human Primate Model for Hematopoietic Aging and for Chip</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108923</Key_PaperID>
<Key_SessionID>11738</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:20 PM
 
</PaperStartTime>
<PaperTitle>Stem Cells Aging and and Immunity </PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108924</Key_PaperID>
<Key_SessionID>11738</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:50 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:35 PM
 
</PaperStartTime>
<PaperTitle>Transplant As a Model for Accelerated T-Cell Aging</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108926</Key_PaperID>
<Key_SessionID>11738</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:50 PM
 
</PaperStartTime>
<PaperTitle>Immunotherapy in Older Adults with Hematological Malignancies</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108927</Key_PaperID>
<Key_SessionID>11740</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:50 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:35 PM
 
</PaperStartTime>
<PaperTitle>Platelet Reprogramming and Thrombosis in Aging</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108928</Key_PaperID>
<Key_SessionID>11740</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	4:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:50 PM
 
</PaperStartTime>
<PaperTitle>In Vitro and In Vivo Models to Dissect the Pathophysiology of Thrombosis in Aging</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108930</Key_PaperID>
<Key_SessionID>11740</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	4:20 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:05 PM
 
</PaperStartTime>
<PaperTitle>The Megakaryocyte-Platelet Axis and Pro-Thrombotic Functional Responses in a Murine Model of Aging</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108933</Key_PaperID>
<Key_SessionID>11741</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:50 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:35 PM
 
</PaperStartTime>
<PaperTitle>Creation of Clinical Infrastructure to Identify Genetic Determinants of Frailty for Patients with Blood Cancers</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108934</Key_PaperID>
<Key_SessionID>11741</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:50 PM
 
</PaperStartTime>
<PaperTitle>Geriatric Assessment Among Older Adults with Lymphoma</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108937</Key_PaperID>
<Key_SessionID>11741</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:20 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:05 PM
 
</PaperStartTime>
<PaperTitle>Brief Comprehensive Geriatric Assessment in Older Patients with Hematological Malignancies: The Gah Scale. a Nation-Wide Dissemination Strategy to Implement the Tool in Spain</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100057</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-1</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Designing a Successful Capacity-Building Program in a Third World Country:the St. Josephs Health System-Mcmaster University CollaborativeInternational Outreach Program for Uganda</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102032</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription> </OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-10</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Providing Molecular Diagnosis and Monitoring of Patients with Chronic Myeloid Leukaemia in Abuja, Nigeria</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100567</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-12</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Developing Collaborations to Establish Low-Cost Advanced Diagnostic Haematology Laboratory in Peshawar, Pakistan</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102602</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-13</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Establishing a Comprehensive Diagnosis of Primary Immunodeficiency Diseases</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102359</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-14</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Establishment of Haploidentical Transplantation Program in a Resource-Constrained Country</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102512</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-15</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Establishment of Stem Cell Research Department through ASH Visitor Training Program</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102619</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-16</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improved Outcomes in Pediatric Acute Lymphoblastic Leukemia (ALL) with Adapted Treatment Intensity: Use of the SIOP-Podc ALL Regimen 2 in a Resource-Limited Tertiary Referral Setting</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99944</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-17</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Laboratory Capacity Building Initiative to Assess Folate Status in Women of Reproductive Age from Haryana, India: The Collaborative Experience of Local and International Partners</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102480</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-18</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>National Capacity Building Initiatives for Childhood Hematological Malignancies in Myanmar</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100617</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-20</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Successful Treatment of Pediatric CML in Cambodia- an International Collaboration</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102373</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-24</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cooperation Program for theHemato-Oncology Development in the Public Health Care System in La Paz, Bolivia: A Bilateral Initiative with a Public Center in Montevideo, Uruguay</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102419</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-28</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Application of an Integrated Clinical, Cytogenetic and Molecular Risk Stratification for Acute Myeloid Leukemia Patients Using a Central Laboratory in a Brazilian Multicentric Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102354</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-29</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Development of the American Society of Hematology  Health Volunteers Overseas Hematology Program in Arequipa, Peru</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101973</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-4</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development of Research Capacity in Sickle Cell Anemia in Uganda: Impact of Collaborations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102029</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-6</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effectiveness in Hemophilia Care through Capacity Building: The Case of Yaound, Cameroon</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100371</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-7</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Healthcare Sciences Academy 57357 "Learn to Teach"; A Real Life Model for Healthcare Capacity Building in Developing Countries</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101266</Key_PaperID>
<Key_SessionID>11749</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>G-8</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Implementing Standard of Care Clinic for Stroke Prevention in Children with Sickle CELL Disease in Nigeria; A Feasible Strategy Outside a Clinical Trial Setting</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108948</Key_PaperID>
<Key_SessionID>11752</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	3:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:00 PM
 
</PaperStartTime>
<PaperTitle>Plenary Introducer</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108949</Key_PaperID>
<Key_SessionID>11752</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	2:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:00 PM
 
</PaperStartTime>
<PaperTitle>Plenary Introducer</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108950</Key_PaperID>
<Key_SessionID>11752</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	2:25 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:20 PM
 
</PaperStartTime>
<PaperTitle>Plenary Introducer</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108951</Key_PaperID>
<Key_SessionID>11752</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	2:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:40 PM
 
</PaperStartTime>
<PaperTitle>Plenary Introducer</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108952</Key_PaperID>
<Key_SessionID>11752</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	3:25 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:20 PM
 
</PaperStartTime>
<PaperTitle>Plenary Introducer</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108953</Key_PaperID>
<Key_SessionID>11752</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	3:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:40 PM
 
</PaperStartTime>
<PaperTitle>Plenary Introducer</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102398</Key_PaperID>
<Key_SessionID>11752</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:20 PM
 
</PaperEndTime>
<PaperNumber>1</PaperNumber>
<PaperStartTime>
	2:05 PM
 
</PaperStartTime>
<PaperTitle>Loss of De Novo DNAMethyltransferase DNMT3A Impacts Alternative Splicing in Hematopoietic Stem Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102910</Key_PaperID>
<Key_SessionID>11752</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	2:40 PM
 
</PaperEndTime>
<PaperNumber>2</PaperNumber>
<PaperStartTime>
	2:25 PM
 
</PaperStartTime>
<PaperTitle>Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105063</Key_PaperID>
<Key_SessionID>11752</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	3:00 PM
 
</PaperEndTime>
<PaperNumber>3</PaperNumber>
<PaperStartTime>
	2:45 PM
 
</PaperStartTime>
<PaperTitle>Customized Induced Pluripotent Stem Cell-Derived Red Cell Reagents</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105882</Key_PaperID>
<Key_SessionID>11752</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	3:20 PM
 
</PaperEndTime>
<PaperNumber>4</PaperNumber>
<PaperStartTime>
	3:05 PM
 
</PaperStartTime>
<PaperTitle>Heterodimerization of TPO and IFN Impairs Human Hematopoietic Stem/Progenitor Cell Signaling and Survival in Chronic Inflammation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107404</Key_PaperID>
<Key_SessionID>11752</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	3:40 PM
 
</PaperEndTime>
<PaperNumber>5</PaperNumber>
<PaperStartTime>
	3:25 PM
 
</PaperStartTime>
<PaperTitle>High Throughput Sequencing in 3449 Patients with Bleeding and Platelet Disorders: Novel Gene Discovery and Robust Diagnosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput>1</HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105589</Key_PaperID>
<Key_SessionID>11752</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The ECHELON-1 trial tests the usefulness of brentuximab vedotin as part of frontline treatment.</OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	4:00 PM
 
</PaperEndTime>
<PaperNumber>6</PaperNumber>
<PaperStartTime>
	3:45 PM
 
</PaperStartTime>
<PaperTitle>Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109048</Key_PaperID>
<Key_SessionID>11761</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:45 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:30 PM
 
</PaperStartTime>
<PaperTitle>Lessons Learned from a Choosing Wisely Champion</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109049</Key_PaperID>
<Key_SessionID>11761</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:00 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:45 PM
 
</PaperStartTime>
<PaperTitle>From One System to Another: Systems-Based Hematology Success in the Academic and Community Settings</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>109050</Key_PaperID>
<Key_SessionID>11761</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	5:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	5:00 PM
 
</PaperStartTime>
<PaperTitle>The Future of Systems-Based Hematology Education at the ASH Annual Meeting</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102236</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2194</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107821</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2195</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Absence of Interleukin-6 Protects Murine Bone Marrow Erythropoiesis Under Inflammation, in a Process Reversible By Iron Mediated Reactive Oxygen Species Upregulation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105943</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2196</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Mobility Group Box 1 Protein (HMGB1) Mediates Anemia of Inflammation through Lineage Skewing and Direct Inhibition of EPO Signaling</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106830</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2197</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dysregulated Transcriptional Upregulation of Cell-Cycle Regulators By KLF1 Mutation E325K Induces Cell-Cycle Arrest in Erythroid Cells Differentiated from the Congenital Dyserythropoietic Anemia (CDA)-Patient Specific Induced Pluripotent Stem Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108037</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2198</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In Vitro Combination Studies of ACH-4471 with Eculizumab to Assess a Potential Switch Treatment Approach for Paroxysmal Nocturnal Hemoglobinuria</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102682</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2199</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Short Course of Bortezomib in Anemic Patients with Refractory or Relapsed Cold Agglutinin Disease. a Phase II Prospective Study By the Gimema Group</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103100</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2200</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Systematic Analyses of Clinically Relevant Single Nucleotide Polymorphisms (SNPs) of NR3C1 in Patients from the Italian Registry of Diamond Blackfan Anemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104748</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2201</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Elucidation of Autoinflammatory Mechanism in Pigt-PNH</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105966</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2202</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>TET2 Deficiency Led to Expansion of Dysfunctional Erythroid Progenitors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104084</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2203</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Potential Role for Genes within the mTORC1 Pathway in the Regulation of Embryonic Globin Expression Revealed By ChIP-Seq, RNA-Seq and eQTL Mapping in the Nan Anemia Mouse Model</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105212</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2204</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Human Hematopoietic Progenitor Cells and Erythrocytes Generated from Human iPSCs Lacking CD55</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106032</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2205</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Erythroid and Cardiovascular High Altitude-Selected Haplotypes in Andean Aymaras and Tibetans</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106054</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2206</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of Possible Driver Gene in Patients with Acquired Pure Red Cell Aplasia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107622</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2207</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>First Report of Reversible Macrocytic Anemia with Dysplastic Features Associated with Palbociclib Use in Patients with Metastatic Breast Cancer</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107784</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2208</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Study of Novel Beta Globin Mutation Associated with Dominant Beta-Thalassemia, Aberrant Erythroid Maturation and Differentiation Compounded with Hereditary Pyropoikilocytosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108461</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2209</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Screening of Mutations Related to Hereditary Anemias Using NGS-Targeted Sequencing Panel</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102502</Key_PaperID>
<Key_SessionID>11775</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2210</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The First Registry for Patients with Congenital Dyserythropoietic Anemia in North America: Design and Preliminary Results</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108139</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3467</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The IL-17 Receptor IL-17RA Is Expressed By Early Erythroid Progenitors and Stimulates Erythropoiesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107306</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3468</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Free Heme Induces a Heme Importer, Heme Catabolism and an Angiogenic Factor in Multiple Organs in Mice: Implications for Organ-Specific Response to Intravascular Hemolysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102727</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3469</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sepsis Induced Red Cell Dysfunction (SiRD): Physiology and Mechanisms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105077</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3470</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intravascular Hemolysis Leads to Increased Esophagus Smooth Muscle Contractions in Mice: Implication for Dysphagia and Odynophagia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104106</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3471</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106034</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3472</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Baseline Clinical Characteristics between Asian Vs. Non-Asian Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from International PNH Registry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107733</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3473</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Role of TCA Cycle Compounds in Erythroid Heme Synthesis and Its Regulation during an Inflammatory Response</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101695</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3474</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Digital PCR Assay to Assess the Alternative Splicing and Absolute Ferrochelatase Expression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103626</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3475</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Whole-Exome Sequencing of Paroxysmal Nocturnal Hemoglobinuria</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104865</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3476</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In Vitro Erythropoietic Response to Enzyme Replacement Therapy in Gaucher Type 1 Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105461</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3477</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of a Digenic Inheritance ofPklr andKLF1 Mutations Resulting in Hemolytic Anemia in a Neonate from a Study of Genotype-Phenotype Correlation of Globin,Pklr andKLF1 in Thai Patients with Pyruvate Kinase (PK) Deficiency</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107838</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3478</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fast Determination of Projected Surface Area in Red Blood Cells from Splenectomised Patients with Imaging Flow Cytometry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103010</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3479</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genotype-Phenotype Correlation and Molecular Heterogeneity in Pyruvate Kinase Deficiency: Data from the PKD Natural History Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102787</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3480</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Use of Next Generation Sequencing Panel to Clarify Undiagnosed Cases of Hereditary Hemolytic Anemias</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99892</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3481</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Basis of Hypoxia-Induced Excessive Erythrocytosis: Critical Role of SENP1 gene Regulation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100715</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3482</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100931</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>SYNT001 is a humanized IgG4 monoclonal antibody designed to disrupt the interaction between FcRn and IgG for the potential treatment of IgG-mediated autoimmune diseases. It is an investigational product and has not been approved for use outside of a clinical trial setting.</OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3483</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>SYNT001: A Humanized IgG4 Monoclonal Antibody That Disrupts the Interaction of FcRn and IgG for the Treatment of IgG-Mediated Autoimmune Diseases</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103985</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3484</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Assessment of Eculizumab and C5 Levels in PNH Treatment: Molar Ratio of Eculizumab to C5 Level Effectively Predicts Ongoing Dosage Changes in a Cohort of 50 Patients Treated with Eculizumab</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101168</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3485</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Large Deletions and Novel Mutations in Genes Coding forRibosomal Proteins (RPL11, RPL35A, RPS19) in theCzech National Registry ofDiamond-Blackfan Anemia (DBA)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101230</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3486</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Interim Analysis of Safety Outcomes during Treatment with Eculizumab: Results from the International Paroxysmal Nocturnal Hemoglobinuria Registry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101237</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3487</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and High Disease Activity with or without History of Aplastic Anemia in the International PNH Registry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101263</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3488</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Analysis of Baseline Clinical Characteristics and Disease Burden in Patients Enrolled in the International Paroxysmal Nocturnal Hemoglobinuria Registry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101543</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3489</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>O-Glcnacylation Modulates Erythropoiesis: O-Glcnac Transferase (OGT) Is an Essential Gene</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101662</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3490</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Syndrome of IgA-Related Polycythemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101738</Key_PaperID>
<Key_SessionID>11776</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3491</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prevalence of Bone Marrow Fibrosis in 47 Cases of Autoimmune Hemolytic Anemia Patients: Clinical and Biologic Relationships</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105295</Key_PaperID>
<Key_SessionID>11777</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2211</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Explore: A Prospective, Multinational Natural History Study of Patients with Acute Hepatic Porphyrias (AHP) with Recurrent Attacks</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106686</Key_PaperID>
<Key_SessionID>11777</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2212</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Measurement of Liver Iron Concentration in a Population of Non-Transfusion Dependent Thalassemia Patients Using a Trained Artificial Neural Network to Analyse Magnetic Resonance Images</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108230</Key_PaperID>
<Key_SessionID>11777</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2213</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Splitting the Functions of a Mitochondrial Iron/Pyrimidine Carrier</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107338</Key_PaperID>
<Key_SessionID>11777</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2214</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle> Non-Transferrin-Bound Iron Serves As Iron Source for Aspergillus Fumigatus Growth </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105650</Key_PaperID>
<Key_SessionID>11777</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2215</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase I Trial Results of a Solid Dispersion Formulation of Deferasirox with Enhanced Bioavailability Relative to Exjade and JadenuTM</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107235</Key_PaperID>
<Key_SessionID>11777</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2216</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Association of GNPAT p.D519G with Higher Iron Phenotypes in Women with HFE p.C282Y Homozygosity</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104344</Key_PaperID>
<Key_SessionID>11777</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2217</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sucrosomial Iron Absorption Involve M Cells Interaction</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108284</Key_PaperID>
<Key_SessionID>11777</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2218</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Endocrinological Abnormalities Among Adult Thallasemic Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107302</Key_PaperID>
<Key_SessionID>11778</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3492</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hemin and Iron Modulated Intrinsic Cellular Factors Regulate HIV-1 Replication in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100961</Key_PaperID>
<Key_SessionID>11778</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3493</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The KAP 2 Study: Preliminary Results from a Pragmatic Cluster Randomized Trial of a Community Education Intervention to Support Childhood Anemia Control in India</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107191</Key_PaperID>
<Key_SessionID>11778</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3494</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Heme Synthesis Is Inhibited in Erythroid Cells Derived from Beta-Thalassemic Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107168</Key_PaperID>
<Key_SessionID>11778</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3495</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Role of Heme in the Regulation of Transferrin Receptor Expression in Erythroid Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108226</Key_PaperID>
<Key_SessionID>11778</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3496</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Heme Regulates the Expression in Erythroblasts of Placenta Growth Factor, a Contributor to Pulmonary Hypertension in Sickle Cell Disease, through the Oxidant Response Transcription Factor NRF2</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104705</Key_PaperID>
<Key_SessionID>11778</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3497</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of Iron Therapy on Fatigue and Work Capacity in Non-Anemic Iron Deficient Adults: A Systematic Review of Randomized Controlled Trials</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102729</Key_PaperID>
<Key_SessionID>11778</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3498</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Investigation of Circulating Plasma Micro RNAs As Biomarkers for Iron Status in Blood Donors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108243</Key_PaperID>
<Key_SessionID>11778</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3499</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Surrogate Thresholds for Iron Chelation in Patients with Hematological Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101852</Key_PaperID>
<Key_SessionID>11778</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ferumoxytol is indicated for the treatment of iron deficiency anemia (IDA) in adults with chronic kidney disease and is being investigated for the broad indication of IDA in those who have failed or who are intolerant of oral iron</OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3500</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Randomized, Double-Blind Trial of Ferumoxytol Compared to Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia: Safety and Efficacy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104172</Key_PaperID>
<Key_SessionID>11779</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2219</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ReprogrammingCell-Signaling By Delivering the Catalytic Domain of Ptpgr Ameliorates Anemia of -Thalassemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105861</Key_PaperID>
<Key_SessionID>11779</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2220</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MBD2-NuRD but Not MBD3-NuRD Mediates Strong Silencing of Fetal -Globin Gene Expression in Human Adult Erythroid Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107218</Key_PaperID>
<Key_SessionID>11779</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>We will discuss hydroxyurea, which is not FDA approved for pediatric patientsw ith sickle cell disease, and metformin as a HbF inducing agent, an off-lable use.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2221</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Piceatannol Induces Fetal Hemoglobin in Erythroid Progenitor Cells from Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107552</Key_PaperID>
<Key_SessionID>11779</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2222</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Screening Fetal Hemoglobin Inducing Compounds in Human Umbilical Cord Blood-Derived Erythroid Progenitor Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107531</Key_PaperID>
<Key_SessionID>11779</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2223</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterization of a HBB-Locus Fetal Chromatin Domain Region during Adult Erythropoiesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107236</Key_PaperID>
<Key_SessionID>11779</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Decitabine- Decitabine is hypomethylating agent, it causes depletion of DNA methyl transferase. This is used in MDS and AML. This property of drug is being evaluated for induction of gamma globin chains which are repressed by methylation.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2224</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Decitabine As Hemoglobin F Inducer in Hemoglobin E/ Thalassemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101149</Key_PaperID>
<Key_SessionID>11779</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2225</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle> Splenectomy Is a Risk Factor for Cardiac Complications in TM </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100452</Key_PaperID>
<Key_SessionID>11779</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2226</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Strong Link between Pancreas and Heart in Thalassemia Major</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100874</Key_PaperID>
<Key_SessionID>11779</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2227</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Quantifying the Pathophysiology of Beta-Thalassemia Using a Novel in-Silico Model of Red Blood Cell Production and Lifespan</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100902</Key_PaperID>
<Key_SessionID>11780</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3501</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long Term Prospective Predictors for Vascular Events and Cardiac Complications in Thalassemia Major Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100722</Key_PaperID>
<Key_SessionID>11780</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3502</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pituitary Iron: Effect on Pituitary Volume and Function in Transfusion Dependent Thalassemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104846</Key_PaperID>
<Key_SessionID>11780</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3503</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Serum Metabolite Profiles Are Strongly Correlated with Membrane Lipid Alterations in Beta Thalassemia Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107896</Key_PaperID>
<Key_SessionID>11780</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3504</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Serum Ferritin Underestimates Liver Iron Concentration in Patients with Homozygous Alpha-0 Thalassemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102976</Key_PaperID>
<Key_SessionID>11780</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3505</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Isolation and Chelation Activity of Plant Phenolic Root Exudates As Potential Clinical Iron Chelators</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108163</Key_PaperID>
<Key_SessionID>11780</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3506</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cognitive, Brain and Intracranial Artery Involvement in Beta Thalassemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103327</Key_PaperID>
<Key_SessionID>11780</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3507</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cardiorenal Syndrome in Thalassemia Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100659</Key_PaperID>
<Key_SessionID>11780</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3508</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Predicting Serum Ferritin Levels in Patients with Iron Overload Treated with the Film-Coated Tablet of Deferasirox during the Eclipse Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99904</Key_PaperID>
<Key_SessionID>11780</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3509</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Endocrine Functions in Hb E Thalassemia Patients with Special Reference to Assessment of Growth and Puberty</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105175</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3510</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Red Blood Cells Microparticles Are Associated with Hemolysis Markers and Leg Ulceration in Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105830</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3511</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Novel Conjugates of Butyrate and -Aminolevulinate Increase -Globin Gene Expression and Fetal Hemoglobin Synthesis in Erythroid Progenitors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107512</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3512</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cardiomyopathy Associated with Worsening Intravascular Hemolysis in Transgenic Knock-in Mouse Model of Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100647</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3513</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>New Insights into F-Cells, F-Reticulocytes and the Role of Fetal Hemoglobin in Protecting Sickle Red Cells from Hemolysis upon Mechanical Stress</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100651</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3514</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Combined Treatment with Hydroxyurea and a Phosphodiesterase 9 (PDE9) Inhibitor Decreases Hepatic Damage in an Animal Model of Sickle Cell Anemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103438</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3515</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>LRP1 Expression in Sickle Cell Disorders: Insights into the Heterogeneity of Monocytic Response to Heme</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104723</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3516</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>GBT1118 Diminishes Vaso-Occlusion in Sickle Cell Disease Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107220</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3517</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pegylated Carboxyhemoglobin (SANGUINATE) Restores Blood Flow and Tissue Oxygenation in a Novel Rat Model of Acute Vaso-Occlusive Crisis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107464</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3518</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Erythroferrone (ERFE) and Hepcidin Levels in Sickle Cell Disease with and without Transfusional Iron Overload</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107608</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3519</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hemechip: An Automated Portable Microchip Electrophoresis Platform for Point-of-Care Sickle Cell Disease Screening</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100018</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3520</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Distinct Biomarkers Reflect Pathophysiological Differences of Sickle Cell Disease Sub-Phenotypes: Viscosity-Vaso-Occlusion Vs. Hemolysis-Endothelial Dysfunction</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105340</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3521</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pathophysiologic Implications of Type-2 Phosphatidylserine-Positive Erythrocytes in Hemoglobin SS Disease (sickle cell anemia) and -Thalassemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104006</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3522</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Arteriolar Neovasculogenesis and Sinusoidal Collapse Are Pathologic Features of the Hematopoietic Stem Cell Niche in Sickle Cell Disease (SCD) Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105932</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3523</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Attention to Pain Modulates the Vasoconstriction Response to Thermal Pain in Sickle Cell Disease Subjects but Not in Controls</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106233</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3524</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Quantification of Whole-Brain Oxygenation Extraction Fraction Among People with Sickle Cell Anemia without Stroke History</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107767</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3525</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Rejuvenated RBCs Increase Oxygen Consumption in a Simulated Exchange Transfusion Model of Sickle Cell Disease Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107120</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3526</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Thromboembolic and Vascular Complications in Patients with Secondary Erythrocytosis Caused By High Oxygen Affinity Variant Hb Coimbra</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107880</Key_PaperID>
<Key_SessionID>11781</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3527</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A New Tool for HbF Quantification Demonstrates That Hydroxyurea Decreases Mostly RBCs Containing Very Low Amounts of HbF</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107846</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2228</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cerebral Metabolic Alterations in Transgenic and Hemizygous Murine Models of Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108073</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2229</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In Vivo Brain Redox Imaging in Transgenic-Knockout Sickle Mice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108681</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2230</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Use of Mobile Health (mHealth) Apps and Wearable Technology to Assess Changes in Pain during Treatment of Acute Pain in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108751</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2231</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Correlations between Transcranial Doppler Velocities and Laboratory Markers of SCA Severity</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105687</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2232</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Oral Carbon Monoxide Therapy in Murine Models of Sickle Cell Disease: Beneficial Effects on Vaso-Occlusion, Inflammation and Anemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100642</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2233</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Canonical Inflammasome Formation in Monocytes of Sickle Cell Anemia Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104789</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2234</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The NLRP3 Inflammasome in Platelets Is Upregulated in Sickle Cell Disease and Promotes Platelet Aggregation and in Vitro Thrombosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107432</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2235</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Salubrinal Mediated Fetal Hemoglobin Induction through the eIF2-ATF4 Signaling Pathway</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104160</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2236</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>RNA-Sequencing of Isolated Cell Populations Expressing Human APOL1 Risk Variants Reveals Molecular Correlates of Sickle Cell Nephropathy in Zebrafish Podocytes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102934</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2237</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Abnormal Presence of Mitochondria in CirculatingRed Blood Cells Cause an Increased Oxygen Consumption Rate, ROS Generation and Hemolysis in Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107215</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2238</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effects of N-Acetylcysteine Infusion in Patients with Sickle Cell Disease during Vaso-Occlusive Crises</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107571</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2239</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Expression of Netosis Regulators and Correlation with Inflammatory and Coagulation Biomarkers in Sickle Cell Anemia Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102691</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2240</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chronic Hemolysis, Oxidative Stress and Inflammation Contribute to Dysfunctional HDL in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105719</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2241</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Diet and Gender Influence Survival in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107259</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2242</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effects of UGT1A1 Polymorphism, Glucose-6-Phosphate Dehydrogenase Deficiency and Deletional (-3.7b) -Thalassemia Among Young Nigerians with Sickle Cell Anemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105601</Key_PaperID>
<Key_SessionID>11782</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2243</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Neutrophil Extracellular Traps Promote Lung Arteriole Occlusion in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103050</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>N-acetylcysteine, off-label use in sickle cell disease to reduce markers of disease and improve clinical symptoms of disease.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2244</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effects of Oral N-Acetylcysteine on Oxidative Stress in Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105850</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2245</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Normalization of Cerebral Hemodynamics after Hematopoietic Stem Cell Transplant in Children with Sickle Cell Anemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108708</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2246</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effect of Renin-Angiotensin-Aldosterone System Blocking Agents on Progression of Glomerulopathy in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102077</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2247</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Impulse Oscillometry with Spirometry to Assess Lung Function inChildren with Sickle Cell Disease (SCD)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106065</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2248</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ventilation-Perfusion Scan Is Superior to CT Pulmonary Angiography in Detection of Chronic Thromboembolic Pulmonary Hypertension in SCD Adults</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103455</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Deferiprone is approved by the FDA for use as a second line agent for transfusion-dependent thalassemia.  This abstract addresses the drug's use in individuals with sickle cell disease</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2249</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety of Deferiprone in Individuals with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103354</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2250</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Low Body Mass Index in Pregnant Women with Sickle Cell Disease Is Associated with Premature Delivery in Sub- Saharan Africa</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106670</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ticagrelor is a P2Y12 platelet inhibitor indicated to reduce the rate of cardiovascular death, myocardial infarction (MI) and stroke in patients with acute coronary syndrome (ACS) or a history of MI. The current study in the submitted abstract is a phase 2 study to characterize the pharmacokinetic, pharmacodynamic and safety profiles of ticagrelor in children aged 2-17 years with sickle cell disease.</OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2251</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pharmacokinetics, Pharmacodynamics and Safety of Ticagrelor in Children with Sickle Cell Disease: Results of a Two-Part Phase 2 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105263</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Hydroxyurea is off label drug for children with sickle cell anemia.</OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2252</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pharmacokinetics of Hydroxyurea Therapy in African Children with Sickle Cell Anemia: Noharm Ancillary PK Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100933</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2253</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gender Differences in the Development of CMR Abnormalities and Cardiac Complications: A Multicentric Prospective Study in a Cohort of Sickle Cell Disease Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107739</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2254</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>NIH Bayesian Score As a Stratification Tool in Sickle Cell Disease - Results from a Single Center Cohort in Brazil</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100334</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2255</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lack of an Alberta Newborn Screening Program Is Associated with Delayed Diagnosis of Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105561</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2256</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Increasedprevalence of Stroke Recurrence and Stroke Related Mortality in Children with Sickle Cell Disease inNigeria:evidencefor a Secondary Stroke Prevention Trial.</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107325</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2257</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Access to Care, and Emergency Department Utilization for Adults and Adolescents with Sickle Cell Disease: Ascq-Me and the SHIP-HU Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105803</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2258</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Adult and Adolescent Quality of Ambulatory and Emergency Care in Sickle Cell Disease: Ascq-Me and the SHIP-HU Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107572</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2259</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cold and Mechanical Hypersensitivity Is Exacerbated during Acute Pain in Children and Adolescents with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103692</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2260</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Management of Male Fertility in Sickle Cell Disease before and after Hydroxycarbamide</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100627</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2261</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pulmonary Hypertension and Associated Risk Factors in a High Burden Sickle Cell Disease Population</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104596</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2262</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Steady-State Cognitive Function and Pain Severity in Youth with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104141</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2263</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Correlation between Body Mass Index and Left Ventricular Remodeling and Function in Children with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101813</Key_PaperID>
<Key_SessionID>11783</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2264</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Use ofan Emergency Department-Based Intranasal Fentanyl Protocol for Vaso-Occlusive Episodes in Sickle Cell Disease: The Unanticipated Consequences</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102674</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3528</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Management of Renal Dysfunctions in Escort-HU Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108026</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3529</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcome of Severe Vaso Occlusive Crisis in Sickle Cell Disease Adults Admitted to Referral Centers in Africa and Europe. Preliminary Results from the Presev 2 Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104386</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3530</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Reduced Hemolysis and Related Complications in Females with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107955</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Plerixafor - to be used alone for mobilization of patients with sickle cell disease</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3531</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells (HPCs) for Globin Gene Transfer in Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102743</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3532</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Silent Cerebral Infarct Pathophysiology Study in Sickle Cell Anemia Children By a Multimodal Approach</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100419</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3533</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Multiple-Ascending-Dose Study of the Soluble Guanylate Cyclase Stimulator, IW-1701, in Healthy Subjects</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104670</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3534</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improved Clinical Outcomes in Adults with Sickle Cell Disease and Diabetes Treated with Metformin</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107586</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3535</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Similar Event-Free Survival but Higher Incidence of Mixed T Cell Chimerism after Hematopoietic Cell Transplantation for Sickle Cell Disease Using Rabbit Versus Horse Atg;a Study from the Sickle Transplant Alliance for Research (STAR)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104437</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3536</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Scheduled Outpatient Red Blood Cell Exchange Program Reduces Admission and Complications in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108225</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3537</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prevention of Morbidity in Sickle Cell Disease Phase II (Improvement of Pain and Quality of Life in Children with Sickle Cell Disease with Auto-adjusting Continuous Positive Airways Pressure: Phase II) (POMS 2b pediatric cohort)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104418</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3538</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Blunted Cardiac Response to Head-up Tilt Occurs in Sickle Cell Disease but Not Healthy Controls</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105831</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3539</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Temporal Evolution of Diffuse Myocardial Fibrosis in Sickle Cell Anemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108590</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3540</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Physician Prescribing Practices in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101820</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Hydroxyurea use in children with sickle cell</OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3541</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Quantitative Sensory Testing in Children with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105716</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3542</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chronic Anemia Is Associated with Lower Cerebral and Peripheral Arterio-Venous Oxygen Gradients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105071</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3543</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Management of Infections in SCD Patients Treated with HU in the Framework of Escort HU</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108242</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3544</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sickle Cell Trait and Cognitive Function in African Americans: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106771</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>GBT440 is in Phase 3 a clinical trial and is not approved for use by the FDA</OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3545</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Single Center Experience of GBT440 Treatment of Severe Anemia in Sickle Cell Disease (SCD)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101239</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3546</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Stopping Folic Acid Supplementation in Hydroxyurea Treated Children with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108339</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3547</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Diastolic Dysfunction Is Associated with Impaired Cardiopulmonary Exercise Performance in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105520</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3548</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pediatric Pain Screening Identifies Youth at Risk for Chronic Pain in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108114</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3549</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>No Impact of Pharmacokinetics Profiles on the Clinical and Biological Response to Hydroxyurea in Children with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104372</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3550</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ventilation-Perfusion Scintigraphy Is Comparable to CT Pulmonary Angiography for the Diagnosis of Pulmonary Embolism in Sickle Cell Disease: A 16-Year Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104667</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3551</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Frequency of Vasocclusive Crises and the Relationship of Vitamin D Deficiency to the Frequency of Pain Crises in Children with Sickle Cell Disease in an Aboriginal Tribal Region in Gadchiroli, India</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107756</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3552</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Moyamoya Syndrome in Children with Sickle Cell Disease: A 10-Year Single-Center Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104206</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3553</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prevalence of High Body Mass Index in Children with Sickle Cell Disease and Its Correlation of Disease Severity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105681</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3554</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Contrary to Expectations: Seasonal Variation in Sickle Cell Crisis - a Nation Wide Data Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108689</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3555</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characteristics of a Chronic Pain Phenotype in Adults with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107538</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3556</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prevention of Morbidity in Sickle Cell Disease Phase II (Improvement of Cognition in children with Sickle Cell Disease with Auto-adjusting Continuous Positive Airways Pressure: Phase II) (POMS 2b paediatric cohort)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107681</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3557</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown, -Globin Induction and Simultaneous Repression of -Globin for the Potential Treatment of Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105811</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3558</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108383</Key_PaperID>
<Key_SessionID>11784</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3559</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Daily Users of Marijuana with Sickle Cell Disease Report More Severe Pain Crisis Yet Have Similar Rates of Admission to Non-Users</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107606</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2265</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Metabolic Reprogramming of Dendritic Cells Is Controlled By the Mir-142</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104310</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2266</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Incidence, Treatment Patterns, and Outcomes of Histiocytic Disorders in the United States: A Forty-Year Population Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105056</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2267</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>G-CSF Vs Haematopoietic Stem Cell Transplantation in Severe Congenital Neutropenia with ELANE Mutation: Role of G-CSF Dose.a Retrospective Controlled Study on Behalf of Saawp (Severe Aplastic Anemia Working Party) of the EBMT, of the Stem Cell Transplant for Immunodeficiency Group in Europe (SCETIDE), of the Severe Chronic Neutropenia French Registry (SCNFR) and Italian Neutropenia Registry (INR)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107573</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2268</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of Neutrophil Extracellular Trap Release through the Disruption of PAD4 Leads to Decreased Neutrophil and Platelet Accumulation at Sites of Venular Vascular Injury in a Murine Model of Heparin-Induced Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102081</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2269</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bortezomib-Activated Macrophages Contribute to Multiple Myeloma Progression Via Cancer Stem Cell Enrichment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102478</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2270</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Differential Use of the Signaling Molecules BTK and PLC- in Mast Cells Stimulated Via the Receptors FcRI and KIT</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106027</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Describes use in pediatric patients</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2271</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase 2, International, Multicenter, Prospective Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients with Solid Tumors Undergoing Chemotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106838</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2272</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Serum Ferritin Trends Are Associated with Survival in Adult Hemophagocytic Lymphohistiocytosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108237</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2273</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characteristics and Outcomes of Malignancy-Associated Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Single-Center Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99985</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2274</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Immunogenicity Assessment of Tbo-Filgrastim in Cancer Patients Receiving Chemotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100713</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2275</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cyclic Neutropenia, Congenital and Idiopathic Neutropenia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107791</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2276</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Phosphoinositide Kinase Pikfyve Regulates Lysosomal Biogenesis in Macrophages By Modulating the Transcription Factor EB (TFEB)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107922</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2277</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Neutrophil to T-Lymphocyte Ratio (NLR) and Neutrophil to Monocyte Ratio (NMR) Are Promising Biomarkers in Chronic Lymphocytic Leukemia Prognostic Assessment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106672</Key_PaperID>
<Key_SessionID>11785</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2278</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effects of CSF3R mutations on Myeloid Differentiation and Proliferation of Hematopoietic Cells of Congenital Neutropenia Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104718</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3560</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Mutant Wasp in X-Linked Neutropenia Partially Recapitulates Defective Neutrophil Production through Its Expression in WASP-Deficient NB4 Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108687</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3561</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Role for Histone Deacetylase 10 (HDAC10) in the Regulation of PD-L1 Expression and Immune Tolerance Mediated By Antigen Presenting Cells (APCs)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103157</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3562</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Defective Function of KCa3.1 Channels in Lysosomal Storage Disorders</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101391</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3563</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An Unbalanced Monocyte Macrophage Polarization in the Bone Marrow Microenvironment of Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106036</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3564</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment Dilemmas in Asymptomatic Children with Primary Haemophagocytic Lymphohistiocytosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102575</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3565</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>HIF1A Is a Critical Downstream Mediator for Hemophagocytic Lymphohistiocytosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107139</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3566</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>HAX1AssociatedCongenital Neutropenia: A 25 Year Long-Term Analysis ofthe European Scnir Cohort</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108016</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3567</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transfusion of Storage-Damaged Red Blood Cells Induces Ferroptosis in Splenic Macrophages</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104352</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3568</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Immunogenicity between the Proposed Pegfilgrastim Biosimilar MYL-1401H and Reference Pegfilgrastim</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104281</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3569</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Idelalisib Impairs TREM-1 Mediated Neutrophil Inflammatory Responses</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108570</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3570</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting Leukocyte Derived MPO in Heart Failure</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103167</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3571</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Correlation between Bone Disease and Genotype in Patients with Type 1 Gaucher Disease. Data from the Spanish Gaucher Disease Registry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104805</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3572</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeted Gene Sequencing of Adult Patients with Hemophagocytic Lymphohistiocytosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106284</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3573</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Features and Treatment Approaches in Patients with Rosai-Dorfman Disease: The Mayo Clinic Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106824</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3574</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Follow-up of Patients with Chronic Granulomatous Disease Receiving Bone Marrow Transplantation Using Immunosuppressive Conditioning Regimen</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107819</Key_PaperID>
<Key_SessionID>11786</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3575</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transcriptome Analysis of Lymphoma Edited Monocyte Phenotype</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102897</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3576</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Immune Clearance of Senescent Cells Via Activation of Endogenous Retroviruses and the Viral Recognition Pathway</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107371</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3577</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Absence of TNF- Promotes Anemia of Inflammation and Inflammatory Bowel Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107140</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3578</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>TET2 Regulates CD4+ T Follicular Helper Differentiation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104785</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3579</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Human Double-Degative Regulatory T Cells Modulate Differentiation and Function of Conventional T Cells By Disrupting mTOR Activity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105926</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3580</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>IRF5 Loss Impairs TLR9/BCR-Induced B Cell Activation, Proliferation and Plasmablast Differentiation through Erk1-Myc Signaling</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106391</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3581</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>the Clinical Impact of Impaired Natural-Killer Cell Cytotoxicity for Diagnosis and Prognostication in Adult Patients with Febrile Cytopenia Including Hemophagocytic Lymphohistiocytosis and Similar Diseases: The Results of Prospective Phase II Observational Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104673</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3582</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High-Throughput Sequencing of IgG B-Cell Receptors Reveals the Frequent Usage of the Rearranged IGHV4-28//IGHJ4 Gene in Primary Immune Thrombocytopenia in Adults</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105796</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3583</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Risk of Developing Tuberculosis in Cancer Patients Is Greatest in Lymphoma: A Large Population-Based Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101342</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3584</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Risk of Hyponatremia and Associated Clinical Characteristics in Patients with Acute Lymphoblastic Leukemia after CD19 Targeted Chimeric Antigen Receptor (CAR) T-Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107195</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3585</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Blockade of IL-2 and IL-15 Gamma Chain Receptor Signaling Decreases Leukemic Cell Viability in T-Cell Large Granular Lymphocyte Leukemia and Adult T-Cell Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107823</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Bendamustine in combination (predominantly with rituximab) for treatment of CLL and indolent NHL. Use of bendamustine in combination with monoclonal antibodies is off label.</OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3586</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Kinetics of T-Cell Subset Reconstitution Following Bendamustine-Containing Therapy for Low-Grade Lymphoproliferative Disease; A Population Based Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101473</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3587</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104763</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3588</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Th1/17 Cells Are Expanded in Bronchial Alveolar Lavage (BAL) Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108366</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3589</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107246</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3590</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterisation of Naive Immunological Profile of Umbilical Cord Blood: The Role of Mucosal-Associated Invariant T Cells and Functional Defects of T Cells and Natural Killer Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103542</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3591</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characteristics of CD4+ and CD8+ Memory T Cell Subsets from Peripheral and Bone Marrow in Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107425</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3592</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals Chemokine Storm and Separates Clinical Subtypes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107181</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The use of rituximab, sirolimus, and intravenous immunoglobulin off-label for the treatment of idiopathic multicentric Castleman disease will be discussed as potential second-line options for patients that do not respond to first line, FDA-approved treatment with siltuximab.</OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3593</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108428</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3594</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Analysis of Outcome of Patients Treated withAnti PD-1/Pdl-1 Therapy According to the Degree of Lymphopenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101586</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Sildenafil was used for immunomodulation instead of it's common erectile dysfunction purpose.  Pfizer was not involved in any aspect of this study.</OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3595</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PDE-5 Inhibition Decreases Cancer Tumor Burden through Immunomodulation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107540</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3596</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterizing the Mechanism of NE and P3 Cross-Presentation in B Cell-Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103629</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3597</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Analysis of CMV pp65 Antigen-Specific CD8+ T Cell Responses According to HLA Class I Alleles and Intra-Individual Dominance</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104843</Key_PaperID>
<Key_SessionID>11787</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3598</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clonal T-Lymphocyte Populations in Healthy Donors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104346</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2279</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>NKG2D Negatively Regulates CD4 T Cells in Allo-Response in Mice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108208</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2280</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Immune Checkpoint Inhibitors Restore Function of Lesion Infiltrating T Lymphocytes in Langerhans Cell Histiocytosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105352</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2281</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Single-Cell Multiplex Proteomics Reveals Synergistic Impact of Antigen and Rimiducid-Dependent Stimulatory Signals on Promoting Polyfunctional GoCAR-T Cells Targeting Prostate Stem Cell Antigen (PSCA)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106851</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2282</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Thermal Ablation of Colorectal Cancer Metastases Leads to Activation of Individual Cancer-Specific T Cell Immunity</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108362</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2283</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Tolerization of CD4+ Recent Thymic Emigrants Is Required to Prevent RBC-Specific Autoimmunity</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105195</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2284</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bloodstream Infection Survey in High-Risk Oncology Patients (BISHOP): Preliminary Report</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100080</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2285</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The STAT Signaling Biosignature at the Single Cell Level Reveals Novel Insights in the Association of FOXP3+ T Regulatory Cells with Recurrent Spontaneous Abortions (RSA)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106531</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2286</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Retrospective Next Generation DNA Sequencing Analysis in Patients with Hemophagocytic Lymphohistiocytosis (HLH) Highlights Genetic Variants Associated with Secondary/Late-Onset Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107378</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2287</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Novel Mutations in RASGRP1 Are Associated with Immune Dysregulation and Predispose to EBV-Induced Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101971</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2288</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Invasive Pulmonary Aspergillosis in Acute Leukemia in the Era of New Antifungal Treatment and Prophylaxis Is Still Frequent, Even in Patients with Acute Lymphoblastic Leukemia, and Adversely Affects the Overall Treatment Outcome. Results of a 5-Year Study at a Single Institution</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106656</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2289</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bispecific Antibodies on Hematological Malignancies: A Novel Mechanism of Action That May Contribute to Therapeutic Efficacy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106433</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2290</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Zika Virus Infection Activates Proinflammatory Cytokines and Triggers Monocyte Differentiation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107147</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2291</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Demonstration of a Single-Parameter, Rapid Flow Cytometry Assay in Assessing Natural Killer Cell Cytotoxic Function</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103237</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2292</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Analysis of Gram-Negative Bacillisepticemia-Associated Hemophagocytic Lymphohistiocytosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105466</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2293</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Unbiased Profiling of the Immunomodulatory Properties of Soluble Proteins</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101171</Key_PaperID>
<Key_SessionID>11788</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2294</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Utility of Computed Tomography for the Diagnosis of Invasive Aspergillosis in Hematological Malignancy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99860</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2295</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Structural and Functional Characterization of a Single Chain 3 Integrin in Solution and on the Cell Surface and the Implications on Integrin Activation and Pathogenesis of Anti-HPA-1a Alloantibodies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102899</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2296</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia on Signaling and Epigenetics in Endothelial Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106346</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2297</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Protein Disulfide Isomerase Negatively Regulates Platelet Function through Modulation of the Thromboxane A2Receptor</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101131</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2298</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The C Loop of Fifth Epidermal Growth Factor-like Domain of Thrombomodulin Exerts Cytoprotective and Angiogenic Effects in Vitro and In Vivo</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108211</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2299</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Noval Insights into the Role of Platelet Angiogenic Growth Factors on the Regulation of Normal Vascular Development</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101385</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2300</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dysfunction of Bone Marrow Endothelial Progenitor Cells from Subjects with Prolonged Isolated Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation Can be Improved By N-Acetyl-L-Cysteine</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104361</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2301</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelet Contraction Cytometry: A Biophysical, High-Throughput Research-Enabling and Diagnostic Platform</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107781</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2302</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>TULA-2 Deficiency Enhances Platelet Response to CLEC-2 Agonists</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104476</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2303</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CD36 Promotes Platelet Phosphatidylserine Exposure through MAP Kinase ERK5</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108506</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2304</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Optimization of Clot Formation Under Blood Flow in a Tissue Engineered Blood Vessel</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103434</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2305</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelet Tissue Factor Activity Is Specifically Induced By GPIbActivation Pathway, Independent of GPVI,IIb3 and Protein Disulfide Isomerase Activities</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108722</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2306</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Effect of ABO Immune Complexes on Endothelial Cell Integrity As Measured By Electric Cell-Substrate Impedance Sensing (ECIS) and Confocal Microscopy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106968</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2307</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Different Conformations of Fibronectin Fibrils Formed Under Cell-Free Condition in Vitro display Distinct Effects on Cell Adhesion and Spreading</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107924</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2308</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cancer Cell-Derived Extracellular Vesicles Are Prothrombotic in an in-Vitro Vessel Model</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102042</Key_PaperID>
<Key_SessionID>11789</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2309</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Critical Extracellular Matrix Proteins Besides Collagen Bind Von Willebrand Factor</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103545</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3599</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mapping the Masked Region of the A1 Domain in Full-Length VWF</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108692</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3600</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Alpha-Granule Release Reaction Is Mediated By SNARE-Dependent Solubilization of the Granule Matrix</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106105</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3601</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>LDL and HDL Have Opposing Effects on VWF Self-Association</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104558</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3602</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Critical Role for the IKK/Lipid Rafts Axis in Regulating Platelet Exocytosis, Via the Spatial Regulation of SNARE Proteins</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104720</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3603</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improved Inhibition of Protease-Activated Receptor 4 (PAR4) with Function-Blocking Antibodies Provides Equivalent Antithrombotic Activity in the Face of the Hyper-Reactive Thr120 PAR4 Variant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107656</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3604</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phosphorylation of Y311 on Pkc Regulates Protease Activated Receptor 4-Mediated Signaling in Platelets</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104243</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3605</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CD36 Activation Enhances Hydrogen Peroxide Generation in Human Platelets</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101138</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3606</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Exogenously Added Cofilin Increases Ex Vivo Production of Functional Platelets By Stimulating Proplatelet Formation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107956</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3607</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Role for PARS and Thrombin-Gpib Interaction for Thrombin Induced Procoagulant Platelet Formation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102678</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3608</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ischemia-Reperfusion Injury with Pringle's Maneuver Induces Increasing of Unusually Large Von Willebrand Factor Multimers after Hepatectomy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102574</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3609</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phenotype of Platelet Is Altered and Associated with Disease Activity of Rheumatoid Arthritis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106847</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3610</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelet Programmed Cell Death Ligand 1 (pPDL-1) Is a Prognostic Marker in Advanced Lung Cancer</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104489</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3611</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transferrin Saturation and Its Association with Platelet Reactivity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105652</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3612</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Brain-Derived Neurotrophic Factor Induces Platelet Aggregation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106814</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3613</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Role of VWF, FVIII, ADAMTS13 and Inflammatory Response in the Outcome of Acute Ischemic Stroke Mechanical Thrombectomy Procedure</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107269</Key_PaperID>
<Key_SessionID>11790</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3614</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Calcium-Induced Conformational Changes in EF hands and Autoinhibitory Linker Region are Critical for Catalytic Activity of CalDAG-GEFI Towards the Small GTPase Rap1</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106998</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2310</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelet Factor 4 Binds to Released Von Willebrand Factor Strands from Injured Endothelium and Forms a Prothrombotic HIT Antigenic Complex</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102941</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2311</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mass Cytometry of Platelets: Simultaneous Functional and Phenotypic Analysis of Multiple Surface Markers in Healthy Subjects and Patients with Inherited Platelet Disorders Reveals Novel Platelet Sub-Populations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106713</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2312</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Glucocorticoid (GC) Induced Cytokine Expression in CD4+ T Cells Is a Candidate Biomarker for Clinical Steroid Response in Patients with Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104449</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2313</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Use of Anticoagulation in Patients with Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105951</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2314</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelet Function in Thrombocytopenic Patients with Chronic Liver Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105305</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2315</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Distinctive Platelet Features and Lymphocyte Sets Distribution in Immune Thrombocytopaenia Patients Responders to Thrombopoietin Receptor Agonists</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105426</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2316</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelet Features from Immune Thrombocytopenia Patients Refractory to Therapeutic Treatments</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103470</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2317</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Atypical Hemolytic Uremic Syndrome-Clinical Presentation, Treatment, and Short Term Outcomes: The Mayo Clinic Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105140</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2318</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Severe Trauma Leads to a Fall in Intracellular Triphosphates and a Rise in cAMP in Platelets</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106905</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2319</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Vincristine-Loaded Platelets Coated with Anti-CD41 MAbs: A New Proposal for the Treatment of Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107885</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2320</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bleeding Risk Assessment By Sonoclot in Severe Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104121</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2321</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long Term Eltrombopag in Paediatric Immune Thrombocytopenia: Update on UK Patients Treated with Eltrombopag As Part of the Petit and PETIT2 Studies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108295</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2322</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A 2 Year of Review of HIT Evaluations at an Urban Medical Center with an Aim Towards Quality Improvement and the Development of Practical Testing Strategies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102775</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2323</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Global Coagulation Assays in Normal and Thrombocytopenic Populations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103195</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>There is no validated or approved treatment of CIT.  At our institution, the thrombopoietin-receptor agonist romiplostim, is being tested in a phase II clinical trial to treat CIT (being reported separately).  Further, since there is no alternative, some oncologists have been using romiplostim off-label/off study to treat CIT and prevent recurrence of CIT when chemotherapy is resumed.  Raising the platelet count could potentially increase the risk of thrombosis.  Therefore, as a Quality Assessment initiative, we conducted a retrospective analysis of all use of romiplostim in cancer patients at MSKCC to determine the efficacy for treatment of CIT, as well as rates of thrombosis.  </OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2324</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Thrombotic Adverse Events of Romiplostim Use in Patients with Thrombocytopenia Related to Underlying Malignancies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100306</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2325</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Incidence and Outcome of Severe Thrombocytopenia Associated with Zika Virus Infection  Puerto Rico, 2016</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100996</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2326</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Successful Treatment of Alemtuzumab Induced Immune Thrombocytopenia with a Thrombopoietin Receptor Agonist</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103938</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2327</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Point-of-Care Quartz Biosensor Chip for Detection of PF4/Heparin Complexes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108111</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2328</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Positive Direct Antiglobulin Test Predicts Development of Chronic Immune Thrombocytopenia and Treatment with Second Line Therapy in Pediatric ITP Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106227</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2329</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Megakaryocyte-Based Screening System Identifies Compounds That Promote Megakaryocyte Maturation and Platelet Production in Vitro</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106630</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2330</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelet Desialylation Is a Novel Mechanism of Thrombocytopenia during Mechanical Circulatory Assistance</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104380</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2331</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes for Atypical Hemolytic Uremic Syndrome (aHUS) Treated with Eculizumab: A Single Center Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104662</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2332</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Heparin-Induced Thrombocytopenia: Are We Ordering Too Much</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105832</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2333</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Defective Rab1b Related Megakaryocytic ER-to-Golgi Transport in RUNX1 Haplodeficiency</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100122</Key_PaperID>
<Key_SessionID>11791</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Romiplostim is approved for use in adults with chronic ITP; use in children is investigational.</OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2334</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ASingle-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105505</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3615</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Performance Characteristics of a Novel Platelet Viability Assay for Heparin-Induced Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108292</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3616</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterizing the United Kingdom Congenital Thrombotic Thrombocytopenic Purpura Population</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100599</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3617</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In Vitro Complement Activation By PF4/Heparin Complexes Is Mediated By Plasma IgM</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107742</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3618</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Whole Exome Analysis and Clinical Relevance in Patients with Atypical Hemolytic Uremic Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103826</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3619</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Analysis of Patients Mislabeled with Heparin Induced Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106842</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3620</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Detectable ADAMTS13 Inhibitor on the Clinical Presentation and Outcome of Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP): Analysis Using the United States Thrombotic Microangiopathy (USTMA) Clinical Registry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104241</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3621</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>HIT Diagnosis: A Proposed New Definition for Clinical Research</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105642</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>IVIg - congenital agammaglobulinaemia and hypogammaglobulinaemia


Anti-D  haemolytic disease 


Rituximab  severe acute rheumatoid arthritis, stage III-IV follicular lymphoma, follicular non-Hodgkins lymphoma, diffuse large B-cell non-Hodgkins lymphoma, active granulomatosis with polyangiitis and microscopic polyangiitis


Azathioprine  severe acute Crohns disease, acute ulcerative colitis, rheumatoid arthritis, severe systemic lupus erythematosus and other connective tissue disorders, polymyositis


Mycophenolate  prophylaxis of acute rejection in renal, cardiac and hepatic transplantation</OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3622</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment, Platelet Count Pattern and Comorbidities Among Primary Immune Thrombocytopenia (ITP) Patients Seen in Routine Clinical Practice: Data from the United Kingdom Immune Thrombocytopenia (UK ITP) Registry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108686</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3623</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Heparin-Induced Thrombocytopenia with Very High Antibody Titer Is Associated with Slower Platelet Recovery</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108213</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3624</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Factors Associated with Mortality in Immune-Mediated Thrombotic Thrombocytopenic Purpura: Results from the United States Thrombotic Microangiopathy TTP Registry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105242</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3625</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105459</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>Oseltamivir phosphate (Tamiflu) is an FDA-approved antiviral sialidase inhibitor and has been prescribed worldwide for the treatment of patients with influenza. </OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3626</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In Non-Selected Patients Treated for Influenza, Oseltamivir, a Glycosialidase Inhibitor, Demonstrates Improvement in Platelet Counts Compared to Time of Dosing, but Not over Baseline Levels</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102297</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3627</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Management of Newly Diagnosed Paediatric ITP in UK</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100881</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Use of the TPO-R agonist, eltrombopag, for the treatment of adult patients with persistent ITP</OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3628</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Eltrombopag (EPAG) Treatment Improved Platelet Counts in Patients with Persistent or Chronic Immune Thrombocytopenia during a 2-Year, Phase IV, Open-Label Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101955</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3629</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Aspirin Inhibits Platelets from Reprogramming Breast Tumor Cells and Promoting Metastasis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99597</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3630</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Single-Center Experience of the Utility of a Rapid ADAMTS13 Assay</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99878</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3631</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Neutropenia Following Intravenous Immunoglobulin Therapy in Adult Patients with Immune Thrombocytopenic Purpura</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104515</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3632</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Biomarkers of Platelet Activation and Their Prognostic Value in Patients in Sepsis Associated Coagulopathy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104332</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3633</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Integrated mRNA and miRNA Profiling Revealed Deregulation of the Cellular Stress Response in Bone Marrow Mesenchymal Stem Cells Derived from Patients with Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107135</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3634</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Aging Significantly Drives Decision Making and Outcome in Immune Thrombocytopenia Patients: A Monocentre Study on 508 Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105162</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3635</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Defective Early B Cell Tolerance in Primary Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107330</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Status of romiplostim use in children with ITP  was off-label during the project</OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3636</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evolution of Platelet Function and Bleeding in Children and Adults with Chronic Immune Trombocytopenia on Romiplostim Treatment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105833</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3637</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Acquired Thrombotic Thrombocytopenic Purpura and Acute Pancreatitis: Variable and Reciprocal Pathophysiologic Relationships</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104866</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3638</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Polymorphisms of Monocyte-Activating Cytokine/Chemokine Genes Affect the Susceptibility to, and Severity of Chronic ITP</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104210</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3639</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Antibodies Against Macrophage CD44 Protect Platelets from FcR-Mediated Phagocytosis: A Potential Mechanism for CD44 Antibody Amelioration of Murine Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108255</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3640</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Early Plasmapheresis Vs Late Plasmapheresis in Patients with Thrombocytopenic Thrombotic Purpura: A Nationwide Analysis from 2005-2014</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108182</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3641</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Anti-Platelet Antibodies Are Predominantly IgM in Childhood Immune Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106956</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3642</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Heparin Induced Thrombocytopenia: A Laboratory Comparison of the IgG Specific EIA Vs Polyspecific EIA</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108458</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3643</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Recognizing the Existence of Heparin Induced Thrombocytopenia and Thrombosis in the Setting of High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Case Series</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102757</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3644</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Differential Expression of IL-17 Correlates with Clinical and Pathological Features of ITP</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103269</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3645</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>TNF- Blockade InhibitsPro-Inflammatory Monocytes/Macrophages in ITP</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100734</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3646</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>External Validation of the Plasmic Score: A Clinical Prediction Tool for Thrombotic Thrombocytopenic Purpura (TTP) Diagnosis and Treatment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101376</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3647</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Heterogeneous Landscape of RUNX1 Related Disorder: Four Families with Inherited Thrombocytopenias and Novel Genetic Variants in RUNX1 Associated to Relevant Clinical Complications</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99785</Key_PaperID>
<Key_SessionID>11792</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3648</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Therapy of Adults Affected By Idiopathic Thrombocytopenic Purpura with 3 Cycles Pulses of High-Dose Dexamethasone (HD-DXM): A Prospective Randomized Clinical Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101227</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2335</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Complete TFPI Gene-Disruption Is More Severe Than TFPI Kunitz-1 Gene-Deletion in Mice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100967</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2336</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Low TFPI Mice in Models of Atherosclerosis and Endotoxemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107760</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2337</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Protamine Sulfate Interacts with Partially Activated Forms of Factor V Which Contributes to Its Paradoxical Anticoagulant Effect</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107478</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2338</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Differentiation of Patients with Type 1 Von Willebrand Disease Vs. Low Normal Levels of the Von Willebrand Factor Using a Very High Shear Rate, Non-Citrated Blood Flow System  </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104326</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2339</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genetic Fusion to Factor XIII B-Subunit Improves the Pharmacokinetic Properties of Factor IX</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108133</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2340</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Molecular Weight Kininogen Alters the Tumor Microenvironment and Reduces Tumor Stem Cell Content</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103813</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2341</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sensitive and Specific Functional Flow Cytometry Assay for Rapid Diagnosis of Heparin Induced Thrombocytopenia and Thrombosis (HIT)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106555</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2342</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Design and Characterization of a Novel, Vwf Independent Coagulation Factor VIII (LAFATE)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105996</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2343</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of Factor IXa By Protein S: Critical Function of the Protein S SHBG-like Domain</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103805</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2344</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Factor VIII Fusion with an Inactivated FIX Generates a Biologically Active Molecule with Delayed Clearance in a FVIII/VWF Knockout Mouse Model</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108664</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2345</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelet-Based Factor VIII Activity Is Inhibited By Anti-C2 Domain Antibodies That Don't Significantly Inhibit Factor VIII Activity in a Standard Assay</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103983</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2346</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prolonged Prothrombin Time in DIC: Contributions of Excess Thrombin and Fibrinogen Degradation Products</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107844</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2347</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of a Tolerogenic Factor V Peptide and Its Potential Role in FVIII Tolerance Induction</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100923</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2348</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pre-Analytical Stability of Coagulation Parameters in Plasma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99818</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2349</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Factor VII Augusta (FVII G395D/G395N):a Compound Heterozygous Deletion Insertion and Missense Variant Manifesting As Moderate Bleeding Disorder</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102273</Key_PaperID>
<Key_SessionID>11793</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2350</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fibrin(ogen)-Pathogen Interactions Support Antimicrobial Host Defense Following Staphylococcus Aureus Peritonitis Infection</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105682</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3649</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Single Cleavage Reaction in the Proteolytic Activation of Factor V to the CofactorIs Rate-Limiting in a Step That Is Selectively Dependent on Anion Binding Exosite 2 of Thrombin</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106133</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3650</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Regulation of Factor VIII By Activated Protein C: Assessment in Vitro and In Vivo</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102344</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3651</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Innate Immune Activation Via TLR9 May Enhance Antibody Formation Against Factors VIII and IX in Protein and Gene Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103498</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3652</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Rutin Increases Shear-Dependent TGF-1 Activation By Interacting with Putative PDI Binding Sites: Role of Oxidation in Shear-Dependent TGF-1 Activation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106236</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3653</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Apolipoprotein B-100 Binds Von Willebrand Factor and Accelerates Its Proteolysis By ADAMTS13 Under Fluidic Shear</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101808</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3654</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Coagulopathy As a Dose-Limiting Toxicity in Systemic Administration of Mesenchymal Stem Cells (MSCs): Relative Safety of Bone Marrow Versus Adipose Derived MSCs </PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104698</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3655</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation the Value of TAT, PIC,Tpaic, TM in Diagnosing Disseminated Intravascular Coagulation in Chinese populationa Multi-Center Prospective Observational Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100740</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3656</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Diagnostic Performance and Prognostic Value of a Chinese Diagnostic Scoring System (CDSS) for Disseminated Intravascular Coagulation---a Multicenter Prospective Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108429</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3657</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparative Glycosylation Mapping of Recombinant and Plasma-Derived Human Factor VIII Reveals Key Biological Differences</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108759</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3658</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Increasing of Ternary Complex Formation By Predominant Accumulation of Factor (F)X Accompanied By Increase of Fixa Contributes to Enhancement of Clotting Function By Apcc in Combination with Emicizumab</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104002</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3659</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In silico Modeling of the Impact of Antithrombin Lowering on Thrombin Generation in Rare Bleeding Disorders</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106215</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3660</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Von Willebrand Factor A1 Domain Binds to Clusters II and IV of Low-Density Lipoprotein Receptor-Related Protein 1</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107889</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3661</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Factor VIII Plays a Direct Role in Osteoblast Development</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101203</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3662</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Heparin Infusion for Central Line PatencyandCorrected Gestational AgeMay Affect Coagulation Studiesin the Neonatal Intensive Care Unit</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104407</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3663</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Physiologically Based Pharmacokinetic (PBPK) Modeling for Betrixaban and the Impact of P-Glycoprotein Inhibition on Betrixaban Pharmacokinetics</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107828</Key_PaperID>
<Key_SessionID>11794</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3664</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Plasma FXIII Mediated Crosslinking Is Necessary for Thrombin Generation and Clot Retraction</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105564</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2351</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real-World Expenditures Associated with Treatment of Hemophilia a and B Patients with Standard and Extended Half-Life Factor Replacement Products in the US</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108830</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2352</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterization of the HLA-Class-II (HLAcII)/Therapeutic Factor VIII (FVIII)-Derived Peptidome By FVIII Domain and Hlacii Isomer</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107525</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2353</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Supra-Physiological Concentrations of C1 Esterase Inhibitor Enhance Thrombin Generation in the Presence of Thrombomodulin</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106365</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2354</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibitor Screening in Severe Hemophilia a: A Six-Year Single Center Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107592</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2355</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelet-Dependent Thrombin Generation Is Correlated with Phenotypic Severity in Severe Hemophilia a</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105869</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2356</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Plasma Proteolytic Cascade Activation and Control during Neonatal Cardiopulmonary Bypass Surgery</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104569</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2357</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Predictors of Outcome in Immune Tolerance Induction Treatment of Hemophilia  Patients with High-Responding Inhibitors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106268</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2358</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Disseminated Intravascular Coagulation Predicts Adverse Outcomes in Children with Suspected Sepsis in the Emergency Department</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107744</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2359</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chronic Kidney Disease in the U.S. Hemophilia Population: A Cohort Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106645</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2360</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Management of Joint Replacement in Hemophilia a with Inhibitors during Emicizumab Prophylaxis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108471</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2361</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pharmacokinetics Using myPKFiTR for Personalized Prophylaxis in Children with Severe Hemophilia a.</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107286</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2362</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of the Functional Characteristics and Post-Translational Modifications of Commercial Factor VIII Products</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104634</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2363</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Acquired Factor X Deficiency in Light Chain (AL) Amyloidosis Is Rare and Associated with Advanced Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105513</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2364</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Epitope Mapping of Inhibitor Patient Plasmas during Immune Tolerance Induction</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100613</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2365</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Factor XI DeficiencyIsNot Associated with Increased Risk of Pneumonia in Adults</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100963</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2366</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Perioperative Management in Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101281</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2367</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Influence of Inhibitor Characteristics on Response to Hemostatic and Immunosuppressive Treaments in Acquired Hemophilia Patients: The Ciha Project</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102288</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2368</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Outcomes of Weekly Prophylaxiswith rFVIIIFc: Longitudinal Analysis of the A-LONG and ASPIRE Study Population</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102901</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2369</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Use of Bleeding Assessment Tools in the Diagnosis of Von Willebrand Disease: Are We Asking the Right Questions?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103810</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2370</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (RIX-FP) in Previously Treated Children &lt; 12 Years of Age with Hemophilia B: Long-Term Efficacy and Safety from an Ongoing Phase 3b Extension Clinical Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104347</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2371</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Computer Modeling Using Historical Data Demonstrates a Significant Reduction in Expected Extravascular Fibrinous Lesions Due to Congenital Plasminogen Deficiency While Receiving Intravenous Plasminogen (PLG) Replacement</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106955</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2372</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Beyond ABR: High FIX Activity Levels Translate into Clinical Benefits over Standard Prophylaxis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104278</Key_PaperID>
<Key_SessionID>11795</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2373</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Anti-Factor VIII A1 and A3 Domain Antibodies in the ImmuneReponse to Factor VIII inPatients with Hemophilia a</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101327</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3665</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Use of Recombinant Factor VIII Fc and Recombinant Factor IX Fc in Patients with Hemophilia A and B</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102157</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3666</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Polyethylene Glycol (PEG) Exposure in Parenteral Therapies Indicated for the Pediatric Population: History and Safety</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102683</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3667</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Outcomes of 14-Day Prophylaxis with rFIXFc: Longitudinal Analysis of the B-LONG and B-YOND Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102724</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3668</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102943</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3669</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Unique Inflammatory Signature in Hemophilic Arthropathy: Epigenetic Changes Due to Interaction between Blood and Fibroblast-like Synoviocytes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103444</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3670</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Risk for Major Bleeding in Patients with Severe Factor XI Deficiency Treated with Aspirin and Clopidogrel</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103459</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3671</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Providing Hemostasis for Long-Term Central Venous Access Device (LTCVAD) Placement in Patients with Factor VIII (FVIII) Inhibitors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103795</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3672</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Concizumab (Anti-TFPI) Exposure-Response Modeling in Patients with Hemophilia a</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103910</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3673</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Understanding Treatment and Care Utilization &amp;amp; Perceptions of Females with Hemophilia A or B in the Choice Project</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104181</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3674</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Excretion and Distribution of the 60-kDa PEG Moiety Used in BAY 94-9027 in Male Wistar Rats</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104275</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3675</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104291</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3676</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Random X-Chromosome Inactivation in Hemophilia A Carriers Does Not Fully Attenuate Bleeding Risk</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104419</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3677</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Novel Correlation between B Cell Survival Cytokines and Inhibitors in Hemophilia a</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99695</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3678</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cardiometabolic Risk Assessment in Children and Young Adultswith Hemophilia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107588</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The use of Wilate for immune tolerance induction therapy in hemophilia A with inhibitors.</OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3679</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Immune Tolerance Induction in Hemophilia a Patients Using Wilate a Canadian 10 Year Study (PREVAIL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101415</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3680</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Diagnosis of Hemophilia B Leyden in Japanese Brothers Reveals Spontaneous Amelioration in Early Childhood withc. -35 G&gt;aOnecut Binding Site Mutation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105959</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3681</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Does Age Affect Desmopressin Responsiveness in Patients with Von Willebrand Disease?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108135</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>VONVENDI [von Willebrand factor (Recombinant)] is indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease.</OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3682</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Recombinant Von Willebrand Factor Administration: Dosing Considerations and Rapid Stabilization of Endogenous Plasma FVIII Levels in Patients with Severe Von Willebrand Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106837</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3683</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Results from a Prospective, Dose Escalating, Prophylaxis Study in Young Boys with Severe Hemophilia a in China: The China Hemophilia Individualized Prophylaxis Study (CHIPS) (NCT02999308)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106266</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3684</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Feasibility of a Smartphone Application (App) Pictorial Blood Assessment Chart (PBAC) As an Endpoint in a Von Willebrand Disease Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105792</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3685</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Reclassification of Pre-Diagnosed Von-Willebrand Disease in the Eldery: A Hospital-Based Cohort Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108048</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3686</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>United States Post-Marketing Safety (PMS) Study of Rpfviii in Patients with Acquired Hemophilia a: Preliminary Data</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105331</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3687</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Thrombin Generation in Patients with Severe Hemophilia a May be Variable but Predictive of Response to Treatment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101285</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3688</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Successful Treatment of Bleeding in Acquired Hemophilia a with Activated Prothrombin Complex Concentrate in Spain</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103322</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3689</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Observational Study of Recombinant Factor-VIII-Fc, Eloctate, in Hemophilia Patients with and without Inhibitors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103716</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3690</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (RIX-FP) in Previously Treated Adolescents/Adults with Hemophilia B: Long-Term Efficacy and Safety from an Ongoing Phase 3b Extension Clinical Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103993</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3691</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Feasibility and Usability Study of a Nursing Orchestrated, Customized 3 Dimensional Virtual Reality Environment in Children with Hemophilia Undergoing Routine Intravenous Procedures</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104514</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3692</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Centralized Laboratory Testing for Inhibitors in the U.S. Hemophilia Treatment Centers Network: Testing Protocol and Results on 10,178 Specimens</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108378</Key_PaperID>
<Key_SessionID>11796</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off label use of low-molecular weight heparin for the prevention of coagulopathy specifically in patients with vascular malformations </OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3693</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Retrospective Study of Hematologic Complicationsin Vascular Malformation Patients with Localized Intravascular Coagulopathy Undergoing Surgical Intervention</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102223</Key_PaperID>
<Key_SessionID>11797</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2374</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Associations of Cholecalciferol Supplementation with Thrombin Generation and Fibrin Clot Structure in Severe Vitamin D Deficiency: A Prospective Cohort Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103097</Key_PaperID>
<Key_SessionID>11797</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Arixtra is currently used to prevent blood clots in patients who will be having certain types of surgeryor other conditions as determined by doctor. Our data suggest potential use of the drug to treat DIC in sepsis.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2375</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Synthetic Pentasaccharide Fondaparinux (Arixtra) Reduces Sepsis Induced Coagulopathy and Promotes Survival in the Baboon Model of E. coli Sepsis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104754</Key_PaperID>
<Key_SessionID>11797</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2376</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phosphatidylserine on Blood Cells and Microparticles Contributes to the Hyper-Coagulable State in Diabetic Kidney Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108176</Key_PaperID>
<Key_SessionID>11797</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2377</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Thrombosis and Von Willebrand Factor in Chuvash Polycythemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106436</Key_PaperID>
<Key_SessionID>11797</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2378</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Small Angle X-Ray Scattering Reveals the Conformation of 2glycoprotein I and the Conformational Binding Epitopes of Autoantibodies </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101206</Key_PaperID>
<Key_SessionID>11797</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2379</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Poor Responsiveness to Low-Dose Aspirin Contributes to Persistent In Vivo Platelet Activation in Polycythemia Vera</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105374</Key_PaperID>
<Key_SessionID>11797</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2380</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Venous Thrombosis and Breast Cancer in Older Women: Racial Disparity in Risk Factors and Outcomes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102693</Key_PaperID>
<Key_SessionID>11797</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2381</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer Associated Thrombosis. the Observational Roadmap-CAT Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104441</Key_PaperID>
<Key_SessionID>11797</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2382</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impaired Contraction (Retraction) of Blood Clots Is a Possible Pathogenic Mechanism in Venous Thromboembolism</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108017</Key_PaperID>
<Key_SessionID>11797</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2383</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pregnancy Outcome in Mice with Protein S Complete Deficiency</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108085</Key_PaperID>
<Key_SessionID>11797</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2384</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Unprovoked Versus Provoked Venous Thromboembolism in Pediatric Patients: Comparison of Characteristics and Outcomes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107830</Key_PaperID>
<Key_SessionID>11797</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2385</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Immunoblot Assay to Detect Contact Activation in Patients with Cancer</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106624</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3694</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prospective Evaluation of Thrombo-Hemorrhagic Events and Hypercoagulation Markers in Patients with Acute Promyelocytic Leukemia (APL) Receiving All-Trans Retinoic Acid (ATRA) Plus Chemotherapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102797</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3695</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104616</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3696</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ABO Blood Type and the Risk of Cardovascular Events: An Analysis of Framingham Data and Meta-Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107250</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3697</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Vwf-ADAMTS13 Axis in Acute Ischaemic Brain Injury:a Prospective Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101169</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3698</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Alteration of Endothelial Cell Hemostatic Equilibrium By Cancer Cell-Derived Microparticles, a New Insight in Pathogenesis of Cancer Associated Thrombosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103667</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3699</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Retrospective Analysis of Cancer-Associated Venous Thromboembolism in Patients with High Risk Cancer Types in Taiwan</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107732</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3700</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Tissue Factor Expression As a Prognostic Marker in Patients with B-Cell Malignant Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107903</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3701</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Alternatively Spliced Tissue Factor Levels in the Plasma of Patients with Liver Fibrosis, Liver Cirrhosis, and Hepatocellular Carcinoma: A Single-Center Retrospective Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108372</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3702</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Higher Rates of Anticoagulation Among Patients with Portal Vein Thrombosis Are Not Associated with Better Outcomes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103771</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3703</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Incidence of Venous Thromboembolism in Korea from 2009 to 2013</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105343</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3704</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Coagulation Activation in Brain Neoplasms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107647</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3705</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of FXII Activation in Human Plasma By Extracellular Vesicles from Cancer Cells Versus Non-Transformed Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108338</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3706</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Central Venous Catheters, a Major Culprit for Pediatric Venous Thrombosis: A Report from the Children's Hospital Acquired Thrombosis (CHAT) Project</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107031</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3707</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pattern of Coagulation Activation in Patients with Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108516</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3708</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>What Predicts Venous Thromboembolism Among Cancer Inpatients: A Proposed Predictive Model</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106026</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3709</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Validation of the Peds Clot Clinical Decision Rule [Pcdr] in Hospital-Acquired Venous Thromboembolism</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108327</Key_PaperID>
<Key_SessionID>11798</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3710</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Thrombotic Risk Factors, Antithrombotic Therapy, and Outcomes of Asymptomatic Carriers of Antiphospholipid Antibodies and Patients with Antiphospholipid Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106772</Key_PaperID>
<Key_SessionID>11799</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2386</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Pooled Analysis of the Xalia and Xalia-Lea Non-Interventional Studies of Rivaroxaban Versus Standard Anticoagulation in Venous Thromboembolism</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99887</Key_PaperID>
<Key_SessionID>11799</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2387</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Risk of Intracranial Hemorrhage with Direct Oral Anticoagulants: A Traditional and Network Meta-Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107005</Key_PaperID>
<Key_SessionID>11799</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2388</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Relevance of Intracranial Hemorrhage Volume in Primary and Metastatic Brain Tumors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104299</Key_PaperID>
<Key_SessionID>11799</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2389</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pyruvate Dehydrogenase Kinase Modulates Platelet Function and Thrombosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107580</Key_PaperID>
<Key_SessionID>11799</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2390</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effectiveness and Safety of the 15 Mg Dose of Rivaroxaban Compared with Vitamin k Antagonists in Patients with Atrial Fibrillation: Results from a Cohort Study in the Nationwide French Claims and Hospitalization Database (SNIIRAM)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108592</Key_PaperID>
<Key_SessionID>11799</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2391</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of D-Dimer Assays Performed at Local Labs Vs. Central Laboratory in the Evaluation of Apex Trial Outcomes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106776</Key_PaperID>
<Key_SessionID>11799</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2392</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Blood Loss in Rivaroxaban Anticoagulated Pigs with Severe Polytrauma Is Significantly Reduced By Early Therapy with Prothrombin Complex Concentrate</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101894</Key_PaperID>
<Key_SessionID>11799</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2393</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effectiveness and Safety of Rivaroxaban Vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation and Moderate-to-Severe Chronic Kidney Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100022</Key_PaperID>
<Key_SessionID>11799</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2394</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Hemostasis with the Thrombodynamics Test Improves Predictability of the Caprini Score for Postoperative DVT</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104491</Key_PaperID>
<Key_SessionID>11799</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2395</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Upregulation of Cortisol in Sepsis and Its Association with Markers of Hemostatic Dysregulation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106688</Key_PaperID>
<Key_SessionID>11799</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2396</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Adverse Events in Patients with Cancer Treated with Direct Oral Anticoagulants and Cancer Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106351</Key_PaperID>
<Key_SessionID>11799</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>LMWH heparin (Enoxaparin) - anticoagulant used commonly for thromboprophylaxis for patients at high risk for developing deep vein thrombosis. Our institution uses a fixed dose (1 mg/kg/day) of LMWH prophylaxis for adults with ALL undergoing induction therapy with L-asparaginase. </OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2397</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Thromboprophylaxis with Fixed Dose, 1mg/Kg/Day, Low Molecular Weight Heparin in Adults Undergoing Induction with Asparaginase for Acute Lymphoblastic Leukemia. Results of a Single Institution Cohort Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103738</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3711</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Rivaroxaban for the Treatment of Acute Venous Thromboembolism in Patients with Active Cancer in a Prospective Multicenter Trial: KVTE13-01</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107475</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3712</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preferential Inhibition of Fibrin Mediated Thrombosis in Rodent Models By JNJ-9375, a Novel exosite1 Thrombin Inhibitor</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106002</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3713</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparing Medication Adherence Tools for the Direct Oral Anticoagulants Rivaroxaban and Apixaban</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106257</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3714</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Descriptive Analysis of Idarucizumab (Praxbind) Use in a National Hospital Database</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108706</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3715</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Direct-Acting Oral Anticoagulation (DOACs) Based on BMI</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99958</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3716</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Thrombosis and Anticoagulation in Malignant Superior Vena Cava Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101921</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3717</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effectiveness and Safety of Rivaroxaban in Patients with Cancer-Associated Venous Thromboembolism</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107018</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3718</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101019</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3719</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Optimal International Normalized Ratio Range for Asian Patients on Anticoagulation Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104290</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3720</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Safety of Aspirin Vs. Direct Oral Anticoagulants: A Meta-Analysis of Currently Published Clinical Trials</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106208</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3721</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Laboratory Assay for Monitoring Unfractionated Heparin in Patients Taking Direct Oral Anticoagulants Prior to Hospital Admission</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102651</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3722</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An Ex Vivo Analysis of Thrombin Generation and Thromboelastometry in Patients Undergoing Treatment with Rivaroxaban Demonstrates Sustained Anticoagulant Effect and High Inter-Individual Variability</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103386</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Direct oral anticoagulants in malignancies which are not yet approved</OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3723</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Direct Oral Anticoagulants in Comparison to Low Molecular Weight Heparin in Hematological Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106123</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3724</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Use of Direct Oral Anticoagulants in Inherited Thrombophilia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100648</Key_PaperID>
<Key_SessionID>11800</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3725</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Optimal Timing of Starting Thromboprophylaxis for Patients with Acute Spinal Cord Injury: A Cross-Sectional Survey of Canadian Spine Surgeons</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102760</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2398</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Incidence and Risk Factors for IVIG-Mediated Hemolysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105818</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2399</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Marginal Zone B Cells Facilitate RBC Alloimmunization Independent of Direct CD4+ T Cell Activation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101913</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2400</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effect of RBC Transfusion on Six Minute Walk Test Performance and Quality of Life in Outpatients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103170</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2401</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Portable System for Processing Donated Whole Blood into High Quality Components without Centrifugation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104071</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2402</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Immunoglobulin G in Normal Plasma Inhibits HIT Antibody-Mediated Platelet Activation: Implications for Therapeutic Plasma Exchange Treatment in HIT</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108691</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2403</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Antibody-Mediated Immunosuppression Can Result from RBC Antigen Loss Independent of Fc Receptors in Mice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106953</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2404</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Population Pharmacokinetics Profiling to Tailor Prophylaxis in Hemophilia a Patients: A Pilot Feasibility Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102914</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2405</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Epidemiology of Platelet Transfusions: An Analysis of Platelet Use at 12 U.S. Hospitals</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104456</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2406</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Skating on Thin Ice: National Audit of TACO Demonstrates Poor Recognition of Risk Factors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105431</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2407</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelets Feeding Bacteria with Lactate during Room Temperature Storage: Mitigated By Refrigeration</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103394</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2408</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Alloimmunization and Autoimmunization in Adult Transfusion Dependent Beta Thalassemia Major Patients: Report from a Comprehensive Center in Israel</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106074</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2409</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Single Institutional Experience Comparing Cryoprecipitate to Plasma in Patients with Disseminated Intravascular Coagulopathy (DIC) from Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101000</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2410</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Granulocyte Transfusions for Neutropenic Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103608</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2411</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Red Cell Alloimmunisation Is Associated with Development of Autoantibodies and Increased Red Cell Transfusion Requirements in Myelodysplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107109</Key_PaperID>
<Key_SessionID>11801</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2412</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Potential Mitigation of the Covert Risk of Bacterial Contamination of RBC: Inactivation of Propionibacterium Acnes in RBC Using Amustaline and Glutathione</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108014</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3726</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Role of Platelets in the Induction of Alloimmunization after Platelet Transfusion</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108120</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3727</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelets from Donors with Consistent Low HLA-B8, B12 or B35 Expression Do Not Undergo Antibody-Mediated Internalization</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106115</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3728</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>No Association between Age of Transfused Red Cells and 30-Day Mortality in Massively Transfused Patients: Results from the Australian and New Zealand Massive Transfusion Registry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102561</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3729</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Factors Affecting Platelet Transfusion Response Following Haploidentical Stem Cell Transplant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106100</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3730</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development of a Complement-Mediated Hemolysis Assay for Immune Globulin Intravenous Products and Characterization of Lots Associated with Clinical Hemolysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108131</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3731</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>HLA and HNA Antibodies Are More Prevalent in Multiparous Women with RED Blood CELL Alloimmunization</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108696</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3732</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Underlying Inflammation Impacts Immune Modulation Following Exposure to Platelet Concentrates and Packed Red Blood Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102755</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3733</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Iron Status of Icelandic Blood Donors and the Impact of Different Ferritin Assay Platforms on Donor Deferral Rates</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102213</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3734</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Systematic Review and Meta-Analysis of the Effect of Iron Chelation Therapy on Survival in Patients with Lower Risk Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104500</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3735</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>How Low Can You Go: What Is the Safe Threshold for Platelet Transfusions in Patients with Hematologic Malignancy in Sub-Saharan Africa</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105648</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3736</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Multicenter, Retrospective Data Collection Study on the Compassionate Use of a Plasma-Derived Factor X Concentrate to Treat Patients with Hereditary Factor X Deficiency</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108643</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3737</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transfusion Dependence Is Common inAdults withHemophagocytic Lymphohistiocytosis (HLH) and Is Associated with EBV Viremia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101818</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3738</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Patient Blood Management: An Initiative Aimed at Improving Outcomes While Decreasing Red Cell Transfusions with Specialty Guidelines for Hematology Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106404</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3739</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Live Immunization Practices for Chronically Transfused Pediatric Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105944</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3740</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Frequency of Both, Short and Long-Term Post-Transfusion Microchimerism Among the Regularly-Transfused Thalassemic Patient Population</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107738</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3741</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Use of Thromboelastography in Monitoring Coagulation Status for Patients Treated with Low Molecular Weight Heparin, Warfarin, Apixaban, and Rivaroxaban</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107954</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3742</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Projected Cost Savings of a Plasmic Score-Based Approach to Patients with Suspected Thrombotic Thrombocytopenic Purpura</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101002</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3743</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Systematic Review of the Effect of Iron Chelation Therapy on Survival in Patients with Sickle Cell Disease and -Thalassemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99626</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3744</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Vitamin K5 Is an Efficient Photosensitizer for Ultraviolet a Light Inactivation of Bacteria</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100214</Key_PaperID>
<Key_SessionID>11802</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3745</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transfusion of Sickle Cell Anemia Patients in Quebec: Challenges and Opportunities</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103931</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2413</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Model of Human Hemopoiesis Based on Single Cell Functional and Transcriptional Analysis of Lympho-Myeloid Progenitors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102594</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2414</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Setd2 Is Critical for Maintaining Hematopoietic Homeostasis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108701</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2415</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Role of Histone Variant H3.3 Regulation By Hira in Hematopoiesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105423</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2416</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>mTOR Restricts Chromatin Access and Genomic Activity to Maintain Hematopoietic Stem Cell Quiescence and Engraftment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99886</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2417</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Wave-Complex-Dependent Actin Dynamics Controls Hematopoietic Stem Cell Bone Marrow Retention and Orderly Differentiation into Mature Hematopoietic Lineages</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104331</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2418</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Population-Scale Identification of Clonal Hematopoiesis Derived Mutations in Solid Tumor Mutation Profiling</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107938</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2419</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of a Hematopoietic Stem Cell Fraction That Retains Normal Function Following Chronic Inflammation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107198</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2420</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mitigating Detrimental Influences of Ambient Air Collection of Bone Marrow By Hypoxic Collection Results in Detection of Functionally Enhanced Aged Mouse Hematopoiesis: Reflecting Stem Cell Expression Levels of CXCR4, CCR5 and ROS</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105388</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2421</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Diaphanous-Related Formin Protein mDia2 Regulates Hematopoietic Stem and Progenitor Cell Functions through Srf-Integrins Pathway</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107654</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2422</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development of RUNX1-Independent Hematopoiesis in Three Zebrafish runx1-KO Models</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107227</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2423</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>NfixPromotes Survival of Immature Hematopoietic Cells Via Regulation of C-Mpl</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102917</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2424</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Engineering of Induced Pluripotent Stem Cell-Derived Hemogenic Endothelium</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100652</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2425</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Insights at the Single Cell Level into the Reprogramming of Human Hematopoietic Stem Cells during Epigenetically Modified Ex Vivo Expansion</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107437</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2426</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Interferon-Gamma Pathway Regulates Emergence of Engraftable Hematopoietic Stem and Progenitor Cells from Human Pluripotent Stem Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108070</Key_PaperID>
<Key_SessionID>11803</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2427</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Spliceosomal Component Sf3b1 is Essential for Hematopoietic Stem Cell Formation through the Regulation of the Jak/Stat Signaling Pathway</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101946</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3746</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MTG16 Variants Provide Context to Notch Signaling to Direct Leukemic Phenotype</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106019</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3747</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Normal Hematopoiesis Is Dependent on the Expression of U2af1, a Spliceosome Gene Commonly Mutated in MDS</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107604</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3748</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Altered HSC Programming Drives Aberrant Blood Output Underlying RA Pathogenesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108863</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3749</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CD99 Regulates Normal and Malignant Stem Cell Function By Restricting Protein Translation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106501</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3750</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Replenishment of Damaged Bone Marrow Niches By Circulating Hematopoietic Stem Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108798</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3751</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Generation of Megakaryocytes and Platelets from Valproic Acid Expanded Human Cord Blood CD34+ Cells in Culture</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104780</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3752</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Engraftment and SDF-1/CXCR4 Signaling in Human CD34+ Hematopoietic Stem/Progenitor Cells Are Regulated By R4 Rgs Subfamily Proteins</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108597</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3753</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Single-Cell Transcriptome Analysis of Embryonic Erythro-Myeloid Progenitor Cells Reveals Lineage Heterogeneity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107574</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3754</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PI3Kinase Inactivation through Combined Loss of Catalytic Subunits p110, p110 and p110 Derails Hematopoietic Homeostasis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108633</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3755</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MiR-199b-5p Differentially Modulates Hematopoietic Stem Cell Self Renewal in Steady State and Stress Hematopoiesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105698</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3756</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MLL3 Deletion Enhances HSC Self-Renewal</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100814</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3757</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improved ES Cell-Derived Erythroid Cell Generation with Robust b-Globin Production through ES-Sacs</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102554</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3758</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Skewed HSC Clonal Output of T-Cells in an Aged Rhesus Macaque after CD3e-Immunotoxin Treatment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104872</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3759</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Functional Impairment of Hematopoietic Stem/Progenitor Cells By Loss of Uhrf2 in Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108477</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3760</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Developing Live Imaging Strategies to Analyze the Influence of Cell Cycle Rate on MEP Fate Decisions at the Single Cell Level</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105384</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3761</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficient Ex Vivo Expansion of Human Umbilical Cord Blood-Derived SmallCD133+lin-CD45- Stem Cells Expressing Pluripotency Markers in Presence of Histone Deacethylase Inhibitors - As a New Challenging Strategy to Obtain Multipotent Cells for Regenerative Medicine</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107057</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3762</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Robust Autonomous Generation of Definitive Hematopoietic Stem Cells from Pre-Circulation Murine Embryos.</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108001</Key_PaperID>
<Key_SessionID>11804</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3763</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>HEME Degradation Enzyme Biliverdin Ixb Reductase Is Required for STEM CELL Glutamine Metabolism</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106010</Key_PaperID>
<Key_SessionID>11805</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2428</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A CRISPR RNA-Binding Protein Screen Reveals Novel Regulators of RUNX1 Alternative Polyadenylation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100035</Key_PaperID>
<Key_SessionID>11805</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2429</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Population-Based Genetic Fine Mapping and Single-Cell Epigenomics Provide Insights into the Regulation of Human Hematopoiesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101962</Key_PaperID>
<Key_SessionID>11805</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2430</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>GFI1B Splice Variants Differentially Regulate Transcription and Megakaryocyte/Erythrocyte Fate in Hematopoiesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102588</Key_PaperID>
<Key_SessionID>11805</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2431</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Unique Roles for Grb2-Associated Binding (Gab) Adaptors in Hematopoietic Stem Cell Homeostasis and Repopulation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100608</Key_PaperID>
<Key_SessionID>11805</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2432</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Irf8 Regulates Cytokine Signaling and Proliferation of Hematopoietic Stem Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106343</Key_PaperID>
<Key_SessionID>11805</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2433</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Regulation of Lipid Metabolism and Cell Cycle Progression By PU.1 in Myeloid Progenitor Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108817</Key_PaperID>
<Key_SessionID>11805</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2434</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>GATA2 Is Essential for Endothelial-to-Hematopoietic Transition but Does Not Affect Formation of Hemogenic Endothelium</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106098</Key_PaperID>
<Key_SessionID>11805</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2435</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gain of Function MLL1 Model Systems Distinguish Hematopoietic from Leukemogenic Pathways</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107925</Key_PaperID>
<Key_SessionID>11805</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2436</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Controlling Hematopoietic Stem Cell Quiescence By Ablating the TGF-Responsive, Hematopoietic-Specific Enhancer of CDKN1C (p57)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101265</Key_PaperID>
<Key_SessionID>11807</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3764</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Epigenetic and Single Cell Analyses Reveal Dual Fate Decision Points in Pre-Primed Hematopoietic Stem Cells during Erythro-Megakaryopoiesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104348</Key_PaperID>
<Key_SessionID>11807</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3765</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gfi1-Mediated Repression of C-Fos, Egr1 and Egr2, and Inhibition of ERK1/2 Signaling Contribute to the Role of Gfi1 in Granulopoiesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108460</Key_PaperID>
<Key_SessionID>11807</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3766</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prostaglandin E2 Prevents Apoptosis and Promotes Homeostasis of Hematopoietic Stem Cells after Lethal Irradiation through Alteration of p53 and TNF Signaling</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100549</Key_PaperID>
<Key_SessionID>11807</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3767</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>HMGB1 Accelerates Regeneration of Multiple Tissues By Transitioning Stem Cells to GAlert</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102776</Key_PaperID>
<Key_SessionID>11807</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3768</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Novel Roles of Separase in Hematopoiesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104018</Key_PaperID>
<Key_SessionID>11807</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3769</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fli1 Is Essential for the Maintenance of Hematopoietic Stem Cell Homeostasis and Function</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105718</Key_PaperID>
<Key_SessionID>11807</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3770</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Extracellular DEK Regulates Hematopoiesis through CXCR2-Mediated Intracellular Signaling That Does Not Require Its Translocation into the Nucleus or Binding to DNA</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106511</Key_PaperID>
<Key_SessionID>11807</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3771</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Metabolic Interplay Coordinated By Hlx Balances Hematopoietic Stem Cell Maintenance and Differentiation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107840</Key_PaperID>
<Key_SessionID>11807</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3772</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Hematopoietic RIPK1 Deficiency Triggers IFN-Mediated Necroptosis and Bone Marrow Failure</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108520</Key_PaperID>
<Key_SessionID>11807</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3773</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Zebrafish gata2Orthologs Are Necessary but Not Sufficient for Developmental Hematopoiesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108753</Key_PaperID>
<Key_SessionID>11807</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3774</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Identification of Cis- and Trans- Elements Driving Human Hematopoiesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101413</Key_PaperID>
<Key_SessionID>11808</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2437</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification and Molecular Characterization of Endothelial Cells Associated with Hematopoietic Niche Formation in Humans Identifies IL-33 As an Anabolic Niche Factor</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107307</Key_PaperID>
<Key_SessionID>11808</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2438</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>TGF- Signaling in Mesenchymal Progenitor Cells during Development Plays an Essential Role in the Emergence of the Bone Marrow Niche</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104232</Key_PaperID>
<Key_SessionID>11808</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2439</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Role of SCF-Expressing Bone Marrow Populations in Hematopoietic and Leukemic Stem Cell Regulation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108399</Key_PaperID>
<Key_SessionID>11808</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2440</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Decreased IGF-1 Expression in the Bone Marrow Microenvironment Drives Hematopoietic Aging</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105490</Key_PaperID>
<Key_SessionID>11808</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2441</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An Enhanced Zebrafish Xenograft Model to Study the Behavior of Human Hematopoietic Stem Cells and Patient Derived Leukemia In Vivo</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102864</Key_PaperID>
<Key_SessionID>11808</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2442</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Niche Regulation of Residual Hematopoietic Stem Cell Protein Synthesis By Extracellular Vesicle (EV) Trafficking in the Acute Myeloid Leukemia (AML) Microenvironment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107108</Key_PaperID>
<Key_SessionID>11808</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2443</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Up-Regulation of iNOS in AML Blasts Creates an Immunosuppressive Microenvironment, Inhibits T-Cell Proliferation and Transforms T-Cells Towards a Tumor-Tolerating Phenotype</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105978</Key_PaperID>
<Key_SessionID>11808</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2444</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Warfarin Impairs the Bone Marrow Microenvironment and Hematopoiesis Via the Periostin/Integrin 3 Pathway</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108806</Key_PaperID>
<Key_SessionID>11808</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2445</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>iPSC-Derived Thymic Epithelial Progenitor Cells As Cell-Based Therapyto Restore Thymic Function in Hematopoietic Stem Cell Transplant Recipients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100175</Key_PaperID>
<Key_SessionID>11809</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3775</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Ameliorate Graft-Versus-Host Disease-Related Manifestations</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102410</Key_PaperID>
<Key_SessionID>11809</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3776</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Novel ARC/IL1/PGE2/-Catenin/ARC Circuit Regulates Leukemia and Leukemia Microenvironment and Drug Resistance in AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105573</Key_PaperID>
<Key_SessionID>11809</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3777</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Early Growth Response (EGR)-1 Is a Key Regulator of Human Primary Bone Marrow Stroma Cells with a Dual Role in Proliferation and Hematopoietic Stroma Support Function</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102008</Key_PaperID>
<Key_SessionID>11809</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3778</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Erythropoietin Eliminates Increased Bone Marrow Adiposity and Alters Bone Features in Obese Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105108</Key_PaperID>
<Key_SessionID>11809</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3779</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Recreating the Hematopoietic Microenvironment in Vitro Using Microfluidic "on-a-Chip" Technology Enables the Study of Interactions of Normal and Malignant HSPC with Specific Bone Marrow Niches</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106371</Key_PaperID>
<Key_SessionID>11809</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3780</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Stromal-Cells Downregulate Mir-23a-5p Levels in Myeloid Leukemic Cells to Activate Protective-Autophagy Against Chemotherapeutic Agents</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100513</Key_PaperID>
<Key_SessionID>11809</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3781</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Role of GATA2 in the Maintenance of the Bone Marrow Microenvironment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104929</Key_PaperID>
<Key_SessionID>11809</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3782</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Manipulating Osteogenic/Adipogenic Balance in Mesenchymal Stromal Cells (MSCs) for Hematopoietic Applications</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101561</Key_PaperID>
<Key_SessionID>11809</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3783</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Metabolic Changes in Aging Bone Marrow</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105204</Key_PaperID>
<Key_SessionID>11809</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3784</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intramuscular Administration of Placenta-Derived Stromal Cells Enhances Survival of Rhesus Macaque Monkeys Exposed to Total Body Irradiation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103817</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2446</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 50 Years or Older with Severe Aplastic Anaemia: Results from the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101770</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2447</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Allogeneic Hematopoietic Stem-Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108171</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2448</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Germline Mutations inCTLA4and Spectrum of Bone Marrow Features Overlapping with Aplastic Anemia and Large Granular Lymphocyte Lymphocytosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102893</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2449</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Systematic Assessment of GATA2 Genetic Variation Reveals the Presence of Novel Disease-Causing Synonymous Exonic Mutations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106679</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2450</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Functional Characteristics of FAS-L Resistant and IL-2 Deprived Regulatory T Cells (Treg A) in Idiopathic Aplastic Anaemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108424</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2451</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Novel Lineage Depletion and Manufacturing Allows for Unprecedented Preservation of Autologous Blood Stem Cells for Gene Therapy of Fanconi Anemia Complementation Group </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102140</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2452</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inflammatory Signature, Oxidative Stress, and DNA Damage Response in DBA Pathogenesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101645</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2453</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Myeloid-Derived Suppressor Cells in Immune-Related Bone Marrow Failure: Novel Therapeutic Implication</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108043</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2454</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Surveillance of the Immune Repertoire of Aplastic Anemia Patients Using Deep Sequencing</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103103</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2455</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>T Cells Trafficking to Bone Marrow Have Different Characteristics from Those to Other Organs in an Immune-Mediated Bone Marrow Failure Mouse Model</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107750</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2456</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Reversal of Aplastic Anemia By Mesenchymal Stem Cell-Derived Extracellular Vesicles</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104343</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2457</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Detection of Clonal Hematopoiesis Is a Rare Event in Patients with Dyskeratosis Congenita</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106289</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2458</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of T Cell Receptors Specific to Antigens Presented By HLA-B5401 onIPS Cell-Derived Hematopoietic Stem Cells in a Patient with Acquired Aplastic Anemia Carrying B5401-Lacking Leukocytes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108394</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2459</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Starvation Stress in the Sbds-Null Zebrafish: Implications for Human Shwachman-Diamond Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107649</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2460</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Re-Analysis of Next Generation Sequencing Gene Panel Data By Normalized Coverage Values Reveals Previously Undetected Copy Number Variations in Inherited Bone Marrow Failure Syndromes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103310</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2461</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Risk Factors for Donor-Type Aplasia after Bone Marrow Transplant in Children with Acquired Bone Marrow Failure</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103352</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2462</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Moderate Increase in the WT1 mRNA Copy Number in Peripheral Blood of Patients with Long-Standing Acquired Aplastic Anemia without Apparent Signs of Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105097</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2463</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Dissection of Infectious Event Following ATG Treatment for Aplastic Anemia and Hypoplastic Myelodysplastic Syndrome Reveals Urgent Need for Anti-Aspergillus Prophylaxis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107772</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2464</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>TGF-1 Production By Bone Marrow Mesenchymal Stem Cells of FANCD2 Differs from Other Fanconi Anemia Complementation Groups</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105301</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2465</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development of Unique Molecular Signatures for Bone Marrow Failure Syndromes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102103</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2466</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Baseline Assessment of Patients with Newly-Diagnosed Acquired Bone Marrow Failure Enrolled in a Prospective Observational Study, Search for Unidentified Links between PNH Clone Size and the Related Clinical Manifestations By High Precision Flow Cytometry (SUPREMACY)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103850</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2467</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Mutation Causing GATA2 Haploinsufficiency Activates a Cryptic Splice Site in Exon 3</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105291</Key_PaperID>
<Key_SessionID>11810</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2468</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Sequencing of 347 Children with Acquired and Inherited Bone Marrow Failure Syndromes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103847</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2469</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Two Hematopoietic Transcription Factors, RUNX1 and FUBP1, Control the Expression of KIT Oncogene in Pre-B Lymphoblasts</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107260</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2470</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Histone Deacetylase Inhibitors Mimic BET Inhibitors and Cause RNA Polymerase Pausing at MYC, KIT, and Other Oncogenes in t(8;21) AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104725</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2471</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>RNA:m5c/Methyltransferases Mediate Chromatin Organization and 5-Azacytidine Response/Resistance in Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106422</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2472</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeted Therapy for AML Expressing RUNX1 Mutation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105865</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2473</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fetal and Neonatal Hematopoietic Progenitors Are Exquisitely Sensitive to MLL-ENL-Driven Leukemia Initiation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107161</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2474</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Role of MMSET E1099K Mutation in Gene Dysregulation, Drug Resistance and Clonogenicity in Acute B-Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108379</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2475</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Leukemogenic Second Hits in CEBPA-Mutated AML Result in Diverse Effects on Haematopoiesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103990</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2476</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>RNA Sequencing Reveals Mechanisms Underlying Modulation of Hodgkin Lymphoma Cells and Tumor Microenvironment By the PI3K / Inhibitor, RP6530</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105705</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2477</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>SF3B1Mutation Causes Aberrant Splicing and Downregulation of PPP2R5A in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106861</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2478</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Insights into Hematopoiesis in GATA2 Deficiency Using Single-Cell Transcriptomics</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107953</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2479</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genomic and Epigenetic Effects of DNA Methyltransferase Inhibition in Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107607</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2480</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long Non-Coding Transcript in LEF1 Locus Is a Novel Regulatorof Cell Cycle and Apoptotic Pathways in Myeloid Leukemic Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107651</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2481</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An Assay for Simultaneous Profiling of Gene Expression, Phospho- and Total Protein Abundance, and Somatic DNA Mutations for Hematology-Oncology Research</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108388</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2482</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Somatic Mutations Associated with Myeloid Transformation of RUNX1-Mutated Familial Platelet Disorders with Propensity to Myeloid Malignancies Using Targeted Next-Generation Sequencing</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108430</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2483</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle> APOC2 Is Upregulated in Acute Myeloid Leukemia and Presents a Novel Therapeutic Target</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101672</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2484</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Highly Sensitive Viral RNA-Seq Is a Powerful Tool to Analyze the Viral Transcripts in HTLV-1-Infected Individuals</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102877</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2485</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>RNA-Seq Revealed an Integration of Multiple Resistance Functions for Predicting Response to the 7+3 Induction Chemotherapy of De Novo Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103317</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2486</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Histone Acetyl-Transferase Kat2a Regulates Transcriptional Heterogeneity and Impacts Self-Renewal of Acute Myeloid Leukemia Cells in a Disease-Specific Manner</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102231</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2487</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PRMT5 Initiates an Epigenetic Program That Promotes Progression of Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100471</Key_PaperID>
<Key_SessionID>11811</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2488</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>AMPK Links Metabolic Regulation to Epigenome Modification in Leukemia-Initiating-Cell</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107329</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order></Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3785</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The AF9-Binding Domain of DOT1L Is Critical for Its Recruitment By MLL Fusion Proteins in Leukemia and Contributes to Its Functions in Normal Hematopoiesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108431</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3786</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Interaction between FLT3 and CD99 in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107737</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3787</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Epigenetic Regulation of c-Kit Expression in Acute Myeloid Leukemia By Oncogenic Casein Kinase II (CK2)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108188</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>BRAF inhibitors (vemurafenib, dabrafenib) for treating BRAF mutated Erdheim-Chester disease patients</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3788</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clonal Hematopoiesis in Erdheim-Chester Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107179</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3789</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cross Talk between Ikaros and RUNX1 in Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108207</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3790</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterization of the Post-Transcriptional Regulation of AML1-ETO Expression in t(8;21) Leukemia Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106952</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3791</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mechanism of Pax5 Down-Regulation and Its Function in Primary Effusion Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107979</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3792</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Altered Transcriptome Uniquely Associated with AML Vs. Normal Hematopoiesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108212</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3793</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>T Cell Responses to Tumor Associated Antigens in Multiple Myeloma Patients Treated with Mv-Nis, an Oncolytic Measles Virus</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108558</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3794</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Overexpression of BRD4 Is an Adverse Prognostic Factor in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108814</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3795</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of microRNA 10a, an Autophagy Modulator, Increases Chemosensitivity to Ara-C in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107826</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3796</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Bioflavonoid Exposure on DNA Damage Response and of Non-Homologous End Joining (NHEJ) Pathway Repair Proteins in Stem Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101126</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3797</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Aberrant Repression of GFI1 Super-Enhancer By LSD1 Plays an Important Role in Leukemia Programs in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102107</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3798</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Mutant Haemopoietic Transcription Factor GATA1s on Haemopoiesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102595</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3799</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long Noncoding RNA Profiling Reveals an Abundant Crnde That Inhibits Granulocytic Differentiation in APL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102958</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3800</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Recurrent Copy Number Variants Are Highly Prevalent in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103084</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3801</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Epigenetic Plasticity in ATP-Dependent Chromatin Remodeling Complexes in Human Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103514</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3802</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impacts of Transcriptional Regulatory Mechanism and Protein Interaction Relationship between RUNX1 and KLF4 on the Biological Functions of t (8;21) Leukemia Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104324</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3803</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Effect of Bioactive Phospholipids on Normal and Malignant Hematopoiesis - Modulation of Their Effects By Downregulating the Activities of Heme Oxygenase 1 (HO-1) and Inducible Nitric Oxygenase Synthase (iNOS)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100179</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3804</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CBFA2T3 Enhances Transcriptional Activity of RUNX1: Implication in Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106079</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3805</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Proteomic Profiling Reveals Targetable Pathways in MGUS (SLAMF6, TNFRSF8, TIMP1, TRL2) That May Contribute to Disease Progression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101511</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3806</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>T-ALL Oncogenes Function in the Context of Pre- and Post T-Cell Commitment Programs</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106748</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3807</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genome-Wide Analysis of the Regulatory Landscape in Different Pre-B-ALL Subtypes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108123</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3808</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ETO2 Regulates Cell-Fate Genes and Controls Relapse in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100422</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3809</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Epigenetic and Transcriptomic Profiling of MLL Rearranged Infant Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106114</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3810</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>C-Terminal BRE Overexpression in 11q23-Rearranged and t(8;16) Acute Myeloid Leukemia Is Caused By Intragenic Transcription Initiation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106326</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3811</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CDK7 Inhibitor THZ1 Inhibits Glycolytic Metabolism By Suppressing HIF1 Activity in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108047</Key_PaperID>
<Key_SessionID>11812</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3812</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Abnormal Splicing Patterns and Novel Intron Retentions Affect Genes Regulating Splicing, NF-Kb, ERK1/2, and TP53 in Waldenstroms Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108177</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2489</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gain of Function Mutant p53 Drives Clonal Hematopoiesis and the Pathogenesis of Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102831</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2490</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104968</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2491</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>DLBCL-Derived NF-b Mutations Exploit Senescence and Immune Evasion Mechanisms to Promote Myc-Driven Lymphomagenesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108046</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2492</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transcriptional Repression of RASSF2 Impairs Hippo Kinase-Dependent p53 Activation and Tumor Suppression in t(8;21) AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108650</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2493</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Genome-Wide, In Vivo, Dropout CRISPR Screen in Acute Myeloid Leukemia Identifies an Essential Role for Beta-Galactosylation in Leukemic Cell Homing</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103045</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2494</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>RUNX3 Promotes the Development of MDS/MPN Overlap Syndrome Via Enhancing Expression of Myc in the Absence of Tet2</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103974</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2495</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Global Crosstalk between Two Histone Modifications That Control Transcriptional Elongation in MLL Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108585</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2496</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Origin and Functional Impact of Mitochondrial DNA Mutations in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104328</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2497</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Activation of SIRT1 Deacetylase As a Therapeutic Approach for Myelodysplastic Syndromes By Restoring TET2 Function</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105625</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2498</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CPSF1 Regulates AML1-ETO Fusion Gene Polyadenylation and Stability in t(8;21) Acute Myelogenous Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107349</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2499</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>FLT3N676K drives Myeloid Leukemia in a Xenograft Model of KMT2A-MLLT3 leukemogenesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108624</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2500</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ca2+ Oscillations and NFATC1-Activation Enable Oncogenic Signaling in Pre-B Cell Transformation and Leukemogenesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107562</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2501</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Integrated Functional Genomic and Pharmacological Characterization of the Kinome of Myeloma Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105032</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2502</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ARID5B Activates the TAL1-Induced Core Regulatory Circuit and the MYC Oncogene in T-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108031</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2503</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Potential Role of Ubiquitin E3 Ligase, FBXO9, As a Tumor Suppressor in AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102348</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2504</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cbfb-MYH11+ Leukemia Stem Cells Are Heterogeneous and Show Dynamic Marker Expression</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108055</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2505</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High-Level EVI1 Perturbs Hematopoietic Function By Skewing Cells Towards Myeloid Phenotype Via Induction of PU.1/Spi1Transcription</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104385</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2506</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>NPM1-ALK Overexpression-Driven Toxicity in ALCL Is Partner Dependent and Mediated By STAT1 Antagonism of STAT3 Survival Signaling, Revealing a Novel Therapeutic Strategy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106373</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2507</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Microrna-211 - a Novel Oncogene in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106891</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2508</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle> Expression of the Tumor Suppressor WT1 Is Induced By PML-Rara in Acute Promyelocytic Leukemia. </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102114</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2509</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterization and Targeting TET2-Mutant HSPCs and AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105428</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2510</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Modeling Lymphoplasmacytic Lymphoma/Waldenstrm Macroglobulinemia in Transgenic Mice Using Human MYD88L256P Mutated Protein</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107253</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2511</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>hnRNP K: A Driver of Myeloid Malignancy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103772</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2512</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The ETO2-GLIS2 Fusion Oncogene Alters Early Human Hematopoiesis in an Induced Pluripotent Stem Cells-Derived Model of Pediatric Acute Megakaryoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106214</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2513</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ADAR1 Is Involved in the Proliferation of Acute Myeloid Leukemia Probably Via Regulating the Wnt Pathway</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107554</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2514</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Stathmin 1 Is Highly Expressed in Acute Promyelocytic Leukemia and Microtubule Dynamics Is a Potential Target for ATRA-Resistant APL Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100344</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2515</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterization of Kinase Activity By Phosphoproteomics in Myeloid Cell Lines for Identification of Driving Oncogenic Pathways</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100956</Key_PaperID>
<Key_SessionID>11813</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2516</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Loss of Ahi-1 Impairs the Self-Renewal Activity of Normal and BCR-ABL+ Stem Cells in Vitro and in Vivo</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103852</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2517</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Direct-Acting Small Molecule Activators of PP2A (SMAPs) in Myeloid Malignancies: Understanding Mechanisms of Cytotoxicity to Inform Rational Combinatorial Therapeutic Strategies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108179</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2518</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PNC27 Targeting Plasma Membrane HDM2: A Potentially Novel Therapeutic Approach for Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103799</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2519</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bone Marrow Stroma Protects FLT3 Acute Myeloid Leukemia (AML) through CYP3A4-Mediated Drug Metabolization of FLT3 Tyrosine Kinase Inhibitors (TKIs)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100619</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2520</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Pharmacological Blockade of Phosphodiesterase IV Potentiates the Anti-Tumor Effects of Arsenic Trioxide (ATO) in Acute Myelogenous Leukemia Cells through Multiple Signaling Pathways</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105947</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2521</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of Carbonic Anhydrase-IX As a Novel Strategy to Overcome Hypoxia Mediated Drug Resistance in FLT3/ITD Mutated Acute Myeloid Leukemia.</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102955</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2522</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>TP-0903, a Novel Axl Inhibitor with Activity in Drug Resistant FLT3-ITD+ AML through a Mechanism That Includes FLT3 Inhibition</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104184</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2523</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Untargeted Metabolomics Identifies Glutamine Metabolism As a Driver of Chemoresistance in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100226</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2524</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Thymidine Dideoxynucleoside Analogue, Alovudine, Inhibits the Mitochondrial DNA Polyermase, Polg, Impairs Oxidative Phosphorylation and Promotes Monocytic Differentiation in AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102520</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2525</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of FLT3-ITD and Melk By Small Molecule Inhibitor OTS167 in FLT3 mutant Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104131</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2526</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Childrens Oncology Group AAML0531 Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104696</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2527</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Persistence of Somatic Mutation Spectrum and Clonal Architecture in Chronic Myelomonocytic Leukemia Treated with Hypomethylating Agents</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107463</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2528</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Proteomic Profiling Identifies c-KIT and 53BP1 As Resistance Factors of AML Relapse Post Allogeneic Stem Cell Transplantation with G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105621</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2529</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Map3k8/COT1/Tpl2 Drives Resistance to Bcr-Abl1 Inhibition through Activation of MEK-ERK and NF-Kb Pathways</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108793</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2530</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>RSK Inhibition Induces Metaphase Arrest and Apoptosis in Acute Myeloid Leukemia Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102637</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2531</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Deubiquitinase Inhibitor WP1130 Blocks FLT3-ITD to Induce Apoptosis in Leukemic Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103940</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2532</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>AVID200: A Novel TGF-Beta Inhibitor for the Treatment of Anemia Associated with Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106451</Key_PaperID>
<Key_SessionID>11814</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2533</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PCT3, a Combination of Active Steroidal Saponins from the Paris Forrestii (Takht.) H. Li, Displays Potent Activity Against Acute Myeloid Leukemia By Suppressing the PBX1/RNF6/AKT/mTOR Signaling Pathway</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108596</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3813</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Unique N-Phenylbenzamide Inhibitor Targeting Non-Receptor Tyrosine Kinases Potently Suppresses AML Cell Growth in Vitro and In Vivo</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105293</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3814</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Concomitant Use of Midostaurin with Strong CYP3A4 Inhibitors: An Analysis from the Ratify Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103941</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3815</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Leukemic Stem Cell Expression Signatures Identify Novel Therapeutics for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105336</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3816</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Disregulation of CTCF Boundary at the HOX Locus Enhances Sensitity to Multiple Drug Treatment in Myeloid Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108544</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3817</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mutation Profiling Reveals Novel Epigenetics and Splicing Mutations in Chemorefractory Pediatric AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107595</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3818</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Anti-Leukemic Properties of Histamine in Monocytic Leukemia: Role of NOX2</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101819</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3819</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102821</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3820</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Suppression of mTOR Signaling Attenuates Apoptotic Effects Induced By the NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Acute Myeloid Leukemia Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103955</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3821</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104367</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3822</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ONC213, a Novel Second Generation Analog of ONC201, Shows Promising Anti-Leukemic Activity Against AML Cells in Vitro and In Vivo</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106960</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3823</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101003</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3824</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development of Foam-Based 3-Dimensional Culture to Investigate Drug Sensitivity in Primary Leukaemia Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105398</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3825</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Association of Hif-1 Expression with Primary Resistance to Azacytidine in Patients with High Risk MDS - Preliminary Data of the Hellenic MDS Study Group</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103435</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3826</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CD33Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Childrens Oncology Group AAML0531 Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105372</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3827</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Artemisinins Synergize with BCL2 Inhibitors By Reducing MCL1 Protein Levels in Leukemia Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106576</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3828</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Aurora a Kinase As a Promising Therapeutic Target in Philadelphia Chromosome Positive Leukemia Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107943</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3829</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pyruvate Dehydrogenase (PDH) Activity Is a Source of Resistance to Sorafenib in FLT3-ITD Expressing Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101724</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3830</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CCL5 Mediates Target-Kinase Independent Resistance to FLT3 Inhibitors in FLT3-ITD-Positive AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104376</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3831</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Plasma-Derived 3D Culture for Leukemic Proliferation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103249</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3832</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of FAO in AML Co-Cultured with BM Adipocytes: Mechanisms of Survival and Chemosensitization to Cytarabine</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107725</Key_PaperID>
<Key_SessionID>11815</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3833</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Deptor As a Target with Chemical Inhibitors; Alternative Therapy in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104927</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2534</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Breaking IL7R Signaling-Induced Glucocorticoid Resistance By Small Molecule Inhibitors in T-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100626</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2535</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Notch Signaling Controls Drug Response in B-Cell Acute Lymphoblastic Leukemia (B-ALL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100171</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2536</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mertk Is a Therapeutic Target in Early T-Precursor Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103132</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2537</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical BET Inhibitor RG6146 Induces Intrinsic Apoptosis and Down-Regulates PD-L1 Expression and Induces Potent Anti-Tumor Activity in Models of Hematological Malignancy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102139</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2538</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effect of Renal and/or Hepatic Impairment on the Pharmacokinetics and Safety of Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108485</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2539</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mutated MYD88 Activates the BCR Component SYK and Provides a Rationale Therapeutic Target in Waldenstroms Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108093</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2540</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Alvocidib Enhances Venetoclax Sensitivity in Unfavorable-Risk Multiple Myeloma Cells in Vitro and In Vivo</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104122</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2541</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cullin4B Induces Autophagy Participating the Tumorigenesis of Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101432</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2542</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>BET Inhibitors in Chronic Lymphocytic Leukemia: JQ1 Synergizes with Venetoclax in Promoting Apoptosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106567</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2543</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Elucidating Exposure-Response (Safety and Efficacy) of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Containing Antibody Drug Conjugate, for Recommended Phase 2 Dose Determination in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104867</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2544</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Population Pharmacokinetic and Exposure-Response Modeling for the EZH1/2 Dual Inhibitor DS-3201b in Patients with Non-Hodgkin Lymphomas</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100550</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2545</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Importance of Mitochondrial Metabolism As a Selective Therapeutic Approach in Chronic Lymphocytic Leukemia Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105493</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2546</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development of a Novel Class of Microtubule Destabilizing Agents with Selectivity Against Diffuse Large B-Cell Lymphoma (DLBCL) with B-Cell Receptor (BCR) Activation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105588</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2547</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Edo-S101, a Bendamustine (BDM)/ Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Demonstrates Potent Preclinical Activity Against T-Cell Malignancies and Overcomes BDM-Resistance</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104057</Key_PaperID>
<Key_SessionID>11816</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2548</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of EHMT2 As a New Target in T-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106146</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3834</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CD25 Enables Oncogenic BCR-Signaling and Represents a Therapeutic Target in B Cell Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104565</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3835</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>RNA Polymerase 1 Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Malignancies: Results of a Phase I First in Human Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105729</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3836</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PSMB9 Mediates Resistance to Bortezomib in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104320</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3837</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>XPO1 Inhibitor Selinexor Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma Via Nuclear Retention of IB</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107265</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3838</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Proteomic Analysis Reveals IRAK4 As a Therapeutic Target in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100157</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3839</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Upregulation of Alternatively Glycosylated Smoothened (SMO) Is Involved inDoxorubicin (DXR) Resistance in Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104360</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ruxolitinib has been approved by the FDA for treatment of Polycthemia  vera and Myelofibrosis. This is a trial of its safety and efficacy in treating adult T-cell leukemia.</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3840</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107765</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3841</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Functional Implication of p53-Mediated DNA Damage Response on the B-Cell Lymphoma Microenvironment Interaction in Chemoimmunotherapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106875</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3842</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Single Agent and Synergistic Combinatorial Efficacy of First-in-Class Small Molecule Imipridone ONC201 in Hematological Malignancies in Vitro and In Vivo through Apoptosis Via the Integrated Stress Response Pathway</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108357</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>this work suggests Dasatinib (indicated for B-ALL and CML) may be useful in DLBCL therapy. </OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3843</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Repurposing Dasatinib for Ibrutinib-Resistant Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107701</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3844</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103884</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3845</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>M7583 Isa Highly Selective and Potent Second Generation BTK Inhibitor for Treatment of B-Cell Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104761</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3846</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lenalidomide and Dexamethasone Therapy in Elderly Patients with Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103831</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3847</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preclinical Anti-Lymphoma Activity of the BCL-2 BH4 Domain Antagonist Bda-366 in Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105341</Key_PaperID>
<Key_SessionID>11817</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>GAZYVA is indicated, in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia. GAZYVA is indicated in combination with bendamustine (benda) followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen, in the EU and Switzerland, but not in the USA.</OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3848</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Influence of Baseline Disease Characteristics and Exposure to Obinutuzumab on Clinical Outcome in Patients with Previously Untreated Advanced Follicular Lymphoma Treated with Obinutuzumab-Based Immunochemotherapy in the GALLIUM Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106020</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2549</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dietary Antioxidant Micronutrient Intake and Toxicity during Remission Induction in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106445</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2550</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Durable Outcomesof a ProspectiveDouble Cord Blood Transplantation Trial inAdults with Acute Lymphoblastic Leukemia: DifferentOutcomes According to the Presence ofPhiladelphia Chromosome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106583</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2551</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Donor Type on Long-Term Outcomes of Hematopoietic Cell Transplantation for AdultAcute Lymphoblastic Leukemia during First Remission</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105152</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2552</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102516</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2553</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pharmacokinetics and Pharmacodynamics of Tocilizumab for the Management of Cytokine Release Syndrome (CRS) in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with CAR T-Cell Therapy, CTL019</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108267</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2554</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105958</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2555</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Sex on Clinical Outcome and Toxicity in Children and Adolescents with Acute Lymphoblastic Leukemia.a Report from the BFM Study Group</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105611</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2556</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Baseline Biomarkers Influencing Clinical Outcomes in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Treated with Blinatumomab Versus Standard-of-Care Chemotherapy (SOC) from a Randomized Phase 3 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102439</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2557</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107416</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2558</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100457</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2559</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intrinsic Activation of the NLRP3 Inflammasome in Primary Human ALL Cells Is Regulated By Endogenous HMGB1 and Bone Marrow Macrophages</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106585</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2560</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improved Outcome with a Pediatric-Inspired Regimen for Philadelphia-Negative Acute Lymphoblastic Leukemia in the Elderly</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102479</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>Assuming approval of CTL019 (tisagenlecluecel)  in pediatric ALL in August 2017, this abstracts discusses clinical trial results of CTL019 in patients with DLBCL</OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2561</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107343</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2562</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High-Density Data Mining to Identify Unique Toxicities of Adolescent/Young Adult Cancer Treatment: A Report from the Childrens Oncology Group</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99882</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2563</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fertility Status Among Long-Term Childhood Acute Lymphoblastic Leukemia Survivors Enrolled between 1971 and 1998 in the EORTC Children Leukemia Group Trials 58741, 58831/2 and 58881</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103653</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2564</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Thromboembolism in ALL Patients 1-45 Years Treated According to the NOPHO-ALL 2008 Protocol</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103565</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2565</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Outcome of Childhood B-Cell Precursor ALL with ETV6-RUNX1 Treated with Japan Association of Childhood Leukemia Study (JACLS) ALL-02 Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106468</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2566</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Adjusting Dosage of Mercaptopurine By NUDT15 Polymorphisms in Childhood Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101536</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2567</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Presence of Philadelphia Chromosome Does Not Confer Poor Prognosis in Adult Pre-B Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era  a Surveillance, Epidemiology, and End Results Database Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104549</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2568</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Second Primary Malignancies in Long Term Acute Lymphoblastic Leukemia Survivors of Three Age Groups</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107088</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2569</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Role and Mechanism of PTPN21 Isoforms in Acute Lymphoblastic Leukemia Escaping NK Cell Killing</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106300</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2570</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Increased Incidence of Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia Among Adults of Hispanic Ethnicity: A Population Based Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107789</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2571</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100020</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2572</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with t(5;14)(q31;q32)/IL3-IGH Rearrangement and Eosinophilia: A PeculiarIGH BCP-ALL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104848</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2573</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>a Decrease in Vitamin D Levels Is Associated with Methotrexate-Induced Oral Mucositis in Children with Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101999</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2574</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108419</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2575</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Incidence and Outcomes of T-Cell Acute Lymphoblastic Leukemia (T-ALL) in United States</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104676</Key_PaperID>
<Key_SessionID>11818</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2576</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107030</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3849</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Combination of Omacetaxine Mepesuccinate (homoharringtonine) and Sorafenib As an Effective Regimen for Acute Myeloid Leukemia (AML) Carrying FLT3-ITD</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105780</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3850</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of the Type of Anthracycline and of Allogeneic Stem Cell Transplantation in the Treatment of Younger Acute Myeloid Leukemia Patients: Long-Term Follow-up of the EORTC-Gimema AML-10 Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104597</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3851</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outpatient Intensive Induction Chemotherapy for Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107114</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3852</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Next-Generation Sequencing on Treatment Choices for Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108646</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3853</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104053</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3854</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Predictors of Response and Survival in 206 AML Patients Treated with Guadecitabine ina Phase 2 Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107130</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>For this abstract --there are no standard/approved therapies for BPDCN, so all therapies discussed for this entity will be off-label, thank you</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3855</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102458</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3856</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart Molecule for T-Cell Redirected Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102551</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3857</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Developing Models to Predict Intensive Care Unit Admission and Mortality for Adults with Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107982</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Sirolimus is not approved for the treatment of AML.  </OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3858</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108204</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3859</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes Based on CNS Disease Status in Pediatric Acute Myeloid Leukemia and the Role of Peripheral Blood Contamination in Diagnostic Lumbar Punctures; A Report from the Children's Oncology Group Studies AAML0531 and AAML1031</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102894</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3860</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Characteristics and Treatment Outcome of Acute Myeloid Leukemia with APL-like Morphology and Uncommon Rara Fusion Variants</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103411</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3861</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effect of Anthracycline Dose on Acute Anthracycline Induced Cardiotoxicity in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105268</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3862</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Plasma HCK Level As a Biomarker Predicting Poor Outcome in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108767</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3863</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Acute Myeloid Leukemia and Myelodysplasia Related Changes: Trends in Survival between 2000 and 2013</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102929</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Azacitidine is FDA approved for myelodysplastic syndromes.</OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3864</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Frontline Azacitidine As a Bridge to Allogeneic Transplantation in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104484</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3865</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Value of Day 14 Bone Marrow Biopsy (d14BM) in Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107832</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3866</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improvement of the Treatment Results in Childhood Acute Myeloid Leukemia in Poland from 1983 to 2017</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104904</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3867</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Epidemiology, Cytogenetic and Molecular Abnormalities and Outcome of Childhood Acute Myeloid Leukemia- an Israeli Retrospective Multicenter Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106876</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3868</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Frontline Induction Therapy Using Idarubicin in Combination with High-Dose (HDAC3) Versus Intermediate-Dose Cytarabine (IDAC3) in Adult Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108648</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3869</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characteristics of Venous Thromboembolism in Patients with Acute Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103451</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3870</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Factors Affecting Transfusion Utilization in Acute Myeloid Leukemia (AML) Patients Undergoing Initial Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107381</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3871</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Favorable Outcomes with Fludarabine, High Dose Cytarabine and Granulocyte Colony Stimulating Factor (FLAG) As Re-Induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108205</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3872</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Retrospective Analysis of Adult Relapsed and Refractory Acute Leukemia Patients Treated with FLAG at a Comprehensive Cancer Center</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106950</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3873</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Multicenter Nonrandom Clinical Study of Induction Regimen of FLAG-ID and Dae in the Treatment of Childhood De Novo Acute Myeloid Leukemia in South of China:the Early Report of Efficacy and Safety</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101013</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3874</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An Evaluation of 17 Years of Low Dose Cytarabine As Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival, Potential Underutilisation and Highlights the Need for New Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101318</Key_PaperID>
<Key_SessionID>11820</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3875</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Occurrence of Cardiotoxicity and the Impact on Outcomes Among Children Treated on the AAML0531 Clinical Trial: A Report from the Childrens Oncology Group</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101298</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2577</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108503</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2578</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Recent Trends in the Incidence and Outcomes of Acute Promyelocytic Leukemia in United States</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107713</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2579</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prospective Study of Acute Myeloid Leukemia (AML) Clinical Epidemiology and Cytogenetic Risk Group in Older Adults in the ECOG-ACRIN E2906 Clinical Trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104151</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2580</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102528</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>In this abstract we discuss the use of romidepsin (Istodax) which is licensed by the FDA for use in  CTCL. The clinical trial described aimed to investigate the safety and efficacy of the combination therapy azacitidine with romidepsin in AML patients.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2581</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Clinical Activity of Combined Romidepsin and Azacitidine Therapy in High Risk Acute Myeloid Leukemia: Preliminary Results of the Romaza Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103302</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2582</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Impacts and Dynamic Changes of Cohesin Complex Gene Mutations in De Novo Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107626</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2583</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106177</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2584</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Strategy of Day 14 Bone Marrows and Early Intervention Is Associated with Similar Outcomes Compared to a Strategy of No Day 14 Bone Marrows and Delayed Intervention in Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102468</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2585</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108078</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2586</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Antimicrobial Prophylaxis during Induction Chemotherapy for Acute Myeloid Leukemia in the Current Era</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106892</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2587</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Addition of Lomustine in the Treatment of Elderly Patients with Acute Myeloblastic Leukemia Improves Survival with Acceptably Increased Infectious Toxicity. a Filo Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103642</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2588</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effectiveness of Supportive Care Measurements to Reduce Infections during Induction for Children with Acute Myeloid Leukemia: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104410</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2589</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Relationship between Complete Remission and Overall Survival in Acute Myeloid Leukemia: A Report from Daco-016 and Daco-017</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107497</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2590</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Incidence and Predictors of Adverse Respiratory Events during Induction Therapy in Children with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106186</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2591</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Single Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105192</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2592</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Rate of Differentiation Syndrome in Patients Based on Timing of Initial All-Trans Retinoic Acid Administration</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101485</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off-label use of sorafenib for treatment of FLT3 ITD AML. </OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2593</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101594</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2594</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Defining Acute Myeloid Leukemia Ontogeny in Older Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99767</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2595</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Promyelocytic Leukemia Patients Surviving the Critical Initial Phase Have Survival Equivalent to That of the Calendar Year-, Sex-, and Age-Matched General Population</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100146</Key_PaperID>
<Key_SessionID>11821</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2596</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106174</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2597</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106200</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2598</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105178</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2599</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Daunorubicin during Delayed Intensification Considerably Lowers the Incidence of Infectious Complications but Might Result in Decreased Disease-Free Survival Compared to Adriamycin in Children with Acute Lymphoblastic Leukemia  a Randomized Comparison in Trial Coall 08-09.</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108731</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2600</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Biologicfor the TreatmentofPh-like B-Cell AcuteLymphoblasticLeukemia with Overexpression of CRLF2</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106313</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2601</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CAR T Cell Relapse CD19 Negative ALL Cells Express Integrins and Integrin Blockade Can Prolong Survival In Vivo</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107632</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>We present data on the antileukemic effects of mizoribine in acute lymphoblastic leukemia. This is an IMPDH inhibitor in clinical use as immunorepressive drug.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2602</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clonal Evolution Mechanisms and Collateral Sensitivity to Impdh Inhibitor Therapy in Relapsed Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107916</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2603</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CCL3 Signaling Is Essential for Leukemia Progression but Dispensable for Hematopoietic Stem Cell Maintenance</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106458</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2604</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Efficacy and Toxicity of Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Russian Multicenter Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106782</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2605</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Crucial Role of ROS-HO-1 Dependent Apoptosis Induced By Pan-HDACi in T-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101431</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>clofarabin: in first line treatment for ALL, approved for second/third line treatment</OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2606</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clofarabin Added to Standard Treatment in Adult Patients with Newly Diagnosed ALL: First Results of the Randomized Phase III HOVON-100 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102618</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2607</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Abnormal Coagulation Function in CD19-Targeted CAR-T Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103787</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2608</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Functional SCD1 Is Critical for Acute Lymphoblastic Leukaemia Maintenance in the Central Nervous System</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100477</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2609</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Therapy for Children and Adults withEGIL- or WHO2008-DefinedMixed Phenotype Acute Leukemia: A Systematic Review and Meta-Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103165</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2610</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Drugging DNA Repair to Target T-ALL Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99915</Key_PaperID>
<Key_SessionID>11822</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Preclinical testing of SYK inhibitor entospletinib in patient-derived xenograft models of childhood ALL</OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2611</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Enhanced Efficacy of the SYK Inhibitor Entospletinib and Chemotherapy in Infant Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106349</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3876</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107225</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3877</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Irinotecan Induces Complete Remission in MLL-Rearranged Acute Lymphoblastic Leukemia Xenografts</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108427</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3878</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Integrin alpha6Deletion Induces Apoptosis and Src Signaling Changes in Acute Lymphoblastic Leukemia Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105413</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3879</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Nudt15-Guided Thiopurine Dose Individualization In Vivo Using CRISPR/Cas9-Edited Mouse Model</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103815</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3880</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting the DNA Damage Response Pathway in MLL-rearranged B-Acute Lymphoblastic Leukemias</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107893</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3881</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Overcoming Leukemia-Induced Immune Suppression in BCR-ABL+ Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108856</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3882</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment Outcome of Dasatinib in Combination with Less-Intensive Induction, Homobarringtonie, Cytarabine, G-SCF in Newly Diagnosed Patients with Ph+ALL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105720</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3883</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Biomarkers for Predicting Toxicity and Response in Adult Acute Lymphoblastic Leukemia (ALL) Patients Treated with Blinatumomab</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106510</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Sorafenib in FLT3-ITD ALL
Dasatinib in IKZF1-del ALL
All-Trans Retinoic Acid in IKZF1-del ALL
</OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3884</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Blinatumomab + Tyrosine Kinase Inhibitorswith No Chemotherapyin BCR-ABL-Positive orIKZF1-Deleted or FLT3-ITD-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia Patients:High Molecular Remission Rate and Toxicity Profile</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107036</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Metformin. Metformin has been reported to decrease the level of ABCB1 gene expression. Therefore, the objective of this study was to evaluate the effect of metformin on the treatment regimen in patients with ALL who exhibit high levels of ABCB1 gene expression and its impact on overall survival.</OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3885</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effect of Metformin in Patients with ALL Who Express High Levels of the ABCB1 Gene and Its Impact on Survival</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107025</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3886</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Investigating the Efficacy of Anti-CD200 Immunotherapy in MRD Low and Risk B Cell Precursor ALL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101406</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3887</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Casein Kinase II Inhibition By CX-4945 and Epigenetic Modulation By Decitabine Demonstrate Significant Antiproliferative Activity As Single Agents As Well As in Combination in Acute B-Lymphoblastic Leukemia Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101472</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Daratumumab is a monoclonal antibody against CD38, which is currently FDA approved for use in patients with refractory multiple myeloma.</OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3888</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targetting CD38 in T Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101940</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3889</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102902</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3890</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Switchable CAR-T Platform for Acute Lymphoblastic Leukemia Treatment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103760</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3891</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Relevance of CD20 Targeting of Oncolytic Measles Virus in the Treatment of Adult Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103905</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3892</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Oncolytic Measles Virus MV-NIS Controls Relapsed ALL Patient-Derived Xenografts</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100319</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3893</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mitoxantrone in Combination with Clofarabine (MITCL) in Children, Adolescents and Young Adults with Refractory/Relapsed Acute Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100688</Key_PaperID>
<Key_SessionID>11823</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3894</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Modulation of CD22 Antigen Density Improves Efficacy of CD22 Chimeric Antigen Receptor (CAR) T Cells Against CD22lo B-Lineage Leukemia and Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105550</Key_PaperID>
<Key_SessionID>11824</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2612</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preferential in Vitro and In Vivo Induction of Endogenous Retrovirus Transcription from a Monoallelic Chromosome 7q in Decitabine (DAC) Treated AML Blasts</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108336</Key_PaperID>
<Key_SessionID>11824</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2613</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>BCL-2 Inhibition with ABT-199 Shows Efficacy in AML Cell Lines with Synergistic Effects upon Addition of the MEK Inhibitor GDC-0973 and Prolongs Survival in an NAS/BCL-2-Mediated Mouse Model of AML Post-MDS</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105539</Key_PaperID>
<Key_SessionID>11824</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2614</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Results and Cost-Effectiveness of the Flagida-Lite Regimen in Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102794</Key_PaperID>
<Key_SessionID>11824</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2615</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Topotecan Plus Cytarabine Is an Effective and Safe Regimen for Newly Diagnosed and Adverse ELN-Risk Acute Myeloid Leukemia Subset in Patients with Cardiac Comorbidities</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103495</Key_PaperID>
<Key_SessionID>11824</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2616</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104626</Key_PaperID>
<Key_SessionID>11824</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2617</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Outcomes of Different Regimens in Patients Newly Diagnosed with Acute Promyelocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101399</Key_PaperID>
<Key_SessionID>11824</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2618</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia  Updated Results of the Prospective German Intergroup Napoleon Registry</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102014</Key_PaperID>
<Key_SessionID>11824</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2619</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prolonged Azacitidine Exposure Alters Immunophenotype in Myeloid Leukemia Cell Lines</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108661</Key_PaperID>
<Key_SessionID>11824</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2620</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intensive Chemotherapy Vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105165</Key_PaperID>
<Key_SessionID>11825</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Decitabine and azacitidine have been approved for use in adults with MDS. In our case series, we are discussing activity in pediatric patients with MDS/AML.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3895</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Exceptional Responses to Epigenetic Based Therapy in Pediatric and Young Adult Monosomy 7 MDS/AML Patients with and without TP53 Mutations</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106924</Key_PaperID>
<Key_SessionID>11825</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>10 Day Regimen of Decitabine</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3896</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real World Data on Decitabine Treatment in 296 Patients with Acute Myeloid Leukemia: Outcome and Impact of TP53 Mutations</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108308</Key_PaperID>
<Key_SessionID>11825</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3897</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108724</Key_PaperID>
<Key_SessionID>11825</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3898</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes By Treatment Setting and Genomic Profile in Patients with AML on Cladribine, Idarubicin, and Cytarabine</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105337</Key_PaperID>
<Key_SessionID>11825</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3899</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Atovaquone Demonstrates Single Agent Activity and an Additive Effect in Combination with Cytotoxic Chemotherapy (Cytarabine and Daunorubicin) in AML </PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105635</Key_PaperID>
<Key_SessionID>11825</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3900</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcome after Midam Regimen and Impact of Post-Remission Strategy in Patients with Relapsing or Refractory Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106577</Key_PaperID>
<Key_SessionID>11825</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3901</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Induction Therapy for AML with 90 Mg/m Daunorubicin Results in Higher Troponin T Serum Levels in Comparison to Treatment with 60 Mg/m Daunorubicin</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102966</Key_PaperID>
<Key_SessionID>11825</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3902</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>AcDVP16 Induction Therapy for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103489</Key_PaperID>
<Key_SessionID>11825</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3903</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.109/L?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108408</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2621</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Midostaurin Reduces Regulatory T Cell Population in Healthy and Acute Myeloid Leukemia Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100686</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2622</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101525</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2623</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting Residual Chemotherapy-Resistant Acute Myeloid Leukemia Cells By a Novel Oxphos Inhibitor IACS010759</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102744</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off label use of autologous fecal microbiota transplant in patients with acute myeloid leukemia</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2624</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105789</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2625</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108094</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>CPI-613 is currently in development for the treatment of cancer, is not currently approved to treat any condition.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2626</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104812</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2627</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Adoptive Immunotherapy with Cord Blood (CB) Grafts Targeting Shared Inherited Paternal Antigens (IPA) and/or Non-Inherited Maternal Antigens (NIMA) during Induction Treatment for High Risk Myeloid Malignancies: Safety and Preliminary Results</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100714</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2628</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106929</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2629</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition with Sonidegib (LDE225) in Myeloid Malignancies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108600</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2630</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia (VITAL) Patients Eligible for Intensive Chemotherapy: A Planned Interim Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100593</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off-label use of lenalidomide for AML will be discussed.</OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2631</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Dose-Finding Study of Lenalidomide As Post-Remission Therapy for Older Adults with Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106477</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2632</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Novel, Irreversible FLT3 Inhibitor FF-10101 Demonstrates Broad in Vitro Activity Against FLT3 Inhibitor Resistance Mutations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107205</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2633</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107944</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2634</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100666</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2635</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Tyrosine Kinase Inhibitor-Induced Defects in DNA Repair Sensitize FLT3(ITD)-Positive Acute Myeloid Leukemia Quiescent and Proliferative Cells to PARP Inhibitors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103580</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2636</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Incorporation of 4-1BB Endowed the Potent CD33 Specific Chimeric Antigen Receptor T Cells with Anti-Exhaustion Capacity and Increased Central Memory Compartment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105866</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2637</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of Translation Initiation and Heat Shock Factor 1 (HSF1): A Novel Strategy Targeting FLT3 Double Mutant and Non-FLT3 Mutant AML Progenitor/Stem Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107495</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2638</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100282</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2639</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bispecific Anti-CD123 x Anti-CD3 Adaptir Molecules APVO436 and APVO437 Have Broad Activity Against Primary Human AML Cells In Vitro</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100966</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2640</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting the GAS6/AXL Pathway with a Newly Developed AXL-Selective Inhibitor SLC-0211 for the Treatment of Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105740</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2641</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107906</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2642</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chimeric Antigen Receptor (CAR) T Cell Therapy for CD7-Positive Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105389</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2643</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preclinical Rationale for the Use of Regorafenib in Myeloid Malignancies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107625</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2644</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Results from a Phase 1b (OX1222) Dose-Ranging Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100200</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2645</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CT7001, a Novel Orally Bio-Available CDK7 Inhibitor, Is Highly Active in in-Vitro and in-Vivo Models of AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102885</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2646</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Next Generation Sequencing of Immunized Mouse Splenocytes to Develop an Anti-TIM3 Chimeric Antigen Receptor for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107764</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2647</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Multivariate Efficacy Analysis of a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108512</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2648</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Blood Dendritic Cell Vaccine for Acute Myeloid Leukemia Expands Anti-Tumour T Cell Responses at Remission</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102799</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>IL-15 &amp; NK Cells to treat AML</OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2649</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106333</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2650</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting PRMT1 As a Novel Curative Therapy for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107548</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2651</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sy-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Anti-Tumor Activity in Preclinical Models of Hematologic Malignancies, and Demonstrates Interactions with the BCL-XL/BCL2 Mitochondrial Apoptosis Signaling Pathway in Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101370</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2652</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Blocking CD70/CD27 Signaling in Combination with Hypomethylating Agents Eradicates Human CD34+ AML Stem and Progenitor Cells in Vitro and In Vivo</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105532</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2653</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107201</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2654</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Therapeutic Targeting of GLI1 in Acute Myeloid Leukemia </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103387</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2655</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pre-Clinical Efficacy of the Anti-CD38 Monoclonal Antibody (mAb) Isatuximab in Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106647</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2656</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Midostaurin Reduces Bite Mediated Cytotoxicity Against Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107802</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2657</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108365</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2658</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PD-1H (VISTA) Induces Immune Evasion in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106243</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2659</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase I/Ib Trial of the MUC1 Inhibitor GO-203-2C Alone and in Combination with Decitabine for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104746</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2660</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dual Sphingosine Kinase and Bcl-2 Inhibition Exhibits Synergistic Cell Death in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108108</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>41</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2661</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CD33 DE2 Transcript Variant Encoded By Splicing Polymorphism Is Devoid of Antibody Binding Site and Lacks Response to CD33 Directed Antibody Drug Conjugates</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103678</Key_PaperID>
<Key_SessionID>11826</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>42</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2662</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Results from an Ongoing Phase 1 Study Indicate Adct-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105703</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2663</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Profiling in Extramedullary Acute Myeloid Leukemia Reveals Distinct Subgroups Defined By Mutations in KIT and RUNX1</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101517</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2664</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Functional Evaluation and Clinical Implications of FLT3 Juxtamembrane Domain Short Variants in Pediatric AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99906</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2665</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mutations in DNMT3A, U2AF1, and EZH2 Identify Intermediate-Risk Acute Myeloid Leukemia Patients with Poor Outcome after CR1</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108838</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2666</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Risk Score Generated from Ara-C Metabolic Pathway Predicts Leukemic Cell Intracellular Ara-CTP Levels in AML-97 Pediatric Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106311</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2667</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Persistent Somatic Mutation at Remission Is Associated with Poor Survival and Higher Risk of Relapse in Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102543</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2668</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>FLT3 Mutation in Acute Myeloid Leukemia: Primary or Secondary Mutation?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103260</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2669</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CSF3R Mutation in Acute Leukemia and MDS Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103423</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2670</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characteristics, Mutation Profiles andOutcomes of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103875</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2671</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characteristics and Outcomes of Pediatric Patients with t(16;16)-AML: Results of a Case Series By the International BFM Study Group</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104584</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2672</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Receptor Tyrosine Kinase-RAS Pathway Mutation Is Enriched in Myeloid Sarcoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104854</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2673</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Whole Genome Sequencing in Combination with Transcriptome Sequencing Unravels the Pathogenetic Impact of Rare Balanced Rearrangements in Myeloid Malignancies and May Lead to Novel Personalized Therapeutic Strategies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105016</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2674</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Post-Allogeneic Stem Cell Transplant Surveillance of CD34+ Sorted Peripheral Blood to Quantify Emergent DNMT3A, IDH and NPM1 clones and Correlation with Clinical Outcome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105512</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2675</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting Aberrant Expression of CD81 Impacts Cell Adhesion and Migration, Drug Resistance and Prognosis of Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106086</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2676</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effect of NPM1 Mutation on Prognosis and Therapeutic Efficacy in Patients Aged 70 Years with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106424</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2677</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Overexpression of Phospholipase C Beta 2 Is Associated with Favorable Prognosis in Normal Karyotype Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106962</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2678</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Downregulation of MHC Class II in Relapsed AML Cells after Allogeneic Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108513</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2679</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Endleukemia Assay v1: Enabling NGS-Based Comprehensive Routine Molecular Profiling of Leukemias in Routine Clinical Care</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108663</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2680</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Overexpression of KMT2E Is Associated with Higher Granulocytic Differentiation Rate in Response to ATRA-Based Treatment in Acute Promyelocytic Leukemia Cell Lines</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99859</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2681</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A New Highly Sensitive Realtime PCR Assay with Faster Turnaround Time for Detecting IDH1 and IDH2 mutations in Acute Myeloid Leukemia (AML) Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100746</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2682</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>IDH1R132, IDH2R140 and IDH2R172 in AML: Different Genetic Landscapes Correlate with Outcome and May Influence Targeted Treatment Strategies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101395</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2683</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>RUNX1 Mutations in MDS, s-AML and De Novo AML: Differences in Accompanying Cytogenetic and Molecular Genetic Alterations, Clonal Architecture and Outcome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102240</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2684</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genetic Profiling and Deep IDH1 Mutation Clearance to 0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103262</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2685</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Relevance of Alternatively Spliced Isoform AML1-ETO9a in Adult Patients with t(8;21)(q22;q22.1) Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103882</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2686</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Dynamic Epigenetic Landscape in Genetic and Immunophenotypic Stable Pediatric AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104473</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2687</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Error-Corrected Sequencing of Cord Bloods Identifies Pediatric AML-Associated Clonal Hematopoiesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104778</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2688</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genetic Heterogeneity of t(8;21)(q22;q22.1) Acute Myeloid Leukemia Revealed By High-Throughput Targeted Sequencing</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104998</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2689</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Acute Myeloid Leukemia Classification System That Associates Normal Myeloid-Cell Subset Gene Signatures with Prognosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105254</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2690</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Select Peripheral Blood Cytokine Levels Are Associated with Survival in Pediatric Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105700</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2691</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Acute Myeloid Leukemia (AML) Patients with an Isolated Trisomy Display Increased Frequency of Spliceosome Mutations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105961</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2692</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Induction Chemotherapy in NSG and NOD-Rag1nullIL2rgnullMouse Models of FLT3 Mutant AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106234</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2693</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of Long Non-Coding RNA Genes Important for Normal Hematopoiesis and Leukemogenesis Using Bioinformatics Tools</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106469</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2694</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Validation of the ELN 2017 Classification for AML with Intermediate Risk Cytogenetics with or without NPM1-Mutations and High or Low Ratio FLT3-ITDs</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106602</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2695</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phosphoproteomic Profiling Reveals Metabolic Factors Facilitating Leukemia-Stroma Crosstalk in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106779</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2696</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Combining Gene Mutation with Gene Expression Data Improves Outcomes Prediction in Acute Promyelocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106874</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2697</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of Relapse Risk Using a Multiparameter Flow Cytometry-Based Detection of Minimal Residual Disease in Adult Patients with Acute Myeloid Leukemia at ELN Intermediate-Risk</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107251</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2698</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Combined Treatment with JQ1 and Curcumin Synergically Modulates Apoptosis, Cell Cycle Features, Micrornas and Gene Expression in High-Risk Pediatric Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107418</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2699</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mutational Frequency in Hispanic and Non-Hispanic Patients with Acute Myeloid Leukemia (AML): Updated Analysis of 227 Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107617</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2700</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107715</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2701</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Significance of Peri-Transplant Measurable Residual Disease Detected By Multiparameter Flow Cytometry and Next-Generation Sequencing in Adults with NPM1-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108049</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2702</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Association between Nuclear SET Domain (NSD) Protein Lysine Methyltransferases (KMT) Expression and Poor Prognosis in Acute Promyelocytic Leukemia (APL) Patients Treated with ATRA and Anthracycline Protocol</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108387</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>41</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2703</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fusion Transcripts without Corresponding Cytogenetic Abnormalities in Acute Myeloid Leukemia: Implications for AML Pathogenesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108576</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>42</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2704</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Single-Cell Transcriptional Profiling of Acute Myeloid Leukemia Identifies Prognostic Transcriptional Profiles at Diagnosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105842</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>43</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2705</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of the Impact of Minimal Residual Disease, FLT3 Allelic Ratio, and FLT3 Mutation Status on Overall Survival in FLT3 Mutation-Positive Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the Chrysalis Phase 1/2 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107228</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>44</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2706</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>AML-Associated Somatic Mutations Can be Detected in Stem and Progenitor Populations in Patients with Antecedent Multiple Myeloma Years before Onset of Therapy-Related Transformation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104284</Key_PaperID>
<Key_SessionID>11827</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>45</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2707</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108235</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3904</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia (MPAL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101313</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3905</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Implications of Detection and Clearance of Post-Induction Residual Disease in 2119 Children and Young Adults with AML: Childrens Oncology Group Studies AAML0531 and AAML1031</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101409</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3906</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characteristics and Outcome of Patients with Acute Myeloid Leukemia and t(6;9)(p22;q34)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103350</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3907</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102970</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3908</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103338</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3909</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103819</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3910</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107710</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3911</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hypomethylating Agents Versus Intensive Chemotherapy in Elderly Patients (Age  70) with Acute Myeloid Leukemia with High White Blood Cell Count</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106012</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3912</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age  70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100117</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3913</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Oncogenic Fusion Protein CBFB-SMMHC Downregulates CD48 to Evade NK Cell Recognition</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101339</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3914</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>N-Myristoyltransferase 2 (NMT2) Protein Levels Predict Survival in Acute Myeloid Leukemia (AML): A Novel Prognostic Biomarker</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101726</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3915</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Simulation of AML Clonality in Patient-Derived Xenografts</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102192</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3916</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeted Mutation Analysis of Acute Myeloid Leukemia at Diagnosis and Relapse Shows Different Clonal Evolution Patterns Involving Different Functional Classes of Genes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102601</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3917</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognosis and Application of Day 14 Bone Marrow Results in Acute Myeloid Leukemia Induction</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103263</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3918</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Putative Autophagy Protein VMP1 Amplifies Protective Autophagy Under Stress Conditions in AML Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103808</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3919</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Canonical Wnt Pathway Is Activated in Myeloid Leukemia Stem Cells Via Hematopoietic Cell Kinase That Is Phosphorylated By an Autocrine TIM-3/Galectin-9 Signaling</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103949</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3920</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Over-Expression of ERG Predicts Poor Outcome in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104150</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3921</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Plasma-Derived Exosomes Carrying Leukemia-Associated Antigens Associate with Leukemia Relapse in AML Patients after Chemotherapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104433</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3922</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Differentiation Response to Quizartinib, a Potent 2nd Generation FLT3 Inhibitor, in Relapsed FLT3-Mutant AML Patients Correlates with Specific DNA Methylation Signature Prior to Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104524</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3923</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterization of Acute Myeloid Leukaemia (AML) Patients with Elevated Peripheral Blood Plasma D-2-Hydroxyglutarate (D-2HG) and/or Isocitrate Dehydrogenase (IDH) Mutational Status</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104661</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3924</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Peripheral Blood As a Substitute for Bone Marrow for Assessing the Immune Profile in AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104820</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3925</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of 9q Deletions on the Classification in AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104905</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3926</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Methylation Analysis in Pediatric Patients with Acute Myeloid Leukemia the Jccg Study, JPLSG AML-05</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105008</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3927</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PGC1 Driven Mitochondrial Biogenesis within the Bone Marrow Stromal Cells of the Acute Myeloid Leukemia Micro-Environment Is a Pre-Requisite for Mitochondrial Transfer to Leukemic Blasts</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105089</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3928</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Low-Level SAMHD1 Expression in Acute Myeloid Leukemia Blasts Correlates with Favorable Outcome in Patients with Diploid Cytogenetics Treated with Cytarabine-Based Chemotherapy Regimens</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105360</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3929</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Epigenetic Drugs Selectively Target a Population of AML Cells Which Are Positive for CD123 Cell Surface Marker and Are Chemoresistant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105600</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3930</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Therapeutically Targetable Activating c-ABL1 Mutations in Philadelphia Chromosome-Negative Leukemias</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105665</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3931</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Monitoring of NPM1 Is a Useful Tool for Detecting Early-Stage Relapse and to Guide Pre-Emptive Treatment Approaches in Patients with NPM1-Mutated Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105871</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3932</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Gene mutations and Dynamics Methylation of CDKN2B and DLC-1 Promoters on Treatment Response with Azacitidine</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106399</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3933</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prohibitin Expression Level As a Companion Diagnostic Marker in Cytogenetically Normal Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106542</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3934</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>NUP98-KDM5A Fusion Gene Is Not Exclusive to Acute Megakaryoblastic Leukemia and Is an Independent Predictor of Poor Prognosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106870</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3935</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long Non Coding RNA BALR2-CDK6 Axis Influences Cell Differentiation and Metabolic Status of Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106993</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3936</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107374</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3937</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Higher Proportion of a Novel PD-1+ Foxp3+  Regulatory T Cell Subset in De Novo and Recurrent AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107945</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3938</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improved Clinical Assessment of Myeloid Malignancies By Transcriptome Profiling</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108030</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3939</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>RNA Editing By APOBEC3A Confers Dynamic Mutational Load in Monocytic Leukemias</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108579</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3940</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An Integer Weighted Genomic Mutation Score (GMS) Using Next Generation Sequencing Is Predictive of Prognosis in Intermediate Risk AML Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108777</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3941</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Utility of Leukemic Stem Cells Markers in Determining Minimal Residual Disease in Patients with AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99659</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3942</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Immune Gene Expression Profiling in Children and Adults with Acute Myeloid Leukemia Identifies Distinct Phenotypic Patterns</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100081</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3943</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Extensive Immunosuppression in the Acute Myeloid Leukemia (AML) Bone Marrow and Discovery of NK Cells As Biomarker of Superior Survival</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100728</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>41</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3944</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterization of Cooperating Mutations in Murine Acute Leukemias: Towards Establishing Leukemia Models with Genetic Lesions in Defined Cellular Pathways</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100765</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>42</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3945</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Interferon- Induces Distinct mRNA and Protein Profiles in Acute and Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101319</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>43</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3946</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bone Marrow CD8 T Cells Express High Frequency of PD-1 and Exhibit Reduced Anti-Leukemia Response in AML Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101872</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>44</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3947</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Robust Parsing and Automated ELN Risk Classification for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102066</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>45</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3948</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Natural Killer Receptor Ligand Expression By AML Blasts Determines Survival and Relapse Following Induction Chemotherapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102701</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>46</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3949</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bitter Taste Receptors Are Expressed on Acute Myeloid Leukemia Cells and Their Activation Results in Quiescence Induction and Prevention of Migration</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103248</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>47</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3950</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MiR-143 Targets ERK5 in Granulopoiesis and Predicts Outcome of Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103339</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>48</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3951</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Monitoring Leukemic Mutations Using UltrasensitiveIbsafe Digital Droplet Analysis Predicts Relapse of Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104264</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>49</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3952</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Importance of DOCK1 Transcript Levels, and Biologic Insights from DOCK1-Associated Gene and Microrna Expression Signatures in De Novo acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104421</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>50</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3953</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Single Cell Transcriptome Analysis Reveals Changing Levels and Distributions of Stemness across Disease States in Pediatric AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104575</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>51</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3954</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Characterization of Transposable Elements in the Acute Myeloid Leukemia Transcriptome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104766</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>52</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3955</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical and Genetic Relevance of Somatic Mutations in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Patients Using Serial Sequencing</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104840</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>53</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3956</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preexisting Mutations in Hematopoietic Stem Cells in Patients with Therapy-Related Myeloid Neoplasms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104978</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>54</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3957</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105013</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>55</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3958</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105150</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>56</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3959</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Longitudinal Detection of DNMT3AR882H Transcripts in Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105421</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>57</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3960</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mutational Landscape and Clinical Outcome Associated with Different Rearrangements Involving 11q23/MLL in De Novo Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105535</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>58</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3961</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Longitudinal Transcriptome Analysis of Myelodysplatic Syndrome Progression to Acute Myeloid Leukemia: Implications for Prognosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105768</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>59</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3962</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Robust Bioinformatics Approach for Identifying Novel AML LSC Targets: Putative Role of Galectin-1 in the Immune-Microenvironment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105915</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>60</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3963</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CSF3R Mutations Synergize with CEBPA and SETBP1 Mutations in Acute Myeloid Leukemia and Chronic Neutrophilic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106033</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>61</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3964</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MAPKAP1 (Sin1), a Key Component of the MTORC2 Complex, Confers Resistance to Sorafenib and Correlates with Adverse Clinical Outcomes in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106087</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>62</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3965</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High-Throughput Single-Cell DNA Sequencing of AML Tumors with Droplet Microfluidics</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106260</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>63</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3966</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>IGF Signaling Predicts Outcomes and Is a Promising Target Therapy for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106777</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>64</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3967</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PML-RARa of the Short but Not the Long/Variant Isoform Initiate from CD34+TIM-3+  LSCs with Hierarchical Leukemic Organization</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107334</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>65</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3968</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of Novel Targets for Antibody or Chimeric Antigen Receptor (CAR) Based Immunotherapy in AML: Characterizing the Surfaceome from Primary Patient Samples</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108008</Key_PaperID>
<Key_SessionID>11828</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>66</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3969</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>DNMT3A Is Highly Expressed in Bone Marrow Cells from Acute Myeloid Leukemia Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104133</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2708</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104993</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2709</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Assessing the Subclonal Genetic Landscape of KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia By Single-Cell Genomics</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101381</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2710</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeted RNA-Seq Identify a Subset of Adolescent and Adult Patients with Acute Lymphoblastic Leukemia with BCR-ABL1-like Characteristics</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104759</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2711</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Feasibility of Targeted RNA Sequencing for Routine Diagnostics of B-Cell Precursor ALL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108371</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2712</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105909</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2713</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Homocygous PAX5 Sequence Mutations Define a Novel Subtype of B Cell Precursor Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100883</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2714</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Persistence of the Minimal Residual Disease at the End of Induction Is Not a Factor of Poor Prognosis If Imatinib Was Changed to the Dasatinib By Ph+ RALL Protocol in Ph-Positive Acute Lymphoblastic Leukemia Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106619</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2715</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Rapid Capture NGS Identifies Genomic Rearrangements in BCP-ALL for MRD Diagnostics</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105207</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2716</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102179</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2717</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Limited Therapeutical Impact of Extensive Genomic Profiling in Relapsed Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia: Population-Based Four-Year Consecutive Cohort</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105934</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2718</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CD123 Expression Patterns and Potential of IMGN632, a CD123-Targeted Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106520</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2719</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dehydropeptidase 1 Promoted Survival and Cell Cycle Progression through Regulation of CREB and P53 Pathways in B-Cell ALL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104909</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2720</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Adult Triple Negative ACUTE Lymphoblastic Leukemia Genome Wide Characterization</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106795</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2721</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Analysis of Mixed Phenotype Acute Leukemia (MPAL) By Whole Genome Sequencing</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107131</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2722</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Fanconi Pathway in Pediatric T-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106558</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2723</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PDX Models Recapitulate Genetics and Epigenetics of Pediatric T-Cell Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100428</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2724</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of Novel Fusion Genes and Characterization of Transcriptome Features in T-Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106673</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2725</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Multi-Omics of Adult T Cell Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106462</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2726</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Relapsing Pediatric T-Cell Acute Lymphoblastic Leukemia Downregulates T-Cell Properties and Upregulates Cell Adhesion</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103582</Key_PaperID>
<Key_SessionID>11829</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2727</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Regulatory T Cells Promote the Stemness of Acute Myeloid Leukemia Cells through IL10 Cytokine Related Signaling Pathway</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107612</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3970</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genomic Analysis and Pathway Characterization of Genes with Somatic Variants in Infant Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108881</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3971</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Defining the Cell Surface Proteome of MLL Rearranged Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104957</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3972</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Detection of ABL1 kinase Domain Mutations in Therapy Naive BCR-ABL1 Positive ALL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102198</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3973</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dissecting Childhood B-Other Acute Lymphoblastic Leukemia: Lower Frequency of Druggable Gene Fusions in European Population?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103183</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3974</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Aberrant ARID5B Expression and Its Association with Ikaros Dysfunction in Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101588</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3975</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Integrated Genetic/Epigenetic Analysis Revealed High Heterogeneity of Acute Lymphoblastic Leukemia in Down Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105941</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3976</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterization ofRB1in PediatricTCF3-PBX1+ acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101697</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3977</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Expression of MEF2D-Fusion Protein Is Caused By Escaping from the Suppression By miRNA and Leads to Suppress Transcriptional Activity of PAX5</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105047</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3978</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Constitutional Ring Chromosome 21 Predisposes to Acute Lymphoblastic Leukaemia (ALL) with iAMP21</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105240</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3979</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Effect of Genetic Alterations in Pediatric Patients with B-Progenitor Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101006</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3980</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An Artificial Intelligence Approach for B Lymphoblastic Leukemia Minimal Residual Disease Detection and Clinical Prognosis Prediction Using Flow Cytometry Data</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104749</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3981</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genome-Wide Association Study (GWAS) of High-Risk Minimal Residual Disease and Relapse in B-Cell Acute Lymphoblastic Leukemia on Trial AIEOP-BFM ALL 2000</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106021</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3982</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>When Standard Markers Are Not Sufficient for Monitoring Minimal Residual Disease or Targeted Treatment: New Transcriptome Derived Flow Cytometry Markers for Switching B Cell Precursor Leukemias</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108080</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3983</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Peg-Asparaginase Administration on Day 3 of Remission Induction Accelerates MRD Response in Children with B-Cell Precursor Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108851</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3984</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Applicability and Prognostic Significance of Flow Cytometric Cerebrospinal Fluid Investigation in Children with Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102097</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3985</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Amount of PD1+TIM3+ T Helper Cells May Predict Poor Outcome in Adult Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104824</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3986</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mutation Topology of Adult B-Cell Acute Lymphoblastic Leukaemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105290</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3987</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Linking Biophysical and Transcriptional Profiles of In Vivo-Treated Human Leukemias on a Single-Cell Level Uniquely Resolves Subpopulations of Response</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104811</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3988</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Increased Palmitoylation Modulates Cytoskeletal Regulators to Enhance CXCR4-Mediated Motility of Malignant B Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108450</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3989</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lgr5 Functions As Negative Regulator of Wnt Signaling in B Cells and Is Critical for Self-Renewal of Normal and Transformed B Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106412</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3990</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Expression of Legumain in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia Is Associated with Central Nervous System Involvement</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107392</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3991</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Changes inLeukemic BlastsCD19 Expression in Children with Relapsed/Refractory B-Cell Precursor ALL Treated with Blinatumomab</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104877</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3992</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Upregulated Cholesterol Biosynthesis Is a Biomarker for Isolated Central Nervous System Relapse in Acute Lymphoblastic Leukaemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103525</Key_PaperID>
<Key_SessionID>11830</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3993</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical and Molecular Characteristics of Therapy-Related Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107908</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2728</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Next-Generation Sequencing Based Monitoring of Circulating-Tumor DNA in Untreated Peripheral T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105237</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated, in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia and, in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. GAZYVA is also indicated in combination with chemotherapy, followed by GAZYVA maintenance in patients achieving a response, in previously untreated advanced FL (EU, Switzerland). In this abstract, Phase III trial data on GAZYVA plus chemotherapy in previously untreated patients with DLBCL are used to characterize the mutational profile of DLBCL and to evaluate the prognostic impact of somatic mutations in relation to cell-of-origin subtype.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2729</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Systematic Analysis of the Prognostic Impact of Somatic Mutations in Diffuse Large B-Cell Lymphoma (DLBCL) with Evaluation of Cell-of-Origin Dependence: Results from the Phase 3 GOYA Trial in Previously Untreated DLBCL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100775</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2730</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genomic Profiling Reveals Spatial Intra-Tumor Heterogeneity in Follicular Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103206</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2731</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of EBV upon the Tumor Microenvironment and Mutational Profile of Primary CNS Lymphoma in PTLD</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101966</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2732</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mitochondrial Metabolism and RNA Methylation in DLBCL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105910</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2733</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ultra Deep Whole Exome Sequencing of Classical Hodgkin Lymphoma (cHL) Reveals Novel Recurrent Somatic Mutations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104188</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2734</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107547</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2735</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Mutational Landscape and Immune Microenvironment of Primary Intestinal Follicular Lymphoma (PIFL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100910</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2736</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genome-Wide Association Study for Waldenstrm Macroglobulinemia Identifies Novel Susceptibility Loci</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104304</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2737</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Exploring the Tumor Clonal Dynamics between Diffuse Large B-Cell Lymphomas and Bone Marrow Involvement By Deep Immunoglobulin Heavy Chain VDJ Sequencing</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107811</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2738</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Pathways Associated with Ibrutinib Resistance in Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106621</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2739</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>SOX11 and CD43 Biomarkers in Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108390</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2740</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mutations in the Phosphoinositide 3-Kinase Pathway (PI3K) Are Associated with Poor Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106262</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2741</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Mutation Landscape of Follicular Lymphoma and Chronic Lymphocytic Leukemia Reveals a Distinctive Frequency and Composition of Aid-Related Mutation Signatures</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103917</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2742</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105198</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2743</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Azacytidine and Decitabine Exhibit Differential Effects on Cytotoxicity and Methylation and Exhibit Class Synergy with Hdaci in Models of Ptcl</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106408</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2744</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Detection of MYD88 L265P Mutation By Next Generation Deep Sequencing in Peripheral Blood Mononuclear Cells of Waldenstrom Macroguloblinemia and IgM Monoclonal Gammopathy of Undetermined Significance</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105158</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2745</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104841</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2746</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>NSE Promotes Macrophage Towards to M2 Polarization in Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108036</Key_PaperID>
<Key_SessionID>11831</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2747</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Impact of Somatic Copy Number Alterations in Circulating Tumor DNA from Diverse Lymphoma Subtypes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107699</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3994</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Deciphering Discordance between MYC mRNA and MYC IHC in DLBCL: The Role of MYC Exon 2 Mutations and N11S Polymorphism</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104770</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3995</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>B-Cell Differentiation Dependent Classification of Diffuse Large B-Cell Lymphoma By the Nanostring Technology</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106828</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3996</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Genomic Profiling Demonstrates Differences in Primary CNS Lymphoma and Systemic Diffuse Large B Cell Lymphoma and Reveals Biomarkers Indicating Potential Benefit from Immune Checkpoint Inhibitors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102074</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3997</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Compendium of Transcriptional and Mutational Data to Improve the Stratification of Peripheral T-Cell Lymphoma Subtypes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105025</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3998</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Definition of Activated B Cell-like (ABC) DLBCL Identifies Patients Who May Benefit from Front-Line Intensive R-HDS Chemotherapy with ASCT</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106541</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3999</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Sequencing Analysis in Subcutaneous Panniculitis-like T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105734</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4000</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Prevalence of Oncogenic MYD88 and CD79B Mutations in Intravascular Large B-Cell Lymphoma: Implication for Therapy with Brutons Kinase Inhibitors?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100885</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4001</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Depict a High Complexity on the Cytogenetic, but Not on the Molecular Genetic Level and Show MYC Mutations As Prognostic Marker</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106521</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4002</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genetic Defects Affecting LymphocyteCytotoxicity in Epstein-Barr Virus-Associated T/NK-Cell Lymphoproliferative Diseases</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107234</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4003</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Whole Genome Sequencing in Hairy Cell Leukemia-Variant (HCL-v) and Splenic Marginal Zone Lymphoma (SMZL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104915</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4004</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ebv-Mir-BART11-3p, Ebv-Mir-BART9 and Ebv-Mir-BART10 Are Present in the Plasma of HIV-Infected Subjects with Lymphoma and Are Potential Lymphoma Biomarkers</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101226</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4005</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Circulating Micrornas (miRNA) As a Novel Liquid Biopsy and Therapeutic Platform in MYC and Non-MYC Diffuse Large B-Cell Lymphoma (DLBCL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107490</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4006</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MYD88 Mutation Status Impacts Overall Survival and Risk of Histological Transformation in Waldenstroms Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104446</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4007</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High-Resolution Architecture and Partner Genes of MYC Rearrangements in Lymphoma with DLBCL Morphology</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107900</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4008</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Th1/2 Immune Response Signature Predicts Outcome after Dose-Dense Immunochemotherapy in Patients with High Risk Diffuse Large B-Cell Lymphoma  Results from Nordic Lymphoma Group Trials</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106405</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4009</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cell of Origin and Genomic Profile of Primary Central Nervous System Lymphoma Determined Using the Nanostring Lst Assay and Ultra Deep Targeted Next Generation Sequencing</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108156</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4010</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ABC Subtype, TP53 Mutation and BCL2 Overexpression Are Associated with a Worse Outcome in Untreated Poor-Risk Young Diffuse Large B-Cell Lymphoma: Results from the Frontline Phase III BIO-DLBCL04 Study of the Fondazione Italiana Linfomi</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108860</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4011</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Genomic Landscape of MYD88 Wild-Type WaldenstrMs Macroglobulinemia Ischaracterized By Somatic Mutations in TBL1XR1, the CBM Complex, and NFKB2</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108879</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4012</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Histone Deacetylase Inhibitors Abolish HBZ Protein Expression and Induce Cell Death in HTLV-1 Related Adult T-Cell Leukemia-Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102865</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4013</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107735</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4014</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Characterization of Post-Transplant Plasmablastic Lymphomas Implicates RAS, TP53, and NOTCH Mutations and MYC Deregulation in Disease Pathogenesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101150</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4015</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterization of Immunological Profiles with Clinical Significance in Patients with Classical Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102645</Key_PaperID>
<Key_SessionID>11832</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4016</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Next Generation Sequencing of Castleman Disease and Follicular Dendritic Cell Sarcomas Associated with Castleman Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101033</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2748</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>FOXP1 Expression Is a Prognostic Biomarker in Follicular Lymphoma Treated with Immunochemotherapy and Is Associated with Distinct Molecular Features</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105821</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2749</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Resistance Mechanisms Underlying Venetoclax Resistance in Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105614</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2750</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Immune Checkpoint Receptors PD-1, PD-L1, TIM-3 and LAG-3 in Lymphoma: Tumor Cell and Tumor Infiltrating Lymphocyte (TIL)Expression, Patient Prognostication, and Identification of Rational Therapeutic Targets</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108325</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2751</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Highly Multiplexed Imaging Mass Cytometry Allows Visualization of Tumor and Immune Cell Interactions of the Tumor Microenvironment in FFPE Tissue Sections</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106658</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2752</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>RAC2 Links B-Cell Receptor Signaling and Cell Adhesion in Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108559</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2753</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Enhanced Spontaneous Anti-Tumor Cytotoxicity of Natural Killer Cells in Cutaneous T-Cell Lymphoma Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107881</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2754</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>T Cell Versus T Cell; A Study of the Immune Checkpoint Landscape in Cutaneous T Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106182</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2755</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>B- Cell Maturation Antigen Is Exclusively Expressed in a Wide Range of B-Cell and Plasma Cell Neoplasm and in a Potential Therapeutic Target for Bcma Directed Therapies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107860</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2756</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Circulating Tumor DNA Recovery from Plasma and Serum</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105161</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2757</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Anaphase Promoting Complex/Cyclosome: A New Promising Target in Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107874</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2758</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106431</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2759</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Altered Peripheral Immune Phenotypes in Mantle Cell Lymphoma Survivors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104726</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2760</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Loss of the GVL Effect By Distinct Expression of Migration Markers As a Mechanism of Immune Escape in Adult T Cell Leukemia/Lymphoma (ATLL), a Malignant Counterpart of Regulatory T Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100856</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2761</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Amount of PD-L1+ Tumor Associated Macrophages Is Associated with Better Survival in Patients with Primary Testicular Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101465</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2762</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Follicular Lymphoma Regulatory T Cell Function and Origin</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102928</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2763</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Integrated Phosphoproteomic and N-Glycoproteomic Landscape of Cutaneous T-Cell Lymphoma Reveals Distinctive Pathogenetic Insights and Therapeutic Vulnerabilities</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103286</Key_PaperID>
<Key_SessionID>11833</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2764</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dynamic BH3 Profiling Reveals Novel Therapeutic Strategies for the Treatment of Double-Hit Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108190</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4017</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Next Generation Sequencing (NGS) Based IGH and TCR Clonality Assays Provide Excellent Specificity and Sensitivity for Routine Clonal Characterization and Monitoring of Lymphoproliferative Disorders</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107670</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4018</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108095</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4019</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Wnt5a Can Induce Activation of Rac1 and Proliferation in Mantle Cell Lymphoma Via a ROR1-Dependent, but BTK-Independent, Signaling Pathway</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106455</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4020</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Selective Inhibition of HDAC1 and HDAC3 Inhibits Survival of Diffuse Large Cell Lymphoma Via Epigenetic Modulation of Death Associated Protein (DAPK)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107465</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4021</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>T-Cell Subsets and Macrophages in the Tumor Microenvironment Are Associated with Early Outcome in Follicular Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108728</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4022</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Predictors of Hyperviscosity Syndrome (HVS) in Waldenstrm Macroglobulinemia (WM)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106063</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4023</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Correlation of Myeloid Derived Suppressor Cells and Response to Standard Chemoimmunotherapy in Diffuse Large B Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103512</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4024</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of the Duration of Methotrexate Administration and the Specific HLA Alleles on the Regressive Methotrexate-Induced Lymphoproliferative Disorders</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104906</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4025</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Aberrant Activation of NF-Kb and Hypoxia Enhances Glycolytic Enzyme Hexokinase II Expression in B- Cell Lymphoma through Activation of HIF-1</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106898</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4026</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Tumor Cells from EBV-Positive T- or NK-Cell Neoplasms Induce Differentiation and Activation of Macrophages By Secreting Humoral Factors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99975</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4027</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Low Expression of T/NK-Cell Signature Predicts Poor Survival in Patients with Primary Testicular and Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104401</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4028</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mast Cell Density and Its Clinical Relevance in Waldenstroms Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102047</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4029</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Neutrophils Extracellular Traps Induced By Lymphoma -Derived IL-8 Could Promote Diffuse Large B Cell Lymphoma Progression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102852</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4030</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evidence That Some Breast Implant Associated Anaplastic Large Cell Lymphomas Arise in the Context of Allergic Inflammation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102951</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4031</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103133</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4032</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gene Regulation and Suppression of Type I Interferon Signaling By STAT3 in Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103456</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4033</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103493</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4034</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Soluble PD-1 Ligands Regulate T-Cell Function in Waldenstroms Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103510</Key_PaperID>
<Key_SessionID>11834</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4035</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Assessment of CD52 Expression in "Double-Hit" and "Double-Expressor" Lymphomas: Implications for Clinical Trial Eligibility</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100821</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2765</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Negative Minimal Residual Disease Associated with Extended Response to Moxetumomab Pasudotox in Patients with Relapsed/Refractory Hairy Cell Leukemia: Long-Term Follow-up of Bone Marrow Immunohistochemistry Analyses from a Phase 1 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107895</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2766</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstroms Macroglobulinemia: Update of Pivotal Clinical Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105275</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2767</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstroms Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101735</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2768</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-2a</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103083</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2769</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in RelapsedNon-Hodgkins Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107000</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2770</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104167</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pembrolizumab is examined in combination with the investigational agent G100 in FL.  Pembrolizumab is not approved for use in FL.</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2771</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108398</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2772</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Follow-up of a Prospective Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in Waldenstroms Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107136</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2773</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Human Pegivirus (HPgV) Infection and Lymphoma Risk and Prognosis: A Study from North America</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105837</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2774</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Utility of Systemic Staging in Low Grade B-Cell Lymphomas Presenting in the Skin</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108845</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2775</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effect of Histologic Grade on Clinical Outcomes of Follicular Lymphoma: Prolonged Progression Free Survival of Grade 3 Follicular Lymphoma in the Rituximab Era</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108613</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2776</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Early Cardiovascular Toxicity with Treatment of Follicular Lymphoma Is Associated with Shorter Overall Survival</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101198</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2777</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106623</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2778</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>First in Human, Phase I/II Trial of the Brutons Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103093</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2779</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Maintenance Rituximab or Observation after Frontline Treatment with Bendamustine-Rituximab (BR) for Follicular Lymphoma: A Real World Analysis Across 13 US Cancer Centers</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107610</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2780</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bendamustine and Rituximab As Initial Therapy in Indolent Non-Hodgkins Lymphoma and Mantle Cell Lymphoma in a Canadian Population; Highly Effective with Frequent Infections</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103972</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2781</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of Radiation Treatement in Ocular Adnexa Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Evaluation in a Single Center Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104508</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2782</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107484</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2783</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Systematic Literature Review of the Clinical Efficacy and Safety of Treatments in the Relapsed/Refractory Setting for Patients with Follicular Lymphoma or Marginal Zone Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103730</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2784</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Rituximab Combined Therapy and Maintenance Eliminate the Follicular Lymphoma with MYC Translocation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108113</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2785</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase Ib-II Study of Brutons Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107122</Key_PaperID>
<Key_SessionID>11836</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2786</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Focal Splenic Lesions May Identify Patients Who Benefit from Anthracycline Based Therapy and Are Significantly Associated with High Grade Transformation in Follicular Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102165</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2787</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chemotherapy of GEP Regimen(Gemcitabine,etoposide and Pegaspargase) for the Patients with Newly Diagnosed Extranodal Natural Killer/T Cell Lymphoma:a Phase II Clinical Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105663</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2788</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101336</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2789</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Study ofTHP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101893</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Yes, brentuximab vedotin is being investigated in a novel combination. </OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2790</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Five-Year Survival Results: Frontline Brentuximab Vedotin in Combination with CHP in Patients with CD30-Expressing Peripheral T-Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102086</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2791</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Anti-Tumour Activity of RP6530, Dual PI3K / Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100841</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2792</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Elderly Hodgkin Lymphoma  Multicenter Retrospective Data Analysis from the Czech Hodgkin Lymphoma Registry</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103605</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2793</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Outcomes of Patients with 3rd or Higher Relapsed Classical Hodgkin Lymphoma: Results from the German Hodgkin Study Group</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108404</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2794</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): Clinical Features, Treatment, and Outcome. a Single Institution Result of 145 Patients from the Middle East</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104409</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2795</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of the NCCN-IPI As a Prognostic Tool in PTCLs</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104494</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2796</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Subtypes, Molecular Features and Treatment Strategies of Aggressive NK-Cell Leukemia: A Multicenter Analysis of 113 Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105446</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2797</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chidamide Oral Subtype-Selective Histone Deacetylase Inhibitor (HDACI) Monotherapy Was Effective on the Patients with Relapsed or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102051</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2798</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Changes in Serum TARC Predict PET Response Among Pediatric Patients with Relapsed or Refractory Hodgkin Lymphoma Treated with Brentuximab Vedotin and Gemcitabine: A Report from the Children's Oncology Group</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102163</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2799</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Escalation from ABVD Following Positive Interim Functional Imaging Improves Progression Free Survival but Not Overall Survival in Advanced Classical Hodgkin Lymphoma  a Real World Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105170</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2800</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Quantitative Analysis of MultiplexedImmunofluorescence in T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103501</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2801</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Population-Based Study of Race &amp; UV Exposure on Incidence &amp; Survivalin Mycosis Fungoides</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103109</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2802</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High-Dose BendamustinePlus Brentuximab Combination Is Effective and Has a Favourable Toxicity Profile in the Treatment of Refractory and Relapsed Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106707</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2803</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Absolute Lymphocyte Count Is Associated with the Prognosis in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108470</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2804</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of PTX3 and S100A9 As Serum Diagnostic and Therapeutic Response Biomarkers of NK/T Cell Lymphoma Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108768</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2805</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes in Patients with Enteropathy-Associated T-Cell Lymphoma (EATL) and Hepatosplenic T-Cell Lymphoma (HSTCL): A Population Based Analysis Using the SEER Data</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101781</Key_PaperID>
<Key_SessionID>11837</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Brentuximab vedotin is approved for use as a single agent in Hodgkin lymphoma after failure of autologous stem cell transplant
(ASCT) or after failure of at least two prior multi-agent chemotherapy
regimens in patients who are not ASCT candidates</OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2806</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102612</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4070</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas  Preliminary Results</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106053</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4071</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Negative (ALCL, ALK-): Analysis of 203 Patients Prospectively Registered in the International T-Cell Project</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105809</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4072</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Positive (ALCL, ALK+): Data from 119 Patients Prospectively Registered in the International T-Cell Project</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101920</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4073</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103125</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4074</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105043</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>A pivotal single-arm phase 1/2 study of forodesine, a potent purine nucleoside phosphorylase inhibitor,at high dose was conducted in patients with relapsed Peripheral T-Cell Lymphoma (PTCL) in Japan. </OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4075</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100952</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>TTI-621 (SIRPaFc) is an immune checkpoint inhibitor consisting of the CD47 binding domain of human SIRPa linked to the Fc region of human IgG1. It is being developed as a therapeutic for various malignancies</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4076</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Single Direct Intratumoral Injection of TTI-621 (SIRPFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Szary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103602</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4077</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>APhase II Study of Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101796</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4078</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Increased Rate of Pulmonary Toxicity in Pediatric Patients with Relapsed Hodgkin Lymphoma Receiving Brentuximab Vedotin</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103851</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4079</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Intratumoral Galectin-1 Is Associated with Adverse Outcome in ALK-Negative, CD30-Positive Peripheral T-Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106297</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4080</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Therapeutic Response of Chidamide Was Associated with Elevated H3 Acetylation Level in Patients with Refractory/Relapsed Non-Hodgkin Lymphoma (R/R-NHL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101449</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4081</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Outcomes By Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD Alone; A Secondary Analysis of the Canadian Cancer Trial Group HD.6 Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102786</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4082</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Patient and Physician Preferences for Front-Line Treatment of Advanced Stage Hodgkin Lymphoma in Germany, France and the United Kingdom</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104252</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4083</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An ABVD-Based Approach Confers Superior Outcomes for Adolescent and Young Adult Patients Compared to Other Adults with Advanced Classical Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106704</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4084</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Differences in Fecal Microbiota in Long-TermAdolscent/Young AdultHodgkin Lymphoma Survivors and Their Unaffected Twins.</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107568</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4085</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108809</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The use of ipilimumab in this study is not an FDA approved indication.</OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4086</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100766</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4087</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Bbv Regimen: A Phase II Study with Bendamustine Plus Brentuximab Vedotin in Hodgkin Lymphoma and CD30+ Peripheral T-Cell Lymphoma in First Salvage Setting</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103689</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4088</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Unmet Needs for a Better Treatment in Patients with Peripheral T Cell Lymphoma: Data from a Nationwide, Multi-Center Prospective Registry Study (CISL 1404)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106252</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4089</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Retrospective Multicenter Analysis of the Safety and Efficacy of Brentuximab Vedotin (BV) As Monotherapy or in Combination with Bendamustine (BV-B) in Relapsed Refractory Classic Hodgkin Lymphoma (cHL) in Argentina</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107690</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4090</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Brentuximab Vedotinin Combination with Bendamustine in Relapsed or Refractory Hodgkin Lymphoma: A Retrospective Analysis on 23 Paediatric Patients or Young Adults</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108198</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4091</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes, Toxicities, and Patterns of Use of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Multicenter Retrospective Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103693</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4092</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Impact of Mogamulizumab Against Aggressive ATL: A Single-Center Retrospective Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104199</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4093</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Use of Extracorporeal Photopheresis (ECP) in the Treatment of Patients with Cutaneous T-Cell Lymphoma (CTCL), 2010-2015</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100256</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4094</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Upfront Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103674</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4095</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dendritic Cells Subsets Profiles in Classical Hodgkin Lymphoma at Diagnosis and upon Treatment Completion: Analysis on 54 Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104589</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4096</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of a Short Course of Chemotherapy with ABVD for Elderly Patients with Hodgkin Lymphoma for All Disease Stages</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106038</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4097</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Changes in Second Primary Malignancies (SPM)after Hodgkin Lymphoma over Time in the United States</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108248</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4098</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bendamustine, Gemcitabine and Dexamethasone Chemotherapy Is Effective Salvage and Stem-Cell Mobilization Regimen in Patients with Relapsed or Refractory Hodgkin Lymphoma  Early Results of the Polish Lymphoma Research Group Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105279</Key_PaperID>
<Key_SessionID>11838</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4099</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Risk of Second Malignancies in Long Term Hodgkin Lymphoma Survivors of Two Age Cohorts</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100024</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2807</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Narciclasine Display Preferential Pre-Clinical Activity Against KSHV-Associated Primary Effusion Lymphoma By Targeting MYC Via NF-b</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107008</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2808</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Xpo-1 Inhibition Synergizes with BCR Inhibition, Blocks Tumor Growth and Tumor-Associated Macrophages Infiltration and Prolongs Survival in a Bioluminescent Animal Model of Primary Central Nervous System Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106213</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2809</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100187</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2810</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106590</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2811</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cyclin D1 Driven CDK4 Activity Is Responsible for Hypersensitivity to NOXA Inducing Combination Treatment in Mantle Cell Lymphoma (MCL) Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100108</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2812</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106519</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2813</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Idelalisib Interferes with the Crosstalk of Follicular Lymphoma and Its Immune Microenvironment and Potentiates the Activity of ABT-199</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106308</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2814</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab Efficiently Targets NK/T Cell Lymphoma with High CD38 Expression</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105403</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2815</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Generation of a Half-Life Extended Anti-CD19 BiTE Antibody Construct Compatible with Once-Weekly Dosing for Treatment of CD19-Positive Malignancies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106909</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2816</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Knockout Tumor Microenvironment HO-1 Enhances the Therapeutic Effect of Histone Deacetylase Inhibitor (RGFP966) on B Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106372</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2817</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Arsenic Trioxide and Lenalidomide: A Promising Combination Therapy for Primary Effusion Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101777</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2818</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting Lymphoplasmacytic Lymphoma through a Novel Anti-FGF-Based Therapeutical Strategy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106907</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2819</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Small Molecule Activators of Protein Phosphatase 2A (SMAPs) Cause c-Myc Degradation and Tumor Growth Suppression in Preclinical Models of Lymphoid Malignancies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105258</Key_PaperID>
<Key_SessionID>11839</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2820</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>NKp46 Is a Useful Diagnostic Biomarker in Gastrointestinal T-Cell Lymphoproliferative Diseases and Constitutes a Therapeutic Target. a Celac Network Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108202</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4100</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Therapeutic Targeting of Microrna-214 in Cutaneous T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103866</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4101</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Novel Calcium Release-Activated Calcium(CRAC) Channel Inhibitor RP4010 Exerts Potent Antitumor Effects in NOD/SCID/IL2Rg-/- Mice with Diffuse Large B Cell Lymphoma (DLBCL) Cell Line Xenografts</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108216</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4102</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In-Situ Vaccination Using Sting Agonists Combined with Immune-Modulating Antibodies to Treat Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103222</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4103</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>TAS4464, a Novel, Highly Potent NEDD8-Activating Enzyme Inhibitor Shows Antitumor Activity in Ibrutinib-Insensitive Mantle Cell Lymphoma Via Inactivation of the NF-B Pathway</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107388</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4104</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Primary CNS Lymphomas (PCNSL) Patient-Derived Xenograft (PDX) Models Capture the Biological and Molecular Characteristics of the Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100840</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4105</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Trph-222, a Novel Anti-CD22 Antibody Drug Conjugate (ADC), Has Signficant Anti-Tumor Activity in NHL Xenografts and Is Well Tolerated in Non-Human Primates</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105554</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4106</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In Situ Vaccination Improves Efficacy of PD-1 Blockade in Unresponsive Lymphoma Tumors through Induction of a Highly Efficient Cross-Presenting Dendritic Cell Subset Expressing TLR3</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107051</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4107</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CTLA4-FasL, the Hexameric Targeted FasL Fusion Protein, As Potential Novel Treatment for DLBCL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104803</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4108</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The BET Inhibitor GS-626510 Converges with Idelalisib through the Inhibition of Tumor-Macrophage Crosstalk and Cytokine Production in Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104427</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Use of MLN-8237 and I-BET-151 in lymphoma</OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4109</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dual Inhibition of Aurora Kinase and BRD4 Leads to Improved Anti-Tumor Activity in Myc-Overexpressing Lymphoma Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106928</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4110</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pre-Clinical Study of Ibrutinib for the Treatment of T-Cell Lymphoma Using Magnetic Resonance Imaging (MRI) Assessment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103006</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4111</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Silencing Oncogene Translation Using Pateamine a Analogues As a Novel Therapeutic Strategy for c-Myc Driven Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106312</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4112</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Marine Natural Compound Elatol Is a Novel Protein Translation Inhibitor with Potent Activity Against Aggressive Non-Hodgkin Lymphomas</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100440</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4113</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Combined Inhibition of mTOR and BTK Signalling Is Required for Optimal Long Term Growth Inhibition in DLBCL Models</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102178</Key_PaperID>
<Key_SessionID>11840</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4114</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Combination of BR101801 and Venetoclax Demonstrates Synergistic Activity in DLBCL Cell Lines Harboring Double Hit and Double Expressor Alterations</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103047</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Rituximab (Rituxan) is approved for use in relapsed/refractory low-grade NHL and in previously untreated DLBCL with CHOP, but is not approved for use in relapsed/refractory DLBCL. Polatuzumab vedotin is an investigational agent.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2821</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107627</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Carfilzomib
It is being studied in combination with standard-of-care chemotherapy in relapsed/refractory DLBCL.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2822</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106857</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated, in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia and, in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. GAZYVA is also indicated in combination with chemotherapy, followed by GAZYVA maintenance in patients achieving a response, in previously untreated advanced FL (EU, Switzerland). In this abstract, analyses of phase III data evaluating the risk of HBV reactivation and risk factors in previously untreated NHL pts with resolved HBV infection who received GAZYVA or MabThera-containing immunochemotherapy are reported.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2823</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Managing the Risk of Hepatitis B Virus Reactivation in Patients with B-Cell Lymphomas Treated with Obinutuzumab or Rituximab Immunochemotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106982</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2824</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Parsimonious Gene Correlation Network Analysis in DLBCL Allows Refined Linkage to Mutation State and Treatment Response</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99987</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Axi-cel (KTE-C19) is not yet approved for the treatment of rDLCBL.</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2825</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Marked Re-Expansion of Chimeric Antigen Receptor (CAR) T Cells and Tumor Regression Following Nivolumab Treatment in a Patient Treated with Axicabtagene Ciloleucel (axi-cel; KTE-C19) for Refractory Diffuse Large B Cell Lymphoma (DLBCL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99993</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Axi-cel (KTE-C19) is not yet approved for the treatment of rDLBCL alone or in combination with atezolizumab.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2826</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100511</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Albumin-bound paclitaxel is used off-lable to treat DLBCL patients refractory to standard first-line and second-line chemotherapy regimens.</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2827</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Old Drugs with New Tricks: Rituximab in Combination with Albumin-Bound paclitaxel and Pegylated Liposomal Doxorubicin in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100805</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2828</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Activity of a Dose-Dense Short-Term Chemoimmunotherapy in HIV-Positive Patients with Burkitt Lymphoma (HIV-BL pts): Final Results of the Carmen Phase II Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101248</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2829</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>R-GEM-Lenalidomide Versus R-GEM-P As Second-Line Treatment of Diffuse Large B-Cell Lymphoma: Results from the UK NCRI Phase II Randomized Legend Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102098</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This is a phase I study evaluating the safety and efficacy of CC-122 in patients with R/R DLBCL. CC-122 is an investigational agent and has not yet been approved in the US
</OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2830</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Discovery of an Immune-Driven Gene Expression Signature That Predicts for Clinical Benefit to CC-122 in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103171</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2831</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Crizotinib in Advanced ALK+ Anaplastic Large Cell Lymphoma in Children and Adults: Results of the Acs Phase II Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103666</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2832</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ANew Dynamic PET-Based Scoring System Improves Outcome Prediction in Patients with Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104269</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pembrolizumab is currently not indicated for the treatment of PMBCL. </OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2833</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105203</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>MabThera (Rituxan; rituximab) is a chimeric anti-CD20 monoclonal antibody that is indicated in relapsed/refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent; in previously untreated follicular lymphoma (FL) in combination with first-line chemotherapy; and as single-agent maintenance therapy in patients achieving a complete or partial response to MabThera in combination with chemotherapy. MabThera indications also include previously untreated diffuse large B-cell lymphoma (DLBCL) in combination with CHOP or other anthracycline-based chemotherapy regimens. In this abstract, safety and efficacy data from the final analysis of the randomized, open-label, crossover, Phase IIIb PrefMab study (rituximab in combination with CHOP, CVP or bendamustine in FL or DLBCL) are reported.</OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2834</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105689</Key_PaperID>
<Key_SessionID>11842</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2835</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100810</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4115</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100943</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>TTI-621 (SIRPaFC) is an immune checkpoint inhibitor consisting of the CD47 binding domain of human SIRPa linked to the Fc region of human IgG1. It is being developed as a therapeutic for various malignancies.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4116</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>TTI-621 (SIRPFc), an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101927</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4117</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Role of Maintenance Therapy in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102096</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This is a phase I study evaluating the safety and efficacy of CC-122 patients with R/R B-cell NHL. CC-122 is an investigational agent and has not yet been approved in the US.</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4118</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Gene Expression Classifier Enriches for Single Agent Clinical Activity of CC-122, a Cereblon Modulator, Administered Orally to Relapsed or Refractory Diffuse Large B-Cell Lymphoma Subjects: Results from the Phase I CC-122-ST-001 Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102453</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4119</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103044</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Obinatuzumab (Gazyva) has indications in CLL and relapsed/refractory FL, but is not approved for use in DLBCL. Polatuzumab vedotin is an investigational agent.</OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4120</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103452</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>pembrolizumab for diffuse large B cell lymphoma</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4121</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103460</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ibritumomab tiuxetan is a CD20 directed radiotherapeutic antibody indicated for follicular lymphoma.  This presentation briefly mentions its use in diffuse large B-cell lymphoma.</OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4122</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103706</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4123</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104236</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4124</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Results of Inter-B-NHL Ritux 2010  Phase II Study of DA-EPOCH-R for Children and Adolescents with Primary Mediastinal Large B-Cell Lymphoma (PMLBL) on Behalf of European Intergroup for Childhood Non Hodgkin's Lymphoma (EICNHL) and Children's Oncology Group (COG)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104311</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4125</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pembrolizumab (MK-3475) in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104891</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4126</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Study of Chidamide Plus R-CHOP in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An Interim Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105244</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4127</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Randomized Phase II Study of R-CHOP-14 Versus R-CHOP-14 Followed By Chaser As Induction Therapy for High-Dose Chemotherapy (HDT), LEED, and Autologous Stem-Cell Transplantation (ASCT) in Poor-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Japan Clinical Oncology Group (JCOG) Study (JCOG0908)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105649</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Tyrosine kinase inhibitor</OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4128</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105914</Key_PaperID>
<Key_SessionID>11843</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>DCDS0780A is a THIOMAB antibody drug conjugate consisting of the potent anti mitotic agent, monomethyl auristatin E (MMAE), conjugated to a humanized IgG1 anti human CD79b monoclonal antibody via a protease labile linker</OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4129</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase I Study of the Anti-CD79b THIOMABTM-Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101639</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2836</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Prognostic Model for Primary Gastric Diffuse Large B-Cell Lymphoma in the Rituximab Era, Integrating EBV Harboring on Tumor Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104940</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2837</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CNS Prophylaxis in DLBCL: A Ten Year Single-Center Review in the Rituximab Era</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101390</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2838</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Beneficial Effect of Microrna-155 in Vincristine Response and Clinical Outcome in Especially GCB Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103825</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2839</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Protein Kinase C Delta in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Potential Prognostic Marker in Germinal Center B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106409</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2840</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Prospective Registry Study of Peg-G-CSF Prophylaxis for Patients with Diffuse Large B-Cell Lymphoma (CISL 1403)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104898</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2841</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Keep an Eye on CXCL-13: A Promising Biomarker to Help IL-10 and IL-6 for the Diagnosis of Intraocular Lymphomas</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108065</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2842</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Central Nervous System Relapse in Diffuse Large B Cell Lymphoma - Predictors at Diagnosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105617</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2843</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lymphoma Patients Treated without Anthracyclines Have Negligible Risk of Cardiotoxicity: A Nationwide Cohort Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103040</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2844</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Rituximab Dose Adjusted EPOCH Improves Progression-Free Survival of Patients Affected By Diffuse Large Cell Lymphomas with Double Expression of MYC and BCL2 Proteins</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108324</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2845</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Temozolomide in Relapse/Refractory Primary Vitreo-Retinal Lymphoma (R/R PVRL): A New Effective, Well-Tolerated and Cheap Reference. Result of a Study on Behalf of the LOC Network</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100356</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2846</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of the Double Expression of MYC and BCL2 on Outcomes of Primary Refractory Diffuse Large B-Cell Lymphoma Following R-CHOP Chemoimmunotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107941</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2847</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103274</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2848</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Type 2 Diabetes Mellitus Strongly Impacts Survival in Patients with Diffuse Large B Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103280</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2849</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Low Serum Cholesterol Levels Predict Inferior Prognosis in Diffuse Large B Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105034</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2850</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High-Dose Ara-C, Carboplatin, Etoposide, and Steroids (ACES) Is Effective in Relapse and Refractory Non-Hodgkin Lymphoma </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108072</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2851</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102362</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2852</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characteristics, Treatments, and Outcomes of Patients with Lymphomatoid Granulomatosis - MD Anderson Cancer Center Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104026</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2853</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PET-CT Invisible Diffuse Large B-Cell Lymphoma Features a Silent B-Cell Receptor Signaling</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100156</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2854</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Location Matters in Nodal Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105145</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2855</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Impact of Extranodal Involvement in Newly Diagnosed Diffuse Large B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108218</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2856</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pretreatment Nutritional Status and Cardiovascular Risk Factors Affect Survival of Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102136</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2857</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PET/CT Guided Biopsy for the Diagnosis of Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108699</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2858</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A New Prognostic Scoring System to Predict Disease Progression and Mortality in Patients with Newly Diagnosed Primary CNS Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108834</Key_PaperID>
<Key_SessionID>11844</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2859</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>End-of-Treatment CT and Serial FDG-PET Imaging to Assess Residual Disease in Primary Mediastinal B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101120</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4130</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Efficacy of Systemic High Dose Methotrexate As Central Nervous System Prophylaxis in Patients with High Risk Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104101</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4131</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Prevalence and Incidence of Fractures in Patients Treated for Aggressive B-Cell Non-Hodgkin Lymphomas</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107077</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4132</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Risk Factors and Survival Effect of Delayed Excretion of High-Dose Methotrexate in Patients with Leukemia and Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104550</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4133</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>R-GCVP As Second Line Treatment in Elderly Patients with DLBCL Who Fail R-CHOP and Are Not Candidates for Intensive Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106126</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4134</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of IRF4/MUM1 Expression on Adult T-Cell Leukemia/Lymphoma and Treatment Outcome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106741</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4135</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Barriers and Opportunities in Accrual of HIV-Positive Minority Underserved Patients with Non-Hodgkin Lymphoma, into AIDS Malignancy Consortium (AMC) Clinical Trials: A Retrospective 12- Year Single Institution Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103523</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4136</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Interim PET-CT Result Is Not Predictive of Survival in Patients with MYC-Rearranged Non-Burkitt Aggressive B Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102999</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4137</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Difference in Survival Outcome of Primary Central Nervous System Lymphoma By Histologic Types</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103009</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4138</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Role of Radiation Therapy and Risk of Developing Secondary Gastric Cancer in Patients Presenting with Early Stage Gastric Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106972</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4139</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Adding Beta-2 Microglobulin for Better Prognostication of Primary Central Nervous System Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108254</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4140</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PET-Derived Tumor Metrics Predict DLBCL Response and Progression-Free Survival</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104400</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4141</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of Salvage Chemotherapy in Diffuse Large B Cell Lymphoma with Primary Treatment Failure According to Putative Cell of Origin</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107977</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4142</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>the Prognostic Implication of Inflammatory Factor-Based Scoring System in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108684</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4143</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Multicenter Retrospective Review of Outcomes of Diffuse Large B Cell Lymphoma (DLBCL) in the Elderly Treated with RCHOP in Australia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100327</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>lenalidomide in first line DLBCL</OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4144</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>First Report on a Successful Screening Program for MYC Rearrangements and a Prospective Clinical Trial Based on MYC Rearrangement in Newly Diagnosed DLBCL Patients in the Netherlands</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102237</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4145</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Assessing the Utility of Immunoglobulin and T Cell Receptor Gene Rearrangement Studies for Cerebrospinal Fluid Specimens</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106360</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4146</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Routine Prophylaxis of Pneumocystis Pneumonia from the Fourth Cycle of R-CHOP Regimen in DLBCL Patients </PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101519</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4147</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Utilizing Digital Pathology Informatics Algorithms for Diffuse Large B-Cell Lymphoma Subtyping</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103740</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4148</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Elevated Pre-Therapeutic Serum Levels of Soluble Programmed Death 1 Protein (sPD-1) Identify DLBCL Patients with Adverse Prognostic Features</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104928</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4149</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sequential Lymphoma between Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma: Clinicopathological Characteristics and Outcome of 18 Patients from Lysa Center</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105656</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4150</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Survival after Diffuse Large B-Cell Lymphoma Among Children, Adolescents and Young Adults in the Era of Immunotherapy: A Population-Based Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106986</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4151</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Validation of the NCCN-IPI and the Geltamo-IPI in a Large Cohort of Patients Diagnosed of Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP/R-CHOP-like in a Single Institution</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108462</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4152</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Incidence of Central Nervous System (CNS) Relapse in MYC Rearranged Diffuse Large B-Cell Lymphoma: Does CNS Prophylaxis Improve Outcome?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100855</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4153</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Poor Prognosis of CD5 Positive with Non Germinal Center Type of Diffuse Large B Cell Lymphoma Especially Having the Aberration of 19q13</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102863</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4154</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103137</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Both methotrexate and cytarabine are commonly administered via the intrathecal route for CNS prophylaxis in patients with DLBCL.</OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4155</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intrathecal Central Nervous System Prophylaxis in Patients with Diffuse Large B-Cell Lymphoma at an Academic Healthcare System</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104223</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4156</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment Outcomes in the Management of Lymphoblastic Lymphoma (LBL) in Adults: An Institutional Review</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103177</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Prednisolone, etoposide, procarbazine, and cyclophosphamide in the palliative treatment of lymphoma.</OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4157</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Cambridge University Hospitals and Anglia Regional Experience of Using PEP-C As Palliative Chemotherapy in Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104889</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4158</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effect on Clinical Outcomes of Anemia and Serum Level of Ferritin in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103876</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4159</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Overall Survival Disparities in Metro/Urban/Rural Diffuse Large B-Cell Lymphoma (DLBCL) Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102590</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4160</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Efficacy of PET-CT in Detecting Bone Marrow Involvement in Patients with Newly Diagnosed Lymphoma: A Retrospective Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105127</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4161</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Absolute Monocyte Count at Diagnosis Predicts Adverse Outcome Among Very Good and Good R-IPI Diffuse Large B Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105199</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4162</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia with High Tumor Burden Treated with BFM95-Based Protocol Combining Rituximab: A Report from Shanghai, China</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105859</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4163</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108478</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4164</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>New Prognostic Classification for Adult T Cell Lymphoma/Leukemia Based on Hypercalcemia and Neutrophil-to-Lymphocyte Ratio</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100384</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4165</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Presence of Pleural Effusion at Diagnosis Predicts Poor Outcomes in Diffuse Large B-Cell Lymphoma Patients with MYC-Rearrangement or Double Protein Expression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102492</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4166</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Primary Dural Diffuse Large B-Cell Lymphoma Is Associated with Good Prognosis and Is Effectively Treated with CHOP-R Alone</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106911</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4167</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Incidence Patterns of Patients with Two or More Lymphoid Malignancies in a Patient with a Prior History of Lymphoid Malignancy: A Population-Based Cancer Registry Study in Nagasaki, Japan</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102188</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4168</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinicopathological Study of Methotrexate-Associated Lymphoproliferative Disorders in Rheumatoid Arthritis Patients:Histological Classification and Predictive Factors for Disease Progression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103089</Key_PaperID>
<Key_SessionID>11845</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4169</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Value of Early 18F-FDG PET/CT Scanner Evaluation in Immunocompetent Primary CNS Lymphoma Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105993</Key_PaperID>
<Key_SessionID>11846</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2860</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Telomerase Inhibition Impairs Self-Renewal of -Catenin Activated Myeloproliferative Neoplasm Progenitors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100137</Key_PaperID>
<Key_SessionID>11846</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2861</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Splenic Red Pulp Macrophages Provide a Secondary Stem Cell Niche for Chronic Myeloid Leukemia Stem Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100892</Key_PaperID>
<Key_SessionID>11846</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2862</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bcr-Abl1 Kinase-Independent Upregulation of FcRIIb Mediates Malignant Signaling That Is Critical for Leukemogenesis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104280</Key_PaperID>
<Key_SessionID>11846</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2863</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>IFN- Upregulates the Expression of C/EBP and Induces Myeloid Differentiation and Exhaustion of CD34+ CML Stem Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104815</Key_PaperID>
<Key_SessionID>11846</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2864</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105585</Key_PaperID>
<Key_SessionID>11846</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2865</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hoxa9 and Hoxa10 Induce CML Myeloid Blast Crisis Development through Activation of Myb Expression</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102265</Key_PaperID>
<Key_SessionID>11846</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2866</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Association between 9p21 Chromosome Polymorphisms rs1333040 and rs7865618 and Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101080</Key_PaperID>
<Key_SessionID>11846</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2867</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Standardization of Two Dpcr Platforms for Detection of BCR/ABL1 - Minimal Residual Disease (MRD) in Ph+ Chronic Myeloid Leukemia (CML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101948</Key_PaperID>
<Key_SessionID>11847</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4170</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Activation of p53 Enhances Antileukemia Activity of Bcr-Abl Tyrosine Kinase Inhibitors in a Murine Model of CML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106006</Key_PaperID>
<Key_SessionID>11847</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4171</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Vitamin K3 (menadione) Induces Cytotoxicity in Chronic Myeloid Leukemia Stem Cells By Upregulating DYRK2 through the Inhibition of SIAH2 Ubiquitin Ligase</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103145</Key_PaperID>
<Key_SessionID>11847</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4172</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106607</Key_PaperID>
<Key_SessionID>11847</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4173</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Loss of G0S2 in Kinase-Independent TKI Resistance and Blastic Transformation of CML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103531</Key_PaperID>
<Key_SessionID>11847</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4174</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Oncogenic Heterogeneous Nuclear Ribonucleoprotein D-like Promotes the Growth of Chronic Myeloid Leukemia Cellsthrough Post-Transcriptional Regulation of Pre-B-Cell Leukemia Homeobox 1</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108446</Key_PaperID>
<Key_SessionID>11847</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4175</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Tumor Suppressor, NORE1A (RASSF5), Is an Icsbp-Dependent Inhibitor of Aberrant Stress Granulopoiesis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102758</Key_PaperID>
<Key_SessionID>11847</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4176</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104643</Key_PaperID>
<Key_SessionID>11847</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4177</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mir-424 and Mir-503 Regulates Cobll1 Expression during the CML Progression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102570</Key_PaperID>
<Key_SessionID>11847</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4178</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Expression Levels of PD-1 on CD8+ T Cells in Chronic Myeloid Leukemia with and without BCR-ABL1 kinase Mutation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108393</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2868</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107833</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2869</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104081</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2870</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle> Imatinib Suspension and Validation Study: Results from the Isav Study at 62 Months</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103618</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2871</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Atherosclerotic Arterial Disease-Related Mortalityin Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104530</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2872</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105100</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2873</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103792</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2874</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sample Exchange to Standardize Molecular Monitoring for CML: The EUTOS Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105230</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This abstract discusses the investigational approach of treatment-free remission following nilotinib therapy in patients with chronic myeloid leukemia in chronic phase (CML-CP). Nilotinib is a tyrosine kinase inhibitor indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) CML-CP, and for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant to or intolerant to prior therapy that included imatinib.</OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2875</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107339</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2876</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of the Outcome between Newly Diagnosed Patients in the Accelerated Phase and Chronic Phase with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106104</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2877</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Association of Tyrosine Kinase Inhibitors with Vascular Adverse Events: A Cohort Study Using Pooled Electronic Health Record</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105531</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This abstract discusses the investigational approach of treatment-free remission following nilotinib therapy in patients with chronic myeloid leukemia in chronic phase (CML-CP). Nilotinib is a tyrosine kinase inhibitor indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) CML-CP, and for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant to or intolerant to prior therapy that included imatinib.</OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2878</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104365</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The NOX2 inhibitor histamine dihydrochloride is currently approved for use in AML within the EU. In the current study we investigate its utility in a murine CML model.</OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2879</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Delayed Expansion of Murine BCR-ABL1+ Leukemia By Genetic and Pharmacological Inhibition of NOX2</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103584</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2880</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106113</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2881</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Management of Chronic Myeloid Leukemia (CML) during Pregnancy Among Patients (pts) Treated with a Tyrosine Kinase Inhibitor (TKI): A Single-Center Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105494</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2882</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Response and Outcomes of Third-Line Tyrosine Kinase Inhibitor Therapy on Patients with Chronic Phase Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103834</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2883</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Potential of Exosomes Derived from Chronic Myelogenous Leukemia Cells As Biomarker Based on the BCR-ABL mRNA Transcript</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106008</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2884</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Role of Erythropoietin in the Late Anemia of Patients with Chronic Myeloid Leukemia Treated Frontline with Imatinib</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105854</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2885</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Tyrosine-Kinase Inhibitors (TKIs) on Primary Hemostasis  Evaluation of Effects In Vitro</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107244</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2886</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Disovery of Novel Mutations Exclusively Shared ByAccelerated and Blast Crisis Phase CML Patients Using Whole Exome Sequencing:Implication in Hunt for Common Biomarker /Drug Target of CML Progression</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107242</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2887</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Concomitant Medications and Comorbidities Affect Early Response in CML Patients Treated with Imatinib: A Retrospective Analysis of 340 Patients from the Polish Adult Leukemia Group (PALG) Registry</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103829</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2888</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hepatitis B Virus Seropositivity in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors:Preliminary Results of a Single-Center Cross-Sectional Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104323</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2889</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106991</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2890</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Assessment of Standardization and International Scale (IS) Alignment Efforts of BCR-ABL1 Testing By the Chinese CML Alliance in an International External Quality Assessment Program</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103762</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2891</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparation of Digital PCR and Quantitative Pcr for Molecular Monitorization of Chronic Myeloid Leukemia Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105390</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2892</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107942</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2893</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Echocardiographic Findings in Patients (pts) Receiving Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Chronic Myeloid Leukemia (CML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100925</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2894</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cytogenetic and Molecular Responses after 2 Years of Tyrosine Kinase Inhibitor (TKI) Treatment in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101427</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2895</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102259</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2896</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107040</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2897</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment Characteristics and Deep Molecular Response in Chronic Phase  Chronic Myeloid Leukemia Patients Treated with Second-Line Nilotinib or Dasatinib: A Multi-Country Retrospective Chart Review Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101579</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pegylated Interferon Alfa-2b is not indicated for frontline treatment of Chronic Phase Chronic Myeloid Leukemia as a current standard of care.</OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2898</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101730</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2899</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Optimizing Dose of Bosutinib to Minimize Adverse Events While Maintaining Efficacy in Patients with Newly Diagnosed Chronic Myelogenous Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101980</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2900</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102964</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2901</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102352</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2902</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Responses and Outcomes of Pediatric CML Treated with Front-Line Imatinib and a Comparison between Pediatric and Adult Cohorts</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103124</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2903</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Results from the U.S. Life after Stopping TKIs (Last) Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103630</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2904</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Both CD4+CD25+Foxp3+ Regulatory T Cells and CD3-CD56+ NK Cells Affect the Response of Newly Diagnosed Chronic Myeloid Leukemia Patients to Treatment with a Tyrosine Kinase Inhibitor</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104535</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2905</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106043</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2906</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101379</Key_PaperID>
<Key_SessionID>11848</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2907</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>No Influence of BCR-ABL1 Transcript Types e13a2 and e14a2 on MR4.5 in Patients with Chronic Myeloid Leukemia Treated with Nilotinib Frontline</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107878</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2908</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106078</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Brentuximab vedotin to treat advanced systemic mastocytosis.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2909</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase 2 Study of Brentuximab Vedotin in Patients with Advanced Systemic Mastocytosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105468</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2910</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108010</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2911</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of I(17q) in Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105454</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2912</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clonal Evolution of Myelofibrosis Patients in Relapse after Allogeneic Stem Cell Transplantation Revealed By Whole Exome Sequencing</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106473</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2913</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Heterogeneity of Bone Marrow Morphology in Patients with Polycythemia Vera Resistant to First and Second Line Therapies  Impact of Hydroxyurea Dosage on MDS-like Progression</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103976</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2914</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Transfusion Dependence on Outcomes of Patients with Acute Myeloid Leukemia (AML) Evolving from Myeloproliferative Neoplasms (MPNs)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108300</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2915</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Niche-Targeted Clinical Grade Immunohistochemistry Reveals Heterogeneous Bone Marrow Neuropathy and Novel Stromal Patterns in Primary Myelofibrosis Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104417</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2916</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104459</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2917</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characteristics and Outcome of Philadelphia(Ph) Negative Myeloproliferative Neoplasms(MPN) in Patients Younger Than 45 Years  a Multicenter Retrospective Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104793</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2918</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Ruxolitinib (rux) in an Open-Label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatments Are Available</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100364</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2919</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeted Deep Sequencing ofGATA1 more Sensitively Identifies Transient Myeloproliferative Disorder in Neonates with Down Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99641</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2920</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Validation of the Who-Defined 20% Circulating Blasts Threshold for Diagnosis of Acute Leukemia in Myelofibrosis: A Single Center Study of 144 Patients with Blast or Chronic Phase Disease with Excess Blasts</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100809</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2921</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Early Thrombotic Events Following Splenectomy for Myelofibrosis: Incidence, Risk Factors and Effect of Pre-Emptive Anticoagulant Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99705</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2922</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Blast Phase Myeloproliferative Neoplasm: A Mayo Agimm Study of 419 Consecutive Cases</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99913</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2923</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Systematic KIT Sequencing Identifies Unsuspected Systemic Mastocytosis with Associated Hematological Neoplasm</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101271</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2924</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Patient-Reported Symptom Burden and Peripheral Blood Counts Among Patients with Polycythemia Vera: An Analysis from the Reveal Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102021</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2925</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Splanchnic Vein Thrombosis in Overt Myeloproliferative Neoplasms: The Mayo Clinic Experience with 107 Unselected Consecutive Cases</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103012</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2926</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real-World Outcomes of Ruxolitinib for Polycythemia Vera</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103429</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2927</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Digital Droplet PCR: Next Generation KIT D816V Testing As Advanced Tool for Diagnosis and Prognostication in Mastocytosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103953</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2928</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Understanding the Secondary Transformation of JAK2 Myeloproliferative Neoplasms: Genomic Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104178</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2929</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Relationship between Cause of Death in Myelofibrosis and the Dynamic International Prognostic Scoring System</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107473</Key_PaperID>
<Key_SessionID>11849</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2930</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>BRAF-V600E in Peripheral Mononuclear Cells and Microglia-like Brain Cells Suggest Hematopoietic Origin of Langerhans Cell Histiocytosis-Associated Neurodegeneration</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104438</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2931</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mechanism of Escape from LNK Negative Regulation: Constitutively Active JAK2V617F Retains Lysine63-Ubiquitin</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106153</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2932</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The JAK2V617F-Bearing Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion through the Thrombopoietin/MPL Signaling</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103013</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2933</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Neuropathy in the Altered Bone Marrow Microenvironment of Patients with Essential Thrombocythemia and the Effects of Interferon-2b on Them</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108888</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2934</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Analysis of Patterns of Co-Occurrence and Mutual Exclusivity of Gene Mutations in Philadelphia-Negative Myeloproliferative (Ph-negative MPNs) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108158</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2935</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting Insulin-like Growth Factor/Insulin Receptor Signaling to Overcome JAK2 Inhibitor Persistence in Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100539</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2936</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ZFP36L1, a Novel Potential Tumor Supressor Gene in Myelofibrosis, Epigenetically Deregulated By Methylation of the Enhancer Region</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106633</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2937</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Acquisition of Non-Driver Mutations during Follow-up in Patients with Polycythemia Vera and Essential Thrombocythemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100671</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2938</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ruxolitinib-Induced Defects in DNA Repair Cause Sensitivity to PARP Inhibitors in Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108552</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2939</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gaining a Better "Sense" for ASXL1Mutations in Myelofibrosis: Assessing the Variable Impact of Frameshift, Nonsense, and Missense Mutations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108609</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2940</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Mir-17/92 Cluster Is Involved in the Molecular Etiology of the SCLL Syndrome Driven By the BCR-FGFR1 Chimeric Kinase</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107631</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2941</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle> Aberrant Trafficking and Signal Propagation By the T618I CSF3R Mutant in Patients with Chronic Neutrophilic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102817</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2942</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clonal Analysis of Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103992</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2943</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Both Short and Long Term Hematopoietic Stem Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105232</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2944</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102767</Key_PaperID>
<Key_SessionID>11850</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2945</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Deletion of Calr By CRISPR/Cas9 Genome-Editing Mimics Abnormalities of Megakaryocytopoiesis Induced By Calr Del52 Mutation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105604</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4209</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mass Cytometry Analysis Reveals Cellular Loci of Cytokine Overproduction in Myelofibrosis with Differential Sensitivity to Ruxolitinib</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105182</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4210</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Beyond JAK-STAT: Contribution of Abi-1, STAT3, and NF-b Signaling to Pathogenesis of Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105504</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4211</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>JAK2V617F Hematopoietic Stem Cells Exhibit a Blunted Response to Acute Inflammation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107481</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4212</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ANovel JAK2 Mutation Confers Cytokine-Independence in the Absence of a Type I Dimeric Cytokine Receptor</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101848</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4213</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Coexisting Oncogenic Signaling Pathway Mutations in Cnl/Acml/CMML/MPN-U</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102500</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4214</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Lysyl Oxidase Inhibitor Attenuates Bone Marrow Fibrosis and Decreases Spleen Size in a Mouse Model of Primary Myelofibrosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104545</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4215</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Leukemic Transformation of Post-Essential Thrombocythemia Myelofibrosis: A Unique Case Presenting with Double MPL and Calr Mutations</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105727</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4216</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Modulating Hedgehog Signaling Reduces MAPK, TGF-, and Marrow Fibrosis in a Transgenic Mouse Model of JAK2V617F Associated Myeloproliferative Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106320</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4217</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The JAK2V617F-Bearing Vascular Niche Regulates Hematopoietic Stem/Progenitor Cell Regeneration Following Radiation Injury</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107780</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4218</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transcriptional Profiles, Lineage Tracing with BRAF-V600E and HLA-DQB2 Expression Support a Model of Blood CD1c+ Cells As Precursors to LCH Lesion CD207+ Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101403</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4219</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Genetic Characterization of 63 Myeloid/Lymphoid Neoplasms Associated with Eosinophilia and Rearrangement of PDGFR-Alpha, PDGFR-Beta, FGFR1 or PCM1-JAK2</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105327</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4220</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105688</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4221</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Imbalance between Tolerant and Cytotoxic Functional Subsets of NK Cells in a JAK2V617F Myeloproliferative Neoplasm Model</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107355</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4222</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Metformin Reduces Tumor Burden and Splenomegaly in JAK2V617F Murine Models</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107160</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4223</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Deep Learning Algorithms Support Distinction of PV, PMF, and ET Based on Clinical and Genetic Markers</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108743</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4224</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Combined Analysis of Whole Exome Sequencing Data in Philadelphia-Negative Myeloproliferative (Ph-negative MPNs) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) Reveals Novel Recurrently Mutated Genes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105351</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4225</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Combination Treatment with an MDM2 Antagonist and a BET Inhibitor Targets Both Myelofibrosis Hematopoietic Stem/ Progenitor Cells and Their Tumor Promoting Microenvironment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101798</Key_PaperID>
<Key_SessionID>11851</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pegylated interferon for essential thrombocythemia and myelofibrosis.</OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4226</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Critical Interferon-Response Genes Are Induced By JAK2V617F but Repressed By BCR-ABL, and They Are Responsible for the Differential Effects of Interferon in PV Vs. CML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103965</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Vismodegib is approved for the treatment of locally advanced and metastatic BCC. This study assesses vismodegib in combination with ruxolitinib for the treatment of myelofibrosis.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4179</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105294</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4180</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Myeloproliferative Neoplasms in Pediatrics and Young Adults: Genetic Lesions, Diagnostic Features, and Clinical Outcomes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105736</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4181</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Critical Evaluation of Who 2016 Criteria for the Diagnosis of Polycythemia Vera: Distinction from JAK2V617+ Essential Thrombocythemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106167</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4182</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Signatures That Predict Response to Azacitidine Treatment for Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105707</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4183</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Non-Driver Mutations and Gene Sequence Variants Identified By Targeted Deep Sequencing in Polycythemia Vera and Essential Thrombocythemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106572</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4184</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Does Bone Marrow Fibrosis Play a Role in the Prognostication of Newly Diagnosed Polycythemia Vera Patients?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107988</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4185</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Myelofibrosis (MF) Leukemic Transformation (LT) in the Era of Ruxolitinib and Genomics: Characteristics and Outcomes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106030</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This abstract will briefly discuss the use of hydroxyurea, thalidomide, lenalidomide, interferon, danazol, and cladribine for the treatment of myelofibrosis. These are off-label for this indication but have historically been utilized in order to treat the clinical signs and symptoms of myelofibrosis. </OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4186</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Between a Rux and a Hard Place: Investigating Causes of Ruxolitinib Discontinuation, Salvage Treatment and Outcome in Myelofibrosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107560</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4187</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An Evaluation of Parental and Perinatal Characteristics and Risk of Langerhans Cell Histiocytosis in Texas Identifies Risk Disparities By Racial/Ethnic Group</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104958</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4188</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Procoagulant Mechanisms in Patients with Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106336</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4189</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sleep and Psychiatric Disturbance in Chronic Philadelphia Negative Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99720</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4190</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>the Anatomy of Recurrent Thrombosis and Its Risk Factors in Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99992</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4191</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>JAK2 Exon 12 Mutated Polycythemia Vera: The Mayo Clinic-University of Florence Experience with 33 Consecutive Cases and Comparison with JAK2V617F Mutated Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100506</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4192</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Revised DIPSS-Plus: A Composite Clinical, Cytogenetic and Molecular Prognostic System for Primary Myelofibrosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100968</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4193</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeted Deep Sequencing in Blast Phase Myeloproliferative Neoplasms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101225</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pegylated interferon for essential thrombocythemia and myelofibrosis.</OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4194</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Higher Rates of Molecular Response to Peg-IFNa in JAK2V617F Vs. Calr Mutant MPN Patients Are Due to JAK1-Mediated STAT1 Activation and Autoregulation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101693</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4195</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101986</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4196</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Shared and Tissue-Specific Genetic Features of Primary Myelofibrosis, Hepatic Fibrosis, Idiopathic Pulmonary Fibrosis and Kidney Fibrosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102377</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4197</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Case Series of Potential Wernickes Encephalopathy in Patients Treated with Fedratinib</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102792</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4198</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Utility of Global Coagulation Assays in Myeloproliferative Neoplasm: Thromboelastography, Thrombin Generation and Overall Haemostatic Potential</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103067</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4199</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cigarette Smoking, Complete Blood Count, and Myeloproliferative Neoplasms  a Meta-Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103374</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4200</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Distinct Diagnostic and Clinical Features of Bone Marrow Mastocytosis: A Study of the Registry of the European Competence Network on Mastocytosis (ECNM)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103625</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4201</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Essential Thrombocythemia Versus Pre-Fibrotic/Early Primary Myelofibrosis: Discrimination By Laboratory and Clinical Data</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103886</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4202</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Younger JAK2V617F+ Individuals with Myeloproliferative Neoplasms Are at Higher Risk of Developing Lymphoproliferative Disorders: A Scoping Review of 214 Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104031</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4203</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real-World Patterns of First-Line Hydroxyurea Treatment Among Patients with Essential Thrombocythemia in US Community Oncology Practices</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104148</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4204</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104412</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4205</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105528</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4206</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact &amp; Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103239</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4207</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelet Function Tests and Inflammatory Markers for the Differentiation of Primary Thrombocytosis and Secondary Thrombocytosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105385</Key_PaperID>
<Key_SessionID>11852</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4208</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hydroxyurea Mucocutaneous Toxicity: A Prospective Cohort Study of 110 ET and PV Patients from a Single Institution</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107390</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2946</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Activation Levels of b-Catenin Signaling in Osteoblasts Define a Threshold for the Development of Myeloid Neoplasia of Variable Severity</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107702</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2947</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Haploinsufficiency of Multiple Genes on Del(5q) Cooperate to Induce B Cell Abnormalities in Mice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107546</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2948</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Understanding Early Stage Myelodysplastic Syndrome Pathobiology</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107871</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2949</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>How Somatic Mutations Carve Morphologic Imprint in MDS?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108196</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2950</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pre-Clinical Modeling of Concomitant Therapy with Azacytidine and Eltrombopag in MDS/AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106818</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2951</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Oxidative Stress in Stem / Progenitor Cells and Specific Antioxidant Response in Bone Marrow from Myelodysplastic Syndrome Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100658</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2952</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Unique Gene Expressional Profile Associated with Lack of Quantifiable Terminal Erythroid Differentiation in Myelodysplastic Syndrome Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102101</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2953</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comprehensive Molecular Characterization of Myeloid Malignancies with 9q Deletion</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103389</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2954</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Computational Biology Approach to Predict Hypomethylating Agent (HMA) Response Using Genomic and Clinical Characteristics in Myelodsyplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104088</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2955</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Patients with MDS Demonstrate Reduced Numbers and Impaired Differentiation of CD141Hi Conventional Dendritic Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104509</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2956</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The High NRF2 Expression Confers Chemotherapy Resistance through Upregulated DUSP1 in Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104920</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2957</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Deep Learning Algorithms Depict New Subgroups of AML and MDS Based on Genetics Only and Allow Distinction of Both Entities with High Accuracy of 90%</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105114</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2958</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Neoantigens in MDS Are Associated with Two Novel CD4+ T Cell Subsets and Improved Overall Survival</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105448</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2959</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Implications of TP53 Mutations and p53 Dysfunction in Patients with Myelodysplastic Syndrome (MDS). a Study from the Italian MDS Clinical Network</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105696</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2960</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Tifab Deficiency Protects Against Stress-Induced Bone Marrow Failure at the Expense of Pre-Leukemic Selection</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106025</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2961</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot Mutations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106544</Key_PaperID>
<Key_SessionID>11853</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2962</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mutational Pattern and Clonal Hierarchy in MDS with Monosomy 7</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100030</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Many of the compounds included in our drug screening approach are not indicated for CMML patients.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4227</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107697</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4228</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clonal Architecture of TET2 Mutations Influences the Clinical Phenotype of Patients with Myeloid Neoplasms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108138</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4229</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Programmed Necrosis Correlates with Development and Progression of Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107442</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4230</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Activation of Autophagy in Models of SF3B1 Mutant MDS</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108858</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4231</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Presence of Rare Germline Variants in Fanconi Anaemia Pathway Genes Confers a Poor Prognosis Comparable to TP53 Mutations in Therapy-Related Myeloid Neoplasms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107361</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4232</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Subclonal Evolution Characterizes MDS Disease Progression Following Allogeneic Stem Cell Transplant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107981</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4233</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PPM1D Mutations and up Modulation Phenocopy TP53 Lesions in Myeloid Neoplasms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108502</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4234</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Modeling Defective Erythropoiesis in Myelodysplastic Syndrome (MDS)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108445</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4235</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106547</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4236</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Serially Transplantable Patient-Derived Xenograft Model of Chronic Myelomonocytic Leukemia (CMML)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106819</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4237</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Visualizing Clonal Hematopoiesis Associated with gata2 Deficiency in Zebrafish Using Color-Barcoding</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100286</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4238</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Human Germline HLTF E259K Mutation Identified in Familial MDS Patients Accumulates DNA Damage through Impaired PCNA Polyubiquitination</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100796</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4239</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Tumor Microenvironment and Clonal Monocytes of Chronic Myelomonocytic Leukemia Induce a Procoagulant Climate within the Tumor Niche</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101717</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4240</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Immunophenotypically Aberrant Stem Cells in Myelodysplastic Syndromes: A Biomarker for Leukemic Progression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102473</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4241</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evidence of Targetable Immune Dysfunction in the Bone Marrow of Patients with Intermediate/High-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103186</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4242</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Effect of 5-Azacitidine Treatment on the Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103891</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4243</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Activation of T Cells Specific to Endogenous Retroviral Peptides: Possible Association with Clinical Response to Azacitidine in Myeloid Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104024</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4244</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Emergence of a Novel Clinical Entity within Myelodysplastic Syndromes Marked By Absence of Quantifiable Terminal Erythroid Differentiation, More Profound Anemia and Significantly Worse Survival across All Prognostic Risk Categories</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104457</Key_PaperID>
<Key_SessionID>11854</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4245</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105153</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2963</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99869</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2964</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Factors and Survival Outcomes in Blast Transformed Chronic Myelomonocytic Leukemia: A Mayo Clinic-MD Anderson Cancer Center Study of 171 Cases</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105163</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2965</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prediction of Clinically Relevant Mutations in (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103110</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2966</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104646</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML</OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2967</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106009</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2968</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic VALUE of EARLY Drop in the Platelet Counts in Patients with VERY Low, Low and Intermediate Risk IPSS-R Myelodysplastic Syndromes. Results from a Single Center Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107050</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2969</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Correlation of Myelodysplasia-Related Flow Cytometric Findings with Mutations in Patients Undergoing Diagnostics for Suspected Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101047</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2970</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Implication of Bone Marrow Abnormality of Appendicular Skeletons Detected By Low-Dose Multidetector Computed Tomography in Patients with Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104591</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2971</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Impact of ASXL1 Mutations and Extent of Bone Marrow Dysplasia in Patients with Who-defined Myelodysplastic Syndrome with Ring Sideroblasts</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104265</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2972</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106363</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2973</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106933</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2974</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Myelodysplastic Syndromes/Myeloproliferative Neoplasms Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103166</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2975</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Can We Diagnose MDS without Bone Marrow Examination? a Proposed EUMDS-Based Non-Invasive Diagnostic Model</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103298</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2976</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Natural Killer Cell Cytotoxicity Is a Predictor of Outcome for Patients with High Risk Myelodysplastic Syndrome and Oligoblastic Acute Myeloid Leukemia Treated with Azacytidine</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106145</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2977</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Correlates and Outcomes of Bone Marrow Failure and Myeloid Clonal Evolution in Patients with Germline GATA2 Haploinsufficiency</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107291</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2978</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Study to Predict Response to Azacitidine or Lenalidomide/Azacitidine Combination Therapy in MDS and AML Patients Using a Computational Biological Modeling (CBM) Approach</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108385</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2979</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108536</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2980</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in MDS-EB and AML-MRC</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103424</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2981</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Refining Hellstrm-Lindberg Score: Which Patients Could Benefit from Standard Dose EPO?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106096</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2982</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106961</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2983</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lenalidomide-Mediated Erythroid Improvement in Non-Del(5q) Myelodysplastic Syndromes Is Associated with Bone Marrow Immuno-Remodeling</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100656</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2984</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effect of Deferasirox Combined with Erythropoietin Versus Erythropoietin Alone on Erythroid Response in Patients with Low- and Int-1-Risk Myelodysplastic Syndromes: Results of the Phase II Kallisto Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101072</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2985</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chromosome Aberrations Detected By SNP Array Technique Indicating a High Risk of MDS Transformationin Patients with Icus and Poor Prognosis of Patients with MDS</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102447</Key_PaperID>
<Key_SessionID>11855</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2986</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Iron Overload in Lower International Prognostic Scoring System Risk Myelodysplastic Syndromes Patients Receiving Red Blood Cell Transfusions: Relation to Infection and Possible Benefit of Iron Chelation Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105685</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4246</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Myelodysplastic Syndromes (MDS) Patients with Chromosome 17 Abnormalities: A Report on Behalf of the MDS Clinical Research Consortium (MDSCRC)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104741</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4247</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fluorescence in Situ Hybridization (FISH) Frequently Upstages Risk Estimates for MDS Patients with Normal Metaphase Karyotype</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105283</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>tacrolimus, sirolimus for GVHD prophylaxis</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4248</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Favorable Impact of Allogeneic Stem Cell Transplantation in Patients with Therapy-Related Myelodysplasia Regardless of TP53 Mutational Status</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106545</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4249</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Implications of Endoplasmic Reticulum Stress Response in the Prognosis and Pathogenesis of Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104219</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4250</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Trial Inclusion of Therapy-Related Myelodysplastic Syndromes (MDS) over the Past 20 Years</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105365</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4251</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106499</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4252</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108716</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4253</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Predictive Factors of Overall Survival and the Completion of Four Cycles of Azacitidine: An MDS-CAN Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103696</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4254</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chromosomal Analysis of Myelodysplastic Syndromes Among Atomic Bomb Survivors in Nagasaki</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104065</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4255</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Model Heterogeneity in Predicting Outcomes in Patients with Chronic Myelomonocytic Leukemia (CMML): An Overestimation of Survival in Lower-Risk Group </PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105028</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The agent is in clinical development, not an  approved drug</OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4256</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106571</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4257</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Factors and Response to the Hypomethylating Agents in Hypocellular Myelodysplastic Syndromes: A Retrospective Study from the Korean Society of Hematology AML/MDS Working Party</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107373</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4258</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clonal Hematopoiesis of Indeterminate Potential - Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108006</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4259</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Additional Prognostic Impact of the Percentage of Erythroid Cells in the Bone Marrow of MDS Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103723</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4260</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Acquisition Patterns and Interaction of Molecular, Obvious and Cryptic Cytogenetic Abnormalities in Myelodysplastic Syndromes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104423</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4261</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106926</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4262</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Response to Erythropoietin in Different Karyotipic Subsets of Myelodysplastic Syndromes (MDS) and MDS with Sideroblasts: Multicentric Real-Life Experience from the Grom-L Cooperative Group</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108480</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4263</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Is Deferasirox Safe and Effective in Very Elderly Patients (&gt; 75 Years) with Myelodysplastic Syndromes and Transfusional Iron Overload?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107962</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4264</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Diabetes Mellitus As Comorbid Condition, in Patients with Lower-Risk Myelodysplastic Syndromes (MDS). a Study of the European Leukemianet-Based MDS (EUMDS) Registry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108877</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4265</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sequential Stratification Prognostic Score for Patients with Intermediate-Risk Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104169</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off label use of eltrombopag in patients with chronic myelomonocytic leukemia.</OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4266</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Trial of Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108384</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Sirolimus is not an FDA approved medication for AML or MDS.  </OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4267</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105977</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4268</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MDS Diagnosis Using Cfrna Profiling By Targeted Enrichment Next Generation Sequencing</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106005</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4269</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clonal Hematopoiesis in Normal Individuals Is Not Random and Likely Reflects Early MDS</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102550</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4270</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Liquid Biopsy As a Diagnostic Test for Myelodysplastic Syndrome and Other Acute and Chronic Myeloid Neoplasms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99760</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The use of darbepoetin alfa for anemia in lower-risk MDS is not approved globally.</OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4271</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99870</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4272</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Extramedullary Manifestations in World Health Organization-Defined Chronic Myelomonocytic Leukemia: Clinical, Molecular and Prognostic Correlates</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100869</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4273</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Multicentric Validation of the Monocyte Assay for Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100063</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4274</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase 2 Dose-Confirmation Study of Oral ASTX727, a Combination of Oral Decitabine with a Cytidine Deaminase Inhibitor (CDAi) Cedazuridine (E7727), in Subjects with Myelodysplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105206</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4275</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PPM1D Mutations in MDS Patients with Deletion of Chromosome 5q</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104683</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4276</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Spliceosome Mutations Are Associated with Frailty in Older Patients with Myeloid Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103870</Key_PaperID>
<Key_SessionID>11856</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4277</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104272</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2987</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genetic and Transcriptomic Characterization of Marrow Progenitor Cells in Patients with Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107762</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2988</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Percentage of Normal B Cells from CLL Patients Express ZAP-70, Which Is Associated with Autoimmunity and Could be Responsible for Arising of Malignant Clone</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107282</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2989</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Primary Chronic Lymphocytic Leukemia Cells Can be Maintained Long-Termin Serum-Free, Cytokine-Free 3D Culture</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107875</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2990</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Computational Integration to Model Tumor Dynamics in CLL Patients Treated with the Btk Inhibitor Ibrutinib (CompuTreatCLL): First Results of an Integrative Systems Biology Approach</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107519</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2991</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gender, Age and TP53 Aberrations in Context of Complex Karyotypes in Chronic Lymphocytic Leukemia Patients in the Era of Chemo +/- Immunotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105463</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2992</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High-Resolution SNP-Array Profiling of Ultra-High Risk CLL Cases Reveals New Recurrent Genomic Alterations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106148</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2993</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Rare Germline Variant in NFATC4 Associated with Familial Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106235</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2994</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106676</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2995</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Outcome and Prognostic Factors of Patients with Richters Syndrome: Retrospective Multicenter Study of the Spanish Chronic Lymphocytic Leukemia (CLL) Study Group (GELLC)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106758</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2996</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Rituximab Activates NOTCH1 Signaling in CLL Cells and Induces Changes in the Cytokine Repertoire Favoring a Tumor-Protective Microenvironment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104048</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2997</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hypogammaglobulinemia in Chronic Lymphocytic Leukemia: A Predictor of Outcome?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104744</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2998</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PI3K- Inhibition Influences T-Cell Populations and Anti-Tumoral Immune Function in Preclinical Models</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105042</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>2999</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Differential Impact of Signaling Inhibitor Treatment Versus Standard Chemoimmunotherapy on Chronic Lymphocytic Leukemia T Cells: Clinical Implications</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105103</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Duvelisib is not approved for the treatment of CLL.</OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3000</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Linear and Branching Progression of Chronic Lymphocytic Leukemia (CLL) Under PI3K Inhibition (PI3Ki)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105260</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3001</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Different Time-Dependent Risk for Disease Evolution in Chronic Lymphocytic Leukemia with Distinct IGHV Gene Somatic Hypermutation Status</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105332</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3002</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CXCL13 (BCA-1) Plasma Levels Are a Useful Biological Marker for Disease Progression in Chronic Lymphocytic Leukemia (CLL) Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103892</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3003</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lck Is a Crucial Anergy Regulator in CLL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101295</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3004</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102121</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3005</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Infrequently Mutated Genes on Prognosis in 531 Untreated CLL Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102328</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3006</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Absolute Percent Deviation of IGHV Mutation As a Continuum Is Prognostically Relevant in Patients with CLL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108132</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3007</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Nurse-like Cells Express High-Levels of Wnt5a, Which Induces ROR1-Dependent Signaling That Promotes Migration and Survival of Neoplastic Cells in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103297</Key_PaperID>
<Key_SessionID>11857</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3008</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clonal Evolution in CLL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105282</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4278</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Predicting Mechanisms of Ibrutinib-Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational-Based Modeling for Personalized Therapy with Clinical Validation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108630</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4279</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Analysis of mRNA Expression in Peripheral, Bone Marrow and Lymph Node Dervied CLL Cells Using the Nanosting Ncounter Platform</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102833</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4280</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genomic Complexity in Chronic Lymphocytic Leukemia Defined By Array-Based Analysis: Definitions, Associations with Other Biomarkers and Clinical Impact</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107144</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4281</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Exhausted PD-1hi T-Cells Are Enriched in Secondary Lymphoid Organs of CLL Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108705</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4282</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Wnt5a Induces Interleukin-6 Via a ROR1-Dependent Pathway in Chronic Lymphocytic Leukemia, Leading to Leukemia-Cell Activation of STAT3</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107526</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4283</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of T Cell Compartment By Mass Cytometry Reveals Distinct Patterns of Expression of Exhaustion Markers in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108116</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4284</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PI3K-Delta Inhibitors Induce Primary Monocyte Cytotoxicity but Do Not Alter Monocyte Differentiation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106528</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4285</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dynamic of Telomeric Parameters in Relapsing or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL), an Analysis of the Filo ICLL001 Bomp Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108367</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4286</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PD-1 Expression in Chronic Lymphocytic Leukemia and Large B-Cell Richter Transformation (DLBCL-RT): A Distinguishing Feature for DLBCL-RT andPromising Surrogate Marker for Clonal Relatedness</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105506</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4287</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Reactive Oxygen Species and Metabolic Gene Expression Profiling Further Differentiate CXCR4/CD5 Fractions in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106172</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4288</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105521</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>E7107,  a SF3B1 inhibitor. </OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4289</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dynamic BH3 Profiling to Assess the Effects of Novel Agents on Anti-Apoptotic Protein Dependence of CLL Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106579</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4290</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PI3K/AKT Inhibition Augments 2-Phenylethynesulfonamide Induced Apoptosis Via the Unfolded Protein Response in Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106696</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4291</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Tumor Microenvironment (TME) Regulation of Programmed Death-1 (PD1) Receptor and Its Ligands PDL1 and PDL2 in Chronic Lymphocytic Leukemia (CLL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101389</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4292</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Increased Levels of Soluble RAGE in CLL Patient Plasma Has a Protective Effect on CLL Disease Progression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107069</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4293</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Over-Expression of Activation-Induced Cytidine Deaminase in TCL1 Mice Leads to the Development of IGHV-Mutated CLL Clones That Associate with More Aggressive Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104548</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4294</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Myeloid-Derived Suppressor Cell Subtypes Are Responsible for the Th2 Phenotype of T Cells in CLL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104797</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4295</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>External Stimuli Modulate EZH2 Expression in Chronic Lymphocytic Leukemia. Rationale and Evidence for Synergistic Anti-Tumor Effects of B Cell Signaling and EZH2 Inhibitors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105051</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4296</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Throughput Immunoprofiling of Low Count B Lymphocytosis Reveals a Distinct T Cell Receptor Repertoire from Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105119</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4297</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genetic and Molecular Characterization of Novel Richter Syndrome Patient-Derived Xenograft Models</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103620</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4298</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genomic Landscape of Chronic Lymphocytic Leukemia in China By Targeted Gene Sequencing</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103633</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4299</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Low-Count Monoclonal B-Cell Lymphocytosis Persists after 7 Years of Follow-up and Confers a Higher Risk of Death</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100424</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4300</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Increase of DNA Damage and Alteration of the DNA Damage Response in Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100584</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4301</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Overexpression of CD36, Driven By STAT3, Mediates Free Fatty Acid Uptake in CLL Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101542</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4302</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102214</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4303</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>AValidated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102577</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4304</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Standardized Targeted Sequencing of 29 Genes with Recurrent Mutations in Chronic Lymphocytic Leukemia (CLL) Helps to Better Define Clinical Correlates and Genomic Hotspots</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102834</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4305</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Interferon Regulatory Factor 4 (IRF4) Is a Master Regulator in the Pathogenesis of Chronic Lymphocytic Leukemia Patients Harboring Trisomy 12</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102249</Key_PaperID>
<Key_SessionID>11858</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4306</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cross-Talk between Cytokine and NF-B Signaling in the CLL Microenvironment Can Affect Sensitivity for Venetoclax</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107043</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3009</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Differential Regulation of T Cells By PI3K Delta Inhibitors in a CLL Murine Model</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108003</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3010</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103191</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3011</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Front-Line Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in the Real World: Responses, Toxicity, Outcomes and Subsequent Therapies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101290</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Lenalidomide is being studied in CLL patients. It is currently indicated in multiple myeloma, MDS and mantle cell lymphoma.</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3012</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase I/II Study of Reduced Dose FCR (FCR-lite) in Combination with Lenalidomide Followed By Lenalidomide Maintenance (FCR2) for Initial Therapyof CLL: Final Results and Long-Term Follow-up</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108563</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3013</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108799</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3014</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Bloodwise TAP Calibre Feasibility Study to Assess the Mechanism of Action of Idelalisib in B-Cell Receptor Pathway (BCR) Inhibition in Chronic Lymphocytic Leukaemia (CLL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106706</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated, in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) and, in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. GAZYVA is also indicated in combination with chemotherapy, followed by GAZYVA maintenance in patients achieving a response, in previously untreated advanced FL (EU, Switzerland). In this abstract, Phase III safety and efficacy data from previously untreated, fit pts with CLL who received GAZYVA plus fludarabine and cyclophosphamide in the GREEN study, are reported.</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3015</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100164</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Idelalisib is a phosphoinositide 3-kinase (PI3K) delta inhibitor FDA approved for the treatment of relapsed chronic lymphocytic leukemia when given with rituximab, and for the treatment, as monotherapy, of relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma.</OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3016</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Risk Factors for Grade 3/4 Transaminase Elevation in Patients with Chronic Lymphocytic Leukemia Treated with Idelalisib</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106064</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3017</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104251</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3018</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Combinatorial Treatment of Chronic Lymphocytic Leukemia with Ibrutinib and Venetoclax Is Superior to Treatment with Single Agents in the TCL1 Mouse Model</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105475</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3019</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab Mitigates B-Cell Receptor Signaling and Enhances Antitumor Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL) Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102527</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3020</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Combination of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with CLL: A Pilot Phase II Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100304</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3021</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Impact of Immunohistochemistry and MRD Results in Bone Marrow after Frontline Chemoimmunotherapy of Chronic Lymphocytic Leukemia (CLL): Results of Central Laboratory Analyses of the CLL10 Trial of the German CLL Study Group (GCLLSG)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100265</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3022</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Obinutuzumab Activates CD64 More Potently Than Other Anti-CD20 Antibodies in Chronic Lymphocytic Leukemia (CLL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100066</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3023</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Center</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100603</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3024</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sustained Long-Lasting Responses after Lenalidomide Discontinuation in Patients with Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101489</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3025</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One BCell Receptor Pathway Inhibitor (BCRi)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100490</Key_PaperID>
<Key_SessionID>11859</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription>TBD Blurb needed </OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3026</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ibrutinib Therapy in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Analysis By Prior Rituximab Treatment and Baseline Mutations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108134</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4307</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Pilot Study of Lower Doses of Ibrutinib in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101107</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4308</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Outcomes of Chronic Lymphocytic Leukemia (CLL) Patientswith Richters Transformation (RT)to Aggressive Non-Hodgkin Lymphoma (aNHL): a Single-Institution Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106662</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4309</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety of Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Results from the Primary Analysis of the Phase 3b GREEN Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107182</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4310</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>B-Cell Prolymphocytic Leukemia, a Rare Lymphoproliferative Disorder: Analysis of 35 Cases, a Study on Behalf of the French Innovative Leukemia Organization (FILO)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105983</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4311</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL  Results from Multicenter Phase II Trial CLL-009</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103747</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4312</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104536</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4313</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Front-Line Ibrutinib Dose Reduction and Interruption on Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104629</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4314</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K- Inhibitor Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103497</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4315</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104967</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4316</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A ROR1 Bispecific T Cell Engager for the Treatment of Chronic Lymphocytic Leukaemia Demonstrates Enhanced Function Following Ibrutinib Treatment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101554</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ibrutinib does not have a label in combination with obinutuzumab</OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4317</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101956</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Venetoclax indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. It is not approved for use in combination with rituximab.</OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4318</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sustained Minimal Residual Disease Negativity Predicted in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax Combination Therapy for 2 Years:an Integrated Mechanistic Analysis of Multiple Phase I and II Studies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102031</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>buparlisib, an oral, pan-PI3K inhibitor, is being testing in patients with chronic lymphocytic leukemia. </OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4319</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND.216</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102235</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4320</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>First-in-Class Oral Small Molecule Against the Tyrosine Kinase ROR1 (KAN0439834) Induced Significant Apoptosis of Chronic Lymphocytic Leukemia Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102642</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4321</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103075</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4322</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Treatment with Ibrutinib in Chronic Lymphocytic Leukemia Patients Normalizes CD3+ and CD8+ TCells and Immune Checkpoints Expression but Gradually Leads to CD4+ T-Cell Depletion</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103334</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4323</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ibrutinib: A Risk Factor for Invasive Fungal Infections?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100347</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>lenalidomide is not approved for the treatment of CLL</OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4324</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase 1 Study of Lenalidomide and Ibrutinib in Combination with Rituximab in Relapsed and Refractory CLL and SLL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100403</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4325</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real-World Evidence for Durable Treatment Responses after Toxicity Related Discontinuation of Idelalisib</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100709</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>This is a pooled analysis of safety data from clinical studies of acalabrutinib monotherapy in hematologic malignancies.</OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4326</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103406</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4327</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Invasive Aspergillosis in Chronic Lymphocytic Leukemia:Therapy and Outcomes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101316</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Lenalidomide for first-line treatment</OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4328</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101512</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4329</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104791</Key_PaperID>
<Key_SessionID>11860</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4330</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Bendamustine and Rituximab As First Salvage Treatment in Chronic Lymphocytic Leukemia: Results of the Gimema-Eric LLC1315 Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107537</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3027</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>FGFR3 Mutations Are an Adverse Prognostic Factor in Patients with t(4;14)(p16;q32) Multiple Myeloma: An Mmrf Commpass Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105157</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3028</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Interactions with Bone Marrow Stromal Cells Alter the Molecular Dependencies of Myeloma Cells: Insights from Genomewide CRISPR-Based Functional Genomic Screens</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107600</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3029</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Multiple Myeloma Drivers of High Risk and Response to Stem Cell Transplantation Identified By Causal Machine Learning: Out-of-Cohort and Experimental Validation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107824</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3030</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Impact of Complete Response after First Line Therapy on Outcomes Following Initial Relapse in Newly Diagnosed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107671</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3031</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes with Early Response to First Line Treatment in Patients with Newly Diagnosed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108320</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3032</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Whole Genome Sequencing Reveals the Extent of Structural Variants in Multiple Myeloma and Identifies Recurrent Mutational Hotspots within the Non-Coding Regions</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108547</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3033</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Analysis of the IgA Heavy Chain Repertoire in Multiple Myeloma: Implications for Host-Microbiome Influences</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105618</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3034</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identifying High-Risk Phenotypes Using Three-Way Feature Interactions in Multiple Myeloma: An Analysis of Publically Available Mmrf Commpass Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106141</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3035</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage - A SingleCenter Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106700</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3036</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Assessment of Anti-Bacterial Antibodies in Multiple Myeloma Patients at Disease Presentation and in Response to Therapy: Implication for Patient Management</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107128</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3037</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Interleukin-6 Drives Multiple Myeloma Progression through Upregulating of CD147/Emmprin Expression and Its Sialylation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102433</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3038</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Defining aBone Marrow Immune Signature Associated with Immunoglobulin Isotype Switchingafter Autologous Stem Cell Transplant</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105312</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3039</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effect of Continuous Lenalidomide Treatment on Copy Number Alteration and Cytogenetic Abnormalities in Multiple Myeloma Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102871</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3040</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Factors Predicting Poor Outcomes for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103325</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3041</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Serum Free Light Chain Assay Measurement at Disease Relapse for Prognostication in Patients with Multiple Myeloma in the Novel Agent Era</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102292</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3042</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Comparison between 3 Staging Systems in Multiple Myeloma Using the Center for International Blood and Marrow Transplant Research (CIBMTR) Database</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102465</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3043</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>C-Reactive Protein Promotes Bone Destruction in Human Myeloma By Stimulating Myeloma Cell Production of Osteolytic Cytokines Via the CD32/FcRII-p38MAPK-Twist Axis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103920</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3044</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Soluble CX3CL1/Fractalkine Is a New Player in the Pro-Inflammatory Microenvironment of Multiple Myeloma Patients Related to Bone Marrow Plasma Cell Infiltration and Neo-Vascularization</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104908</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3045</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CD200 Is a Potent New Growth Factor in Multiple Myeloma through IGF-1R Interaction</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100047</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3046</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Composite Organ and Hematologic Response Model Risk Stratifies Patients with Light Chain Amyloidosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101531</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3047</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical and Molecular Characterization of Primary Plasma Cell Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101807</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3048</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pro-Inflammatory State of MGUS and Myeloma Patients Presenting with a Monoclonal Immunoglobulin Specific for an Infectious Pathogen</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107533</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3049</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Perturbation in B Cell-Subsets Can Explain the Observed Suppression of Uninvolved Immunoglobulins and Their Impact on T Tell-Subsets As Well As Patients Outcome in Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108466</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3050</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identifying Novel Genes Involved in Dysregulation of Homologous Recombination and Genomic Integrity in Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106357</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3051</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Arginine Deprivation and Autophagy Sustain Bioenergetics in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105456</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3052</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103154</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3053</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Definition of a Prognostic Risk-Classifier Based on SNPs Array Analysis of Copy Number Alterations in Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105033</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3054</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Peripheral Cellular Immunome Reveals Heterogeneity Spanning Myeloma Spectrum Diseases</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101618</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3055</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108426</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Venetoclax is a Bcl2 inhibitor that is FDA approved for CLL but not for myeloma. Samples from patients on clinical trials or treated off label will be discussed.</OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3056</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Predicting Venetoclax Sensitivity in Multiple Myeloma Using Biologic Activity Assays</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105851</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3057</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeted-Capture Sequencing Approach to V(D)J Rearrangement, Immunoglobulin (Ig) Translocation and Mutation Detection in Multiple Myeloma (MM): Potential Applications in Minimal Residual Disease (MRD) Analysis and Comparison to Multiparameter Flow Cytometry (MFC) in the Myeloma Canada Research Network (MCRN) 001 Study with Intravenous Busulfan and Melphalan (BuMel) Conditioning Followed By Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106661</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3058</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>AMeta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry (African-American Multiple Myeloma Study (AAMMS)) IdentifiesSuggestive Risk Variants</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107232</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3059</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cellular Proliferation By Multiplex Immunohistochemistry Identifies Aggressive Disease Behavior in Relapsed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105354</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3060</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103253</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3061</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hypoxia-Inducible KDM3A Addiction in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102044</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3062</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gene Expression Profiling (GEP) As a Prognostic Indicator of Multiple Myeloma, Irrespective of Disease Stage, Prior Treatment and Prior Transplant - a Single Center Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102846</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3063</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Leeds Risk Profile Predicts Outcome for Older Myeloma Patients: A Prognostic Score Using Frailty Biomarkers Derived and Tested Using 2371 Clinical Trial Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105078</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3064</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>18f-Fluorocholine Versus 18f-Fluorodeoxyglucose for PET/CT Imaging in Staging, Follow up or Suspected Relapse of Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101533</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3065</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Aplidin (Plitidepsin) Regulates Viability and Function of Myeloma Cells and Bone Cells in Combination with Other Anti-MM Drugs</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102467</Key_PaperID>
<Key_SessionID>11861</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3066</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Proliferation Inducing Ligand (APRIL) Directly Impacts Immune Regulatory Subsets to Regulate Suppressive Multiple Myeloma Bone Marrow Microenvironment</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103848</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4331</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105762</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4332</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MAGE-a Inhibits Apoptosis in Multiple Myeloma through Regulation of Bim and PUMA</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107247</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4333</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Immune Microenvironment Contributes to Dysregulation of Aid/Apobec Expression and Genomic Instability in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107516</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4334</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Apobec Family of Proteins Mediate Genomic Changes in Multiple Myeloma By Inducing DNA Damage and C&gt;T Mutations</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107409</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4335</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Overexpression of EZH2 in Multiple Myeloma Is Associated with Poor Prognosis Regardless of Treatment with Novel Agents or High-Dose Chemotherapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107639</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4336</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>5-Hydroxymethylcytosine of Circulating Cell-Free DNA in Plasma: A Novel Non-Invasive Marker for Progression and Prognosis in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107755</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4337</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeted Next Generation Sequencing of Circulating Tumor DNA in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107928</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4338</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Peripheral Neuropathy Is an Under-Recognized Feature of Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 18,668 MGUS Patients and Their 97,641 Matched Controls</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108253</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4339</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Method to Identify Patients with Multiple Myeloma Who Are at Risk of Developing Concomitant Amyloidosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108422</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4340</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification Cause of Aberrant Splicing and Novel Drug Targets in Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108490</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4341</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Role of Sclerostin in Multiple Myeloma Progression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105846</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4342</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MAF and NF-b Signaling Pathways Regulate Expression of APOBEC3B in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105972</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4343</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Post-MGUS Diagnosis Serum M-Protein Velocity and the Risk of Progression of MGUS to Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106582</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4344</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Whole Blood Gene Expression Signature Accurately Diagnoses Multiple Myeloma and Differentiates Patients in Remission from Those with Active and Progressive Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106667</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4345</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Comparison of a New Serum Free Light Chain (FLC) Assay Based on the Seralite Monoclonal Anti-FLC Antibodies with the Freelite and N-Latex FLC Assays in the Diagnosis of AL Amyloidosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106913</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4346</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107058</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4347</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Role of MAX As a Tumor Suppressor Driver Gene in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107167</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4348</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105474</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4349</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is an Independent Prognostic Factor for Overall Survival in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105364</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4350</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Suppression of Cdc37 Induces BTZ Resistance through XBP1s Mediated Plasma Cell Immaturation in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102460</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4351</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MiR-16 Regulates Crosstalk in NF-b Inflammatory Signaling between Myeloma Cells and Bone Marrow Macrophages</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102959</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4352</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>FDA Analysis of Racial Demographics in Multiple Myeloma Trials</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103218</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4353</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>What Does AL Amyloidosis Look like in the Era of Mass Spectrometry Typing?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103359</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4354</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Relevance of Clonal Circulating Plasma Cells Detected By Multiparameter Flow Cytometry in Patients with Newly Diagnosed Multiple Myeloma Treated with Novel Agents: Comparative Investigation with the Revised International Staging System</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103437</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4355</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Early Paraprotein Kinetics and Response to Treatment in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103721</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4356</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Histone Methyltransferases G9a and Glp; Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma Treatment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103739</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4357</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Implication of the Long Non-Coding RNA Crnde in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102171</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4358</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mmprofiler with SKY92 Combined with ISS Identifies High and Low Risk Multiple Myeloma in the VTD Arm of Gimema-MMY-3006</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102774</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4359</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103984</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4360</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle> a Novel Ex-Vivo Model of Prolonged Osteoblast Suppression in Multiple Myeloma  </PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104895</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4361</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mesenchymal Stromal Cells (MSC) As Key Players in the Tumor Microenvironment Transformation from MGUS to Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104917</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4362</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Micrornas in Bone Marrow Mesenchymal Stromal Cells Are Differentially Expressed According to Response in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105134</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4363</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Whole Exome Sequencing Reveals High Genetic Diversity in Relapsed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100451</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4364</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Whole Exome Sequencing of Plasma Cells Precancerosis MGUS and Malignant AL Amyloidosis Reveals Small Number of Shared Mutated Genes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102283</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4365</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101578</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4366</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evolution of Monoclonal Gammopathy of Undetermined Significance in Kidney Transplant Recipients at the CHUM (Centre Hospitalier de lUniversit de Montral)  a Single-Institution Retrospective Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101722</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4367</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intra-Individual Changes in Immune Marker Concentrations and Multiple Myeloma Risk: A Longitudinal Prospective Study Using Repeated Pre-Diagnostic Plasma Samples</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100887</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4368</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107405</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4369</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lenalidomide, Pomalidomide and CC-220 Resistant Multiple Myeloma: Confirmation of Role of CRBN/IRF4 Axis and Identification of Multiple Disruption Mechanisms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107663</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4370</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Early Enrichment and Subsequent Dysfunction of Marrow ILC Subsets in Monoclonal Gammopathy: Target for IMiD Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108265</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>41</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4371</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108521</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>42</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4372</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105948</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>43</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4373</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Daratumamab in High Risk Relapse/Refractory Myeloma Patients Effect of 1q21 Gain and GEP70 Status</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106522</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>44</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4374</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Exosome-Mediated Transfer of lncRUNX2-AS1 from Multiple Myeloma Cells to Mesenchymal Stem Cells Contributes to Osteogenic Differentiation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105117</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>45</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4375</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transcriptome Alterations of Prospectively Isolated Bone Marrow Stromal Cells Provide Potential Cues to MGUS and Multiple Myeloma Pathobiology</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105559</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>46</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4376</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting of the Hypoxia-Induced Acid Microenvironment of Multiple Myeloma Cells Increases Hypoxia-Mediated Apoptosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105236</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>47</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4377</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting of Marcks By MiR-34a Overcomes Drug Resistance in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103458</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>48</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4378</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Abnormalities in Mitochondrial DNA Copy Number Have Pathogenetic and Prognostic Implications in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102152</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>49</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4379</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Quantitative and Functional Alterations of 6-Sulfo Lacnac Dendritic Cells in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102822</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>50</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4380</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Th17 Cells Targeting By MiR-21 Inhibitor Impairs Multiple Myeloma Related Bone Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104350</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>51</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4381</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Age Related Distribution of Cytogenetic Abnormalities in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105149</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>52</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4382</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>RNA Sequencing Data-Driven Dissection of Human Plasma Cell Differentiation Reveals New Potential Transcription Regulators</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101142</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>53</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4383</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107396</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>54</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4384</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Risk Stratification of Smoldering Multiple Myeloma in the Light of the Revised IMWG Diagnostic Criteria</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107624</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>55</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4385</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Differential Diagnosis of Suspected MYD88 Wild-Type Waldenstroms Macroglobulinemia Includes Other Malignant and Non-Malignant IgM Secreting Entities, Including Frequent Cases of IgM Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107758</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>56</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4386</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108341</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>57</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4387</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Molecular Subtypes of Plasma Cell Neoplasms with Circulating Neoplastic Plasma Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108469</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>58</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4388</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting Homologous Recombination Increases Cytotoxicity While Reducing Genomic Instability Induced By Melphalan in Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105566</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>59</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4389</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Immunologic Characterization of Tumor Antigen-Specific T Cells in Multiple Myeloma: Implication in Immune Checkpoint Blockade</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106140</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>60</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4390</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Protein Synthesis Rates Regulate Tumor-Initiating Potential and Chemoresistance in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106414</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>61</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4391</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High PD-1 and Tim-3 Expression Concurrent with Exhausted CD4+ and CD8+ T Cells in Bone Marrow Compared with Peripheral Blood from Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107065</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>62</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4392</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107141</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>63</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4393</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Proteotoxicity in Cardiac Amyloidosis: Amyloidogenic Light Chains Affect the Levels of Iintracellular Proteins in Human Heart Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107238</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>64</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4394</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mafa Expression Promotes Proliferation of Myeloma Cells and Its Protein Stability Is Regulated By Proteasome Inhibitors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105209</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>65</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4395</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>BCMA Versus CD138 for Identifying Multiple Myeloma on Flow Cytometry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102869</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>66</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4396</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) after Multiple Myeloma: Assessment of Risk Factors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103198</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>67</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4397</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long Noncoding RNA PVT1 and MYC Are Co-Regulated By Bromodomain Protein BRD4 in Multiple Myeloma and Associated with Disease Progression</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103370</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>68</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4398</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Protein Kinase CSNK1A Regulates the Multiple Myeloma Plasma Cell-Microenvironment Interplay</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103572</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>69</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4399</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Reduction of Dicer1 By Multiple Myeloma Cells in Mesenchymal Stem Cells Promotes Cellular Senescence and Tumor-Supporting Effect and Decreases the Differentiation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102111</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>70</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4400</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Immune Checkpoint (PD-1, PD-L1, PD-L2, and CTLA-4) Expression in Plasma Cell Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103804</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>71</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4401</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Automatic Digital Quantification of Bone Marrow Myeloma Volume in Appendicular Skeletons  Clinical Implications and Prognostic Significance</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103868</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>72</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4402</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Significance of Plasma Cell Tetrasomy in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104924</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>73</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4403</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Role and Therapeutic Target of Base Excision Repair Genes in Multiple Myeloma (MM)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105106</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>74</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4404</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Diffuse Medullary Hyperdensities of the Femora and Humeri on Whole-Body Low-Dose Computed Tomography Identify Diffuse MRI Pattern of Involvement and Correlate with Advanced Disease Stage in Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101091</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>75</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4405</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gene Expression Profiling of Kinetic Response to Proteasome Inhibitors in Innate and Acquired Resistant Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101700</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>76</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4406</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ral Mediates Multiple Myeloma Cell Survival Independently of Oncogenic RAS</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104639</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>77</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4407</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Gamma Gap: A Point-of-Care Test That Correlates with Disease Burden and Treatment Response in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107389</Key_PaperID>
<Key_SessionID>11862</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>78</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4408</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bone Marrow Microenvironment Induces Genomic Instability and Enables Clonal Evolution in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102989</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3067</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CD8+ Anti-Bcma mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells in Vitro and In Vivo</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106130</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3068</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/- and Patient-Derived Multiple Myeloma Tumors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105756</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3069</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Unbiased Phosphoproteomics Reveals a Therapeutically Relevant Connection between Pre-mRNA Splicing and Proteasome Inhibition in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104939</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3070</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preclinical Evaluation of Hdp-101, a Novel Anti-Bcma Antibody-Drug Conjugate, in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107027</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3071</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Generation of a Lenalidomide-Sensitive Mouse Model for Multiple Myeloma By Expression of the CrbnI391V Mutant in Mopc-315.BM Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101896</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3072</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108201</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3073</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A B-Cell like Phenotype Is Associated with Sensitivity to Venetoclax in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103944</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3074</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Nelfinavir Blocks Export of Newly Synthesized Protein from the ER and Interacts with ER-Resident and Mitochondrial Proteins in an Activity-Dependent Fashion</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105690</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3075</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting Proteasome- Associated Ubiquitin Receptor PSMD4/Rpn10 in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107499</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3076</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Glutamine Catabolism Maintains MCL-1 Expression in Glucose-Deprived Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102702</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3077</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>HUWE1 Inhibition As a Therapeutic Strategy to Target MYC in MM</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105441</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3078</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Therapeutic Targeting of Interferon Regulatory Factor 4 with Next Generation Antisense Oligonucleotides Produces Robust In Vivo Antitumor Activity in Preclinical Models of Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103115</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3079</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105991</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3080</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Direct to Drug Screening As a Route to Individualized Therapy in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107855</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3081</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Charting Venetoclax Sensitivity and Synergism Ex Vivo in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108028</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3082</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>AFM26  Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100341</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3083</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Copper-64-Labeled Daratumumab As a PET Imaging Tracer for Multiple Myeloma: Potential Use for Minimal Residual Disease Detection</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108147</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3084</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of PI3K Alpha and PI3K Delta with Copanlisib Shows Preclinical Activity As a Single Agent and in Combination in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107511</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3085</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CircPVT1 Inhibit Apoptosis and Enhance Drug Resistance in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100812</Key_PaperID>
<Key_SessionID>11863</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3086</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Proteasome Inhibitors-Induced Cardiotoxicity (carfilzomib vs. bortezomib): Insights into the Molecular Mechanisms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107500</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4409</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Succinate Ubiquinone Reductase Activity Predicts Multiple Myeloma Sensitivity to Venetoclax</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103376</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4410</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Single Gene-Mediated Perturbation of the Human Genome Leads to Malignant Transformation in a Murine Transgenic Model</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108231</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4411</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of Target Pathways of Acquired IMiD and Proteasome Inhibitor Resistance in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106609</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4412</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Midostaurin Shows Efficacy in Refractory Multiple Myeloma with TP53 Mutation and Elevated Expression of NTRK1, NTRK3 and AURKA</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105620</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4413</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Serum Bcma May Interfere with Anti-Bcma-CAR-Transduced T Cells or Other Anti-Bcma Antibody-Based Immunotherapy in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107801</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4414</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In Vivo Validation of Essential Genes for Myeloma Cells By CRISPR/Cas9 Studies in a Scaffold-Based System Engineered to Establish a "Humanized" Bone Marrow-like Microenvironment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101810</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4415</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105523</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4416</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Maternal Embryonic Leucine Zipper Kinase Inhibitor OTSSP167 Inhibits Osteoclast Activity and Restores Osteoblast Activity in a Murine Model of Multiple Myeloma Bone Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107212</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4417</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Eosinophils Upregulate PD-L1 and PD-L2 Expression to Enhance the Immunosuppressive Microenvironment in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102856</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Lenalidomide and Pomalidomide, positive control for pre-clinical homeostatic modulators study in cancer cells</OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4418</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Protein Homeostatic Modulators, a Novel Class of Cereblon-Targeting Small Molecules As Potential Clinical Candidates in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101526</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4419</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bone-Targeted Pharmacological Inhibition of Notch Signaling As a Novel Approach to Inhibit Myeloma Growth and Bone Destruction</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104213</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4420</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug Conjugate, SRO-001</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108256</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4421</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inhibition of p62-ZZ Domain-Mediated Signaling Overcomes Bortezomib Resistance in Multiple Myeloma Cells Independent of Their p53 Status</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105590</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4422</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107638</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4423</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pikfyve Inhibitors for the Treatment of Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99608</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4424</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Humanized Anti-CD26 Monoclonal Antibody Has Anti-Myeloma Efficacy for the Treatment of High-Risk Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103023</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4425</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>HIF-2 Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108537</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Leflunomide (Arava) is a commercially available oral immunosuppressive agent that has been FDA-approved since 1988 for the treatment of rheumatoid arthritis. Our laboratory has repurposed leflunomide for treatment of multiple myeloma. </OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4426</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Leflunomide Inhibits c-Myc Signaling and Impairs Myeloma Cell Growth</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105329</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4427</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Actinium Labeled Daratumumab Demonstrates Enhanced Killing of Multiple Myeloma Cells over Naked Daratumumab</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102284</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4428</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluating Pembrolizumab Interference with Monoclonal Protein Detection By Immunofixation and By MALDI-TOF Mass Spectrometry (MASS-FIX)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102919</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4429</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102238</Key_PaperID>
<Key_SessionID>11864</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4430</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development of an Antibody-Targeted Nanoparticle for Early Detection of Minimal Residual Disease in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104268</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3087</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Combined Study from the Greek, Czech and UK Databases</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100827</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3088</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Next Generation Flow (NGF) Cytometry for Minimal Residual Disease (MRD) Evaluation in Multiple Myeloma (MM) Patients with Sustained Complete Response (CR) after Frontline Therapy: Results of a Prospective Single-Center Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101016</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pembrolizumab in the treatment of smoldering multiple myeloma</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3089</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101007</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>High dose pomalidomide in relapsed/refractory myeloma</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3090</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101877</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3091</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Interim Results from the Phase 1a/1b Dose-Finding Study of CWP232291 (CWP291) in Relapsed or Refractory Myeloma (RRMM) Alone or in Combination with Lenalidomide and Dexamethasone</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106844</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3092</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Systemic Versus Local Treatment in Patients with Multiple Myeloma and a Single Lesion in Whole Body Imaging</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106323</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3093</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Efficacy Outcomes Among Relapsed/Refractory Multiple Myeloma Treated Patients in a Real-World Setting</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106350</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3094</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Overall Survival Associated with Lenalidomide+Dexamethasone and Bortezomib+Dexamethasone Among Relapsed/Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106996</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>use of selinexor in combination with liposomal doxorubicin in patients with myeloma</OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3095</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107243</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3096</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of VDT PACE-like Regimens in Treatment of Relapsed/Refractory Multiple Myeloma- a Single Center Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107438</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3097</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Significance of Flow Cytometry and Positron Emission Tomography and Computed Tomography (PET-CT) in the Assessment of the Minimum Residual Disease in Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107669</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3098</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Maintenance Treatment with Lenalidomide for Multiple Myeloma Increases the Proportion of MRD Negative (Flow-/PET-CT-) Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107975</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3099</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting CD47 As a Novel TherapeuticStrategy in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108034</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3100</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100272</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3101</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect MM Registry</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108510</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Carfilzomib/kyprolis is approved for relapsed myeloma. The patients in this abstract were part of a clinical trial using it upfront.</OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3102</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103187</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3103</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Measuring Cardiopulmonary Complications of Carfilzomib Treatment and Associated Risk Factors Using the SEER-Medicare Database</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105314</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3104</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effect of Proteasome Inhibitors and/or Immunomodulatory Drugs on the Risk of Early Death of 991 Newly Diagnosed Symptomatic Multiple Myeloma Patients: A Single Centre Retrospective Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105450</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3105</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Navigating the Changing Multiple Myeloma (MM) Treatment Landscape: Real-World Data on Clinical Practice Patterns in 287 MM Patients Treated in and Outside German DSMM (Deutsche Studiengruppe Multiples Myelom) Study Group Trials</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105786</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3106</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105841</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3107</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105950</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3108</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Cost-Benefit Analysis of Bortezomib, Lenalidomide, and Bortezomib/Lenalidomide Combination Therapy for Newly Diagnosed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101983</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3109</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Correlative Analyses of Cereblon (CRBN), cMYC, IRF4, BLIMP1, and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104318</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3110</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100918</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ibrutinib, a BTK inhibitor, is approved in the US for the treatment of various B-cell malignancies. Use of ibrutinib is investigational in patients with multiple myeloma, and investigational in combination with carfilzomib with and without dexamethasone.</OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3111</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104468</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3112</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Attenuated Interferon- Targeted to CD38 Expressing Multiple Myeloma Tumor Cells Induces Robust and Durable Anti-Tumor Responses through Direct Anti-Proliferative Activity in Addition to Indirect Recruitment and Activation of M1 Macrophages</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102383</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3113</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104753</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3114</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of Bortezomib-Based Regimens for Patients with Newly Diagnosed AL Amyloidosis Not Receiving ASCT Compared with Alkylators and Dexamethasone-Based Regimens</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105005</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3115</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effective Treatment of Relapsed/Refractory Multiple Myeloma Including Extramedullary Involvement By Bcma-Specific Chimeric Antigen Receptor-Modified T Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103466</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3116</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Acquired Chromosomal Abnormalities t(14;16), Del(17p) or Del(13q) after Receiving Chemotherapies Predict the Poor Prognosis of Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103596</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3117</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Early Relapse Post Autologous Transplantation Is Associated with Very Poor Survival and Identifies an Ultra High Risk Group of Myeloma Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101641</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Lenalidomide in AL amyloidosis</OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3118</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of Lenalidomide As Salvage Therapy for Patients with AL Amyloidosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103319</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3119</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Conventional Karyotyping Is Still an Important Prognostic Marker for Myeloma in the Era of R-ISS Staging</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99851</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3120</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100180</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3121</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100373</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3122</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect MMpatient Registry</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100921</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3123</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment Patterns and Associated Outcomes in Patients with Relapsed or Refractory Multiple Myeloma in the US and Non-US Countries: Findings from Preamble</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104207</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3124</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101445</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3125</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Proteasome Inhibition Activity between Carfilzomib and Bortezomib in the Phase 3 Endeavor Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101529</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3126</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Final Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) in Transplant-Ineligible Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101670</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>41</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3127</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment Sequencing Patterns Observed in Patients Treated Initially with Lenalidomide/Dexamethasone Combination As Frontline Multiple Myeloma Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102256</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Use off-label of drugs for the dose and/or schedule and/or association.</OffLabelUseDescription>
<Order>42</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3128</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bortezomib-Dexamethasone Re-Treatment at Biochemical Relapse Vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II Multi-Center, Randomized Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102672</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>43</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3129</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Randomized Placebo-Controlled Phase II Study of Clarithromycin or Placebo Combined with VCD Induction Therapy Prior to High-Dose Melphalan with Stem Cell Support in Patients with Newly Diagnosed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102132</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>44</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3130</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>the Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma : A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP) </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100825</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>45</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3131</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106403</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>46</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3132</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Survival Impact of Lenalidomide Maintenance Chemotherapy in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplant and Bortezomib-Based Induction; An Analysis of Real World Data</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106848</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Carfilzomib is not labeled for use in newly diagnosed multiple myeloma</OffLabelUseDescription>
<Order>47</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3133</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MRD Response-Driven Phase I/II Study forNewly Diagnosed Multiple MyelomaPatients Using HigherDoses of Twice-Weekly Carfilzomib(45 and 56 mg/m2) in Combination with Lenalidomideand Dexamethasone</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107422</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>48</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3134</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107659</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>49</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3135</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107841</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>50</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3136</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108020</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>51</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3137</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Oncolytic Reovirus Sensitizes Multiple Myeloma Cells to Anti-PD-L1 Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108278</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Carfilzomib, Ixazomib for frontline treatment of myeloma.</OffLabelUseDescription>
<Order>52</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3138</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Overall Survival of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Comparative Effectiveness Analysis of Modern Induction Regimens on Outcome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108491</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>53</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3139</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105361</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>54</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3140</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Incidence and Outcome of Soft-Tissue Plasmacytomas in Patients with Multiple Myeloma before and after the Introduction of Novel Drugs</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105603</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>55</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3141</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105776</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>56</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3142</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chimeric Antigen Receptor (CAR) T Cells Specific for CD229: A Potentially Curative Approach for Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105822</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>57</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3143</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Novel CT-Based Bone Strength Assessment By Finite Element Analysis for Monitoring Bone Involvement in Myeloma: a Proof of Concept Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105945</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Leflunomide is given for rheumatoid arthritis.</OffLabelUseDescription>
<Order>58</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3144</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104182</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>59</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3145</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104037</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>60</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3146</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105492</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>61</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3147</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>3D-Tissue Engineered Bone Marrow (3DTEBM) Culture Predicts Clinical Efficacy of Drugs Better Than Regular Culture Systems in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104702</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>62</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3148</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Infectious Complications of Daratumumab-Containing Therapy for Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105006</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>63</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3149</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101876</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>64</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3150</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103471</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>65</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3151</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bortezomib-Maintenance for Patients with AL Amyloidosis: A Single Center Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104094</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>66</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3152</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Vulnerability Variables Among Octogenarians Myeloma Patients: A Single-Center Analysis in 110 Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102936</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>67</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3153</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preclinical Evaluation of MEDI2228, a BCMA-Targeting Pyrrolobenzodiazepine-Linked Antibody Drug Conjugate for the Treatment of Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103210</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>68</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3154</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Depth of Organ Response in Newly Diagnosed AL Amyloidosis Is Associated with Improved Survival: Improved Outcome Discrimination with Graded Organ Response</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99709</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Siltuximab is currently indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. </OffLabelUseDescription>
<Order>69</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3155</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99956</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>70</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3156</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100556</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>71</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3157</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Healthcare Resource Utilization and Costs Associated with Different Treatment Modalities of Relapsed/Refractory Multiple Myeloma Patients in the US: Findings from Preamble</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106261</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pomalidomide, Bortezomib, and Dexamethasone are all being used in an off-label combination for the upfront treatment of AL amyloidosis.</OffLabelUseDescription>
<Order>72</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3158</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase I Trial of Pomalidomide, Bortezomib, and Dexamethasone As Frontline Treatment of AL Amyloidosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101213</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>73</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3159</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real World Management of Multiple Myeloma in Asia: Treatment Pattern and Cost</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102116</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>74</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3160</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102230</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>75</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3161</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102796</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>76</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3162</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase II Clinical Trial of Personalized-VCD-VTD Sequential Therapy Using VES-13 for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101050</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Use of Daratumumab as initial treatment of Multiple Myeloma</OffLabelUseDescription>
<Order>77</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3163</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Weekly Cybord-Dara Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101587</Key_PaperID>
<Key_SessionID>11865</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>78</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3164</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Daratumumab Activity Is Agnostic to Fc Gamma Receptor 3A (FcR3A) 158 Genotype in Patients with Primary Refractory or Relapsed Systemic AL Amyloidosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106974</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3204</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104039</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3205</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High-Dose Melphalan-Based Sequential Conditioning Chemotherapy Followed By Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104611</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3206</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Favorable Outcome in Patients with Pre-Transplant Gut Colonization with Intrinsically Vancomycin-Resistant Enterococci</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104800</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3207</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improved Survival Outcomes By Iron Chelating Therapy with Deferasirox after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105960</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3208</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CCR6, IL7R, FAS and Madcam-1 Single Nucleotide Polymorphisms Are Associated with Higher Incidence of Infections in Allogeneic Stem-Cell Transplant from a Related Donor after a Reduced Intensity Conditioning Regimen: A Multicenter Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104338</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>We present transplant outcomes in AML/MDS patients who received Nivolumab and Ipilimumab before allogeneic stem cell transplantation. </OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3209</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105415</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3210</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107909</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3211</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Toxigenic Clostridium Difficile Colonization in Patients with Hematologic Malignancies Admitted to the Hospital for Chemotherapy or Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108250</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3212</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transfusion- Related Iron Overload (TRIO) Is Associated with Delayed Engraftment and Increased Non Relapse Mortality (NRM) in Patients Undergoing Umbilical Cord Blood (UCB) Hematopoietic Cell Transplantation (HCT)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106204</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3213</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105154</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3214</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intravenous Busulfan-Based Conditioning Regimens in Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106228</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3215</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Busulfan Pharmacogenetics and Drug Exposure in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108497</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3216</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Patients with Pre-Existing Invasive Fungal Disease Undergoing Allogeneic Haematopoietic Stem Cell Transplantation - 5 Years Single Centre Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103070</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3217</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CMV Status Predicts Survival in Refractory/Relapsed Myeloid Patients after a Clofarabine-Based Sequential Regimen: A Retrospective Study on Behalf of the SFGM-TC</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107084</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3218</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>UGT1A1 Polymorphism and Mortality Outcome after Allogeneic Stem Cell Transplantation with Busulfan Based Regimen</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107722</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3219</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pharmacokinetics of Treosulfan in Patients with Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation  a Comparison of Two Formulations and Correlation with Clinical Outcomes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101729</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Fosaprepitant is an antiemetic drug used against CINV. It was approved for adult patients by the U.S. Food and Drug Administration and the European Medicines Agency in 2008. </OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3220</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Single-Dose Intravenous Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients with Hematooncological Malignancies after Moderate and High Emetogenic Chemotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107935</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3221</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of the Power of Procalcitonin and C-Reactive Protein to Differentiate between Different Etiologies of Febrile Neutropenia in Patients with Prolonged Profound Neutropenia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105048</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Thrombopoietin receptor agonist (Eltrombopag and Romiplostin): Usefulness for thrombocytopenia after allogeneic hematopoietic stem cell transplantation.</OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3222</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Usefulness of Thrombopoietin Receptor Agonists for Thrombocytopenia after Allogeneic Stem Cell Transplantation. An Eight-Year Single Center Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107278</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3223</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prospective Study of High Dose Foscarnet Prophylaxis for HHV-6 Related CNS Diseases in Cord Blood Transplantation for Adult Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104155</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Defibrotide is approved for treatment of hepatic VOD/SOS with renal/pulmonary dysfunction post-HSCT in the United States and for treating severe hepatic VOD/SOS post-HSCT in the European Union.</OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3224</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Final Analysis of Day +100 Survival By Prior Hematopoietic Stem Cell Transplant Type from an Expanded Access Study of Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104458</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Defibrotide is approved for treatment of hepatic VOD/SOS with renal/pulmonary dysfunction post-HSCT in the United States and for treating severe hepatic VOD/SOS post-HSCT in the European Union. </OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3225</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Adults Receiving Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplantation (HSCT): Final Results from the Expanded-Access Program</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105205</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3226</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cyclophosphamide Followed By Intravenous Busulfan (Cy-Bu) As Myeloablative Conditioning: Impact on Venoocclusive Disease and Transplant Outcomes, Real World Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108807</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3227</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improved Outcome of Haploidentical Peripheral Blood Stem Cell Transplant Treating Severe Aplastic Anemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104773</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Fosaprepitant is an antiemetic drug used against CINV. It was approved for adult patients by the U.S. Food and Drug Administration and the European Medicines Agency in 2008.  </OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3228</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Antiemetic Prophylaxis with Granisetron and Fosaprepitant during Moderate and High Emetogenic Chemotherapy in Pediatric Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107613</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3229</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Differential Impact of Conditioning Intensity on Post-Transplant Outcome of FLT3-Mutated and FLT3 Wild Type AML in First Remission, a Report from Taiwan Bone Marrow Transplant Registry (TBMTR)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107894</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3230</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Reduction of Immunosuppression after Disease-Specific Donor Cell Chimerism Decrease Can Prevent Hematological Relapse Following Allogeneic Stem Cell Transplantation after Non-Myeloablative (NMA) Conditioning - Results of a Prospective Phase II Study. Eudract #: 2007-002420-15</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106742</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3231</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effectiveness of Acyclovir Prophylaxis Against Varicella Zoster Virus Infection after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104952</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3232</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hypomethylation of Decitabine Improved Outcomes of Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102070</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3233</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fluid Overload Early after Allogeneic Hematopoietic Stem Cell Transplantation Was Associated with Poor Survival</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102625</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3234</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Role of Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells in Allogeneic Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100806</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3235</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Once-Daily Intravenous Busulfan in Allogeneic Transplantation: A Matched-Pair Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100866</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3236</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Liver Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Descriptive Longitudinal Study Using Liver Parameters Monitoring and Their Impact on Transplantation Outcomes Using a Prediction Score</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100982</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3237</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Post-Transplantation Cyclophosphamide and Short-Term Methotrexate for Tolerance Induction in HLA-Haploidentical Transplantation for Severe Aplastic Anemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101260</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3238</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Outcomes of Total Body Irradiation Plus Cyclophosphamide Versus Busulfan Plus Cyclophosphamide As Conditioning Regimen for Acute Lymphoblastic Leukemia: A Comparative Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101382</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3239</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Determinants for Oral Mucositis in Allogeneic Hematopoietic Stem Cell Transplantation: Prospective Evaluation and Risk Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101537</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Inotuzumab ozogamicin (CMC 544) in allogeneic transplantation. </OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3240</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99994</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3241</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment Evolution for Multiple Myeloma before Autologous Stem Cell Transplant and Its Relation with Engraftment Syndrome: 15 Years of Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100310</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3242</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Outcome after Allogeneic Stem Cell Transplantation in AML Patients in First or Second Complete Remission Following Either Fludarabin/Busulfan, Flamsa-TBI or Flamsa-Bu Conditioning</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101875</Key_PaperID>
<Key_SessionID>11867</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3243</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Malyglycemia Is Associated with Increased Infection in Pediatric Hematopoietic Stem Cell Transplant Recipients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101430</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3422</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Health-Related Quality of Life and Symptom Burden in Chronic Myeloid Leukemia Patients Treated with First Line with Imatinib Versus Those Treated with Dasatinib: First Results of the Leonidas Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103091</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3423</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104519</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3424</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Systematic Literature Review of Overall Survival and Delivered Dose Intensity in Cancer Patients Receiving Chemotherapy and G-CSF in Randomized Control Trials</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102868</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3425</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Growth Disturbances in Pediatric Patients Receiving Long-Term Tyrosine Kinase Inhibitor Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103961</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3426</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Racial Disparities in Treatment Patterns and Outcomes Among Patients with Multiple Myeloma: A SEER-Medicare Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101914</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3427</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Economic Burden of Stem Cell Transplant Among Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101959</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3428</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparative Analysis of Clinical Trial Outcomes between African American and White Patients Treated with Lenalidomide and Dexamethasone for Multiple Myeloma (MM)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108257</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3429</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Role of Health Literacy, Acculturation and Socio-Demographics on Perception of Voluntariness during Informed Consent for Pediatric Leukemia Clinical Trials</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99817</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3430</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Complications and Early Mortality in Patients with Acute Promyelocytic Leukemia Treated in California</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104579</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3431</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Socioeconomic Factors Associated with Overall Survival (OS) in Adults with Acute Lymphoblastic Leukemia (ALL)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105928</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3432</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Adherence to Lenalidomide in Older Patients with Multiple Myeloma (MM): A SEER-Medicare Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107630</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3433</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Carfilzomib Dosing Patterns and Time to Next Treatment Among Adult Patients with Multiple Myeloma Treated in the US Community Oncology Setting</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106887</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3434</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Real-World Comparative Analysis of Carfilzomib and Other Systemic Multiple Myeloma Chemotherapies in the US Community Oncology Setting</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108467</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3435</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Urine Cultures at the Onset of Febrile Neutropenia (FN) in Patients with Haematological Malignancies Rarely Impact Antibiotic Management in the Absence of Urinary Symptoms</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105434</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3436</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Functional Assessment (FA) in Multiple Myeloma (MM) Patients Predicts Survival: Use of Most Valuable Comorbidity Scores and Functional Tests in a German Study Group (Deutsche Studiengruppe Multiples Myelom [DSMM]) Incentive</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108197</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3437</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Conditional Long-Term Survival Among Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Autologous Hematopoietic Cell Transplantation (AHCT) </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104339</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3438</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Population Level Survival for Patients with Multiple Myeloma By Insurance Type and Early Indications of Changes with Adoption of the Medicaid Expansion of the Affordable Care Act</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105467</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3439</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High-Intensity End-of-Life Care of Allogeneic Hematopoietic Cell Transplantation Recipients (HCT)  a Population-Based Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106946</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3440</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cognitive Function in Older Adults with Hematological Malignancies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100850</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Nivolumab is a monoclonal antibody indicated for treatment of patients with classical Hodgkin lymphoma that has relapsed after autologous hematopoietic cell transplantation (auto-HCT) and brentuximab vedotin (BV) or &gt;=3 lines of systemic therapy including auto-HCT. Cohort A of the CheckMate 205 study, reported here with Cohorts B and C, included BV-naive patients who received &lt;3 prior therapies.</OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3441</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effect of Nivolumab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplantation: Results from the Multicohort Phase 2 Checkmate 205 Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105169</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3442</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Adverse Events, Resource Use, and Economic Burden in Patients with Mantle Cell Lymphoma in the United States</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101904</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3443</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Pilot Study of Online Yoga to Improve Fatigue and Quality of Life in Myeloproliferative Neoplasm Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103199</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3444</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Rothman Index As a Real-Time Predictor of Intensive Care Unit Admissions and Mortality in Acute Myeloid Leukemia Patients Undergoing Induction Chemotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105917</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3445</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Severe Sepsis As Immune Stimulation and Protection from Relapse of Childhood Acute Lymphoblastic Leukemia (ALL): Results from a Pilot Study and Validation of Events in a National Administrative Dataset</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106176</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3446</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Use of a Fitness Tracking Device to Monitor Physical Activity and Sleep Patterns during Hospitalization for Hematopoietic Stem Cell Transplant. Results of a Prospective Observational Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105766</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3447</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Patient-Reported Sleep Quality at Baseline Correlates with 1-Year Survival after Allogeneic Hematopoietic Cell Transplantation in Adults</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103903</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3448</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Retrospective Real-World Study of Incident Comorbidities and Complications Among Acute Myeloid Leukemia Patients and Non-Cancer Comparison Patients in the US</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104308</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3449</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105019</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3450</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cognitive Impairment in Hodgkin Lymphoma Survivors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100447</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3451</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Delphi, a Data Warehouse to Discover Associations between Variables in Clinical Trials: Application to the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106798</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3452</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Factors and Survival Outcomes in Phase I Patients with Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108713</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3453</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Quality of Life and Symptom Burden Among Patients with Myeloproliferative Neoplasms: Do Symptoms Impact Quality of Life?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101882</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3454</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cognitive Outcomes Among Patients with Hematological Cancer with Access to Computerized Cognitive Training: Results from a Feasibility Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103883</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3455</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Hospital Mortality, Cost and Length of Stay Among Hodgkins Lymphoma and Venous Thromboembolism Patients: An Analysis from National Inpatient Sample</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104196</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3456</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Diagnostics of Pulmonary Aspergillosis in Critically Ill Hematological and Non-Hematological Patients in the Intensive Care Unit By Combined Use of Galactomannan, 1-3-Beta-D-Glucan, Aspergillus Specific PCR and Conventional Culture in Concurrent Blood and Bronchoalveolar Lavage Samples  Results of a Multicenter Prospective Pilot Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104403</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3457</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Enhancing the Content of the EORTC QLQ-C30 to Maximize the Detection of Treatment Benefit in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myeloid Leukemia Using the EORTC Item Bank</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104125</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3458</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105965</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3459</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Healthcare Costs in Elderly Patients with Acute Myeloid Leukemia (AML) in Routine Clinical Care in the United States (US)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108712</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3460</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Systematic Review of Infectious Events in Prospective Trials of Ibrutinib</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102652</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3461</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bacterial Infectionsin Patients with Chronic LymphocyticLeukemia: A LongitudinalNation-Wide Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100366</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>41</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3462</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102392</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>42</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3463</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102610</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>43</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3464</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gender and Marital Status Influence Survival of Myelodysplastic Syndrome and Risk of Secondary Acute Myeloid Leukemia: A Population-Based Study of Patients in the Surveillance, Epidemiology, and End Results (SEER) Database</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104672</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>44</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3465</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Potentially Inappropriate Medication Use in Elderly Patients with Diffuse Large B-Cell Lymphoma Predicts Inferior Survival and Treatment-Related Toxicities</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107393</Key_PaperID>
<Key_SessionID>11868</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>45</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3466</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107042</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order></Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4431</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Reduced GvHD in Recipients of BM Derived Versus G-CSF Mobilized Plasmacytoid Dendritic Cells: Role of Inducible IL-12</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105828</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4432</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Process for the Expansion of Functional Human ILC2 Cells for Gvhd Prevention</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106836</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4433</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Post-Transplantation Cyclophosphamide Induces Alloreactive T-Cell Functional Impairment and Depends on Foxp3+ Regulatory T Cells Not Selective Elimination or Intrathymic Clonal Deletion of Alloreactive T Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107672</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4434</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Regulatory T Cells Expanded Via TL1A-Ig Fusion Protein and Low Dose IL-2 Demonstrate Potent Suppression of Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107202</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4435</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Syngeneic Fecal Microbiota Transplant Effectively Attenuated Graft-Versus-Host Disease after Bone Marrow Transplantation in Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108589</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4436</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Memory T Cells from Minor Histocompatibility Antigen-Vaccinated Donors Improve Engraftment with Low Intensity Conditioning</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107931</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4437</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Absence of Vasoactive Intestinal Peptide Synthesis in Recipients in Allogeneic Bone Marrow Transplant Increases Graft Versus Host Diseases</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107515</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4438</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PD-1 through Asparaginyl Endopeptidase Regulates Foxp3 Stability in Induced Regulatory T Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107660</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4439</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>T Follicular Regulatory (TFR) Cell Deficiency during Chronic Graft-Versus-Host Disease Is Improved By Low-Dose IL-2 Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101429</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4440</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impaired Bone Marrow Endothelial Progenitor Cells May Contribute to Acute Graft-Versus-Host Disease after Allotransplant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101711</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4441</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Recipient Hematopoietic, but Not Non-Hematopoietic, Antigen-Presenting Cells Are Indispensable for CD4+ T-Cell-Mediated Xenogeneic Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101987</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4442</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Iron Overload Decreases Engraftment of Mice Receiving Allogeneicor Syngeneic Bone Marrow Transplant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103025</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4443</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In Vivo Expansion of Recipient DC Leads to Deletion of Donor Alloreactive CD8+ T Cells and Is an Alternative to Post-Transplant Cyclophosphamide for the Prevention of Graft-Versus-Host Disease after BMT</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103324</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4444</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Regulatory T Cells Prevent Donor Cell Rejection in a Mouse Model of Delayed Gestational Age in Utero Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103686</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4445</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Results of a Non-Interventional Clinical Trial of Apograft - a Novel Technology for GvHD Prevention</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104317</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4446</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Enhanced Expression of CXCR4 Facilitates the Trafficking of Anti-c-Kit Chimeric Antigen Receptor (CAR) T Cells to Bone Marrow and Achieves Effective Donor Stem Cell Engraftment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105050</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4447</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Essential Role of Regulatory T Cells on Early B Cell Reconstitution after Haploidentical BMT with Posttransplant Cyclophosphamide</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100133</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4448</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Post-Transplant Cyclophosphamide Contributes to ImpairedGraft-Versus-Leukemia Effects and Regulates Graft-Versus-Host Disease in the Murine Stem Cell Transplant Model</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101386</Key_PaperID>
<Key_SessionID>11869</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4449</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>N-Acetyl-L-Cysteine Improves Mesenchymal Stem Cell Function in Prolonged Isolated Thrombocytopenia Post-Allotransplant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107532</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3165</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Microrna-31 Promotes T-Cell Pathogenicity in Chronic Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104842</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3166</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intestinal Microbiota Play a Critical Role in Neutrophil Engraftment Posttransplant and Recovery after Chemotherapy By Stimulating T Cell Production of IL-17A</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107575</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3167</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characterizing Graft-Vs-Host Disease of the Bone Marrow Post Allogeneic Hematopoietic Cell Transplantation in Mice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105857</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3168</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Oxidative Stress Regulates T Cell Pathogenicity in Gvhd</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107590</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3169</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>TNFAIP8 (TIPE) Deficiency Exacerbates Acute Graft Versus-Host Disease in Murine Model</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105541</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3170</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Generation and Characterization of Murine Allogeneic T Cell Resistant APL Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106550</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3171</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Highly Variable Frequencies of Donor Antigen-Specific Naive Cells May Dictate the Immunogenicity of Minor Histocompatibility Antigens after Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101495</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3172</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Allogenic C57B/6-&gt;B6D2F1 Transplantation As a Model for Graft Versus Host Disease in the Brain</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102627</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3173</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gastric Stem Cells Are Targeted in Upper Gastrointestinal Gvhd</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103241</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3174</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Modulation of Donor Graft By the Steroidal Lactone Withaferin A Alleviates Post-Transplant Acute GVHD Via Nrf-2 Independent T-Reg Induction</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103672</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3175</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>TAT-MYC Recombinant Fusion Protein Enhances Hematopoietic Stem Cell Graft Performance and Immune Cell Reconstitution after Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103915</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3176</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genetically Engineered Regulatory T Cells for Treatment of Graft-Versus-Host-Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104760</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3177</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pharmacological Control of Recipient NK Cell Function By Venetoclax Promotes Engraftment and LimitsGvhd Following Reduced Intensity Conditioning without Impacting the Graft Versus AML Effect</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105410</Key_PaperID>
<Key_SessionID>11871</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3178</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Anti-Viral Compound Cosalane Attenuates Acute Graft-Versus-Host Disease in Murine Hematopoietic Stem Cell Transplant Models</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103307</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3179</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104619</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3180</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CAR-T Cells Targeting BAFF-Receptor for B-Cell Malignancies: A Potential Alternative to CD19</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105422</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3181</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104882</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3182</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CRISPR/Cas9-Mediated Diacylglycerol Kinase Knockout Potentiates Anti-Tumor Efficacy of Human Chimeric Antigen Receptor T-Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105155</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3183</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Combination of 41BB and CD28 Costimulatory Signals Endows Lower Affinity CAR T Cells with the Most Optimal Properties for Selective Targeting of the Tumor Associated Antigen CD38</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107856</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3184</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dual-Switch CAR-T Cells: Orthogonal Molecular Switches to Control Activation and Elimination of CAR-T Cells to Target CD123+Cancer</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103935</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3185</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>NOTCH Activation at the Definitive Mesoderm Stage Facilitates Efficient Generation of T Cells with High Proliferation Potential from Human Pluripotent Stem Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106967</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3186</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Generation of Fungus-Specific T Lymphocytes for Use in HSCT Patients with Invasive Fungal Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106246</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3187</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Multi-Functional Genetic Engineering of Pluripotent Cell Lines for Universal Off-the-Shelf Natural Killer Cell Cancer Immunotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105664</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3188</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of Cross-Reactive Targets of TCR-Based Therapeutic Agents within the Human Proteome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105779</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3189</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination with Daratumumab over CAR-Based Approaches</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106896</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3190</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Dominant Negative SHP-2 Which Abrogates PD-1 Signalling Pathways and Restores Function of Cytotoxic CAR T Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100395</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3191</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treg in Gvhd Prophylaxis: Unique Transcription Factor Regulation of Foxp3 Expression in Itreg Derived from Human Umbilical Cord Blood (UCB) Vs Adult (AB) Naive CD4 T Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101606</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3192</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Early Administration of Low-Dose IL-2 Intensify Graft-Versus-Leukemia Effect without Worsening Gvhd through Sequential Enhancement of Effector T Cell and CD62L+ Regulatory T Cell Subset</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103164</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3193</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Randomized Phase II Trial of Combination Idiotype Vaccine and Adoptive Cell Transfer of Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103643</Key_PaperID>
<Key_SessionID>11872</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3194</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PI3K Inhibition with Idelalisib for Optimized Production of Chimeric Antigen Receptor T Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107477</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4450</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control. </PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107686</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4451</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Direct Comparison of the In Vivo Efficacy and in Vitro Signaling of Chimeric Antigen Receptors and Endogenous T Cell Receptors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105631</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4452</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genetically Engineered Pluripotent Cell-Derived Natural Killer Cell Therapy Provides Enhanced Antibody Dependent Cellular Cytotoxicity Against Hematologic Malignancies and Solid Tumors in Combination with Monoclonal Antibody Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103506</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4453</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cord Blood NK Cells Engineered to Express a Humanized CD123-Targeted Chimeric Antigen Receptor (CAR) and IL-15 As Off-the-Shelf Therapy for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108061</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4454</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CS1-Specific Chimeric Antigen Receptor Drives Cord Blood NK Cell Maturation and Expansion In Vivo</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108818</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4455</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Phosphorylation State of Ezh2 Determines Its Capacity to Maintain CD8+ Memory T Cells for Antitumor Immunity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104123</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4456</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting T Cell Bioenergetics By Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells to Prevent Graft-Versus-Host Disease While Maintaining Antitumor Immunity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105049</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4457</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CAR19 T Cells Redirected to Novel Antigens Mediate Robust Cytotoxicity Against Diverse Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104434</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4458</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CompleteRemission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106248</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4459</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>NK Cell Homing and Persistence in Bone Marrow after Adoptive Immunotherapy Correlates with Therapy Response</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108035</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4460</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identification of Myeloperoxidase As a Leukemia-Associated Antigen and Therapeutic Target for Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108319</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4461</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mechanisms of GVL-Resistance: T Cell Exhaustion and a Failure of Antigen Cross-Presentation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108475</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4462</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting T-Cell Malignancies with Chimeric Antigen Receptors Using Two Structurally Different Antigen Binding Domains Against CD5</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100826</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4463</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102155</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4464</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>AProspective, Non-Randomized, Multicenter, Phase II Study to Assess Safety and Efficacy of the Infusion of Peripheral Blood Stem Cells Obtained from HLA-Haploidentical Familial Donors (mHaploSCI) after Standard Chemotherapy in Elderly Patients with Acute Myeloid Leukemia at Intermediate or Adverse Risk</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104145</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Immunotherapy to treat AML</OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4465</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103665</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4466</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Activated and Expanded Natural Killer Cells Expressing an NKG2D-CAR Efficiently Target Multiple Myeloma Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108056</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4467</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Exploring the Cord Blood T Cell Compartment with Mass Cytometry Reveals the Existence of Memory CD4, CD8 and Regulatory T Cell Pools in the Fetal Period</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107380</Key_PaperID>
<Key_SessionID>11873</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Abatacept has been used in this study to optimise GVL effect of NK cells without increase in GVHD</OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4468</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CTLA4Ig Primed Donor Lymphocyte Infusions (DLI): A Novel Approach to Natural Killer Cell Immunotherapy Following Haploidentical PBSC Transplantation for Advanced Hematological Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107503</Key_PaperID>
<Key_SessionID>11874</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3195</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Optimization ofEx VivoActivation and Expansion of T Cells for Therapy of Lymphoma Via Antagonism of PI3K  and Vasoactive Intestinal Peptide Signaling</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108346</Key_PaperID>
<Key_SessionID>11874</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3196</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle> Multi-Phase Ex Vivo Generation of Platelet-like Particles from CD34+ Cord Blood Cell-Derived Megakaryocytes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106322</Key_PaperID>
<Key_SessionID>11874</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3197</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Generation and Characterization of Novel VLA-4 Inhibitors for Stem Cell Mobilization in Combination with a CXCR2 Agonist</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107527</Key_PaperID>
<Key_SessionID>11874</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3198</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Large-Scale, Bioreactor-Generated Expansion of Umbilical Cord Blood Tissue-Derived Mesenchymal Stromal Cells for Clinical Use</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108541</Key_PaperID>
<Key_SessionID>11874</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3199</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>IL-2 Plus IL-15 Leads to Enhanced Ex Vivo Expansion of Human Invariant Natural Killer T Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103509</Key_PaperID>
<Key_SessionID>11874</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3200</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Differences in Allogeneic Product T-Cell Subsets According to Donor Age: Associations with Immune Reconstitution and Acute Graft Versus Host Disease (aGVHD) in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106540</Key_PaperID>
<Key_SessionID>11874</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3201</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Results of Using Automated Clinimacs Prodigy for CD34 Selection from Mobilized Peripheral Blood Stem Cell Products</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101829</Key_PaperID>
<Key_SessionID>11874</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3202</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Acting, Oxidation-Resistant IL-33 Mobilizes High-Quality Hematopoietic Stem and Progenitor Cells More Efficiently Than Wild-Type IL-33, G-CSF or AMD3100</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103571</Key_PaperID>
<Key_SessionID>11874</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3203</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>VRD-CEP: An Effective and Tolerable Chemo-Mobilization and Debulking Regimen for Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104047</Key_PaperID>
<Key_SessionID>11875</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4469</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Single Dose Plerixaforas an Adjunct to G-CSF Based Peripheral Blood Stem Cell Mobilisation on the Graft Composition and Outcome for T Replete Haploidentical Pbsc Transplantation with Post Transplantation Cyclophosphamide : A Pilot Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105954</Key_PaperID>
<Key_SessionID>11875</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4470</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Use of CMV-Specific T Cells Derived from CMV-Naive Donors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107309</Key_PaperID>
<Key_SessionID>11875</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4471</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>JCAR017 Is a Defined Composition CAR T Cell Product with Product and Process Controls That Deliver Precise Doses of CD4 and CD8 CAR T Cell to Patients with NHL</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101520</Key_PaperID>
<Key_SessionID>11875</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4472</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>IFN- Induces Distinct Single Cell Transcriptomes in Clinical-Grade Mesenchymal Stromal Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101311</Key_PaperID>
<Key_SessionID>11875</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4473</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Studies for Stability of Ex Vivo Produced Megakaryocytes and Their Distribution in Transplanted Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108622</Key_PaperID>
<Key_SessionID>11875</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4474</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle> Gaussian Mixture Models and Machine Learning Predict Megakaryocytic Growth and Differentiation Potential Ex Vivo </PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107070</Key_PaperID>
<Key_SessionID>11875</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4475</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Post-Thaw Recovery of Cryopreserved Chimeric Antigen Receptor (CAR) T-Cells during Manufacture Is Better Than That of Cryopreserved Peripheral Blood CD3+ Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101144</Key_PaperID>
<Key_SessionID>11875</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4476</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outpatient Stem Cell Mobilization with Low and Intermediate Dose Cyclophosphamide Is a Safe andEffective Procedure in Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104200</Key_PaperID>
<Key_SessionID>11875</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4477</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sphingosine Kinase 2 (Sphk2) Deficiency Does Not Lower but Instead Surprisingly Increases the Level of Sphingosine-1-Phosphate (S1P) in Peripheral Blood, Providing a Novel Strategy for Stimulating Hematopoietic Stem Cell Mobilization By Inhibiting Sphk2 Activity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103428</Key_PaperID>
<Key_SessionID>11875</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4478</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Feasibility and Kinetics of CD34+ Hematopoietic Cells Mobilization By Low-Dose Pegfilgrastim in Lymphoma Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105443</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3244</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mortality after Allogeneic Stem Cell Transplantation Associates with Gene Polymorphisms in CD40L and Thrombomodulin in the Absence of Statins</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108417</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3245</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intermediate Post-HCT Exposure to Thymoglobulin Minimizes Mortality and High Exposure Minimizes the Composite of Death, Relapse or Chronic Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103114</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3246</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cord Blood Regulatory T Cells for Prevention of Graft Versus Host Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101143</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Carfilzomib for GVHD prevention</OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3247</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Carfilzomib in Addition to Standard Cyclosporine/ Methotrexate Combination Effectively Prevents Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation from Unrelated Donors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106203</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3248</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Individual Patient Dose-Escalated Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease in Children and Adults: Safety, Efficacy and Immune Correlates</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103385</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3249</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prediction of Severe Acute Graft-Versus-Host Disease (aGVHD) Based on Whole Transcriptome Sequencing of Donor CD4 T Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104235</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3250</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Effects of Various ATG Doses on Rejection Rate and Immune Recovery in Haploidentical T and B Cell Depleted Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107731</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3251</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Influence of VDR Polymorphisms on the Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) within the Alovita Trial. </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105816</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Natalizumab (Tysabri) for GVHD treatment</OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3252</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase II Trial of Natalizumab (Tysabri) with Corticosteroids As Initial Treatment of Gastrointestinal Acute Graft Versus Host Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99888</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3253</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Thymic Function Predicts Response to Mesenchymal Stromal Cell Treatment in Chronic GvHD: A Phase II Clinical Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102388</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3254</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Donor Lymphocyte Cell-Specific Telomere Length and Causes of Death after Unrelated Hematopoietic Cell Transplant in Patients with Marrow Failure</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107401</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3255</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Omitting Post-Transplant Mini-Methotrexate Doses in Allogeneic Hematopoietic Cell Transplantation: A Single-Center Retrospective Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104462</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3256</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Initial Results of KD025-208: A Phase 2a Open Label Trial of KD025 for Steroid-Dependent Chronic Graft Versus Host Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106513</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3257</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Donor and Recipient HLA Class I Molecule Are Required for Maximum NK Cells Cytotoxicity Reconstitution Post Haploidentical Hematopoietic Stem Cells Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104351</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3258</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Towards Functional Immune Monitoring in Allogeneic Hematopoietic Stem Cell Transpant Recipients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108831</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3259</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transcriptomal Evidence for Dysregulation of Angiogenic Factors and Inflammatory Markers after Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101748</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3260</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Increased Naive, Stem Cell Memory and Terminally Differentiated CD8+ T Cells in Chronic Graft Versus Host Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102503</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3261</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Recovery of Thymic Function after Allogeneic Hematopoietic Stem Cell Transplantation in with Sickle Cell Anemia Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103041</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3262</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>NK-Cell Alloreactivity Is Associated with Acute Gvhd and Decreased Relapse Incidence after T-Replete Haplo-Identical Allotransplant with High-Dose Post-Transplant Cyclophosphamide</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101139</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3263</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Anti 47 Integrin Monoclonal Antibody (Vedolizumab) for the Treatment of Steroid-Resistant Severe Intestinal Acute Graft Versus Host Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106900</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3264</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Biomarkers for Clinical Response of Extracorporeal Photopheresis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103557</Key_PaperID>
<Key_SessionID>11876</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3265</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inverse Correlation of V2-T-Cell Recovery with EBV Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105392</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1970</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>ARandomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX (Methoxsalen) for National Institutes of Health (NIH)-Graded Moderate to Severe Chronic Graft-Vs-Host Disease (cGVHD)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106397</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1971</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>The Use of Anti-Thymocyte Globulin Is Associated with Decreased Risk of Chronic Graft-Versus-Host Disease without Impact on Survival after Allogeneic Peripheral Blood Stem Cell Transplantation for Adults with Philadelphia-Positive Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100977</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1972</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of Early Post-Transplant Vaccination Using a Prime and Boost Strategy Is Independent of a Prior History of GvHD: Results from BMT CTN 0201</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105144</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1973</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Pre-Transplant Pulmonary Function Test Parameters of FEF50% (Forced expiratory flow at 50% of forced vital capacity) and RV (residual volume) in Combination Can Predict the Risk for Development of Lung Gvhd after Allogeneic Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107776</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1974</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis in Patients Undergoing Allogeneic Transplantation (alloHCT): Preliminary Results of a Phase I/II Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100410</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1975</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Similar Outcomes of Early Failure Steroid Dependent Acute GvHD and Upfront Steroid Refractory Acute GvHD: Implications on Clinical Trials</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104276</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Ruxolitinib is a JAK 1/2 inhibitor that is FDA approved for treatment of myelofibrosis. It is being used off-label for management of chronic graft versus host disease.</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1976</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ruxolinitib As Salvage Therapy for Chronic Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105574</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1977</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Identifying Risk Factors for Acute and Chronic Graft-Versus-Host Disease in T-Replete HLA-Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99645</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1978</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) AsGvhd Prophylaxis Is Effectivein Haploidentical Peripheral Stem Cell Transplantation andwithout Increasing Risk of Relapse</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107629</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1979</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>NK Cell Diversity Influences Outcomes after Cord Blood Transplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105775</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1980</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Assessment of a Multi-Cytokine Profile By a Novel Biochip-Based Assay Reveals Unique Correlation Patterns with Immune Reconstitution after Cord Blood Transplantation in Adults</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107951</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1981</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Mesenchymal Stromal Cells for Refractory Acute Graft-Versus-Host Disease By Compassionate Use Provide Comparable Results to Those of Phase II Clinical Trials</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100449</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1982</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Quantitative Assessment of TCR Repertoire and Allo-Reactivity of Human Acute Gvhd Tissue-Infiltrating T Cells</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105430</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Graft-versus-host disease (GVHD) is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Although first-line treatment is based on the use of high doses of corticosteroids, more than 50 % of patients will develop treatment failure. 
Ruxolitinib is an orally administered
tyrosine kinase receptor inhibitor used in the treatment of
myelobrosis (Harrison et al, 2012). Experiments in an ani-
mal model have shown that, by inhibiting the JAK-STAT sig-
nalling pathway (involved in the development of T-cell
alloreactivity), ruxolitinib is effective in GVHD and does not
affect GVL activity (Choi et al, 2014).
Ruxolitnib is an orally administered selective Janus Kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera. It has been previously reported its effectiveness in the treatment of GVHD in pre-clinic models and results in the clinical setting have recently been reported. 
</OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1983</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Ruxolitinib in Refractory Acute and Chronic Graft-Versus-Host Disease: A Multi-Center Survey Study</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106611</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1984</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Gvhd after PBSC-Haploidentical Stem Cell Transplantation (Haplo-SCT) with Post Transplantation-Cyclophosphamide (PT-Cy)</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108149</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Panobinostat for GVHD prevention</OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1985</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Trial Evaluating the Use of the Histone Deacetylase Inhibitor Panobinostat for Graft-Versus-Host Disease (GVHD) Prevention</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101384</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1986</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Fecal Microbiota Transplantation As Safe and Successful Therapy for Intestinal Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108126</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1987</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Class I HLA Peptide Epitope Binding Efficiency Has No Impact on Graft Vs. Host Disease Incidence Following AllogeneicHematopoietic CellTransplantation</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103043</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1988</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Invasive Fungal Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients Is an Important Risk Factor Not Only for Acute Graft-Versus-Host Disease but Also for Chronic Graft-Versus-Host Disease</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106592</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1989</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>How to Identify Patients for Treg DLI - Treg Subsets in Gvhd As Biomarker for SuccessfulTreg DLI</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101010</Key_PaperID>
<Key_SessionID>11877</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	7:30 PM
 
</PaperEndTime>
<PaperNumber>1990</PaperNumber>
<PaperStartTime>
	5:30 PM
 
</PaperStartTime>
<PaperTitle>Granzyme B Expression in Conventional CD4+ T-Cells Is Strongly Associated with Increased Relapse Rate during First 6 Months after Allo-HSCT</PaperTitle>
<Paperdate>2017-12-09</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102857</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3266</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Early Post-Transplant 5-Point Deauville Scale (18)F-FDG-PET Status on Survival Outcomes after Allogeneic Transplantation for Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106415</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3267</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103603</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3268</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Personalized Circulating Tumor DNA Predicts Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104768</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3269</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lifestyle Factors and Subsequent Ischemic Heart Disease Risk after Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106976</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3270</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Severe Ocular Graft-Versus-Host Disease Successfully Treated with Amniotic Membrane Transplantation  Case Series</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108607</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3271</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development of a Multi-Center Cohort to Evaluate Long-Term Outcomes and Late Effects Following Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Initiative</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104590</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3272</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mutational Burden before and after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101994</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3273</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Efficacy of Idelalisib Treatment of Chronic Lymphocytic Leukemia (CLL) or Lymphoma Relapsing after Allogeneic Hematopoietic Cell Transplantation (alloHCT): A Survey By the EBMT Chronic Malignancies and Lymphoma Working Parties</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102271</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3274</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Secondary Solid Cancer Following Hematopoietic Cell Transplantation in Patients with Thalassemia Major</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104465</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3275</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transaminase Elevation As a Marker of Liver Gvhd Is Associated with Poor Survival Among Allogeneic Stem Cell Transplant Recipients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106702</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3276</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prophylactic Donor Lymphocyte Infusions after Haploidentical Hematopoietic Stem Cell Transplantation for High Risk Hematological Malignancies: A Retrospective Bicentric Analysis of Serial Infusions of Increasing Doses of CD3+ Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108703</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3277</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of Donor Lymphocyte Infusion in CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplant for Myeloid and Lymphoid Malignancies: A Single Center Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101421</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3278</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>This Is a Title inHbi-8000, a Novel HDAC Inhibitor, Is Effective for Treating Leukemia Relapse Post Allogeneic Stem Cell Transplantation and Results in Th1 Polarization in AML Patients with AML1-ETO</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103619</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3279</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development of Prognostic Prediction Model for Decision of Secondary Allogeneic Stem Cell Transplantation for Relapsed Acute Myeloid Leukemia after First Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103911</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>lenalidomide for the treatment of acute myeloid leukemia.
bortezomib for the treatment of acute myeloid leukemia and myelodysplastic syndrome.</OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3280</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase I Study of Bortezomib Combined with Lenalidomide for Relapsed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Following Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105401</Key_PaperID>
<Key_SessionID>11878</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3281</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score Predicts Non-Relapse Mortality (NRM) and Overall Survival (OS) in Multiple Myeloma Patients Undergoing Intensive Preparative Regimen with Autologous Stem Cell Transplantation (ASCT) Followed By Maintenance Therapy Using Novel Agents</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101562</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4509</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PD-1 Is Not a Reliable Marker of Impending Relapse after Allogeneic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107705</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4510</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102793</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4511</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104190</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4512</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105404</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4513</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Next-Generation Sequencing-Based Measurable Residual Disease (MRD) Monitoring Is Highly Predictive for Outcome after Allogeneic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105407</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4514</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Longitudinal Changes in Body Composition Following Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100561</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>this is a prospective phase II trial</OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4515</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase II Trial of Bortezomib Plus Rituximab As Maintenance Therapy Post ASCT for Patients with Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108203</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4516</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Complete Remissions Post Infusion of Multiple Tumor Antigen Specific T Cells for the Treatment of High Risk Leukemia and Lymphoma Patients after HCT</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103614</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4517</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Post-Transplant Maintenance Therapy with Azacitidine and Gemtuzumab Ozogamicin for High-Risk Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106324</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4518</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Secondary Solid Cancers after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experience of 1374 Patients Including 812 Cord Blood Transplant Recipients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106643</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4519</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Pre-Emptive Rituximab Treatment for Epstein-Barr Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Longitudinal Study of 110 Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107933</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Rituximab for treatment of EBV-PTLD.</OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4520</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102068</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Lenalidomide is not licensed for the treatment of MDS, CMML and AML.</OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4521</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions  Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102872</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4522</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Front-Line Treatment with Second-Generation Tyrosine Kinase Inhibitors Following By Allo-Transplantation Benefits Patients with Better Survival Inph-Positive Acute Lymphoblastic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99759</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4523</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Accelerated T Cell Senescence after Allogeneic Hematopoeitic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107799</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4524</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Single Center Study of Outcomes of Patients Admitted to ICU Following Allogeneic Hematopoietic Cell Transplantation: Patients Who Have Experienced Post Transplant Relapse Prior to ICU Admission Have the Worst Outcomes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108789</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>mycophenolate mofetil is used off-label as post-hematopoietic cell transplant immune suppression</OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4525</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Haploidentical Hematopoietic Cell Transplantation Followed By Donor Natural Killer Cell Infusion and Sirolimus Maintenance Can Successfully Treat Patients with High-Risk Ewing Sarcoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102323</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4526</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hematopoietic Stem Cell Transplantation for Children with Neurological Diseases Improves the Outcomes and Not Leads to Significant Late Effects  Report from Russian Group</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103650</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4527</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cerebrovascular Disease after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, Risk and Clinical Outcome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103841</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4528</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-Conditioned Autologous Stem Cell Transplantation Are at a Higher Risk for DNA Virus Infections Than Patients with Systemic Non-Hodgkin Lymphoma Receiving Traditional Conditioning</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104166</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4529</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Poor Graft Function Following Autologous Stem Cell Transplant (ASCT): A Retrospective Analysis over Two Decades at a Transplant Center</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105930</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4530</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Erectile Dysfunction after Allogeneic Hematopoietic Stem Cell Transplant: Results from a Single Center Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106816</Key_PaperID>
<Key_SessionID>11879</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4531</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Scoring System for Predicting Risk of Relapse in Patients with Multiple Myeloma within Two Years after Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107489</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Elotuzumab; FDA approved for relapsed multiple myeloma. Discussion of investigational application in consolidation therapy for multiple myeloma.</OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3282</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107274</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3283</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cyclophosphamide Based Regimens Comparedto Plerixafor-Based Regimens for Stem Cell Mobilization in Patients with Multiple Myeloma Result in Higher CD34+ Cell Yield, Lower Cost and Similar Outcome Post Autologous Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107407</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3284</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Risk of Engraftment Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma Increases with Age and Lower Dose of CD34+ Cells, but Is Not Impacted By Immunomodulatory Chemotherapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107897</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3285</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transplant Still Relevant Even in the Era of Novel Treatments for Multiple Myeloma  National Cancer Database Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108865</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3286</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Which Patients with Ph+ Acute Lymphoblastic Leukemia Should Undergo Autologous Hematopoietic Stem Cell Transplantation in TKI Era?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108666</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3287</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Association between CD34+ Dose, Platelet Recovery and Incidence of Relapse after Autologous Stem Cell Transplant in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100292</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3288</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chidamide, a HDAC Inhibitor, Combined with Cladribine,High Dose Gemcitabine and Busulfan with Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory and Poor-Risk Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101140</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3289</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Destiny of Elderly Patients with Lymphoma Indicated for Autologous Stem Cell Transplantation (ASCT)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101235</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3290</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Modifications to the Classical Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: Efficacy and Safety Study of a Less Toxic Approach Which Improves the Neurological Condition. a Mexican Perspective</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101860</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>High-dose bendamustine is not approved as part of conditioning regimens prior to autologous stem cell transplant for relapsed/refractory HL.</OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3291</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102519</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3292</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102998</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3293</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Autologous Transplantation Is Associated with Better Outcomes Compared to Chemotherapy Alone in a Minority-Rich Non-High-Risk Acute Myeloid Leukemia Cohort</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103127</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3294</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Duration of MRD-Negative Status in Multiple Myeloma (MM) Patients after Auto-HSCT Is a Criterion for Prolonged Remission without Maintenance Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103345</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3295</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Impact of Tandem Autologous Stem Cell Transplantation (ASCT) in Different Response Subgroups after 1st ASCT</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103546</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3296</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pharmacokinetics and Toxicities after Evomela (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103948</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3297</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104436</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3298</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Autologous Transplantation Improves Survival Rates for Follicular Lymphoma Patients Who Relapse within 2-Years of Chemoimmunotherapy: A Multi-Centre Retrospective Analysis of Consecutively Treated Patients in the Real World</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105645</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3299</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In the Era of Chemoimmunotherapy, Relapse Post Autologous Stem Cell Transplantation for Follicular Lymphoma Is Associated with Prolonged Overall Survival. an Analysis By the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106498</Key_PaperID>
<Key_SessionID>11880</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3300</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Thiotepa, Busulfan, and Cyclophosphamide and Busulfan, Cyclophosphamide, Etoposide As Autologous Stem Cell Transplantation Conditioning Regimen in Primary Central Nervous System Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106627</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4532</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Positive Minimal Residual Disease By Multiparameter Flow Cytometry in 9 Months after Autologous Stem Cell Transplantation and High-Risk Cytogenetics Predict Poor Outcome in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107354</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Carfilzomib is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. In the current study the combination of carfilzomib, lenalidomide and dexamethasone is used in newly-diagnosed patients with multiple myeloma.</OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4533</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108540</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4534</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase I/II Study of Infusional Gemcitabine and High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma: Interim Safety Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108318</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4535</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>EBV Reactivation Incidence and Severity in Multiple Sclerosis Patients Treated with Autologous Haematopoietic Stem Cell Transplant and Comparing with Aplastic Anaemia Treated with ATG- Single Site Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108144</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4536</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in the Elderly (65 Years Of Age): The Mayo Clinic Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102477</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4537</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107456</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4538</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Patients Responding to Any First Line Therapy for Multiple Myeloma Should Proceed to Autologous Stem Cell Transplantation Instead of Receiving Second Line Therapy to Deepen Response</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99655</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4539</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Clinical and Molecular Remissions in Patients with Follicular Lymphoma (FL) Following High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100858</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4540</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Survival of Patients with Chronic Phase Chronic Myeloid Leukemia Who Received Autologous Stem Cell Transplantation and Further Exposed to Tyrosine Kinase Inhibitors. a Study on Behalf of the French Society of Blood and Marrow Transplantation and the French Group of CML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101152</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Use off-label of drugs for the dose and/or schedule and/or association.</OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4541</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101619</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4542</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Retrospective Analysis of High-Dose Melphalan and Autologous Stem Cell Transplantation for Systemic Light-Chain Amyloidosis: A Single Center 63 Cases</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102039</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4543</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy Is Safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective Phase II Trial (NCT01849783)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102628</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4544</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Intermediate Risk Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared to Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-Score Adjusted Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103037</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4545</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bortezomib-Based Therapy Overcomes the Adverse Impact of Renal Impairment in Transplant Eligible Patients : An Analysis of the Prospective Randomized EMN02/HO95 Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103174</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4546</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed By Autologous Stem Cell Transplant for Patients with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103442</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4547</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inability to Complete the Second of Planned Tandem Autologous Stem Cell Transplantations for Metastatic Germ Cell Tumors: Reasons, Toxicity and Impact on Outcomes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103581</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4548</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Impact of Maintenance Therapy in the Treatment of Multiple Myeloma with a Subset Analysis on Patients Who Achieve a Complete Response (CR) or Better: A Retrospective Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104098</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Defibrotide is approved for treatment of hepatic VOD/SOS with renal/pulmonary dysfunction post-HSCT in the United States and for treating severe hepatic VOD/SOS post-HSCT in the European Union.</OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4549</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Neuroblastoma: Final Data from the Defibrotide Expanded-Access Program</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104612</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4550</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Baseline Immune Dysregulation in Autologous Stem Cell Transplant Recipients Is Associated with a Graft Versus Host-like Syndrome and Results in Poor Outcomes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106237</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4551</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Effect of Decline in Pulmonary Function Testing after Autologous Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106584</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4552</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Autologous Stem Cell Transplant in the Era of Bortezomib-Based Induction for AL Amyloidosis Results in Improved Hematologic Response Rates:a Single Institution 11 Year Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106653</Key_PaperID>
<Key_SessionID>11881</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4553</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Advanced, Treatment Refractory Multiple Sclerosis (MS) - a Phase II Clinical Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101112</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3301</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Which Patients with Myelofibrosis Should Receive Allogeneic Stem Cell Transplantation? a Decision Analysis Based on the Systematic Review of 4,341 Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101159</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3302</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>KIR- Ligand Mismatching Is Associated with Inferior Survival in Patients with Acute Leukemia Following T-Cell Replete Peripheral-Blood Stem Cell Haplo-Identical Transplantation with Post-Transplant Cyclophosphamide. a Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101998</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3303</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Discovery of Donor Genotype Associated with Long-Term Survival of Patients with Hematopoietic Stem Cell Transplantation in Refractory Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102789</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3304</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100040</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3305</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Reduced-Intensity Conditioning Is Successful in Matched Sibling Bone Marrow Transplantation As a Cure for Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103556</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3306</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) Transplant Outcomes Post HMA Therapy in a Large International Patient Cohort</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100336</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3307</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Life Expectancy in Long-Term Survivors Transplanted for Myelofibrosis: A Registry Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104947</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Lenalidomide as adjunctive therapy for 12 months following allogeneic stem cell transplantation</OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3308</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Reduced Intensity Stem Cell Transplantation Followed By Adjunctive Lenalidomide Is Tolerable and Safe and Improves Complete Response Rate in Multiple Myeloma:a UK NCRI Phase 2 Feasibility Study (LenaRIC)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105534</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3309</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Reduced Relapse and Improved Survival in Chemosensitive Hodgkin Lymphoma Patients Undergoing Haploidentical Related Donor Compared to HLA-Identical Donor Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105908</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3310</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Genetic Ontogeny Defines Distinct Prognostic Subgroups in AML Patients Age 60 and Older Following Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106663</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3311</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Novel Endpoints As Treatment Outcome in Allogeneic Hematopoietic Stem Cell Transplantation: A Comparison of Classical and Refined Definition of Graft-Versus Host Disease Free and Relapse Free Survival for Registry-Based Studies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107022</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Selinexor as post-SCT maintenance</OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3312</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107598</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3313</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>ST2 As a Biomarker of Non-Relapse Mortality after HLA-Haploidentical SCT with High-Dose Post-Transplantation Cyclophosphamide</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108355</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3314</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>a New Risk Assessment Tool for Allogeneic Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99763</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3315</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Significance of Natural Killer Cell-Mediated Alloreactivity in Unrelated Cord Blood Transplantation for Children with Acute Leukemia: A Japanese National Registry Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101015</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3316</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101419</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3317</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Risk Factors and Outcomes According to Age at Transplant with an HLA Identical Sibling for Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102659</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3318</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Cord Blood Transplantation for Adult Patients with Hodgkin Lymphoma, a Eurocord and EBMT Lymphoma Working Party Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102873</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3319</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CMV Reactivation Post CD34+ Selected Allo-HCT Has Adverse Outcomes on Blood Counts Recovery </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103484</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3320</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transplant Outcome for Secondary Acute Myeloid Leukemia Based on Prior Hematological Disease or Solid Malignancy - on Behalf of the ALWP of the EBMT</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103999</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3321</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Distinct HLA-DPB1 Matching of Unrelated Donors for Malignant and Non-Malignant Indications Is Critical in Pediatric Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104397</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3322</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intention-to-Treat Analysis of Allogeneic Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Non-Hodgkin Lymphomas: A Large Italian Single-Center Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105126</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3323</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in b Thalassaemia Major Leads to Early and Sustained Engraftment with Low Incidence of VOD and GvHD but a High Rate of Long-Term Mixed Chimerism</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105469</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The use of rituximab as part of conditioning regimen for reduced intensity allogeneic HCT.</OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3324</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: An Analysis By the EBMT Complications and Quality of Life WP</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105919</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3325</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Optimized EBMT Transplant-Specific Risk Score of Patients with Myelodysplastic Syndromes Following Allogeneic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107068</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3326</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transplant Outcome for Patients with Acquired Aplastic Anemia over the Age of 40: Mortality HAS NOT Been Reduced in 2015</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107736</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3327</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome of Patients &gt; 60 Years with Acute Myeloid Leukemia in First Complete Remission: A 10-Year Single Center Transplantation Program Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108174</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3328</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fludarabine Melphalan Conditioning Followed By T-Replete Haplo Identical (Haplo) Transplantation or Haplo Cord (HC) Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108448</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3329</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hematopoietic Stem Cell Transplantation from Full Matched Alternative Donor Has Same Results As Those from Matched Sibling for Patients with Beta-Thalassemia Major -a Large-Cohort Multicenter Study from China</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101480</Key_PaperID>
<Key_SessionID>11882</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3330</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hematopoietic Stem Cell Transplantation in 65 Patients with Leukocyte Adhesion Deficiency Type I and Type III - A Retrospective Multi-Center Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104102</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4554</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcome of Children with Acute Leukemia Given Allogeneic HSCT Either from an Unrelated Donor or from an HLA-Partially Matched Relative after -T Cell/B-Cell Depletion: A Multicenter, Retrospective, Comparative Analysis of the AIEOP Network</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100420</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4555</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Relationship between HLA Disparity and Clinical Outcomes in Peripheral Blood T Cell Replete Haploidentical Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100277</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Bortezomib used as consolidation after allogeneic stem cell transplantation in order to decrease myeloma relapse and chronic graft-versus-host disease.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4556</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Bortezomib Consolidation after NonmyeloablativeAllogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101416</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4557</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Outcomes of Elderly Patients with Acute Myeloid Leukemia (AML) in CR1 Receiving Reduced Intensity Allogeneic Stem Cell Transplantation (RICT) from Matched Sibling (MSD) or Unrelated Donors (URD)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101631</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4558</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Validation of Pre-Transplant Biomarker Measurement and Risk Score for Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant (HCT)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102312</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4559</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Follow up of 90y-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102666</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4560</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Intensified Conditioning and DLI for Relapsed/Refractory Acute Leukemia: Real-World Data from China Registry</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102908</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4561</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transfusion Dependence at Day +100 Predicts Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation for Myelofibrosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103054</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4562</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Value of Computed Tomography-Defined Sarcopenia: A Prognostic Predictor of Non-Relapse Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103189</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4563</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long Term Follow up of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Children and Teenagers &lt; 18 Years Old with High-Risk Acute Leukemia. Very Good Results in CR1 and CR2 Patients but Unexpected High Incidence of Severe Acute Graft Versus Host Disease in Children &lt; 10 Years</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103431</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Off label use of antithymocyte globuline for GVHD prophylaxis</OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4564</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Ex Vivo T Cell-Depleted and In Vivo T Cell-Depleted Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in First Complete Remission Resulted in Similar Overall Survival Survival: On Behalf of the ALWP of the EBMT and the MSKCC</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103864</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4565</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Unmanipulated Haploidentical Transplant for Acquired Severe Aplastic Anemia Achieved Comparable Outcomes with Unrelated Donor Transplant in Adult and Children Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104019</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4566</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML  Poor Outcomes Despite Longer Time to Relapse</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106880</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4567</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation  Allo-HCT Is an Ineffective Salvage Strategy in Active AML</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104381</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4568</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Thiotepa-Busulfan-Fludarabine in Comparison to Busulfan-Cyclophosphamide As Myeloablative Conditioning Regimen Pre Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104615</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4569</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Determinants of Long-Term Survival Following Allogeneic Stem Cell Transplantation for Multiple Myeloma: A Multi-Centre Analysis across the United Kingdom and Australia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105159</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4570</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Demographic and Socioeconomic Factors on Outcomes Following Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105412</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4571</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Progression-Free Survival after Reduced Intensity Total Body Irradiation-Based Conditioning in Patients Allografted for Chronic Myelomonocytic Leukemia (CMML)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105661</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4572</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105839</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4573</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Allogeneic Stem Cell Transplantation for the Treatment of Lymphoproliferative Disorders in Patients Affected By Primary Immunodeficiencies: The UK Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106120</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4574</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes of Combination of HLA-Haploidentical Hematopoietic SCT with an Unrelated Cord Blood Unit for 127 Patients with Acquired Severe Aplastic Anemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106331</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4575</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hematopoietic Cell Transplant for Adults Age 65: Does Donor Type Matter?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106791</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4576</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Remission Status at Transplantation and Treatment History Determine the Survival Chances of Patients after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia Who Had Received Pre-Treatment with Idelalisib: A Report from the EBMT Chronic Malignancies Working Party</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106732</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4577</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Favorable Long-Term Outcomes after Allogeneic Transplantation for Elderly Patients with Myelodysplastic Syndromes: A Report from the Chronic Malignancies Working Party of EBMT</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107183</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4578</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle> Outcomes of Hematopoietic Stem Cell Transplantation after Chronic Graft Versus Host Disease and Evaluation of Revised Failure Free Survival in a Retrospective Analysis from Two Referral Centers. </PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107428</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Mycophenolate - GVHD prophylaxis</OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4579</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sequential Therapy for Patients with Primary Refractory AML  a Retrospective Analysis of the German and Israeli Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107753</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>bortezomib used as GVHD prophylaxis</OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4580</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Alpha/Beta T Cell Depleted Haploidentical Transplantation Results in High Survival in Pediatric Patients with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108194</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4581</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Allogeneic Blood and Marrow Transplantation for Pediatric Patients with Sickle Cell Anemia: An Institutional Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108619</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4582</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100296</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Chidamide was used as prophylaxis of acute graft versus host disease.</OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4583</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pilot Study of Safety and Efficacy of Chidamide in Allogenic Peripheral Hematopoietic Stem Cell Transplantation: Better Disease Control and Positively Lower Graft Versus Host Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99945</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4584</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Haploidentical Stem Cell Transplantation Attenuates the Prognostic Impact of FLT3-ITD in Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100523</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4585</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Melphalan Dose in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation with Reduced-Intensity Fludarabine and Melphalan</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101095</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4586</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Efficacy of Reduced-Intensity Conditioning Compared to Standard Myeloablative Conditioning before Allogeneic Hemopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia in First Complete Remission: 10-Year Follow-up of a Prospective, Open-Label Randomized Phase III Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101208</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4587</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CD3 Lymphocyte Graft Content and Not Hematopoietic Stem Cell Source Is Associated to Higher Chronic Gvhd after Haploidentical Transplantation with Post-Transplant Cyclophosphamide</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102260</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4588</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sequential High-Dose Chemotherapy Reinduction Followed By Haploidentical Transplantation in Acute Leukemias</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102509</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4589</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long-Term Follow-up of Adult Double Unit Cord Blood (CB) Transplantation (dCBT) Recipients Reveals High Rates of Progression-Free Survival after a Novel Cy/ Flu/ Thio/ TBI 400 Intermediate Intensity Conditioning Regimen</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102673</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4590</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Further Prognostic Factors for Stratification of Patients in the High-Risk HCT-CI Group Undergoing Allogeneic HCT</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102819</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4591</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Stable Engraftment with Haploidentical Peripheral Blood Stem Cell Transplantation in Adult Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102933</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4592</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Alemtuzumab/Low Dose TBI Conditioning Facilitates Stable Long-Term Donor Hematopoietic Cell Engraftment from Sibling Donors in Children with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103341</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4593</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An EBMT Analysis of Matched Sibling, Mismatched Family or Matched Unrelated Donors for Allogeneic Stem Cell Transplants in MDS</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103727</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>41</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4594</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparable Outcome of CD3+-/CD19+ Depleted Haploidentical with Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Advanced Stage Sickle Cell Disease: Result of a Pilot Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103899</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>42</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4595</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Autologous Stem Cell Transplantation Versus Haplo-Identical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104093</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>43</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4596</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle> Outcomes and Risks of Allogeneic Hematopoietic Stem Cell Transplant for Hematological Malignancies in Patients with HIV Infection</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104305</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>44</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4597</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104540</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>45</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4598</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pre-Transplantation Predictors of Survival in Patients Undergoing Allogeneic Stem Cell Transplant for Myelofibrosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104973</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>46</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4599</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention  Final Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO  SFGM-TC French intergroup)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105271</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>47</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4600</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Stem Cell Transplantation for Congenital Dyserythropoietic Anemia. a Retrospective Study on Behalf of Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105378</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>48</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4601</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Low-Toxicity/High-Efficacy HLA Haploidentical Transplantation for Elderly/Unfit Patients with Acute Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105549</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>49</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4602</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Promising Results at 1 Year Follow-up Following Familial Haploidentical (FHI) T-Cell Depleted (TCD) with CD34 Enrichment and T-Cell (CD3) Addback Allogeneic Stem Cell Transplantation in Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105875</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>50</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4603</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fractionated Gemtuzumab Ozogamicin in Association with High Dose Chemotherapy: A Bridge to Allogeneic Stem Cell Transplantation in Refractory and Relapsed Acute Myeloid Leukemia?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106852</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>51</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4604</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA- Haploidenitcal Relative or an Older Fully HLA-Matched Sibling or Unrelated Volunteer?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107170</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>52</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4605</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Biologically Assigned HLA-Identical Versus Haploidentical Related Donor Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107357</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>53</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4606</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Long Term Followup of Sickle Cell Disease Post Hematopoietic Stem Cell Transplant from Uganda</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107864</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>54</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4607</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) in Combination with Cyclophosphamide and Etoposide in Patients with Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108107</Key_PaperID>
<Key_SessionID>11883</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>55</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4608</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Outcomes Following Allogeneic HCT for Adverse Cytogenetic/Molecular Risk AML Using T-Replete Haploidentical Donors to Optimally Matched Related and Unrelated Donors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100464</Key_PaperID>
<Key_SessionID>11884</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3331</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>101HEMB01 Is a Phase 1/2 Open-Label, Single Ascending Dose-Finding Trial of DTX101 (AAVrh10FIX) in Patients with Moderate/Severe Hemophilia B That Demonstrated Meaningful but Transient Expression of Human Factor IX (hFIX)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104330</Key_PaperID>
<Key_SessionID>11884</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3332</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Pre-Existing Immunogenicity to AAV on Vector Transduction By Bmn 270, an AAV5-Based Gene Therapy Treatment for Hemophilia a</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108261</Key_PaperID>
<Key_SessionID>11884</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3333</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Immune Responses in 101HEMB01, a Phase 1/2 Open-Label, Single Ascending Dose-Finding Trial of DTX101 (AAVrh10FIX) in Patients with Severe Hemophilia B</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104786</Key_PaperID>
<Key_SessionID>11884</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3334</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Durable Remission after Salvage Chemotherapy with Combining Bortezomib and Vorinostat Followed By CD19 CAR-T Therapy in a Patient with MLL-Rearranged ALL after Early Relapse Post Allogeneic Hematopoietic Stem Cell Transplantation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104863</Key_PaperID>
<Key_SessionID>11884</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3335</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105141</Key_PaperID>
<Key_SessionID>11884</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3336</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Towards the Next Generation CAR T Cells with TEGs: In Vivo Efficacy  Toxicity Profile in Xenografts of Primary Human AML Disease and Healthy Bone Marrow</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108594</Key_PaperID>
<Key_SessionID>11884</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3337</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inducible MyD88/CD40 (iMC) Costimulation Enhances Polyclonal Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte (EBV-CTL) Proliferation and Anti-Tumor Activity</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101280</Key_PaperID>
<Key_SessionID>11884</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3338</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Selective Proliferation of Gene-Modified Human Erythroid Cells with Truncated Erythropoietin Receptors</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105427</Key_PaperID>
<Key_SessionID>11884</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3339</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Novel Highly Conserved Hematopoietic Stem/Progenitor Cell Population for Stem Cell Transplantation and Gene Therapy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105677</Key_PaperID>
<Key_SessionID>11884</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3340</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Talen Mediated Therapeutic Gene Editing Strategy for -Hemoglobinopathies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107947</Key_PaperID>
<Key_SessionID>11884</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3341</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Aryl Hydrocarbon Receptor Antagonists Expand Adult Hematopoietic Stem Cells from Mobilized Peripheral Blood and Bone Marrow and Increase the Dose of CRISPR/Cas9 Gene-Edited NSG-Repopulating Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108837</Key_PaperID>
<Key_SessionID>11884</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3342</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Priming Human Hematopoietic Stem and Progenitor Cells for Cas9/Sgrna and rAAV6-Mediated Homologous Recombination</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105767</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4609</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Longer Term Follow-up on the First Patients with Severe Hemoglobinopathies Treated with Lentiglobin Gene Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102229</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4610</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Adeno-Associated Virus Mediated Gene Transfer with Hyperfunctional FIX-E410H Variant Improves Mean Factor IX Activity Levels in Hemophilia B Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104244</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4611</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Interim Analysis of Immunogenicity to the Vector Capsid and Transgene-Expressed Human FVIII in a Phase-1/2 Clinical Study of Bmn 270, an AAV5-Mediated Gene Therapy for Hemophilia a</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106328</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4612</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Platelet-Targeted Gene Transfer Induces Immune Tolerance in a Primed Model</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105168</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4613</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Invariant NKT Are a More Effective and Versatile Platform Than T Cells for CAR Immunotherapy of CD1d-Expressing B Lineage Malignancies: Cellular and Molecular Mechanisms</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106241</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4614</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Targeting Primary Pre-B Cell Acute Lymphoblastic Leukemia and CD19-Negative Relapses Using Trivalent CAR T Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108498</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4615</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MyD88/CD40 Enhanced CD19-Specific CAR-T Cells Maintain Therapeutic Efficacy Following Resolution of Cytokine-Related Toxicity Using Inducible Caspase-9</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102425</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4616</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In Vivo HSC Transduction and Selection Results in Long-Term, High-Level Expression of Human Gamma Globin in Peripheral Blood Erythrocytes of Mice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105202</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4617</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fetal Hemoglobin Induction with Forced Chromatin Looping in Gene-Modified Erythroid Cells Differentiated from Rhesus Hematopoietic Progenitor Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106885</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4618</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Diverse and Distinct Human Hematopoietic Differentiation Programs Generate By Bone Marrow and G-CSF Mobilized Hematopoietic Stem and Progenitors Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104451</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4619</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Expanding CRISPR Genome Editing Strategies in Hematopoietic Stem and Progenitor Cells for the Treatment of Hematologic Diseases</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108311</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4620</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preclinical Development of HBBGene Correction in Autologous Hematopoietic Stem and Progenitor Cells to Treat Severe Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108532</Key_PaperID>
<Key_SessionID>11885</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4621</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transcriptional Response to Genome Editing Machinery in CD34+ HSPCs</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107597</Key_PaperID>
<Key_SessionID>11886</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3343</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Systematic Characterization of the "Resistome" of Tumor Cells Against Panels of Small Molecule Inhibitors - Application in the Context of Inhibitors of Transcriptional Cyclin-Dependent Kinases (tCDKs) and Implications for Future "Individualized" Clinical Applications</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101778</Key_PaperID>
<Key_SessionID>11886</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3344</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Transient Induction of Blood-Circulating Bile Acid Is a Therapeutic Marker and Target of Chemotherapy-Oriented Myelosuppression</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104025</Key_PaperID>
<Key_SessionID>11886</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3345</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Structure-Function Relationships of Novel Benzimidazole-Based Inhibitors of the Isoprenoid Biosynthetic Pathway in Myeloma Cells</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104234</Key_PaperID>
<Key_SessionID>11886</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3346</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Aptamer C10.36 Reveals a Ribonucleoprotein Complex on the Surface of Non-Hodgkin Lymphoma Cells Providing Candidates for Multi-Target Therapeutics</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105189</Key_PaperID>
<Key_SessionID>11886</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3347</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>DNA Demethylating Agents Generate a Brcaness Effect in Multiple Sporadic Tumor Types: Prediction for Sensitivity to PARP Inhibitors in AML</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105793</Key_PaperID>
<Key_SessionID>11886</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3348</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Pan-FLT3/BTK Multi-Kinase Inhibitor CG 806 Induces AML Killing in FLT-Mutant and Wild Type Cells, and Exerts Synergistic Pro-Apoptotic Effects with Concomitant Targeting of Anti-Apoptotic Bcl-2 and/or Mcl-1</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106778</Key_PaperID>
<Key_SessionID>11886</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3349</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development of Novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101666</Key_PaperID>
<Key_SessionID>11887</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4622</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Barriers to Successful Implementation of Precision Medicine to the Treatment of Refractory AML: Lessons Learned</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100672</Key_PaperID>
<Key_SessionID>11887</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4623</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Leukemia Cells</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101804</Key_PaperID>
<Key_SessionID>11887</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4624</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase 1-2 Dose-Escalation and Cohort- Expansion Study of eFT508, a Selective, Orally Bioavailable Inhibitor of MNK1and MNK2,inPatientswith Hematological Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104064</Key_PaperID>
<Key_SessionID>11887</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4625</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preclinical Investigation of a Potent Geranylgeranyl Diphosphate Synthase Inhibitor</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104477</Key_PaperID>
<Key_SessionID>11887</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4626</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CG 806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105586</Key_PaperID>
<Key_SessionID>11887</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4627</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Small Molecule RAD51 Inhibitor Preferentially Affects Cells Expressing High Cytidine Deaminase Activity</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108027</Key_PaperID>
<Key_SessionID>11887</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4628</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Synthetic Lethality Targeting the Aid/RAD51 Axis for Treatment of AICDA-Expressing Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105949</Key_PaperID>
<Key_SessionID>11887</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4629</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CG 806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108603</Key_PaperID>
<Key_SessionID>11887</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4630</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In Utero Injections of Nanoparticle Encapsulated Myelin Oligodendrocyte Glycoprotein Peptides Prevent Experimental Autoimmune Encephalopathy Via Central Tolerance</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101353</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3350</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Caregiver Perceptions of Adolescent Self-Management Skills Predicts Higher Disease Knowledge Among Adolescents with SCD</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108101</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3351</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Risk Factors for Thrombosis in the Neonatal Intensive Care Unit: Analysis of a Large National Database</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105320</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3352</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Cost-Effective Implementation of Pre-Operative Protocol with Sucrosomial Iron Supplementation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107641</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3353</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improving the Diagnosis and Early Follow-up of Children with Sickle Cell Disease Born in Mirebalais Haiti</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106278</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3354</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Gender Differences in Faculty Rank, Departmental Leadership, and Research OutputAmongst Hematology/OncologyFacultyin United States</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108836</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3355</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Using Electronic Best Practice Alerts to Improve Thrombophilia Testing Based on ASH Choosing Wisely Guidelines</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108263</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3356</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>B-Cell Lymphoma Patients Have a 10% Risk of Shingles, 7% in Cutaneous T-Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106765</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3357</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lack of Inter-Laboratory Agreement in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa Activity and the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108816</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3358</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Assessment of Referral Patterns of Adult Patients to a Sickle Cell Disease Specialty Clinic within a Statewide Sickle Cell Network</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108634</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3359</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Recent Trends in Incidence and Financial Impact of Peripherally Inserted Central Catheter (PICC)-Associated Upper Extremity Deep Vein Thrombosis (DVT): Data from National Inpatient Sample</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104621</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3360</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Stroke in Pediatric Sickle Cell Disease in Sub-Saharan Africa: Systematic Review and Estimated Prevalence</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108103</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3361</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Implementation of an Electronic Medical Record Tool for Early Detection of Deep Vein Thrombosis in the Ambulatory Oncology Setting: The Cleveland Clinic Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101272</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Four-factor prothrombin-complex concentrate (PCC) is currently approved by the FDA for use in the treatment of severe bleeding in patients with vitamin K antagonist-associated coagulopathy. However it is increasingly used on an off-label basis in many other clinical situations related to major bleeding, and occasionally even in situations in which there is no bleeding at all. The purpose of our retrospective analysis was to identify the indications for which 4-factor PCC has been utilized at our institution, and the associated indications.</OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3362</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Off-Label Use of Four-Factor Prothrombin Complex Concentrate: A Single Institution Retrospective Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103524</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3363</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Resource Utilization Associated with the Management of Adults with Hemophagocytic Lymphohistiocytosis (HLH): A Benchmark Analysis for Improving Inpatient Care at a Quaternary Hospital </PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108640</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3364</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Venous Thromboembolism (VTE) Increases the Healthcare Burden in Patients with Malignant Glioma (MG)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99596</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3365</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Determinants of Hematology-Oncology Trainees Post-Fellowship Career Pathways with a Focus on Non-Malignant Hematology</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99748</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Hydroxyurea treatment for children with sickle cell disease</OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3366</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development and Validation of a Patient/Caregiver-Report Hydroxyurea Treatment Adherence Scale</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100149</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3367</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparative Use of Direct Oral Anticoagulants and Warfarin in the Treatment of Atrial Fibrillation and Venous Thromboembolism and Prophylaxis: A Retrospective Single Center Utilization Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100782</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3368</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Direct Medical Care Costs Associated with -Thalassemia Care in Italy</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101549</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3369</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>County Level Surveillance of Sickle Cell Disease Population, Healthcare Utilization, and Fragmentation to Support Improvements in Access to Care</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101665</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3370</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Healthcare Resource Utilization in Autoimmune Hemolytic Anemia Patients: Analysis of 190 Cases from a Single Center</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102730</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3371</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Oral Voriconazole As Prophylaxis during Intensive Chemotherapy for Adult Patients with Acute Myeloid Leukemia: A Retrospective Cohort Study Using Japanese Administrative Database</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103365</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3372</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inflammatory Bowel Disease and Thrombosis: A National Inpatient Sample (NIS) Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103392</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3373</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Obstetric and Bleeding Complications in Pregnancy with Von Willebrand Disease: Results from Nationwide Inpatient Sample Database 2003-2011</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104033</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3374</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Utilizing the EMR to Curb Inappropriate Inpatient Thrombophilia Testing</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104142</Key_PaperID>
<Key_SessionID>11888</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3375</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Prospective Multi-Centered Registry Is Feasible in Sickle Cell Disease: Globin Regional Network for Data and Discovery (GRNDaD)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103862</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4631</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>VTE Recurrence and Safety of Anticoagulants Among Patients with Cancer Treated for Venous Thromboembolism</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106111</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4632</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Estimating the Cost Savings and Cost Effectiveness of Low Dose Immune Tolerance Induction (ITI) Therapy with Bypassing Agent Prophylaxis Compared to High Dose ITI and Low Dose ITI</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108142</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4633</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment of Cancer Associated Venous Thrombosis; The Cleveland Clinic Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105724</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4634</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An Intensive Transition Navigator Intervention Improves Transition Readiness to Adult Care in Youth with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108104</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4635</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Modified Khorana Models for Prediction of Cancer-Associated Venous Thromboembolism: An Exploratory Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107353</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4636</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Health Disparity in Hematopoietic Cell Transplantation for Sickle Cell Disease: Analyzing the Association of Insurance and Socioeconomic Status Among Children Undergoing Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107394</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4637</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Clinical and Radiological Factors Associated with Thrombosis Recurrence in Cancer Associated Subsegmental Pulmonary Embolism</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106282</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4638</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Spectrum of Hematological Disorders in Young Navy Recruits</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101273</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4639</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Striving to HIT the Bullseye When Diagnosing Heparin-Induced Thrombocytopenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102331</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4640</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Healthcare Costs Associated with Venous Thromboembolism in Cancer Patients Treated with Anticoagulants</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99766</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4641</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Decision Model to Estimate Risk Thresholds for Guiding Duration of Anticaogulation in Unprovoked Venous Thromboembolism</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107688</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4642</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Thirty Day Readmissions Due to Venous Thromboembolism in Patients Discharged with Syncope</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108746</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4643</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Utilization of a Pediatric Sickle Cell Day Hospital By Patients with Sickle Cell Disease and Pain Events Is Associated with a Lower Rate of Inpatient Hospital Admission Compared to Utilization of the Pediatric Emergency Department</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106031</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4644</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cerebrovascular Accidents Among African American Adults with Sickle Cell Disease: A Nationwide Outcomes and Trend Analysis over Two Decades</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108560</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4645</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Shingles Occurs in Only 0.5% of Myeloma Patients on Any Dose of Antiviral Prophylaxis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106274</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4646</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High Incidence of True Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia Antibody Development in Critically Ill Medical Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107618</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>The medications that were given to 2 or more idiopathic multicentric Castleman disease (iMCD) patients are listed in the abstract. Only siltuximab is FDA approved for iMCD. The remaining drugs listed (rituximab, corticosteroids, tocilizumab, and cyclophosphamide) are all off-label treatments for iMCD.</OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4647</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106628</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4648</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Systematic Literature Review of Patient-Reported Outcome Instruments Used in Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107761</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4649</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Early Analgesia on Hospitalization for Sickle Cell Pain Crisis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104061</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4650</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Splenic Infarct As an Harbinger for Sickle Cell Traits in High Altitude</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108566</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4651</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Simple Bundle to Control an Outbreak of Carbapenem-Resistant Enterobacteriacae in an Onco-Hematological Inpatient Unit: Report from a Single Center</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102234</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4652</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sickle Cell Disease and the Adherence to Guidelines for Use of Blood Transfusions</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106245</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4653</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Diagnosis and Management of Heparin Induced Thrombocytopenia - Are We Choosing Wisely?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107328</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4654</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>BleedingRiskUsingINR/aPTT Pre-Surgery:SystematicReview (BRUISR)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99623</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4655</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hematology Referrals for Mild Thrombocytopenia in a Tertiary Center in Detroit: A Step Towards a Standardized Approach for Referrals and Testing</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99893</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4656</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Improving Access to Care for Adults with Sickle Cell Disease in Los Angeles County</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100254</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4657</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Anticoagulation Champion Efficacy of Warfarin Anticoagulation in a Resident Based Primary Care Clinic</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100723</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4658</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Systems-Based Hematologists in Maintaining a HIT Program Using Continuous Clinical Audit and Education in an Academic Medical Center</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102003</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4659</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Healthcare Utilization and Costs in Commercially Insured Patients with AL Amyloidosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102469</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4660</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Access to Care for Medicaid and Commercially-Insured United States Patients with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102810</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4661</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Predictive Tool to Support Decision-Making about Management of Conflicts of Interest for Guideline Development: Derivation and Validation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103377</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4662</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Trends and Outcomes of Venous Thromboembolism in Hospitalized Patients with Ovarian Cancer: Results from Nationwide Inpatient Sample Database 2003 -2011</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103750</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4663</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Transition Readiness Assessment of Adolescents with Sickle Cell Disease and Their Caretakers at the Sickle Cell Clinic in Kumasi, Ghana</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106917</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4664</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Program Expansion of a Day Hospital Dedicated to Manage Sickle Cell Pain</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100643</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4665</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Impact of Pregnancy on Long-Term Outcome in Acute Leukemias Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103412</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4666</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pharmacy Hydroxyurea Education Materials for Patients with Sickle Cell Disease: An Environmental Scan and Assessment of Accuracy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106066</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4667</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparative Cost-Efficiency Analysis of Granulocyte Colony-Stimulating Factors for Use in Chemotherapy Patients in the United States</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101538</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4668</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Budget Impact Analysis of Switching Chemotherapy Patients Using Granulocyte Colony-Stimulating Factors (G-CSFs) from Pegfilgrastim to Short-Acting G-CSFs in the United States</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107759</Key_PaperID>
<Key_SessionID>11889</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4669</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Iron Deficiency Anemia on Inpatient Mortality, Hospital Cost, and Length of Stay in Patients with Luminal Gastrointestinal Cancers: Data from the Healthcare Cost and Utilization Project from 1999-2014</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105591</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3376</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Economic Burden of Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Acute Lymphoblastic Leukemia (ALL) in the US</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102552</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3377</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Expert Elicitation of Long-Term Survival for Pediatric Acute Lymphoblastic Leukemia Patients Receiving CTL019 in Eliana Phase II Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104327</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3378</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Economic Modeling of the Potential Impact of Chronic Myeloid Leukemia (CML) Monitoring on Healthcare Costs</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108117</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3379</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comorbid Conditions in Newly Diagnosed Patients with Acute Promyelocytic Leukemia (APL)in "Real World" Patients; Decreased Induction Mortality Despite a High Comorbid Index</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105737</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3380</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107910</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3381</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase 1 Clinical Trial Methodology in Hematological Malignancies from 2005 - 2015: A Systematic Review</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108239</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3382</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Management of Polycythemia Vera: a Survey of Canadian Physician Practice Plans</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105411</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3383</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Protecting Minor Donors of Hematopoietic Stem Cells: A Survey in EBMT Transplant Centers</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104466</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3384</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real-World Testing and Treatment Patterns in Chronic Lymphocytic Leukemia (CLL) in the United States during the Modern Era: A SEER Patterns of Care Analysis</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108128</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3385</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105527</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3386</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Economic Burden of Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the US</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107375</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3387</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of the Safety and Tolerability of Rapid Infusion of Biosimilar Rituximab Truxima - the University College London Hospitals (UCLH) Experience</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107517</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3388</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>What Do Transplant Physicians Think about Palliative Care?a National Survey Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106975</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3389</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Narrowing the Gap for Hematopoietic Cell Transplantation in the East-Mediterranean/African Region: Comparison with Global HSCT Indications and Trends. a Report on Behalf of the East Mediterranean (EMBMT), African Blood and Marrow Transplantation Group (AfBMT) and Worldwide Network for Blood and Marrow Transplantation (WBMT)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108620</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3390</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Recent Trends in the Incidence and Outcomes of Tumor Lysis Syndrome in Hematological Malignancies: Data from 2010-2014 National Inpatient Sample</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100667</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3391</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106733</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3392</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Resource Utilization Using Micro-Costing Method and Cost Effectiveness Analysis of Treatment of Acute Promyelocytic Leukemia with Generic Arsenic-Trioxide</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107902</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3393</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evolving Treatment Patterns of Healthcare Providers (HCPs) and Multiple Myeloma (MM) Experts from 2013-2017: Analysis of an Annually Updated Online Treatment Decision Tool</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104707</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3394</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Detecting Cases of Monoclonal Gammopathy of Undetermined Significance in Electronic Health Data</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107162</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3395</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Utilization of Radiation Therapy in Multiple Myeloma: Trends and Changes in Practice</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100670</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3396</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99897</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3397</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Estimating the Need for Complex Malignant Hematologists in Ontario Using Monte Carlo Simulation</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100178</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3398</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Protective Environment for Hematopoietic Cell Transplant (HSCT) Recipients: The Infectious Diseases Working Party EBMT Analysis of Global Recommendations on Health-Care Facilities</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100612</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3399</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle> Low Enrollment of Adult Patients in Clinical Trials: Is Communication Still a Problem?</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100261</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients With Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial</OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3400</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cost-Effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Castor Trial</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100965</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3401</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of a Brief Touchscreen Based Modified Geriatric Assessment on the Care of Older Adults with Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101566</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3402</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Antibiotic Overload: Antibiotic Stewardship in Febrile Patients with Hematologic Malignancies</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101827</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3403</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Incremental Financial and Health-RelatedBurdenof Novel Drugs Used in the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM): A Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102232</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3404</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inferior Clinical Outcomes with Fixed Duration Therapy for Transplant Ineligible Myeloma Patients: UK Real-World Data in Comparison with First Trial (MM-020)</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102291</Key_PaperID>
<Key_SessionID>11891</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3405</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lenalidomide Maintenance Therapy PostAutologous Stem Cell Transplant: A Healthcare Cost-Impact Analysis in Europe</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107178</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4670</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Trends in Hospital Cost, Length of Stay, Complication Rates, and Mortality in Patients with Acute Lymphoblastic Leukemia in Teaching Versus Nonteaching Institutions: Data from the Nationwide Inpatient Sample from 1999-2014</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107594</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4671</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real-World Characteristics of CLL Patients Receiving Front-Line Therapy, Using the Flatiron Health Database</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104205</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4672</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Identifying Clinical Gaps in the Diagnosis, Monitoring, and Management of Immunoglobulin Light Chain (AL) Amyloidosis Among Hematologist/Oncologists</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104689</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4673</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108281</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4674</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104314</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4675</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Frailty Evaluation in a Cohort of Onco -Hematology Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104029</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4676</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Home Administration of Subcutaneous Rituximab Is Safe and Associated with Significant Cost Saving: A Single Center Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104685</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4677</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Apache II and Sofa Scores Predict Mortality in Hematologic Malignancies Patients at Intensive Care Unit Admission</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104735</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4678</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Economic Evaluation for the US of Venetoclax Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104414</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4679</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Economic Evaluation for the US of Ibrutinib Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108401</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4680</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Insurance Design and out-of-Pocket (OOP) Costs:a Comparison of Oral and Intravenous (IV) Treatment Plans for Chronic Lymphocytic Leukemia (CLL) in the Era of the Affordable Care Act (ACA)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104035</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4681</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Drivers of Treatment Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with B-Cell Receptor Inhibitors (BCRis)  a Medical Chart Review Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105180</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4682</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Utility of Early Broncholaveolar Lavage in Prolonged Neutropenic Patients with Pulmonary Nodules</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107137</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4683</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Economic Burden Associated with Adverse Events of Special Interest (AESI) in Patients with Relapsed Acute Lymphoblastic Leukemia (ALL) in the US</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107961</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4684</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>MCL Treatment Patterns and Outcomes: A Community Oncology Practice Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108058</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4685</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Measurable Residual Disease (MRD) Testing in Multiple Myeloma Using an Improved Testing Technology: Population Impact</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105262</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4686</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>High-Intensity Healthcare Utilization and Costs Among Older 10+y Survivors of Allogeneic Blood or Marrow Transplantation (BMT): A Report from the BMT Survivor Study-2 (BMTSS-2)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108315</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4687</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Easy-to-Read Informed Consent (ETRIC) Form for Hematopoietic Cell Transplantation (HCT) Clinical Trials: Results from Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1205 Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103609</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4688</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Survival Trends Among Patients with Acute Myeloid Leukemia with Favorable Cytogenetics in the United States</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106276</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4689</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Disparities in Outcomes of Patients with Multiple Myeloma Based on Geographic Distance from NCI-Designated Cancer Centers: A SEER Based Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108756</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4690</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>In-Hospital Mortality and Cost of Allogeneic Hematopoietic Cell Transplant (HCT) in Adult Acute Myeloid Leukemia: National Inpatient Sample (NIS) Years 2002-2013</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106132</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4691</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>US Regional Difference in Hospitalization Cost for Autologous Stem Cell Transplantation in Multiple Myeloma Patients: A Nationwide 10-Year Analysis from 2005 to 2014</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104340</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4692</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Comparative Study of Cardiovascular Co-Morbidities between Ibrutinib and Non-Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL) Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106396</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4693</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Clinical Benefit of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML): A Surrogate of Overall Survival (OS) or Meritorious on Its Own Right?</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106052</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4694</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Economic Burden of Treatment Episodes in Acute Myeloid Leukemia (AML) Patients in the US: A Retrospective Analysis of a Commercial Payer Database</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107262</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4695</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Healthcare Reimbursement and Service Utilization for One Year of Post-Allogeneic Hematopoietic Cell Transplantation (alloHCT) Care for Medicare Beneficiaries Ages 65 and Older with Acute Myeloid Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108843</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4696</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Widow Maker: A National Inpatient Sample Study of Health Care Utilization Costs for Cardiovascular Complications Patients Diagnosed with Non-Hodgkins Lymphoma from 2000-2014</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103528</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4697</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>HBV Care Map for Patients Receiving Anti-CD20 Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107333</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4698</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Economic Model Shows That Guideline Recommended Testing of Patients with Early Symptoms of Myeloma Results in Improved Patient Outcomes and Decreased Hospital Costs</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107786</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4699</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>AssessingSafe Discharge Criteria for Pediatric Oncology Patients Admitted for Febrile Neutropenia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106867</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4700</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Primary Caregivers Knowledge Related to Cancer: Opportune Detection and Prevention of Treatment Complications in a Pediatric Hematology-Oncology Unit</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103348</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4701</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Cost-Effectiveness of Therapeutic Drug Monitoring (TDM) of Generic Imatinib for the Treatment of Chronic Myelogenous Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103393</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4702</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Utility of End of Treatment PET- CT in Patients with Diffuse Large B-Cell Lymphoma and Documented Complete Remission By Interim PET</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100115</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4703</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100486</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>35</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4704</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Symptom Burden, Palliative Care Needs, and Patient-Provider Communication Among Chronic Myeloid Leukemia Survivors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100703</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>36</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4705</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Economic Burden in US Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin or Chemotherapy after Failure of Autologous Hematopoietic Cell Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100795</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>37</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4706</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real-World Patterns of Care for Patients with Follicular Lymphoma Treated with Lenalidomide and Rituximab (R2) in the US Medicare Population</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101264</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>38</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4707</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Who Is Receiving Novel Therapies for Relapsed/Refractory Follicular Lymphoma? a Retrospective Chart Review of Recent Real-World Practice</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101625</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Pegfilgrastim for mobilization of hematopoietic progenitor cells </OffLabelUseDescription>
<Order>39</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4708</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Autologous Hematopoietic Progenitor Cells Mobilization with Combination of Pegfilgrastim and Plerixafor: Efficacy and Cost Assessment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101947</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>40</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4709</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Assessing Outcomes, Healthcare Resource Utilisation and Costs across Europe in Newly Diagnosed Multiple Myeloma (NDMM) Patients Post Autologous Stem Cell Transplant (ASCT)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102246</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>41</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4710</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Deutsche Studiengruppe Multiples Myelom (DSMM) Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100263</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients With Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial</OffLabelUseDescription>
<Order>42</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4711</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Cost-Effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Pollux Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102483</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>43</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4712</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Fulfillment of Postmarketing Commitments for Novel Malignant Hematology Products Granted Accelerated Approval By the FDA between 2011-2016</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102853</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>44</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4713</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hematologic Cancers More Costly and Have Fewer Savings Options Than Solid Tumors Under the OCM</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100264</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization</OffLabelUseDescription>
<Order>45</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4714</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? an Analysis of Treatment Patterns and Healthcare Resource Utilization</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103095</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>46</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4715</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Combined Oral Administration of Analgesia and Anxiolysis for Pain Associated with Bone Marrow Aspiration and Biopsy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108804</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>47</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4716</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Multicenter Retrospective Experience of Hematologic Neoplasms in Pregnancy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107901</Key_PaperID>
<Key_SessionID>11892</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>48</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4717</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Value-Based Approach to Optimizing Peripheral Blood Progenitor Cell (PBPC) Mobilization and Collection for Autologus Hematopoietc Cell Transplantation (AHCT)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101712</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3406</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Intracranial Hemorrhage in Patients with Haematological Malignancy, a Nested Case-Control Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102880</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3407</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Potential Association between Sickle Trait and MRI-Defined Cerebrovascular Outcomes in Two Multi-Ethnic Elderly Populations</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105598</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3408</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Characteristics of Males with Hemophilia in the United States Hemophilia Treatment Center Network (USHTCN) with New-Onset Elevated Inhibitor Titers, December 15, 2013  December 31, 2016</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104390</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3409</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Benefit-Risk Comparison in Patients with Immune Thrombocytopenia (ITP) Receiving Eltrombopag or Romiplostim: Real World Evidence (RWE) from 26 Hospital Institutions</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105151</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3410</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Canadian Cost-Effectiveness Analysis for the Treatment of Immune Thrombocytopenia: Assessing the Relative Value of with Eltrombopag Versus Romiplostim</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108614</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3411</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Burden of Comorbid Diseases in Patients with Hemophilia: The Cross-Sectional Analysis of the Patient Reported Outcomes, Burden and Experiences (PROBE) Study</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101097</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3412</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Quality Improvement in the Care of Patients with Asplenia: Focus on Diminishing Risk of Infection</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104493</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3413</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Re-Presentation to Medical Care Due to Adverse Effects of Intravenous ImmunoglobulinTherapy in Pediatric Immune ThrombocytopeniaPatients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107414</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3414</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Chronic Red Blood Cell Exchange Transfusion Therapy Does Not Impact Hospital Utilization or Ascq-Me Pain Domains in Adults Living with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107172</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3415</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Defining Vaso-Occlusive Crises in Sickle Cell Disease from the Perspective of the Patient: Development of a New Toolbox to Measure Treatment Outcomes</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104486</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3416</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Did Patients with Renal Disease Receive Sufficient Prophylaxis for Venous Thromboembolism in the Real-World Settings?: A Study Among Hospitalized Acutely Medically Ill Patients</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102563</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3417</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Outcomes and Risk Factors Associated with Thrombosis Recurrence and Post-Thrombotic Syndrome in Children and Adolescents with May-Thurner Syndrome</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107529</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3418</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Enhancing Adherence to Prescribed Opioids Using a Mobile-Based App: A Feasibility Study in Non-Cancer Pain</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106185</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3419</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Aspirin May be Inadequate Thromboprophylaxis in Multiple Myeloma</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105451</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3420</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Health Utility Analyses in AL Amyloidosis  Existing Mapping Algorithms May be Inadequate</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107683</Key_PaperID>
<Key_SessionID>11893</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>3421</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Influence of the Age of Adults with Sickle Cell Disease on the Uptake, Utilization and Efficacy of Hydroxyurea</PaperTitle>
<Paperdate>2017-12-10</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108465</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4718</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Vascular Thrombosis Leading to Graft Failure Following Pediatric Liver Transplantation</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100580</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4719</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Integration of a Heparin-Induced Thrombocytopenia Order-Set (HITOS): A Retrospective Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103193</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4720</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Large Cohort Comparison of 2005 National Institutes of Health Chronic Graft-Versus-Host Disease Staging Criteria to 2014 National Institutes of Health Chronic Graft-Versus-Host Disease Staging Criteria</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107406</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4721</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Direct Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism: A Systematic Review &amp; Network Meta-Analysis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104161</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4722</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Developmental Examination of Pain Among Youth with Sickle Cell Disease</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101124</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4723</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Deferasirox Adherence and Persistence Among Texas Medicaid Patients Taking Dispersible Tablets and Film-Coated Tablets</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106093</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4724</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Post-Thrombotic Syndrome and Recurrent Thromboembolism in Patients with Upper Extremity Deep Vein Thrombosis: A Systematic Review and Meta-Analysis of Proportions</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100262</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4725</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Anticoagulant Prescription Patterns for Cancer Associated Thrombosis: New Insights into the Use of Direct Oral Anticoagulants</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106726</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4726</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Real-World Adherence to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation: Results of an International Survey</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106678</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4727</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Patient Preferences Regarding Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients - a Discrete Choice Experiment</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103291</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4728</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Sirolimus Is Effective in Refractory Immune Thrombocytopenia: Results of an Open-Label Prospective Multicenter Trial in China</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104694</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4729</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Catheter-Associated Bloodstream Infections (CA-BSI) in Adults with Cancer: A Prospective Randomized Controlled Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107045</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4730</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Correlations between Patient-Reported Outcomes and Self-Reported Characteristics in Adults with Hemophilia B and Caregivers of Children with Hemophilia B: Analysis of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101174</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4731</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Physical Activities in Patients with -Thalassemia As Measured By Fitbit in Association with Patient-Reported Outcomes</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104431</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4732</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Development of a Concept-Driven Disease Impact Instrument from Patients with Hemophilia (Pediatric and Adult) and Caregivers</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105610</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4733</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Associations between Socioeconomic Status and Health-Related Quality of Life in Patients with AL Amyloidosis</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102956</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4734</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Frequency of Venous Thromboembolism (VTE) Prophylaxis Among Patients Hospitalized for Cancer in the US</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103156</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4735</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Inferior Vena Cava Filter Utilization at Kingston Health Sciences Centre: A Comparison of Practice with Guidelines</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105497</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4736</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Health-Related Quality of Life and Health Insurance Coverage Among Persons with Hemophilia a Inhibitors</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103395</Key_PaperID>
<Key_SessionID>11894</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4737</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Hemoglobin Levels, Sex, Race and Coronary Heart Disease Risk in the Reasons for Geographic and Racial Differences in Stroke Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104132</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4036</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>P53 and P16 Protein Expression Have Prognostic Value in Mantle Cell Lymphomas in the Lyma Trial in the Lysa Group</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107341</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4037</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An Integrated Safety Analysis of the Next Generation PI3K Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106483</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Everolimus is currently approved for advanced breast cancer, neuroendocrine tumors, and renal cell carcinoma. Bendamustine is currently approved for CLL and indolent B-cell NHL. Due to promising preclinical data, we reports its use with bendamustine in lymphoid malignancies and myeloma.</OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4038</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>A Phase 1 Study of Everolimus and Bendamustine in Patients with Relapsed or Refractory Lymphoid Malignancies and Myeloma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105287</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Lenalidomide. Off- label use in patients with relapsed/refractory non-hodgkin's lymphoma. It is FDA approved in relapsed mantle cell lymphoma. </OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4039</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>99986</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4040</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103002</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4041</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Significant Adverse Consequences of Initial Watchful Waiting for Follicular Lymphoma Patients: A Retrospective Analysis of Patients Diagnosed in Alberta from 1994-2011</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101749</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>7</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4042</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkins Lymphoma Treated with Intravenous Copanlisib</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102832</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>8</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4043</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Survival Rates and Clinical Characteristics of Young Patients with Waldenstrm Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103360</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>9</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4044</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Clinical Significance of Low Grade Follicular Lymphoma with High Proliferative Index</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102298</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>10</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4045</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Lymphoplasmacytic Lymphoma Not Associated with an IgM Monoclonal Paraprotein Has Distinctive Clinical and Biological Features and a Similar Outcome As Compared with Waldenstroms Macroglobulinemia: Multicentric Study of the Rete Ematologica Lombarda</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103346</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>11</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4046</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenstrm Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103202</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>12</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4047</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prognostic Value of Baseline and Interim Total Metabolic Tumour Volume and Total Lesion Glycolysis Measured on 18f-FDG PET/CT in Patients with Follicular Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102482</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>13</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4048</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104110</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>14</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4049</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Mantle Cell Lymphoma Mimicking Mucosa-Associated Lymphoid Tissue (MALT) Lymphomas: A Pathological Characterization (on behalf of the Fondazione Italiana Linfomi (FIL) - Postgraduate Master Course)</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104404</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>15</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4050</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Increased Risk of Toxicity with Novel PI3K Delta Inhibitor Combinations Compared with Standard Use in Non-Hodgkin Lymphoma Patients</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101708</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>16</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4051</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated Waldenstrm Macroglobulinemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105324</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>17</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4052</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>An International Multicenter Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Patients with Transplant-Eligible Mantle Cell Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101481</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>18</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4053</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104129</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>19</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4054</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Natural History of Hypogammaglobulinemia in Patients with Follicular Lymphoma and the Impact of Anti-CD20-Based Therapy</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107443</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>pembrolizumab, tested in a trial for relapsed NHL</OffLabelUseDescription>
<Order>20</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4055</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>PD-1 Blockade with Pembrolizumab in Relapsed Low Grade Non-Hodgkin Lymphoma</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103929</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>21</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4056</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Simultaneous Global Phase I Studies of a Differentiated BTK Inhibitor, Dtrmwxhs-12, in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphomas</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>102436</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>BGB-3111 and BGB-A317 are investigational agents and have not yet been approved in the United States.</OffLabelUseDescription>
<Order>22</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4057</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>101234</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>23</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4058</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Patient-Reported Symptoms during Ibrutinib Holds: A Withdrawal Syndrome</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106205</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>24</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4059</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Treatment Patterns in Newly Treated and Relapse/Refractory Patients with Follicular Lymphoma in Routine Clinical Care  a United States Electronic Medical Record Database Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>107124</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>25</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4060</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Understanding Ibrutinib Treatment Discontinuation Patterns for Chronic Lymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>105310</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>26</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4061</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>CD5-Negative Mantle Cell Lymphoma Defines a Distinct Disease Entity Characterized By an Indolent Clinical Course Irrespective of Known Prognostic Markers</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103119</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>27</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4062</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>BendamustineinCombination with Rituximab As First-Line Treatmentof Splenic Marginal Zone Lymphoma (BRISMA). Results of theIELSG-36 Phase II Study</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103728</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>28</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4063</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Evaluation of Tumor Burden for Predicting Survival in Patients with Follicular Lymphoma Receiving First-Line R-CHOP Treatment: Comparison of Different Definition of GELF Criteria</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>106210</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>29</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4064</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Rituximab Maintenance for Two Years in Previously Untreated Follicular Lymphoma: No Difference in Outcome between Patients Receiving Treatment at Two Month Versus Three Month Interval</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108059</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>30</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4065</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>VR-CAP Alternating with Rituximab and High-Dose Cytarabine: An Effective First-Line Mantle Cell Lymphoma Regimen Prior to Autologous Stem Cell Transplant</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>104208</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>31</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4066</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Efficacy of 90Y-Ibritumomab Tiuxetan in the Older Population with Non-Hodgkin Lymphoma Pre-Treated with Rituximab-Based Regimens: A Single-Institution Experience</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>103606</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>32</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4067</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Increased C-Reactive Protein Level Is Associated with Poor Prognosis in Patients with Follicular Lymphoma Treated with Rituximab-Containing Regimens</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100404</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>Yes</OffLabelUse>
<OffLabelUseDescription>Idelalsib-rituximab is licensed in relapsed CLL and first line in patients with TP53 disrupted CLL</OffLabelUseDescription>
<Order>33</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4068</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Idelalisib-Rituximab Results in Considerable Toxicity but Induces Durable Clinical Remissions in Patients with TP53 Disrupted B Cell Prolymphocytic Leukemia</PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>100798</Key_PaperID>
<Key_SessionID>11895</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>34</Order>
<PaperEndTime>
	8:00 PM
 
</PaperEndTime>
<PaperNumber>4069</PaperNumber>
<PaperStartTime>
	6:00 PM
 
</PaperStartTime>
<PaperTitle>Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon </PaperTitle>
<Paperdate>2017-12-11</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108965</Key_PaperID>
<Key_SessionID>12024</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	1:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:05 PM
 
</PaperStartTime>
<PaperTitle>Overview of the World Health Organization Hemoglobin Thresholds Project</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108966</Key_PaperID>
<Key_SessionID>12024</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	1:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:15 PM
 
</PaperStartTime>
<PaperTitle>Current Hemoglobin Cutoffs: How Did We Get Here</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108967</Key_PaperID>
<Key_SessionID>12024</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	1:55 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:35 PM
 
</PaperStartTime>
<PaperTitle>Effects of Inflammation on Hemoglobin Concentrations - Mechanisms and Clinical Effects</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108968</Key_PaperID>
<Key_SessionID>12024</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	2:15 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:55 PM
 
</PaperStartTime>
<PaperTitle>Evidence for Hemoglobin Thresholds and Functional Outcomes in Young Children and in Pregnancy</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108969</Key_PaperID>
<Key_SessionID>12024</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>5</Order>
<PaperEndTime>
	2:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:15 PM
 
</PaperStartTime>
<PaperTitle>The Epidemiology and Determinants of Anaemia in Low Income Countries</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108970</Key_PaperID>
<Key_SessionID>12024</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>6</Order>
<PaperEndTime>
	2:55 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:35 PM
 
</PaperStartTime>
<PaperTitle>Effects of Hypoxia, Altitude and Smoking on Hemoglobin Concentrations</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108957</Key_PaperID>
<Key_SessionID>12025</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	1:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:05 PM
 
</PaperStartTime>
<PaperTitle>Methods and Results from Single Cell Analysis of Tumor Microenvironment </PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108959</Key_PaperID>
<Key_SessionID>12025</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	2:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	1:35 PM
 
</PaperStartTime>
<PaperTitle>In Situ Methods of Analysis of Tumor Microenvironment </PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108961</Key_PaperID>
<Key_SessionID>12028</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:05 PM
 
</PaperStartTime>
<PaperTitle>Tigit, a New Target in the Tumor Microenvironment</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108962</Key_PaperID>
<Key_SessionID>12028</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	2:35 PM
 
</PaperStartTime>
<PaperTitle>New Methods of Tumor Vaccination </PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108963</Key_PaperID>
<Key_SessionID>12029</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	4:35 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:05 PM
 
</PaperStartTime>
<PaperTitle>Bispecifics Targeting CD20</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108964</Key_PaperID>
<Key_SessionID>12029</Key_SessionID>
<OffLabelUse>No</OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	5:05 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	4:35 PM
 
</PaperStartTime>
<PaperTitle>CAR-T Cells: Beyond CD19 (BCMA/CD30/armored CARs)</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108971</Key_PaperID>
<Key_SessionID>12040</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>1</Order>
<PaperEndTime>
	3:25 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:10 PM
 
</PaperStartTime>
<PaperTitle>Hemoglobin Thresholds in the Elderly</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108972</Key_PaperID>
<Key_SessionID>12040</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>2</Order>
<PaperEndTime>
	3:40 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:25 PM
 
</PaperStartTime>
<PaperTitle>Hemoglobin Concentrations and Transfusion Thresholds</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108973</Key_PaperID>
<Key_SessionID>12040</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>3</Order>
<PaperEndTime>
	3:55 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:40 PM
 
</PaperStartTime>
<PaperTitle>Laboratory Measurement of Hemoglobin in Clinical Laboratory Practice and the Field</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>
<row disposition="INSERT">
<HideFromOutput></HideFromOutput>
<Key_AorB>A</Key_AorB>
<Key_PaperID>108974</Key_PaperID>
<Key_SessionID>12040</Key_SessionID>
<OffLabelUse></OffLabelUse>
<OffLabelUseDescription></OffLabelUseDescription>
<Order>4</Order>
<PaperEndTime>
	4:10 PM
 
</PaperEndTime>
<PaperNumber></PaperNumber>
<PaperStartTime>
	3:55 PM
 
</PaperStartTime>
<PaperTitle>Erythroid Genetics and Hemoglobin Concentrations</PaperTitle>
<Paperdate>2017-12-08</Paperdate>
</row>